Abstracts
Transcription
Abstracts
The International Stroke Conference welcomes these organizations to our annual meeting: ® AANS/CNS Cerebrovascular Section ® American Society of Interventional and Therapeutic Neuroradiology Nursing Symposium: February 19 Sessions: February 20-22 Exhibits: February 20-21 New Orleans, Louisiana Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Prevention Diagnosis Tr e a t m e n t / I n t e r v e n t i o n Rehabilitation Basic Science stro keco nfer ence .o r g Abstracts 528 Stroke Vol 39, No 2 February 2008 International Stroke Conference Oral Presentations 1 Subgroup Analysis In the Fast Trial: A Subset of Intracerebral Hemorrhage Patients That Benefit from Recombinant Activated Factor VII? Stephan A Mayer, Columbia Univ, New York, NY; Stephen M Davis, Univ of Melbourne, Melbourne, Australia; Kamilla Begtrup, Novo Nordisk A/S, Copenhagen, Denmark; Joseph P Broderick, Univ of Cincinnati, Cincinnati, OH; Michael N Diringer, Washington Univ, St. Louis, MO; Brett E Skolnick, Novo Nordisk, Inc, Princeton, NJ; Thorsten Steiner; Univ of Heidelberg, Heidelberg, Germany Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: The recombinant activated Factor VII (rFVIIa) FAST trial was a randomized, double-blind placebo-controlled study of 821 spontaneous intracerebral hemorrhage (ICH) patients diagnosed by computed tomography (CT) scan ⱕ3 hours after symptom onset and treated with placebo, 20 or 80 g/kg rFVIIa ⱕ1 hour after CT. FAST showed that rFVIIa (80 g/kg) given ⱕ4 hours after ICH onset significantly limits hematoma growth. However, in contrast to an earlier phase 2b trial, survival and functional outcome were not improved at 90 days. In this post-hoc analysis we hypothesized that earlier treatment and exclusion of patients with high probability of poor outcome (massive hemorrhage volumes, substantial intraventricular hemorrhage [IVH] and advanced age) might enhance the ability of rFVIIa to impact positively on clinical outcome. Methods: Combinations of predictive factors for outcome after ICH were analyzed at different clinically meaningful cut-offs to identify a candidate subgroup. The impact of treatment on outcome and volume change in this group were analyzed by logistic regression (mRS) and linear mixed models (ICH volumes). The same criteria were then applied to the data from the phase 2b trial to examine our hypothesis of the assumed responder subgroup. Results: A candidate subgroup (n⫽160) was identified comprising patients aged ⱕ70 years, with baseline ICH volume ⬍60 ml, baseline IVH volume ⬍5 ml, and time from symptom onset to rFVIIa treatment ⱕ2.5 hours. The adjusted odds ratio (OR) for poor outcome in patients receiving 80 g/kg rFVIIa was 0.28 (95% CI 0.08 to 1.06). The reduction in hemorrhage growth relative to placebo was almost doubled by limiting onset to treatment to 2.5 hours (-7.3 ⫾ 3.2 ml [P⫽0.02] versus -3.8 ⫾ 1.5 ml in the 80 g/kg group overall). The improved treatment effect was then confirmed in an analysis of a patient subgroup (n⫽56), from the earlier phase 2b study, which was defined by the same criteria (OR 0.02, P⫽0.02 versus OR 0.47, P⫽0.01 overall). Conclusions: This exploratory analysis provides evidence that with an earlier treatment window and exclusion of known determinants of poor outcome at baseline (age and magnitude of ICH and IVH), a subpopulation of ICH patients may benefit from hemostatic therapy with rFVIIa. 2 Microbleeds Versus Macrobleeds: Evidence for Distinct Processes. Steven M Greenberg, R. N. Kaveer Nandigam, David Schoenfeld, Hui Zhang, Massachusetts General Hosp, Boston, MA; Rebecca A Betensky, Harvard Sch of Public Health, Boston, MA; Jonathan Rosand, Anand Viswanathan, Eric E Smith; Massachusetts General Hosp, Boston, MA Background and Purpose: Small, asymptomatic hemorrhagic lesions (or microbleeds) are a commonly recognized feature accompanying larger symptomatic hemorrhages (macrobleeds). It is unclear whether microbleeds and macrobleeds represent two extremes within a single continuum of hemorrhage sizes, or rather two distinct processes with separate risk factors. Methods: We determined the volumes of all 163 hemorrhages detected by gradient-echo MRI in 46 consecutive subjects with primary lobar hemorrhage diagnosed as cerebral amyloid angiopathy and modeled their distribution. We also analyzed the appearance of new macrobleeds and microbleeds in 94 consecutive survivors of lobar hemorrhage and a subset of 34 with additional follow-up MRI 15.8⫹-6.5 months after baseline. Appearance of new hemorrhages was modeled as a Poisson distribution with maximum-likelihood estimation of parameters for the rate of appearance of any new hemorrhagic lesion (R) and the probability that a given new hemorrhage would be a symptomatic macrobleed (P). R and P were compared between categories of subjects with low or high numbers of hemorrhages at baseline (categorized according to the group median). Results: Hemorrhage volumes occurred in a distinctly bimodal distribution (Figure) represented as a mixture model with peaks at 0.009 cm3 and 16.4 cm3. The optimal threshold (determined by receiver operating characteristic) for distinguishing the two groups was 0.069 cm3, corresponding to a spherical diameter of 0.51 cm. Subjects with more hemorrhages at baseline had a substantially higher rate of new hemorrhage formation (R⫽0.19 versus 0.01 hemorrhages per month, p⬍0.0001) but a lower probability that a new hemorrhagic lesion would be a symptomatic macrobleed (P⫽0.10 versus 0.50; p⬍0.0001). Conclusion: Based on the bimodal distribution of hemorrhage volumes and the differential risks observed for small and large hemorrhages, microbleeds and macrobleeds appear to represent distinct pathophysiologic entities. These data are consistent with a threshold model, whereby hemorrhagic lesions reaching a particular volume proceed to enlarge into a full-sized macrobleed. Modeling the bleeding process as distinct initiation and enlargement events may be a useful framework for understanding the pathogenesis of hemorrhagic stroke. 3 Multicentre Prospective Study Demonstrates Feasibility Of CT-Angiography In Intracerebral Hemorrhage And Validity Of “Spot Sign” For Hematoma Expansion Prediction. Andrew M Demchuk, Suresh Subramaniam, Jayme Kosior, Sarah Tymchuk, Christine O’Reilly, Univ of Calgary, Calgary, Canada; Carlos Molina, Vall d’Hebron Hosp, Barcelona, Spain; Jayanta Roy, Advance Medicare and Rsch Institute, Kolkata, India; Imanuel Dzialowski, Univ of Dresden, Dresden, Germany; Jean-Martin Boulanger, Univ of Sherbrooke, Greenfield Park, Canada; Mohammed Alzawahmah, Nic Weir, Michael D Hill, Univ of Calgary, Calgary, Canada; David Gladstone, Richard Aviv, Univ of Toronto -Sunnybrook Health Sciences Cntr, Toronto, Canada; PREDICT/Sunnybrook ICH CTA Study Group Background: Previous hemostatic therapy trials have demonstrated efficacy against hematoma expansion but this has not translated into improved clinical outcomes. Better selection of ICH patients at risk for hematoma expansion is needed for future hemostatic therapy trials. Single centre ICH CT angiography (CTA) studies have detected small, enhancing foci (‘spot sign’) within acute hematomas which appear to predict ICH expansion. The PREDICT/ Sunnybrook study is an ongoing prospective observational study that aims to determine the validity and feasibility of contrast extravasation to predict ICH expansion in a large, multicentre cohort. We present our preliminary findings. Methods: ICH patients enrolled in study at 6 centres since May 2006. All enrolled patients underwent acute CT angiography. Scans reviewed for “spot sign” by 3 blinded readers. ICH/IVH volumes quantified using computer assisted segmentation algorithm. Significant hematoma expansion defined as ⬎5 ml increase in total hematoma volume (ICH⫹IVH). Results: 43 patients enrolled and all received baseline CTA. Fifteen patients (35%) demonstrated 25 enhancing foci. Median onset-CTA time 213.5 minutes and median non-contrast CT to CTA time 7.5 minutes. Median baseline ICH volume was 25.3 ml (14.6 –53 iqr) for “spot sign” positive group and 12.2 ml (5.2–34.7 iqr) for “spot sign” negative group (p⫽0.087). Hematoma expansion analysis limited to 36 patients (excluded 2 early deaths, 2 surgical evacuations and 3 rFVIIa all before follow-up scan; 5/7 of these excluded patients were “spot sign” positive). Significant hematoma expansion occurred in 6/36 patients (16%), all had “spot sign” on CTA (p⫽0.0001). For significant hematoma expansion the positive predictive value for “spot sign” was 60% (6/10) and negative predictive value was 100% (26/26). Mean ICH volume expansion was 12.2 ⫹/- 22.3 ml for “spot sign positive” cases and minus 1.1 ⫹/- 4.4 ml for “spot sign” negative cases (p⫽0.006). Mean IVH volume expansion was 13.4 ⫹/- 28.6 ml for “spot sign” positive cases and 0.6 ⫹/- 2.3 ml for “spot sign” negative cases (p⫽0.03). Total hematoma volume expansion was 25.5 ⫹/- 32.8 ml for “spot sign” positive cases and minus 0.6 ⫹/- 3.8 ml for “spot sign” negative cases (p⫽0.0003). Conclusions: This study demonstrates the feasibility of performing acute ICH CTA at multiple centres with short noncontrast CT to CTA time delay. The data validates the “spot sign” as a strong predictor of ICH, IVH and total hematoma expansion with very high negative predictive value. “Spot sign” negative patients appear to be at very low risk for significant hematoma expansion. The study will continue to recruit cases for further characterization. However a clinical trial selecting ICH patients for hemostatic therapy using CTA “spot sign” appears warranted. 4 Polymorphisms in the Aquaporin 4 and Thrombin protease-activated receptors gene are related to Edema Volume In Patients With Acute Intracerebral Hemorrhage. Yolanda Silva, Sebastian Remollo, Judith Mallolas, Hosp Dr Josep of Girona, Girona, Spain; Natalia Pérez de la Ossa, Hosp Germans Trias i Pujol, Badalona, Spain; Mar Castellanos, Verónica Cruz, Hosp Dr Josep of Girona, Girona, Spain; Florentino Nombela, Hosp de la Princesa, Madrid, Spain; José Castillo, Hosp Clı́nico Universitario, Santiago de Compostela, Spain; Joaquı́n Serena; Hosp Dr Josep of Girona, Girona, Spain Background and purpose: The expression of aquaporin 4 (APQ4), a water channel protein, has been related to blood brain barrier (BBB) differentiation and brain edema after experimental Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 529 cerebral ischemia. On the other hand, thrombin could play a role in edema formation by affecting the permeability of the BBB in experimental intracerebral hemorrhage. Thrombin signalling is mediated in part by protease-activated receptors (PAR). We investigated whether APQ4 and PAR-1 gene polymorphisms were associated with edema volume in patients with an ICH. Methods: Genomic DNA was isolated from peripheral blood samples of 44 patients with an acute primary supratentorial intracerebral hemorrhage. Polymorphism screening of the AQP4 and PAR-1 gene was performed by polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP) and sequencing analysis. A cranial CT was performed within the first 12 hours from symptoms onset and at 72⫾12 hours. The volume of the perihematoma edema was determined by a planimetric method. Results: Two polymorphisms, one in the AQP4 gene and another in the PAR-1 gene were associated with the volume of perihematomal edema at 72 hours. The first was identified in the 5’UTR of the AQP4 gene which corresponded to an G-to-A transition at -39 bp from the transcription start site (X2⫽6.7, p⫽0.03). The second polymorphism was found in the 5’ regulatory region of the PAR-1 gene which corresponded to a 13-bp insertion repeating the preceding -506 sequence (X2⫽7.7, p⫽0.02). Conclusions: The -39 G/A polymorphism in the 5’UTR of the AQP4 gene and the -506 I/D in the PAR-1 gene are associated with the volume of edema at 72 hours in patients with acute ICH. These polymorphisms might be indicative of a higher genetic susceptibility to BBB disruption. 7 5 Antiplatelet Medications and Hemorrhage Growth After Intracerebral Hemorrhage. In Vivo 11C PIB Binding is Increased in Patients with Cerebral Amyloid Angiopathy Haemorrhage. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Lauren H Sansing, Steven R Messe, Brett L Cucchiara, Univ of Pennsylvania, Philadelphia, PA; Stanley N Cohen, Univ of Nevada, Las Vegas, NV; Patrick D Lyden, Univ of CaliforniaSan Diego, San Diego, CA; Scott E Kasner, Univ of Pennsylvania, Philadelphia, PA; for the CHANT Investigators John V Ly, Geoffrey A Donnan, National Stroke Rsch Institute, Heidelberg Heights, Australia; Victor L Villemagne, Dept of Nuclear Medicine, Cntr for PET, Austin Health, Heidelberg, Australia, Heidelberg, Australia; Jorge A Zavala, Henry Ma, National Stroke Rsch Institute, Heidelberg Heights, Australia; Graeme O’Keefe, Uwe Ackerman, Henri Tochon-Danguy, Christopher C Rowe; Dept of Nuclear Medicine, Cntr for PET, Austin Health, Heidelberg, Australia Introduction: There has been conflicting evidence about the effect of antiplatelet medication use on hemorrhage growth and outcome after spontaneous intracerebral hemorrhage (ICH). Methods: The CHANT trial was a randomized, placebo-controlled trial of NXY-059 after spontaneous ICH. We analyzed patients in the placebo arm, and correlated antiplatelet medication use at the time of ICH with initial ICH volumes, ICH growth in the first 72 hours, and modified Rankin Score at 90 days. Results: There were 303 patients included in this analysis including 76 (25%) who were taking antiplatelet medications at ICH onset. Of these, 62 patients were taking aspirin alone, 5 clopidogrel alone, 3 aspirin and clopidogrel, 2 aspirin and dipyridamole, 2 triflusal, 1 dipyridamole alone, and 1 ibustrin. Older age and male sex were significantly associated with antiplatelet medication use. Six patients taking antiplatelet medications were also taking warfarin. None of the patients received platelet transfusions. Use of antiplatelet medications at ICH onset had no effect on the volume of ICH at presentation or on growth of ICH at 72 hours. There was also no effect on initial edema volume or edema growth. In multivariate analysis, controlling for initial hemorrhage volume, initial Glasgow Coma Scale score, presence of intraventricular hemorrhage, age, infratentorial location and warfarin use, there was also no significant association of use of antiplatelet medications with either hemorrhage growth or outcome at 90 days. Conclusions: Use of antiplatelet medications at ICH onset is not associated with the size of the initial ICH or expansion of ICH in the first 72 hours. There was also no association between use of antiplatelet medications and outcome at 90 days. These findings suggest that attempts to reverse antiplatelet medications after ICH may not be warranted. Abstract: Background: Cerebral amyloid angiopathy (CAA) is an important cause of intracerebral haemorrhage (ICH). However, in-vivo diagnosis is difficult and usually inferred from clinical and imaging criteria. N-methyl-[11C]2-(4’-methylaminophenyl)-6hydroxybenzothiazole ([11C]PIB) is a ligand which binds to beta-amyloid both in plaques and vessel walls and may be imaged with PET. We tested the hypothesis that patients with a clinical diagnosis of CAA related ICH (CAAH) will have increased PIB PET uptake. Methodology: Patients with CAAH based on the Boston criteria were studied using PIB PET and compared to age matched controls. Distribution Volume Ratio (DVR) maps were created using Logan graphical analysis and the cerebellar cortex as a reference. Differences between means were assessed by Kruskal Wallis test. Results: Eleven patients with CAAH of mean age 73.5 yrs (58 –93) were studied at a mean of 71 days (6 –270) post-ICH and compared to 21 normal controls of mean age 71.8 yrs (59 – 83). The mean whole Brain PIB uptake among patients was higher compared to normal controls with mean DVR of 1.56⫾0.17 SD and 1.37⫾0.09 SD respectively (p⫽0.002). PIB binding was particularly high in the Neocortical regions with a mean DVR of 1.67⫾0.28 SD in patients compared to 1.34⫾0.15 SD in controls (p⫽0.003). One patient had neocortical DVR less than the 75% percentile of controls. Conclusion: [11C]PIB uptake is higher in patients with CAAH compared to normal aged matched controls. [11C]PIB PET may assist the in-vivo diagnosis of CAAH. Equally important is the potential for PIB PET to serve as a surrogate marker for future therapeutic studies. Initial ICH volume (mean), mL Initial ICH volume (median), mL ICH growth at 72 hours (mean), mL ICH growth at 72 hours (median), mL Modified Rankin Scale ⱕ3 at 90 days Antiplatelet medication No antiplatelet medication p value 22.5⫾24.3 13.3 8.0⫾26.2 1.0 45% 23.5⫾22.3 15.8 7.7⫾21.5 1.0 47% 0.74 0.53 0.93 0.38 0.72 6 Withdrawn 8 Long-Term Prognosis After Transient Ischemic Attack (TIA). Anthony S Kim, UCSF, San Francisco, CA; Stephen Sidney, Div of Rsch Kaiser Permanente Northern California, Oakland, CA; Allan L Bernstein, Kaiser Santa Rosa Med Cntr, Santa Rosa, CA; S. Claiborne Johnston; UCSF, San Francisco, CA OBJECTIVE. To evaluate the long-term mortality of patients after TIA BACKGROUND. Risk factors for short-term stroke and mortality after TIA have been previously defined but the long-term mortality after TIA has received less attention. DESIGN/METHODS. Patients diagnosed with TIA in the emergency rooms of a California managed care plan from March 1997 to May 1998 were enrolled and followed until November 1999. Patients were censored at last known followup date or death from nonvascular cause for analyses of mortality from vascular causes. Clinical data were abstracted from databases and medical records and mortality was ascertained from clinical databases and public records. Kaplan-Meier life table analysis was used to generate mortality estimates. RESULTS. Mean age was 70.1 years. Patients were followed for an average of 503 days (median 539 days, maximum 977 days, n⫽1,706) for a total of 2,349 person-years of followup. A total of 217 patients died during the followup period (12.7%) at an average of 277 days (median 210 days, max 958 days) after enrollment for TIA. Of the patients that died during the study, 68 (31.3%) died within 90 days of enrollment, a total of 99 (45.6%) died within 180 days of enrollment, and 144 (66.4%) died within one year of enrollment. For all patients the cause of death was listed as stroke in 50 (23.0%) and cardiovascular disease in 32 patients (14.7%), cancer in 20 patients (9.2%), infection in 20 patients (9.2%), and other in 22 (10.1%). Cause of death was unknown in 74 (34.1%). The overall rate of all-cause mortality was estimated at 9.1% at one year (95% confidence interval ⫽ 7.8 –10.7%) and 16.3% at two years (14.1–18.8%). The rate of mortality for cardio or cerebrovascular disease was 3.9% (3.0 –5.0%) at one year and 6.5% at two years (5.1– 8.3%) and the rate of mortality from stroke alone was 1.5% at one year (1.0 –2.2%) and 3.3% at two years (2.1– 4.9%). (See figure for cumulative mortality risk curves.) CONCLUSIONS/ RELEVANCE. Mortality from stroke figures more prominently than cardiovascular risk in the Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 530 Stroke Vol 39, No 2 February 2008 long-term cumulative mortality after TIA and presents a target for aggressive secondary prevention measures. STUDY SUPPORTED BY NIH/NINDS had a favorable outcome after 90 days. The t-PA treated patients weighing ⬎100kg were younger (57⫾10 vs 69⫾10; p⫽0.0001) and had lower rate of atrial fibrillation (0% vs 20%;p⫽0.018), compared to their slimmer counterparts. On univariate analysis, older age, higher baseline NIHSSS, the presence of hypodensity on initial scan, and history of hypertension, diabetes, or heart failure were statistically associated with worse outcome 90 days after treatment with t-PA. On logistic regression, body weight ⬎100kg emerged as one of 3 significant predictors of unfavorable outcome after t-PA (adjusted OR 5.76; p⫽0.017). Other predictors were older age and higher baseline NIHSSS. Body weight ⬎100kg was also associated with neurological deterioration (ⱖ 4 points on NIHSSS) 7–10 days after t-PA (OR⫽3.4; p⫽0.07). This impact of body weight on outcome was not seen among the placebo-treated patients. Conclusions: In the NINDS cohort, stroke patients weighting ⬎ 100kg seem to derive less benefit from IV t-PA than their slimmer counterparts. The link between obesity and higher levels of PAI-1, and restricting the maximal dose of IV t-PA in these patients might account for our findings. The exact mechanism(s) underlying this observation and its potential therapeutic implications require further investigations. 11 Chronic Kidney Disease is a Strong Independent Predictor of Poor Outcome in Patients With Acute Stroke. 9 Low-Income, Low-hospital Volume And High Stroke Mortality: The Puzzling Route Of Inequity. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Gustavo Saposnik, Univ of Toronto, Toronto, Canada; Thomas Jeerakathil, Univ of Alberta, Edmonton, Canada; Daniel Selchen, Univ of Toronto, Missassauga, Canada; Vladimir Hachinski, Univ of Western Ontario, London, Canada; Moira K Kapral, Univ of Toronto, Toronto, Canada; on behalf of the Stroke Outcome Rsch Canada (SORCan) Working Group Background: Socioeconomic status has been associated with inequality in delivery of services, increased incidence of stroke and poor outcomes. Most prior studies have explored individual patient factors rather than health system variables as explanations for the association between socioeconomic status, stroke care and outcome. Objective To identify whether low-income individuals were more likely to be admitted to facilities with low-stroke volume, and whether this contributed to differences in outcomes. Methods: We identified all patients with ischemic stroke admitted to acute care hospitals in Canada between April 2003, and March 2004 through the Hospital Morbidity and Mortality Database (HMDB). The HMDB is a National database that contains patient-level socio-demographic, diagnostic, procedural and administrative information across Canada.There are 680 acute care facilities across the country reporting to the HMDB, which covers 99.8% of all acute care hospitals. Ischemic stroke was identified through patient’s principal diagnosis recorded using the International Classification of Diseases. We evaluated the association between socioeconomic status and hospital admission based on facility volume. Multivariable analysis was performed using generalized estimating equations to account for clustering observations at institutions. Statistical analyses were performed using SAS and STATA 8.0 . Results: Overall 25,228 patients with ischemic stroke were included in the analysis. Lower socioeconomic status was associated with higher admission to non-teaching, low-volume hospitals, more medical complications, and poor stroke outcomes. Mortality at 7 days was 8.4%, 8.2%, 7.7%, 7.1, and 6.6% (p⫽0.002) for income quintiles 1 (lowest), 2, 3, 4, and 5 (highest) respectively. Low-income patients admitted to low-volume hospitals was associated with a higher risk-adjusted stroke mortality when compared to high-income patients admitted to high-volume hospitals (7.8% versus 6.2% at 7 days, p⬍001; 15.2% versus 12.5% discharge mortality, p⬍0.001). In the multivariable analysis, low-income patients admitted to low-volume hospitals had a higher mortality after adjusting for covariates (For 7-day mortality: OR 1.26, 95%CI 1.07–1.49; and for mortality at discharge OR 1.17, 95%CI 1.11–1.45). Conclusions: Low-income patients presenting with an acute stroke are more likely to be seen in low-volume facilities. This subgroup of patients had higher risk-adjusted mortality than other groups. Understanding the pathways through which socioeconomic status affects health care may lead to strategies for quality improvement. 10 Does Stroke Patient’s Weight Influence The Response To Intravenous t-PA? Min Lou, The 2nd Affiliated Hosp of Zhejiang Univ, Hangzhou, China; Magdy H Selim; Beth Israel Deaconess Med Cntr, Boston, MA Background and Purpose: The current guidelines for intravenous thrombolysis with t-PA for ischemic stroke recommend a maximum dose of 90 mg, irrespective of patient’s weight. Elevated levels of plasminogen-activator inhibitor-1 (PAI-1), the main inhibitor of plasminogen activation, have been linked to obesity. Therefore, we hypothesized that stroke patients weighting ⬎100kg may require higher doses of t-PA and thus, are less likely to benefit from t-PA compared to patients who weigh ⱕ100Kg and receive weight-based dose of t-PA. Methods: We queried the NINDS t-PA study database, and divided each cohort (t-PA and placebo) into 2 groups (favorable vs. unfovarobale outcome) based on functional outcome at day 90. We defined favorable outcome as Barthel Index (BI) ⱖ95 or NIHSSS 0 –1 or modified Rankin scale (mRS) 0 –1 at day 90. We used univariate analyses to determine inter-group differences in 25 demographic, clinical, laboratory, and radiological variables. Variables with pⱕ0.2 on univariate testing were tested in a multivariate logistic regression model to analyze the effects of weight (⬎100kg vs. ⱕ100Kg) in each cohort on functional outcomes. Results: Twenty patients (6%) of the t-PA and 32 patients (10%) of the placebo cohorts had an actual body weight ⬎100 kg; 168 t-PA treated patients (54%) vs. 127 placebo-treated patients (41%) Gilad Yahalom, Roseline Schwartz, Yvonne Schwammenthal, Oleg Merzeliak, Maya Toashi, David Orion, David Tanne; Chaim Sheba Med Ctr, Tel-Hashomer, Israel Background and purpose: Chronic kidney disease (CKD) is increasingly recognized as an independent risk factor for cardiovascular disease and stroke. Our aim was to examine the prevalence of CKD and the association between CKD and its severity with stroke outcome in a large prospective cohort of unselected patients with acute stroke. Methods: We examined the association between baseline CKD and one year outcomes in 822 consecutive patients with acute stroke (ischemic or hemorrhagic). Glomerular filtration rate (GFR) was estimated by 2 methods: the Modification of Diet in Renal Disease (MDRD) equation and the Mayo Clinic qadratic equation. An eGFR rate ⱕ60 ml/min/1.73m2 defined CKD. After excluding patients with kidney failure, ORs adjusting for age, gender, stroke type and severity, anemia, hypertension, diabetes, cardiac disease, past stroke, malignancy, and prior disability were estimated to study the associations between eGFR 45– 60 and 15– 44 as compared to ⬎60 ml/min/1.73m2 with outcome. Results: CKD was present in 38% (n⫽311) of patients based on the MDRD equation and 21% (n⫽170) based on the Mayo Clinic equation. The adjusted ORs for 1-year mortality based on the MDRD equation were 0.7 (95%CI, 0.4 –1.2) associated with eGFR 45– 60 and 3.0 (1.6 –5.7) associated with eGFR 15– 44, while those based on the Mayo Clinic equation were 2.3 (1.2– 4.8) and 3.5 (1.7–7.4), respectively. The adjusted ORs for nursing home dwelling or death were 0.7 (0.4 –1.3) and 2.7 (1.4 –5.5) by the MDRD equation and 2.4 (1.1– 4.9) and 3.3 (1.4 –7.9) by the Mayo Clinic equation, and for Barthel Index ⬍75, 0.9 (0.5–1.6) and 2.7 (1.2– 6.0) by the MDRD equation and 1.9 (0.9 – 4.3) and 4.2 (1.6 –11.3) by the Mayo Clinic equation, respectively. Conclusions: CKD is a strong independent predictor of mortality and poor outcome in patients with acute stroke. The estimation of the prevalence of CKD and the GFR cut-off associated with poor outcome depend on the equation used to estimate GFR. 12 The Impact of Case Managed Care in Patients with Acute Stroke and Transient Ischemic Attack. Annette C Robertson, Jiming Fang, Institute for Clinical Evaluative Sciences, Toronto, Canada; M P Lindsay, Canadian Stroke Network, Ottawa, Canada; Moira K Kapral, Frank L Silver; Univ of Toronto, Toronto, Canada Background: Nurse case managers coordinate and facilitate access to timely and appropriate health care services. Little is known about the impact of case managed care on patients hospitalized during the acute phase of their stroke. Methods: The Registry of the Canadian Stroke Network (RCSN) collects data on consecutive patients presenting to designated stroke centres in Ontario and Nova Scotia within 2 weeks of an acute stroke or TIA. We included patients from RCSN Phase 3 who were admitted to 9 Ontario regional stroke centres between October 2005 and March 2007. We excluded patients with in-hospital strokes and subarachnoid hemorrhages from the cohort. We compared the care delivered and the outcomes between patients managed with and without a nurse case manager. Results: Over this period of 18 months, a total of 4,012 patients were admitted to hospital with a final diagnosis of ischemic stroke, TIA, or intracerebral hemorrhage. Nurse case managers were involved in the care of 1787 patients (45%). Gender, age, and initial stroke severity (based on the Canadian Neurological Score) were not significantly different between the groups. Co-morbidity as measured by the Charlson index was lower in the case manager group (31.1% vs. 34.6%, p⫽0.021). Allied health services provided in the acute phase including occupational therapy, physiotherapy, speech language pathology, and nutritionist were utilized more frequently for the case managed group (p⬍0.0001 for each). The length of hospital stays (LOS) were longer (median 9 vs. 7, p⬍0.0001). Preventable in-hospital complications including deep vein thrombosis, decubitus ulcer, pneumonia, fall with injury, and pulmonary embolism were not reduced. Only urinary tract infections were reduced (12.9% vs. 15.2%, p⫽0.0328). In-hospital deaths were reduced in the case managed group however, after adjusting for age, gender, stroke severity and co morbidity this reduction became non-significant (4.2%; 95%CI 3.3–5.3 vs. 5.1%; CI 95% 4.3– 6.2). Functional recovery assessed by the Modified Rankin scale (mRS) showed no significant differences between the two groups for mRS ⬎1 or ⬎2. Conclusion: The addition of a nurse case manager increased access to allied health care but also slightly increased the LOS. Patient outcomes were not significantly changed by the presence of a case Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations manager. However, the impact of case managers may be diminished by our cohort that includes only patients managed in designated stroke centres. 13 Long-term Use of Secondary Stroke Prevention Therapies among US Veterans. Deborah A Levine, Monika M Safford, Jeroan J Allison, Thomas K Houston, Univ Alabama Birmingham, Birmingham, AL; Dean M Reker, Kansas VA Med Cntr, Kansas City, MO; Peter H King, Birmingham VA Med Cntr, Birmingham, AL; Linda S Williams, Roudebush VA Med Cntr, Indianapolis, IN; Mark S Litaker, Catarina I Kiefe; Univ Alabama Birmingham, Birmingham, AL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Long-term use of secondary prevention therapies among stroke survivors who use the Veterans Administration (VA) health system has not been examined. We assessed use of secondary prevention medications in a recent national sample of US veterans hospitalized with acute ischemic stroke (IS). Methods: We identified all consecutive patients aged 40 – 85 years discharged from all US VA Medical Centers with a primary diagnosis of IS from 10/1/01 through 9/30/03 by ICD-9 codes (434.xx and 436.xx) using VA data. Patients with atrial fibrillation, on warfarin, or without an outpatient primary care or neurology clinic visit ⬍365 days of discharge were excluded. We measured filled prescriptions of anti-platelets, thiazide diuretics, ACE inhibitors or angiotensin receptor blockers (ACE/ARBs), and statins, from 90 days before to 365 days after index IS hospitalization. Results: The study cohort (n⫽5,850; mean age 66 ⫾ 10.7 years) was mostly male (98%), and racially diverse (66% white, 23% black). There was a 76% prevalence of hypertension, 38% of diabetes, 42% of hyperlipidemia, 33% of coronary heart disease, and 17% of prior stroke. Contraindication rates were 8% for ACE/ARBs, 3% for aspirin, 3% for other anti-platelets, 6% for statins, and 0.1% for thiazides. Utilization of all drug classes increased significantly during the 90 days following index IS, and, except for the anti-platelets, were maintained moderately up to 365 days (Table 1). Because of underestimation of over-the-counter aspirin use, we analyzed the cumulative use of the other 3 drug classes (Table 2). While patients used more drug classes following the index IS, one third of IS survivors were using none of three drug classes at 365 days post-hospital discharge. Conclusions: Use of secondary stroke preventive medications among veterans is likely sub-optimal. Quality improvement programs to increase prescription and adherence of these therapies are needed. TABLE 1: USE OF SECONDARY STROKE PREVENTIVE THERAPIES, BY DRUG CLASS, AMONG US VETERANS DISCHARGED FROM A VA MEDICAL CENTER WITH ACUTE ISCHEMIC STROKE, OCTOBER 1, 2001 THROUGH SEPTEMBER 30, 2003 Filled Prescription Rate (%) during Specified Interval Drug Class Aspirin Other anti-platelet Total anti-platelet Thiazide diuretic ACE/ARB Statin 90 days pre-stroke discharge 0 –90 days post-stroke discharge 91–180 days post-stroke discharge 181–270 days post- stroke discharge 271–365 days post-stroke discharge 22.2 11.4 28.8 15.3 36.4 27.2 56.9 57.7 83.6 22.3 54.0 52.7 33.6 46.5 63.2 18.8 47.0 46.1 30.1 43.1 58.1 18.8 44.3 43.9 28.3 42.7 57.2 20.2 44.0 45.0 TABLE 2: USE OF SECONDARY STROKE PREVENTIVE THERAPIES, BY NUMBER OF DRUG CLASSES, AMONG US VETERANS DISCHARGED FROM A VA MEDICAL CENTER WITH ACUTE ISCHEMIC STROKE, OCTOBER 1, 2001 THROUGH SEPTEMBER 30, 2003 Number of Drug Classes (3 maximum) 3 2 1 0 90 days pre-stroke discharge 3.9 18.6 30.0 47.5 531 of ischemic stroke and an NIH Stroke Scale score ⬎1. After consent and randomization, in-hospital baseline measures were obtained. For both the intervention (n⫽190) and control (n⫽190) groups PCPs received written patient summaries of baseline data. For the intervention an Advanced Practice Nurse/Care Manager (APN-CM) performed an in-home assessment within 1 week of discharge. The results of the home assessment were reviewed by an interdisciplinary post-stroke consultation team (PSC-Team) who developed patient care plans specific to each problem identified by the APN-CM. A copy of the care plans, evidence-based guidelines, pertinent references, and “academic detailing” were given to the patient’s PCP. The APN-CM worked with the PCP to implement the recommendations and provide ongoing monitoring over the next 6 months via periodic phone calls and PRN home visits. Outcomes: Multiple outcomes across 5 domains were used to capture both functional and management effects. The 5 domains included 1) Neuromotor Function, 2) Institutional utilization and death, 3) Quality of Life, 4) Medical Management for common post-stroke complications and recurrent stroke, and 5) Self-management. Results: The two groups were highly similar at baseline with almost all confidence intervals including zero. The effect of the treatment was near zero standard deviations for all but domain 5. The global test for the function domains proved non-significant at the alpha⫽0.04 level (p⫽0.53). The global test of the management domains were significant at alpha⫽0.01 (p⫽0.002). The closed tests for the medical management domain proved non-significant (p⫽0.62), while the one for self-management proved significant (p⫽0.0003). Discussion The results showed no significant effect of the intervention on the primary outcome at 6 months. Potential reasons include the effectiveness of the stroke unit in post-discharge planning and the lack of baseline deficits in the study population. 15 The Combined Approach To Lysis Utilizing Eptifibatide And rt-PA In Acute Ischemic Stroke (the CLEAR Stroke Trial): Final Results From Tier I and II. Arthur M Pancioli, Univ of Cincinnati, Cincinnati, OH; for the CLEAR Trial Investigators The combined approach to lysis utilizing eptifibatide and rt-PA (CLEAR) stroke trial is a multi-center, double-blind, randomized, dose-escalation and safety study. This trial was a part of the NINDS SPOTRIAS program. Methods - The CLEAR Trial evaluated the risks and benefits of eptifibatide, a GP llb/IIIa antagonist, combined with low-dose IV rt-PA in ischemic stroke patients treated within 3 hours of onset (age 18 – 80 years and baseline NIHSS⬎5). Patients were randomized 3:1 to IV eptifibatide plus low-dose rt-PA, or standard dose rt-PA. The primary safety endpoint was the incidence of symptomatic ICH within 36 hours. The CLEAR trial studied 2 dose tiers of combined therapy compared to standard dose rt-PA. In dose tier 1 the rt-PA dose was 0.3 mg/kg. In dose tier 2 the rt-PA dose was 0.45 mg/kg. In both tiers the eptifibatide dose was a 75 mcg/kg bolus and a 0.75 mcg/kg/hr infusion for 2 hours. The control for both dose tiers was standard 0.9 mg/kg rt-PA. Results - The study enrolled a total of 94 subjects; 40 in dose tier 1 and 54 in dose tier 2. The combination cohort had a total of 69 patients with a median age of 71, and a median baseline NIHSS of 14. The standard dose rt-PA group had 25 patients with a median age of 61 and a median baseline NIHSS of 10 (p⫽0.014 for NIHSS). There was 1 (1.4%) symptomatic ICH in the combination group and 2 (8.0%) in the standard treatment arm (p⫽0.17). There was a non-significant trend toward increased efficacy with the standard dose rt-PA treatment arm. The adjusted odds ratio and associated 95% confidence intervals for achieving a good outcome in the experimental group as compared to the control group: 90-day mRS 0.59 (0.21, 1.67), 90-day Barthel 0.51 (0.15, 1.71) 90-day GOS 1.08 (0.36, 3.18). (Adjusted for age, baseline NIHSS and baseline Rankin) Conclusion - The combination of eptifibatide and reduced dose rt-PA is safe enough for consideration of further dose ranging trials in acute ischemic stroke. Filled Prescription Rate (%) during Specified Interval 0 –90 days 91–180 days 181–270 days 271–365 days post-stroke post-stroke post- stroke post-stroke discharge discharge discharge discharge 8.2 33.4 37.5 20.9 6.9 28.2 34.8 30.1 6.4 27.4 32.9 33.3 16 Does Study Enrollment Delay Treatment with Intravenous Thrombolytics for Acute Ischemic Stroke? 7.8 27.6 30.7 33.9 *Three drug classes are thiazide diuretics, ACE/ARBs, and statins. # 14 Randomized Controlled Trial of a Post-stroke Post-discharge Care Management Intervention. Kyle R Allen, Susan Hazelett, Summa Health System, Akron, OH; Dave Jarjoura, Ohio State Univ, Columbus, OH; Kathy Wright, Janice Weinhardt; Summa Health System, Akron, OH Background: Stroke is the leading cause of disability, the third leading cause of death, and one of the most expensive medical problems in the United States. Acute care institutions and rehabilitation programs that utilize a comprehensive interdisciplinary team approach to patient care demonstrate improved patient outcomes. It is unclear whether comprehensive postdischarge care can further optimize post-stroke outcomes. Purpose: This randomized controlled trial tested the effectiveness of a comprehensive interdisciplinary post-discharge stroke care management intervention in improving the overall well-being of stroke survivors 6 months post-discharge. Methods: Patients were recruited from the acute stroke unit at our 963 bed community teaching hospital in Northeastern Ohio. Inclusion criteria included a diagnosis Sheryl Martin Schild, UT Houston Health Science Cntr, Houston, TX; Karen C Albright, UCSD, San Diego, CA; Hen Hallevi, Andrew D Barreto, Nicole R Gonzales, UT Houston Health Science Cntr, Houston, TX; Aslam M Khaja, Univ of Illinois at Chicago, Chicago, IL; Kachi Illoh, Elizabeth A Noser, James C Grotta, Sean I Savitz; UT Houston Health Science Cntr, Houston, TX Background: Enrollment in acute stroke trials at a stroke center with multiple study protocols may delay the initiation of IV thrombolytics in patients who present within 3 hrs of symptom onset. Some trials require enrollment and randomization before or during thrombolysis. Rapid treatment decisions are critical in the acute setting. Delays in reperfusion not only limit tissue salvage but also may impair the detection of potential clinical improvements from study treatments. Methods: We prospectively studied all patients presenting to our emergency department with acute ischemic stroke over the past 3.5 years who qualified for thrombolysis within 3 hours of onset. We collected demographics, baseline NIHSS scores, CT findings, and door-to-needle times and compared patients treated with IV thrombolytics in a clinical trial with patients who received standard of care IV t-PA. Results: Out of 290 patients treated with IV thrombolytics, 46 were enrolled in trials after starting t-PA (adjunctive therapies), 19 were enrolled in trials prior to starting thrombolytics (comparing different thrombolytics), and 225 were treated with standard IV t-PA. There was no significant difference in age, gender, NIHSS score, admission glucose, changes on CT, onset to arrival time, or door-to-needle time between Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 532 Stroke Vol 39, No 2 February 2008 patients enrolled in clinical studies and those who received standard treatment. However, among study patients, pre-lytic randomization led to a significantly longer door-to-needle time by 13 minutes (p⫽.028). Discussion: Patients participating in our trials are representative of our overall population of acute stroke patients. We found that trials requiring pre-lytic randomization can lead to a short delay in the initiation of treatment. Future studies are needed to determine if such a short delay is clinically significant and can be shortened by improved enrollment strategies. Variable Age, median (range) Gender (% male) Race (%) African-American Hispanic White Other Admission Glucose, median (range) Early Ischemic changes on initial CT % Baseline NIHSS Score, median (range) Onset to needle, median (range) Door to needle, median (range) Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Variable Onset to needle, median (range) Door to needle, median (range) Not enrolled 135(64–180) n⫽225 62(20–131) n⫽222 Not enrolled Enrolled p value 63 (19–91) n⫽225 56.4 (127/225) 38.7 (87/225) 14.2 (32/225) 44.9 (101/225) 2.2 (5/225) 122 (62–536) n⫽225 15.6 (35/225) 65 (38–91) n⫽65 50.8 (33/65) 32.3 (21/65) 13.8 (9/65) 49.2 (32/65) 4.5 (3/65) 135 (78–414) n⫽65 16.9 (11/65) .285 12 (0–39) n⫽225 135 (64–180) n⫽225 62 (20–131) n⫽222 13 (3–26) n⫽65 127 (64–180) n⫽65 61 (23–135) n⫽63 .696 .418 .168 .170 .790 .636 .725 Studies with post-lytic enrollment 46/65 (70.8%) Studies with pre-lytic enrollment 19/65 (29.2%) 126(64–180) n⫽45 59(23–135) n⫽45 128(92–178) n⫽19 72(52–111) n⫽18 18 Feasibility of Caffeinol and Hypothermia for Acute Ischemic Stroke. Sheryl Martin-Schild, Andrew D Barreto, Hen Hallevi, UT Houston Health Science Cntr, Houston, TX; Aslam M Khaja, Univ of Illinois at Chicago, Chicago, IL; Hashem Shaltoni, Nicole R Gonzales, Kachi Illoh, Elizabeth A Noser, Jarek Aronowski, Sean I Savitz, James C Grotta; UT Houston Health Science Cntr, Houston, TX Background: Caffeinol and hypothermia have each been shown to be neuroprotective and the combination robustly reduces infarct volume and deficits in our animal stroke model. Prior studies also support the safety of caffeinol infusion in acute stroke patients. We tested whether combining these two approaches is safe and feasible. Methods: In a non-randomized trial, 20 patients with acute ischemic stroke were enrolled to receive caffeinol and hypothermia. Caffeinol IV (caffeine 8 –9 mg/kg; ethanol 0.4g/kg) was administered within 4 hrs while hypothermia was started within 5 hrs after symptom onset and continued for 24 hrs (target temp 33–350C) followed by 12 hrs of rewarming. The protocol included meperidine and buspirone to treat shivering. IV t-PA was given to patients who met eligibility criteria. Results: Fourteen of 20 patients received t-PA followed by caffeinol and hypothermia. Three of the 20 had contraindications to t-PA and the other 3 received t-PA either with hypothermia or caffeinol. Cooling was attempted in 18 patients via endovascular (n⫽8) or surface (n⫽10) approaches; in the other 2 patients, there was machine failure or complete resolution of deficits before instituting cooling. Of those 18 patients enrolled in the hypothermia protocol, 5 did not reach the target temperature. Two reached the target temperature within 1 hr, a total of 4 reached the target temperature within 2 hrs, and 8 within 3hrs of induction. Of the 13 patients that reached the target temperature during active cooling, the average time to target from symptom onset was 9hrs, 43min. The last 5 hypothermia patients received iced saline and surface cooling and their temperatures reached the target on average within 2hrs 30min. Their average time to target from symptom onset was 6hrs 21min. One symptomatic hemorrhage occurred in a patient who received t-PA and died. One patient died of malignant edema and a third patient died of unrelated medical complications. No adverse events were attributed to caffeinol. One patient had reduced respiratory drive due to meperidine, requiring BiPAP. Discussion: Our study supports the feasibility of combining caffeinol with hypothermia in acute stroke patients. A prospective multi-center placebo-controlled phase 2 randomized study has been designed to test the efficacy of caffeinol, hypothermia or both in patients presenting within 3 hrs of stroke onset. 19 17 Lack of Adherence to Guidelines for Pre-TPA Blood Pressure Levels Is Associated with Higher Risk of Symptomatic Intracerebral Hemorrhage. Georgios Tsivgoulis, Stroke Program, Barrow Neurological Institute, Phoenix AZ and UAB Comprehensive Stroke Cntr, Birmingham, AL; James L Frey, Stroke Program, Barrow Neurological Institute, Phoenix, AZ., Phoenix, AZ; Vijay K Sharma, Div of Neurology, Dept of Medicine, National Univ Hosp, Singapore, Singapore; Annabelle Y Lao, Steven L Hoover, Wei Liu, Murray Flaster, Stroke Program, Barrow Neurological Institute, Phoenix, AZ., Phoenix, AZ; Anne W Alexandrov, Comprehensive Stroke Cntr, Univ of Alabama at Birmingham Hosp, Birmingham, AL; Marc Malkoff, Stroke Program, Barrow Neurological Institute, Phoenix, AZ., Phoenix, AZ; Andrei V Alexandrov; Comprehensive Stroke Cntr, Univ of Alabama at Birmingham Hosp, Birmingham, AL Background&Purpose: Based on small pilot studies, exclusionary blood pressure parameters for TPA treatment in the NINDS TPA trial were set at SBP ⬎185mmHg and DBP⬎110mmHg. Current guidelines endorse these thresholds despite little data to substantiate the choice of these specific BP values. We sought to determine if pre-treatment BP protocol violation in acute IS patients receiving iv-TPA are related to the subsequent risk of sICH. Subjects&Methods: We reviewed medical records of consecutive IS admissions treated with intravenous TPA over 10 year period at our tertiary care hospital. The National Institutes of Health Stroke Scale (NIHSS) scores on admission and modified Rankin Scores (mRS) at discharge were documented as standard of care. The closest documented BP values to the time of TPA-bolus (range 0 –10 min) were considered as pre-treatment BP. BP protocol violation was identified as SBP⬎185 or DBP⬎110 mmHg pre-bolus. sICH was defined as brain imaging evidence of ICH with clinical worsening by the NIHSS score increase of ⱖ4 points. Results: Among 510 IS patients treated with iv-TPA (282 men; mean age 65⫾15 yrs), 63 patients (12.4%) had BP protocol violations. Patients with sICH had higher pre-treatment SBP levels (169⫾29mmHg vs. 156⫾24mmHg; p⫽0.006) while pre-treatment DBP levels were similar in those with and without sICH (85⫾21mmHg vs. 82⫾16mmHg; p⫽0.430). Pre-treatment BP protocol violation was more frequent in patients with sICH (26% vs. 12%; p⫽0.019). Patients with BP protocol violation had an absolute sICH risk of 12.7% compared to 5.1% without BP violation. The number-neededto-harm for one more patient to have sICH was 13. After adjusting for demographic characteristics, stroke risk factors, onset-to-treatment time and baseline stroke severity, pre-treatment BP protocol violations were independently associated with a higher likelihood of sICH (OR: 2.49; 95%CI: 1.04 –5.97; p⫽0.040). Patients with BP violation tended to have lower rates of functional independence (mRS 0 –1) at hospital discharge (9%) compared to patients without BP protocol violation (14%; p⫽0.074). Conclusions: These data demonstrate an independent association between BP protocol violation and likelihood of sICH and provide support for current guidelines advising caution in using iv-TPA when pre-treatment BP exceeds the pre-specified threshold. The Metabolic Syndrome is Associated with a Higher Resistance to i.v. Thrombolysis for Acute Ischemic Stroke in Women Than in Men. Juan F Arenillas, Patricio Sandoval, Natalia Pérez de la Ossa, Mónica Millán, Cristina Guerrero, Domingo Escudero, Laura Dorado, Elena López-Cancio, Ana C Ricciardi, Neurosciences Dep. Germans Trias i Pujol Universitary Hosp, Barcelona, Spain; José Castillo, Neurosciences Dep. General Universitary Hosp, Santiago de Compostela, Spain; Antoni Dávalos; Neurosciences Dep. Germans Trias i Pujol Universitary Hosp, Barcelona, Spain Background and purpose: Metabolic syndrome (MetS) is associated with defective endogenous fibrinolysis. Previous studies suggested that MetS might confer a higher resistance to i.v. thrombolysis in acute middle cerebral artery (MCA) ischemic stroke. As the MetS increases the risk of stroke and coronary heart disease in women to a greater extent than in men, we aimed to investigate whether there may be gender differences in the impact of MetS on the response to i.v. thrombolysis for acute MCA ischemic stroke. Methods: We prospectively studied consecutive ischemic stroke patients treated with intravenous t-PA following SITS-MOST criteria, who showed an MCA occlusion on prebolus transcranial Doppler (TCD) examination. TCD monitoring of the occluded MCA was performed, and resistance to thrombolysis was defined as the absence of complete MCA recanalization 24 hours after t-PA infusion, according to Thrombolysis in Brain Ischemia criteria. MetS was diagnosed following the criteria established by the AHA/NHLBI-2005 statement modified for abdominal obesity, which was defined by a body-mass indexⱖ25. Results: A total of 132 patients (82 men, 50 women, mean age 67.6 ⫾ 11) with an acute MCA occlusion were included. Median baseline NIHSS score was 17 (interquartile range 10 –20). MetS was diagnosed in seventy-eight (60%) patients. Resistance to complete clot lysis at 24 hours was observed in 53 (40%) patients. Two multivariate-adjusted logistic regression models identified MetS as associated with a higher resistance to t-PA, independently of other significant baseline variables (OR 10.1, 95% CI [3.7–27.6], p⫽0.0006) and of the individual components of the MetS. A positive interaction was found between MetS and gender. The MetS was associated with a significantly higher odds of resistance to thrombolysis in women (OR 17.5, 95% CI [1.9 –163.1]) than in men (OR 5.1, 95% CI [1.6 –15.6]), (p for interaction ⫽ 0.0001). Among the subcomponents of the MetS, obesity showed the strongest impact on the resistance to clot lysis in women, whereas blood glucose ranked first in men. Conclusion: The effect of MetS on the resistance to i.v. thrombolysis for acute MCA ischemic stroke appears to be more pronounced in women than in men. 20 A Method to Predict Stroke Trial Success Based on Pooled Control Arms. Pitchaiah Mandava, Thomas A Kent; MEDVAMC/BCM, Houston, TX Background: Many promising phase I/II trials of treatment for stroke have not been confirmed. While many factors have been suggested to account for this lack of success, robustness of Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations clinical effect may be important. Because outcome is highly dependent on baseline variables, lack of a control group or small differences in randomization that may occur in early trials are difficult to account for post-hoc. We hypothesized that a pooled control arm adjusted for variables of interest and sample size would provide a more reliable predictor that could be used for decision making prior to proceeding to full Phase III trials. Methods: All randomized controlled trials (RCT) for acute stroke with ⬎ 10 subjects including baseline NIHSS, age and 3 month outcomes were identified. Freeman-Tukey modification of the arc-sine square-root function was applied to the outcomes of control arms to account for the variations in the number of patients. A locally written Matlab© program (PPREDICTS©) performed data storage, transformation, function minimization/optimization and provided the ability to map onto, visualize and test/validate outcomes onto the functions. The novel feature was the generation of multi-dimensional ⫾ 95% prediction interval surfaces based on local and global statistical factors. Here, mRS0 –2 was the outcome, and baseline NIHSS and age were selected for this proof of principle study. Results: A function based on the control arms of 15 RCTS (n⫽5437) was generated (mRS figure; R2⫽0.89, p⬍0.0001; mortality not shown). ABESTT and SAINT-I treatment arm outcomes fell within prediction surface bounds and would have predicted futility while NINDS rt-PA mRS0 –2 outcome (’N’, figure) was above the ⫹95% surface. Enlimomab mRS0 –2 fell below the -95% surface, consistent with reported worsening. Several new therapies were identified as promising while the failure of all others was confirmed by this method. Conclusion: The use of a pooled placebo group function may provide an accurate method to predict success of early trials. In addition, the degree to which an individual study’s placebo group is representative can be checked as well. While we selected mRS0 –2 as the outcome and NIHSS and age as predictor variables in this study, in theory this method could employ any variable of interest provided that sufficient data was available. 533 22 Selective ETA Receptor Antagonism: Perfusion/Diffusion MRI Defines Treatment Efficacy, Mechanism and Translatable Stroke Model for SB 234551. Frank C Barone, Stephen C Lenhard, Robin E Haimbach, Thomas R Schaeffer, Ross G Bentley, Matthew J McVey, Sudeep Chandra, Elaine A Irving, Andrew A Parsons, Jeffrey J Legos; GlaxoSmithKline, King Of Prussia, PA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Mismatches between tissue perfusion (PWI; an index of blood flow) and cellular diffusion (DWI; an index of tissue injury) images allow the identification of “treatable” (i.e., containing salvageable penumbra) clinical stroke patients. The present pre-clinical studies were conducted to: (a.) Determine PWI (perfusion delay) and DWI measurements in experimental stroke models, (b.) Utilize these measurements to characterize selective ETA receptor antagonism (i.e., determine efficacy, time-to-treatment and “treat-ability” in different models), and (c.) Determine if increased blood flow following focal stroke is a mechanism of neuroprotection in a “treatable” model. Methods: Permanent middle cerebral artery occlusion (MCAO) or sham surgeries were produced in Sprague Dawley rats (SD; proximal MCAO; hypothesized to be a slowly evolving brain injury with significant penumbra) and in spontaneously hypertensive rats (SHR; distal MCAO; hypothesized to be a rapidly evolving brain injury with little penumbra). At 0, 75, and/or 180 min post-surgery, SD and SHR received either vehicle or SB 234551 (3, 10, or 30 g/kg/min). The hyper intense area of perfusion delay was measured using Gadolinium bolus contrast and the DWI hyper intense area was also measured, and the degree of DWI-perfusion mismatch was determined. Results: Following SD proximal MCAO, there was a significant mismatch at 60min which was maintained up to 150min. By 24 hours infarct volume was identical to the area of early perfusion deficit. SB 234551 administered within the period of peak mismatch produced a significant dose-related reduction in cortical (penumbral) infarct volume and increased cortical tissue perfusion (p⬍0.05). When SB-234551 was administered beyond the time of mismatch, no effect on infarct volume was observed. Comparatively, following SHR distal MCAO there was no mismatch between perfusion and DWI, suggesting a rapidly occurring brain injury with little penumbra. SB 234551 administered immediately at the time of MCAO did not affect infarct volume. Conclusions: Selective ETA receptor blockade is neuroprotective in SD (i.e. a model similar to “treatable” clinical patients). The protective mechanism appears to be due to enhanced collateral blood flow and salvage of penumbra. Perfusion/diffusion mismatch signatures can allow selection of a translatable stroke model, can define time to treatment protocols, and can clarify vascular mechanism of protection in focal stroke. 23 NADPH Oxidase from Circulating Inflammatory Cells Exacerbates Injury in Experimental Stroke. 21 Influence Of Polymorphisms Of F12 46 C/t, F7 670 A/c And F7 401/-323 On The Outcome And The Risk Of Cerebral Hemorrhage In Patients With Ischemic Stroke Treated With Rt-pa. Joan Martı́-Fàbregas, Dolores Cocho, José Manuel Soria, Hosp de la Santa Creu i Sant Pa, Barcelona, Spain; Joan Montaner, Hosp Vall d’Hebron, Barcelona, Spain; Isabel Tirado, Hosp de la Santa Creu i Sant Pa, Barcelona, Spain; Israel Fernández-Cadenas, Hosp Vall d’Hebron, Barcelona, Spain; Sergi Martı́nez-Ramı́rez, Eugenia Martı́nez-Hernández, Daniel Alcolea, Marta Marquié, Jordi Fontcuberta, Josep-Lluis Martı́-Vilalta; Hosp de la Santa Creu i Sant Pa, Barcelona, Spain Introduction. FXII and FVII play a central role in activation of coagulation. We analyzed whether polymorphisms of these factors influence the results of thrombolysis.Methods. A case series of patients treated with intravenous rt-PA within the first 3 hours after symptom onset. We genotyped the following polymorphisms: F12 46C/T, F7 670A/C and F7 G/T401/-323. Neurological deficit was assessed with the NIHSS score. Symptomatic intracranial hemorrhage (sICH) was diagnosed when a parenchymal hematoma (pH-2) occurred within the first 36 hours after treatment, and was associated with an increase ⬎3 points on the NIHSS score. A favourable outcome was defined as Rankin scale score ⬍2 at 3 months.Results. We studied 419 patients with a mean age of 70⫾10 years, and 49.4% were men. Median NIHSS score at baseline was 16. Mean time to treatment was 142⫾30.7 minutes. A favourable outcome was observed in 37.6% and sICH in 2.5% of patients. We detected the following polymorphisms: F12 C46T (n⫽221, 66.5% C/C, 30.3% C/T, 3.2% T/T); F7 670A/C (n⫽204, 60.3% AA, 33.9% AC, 5.8% CC); F7 G/T401/-323 (n⫽205, 65% G/G, 34.1% G/T, 0.9% TT). Polymorphisms F1246 C/C and F7 670 A/A were statistically associated with an increased frequency of asymptomatic hemorrhagic transformation (24.3% versus 11.9%, and 29.4% versus 13.1%, respectively, p⫽0.05). Discussion. In conclusion, the polymorphisms analyzed significantly increased the risk of asymptomatic hemorrhagic transformation, without influencing the risk of symptomatic hemorrhage or the clinical outcome. Xian N Tang, UCSF & SF VAMC, Stanford Univ, San Francisco, CA; Zhen Zheng, UCSF & SF VAMC, San Francisco, CA; Nick Cairns, Combinix, Inc., Mountain View, CA; Belinda Cairns, Combinix, Inc, Mountain View, CA; Rona G Giffard, Stanford Univ, Stanford, CA; Midori A Yenari; UCSF & SF VAMC, San Francisco, CA NADPH oxidase (Nox2) is a major enzyme system which generates superoxide generation in inflammatory cells, but has recently been found in non inflammatory cells such as endothelial cells and neurons. Here we show that Nox2 contributes to experimental stroke, especially in circulating inflammatory cells. Experimental stroke was produced in mice by 2h transient middle cerebral artery occlusion (tMCAO), followed by 22h reperfusion. Three different paradigms were studied: 1) Mice treated with the Nox2 inhibitor, apocynin (Apo, 2.5 mg/kg IV 30 min prior to reperfusion) or vehicle (Veh). 2) Nox2 deficient (X-CGD, deficient in the gp91 subunit) vs wildtype (Wt) mice were studied. 3) To determine whether Nox2 in circulating cells vs brain resident cells contribute to ischemic injury, bone marrow chimeras were generated by transplanting bone marrow from Wt or X-CGD into X-CGD or Wt, respectively. Brains were assessed for infarct volume, hemorrhage, in situ O.- detection, as well double labeling for O.in neurons (NeuN), endothelial cells (CD31) and microglia (CD11b). Brain tissue within peri-infarct regions was sampled and used for Western blots. Infarct size was reduced whether Nox2 was pharmacologically (by 37% vs vehicle, P⬍0.05) or genetically (by 54% vs Wt, P⬍0.001) inhibited. This was also associated with reduced incidences of cerebral hemorrhage (17% vs. 58%, Apo vs Veh; 14% vs 58%, X-CGD vs Wt). After ischemia, most of the O.- was generated by neurons, some microglia, and rare endothelial cells. O.- was markedly reduced by Apo treatment and in X-CGD mice in all cell types (1% vs. 448%, Apo vs Veh; 11% vs 448%, X-CGD vs Wt). Apo treatment and X-CGD mice showed decreased MMP9 (40% vs. 86%, Apo vs Veh; 50% vs 86%, X-CGD vs Wt) and decreased loss of ZO-1(182% vs. 27%, Apo vs Veh; 48% vs 27%, X-CGD vs Wt). Infarcts in Wt mice who received Nox2 deficient marrow (40.1⫾6.7 mm3) were decreased significantly compared to either the Wt mice who received Wt marrow (100.4⫾9.9 mm3, P⬍0.01) or X-CGD mice who received Wt marrow (74.5⫾6.5 mm3, P⬍0.05). We conclude that either pharmacologic or genetic inhibition of Nox2 leads to reduced brain injury and hemorrhage, and is correlated to decreased O.- and MMP9 expression and prevents the loss of ZO-1. Nox2 originating from the circulating inflammatory cells contributes more to exacerbating experimental stroke than that of the brain resident cells. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 534 Stroke Vol 39, No 2 February 2008 24 Mast Cells Are Early Responders After Hypoxia-ischemia In Immature Rat Brain. Yuxuan Jin, Susan J Vannucci, Ann-Judith Silverman; Columbia Univ Med Cntr, New York, NY Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose: Perinatal hypoxia-ischemia (HI) produces acute and prolonged inflammation of the brain. Mast cells (MCs) can initiate inflammation due to pre-formed and made-upon-demand mediators. MCs are numerous in the pia of neonatal rats and enter the CNS on postnatal day (P) 7 with penetrating blood vessels. Using an established model of perinatal HI, we previously reported that MCs contribute to brain damage and MC stabilization protects through 48 hrs post-HI. Here we hypothesize that HI induces early MC migration/ activation with subsequent release of proinflammatory molecules and MC inhibition is neuroprotective. To test this hypothesis we examined the time course of MC and neural cell activation post HI and MC stabilization with Cromolyn. Methods: P7 rat pups were subjected to HI according to our standard model of permanent occlusion of the right carotid artery, 75min hypoxia (8% oxygen). Cromolyn (50 mg/kg sc) or saline was injected at 0, 1, 24 hrs after HI. Animals were killed immediately after HI, or at 1, 2, 4, 24 hrs; 1, 2 or 4 wk after HI. Brains were fixed, sectioned, and analyzed with histochemistry and immunocytochemistry and data collected with standard fluorescent and scanning confocal microscopy. Results: Brain MC numbers were elevated throughout the ipsilateral (ischemic) hemisphere immediately after HI (P⬍0.05), and were degranulated. MC activation was observed prior to detection of cleaved caspase-3 in apoptotic neurons (TuJ1⫹; 2hrs), or glial activation (GFAP⫹) or microglia (OX42⫹) (4 hrs). MC numbers remained elevated for 1 week, with the largest accumulation at 48hrs (P⬍0.01). In normal CNS only MC produce TNF-alpha. Immediately following HI TNF-alpha positive MC increased in ipsilateral hemisphere (p⬍0.01) and remained high for 24 hrs. Activated microglial TNF-alpha was evident at 4 hrs while endothelial cells had no detectable cytokine until 48hrs post HI. Cromolyn reduced MC migration and reduced brain damage/neuronal loss for up to 4 weeks post HI (P⬍0.05). Conclusions: These data support our hypothesis that MCs are early responders to HI in neonatal brain. MCs are present in large numbers in HI brain with preformed and induced proinflammatory molecules key to inflammation. Prevention of MC activation provides lasting protection and suggests a new target for therapeutic interventions. 25 Key Role of the Scavenger Receptor CD36 in Postischemic Inflammation and Ischemic Brain Injury. Alexander Kunz, Dept. of Neurology, Univ Hosp, Dresden, Germany; Takato Abe, Karin Hochrainer, Josef Anrather, Gianfranco Racchumi, Ping Zhou, Costantino Iadecola; Div. of Neurobiology, Weill Cornell Med College, New York, NY Background: CD36, a scavenger receptor found in macrophages, endothelium and microglia, contributes to ischemic brain injury (J Neurosci 25: 2504, 2005). The mechanisms of CD36-mediated neurotoxicity are not known. In some organs, CD36 is involved in inflammatory responses (J Clin Invest 108: 785, 2001). Therefore, we investigated whether CD36 contributes to ischemic injury by mediating postischemic inflammation. Methods: The middle cerebral artery (MCA) was transiently occluded in wild type mice (WT) or CD36-null mice (KO) and 72 hrs later, injury volume, mRNA expression of the inflammatory genes iNOS, ELAM, ICAM, nox2, rac2, and neutrophil infiltration were analyzed. Results: In KO, the injury volume was reduced (-62⫾5%; p⬍0.05; n⫽6/group) and mRNA expression of inflammatory genes was markedly attenuated (iNOS: -74⫾3%; ELAM: -80⫾11%; ICAM: -70⫾3%; nox2: -76⫾4%; rac2: -67⫾5%; p⬍0.05; n⫽5/group). Also, the number of neutrophils infiltrating the infarct was reduced (KO: 281⫾93; WT: 1938⫾296; p⬍0.05; n⫽5/group). WT treated with NS398, an agent that blocks COX2-mediated neurotoxicity, had a reduction in injury (40⫾15%; p⬍0.05; n⫽6) not different from that of KO (p⬎0.05), but did not exhibit comparable reductions in gene expression and neutrophils (p⬍0.05 from KO). Thus, the suppression of postischemic inflammation in KO is not secondary to reduced injury volume. In contrast to postischemic gene expression, brain expression of inflammatory genes induced by intracerebroventricular injection of interleukin (IL)-1 was not attenuated in KO (p⬎0.05; n⫽5/group). If the protection in KO is due to suppression of inflammation, then treatments antagonizing postischemic inflammation should not be effective in KO. Consistent with this prediction, the iNOS inhibitor aminoguanidine reduced infarct volume in WT (-45⫾13%; n⫽6), but not in KO (p⬎0.05 from vehicle; n⫽6). In contrast, NS398 reduced injury both in WT (-40⫾15%) and KO (-59⫾4%; p⬍0.05; n⫽6/group). Conclusions: The data demonstrate that CD36 is a key factor triggering inflammatory gene expression and tissue damage following cerebral ischemia. The observation that, contrary to ischemia, IL-1ß induces a normal inflammatory response in KO indicates that CD36 is specifically involved in the cellular and molecular mechanisms underlying postischemic inflammation. The identity of the ligand(s) activating CD36 during cerebral ischemia and the signaling pathways linking CD36 to postischemic gene expression remain to be defined. cerebral ischemia was induced by occluding the middle cerebral artery (MCAO) using an intraluminal filament technique (ischemia duration 3 h). Our laboratory had previously established a hypothermia model in mice. Eight C57BL/6 (wild type) mice received normothermia (37°C; NT), eight C57BL/6 mice received hypothermia (32–34°C; HT), seven plasminogen knockout mice (Plg-/-) received normothermia, and nine Plg-/- received hypothermia treatment during 24 hours of reperfusion. The infarct size was volumetrically determined. Gelatine zymography was used to detect MMP-9 and MMP-2 activity. The MMP content was measured by the ratio of the ischemic- to the non-ischemic side. The statistical analysis was based on Scheffe’s test and the Mann-Whitney U test with SEM. The infarct size was 69⫾8mm3 in NT and 38⫾5mm3 in HT (p⫽0.024) in C57BL/6 (wild-type) mice. MCAO produced larger infarcts in Plg-/- mice (91⫾8mm3 NT; 52⫾6mm3 HT; p⫽0.004). Hypothermia significantly reduced the proteolytic activity of MMP-9 in C57BL/6 (NT: 372⫾85%; HT: 203⫾35%; p⫽0,048), whereas MMP-9 in Plg-/- was not affected (NT: 1007⫾129%; HT: 767⫾182%; p⫽0.281). Furthermore, the MMP-9 level was 2.71 times higher in Plg-/- than in C57BL/6 during normothermia (p⫽0.018); it increased by 3.77-fold during hypothermia (p⫽0.034). The MMP-2 level remained unchanged in all conditions (C57BL/6: NT 228⫾62%, HT 135⫾29%; Plg-/-: NT 222⫾75%, HT 167⫾36%). In conclusion, this study demonstrates that hypothermia is as effective in Plg-/- mutants as it is in wild type mice in reducing infarct size. A novel finding of the study is the high level of MMP-9 in PLG-/- mice, which was not significantly affected by hypothermia. This high MMP-9 in the plasminogen knockout situation might reflect a compensatory increase in an alternative proteolytic system, resulting in larger infarcts. Further studies are needed to clarify the pathophysiological relevance of this observation. 27 Timing Of MGE Cell Transplantation After Distal Middle Cerebral Artery Occlusion Significantly Influences The Cell-host Interaction. Hideo Shichinohe, Marcel M Daadi, Nobutaka Horie, Theo D Palmer, Tonya Bliss, Gary K Steinberg; Stanford Univ, Stanford, CA Introduction: Growing evidence suggests that cell transplantation holds great potential as stroke therapy. One fundamental variable that needs to be defined is the optimal time after stroke for transplantation. This study describes the difference that the time of transplantation makes to the host response and graft biology. Methods: Primary medial ganglionic eminence (MGE) neural precursors were isolated from E15 rat embryos carrying the transgene for EGFP. Stroke was induced in rats by distal middle cerebral artery occlusion. A suspension of MGE cells was transplanted into the rat cortex at day 2 (n⫽5) or day 14 (n⫽6) after stroke. Animals were sacrificed at day 42 post-stroke and we had histological analysis. Results: There was a significant difference in transplanted cell survival between the two transplant groups. Cells transplanted at day 2 post-stroke showed very little survival at day 42; the cells in the core appeared to be dead but a thin layer of cells survived around the periphery of the graft. In contrast, when examined at day 42, the cells transplanted at day 14 exhibited much more robust survival throughout the graft and formed a much more elongated graft. Furthermore, the grafts of the day 2 group showed a greater migratory capacity towards the lesion that the day 14 grafts. The day 2 grafts had migrated 1.26 ⫾ 0.42 mm from the site of transplantation and were close to lesion edge whereas the day 14 grafts showed little migration from the site of transplantation (0.27 ⫾ 0.17 mm) and were thus further from the lesion. The host inflammatory response was dependent on the timing of transplantation. The day-2 group showed a robust inflammatory response at six weeks post-stroke, with microglia both within and surrounding the graft. In the day-14 group at six weeks poststroke, there were very few microglia in the graft and a dramatic lack of them immediately surrounding the graft. However, in this microglia sparse area there were many host astrocytes which appeared to form a barrier around the graft precluding the monocytes. Conclusions: The timing of transplantation after stroke has a long-term effect on the host response to the graft. This response can dramatically affect the graft’s microenvironment and ultimately determine the success of cell-based therapy. 26 Effects Of Hypothermia On Focal Cerebral Ischemia In Plasminogen Knockout Mice. Jan Burk, Dorothe Burggraf, Ludwig-Maximilians Univ - Dept of Neurology, Munich, Germany; Milan Vosko, AKh Linz, Linz, Austria; Martin Dichgans, Ludwig-Maximilians Univ Dept of Neurology, Munich, Germany; Gerhard F Hamann; HSK Dr. Horst-Schmidt-Klinik Dept of Neurology, Wiesbaden, Germany The effects of focal cerebral ischemia were studied in plasminogen knockout mice (Plg-/-) under normothermic and hypothermic conditions, and compared to wild type animals. Focal Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 28 Resveratrol Preconditioning Induced Neuroprotection Is Mediated Via Sirt1-Uncoupling Protein 2 Pathway. David Della Morte, Kunjan R Dave, Miguel A Perez-Pinzon; Univ of Miami, Miami, FL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Ischemic preconditioning (IPC) is a phenomenon whereby an organ’s adaptive transient resistance to a lethal insult occurs by preconditioning this organ with a sub-lethal/mild insult of short duration. Using an in vitro model of cerebral ischemia, resveratrol mimics IPC via the SIRT1 (member of Sirtuin family of proteins) pathway. In the present study, we show that tolerance for cerebral ischemia can be induced by resveratrol preconditioning (RPC) in vivo. We compared efficacy of RPC with IPC in protecting CA1 hippocampal neurons in the rat model of asphyxial cardiac arrest (CA). IPC was induced by tightening the carotid ligatures bilaterally following hypotension for 2 min. RPC was induced by injecting resveratrol (i.p.) at 10, 50 and 100 mg/kg. Eight minutes of CA was induced 48 hrs after IPC or resveratrol injection. Following 7 days of reperfusion, brain sections were examined for histopathological changes. Since it has been demonstrated that SIRT1 repressed the mitochondrial uncoupling protein 2 (UCP2) transcription by directly binding to its’ promoter, we determined if RPC induces neuroprotection via the SIRT1-UCP2 pathway. Statistical significance was determined via ANOVA followed by Bonferroni’s post-hoc test. The number of normal neurons in sham rats were 1328⫾23 (n⫽9) and 70% lower in CA/vehicle rats (405⫾78, n⫽5; p⬍0.001). Normal neurons in IPC group were higher by 88% (760⫾120, n⫽5; P⬍0.01) as compared with the CA group suggesting IPC tolerance against CA. The number of normal neurons in 10 and 50 mg/kg resveratrol groups were higher by 73% (702⫾54, n⫽7, p⬍0.05) and 63.4% (449⫾57, n⫽7) as compared to CA group, respectively. No significant protection was observed at higher resveratrol concentrations (100 mg/kg, 292⫾15, n⫽6). To determine if IPC and RPC resulted in enhanced SIRT1 activity, we measured SIRT1 activity following IPC and RPC. IPC and RPC were able to stimulate SIRT1 activity by 29 % (n⫽4, p⬍0.02) and 36 % (n⫽4, p⬍0.01) as compared to control (n⫽4), respectively. RPC was able to decrease levels of UCP2 by 35% (n⫽4, 65.05⫾2.08, p⬍0.05) as compared to vehicle group (n⫽4, 100⫾13.08). In conclusion, IPC can be emulated by pre-treating rats with low concentrations of resveratrol. Moreover, our data suggests that resveratrol may exert its’ neuroprotective effects through activation of the SIRT1 pathway by decreasing UCP2 levels. 29 Management of Unruptured Intracranial Aneurysm: Part 1 Natural History. Yuichi Murayama, Toshihiro Ishibashi, Takayuki Saguchi, Masaki Ebara, Hideki Arakawa, Koreaki Irie, Hiroyuki Takao, Toshiaki Abe; Jikei Univ, Tokyo, Japan Purpose: We report prospective analysis of natural history of unruptured intracranial aneurysms (UIA). Methods: Between January 2003 and August 2007, a total of 897 patients with 1084 saccular UIA were referred to our institution. The aneurysm sizes were measured by three-dimensional computed tomography angiography (3DCTA). When patient choose conservative management, clinical and CTA follow-up were obtained every 6 months. Results: Overall 771 aneurysms followed more than 6 months with multiple CTA and clinical evaluation. Of these 242 aneurysms received surgical or endovascular treatment and 529 aneurysms were followed without treatment. Mean follow up duration was 679 person-year. There were sixteen aneurysms rupture (2.4%/year) during observation. Thirteen out of 16 patients suffered severely disabled statusor death after bleeding. Annual rupture rate of the aneurysms smaller than 5mm and greater than 5mm were 1.2% and 5.8%, respectively. History of subarachnoid hemorrhage (SAH) (relative risk [RR] 5.3, 95% confidence interval [CI] 1.7–16.2, P⫽0.003) and large size were significant independent predictors for aneurysm rupture. None of ruptured patients who had large or giant aneurysms survived in the good clinical condition. Conclusion: The incidence of rupture of UIA may be higher than previous report. Size and history of SAH were important factors to predict rupture of the UIA. Clinical outcome after bleeding of incidentally found aneurysms seems worse than previous reports. 30 The Impact of Family History of Aneurysm or Subarachnoid Hemorrhage on Aneurysm Characteristics and Outcome: Results from the International Study of Unruptured Intracranial Aneurysms. Robert D Brown, Jr., Irene Meissner, John Huston, III, David G Piepgras, David O Wiebers, Mayo Clinic, Rochester, MN; Joseph P Broderick, Daniel Woo, Univ of Cincinnati, Cincinnati, OH; Elizabeth J Cozzie, Univ of Iowa, Iowa City, MN; James C Torner; Univ of Iowa, Iowa City, IA Background and Purpose: Unruptured intracranial aneurysms (UIAs) occur in about 1–2% of the population. There is a potential genetic role in the occurrence of these UIAs. The current analysis assesses the role of family history of aneurysm and subarachnoid hemorrhage (SAH) in the cohort of UIAs in the NIH-sponsored International Study of Unruptured Intracranial Aneurysms (ISUIA). Methods: In 61 centers participating in ISUIA, 4,060 patients with at least one UIA were entered into the prospective cohort. We prospectively collected family history information, including whether there was a family history of intracranial aneurysm or SAH. For 442 patients, family history was unknown. We divided the entire cohort into 3 groups: no prior SAH/single aneurysm; no prior SAH/multiple aneurysms; and those with prior SAH and at least one UIA. Differences between groups were examined using contingency table tests. We hypothesized that among patients with a UIA, demographic features, aneurysm diameter at 535 diagnosis, and outcomes may differ based on whether a family history of intracranial aneurysm or SAH was reported. Results: Eight hundred and thirty-four patients (20.5%) reported a positive family history of intracranial aneurysm or SAH. A positive family history was more common among women (23.4%) than men (18.0%) in patients with no history of SAH and single aneurysm. In patients with no prior history of SAH, a family history was more likely in 20 – 49 year olds compared to those ⬍20 years of age (p⬍0.05). The percentage of patients with a positive family history was lower in those with prior SAH/at least one UIA (18.0%) compared to those with no SAH/single aneurysm (19.4%) and no SAH/multiple aneurysms (25.8%). For aneurysm characteristics, a family history was associated with a smaller aneurysm diameter at the time of UIA diagnosis in those with no prior SAH/single aneurysm, and no prior SAH/multiple aneurysms. In general, patients with a negative family history generally had poorer outcomes than patients with a positive family history. Poorer outcomes were noted among patients with no prior SAH/single aneurysm, including all-cause mortality (p⬍0.01), non-aneurysm-related death (p⬍0.01), and aneurysm-related death (p⫽0.02). Conclusion: One in 5 patients with a UIA reported a family history of brain aneurysm or SAH. Women were more likely to report a family history. Patients with a UIA but without a prior SAH were more likely to have a family history. Those with a family history were more likely to be diagnosed with a smaller aneurysm. Patients with a negative family history generally had poorer outcomes 31 Cost-effectiveness Analysis of Endovascular Treatment versus Neurosurgical Treatment for Ruptured Intracranial Aneurysms in the United States. Alberto Maud, M. Fareed K Suri, Kamakshi Lakshminarayan, Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN Introduction: The International Subarachnoid Aneurysm Trial (ISAT) demonstrated reduced death and disability with endovascular treatment compared with neurosurgical treatment among patients with ruptured intracranial aneurysms. However, the need for follow-up cerebral angiography and re-treatment was higher among patients with endovascular treatment, which may offset the cost-benefit. Objective: To determine and compare the cost-effectiveness of endovascular and neurosurgical treatment among patients with ruptured intracranial aneurysms that could be treated with either modality. Design: The probability of poor outcome (moderate to severe disability) and frequency of retreatment and rebleeding following neurosurgical and endovascular treatment were obtained from ISAT population. Qualityadjusted life years (QALYs) gained was estimated by combining the frequency of each outcome at one year (healthy, mild, moderate and severe disability) with each treatment. Net costs were defined as the total of cost associated with moderate to severe disability, hospitalizations, retreatment and rebleeding in each group. Costs are in 2005–2006 United States’ charges. Incremental cost-effectiveness ratios (ICERs) were estimated over one year period following the procedure. Results: The estimated net cost at 1 year for endovascular and neurosurgical treated patients was $45,227 and $41,534 respectively. Overall QALY for endovascular coiling was 0.69 and for neurosurgery it was 0.64 (ranging from 0.0 meaning death to 1.0 meaning healthy). The cost per QALY in the endovascular treatment was $65,032 and in the neurosurgical treatment was $64,454. The estimated ICER for endovascular treatment versus neurosurgical treatment was 72,338 US dollars per QALY gained. Conclusions: From the United States’ perspective, endovascular treatment costs more but appears to deliver better outcomes than the neurosurgical alternative among patients with ruptured intracranial aneurysms that are suitable for either therapeutic modality. 32 Long-term Follow-up Patients With Unruptured Intracranial Aneurysms. James C Torner, Univ of Iowa, Iowa City, IA; Robert D Brown, Jr., Irene Meissner, David G Piepgras, John Huston, III, Jack Whisnant, David O Wiebers, Mayo Clinic, Rochester, MN; International Study of Unruptured Intracranial Aneurysms Investigators Introduction: Few studies have examined the long-term rates of hemorrhage, mortality and neurological outcome in patients with an unruptured intracranial aneurysm (UIA). Hypothesis: The hypothesis was that the likelihood for hemorrhage would continue at constant rates for observed patients, and that treatment would have decreased rates from obliteration of the aneurysm. Methods: Patients with a UIA were prospectively entered at 61 centers for the NIH-sponsored International Study of Unruptured Intracranial Aneurysms. In 2003 we began an extended follow-up to add to the initial follow-up of 4060 patients. The mean follow-up was 7.2 years, with a total of 29,280 person-years. Detailed outcomes were defined in advance, and included living/dead status and neurological assessment using the Rankin Scale and cognition based upon the Telephone Interview for Cognitive Status. Hemorrhage, neurological change and other endpoints were centrally adjudicated. Analysis was done with categorical analysis and logistic regression. Results: Of the 4060 prospectively evaluated UIA patients, those with surgical clipping included 1917 patients, endovascular treatment included 451 patients and conservative management included 1692 patients. Loss to additional follow-up occurred in 16% of patients. At the last known follow-up, 73% of the patients were Modified Rankin Scores 0 –2. To date, 823 deaths have been reported. Nine percent of deaths were due to subarachnoid hemorrhage (SAH); 74% in the observed patients, 3% in the surgery patients and 15% in the endovascular treated patients. The major single cause of death was cancer (20% of deaths) and was uniformly distributed in the treatment groups. There were 72 SAHs reported to date in the untreated group; 49 in the surgery group and 25 in the endovascular group, with the highest risk of hemorrhage still within the first year after diagnosis in all groups. Data collection and adjudication will continue through October and the final results will be analyzed. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 536 Stroke Vol 39, No 2 February 2008 Conclusions: Long-term outcome of patients with UIAs is important for the planning and comparison of clinical trials of treated patients, with the goal being to prevent hemorrhage and other adverse neurological consequences. Morbidity and mortality from intracranial aneurysms continues longitudinally but competing risks, including other co-morbidities, also play a role when informing patients of treatment choices. 33 Under-Treatment and Outcomes of Non-Traumatic Subarachnoid Hemorrhage by Hospital Volume: A Multi-State Study. p⫽0.0004), African American ethnicity (HR⫽2.91, CI⫽1.2–7.0; p⫽0.0171), and less than 90% aneurysm occlusion (HR⫽4.46, CI⫽2.0 –9.9; p⫽0.0003) were associated with increased risk of retreatment. For surgically treated patients, only incomplete aneurysm occlusion (⬍100%) was associated with retreatment (HR⫽11.5, CI 3.7–35.8; p⬍0.0001). Conclusions: Aneurysm retreatment is frequently required after treatment of ruptured intracerebral aneurysms, particularly in younger patients, those treated with coil embolization, and in those with incomplete initial aneurysm occlusion. Although rerupture is already a strong incentive to strive for complete aneurysm occlusion initially, a greater need for retreatment in subtotally treated aneurysms provides some additional support. Lucas Elijovich, UCSF, San Francisco, CA; Nancy A Dreyer, Outcome, Cambridge, MA; Jill Van Den Bos, Milliman, Denver, CO; S. Claiborne Johnston; UCSF, San Francisco, CA 35 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Prior studies have suggested that outcomes of patients with complex medical conditions, such as non-traumatic subarachnoid hemorrhage (SAH), are improved by referral to tertiary care centers. In this study we examined the hypothesis that SAH remains under-treated throughout the United States, particularly in centers with low volume of SAH patients, and that outcomes are improved at high volume centers. Methods: We conducted a review of discharge data from eighteen states throughout the United States from 2001–2004 to determine the volume of SAH admissions at each hospital. Hospitals were subdivided into annual volume quartiles based on the number of SAH admissions per year (1–5, ⬎ 5–12, ⬎ 12–25, ⬎ 25–218). We analyzed outcomes and rates of treatment of aneurysms for patients initially admitted through the emergency department with SAH and not transferred to another acute-care hospital. Univariate analysis was used to calculate the rates of in-hospital mortality, adverse outcomes (defined as in-hospital death or discharge to a nursing home or rehabilitation hospital), treatment type, and treatment rates by quartile. Multivariable analysis with generalized estimating equations was performed to determine the effect of these variables on adverse outcomes. Results: A total of 23,458 patients from 1,944 hospitals were included. The mean age of patients was 59.5 and 62.5% were female. Hospitals in the lowest quartile comprised 75.9% of participating hospitals, while the highest quartile hospitals consisted of 4.7% of all hospitals. Only a small minority of patients had an aneurysm treated among those admitted to hospitals in the lowest quartile hospitals (6.3% of all patients; 2.3% of patients ⬎ 65) compared to the highest quartile (37.5% all patients and 24.6% of patients ⬎ 65). The proportion of patients treated with coiling increased in the higher volume quartiles. Rates of in hospital death decreased from 34.9% to 31.4% from the lowest to highest volume quartile. The rate of adverse outcomes decreased successively by quartile, from 79.3% in the lowest volume quartile to 55.2 % in the highest volume quartile; similar results were observed in patients ⬎ 65 with a decrement from 87% to 78% adverse outcomes from the lowest to highest volume quartiles. Multivariate analysis demonstrated a decrease in mortality for admissions to highest quartile hospitals compared to the lowest, (OR 0.88 95% CI 0.81– 0.94, p⬍0.008). Significant reductions in adverse outcomes were demonstrated comparing the highest to the lowest volume quartiles in all patients (0.32, 0.27– 0.35, p ⬍ 0.0001) and in patients ⬎65 (0.54, 0.47– 0.63, p ⬍ 0.0001). Conclusion: Only a minority of patients with non-traumatic SAH have an aneurysm treated, particularly among the elderly and at low-volume hospitals. Adverse outcomes and in hospital mortality are improved at high-volume centers. 34 Predictors of Retreatment of Ruptured Intracranial Aneurysms: The Cerebral Aneurysm Rupture After Treatment Study. Chirag G Patil, Stanford Univ, Stanford, CA; Lucas Elijovich, Univ of California, San Francisco, San Francisco, CA; Gary K Steinberg, Stanford Univ, Stanford, CA; Robert F Spetzler, Cameron G McDougall, Joseph M Zabramski, Barrow Neurological Institure, Phoenix, AZ; Daryl R Gress, Michael T Lawton, Randall T Higashida, Univ of California, San Francisco, San Francisco, CA; Gary R Duckwiler, Univ of California, Los Angeles, Los Angeles, CA; Phillip D Purdy, Univ of Texas, Southwestern, Dallas, TX; David G Piepgras, Mayo Clinic, Rochester, MN; Steven L Giannotta, Univ of Southern California, Los Angeles, CA; S. Claiborne Johnston; Univ of California, San Francisco, San Francisco, CA Background: Rates and predictors of retreatment after endovascular and surgical treatment of ruptured intracranial aneurysms have not been clearly established. Methods: Data from the Cerebral Aneurysm Rupture After Treatment (CARAT) study were utilized to determine retreatment rates after surgical clipping and coil embolization of ruptured intracranial aneurysms. Potential predictors of retreatment were evaluated using univariate and multivariate Cox-proportional-hazards models. To aid interpretation, degree of aneurysm occlusion after the first treatment was also evaluated as a predictor of retreatment in a univariate Kaplan-Meier analysis (log-rank test). Results: Retreatment of the ruptured aneurysm occurred in 45 of the 1,010 patients (4.5%) followed for a median of 4 years. Retreatment was performed after recurrent hemorrhage in 8 (17.8%) patients and for aneurysm recurrence after complete occlusion in 14 (31.1%) patients. Only five patients underwent recoiling of subtotally occluded aneurysms within 1 week of initial treatment and may have been retreated as part of a planned retreatment. Retreatment was less frequent in those treated with surgical clipping than with endovascular coiling (2.1% versus 17.0% 5-year actuarial retreatment rate; p⬍0.0001, log-rank test). Retreatment was strongly associated with the degree of aneurysm occlusion after the initial treatment in univariate and multivariate analysis (5-year actuarial retreatment rates: 2.7% for complete occlusion, 13.3% for 91–99% occlusion, 33.4% for 70 –90% occlusion and 45.6% for ⬍70% occlusion). In multivariate analysis, older patients (HR⫽0.64 per decade, CI⫽0.49 – 0.82) and patients initially treated with surgical clipping (HR⫽0.28, CI⫽0.12– 0.65) were less likely to be retreated. In the multivariate model of patients who underwent endovascular treatment, younger age (HR [per decade]⫽0.57, CI⫽0.42– 0.78; Unruptured Cerebral Aneurysms Presenting with Ischemic Events. Nancy McLaughlin, Michel W Bojanowski; CHUM - Hopital Notre-Dame, Montreal, Canada Background: Patients harboring an unruptured cerebral aneurysm may present with ischemic events. The goal of this study is to assess the clinical and radiological characteristics of these patients and the outcome following aneurysmal treatment. Methods: The study population included 463 patients with unruptured cerebral aneurysms that were treated between 01–2000 to 11–2006. Patients with aneurysms manifesting with ischemic events were retained in this series. Outcome was assessed 12 months following aneurysm treatment using the Modified Rankin Scale. Results: Eleven patients were included in this series. On admission, patients were investigated with a cerebral CT and/or MRI and angiography. An acute ischemic lesion in the symptomatic territory was demonstrated in 6 patients. The symptomatic aneurysm was located on the internal carotid artery (n⫽4), the middle cerebral artery (n⫽4), superior cerebellar artery (n⫽2) and the basilar artery (n⫽1). They measured 10mm or less (n⫽7); 11–20mm (n⫽2); more than 20mm (n⫽2). Five aneurysms were partially thrombosed on imagery. Five patients were oriented towards endovascular treatment. Of these, one patient had an unsuccessful coiling attempt, one had a residual neck, and three presented an aneurysmal recurrence. A symptomatic thromboembolism occurred after endovascular re-treatment of a recurrent aneurysm. Six patients were treated surgically. A symptomatic thromboembolism occurred after surgery in 3 patients. Complete aneurysm exclusion was documented in 5 of 6 operated patients. Nine of the ten treated patients had a favorable outcome.Conclusion: Aneurysms presenting with ischemic events are often small and located on the anterior circulation. In this series, although the risk of thromboembolic events following surgery is noteworthy, the outcome remains favorable. 36 C-reactive Protein Gene C1444T Polymorphism Is Associated With An Increased Risk Of Further Ischemic Events In Patients With Symptomatic Intracranial Atherostenoses. Juan F Arenillas, Neurosciences Dep. Germans Trias i Pujol Universitary Hosp, Barcelona, Spain; Israel Fernández-Cadenas, Neurovascular Rsch Laboratory. Vall d’Hebron Universitary Hosp, Barcelona, Spain; Carlos A Molina, Neurovascular Unit. Vall d’Hebron Universitary Hosp., Barcelona, Spain; Pilar Chacón, Lipid Rsch Unit. Vall d’Hebron Universitary Hosp., Barcelona, Spain; Anna Rosell, Anna Penalba, Neurovascular Rsch Laboratory. Vall d’Hebron Universitary Hosp., Barcelona, Spain; Pilar Delgado, Marc Ribó, José Álvarez-Sabı́n, Neurovascular Unit. Vall d’Hebron Universitary Hosp., Barcelona, Spain; Joan Montaner; Neurovascular Rsch Laboratory. Vall d’Hebron Universitary Hosp., Barcelona, Spain Background and purpose: Symptomatic intracranial atherosclerotic disease (ICAD) is burdened with a high risk of clinical recurrence. High blood concentration of proinflammatory molecules, such as C-reactive protein (CRP), and raised level of inhibitors of endogenous fibrinolysis, such as plasminogen activator inhibitor-1 (PAI-1), may be associated with an increased risk of further ischemic events in patients affected by this disease. However, it remains unknown to which extent this excess risk might be predetermined genetically. We aimed to investigate whether common genetic polymorphisms of CRP and PAI-1 genes are associated with a higher risk of suffering recurrent ischemic events in patients with symptomatic ICAD. Methods: We studied 75 consecutive patients with a first-ever ischemic stroke attributable to a symptomatic intracranial atherostenosis, which was confirmed angiographically. Blood samples were drawn three months after the qualifying event. Genomic DNA was isolated and the following single nucleotid polymorphisms (SNPs) were determined by polymerase chain reaction: C1444T and 1059 GC of CRP gene and 4G/5G of PAI-1 promoter. Blood concentration of CRP and PAI-1 was also measured. Patients underwent long-term clinical follow-up to detect the occurrence of further major ischemic events. Results: During a median follow-up time of 23 months, 18 (24%) patients suffered a major ischemic event (10 ischemic strokes, 3 transient ischemic attacks and 5 myocardial infarctions). Kaplan-Meier and multivariate-adjusted Cox-regression analyses identified raised CRP and PAI-1 level as predictors of further ischemic events. Patients carrying allele T of CRP C1444T SNP were exposed to a higher risk of recurrent ischemic events during follow-up (35% vs. 12.5%, p⫽0.02). Carriers of 4G/4G allele in the PAI-1 SNP showed a non-significant trend towards a higher recurrence risk (35% vs. 17.4%, p⫽0.1). A Cox-regression model adjusted by age, sex and vascular risk factors identified that the mutation in CRP gene C1444T polymorphism predicted the occurrence of further ischemic events (HR 3.42, 95% CI [1.1–10.1], p⫽0.03). Conclusion: A mutation in the C1444T polymorphism of CRP gene may be associated with a higher risk of further ischemic events in patients with symptomatic ICAD. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 37 Relationship of Site Experience with Clinical Outcomes in Patients Undergoing Intracranial Stenting in the NIH Multicenter Wingspan Registry. Fadi Nahab, Emory Univ, Atlanta, GA; Osama O Zaidat, Med College of Wisconsin/Froedtert Hosp, Milwaukee, WI; Michael Lynn, Marc I Chimowitz, Emory Univ, Atlanta, GA; for the NIH Multi-Cntr Wingspan Intracranial Stent Registry Study Group Background: There are limited data on the relationship between site experience and clinical outcomes after intracranial stenting. Hypothesis: High enrolling sites in an intracranial stenting registry will have lower cerebrovascular complication rates within 24 hours and better long term patient outcomes than low enrolling sites. Methods: We compared outcomes of patients enrolled at high volume sites (enrolled ⬎ 10 patients) vs. low volume sites (enrolled ⬍ 10 patients) participating in the registry. All stented patients presented with a TIA or ischemic stroke in the territory of a single 50 –99% stenosis of a major intracranial artery while on antithrombotic therapy. Results: Low volume sites (10 centers that collectively enrolled 41 patients) had significantly higher cerebrovascular complications (stroke, TIA, intracerebral hemorrhage, vasospasm, parent vessel dissection, parent vessel perforation, or stent thrombosis) within 24 hours compared with high volume sites (6 centers that collectively enrolled 119 patients) (29.3% vs 4.2%, p⫽0.00005). Cerebrovascular complications within 24 hours in patients done early in the sequence at a site (up to first 5 patients enrolled) remained significantly higher at low volume vs high volume sites (32.4% vs. 6.7%, p⫽0.013). Median follow-up in the study was 5.5 months. The rates of stroke or death within 30 days or stroke in the territory after 30 days at 6 months was 24.1% at low volume sites vs 10.7% at high volume sites (p⫽0.058). Conclusions: Intracranial stenting at high volume sites is associated with lower rates of cerebrovascular adverse events within 24 hours and better 6 month patient outcomes than at low volume sites. This difference appears to be independent of the patient sequence at a site. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 38 Analysis of Recurrent Ischemic Events Following Successful Therapy with the Wingspan System. Babu G Welch, UT Southwestern Med Cntr, Dallas, TX; Neuroendovascular Rsch Collaboration Background: Despite successful treatment of symptomatic intracranial atherosclerotic disease with the Wingspan stent system, some patients may have recurrent ischemic events. An interim analysis of our data was performed to determine the rate of delayed events (⬎30 days after treatment) and any contributing factors. Methods: A prospective, intent-to-treat registry was maintained of patients in whom the Wingspan stent system was used to treat symptomatic ICAD at five participating US institutions. Clinical and angiographic follow-up data available through July 2007 were analyzed. ISR was defined as ⬎50% stenosis within or immediately adjacent (within 5 mm) to the implanted stent(s) AND ⬎20% absolute luminal loss. Results: One-hundred and three patients who had undergone successful treatment with the Wingspan stent system have had at least 3 months of clinic follow up. Of these, 15 have had recurrent ischemic symptoms ipsilateral to the lesion treated - 8 strokes (7.8%) and 7 TIAs. Of the patients with stroke, 6 were classified as minor, one as major and one as stroke with subsequent death. In 5 of these 15 patients with recurrent symptoms the recommended dual antiplatelet therapy regimen was interrupted. In 9, angiographic evaluation demonstrated ISR or stent thrombosis. Conclusions: Recurrent ischemic events after successful PTAS with Wingpsan are not uncommon, occurring in approximately 15% of patients. The vast majority (⬎85%) of these are either TIA or minor stroke. Most recurrent ischemic events (⬎85%) can potentially be accounted for by either ISR or interruption of the recommended dual anti-platelet regimen. Mechanisms to maintain medication compliance and to survey for, or reduce, ISR have the potential to substantially reduce recurrent ischemic events after therapy. 39 Safety and Efficacy of Endovascular Thrombectomy in Patients with Abnormal Hemostasis: Pooled Analysis of the MERCI and Multi MERCI Trials. Raul G Nogueira, Massachusetts General Hosp, Boston, MA; on Behalf of the MERCI and Multi MERCI Writing Committee Background and Significance: Patients with abnormal hemostasis including INR ⬎ 1.7, elevated PTT, and/or platelet count ⬍ 100,000/L are not considered candidates for intravenous rt-PA. Similar criteria have been arbitrarily adopted by studies evaluating intra-arterial thrombolysis including the PROACT I-II and the IMS I-II trials. Endovascular thrombectomy obviates or lessens the use of thrombolytic drugs. Therefore, different inclusion criteria were adopted during the MERCI and Multi MERCI trials. We performed a retrospective analysis of the MERCI/Multi MERCI cohort as an attempt to establish the risks and benefits of thrombectomy in patients with abnormal hemostasis. Methods: Two patient groups were identified: Group 1 (n⫽35): patients with INR ⬎ 1.7 and/or PTT ⬎ 45 seconds and/or platelet count ⬍ 100,000/L; Group 2 (n⫽270): patients with INR ⱕ 1.7, PTT ⱕ 45 seconds, and platelet count ⱖ100,000/L. The rates of symptomatic intracranial hemorrhage (sICH), vascular recanalization, good clinical outcomes (90-day mRS ⱕ 3), and mortality were compared between the two groups. Results: Of the 35 patients in Group 1, nineteen had INR ⬎ 1.7 (mean: 2.4; range: 1.8 – 4.9), 11 had PTT ⬎ 45 seconds (mean: 95; range: 46 –190), and 537 six had platelets ⬍ 100,000/L (mean: 63,400; range: 16,000 –94,000). Two patients had both INR ⬎ 1.7 and PTT ⬎ 45 seconds. The two groups did not significantly differ in terms of age (median: 71 vs. 72 years), gender (female: 60% vs. 51%; p⫽0.371), baseline NIHSS (median: 20 vs. 19), intra-arterial thrombolytic use (40% vs. 31%; p⫽0.334), or site of occlusion (ICA: 34% vs. 32%; MCA: 57% vs. 59%; Vertebrobasilar: 9% vs. 9%). Time-to-treatment was slightly earlier in Group 1 (median: 3.6 vs. 4.3 hours; p⫽ 0.03). Forty-eight patients in Group 2 and none of the patients in Group 1 received intravenous rt-PA (p⫽0.002). There was no significant difference in terms of revascularization (TIMI 2–3: 60% vs. 65%; p⫽0.58) or mortality rates (40% vs. 38%; p⫽0.85). There were three sICHs in group 1 (one PH-1 with platelet count⫽16,000; one PH-2 with INR⫽1.8; and one SAH with INR⫽2.3). The incidence of sICH did not differ between groups (8.6% vs. 8.5%; p⫽1.0; RR: 1.01 [95%CI: 0.33–2.87]). There was a trend towards higher rates of good clinical outcomes in Group 2 (28% vs. 46%; p⫽0.062). In Group 1, successful revascularization was associated with higher rates of good clinical outcomes (44% vs. 7%; p⫽0.044; RR: 6.2 [95%CI: 1.26 –37.4]) and lower mortality (24% vs. 64%; p⫽0.033; RR: 0.37 [95%CI: 0.17– 0.84]). Conclusion: Patients with abnormal hemostasis who undergo thrombectomy do not appear to be at a significantly higher risk for sICH. In this patient group, successful revascularization is associated with higher rates of good clinical outcomes and lower mortality. 40 US Multi-Center Experience with the Wingspan Stent System for the Treatment of Intracranial Atheromatous Disease: Periprocedural Results for 156 patients. Peter Rasmussen, Cleveland Clinic Foundation, Cleveland, OH; Neuroendovascular Rsch Collaboration Background and Purpose The current report details our periprocedural experience with Wingspan (Boston Scientific/Target, Fremont CA), the first self-expanding stent system designed for the treatment of intracranial atheromatous disease (ICAD). Methods All patients undergoing angioplasty and stenting with the Gateway balloon-Wingspan stent system were prospectively tracked at five participating institutions. Results Over a 20-month period, the Wingspan stent system was successfully used to treat 156 patients with 166 intracranial atherosclerotic lesions (average age 62.7 years; 64 women). The stent was successfully deployed 96.5% of the time during the initial treatment session. Lesions treated involved the internal carotid (n⫽50; 14 petrous, 15 cavernous, 16 supraclinoid segment, 5 terminus), vertebral (n⫽32; V4 segment), basilar (BA, n⫽38), and middle cerebral (MCA, n⫽45) arteries. Mean pretreatment stenosis, %(SD), was 75.3 (12.6), improving to 42.6 (15.2) after balloon angioplasty and to 27.6 (15.0) after stent placement. Of the 166 lesions successfully treated, there were nine (5.4%) major peri-procedural (within 30 days) neurological complications, four of which ultimately led to patient death. All periprocedural complications were encountered during the treatment of lesions within the MCA and BA. Stenosis severity did not influence the rate of complications. Conclusions Angioplasty and stenting for symptomatic ICAD can be performed with the Gateway balloon-Wingspan stent system with a high rate of technical success and low peri-procedural morbidity. The severity of the stenosis treated did not influence the complication rate. 41 Natural History of Asymptomatic Restenosis following Endovascular Treatment of Symptomatic Intracranial Stenosis Does Not Support Retreatment. Haitham Hussein, Zeenat Qureshi Stroke Rsch Cntr Univ of Minnesota, Minneapolis, MN; Mohammad Abdelmoula, UMDNJ, Newark, NJ; Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr Univ of Minnesota, Minneapolis, MN Background Restenosis is an angiographic finding that is frequently observed after angioplasty and/or stent placement for intracranial atherosclerosis. However, due to lack of data regarding clinical outcome of restenosis, particularly when asymptomatic, the decision to retreat is arbitrarily based. We report on the short and intermediate clinical outcome of patients with asymptomatic restenosis treated with medical management. Method We analyzed the data of patients treated with either primary angioplasty or stent placement for symptomatic intracranial atherosclerosis from 2 centers. The initial and post-procedure severity of stenosis was estimated using Warfarin versus Aspirin for Symptomatic Intracranial Disease (WASID) trial criteria. We identified restenosis by target lesion stenosis ⱖ 50% or increase in severity of stenosis by ⱖ 25% (compared with immediate post-procedure measurements) on a follow up imaging study. All patients were followed and any new stroke or death was ascertained. Results Of 68 patients analyzed, 37 had a follow up imaging study performed at a mean period of 14.6 months (range 1.3–35 months). Angiographic restenosis was detected in 16 patients and was asymptomatic in 13 patients (mean age 62⫾13; 4 were women). Restenotic lesions were located in the middle cerebral artery (n⫽5), vertebral artery (n⫽4), basilar artery (n⫽3), and internal carotid artery (n⫽1). The primary treatment modality had been angioplasty in 9 patients and stent placement in 4 patients. Stenosis averaged 79⫾17% pre-procedure, and 13⫾14% after treatment. Restenosis (WASID criteria) was detected using an angiogram performed over a mean interval of 21⫾10 months from the primary procedure. Clinical follow up period ranged from 4 to 31 months (mean 20⫾9 months). During the follow-up, only 1 event was reported; a disabling frontal intracerebral hemorrhage at 26 months in a patient who had undergone a stent placement in the basilar artery. Conclusion Asymptomatic angiographic Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 538 Stroke Vol 39, No 2 February 2008 restenosis is associated with a low rate of stroke and death suggesting that retreatment in the absence of clinical ischemic symptoms may not be warranted. 42 Treatment of Moyamoya Disease in the Adult Population with Indirect Cerebral Revascularization Utilizing Pial Synangiosis. Edward R Smith, Ronald T Grondin, R. Michael Scott; Children’s Hosp Boston, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: Surgical treatment of moyamoya disease in the adult population commonly employs direct revascularization using the superficial temporal artery to middle cerebral artery (STA-MCA) bypass. Because of small caliber scalp or middle cerebral artery branches, it may be technically impossible to perform direct anastomosis in certain patients. Pial synangiosis, a method of indirect revascularization, has been utilized in adult patients treated at our institution when STA-MCA bypass has not been feasible. Although the effectiveness of pial synangiosis has been well described in children, only limited reports have examined its role in adult patients. Here we report on our experience with pial synangiosis for the treatment of moyamoya in the adult population. Methods: Case series Results: Twenty (20) adult moyamoya patients (21 y/o or older, mean ⫽31.9, median ⫽30) were treated with pial synangiosis. Of these, 11 have 1 year follow-up imaging (MRI/A and/or angiogram) and clinical follow-up (range⫽2–14 years). 9/11 had radiographic evidence of significant collateral development on angiographic studies at 1 year. With extended follow-up (2–14 years) 8 patients have all been clinically stable or improved. 2/11 patients experienced recurrent ischemic events requiring reoperation (one at 8 months, the other at 7 years postop) and 1/11 had a perioperative stroke without reoperation. All patients have subsequently done well (3– 6 years f/u). One patient underwent a STA-MCA bypass on one hemisphere and pial synangiosis on the opposite side, with equally successful radiographic and clinical results (5 years follow-up). Conclusions: Pial synangiosis is a safe and effective method of cerebral revascularization in adult moyamoya patients. In our series, beneficial results were found to be significant and durable, with outcomes that compare favorably to STA-MCA bypass results as reported in the literature. Our data supports utilization of pial synangiosis as a treatment option for moyamoya syndrome in adults, particularly when STA-MCA bypass is not technically feasible. 43 Blood Pressure in Acute Stroke is Inversely Related to the Extent of Collaterals. David S Liebeskind, Sidney Starkman, Kwang D Jo, Arbi G Ohanian, James W Sayre, Susan Yun, Doojin Kim, Latisha K Ali, Bruce Ovbiagele, Amytis Towfighi, Samir H Shah, Reza Jahan, Gary R Duckwiler, Fernando Vinuela, Jeffrey L Saver; UCLA, Los Angeles, CA Background: Collateral circulation strongly influences outcome in acute ischemic stroke, improving perfusion and decreasing hemorrhagic transformation. Predicting the extent of collaterals based on clinical variables has not been explored in detail. We hypothesized that baseline demographics, co-morbidities, and clinical data including baseline vital parameters may be predictive of collateral status in acute ischemic stroke. Methods: Angiographic collaterals were graded with the ASITN/SIR scale, blinded to clinical data, on the pretreatment injections of collateral routes in a consecutive series of mechanical thrombectomy cases. Baseline demographics, co-morbidities, and other clinical parameters were obtained from a prospectively maintained database. Multivariate logistic regression analyses determined predictors of collateral grade. Results: Collateral flow was graded on angiography in 100 cases of acute ischemic stroke (mean age 68 years, SD 17.3; 53 men, 47 women). Collateral grade was evenly distributed across all categories of the ASITN/SIR scale. The extent of collaterals was correlated with history of hypertension (p⫽0.003), baseline SBP (p⫽0.004) and baseline DBP (p⫽0.028). Multivariate logistic regression analyses demonstrated a dramatic association between baseline SBP (p⫽0.001) and history of hypertension (p⫽0.026) with extent of collaterals. Patients with higher SBP on admission had poorer collaterals, whereas those with lower SBP demonstrated more robust collateral flow. Collateral flow was not associated with any other demographic or clinical variables. The presence or history of atrial fibrillation or any other cardioembolic source had no relationship with collaterals. Collateral grade was also unrelated to stroke mechanism. Conclusions: Blood pressure on admission is the strongest predictor of collateral flow in acute ischemic stroke. Elevated SBP is associated with poor collaterals, likely reflecting upregulation of angiotensin II due to attempted arteriogenesis. Stroke patients with lower SBP demonstrate more robust collaterals and therefore may not benefit from pressure augmentation. Contrary to traditional dogma, atrial fibrillation and cardioembolic events have no relationship with respect to collateral flow in acute ischemic stroke. 44 clinical trials, but its efficacy in survivors of in-hospital cardiac arrest, and arrests with rhythms other than VT/VF, is unknown. Here we report our experience for patients treated with MH after cardiac arrest under a wide variety of settings using a hospital-wide protocol. Methods: We prospectively collected clinical, demographic, and outcome data on consecutive patients treated with MH after cardiac arrest. Cooling was initiated if the patient did not follow commands after resuscitation, regardless of initial rhythm or location of arrest. Goal temperature was 91.4 F for 24 hours. Good outcome was defined as discharge to home or acute rehabilitation; poor outcome was discharge to a nursing home, or death. All patients were treated in a cardiac or medical ICU and all were assessed by a stroke neurologist. Non-normally distributed variables were described with median [interquartile range, IQR], and normally distributed variables as mean [Standard deviation]. Univariate predictors of outcome were explored with Mann-Whitney U, Kruskal-Wallis K, or ANOVA, as appropriate. We performed multinomial logistic regression to evaluate predictors of discharge disposition, coded as an ordinal variable (dead⫽0, nursing home⫽1, rehabilitation⫽2, home⫽3), using mortality as the reference. Results: The 35 treated patients had a median age of 58 years (IQR 48 – 69), 63% were men, and 72% of patients had initial rhythms other than VT/VF. Two thirds of patients had in-hospital cardiac arrest. The median time to return of spontaneous circulation (ROSC) was 14 minutes [IQR 9 –27.5 min]. Good outcome was achieved in 34% of patients and mortality was 49%. Increased time to return of spontaneous circulation and absent brainstem reflexes on day 3 both independently predicted poor outcome in a multivariate model (P⬍0.05). In patients without brainstem dysfunction on day 3, time to ROSC was the only predictor of outcome. Age, gender, type of arrest, and location of arrest were not associated with outcome. Conclusion: MH is feasible, safe, and may be effective in routine clinical practice at an academic medical center. Our data do not support limiting MH only to VT out-of-hospital arrests, as neither initial cardiac rhythm nor location of arrest were predictive of outcome. Our results in out-of-hospital arrests match those in randomized trials, and we found no difference in outcome with in-hospital arrests. MH is an underused therapy with the potential to improve outcome in many survivors of cardiac arrest. 45 Slow Initiation of Care and Poor Outcomes for Patients Having In Hospital Ischemic Strokes. Frank L Silver, Univ of Toronto, Toronto, Canada; Jiming Fang, Institute for Clinical Evaluative Studies, Toronto, Canada; Annette C Robertson, M P Lindsay, Institute for Clinical Evaluative Sciences, Toronto, Canada; Moira K Kapral; Univ of Toronto, Toronto, Canada Background: Few studies have focused on patients with in hospital strokes. Given that these patients are already in hospital, they should benefit from rapid access to acute stroke care. Methods: The Registry of the Canadian Stroke Network (RCSN) collects data on all consecutive patients presenting within 14 days of an acute stroke or TIA to 12 designated stroke centres in Ontario and Nova Scotia. After selecting patients with a final diagnosis of ischemic stroke, patients with In Hospital Strokes between July 2003 and March 2007 were characterized with descriptive statistics and compared to the larger RCSN cohort of patients presenting via emergency departments. Results: Over this 45-month period there were 12,506 patients in the RCSN admitted to hospital with an acute ischemic stroke including 535 patients who had In Hospital strokes (IHS). There was no difference between the IHS and other patients in gender (52.1 vs. 51.4 % male) or mean age (72.9 vs. 72.7). The IHS patients tended to have more severe initial deficits (Canadian Neurological Score ⱕ 8 in 62.7 vs. 30.8%, p⬍0.0001) and more co-morbidities (Charlson index ⬎ 1 in 51.0 vs. 35.2%, p⬍0.0001). After adjusting for age, gender, stroke severity and co-morbidity the IHS patients had a higher in-hospital mortality (14.3%; 95%CI 11 18 vs. 10.9%; 95%CI 10 - 12) and worse functional outcomes (mRS ⬍3 at discharge 32.4%; 95%CI 26 –39 vs. 42.6%; 95%CI 42– 44). The use of tPA was the same (64/535; 12% vs. 1,399/11,971; 11.7%). For the tPA treated patients the median NIHSS was the same for both groups (13). The median ED (emergency department) arrival to CT and the median ED to tPA treatment were longer for the IHS group (61 vs. 30 minutes; p⬍0.0001 and 138 vs. 75 minutes; p⬍0.0001, respectively). (For IHS patients, the time the stroke was first recognized was used in place of the ED arrival time). Adjusted outcomes for the tPA treated patients were not different for the IHS group. Conclusions: Patients suffering in hospital strokes are a unique group with overall worse hospital outcomes. IHS patients took longer to be investigated and receive thrombolytic therapy. Education to increase the awareness of hospital staff to recognize patients with acute stroke and special protocols to facilitate access to acute stroke care are needed. 46 Stroke Response Nurses - Success in Ischemic Stroke Treatment Parallels Increase in Utilization Eight Years’ Experience with 24/7 Stroke Response Nurses. Outcomes of Moderate Hypothermia for Survivors of In-Hospital and Out-of-Hospital Cardiac Arrest. Barbara L Mancini, Patricia Lane, Betsy Stagno, Debbie Healy, John W Cochran, II; Inova Fairfax Hosp, Falls Church, VA Richard A Bernstein, Andrew M Naidech, Northwestern Med Sch, Chicago, IL; Julie Garrett, Robin Oakley, Deborah L Bergman, Northwestern Memorial Hosp, Chicago, IL; Mark J Alberts, Dan J Fintel; Northwestern Med Sch, Chicago, IL Background and Purpose: Stroke Response Nurses (SRN) have been utilized in our hospital for more than eight years. They are to evaluate all patients coming to the Emergency Department (ED) with symptoms of stroke, transient ischemic attack (TIA) as well as patients already in-house for consideration of thrombolysis or other intervention. In addition they are to screen patients with intracerebral and subarachnoid hemorrhages. Patients are considered for inclusion in research protocols. The goal is for SRN to rapidly evaluate all patients arriving Objectives: Moderate Hypothermia (MH) has been shown to improve neurological outcome in survivors of out-of-hospital ventricular tachycardia/fibrillation (VT/VF) cardiac arrest in Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations within the three-hour window for IV tPA and the six-hour window for intra-arterial treatment. SRN are supported by the Stroke Team consisting of neurologists and NPs who confer with the nurse; act as consultants and see all patients treated with thrombolytics. We determined the need to review the performance of SRN looking for any trend in these patients and to discern why all stroke patients were not being seen. Method: The records of all SRN encounters since 1999 were reviewed and compared with the number of stroke and TIA discharges. The number of patients seen, the diagnoses of the patients and the percent of the total stroke/TIA patient population evaluated was tabulated. For 2007 the data reflects projections based on 6 months’ data. See Figure. Results: By 2005 most stroke patients were evaluated by SRN, the percent seen now stands at 70%. Patients that have eluded the SRN evaluation included patients for whom the protocol of calling the SRN was not followed, patients discovered to have had a stroke post-operatively or in the midst of a critical illness and others who developed symptoms of stroke while already inpatients and direct admissions. Most of the patients admitted via the ED are now evaluated by SRN. The increase in treatment with Merci device and IV or IA thrombolytics has closely paralleled the rise in percent of ischemic patients evaluated by SRN. Conclusions: Over the last 8 years, SRN have been effective in screening more patients with stroke. They now see 70% of these patients. The doubling of the number of thrombolytic/Merci treated patients over the last few years parallels this growth. Successful deployment of SRN has been a critical element of this improvement at our hospital. We continue to strive to have all stroke patients seen by SRN. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 47 Impact of Dedicated Stroke Response System on In-Hospital Assessment and Outcomes of Patients with Acute Ischemic Stroke. Gustavo J Rodriguez, Sheetal Patel, Mary DuPlessis-Tchida, Adnan I Qureshi, David C Anderson, Kamakshi Lakshminarayan; Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN Objective: We report the effect of system changes on various quality measures focused on the delivery of intravenous thrombolytics in patients with acute ischemic stroke at a teaching hospital. Methods: The following system changes were instituted in the year 2005: i) stroke responder teams with linked pagers which could be activated by a single stroke code; ii) 24/7 neurology and radiology staff availability to assist emergency department personnel; iii) clear established protocols of intervention in the evaluation and treatment. We evaluated the change in the rates of the following quality parameters over a 6 year period: i) rates of intravenous thrombolytic use in acute ischemic stroke; ii) time interval between door and treatment,and symptom onset and treatment; and iii) in-hospital mortality. Results: A total of 75 patients received intravenous (IV) thrombolytic therapy from 2001 through 2006. The results are tabulated below demonstrating a significant reduction in time interval between door and treatment following institution of a dedicated stroke response system (table) Weekends and weekdays did not significantly differ in terms of speed of response (Door to Needle, 54.5⫾21 vs. 56.3⫾34). However, patients presenting at a public place (e.g., at work, driving, or in public) had a significantly lower door to needle time compared with those whose event occurred at home or at a nursing home (p⬍0.05). Conclusions System changes instituted at our hospital have significantly improved the quality indices associated with intravenous thrombolytic utilization in acute ischemic stroke patients. The increasing rates of utilization (the 17% treatment rate is among the highest reported) and decreasing in-hospital mortality validate the use of indices such as door-to-needle time as performance target. 539 TABLE 1 IV thrombolytic use rate * Door to needle ⬍ 60 minutes Door to needle (mean) * Onset to needle (mean) In-hospital mortality 2001 2002 2003 2004 7% (8/109) 57% (4/7) 2% (3/140) 100% (3/3) 49 min (3) 91 min (3) 33% (1/3) 6% (6/97) 33% (2/6) 9% (8/90) 76 min (7) 120 min (7) 25% (2/8) 2005 2006 112 min (8) 50% (4/8) 80% (8/10) 17% (22/126) 86% (18/21) 67 min (6) 74 min (8) 48 min 43 min (10) (21) 130 min 112 min 82 min (9) 91 min (6) (8) (21) 33% (5/6) 112 min 20% (2/10) 9% (2/22) (8) *Signifjicant at P⬍0.05. 48 A Simplified Model for the Assessment of Quality of Stroke Care in Emerging Countries. The Argentinian National Stroke Registry (ReNACer). Luciano A Sposato, Favaloro Foundation & Argentinian Neurological Society, Buenos Aires, Argentina; Marı́a M Esnaola, Hosp Francés & Argentinan Neurological Society, Buenos Aires, Argentina; Rafael Zamora, Hosp de Clı́nicas, Buenos Aires, Argentina; Marı́a C Zurru, Hosp Italiano & Argentinian Neurological Society, Buenos Aires, Argentina; Osvaldo Fustinoni, INEBA & Argentinian Neurological Society, Buenos Aires, Argentina; Gustavo Saposnik; St. Michael’s Hosp, London, Canada Background. Projections from the World Health Organization indicate that stroke incidence and mortality will increase faster in low-income countries. Unfortunately, limited information is available on cerebrovascular disease in emerging/low income countries, and particularly in South America. Data on the processes of care will become crucial to improve the quality of stroke care and subsequently reduce the stroke burden. Objectives. To measure standardized indicators of quality of stroke care in Argentina. Our secondary goal was to compare stroke care between teaching and non-teaching hospitals. Methods. ReNACer is a prospective, multicenter, countrywide, cooperative, hospital-based stroke registry that included different facility types (small/large, community, teaching hospitals). We selected 9 key performance indicators of quality of stroke care, including different domains. We used Chi-square tests to compare categorical variables and Student’s t-tests for continuous variables. We conducted A reabstraction study of 10% of the randomly selected charts for data quality analysis. Results. From November 2004 to October 2006, 1991 patients with ischemic stroke were admitted to 74 institutions in Argentina. Mean age was 69.4 ⫾ 13 years, and 1100 (56%) were males. Antithrombotic therapy was initiated within 48 hours in 79% of the patients. All patients had a neuroimaging study during hospital stay. Median length of stay was 5 days (IQR 3–9). There was a significant difference in average length of stay (ALOS) between teaching and non-teaching centers (6.3 days vs 9.5 days, p⬍0.001). Only 1% of patients received thrombolytic therapy and 5.7% were admitted to designated stroke units. The overall proportion of patients with intranosocomial pneumonia was 14.3%, higher in non-teaching hospitals (16.4% vs 11.4%, p 0.02). The overall adjusted in-hospital mortality rate was 9.1%, higher in non-teaching centers (10.6% vs 7.1%, p 0.008). Antithrombotics were indicated in 90.2% and antihypertensive agents in 63.6% of the patients, on discharge. Patients admitted to teaching facilities had lower complication rates and ALOS that their counterparts. On the contrary, discharge on antithrombotics and antihypertensive medications was more common in non-teaching facilities (Table). Conclusions. Despite the lower rate of thrombolysis, admissions to stroke units, and higher rate of pneumonias, the performance of other indicators were similar to those reported in other countries. Differences were observed in care provided at teaching vs non-teaching institutions. QUALITY OF STROKE CARE INDICATORS Domains & Indicators Acute treatment of ischemic stroke 1. Rate of thrombolysis, No. (%) 2. Rate of patients receiving aspirin in the first 48 hours, No. (%) Organization and delivery of stroke evaluation and care 3. Rate of admissions to designated stroke units, No. (%) 4. Rate of patients with CT/MRI performed during hospital stay, No. (%) 4a. Computed axial tomography 4b. Magnetic resonance imaging 5a. Average length of stay, median (interquartile range 25%,75%), d 5b. Average length of stay, mean (SD), d Stroke complications and outcome 6. Intranosocomial pneumonia, No. (%) 7. Overall in-hospital mortality, No. (%) Secondary Prevention Overall Teaching Non-Teaching n ⫽ 1,991 21 (1.05) 1,571 (78.9) n ⴝ 868 10 (1.15) 673 (77.5) n ⴝ 1,123 11 (0.98) 898 (80.0) n ⴝ 1,991 n ⴝ 868 n ⴝ 1,123 p 0.88 0.19 113 (5.7) 74 (8.5) 36 (3.2) ⬍0.001 1,991 (100.0) 868 (100.0) 1,123 (100.0) NA 1,904 (95.6) 357 (17.9) 5 (3–9) 805 (92.7) 207 (23.8) 4 (3–7) 1,099 (97.9) 150 (13.4) 6 (4–11) ⬍0.001 0.008 NA 8.1 (10.2) 6.3 (7.1) 9.5 (11.9) ⬍0.001 n ⴝ 1,991 n ⴝ 868 n ⴝ 1,123 164 (14.3) 55 (11.4) 109 (16.4) 0.02 181 (9.1) 62 (7.1) 119 (10.6) 0.008 n ⴝ 1,810 n ⴝ 806 n ⴝ 1,004 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 540 Stroke Vol 39, No 2 Domains & Indicators 8. Rate of patients receiving antithrombotics at discharge, No. (%) 9. Rate of patients receiving antihypertensive drugs discharge, No. (%) Overall February 2008 Teaching Non-Teaching p 1,632 (90.2) 712 (88.3) 920 (91.6) 0.02 1,152 (63.6) 443 (55.0) 709 (70.6) ⬍0.001 *Intranosocomial pneumonia was evaluated during a second recruitment period in 1,148 patients (483 from teaching centers and 665 from non-teaching centers). 49 Intravenous Tissue Plasminogen Activator Use Has a Low Risk of Neurosurgical Intervention. Aslam M Khaja, Univ of Illinois at Chicago, Chicago, IL; Sheryl Martin-Schild, Miriam Morales, Andrew D Barreto, Hen Hallevi, Nicole R Gonzales, Kachi Illoh, Elizabeth A Noser, James C Grotta; Univ of Texas - Houston, Houston, TX Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: Many physicians and community hospitals are reluctant to administer intravenous (IV) tissue plasminogen activator (tPA) due to the lack of neurosurgical expertise at the institution. We sought to determine the incidence of neurosurgical intervention in patients treated with IV tPA for acute ischemic stroke at our institution. Methods: We prospectively collected data on acute ischemic stroke patients treated with IV tPA at our institution. Data included baseline demographics, stroke severity, and admission variables. In addition, we tracked the number of patients requiring neurosurgical intervention consisting of a hemicraniectomy, ventriculostomy or hematoma evacuation. Patients were followed until discharge from the stroke service. A favorable outcome was defined as a discharge to home or inpatient rehabilitation. Results: Between January 2004 and December 2006 we treated 405 patients with IV tPA for ischemic stroke. Sixteen patients underwent neurosurgical intervention (4.0%); 13/405 (3.2%) received a hemicraniectomy and 5/405 (1.2%) received a ventriculostomy. Two patients underwent both interventions. Hematoma evacuation was not performed in any patient. The mean time from admission to intervention was 1.4 ⫾ 1.1 days (1.5 ⫾ 1.2 days for hemicraniectomies and 1.2 ⫾ 0.8 days for ventriculostomies). We then compared patents that underwent neurosurgical intervention with those who did not. There were no significant differences with respect to age, race, gender, baseline NIH Stroke Scale, symptom onset to treatment time, and presence of early ischemic changes on CT scan. Patients receiving surgery were more likely to have neurologic deterioration (12/16 vs. 87/389) during their hospital admission (pⱕ.0001). Symptomatic intracranial hemorrhages occurred in 20 patients (5%); 6/16 (38%) of intervention patients versus 14/389 (4%) of non-intervention patients (pⱕ.0001). Patients with neurosurgical intervention had a significantly longer length of hospital stay (13 vs. 6 days) (pⱕ.0001). Only 6% (1/16) patients had a modified Rankin Scale at discharge of ⱕ3 after neurosurgical intervention compared with 59% (229/388) (pⱕ.0001). Only 19% (3/16) had a favorable outcome compared to 36% (140/389) (pⱕ.0001). Conclusion: Ischemic stroke patients treated with IV tPA have a low probability of undergoing neurosurgical intervention. Patients with neurologic deterioration or symptomatic hemorrhage were more likely to receive neurosurgical intervention. On average, there is greater than one day between admission and neurosurgical intervention. Lack of neurosurgery at an institution should not preclude the use of IV tPA for acute ischemic stroke. 50 Chronic Intermittent Mild Hypoglycemic Episodes Exacerbate Ischemic Damage In Streptozotocin-induced Diabetic Rats. Kunjan R Dave, Antonello Pileggi, Isabel Saul, Miguel A Perez-Pinzon; Univ of Miami, Miami, FL Introduction: The American Diabetes Association estimates that stroke and heart disease are the most serious complications of diabetes, as they account for more than 65 % mortality among diabetics. Hyperglycemia is one of the factors responsible for a worse outcome following stroke in diabetics. Clinical studies demonstrate that intensive therapy targeted to control blood glucose and glycosylated hemoglobin was able to delay onset and retard the progression of secondary complications of diabetes. The major side effect of intensive therapy to diabetics is hypoglycemia. There are several reports describing hypoglycemic episodes in both patients with type 1 and type 2 diabetes receiving intensive therapy. We tested the hypothesis that chronic intermittent mild hypoglycemic (CIMH) episodes exacerbate cerebral ischemic damage in a rodent model of diabetes. Method: Global cerebral ischemia was induced by tightening the carotid ligatures bilaterally following hypotension (50 mmHg) for eight minutes. We determined the extent of neuronal death at 7 days of reperfusion in CA1 hippocampus following global cerebral ischemia in control, streptozotocin (Stz)-induced diabetic, insulin treated Stz-diabetic (ITD), and ITD rats exposed to 10 episodes of CIMH (ITD-CIMH) compared with sham ischemic rats. Hypoglycemia (⬃55– 65 mg / dl blood glucose) was induced twice daily for 5 days by hypoglycemic / hyperinsulinemic clamp. Cerebral ischemia was induced 24 hours after the last CIMH treatment. The duration of diabetes was 28 - 32 days while insulin treatment was given for the last 21 days. Results: At the time of ischemia induction, the mean blood glucose for sham, control, Stz-diabetic, ITD, and ITD-CIMH groups was 117⫾6, 127⫾3, 613⫾46, 183⫾5, and 177⫾9 mg / dl, respectively. As expected, Stz-diabetes (18⫾4%, n ⫽ 4) resulted in 216 % (p⬍0.001) increase in ischemic damage as compared to control group (62⫾3 %, n⫽4). Insulin treatment (55⫾2 %, n ⫽ 3) was able to lower ischemic damage by 41 % (p⬍0.001) as compared to diabetic group. ITD-CIMH rats (36⫾4, n ⫽ 5) had 34 % (p⬍0.05) and 41 % (p⬍0.001) more damage as compared to ITD or control group, respectively. Conclusion: This is the first report that CIMH episodes in diabetic animals exacerbate cerebral ischemic damage. CIMH thus may be an unexplored but important factor responsible for increased ischemic damage in diabetes. 51 Intracarotid Delivery Of CD49d FACS Sorted Neural Stem Cells Enhances Angiogenesis And Improves Functional Outcome After Experimental Stroke. Raphael Guzman, Alejandro De Los Angeles, Kevin Choo, Xavier Gaeta, Joey Cote, Samuel Cheshier, Gary K Steinberg; Stanford Univ, Palo Alto, CA Background: Intravascular delivery of NPC after stroke has been limited by the low efficiency of transendothelial migration. VCAM-1 is one of the endothelial adhesion molecules known to be upregulated early after stroke and is responsible for the firm adhesion of CD49d expressing inflammatory cells. We hypothesized that selecting CD49d positive NPC would improve their homing to the injured brain and improve functional outcome after stroke. Cell number and angiogenesis were correlated to behavioral outcome. Methods: On the day of intraarterial injection, a CD49d enriched (⬎90%) and depleted (⬍1%) NPC population was obtained by magnetic bead enrichement and double FACS sorting. Bl6 mice (20 –25g, n⫽18) were subjected to a left side hypoxia ischemia (20min 8% O2 ⫹ temporary right common carotid artery (CCA) occlusion). All mice were tested by rotarod for behavioral deficits and assigned to receive 3x105 CD49d enriched (n⫽6) or CD49d depleted (n⫽6) stem cells or vehicle (n⫽6) injection into the right CCA 48 hours after stroke. Animals were tested by rotarod at 7 and 14 days after stroke and subsequently sacrificed and the brains processed for immunohistochemistry. Cell density was analyzed in the cortex, hippocampus and subventricular zone adjacent to the stroke. Angiogenesis was analyzed by quantifying the lectin positive surface in the penumbral region and the healthy contralateral hemisphere. Results: Two weeks after intracarotid injection significantly more NPC were found in the cortex, hippocampus and subventricular zone adjacent to the stroke in animals receiving CD49d positive as compared to CD49d negative NPC’s (1066/cm2 vs. 583/cm2, p⬍0.05). Behavioral recovery was significantly better for the CD49d positive cells injected group as compared to CD49d negative and vehicle injected animals (p⫽0.031). The CD49d negative group had a better recovery than the vehicle injected group (ns.). There was a positive correlation between the number of cells and the behavioral performance on rotarod (r⫽0.51, p⬍0.05). Analysis of angiogenesis revealed a significantly higher ratio of lectin positive vessels (comparing stroke penumbra to contralateral side) in the CD49d positive group as compared to the CD49d negative and control group (p⬍0.05). Stroke size was not significantly different between the CD49d positive and the CD49d negative group. Conclusions: We show that enrichment of NPC by FACS sorting for the surface integrin CD49d and intracarotid delivery promotes cell homing to the area of stroke in mice and improves sensorimotor recovery. Behavioral improvement seems to be correlated with higher cell numbers and increased angiogenesis. We present two concepts, functional cell selection and intracarotid delivery, which potentially improve the efficiency of intravascular delivery of stem cells for stroke treatment. 52 Sex Differences in micro-RNA Expression in Cerebral Ischemia. Chad Siegel, Fudong Liu, Louise D McCullough; Univ Connecticut Health Cntr, Farmington, CT Introduction: Ischemic cell death pathways differ based on biologic sex. The male ischemic cell death pathway appears to be mediated via nitric oxide, poly (ADP-ribose) polymerase, and apoptosis-inducing factor. The female ischemic cell death pathway involves cytochrome c and caspase activation. While sex differences in the expression of these proteins exist, there is little data regarding the mechanism of their regulation. Micro-RNAs (miRNAs) are a class of novel, non-coding transcripts involved in post-transcriptional gene regulation. There are no current data regarding the role of miRNAs in either the male or the female ischemic brain. miR-15b, miR-21, miR-23a, and miR-138 have all been implicated in cell growth and apoptosis. Current literature suggests miR-15b inhibits Bcl-2 and miR-21 activates caspases. Three databases utilized to determine possible miRNA binding predicted that miR-23a binds to and regulates caspase-3, while miR-138 binds to and regulates X-linked Inhibitor of Apoptosis. We hypothesize that sex differences exist in the expression of all four of these miRNAs in the ischemic brain. Methods: Reversible middle cerebral artery occlusion (MCAo - 90 minute) was performed on male and female C57Bl/6 mice (n⫽3/group). Total RNA was Trizol-extracted 4 hours after ischemic onset and quantitative RT-PCR was performed. miRNA expression was analyzed in sham and stroke brains. Data is normalized to 5s, expressed in Ct values, and significance is defined by p⬍0.05. Results: miR-15b expression is unchanged between the sexes in sham animals, but female stroke animals have increased miR-15b and increased miR-21 expression as compared to male stroke animals (miR-15: 5.03⫾0.14 vs. 5.46 ⫾ 0.20; miR-21: 3.29⫾0.07 vs. 3.77⫾0.16). miR-23a expression is decreased in stroke males and increased in stroke females as compared to sham (male: 1.95⫾0.09 vs. 1.51⫾0.02; female:1.52⫾0.12 vs. 1.77⫾0.03), and increased in stroke females as compared to stroke males (1.52⫾0.12 vs. 1.95⫾0.09). miR-138 expression is decreased in stroke males and increased in stroke females as compared to sham (male: 4.23⫾0.04 vs. 4.68⫾0.01; female: 4.67⫾0.15 vs. 4.34⫾0.11), and increased in stroke females as compared to stroke males (4.34⫾0.11 vs. 4.68⫾0.01). Conclusions: This is the first time any differences in miRNA expression have been seen in the ischemic brain. Upregulation of miR-15b, miR- 21, miR-23a, and miR-138 occurs in the ischemic female brain as compared to males. miR-23a and miR-138 are reciprocally regulated with decreased expression in stroke males and upregulation Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations in stroke females. Future experiments will elucidate the specific targets of miR-21, 23a, and 138 in the ischemic brain. 53 The Role of Toll-Like Recptor(TLR) Signaling in Ischemic Precconditioning. Bolanle M Famakin, Yongshan Mou, Ryo Ohtani, Christl A Ruetzler, John M Hallenbeck; National Institutes, Bethesda, MD Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 The Role of the Toll-like Receptor (TLR) Signaling pathway in Ischemic Preconditioning. Background and purpose: there are limited therapies for stroke despite great strides made in this field of research. The TLR signaling pathway is evolutionarily conserved and critical in immunity, but now appears to participate in ischemia and reperfusion. We tested the hypothesis that the TLR signaling pathway is differentially regulated during ischemic tolerance and cerebrovascular ischemia. Since the two major signaling pathways involved in TLR signaling are the Myd88-dependent and Myd88-independent (TRIF) pathways, we used mice with a mutation in the TRIF gene and mice with deletion of the MyD88 gene in our studies. Methods: Bilateral common carotid artery occlusion (BCCAO) was used to model global cerbrovascular ischemia. BCCAO was performed in C57BL6 mice aged 12–16 weeks with a mutation in the TRIF gene and a deletion in the MyD88 gene. TRIF mutant and wild type C57BL6/J mice were obtained from Jax laboratories. MyD88 breeder pairs were obtained from the Institute for Systems Biology, Seattle, WA. Ischemic preconditioning (IP) was performed by subjecting mice to BCCAO for 6 minutes 24 hours prior to 18 minutes BCCAO (severe global ischemia). Mice in the control group had sham IP (exposure of bilateral common carotid arteries, but no occlusion) followed by severe global ischemia 24 hours later. Seven days after severe global ischemia, brains were harvested and examined for evidence of delayed neuronal loss in the CA1 region of the hippocampus using cresyl violet staining. Results: Three (100%) wild type C57BL6 /J mice from Jackson laboratories exhibited delayed neuronal loss in the CA1 region after 18 minutes of BCCAO without IP.. However, only 25 % (2/8) of TRIF mutant and 20% (1/5) of MyD88 -/- mice showed evidence of delayed neuronal loss under the same conditions.. With IP, none of the TRIF (0/4) mutant mice and (1/4) 25% of the MyD88 -/- mice showed evidence of delayed neuronal loss in the CA1 region. Conclusions: Inhibition of MyD88 or TRIF pathways appears cytoprotective. Mice with a mutation of the TRIF gene respond to IP. However, IP does not seem effective in MyD88 -/- mice. The MyD88 pathway of the TLR signaling pathway may play an important role in mediating responses to IP in the brain. 54 Chronic Soluble Epoxide Inhibition is Protective Against Cerebral Ischemia During Hypertension. Alexis N Simpkins, R D Rudic, David Stepp, Derek A Schreihofer, Siddhartha Roy, Med College of Georgia, Augusta, GA; Bruce D Hammock, Univ of California, Davis, CA; John D Imig; Med College of Georgia, Augusta, GA Epoxyeicosatrienoic acids (EETs), lipid metabolites produced by CYP450 enzymes in neurons and endothelial cells, are novel mediators with cardioprotective effects and modulate cerebral blood flow. EETs are converted by soluble epoxide hydrolase (SEH) enzyme to less active diols, attenuating their protective properties. We have previously shown that adamantanyl dodecanoic acid (AUDA), an SEH inhibitor, can protect against cerebral ischemia and increase middle cerebral artery (MCA) compliance in spontaneously hypertensive stroke prone rats (SHRSP) at a dose of 25mg/L in the drinking water for 6 weeks without decreasing systolic blood pressure of the SHRSPs. Here in this study, we show that 50mg/L of AUDA in the drinking water for 6 weeks does not decrease systolic blood pressure in SHR-SPs 230⫾5mmHg versus (vs.) control SHR-SP 224⫾5mmHg, unlike 6 weeks of enalapril (10mg/kg/day) 152⫾6mmHg. However, AUDA is as effective as enalapril in reducing percent hemispheric infarct size in the SHR-SP with 6 hours of permanent MCA occlusion (50.3⫾2.7 n⫽16 in control, 46.2⫾4.0 n⫽10 in enalapril treated, and 44.2⫾2.3 n⫽16 in AUDA treated, P⬍0.05), which correlates with a smaller neurodeficit score 7.1⫾0.4 in the AUDA treated vs. 8.2⫾0.3 control (P⬍0.05). The protection from cerebral ischemia with AUDA is associated with a reduction in the wall to lumen ratio of the MCA in SHR-SP treated with AUDA (0.19⫾0.01 n⫽6 treated vs. 0.26⫾0.02 n⫽6 control, p⬍0.05) and an increase in the cerebral microvessel density (7127 ⫾ 211.0 m2/per mm2 n⫽3 control vs. 9656 ⫾ 598.0 m2/per mm2 n⫽5 AUDA treated, p⬍0.05). Furthermore, AUDA’s protective effects are sustained when treatment is withheld for one week (45.8⫾8.8 percent hemispheric infarct and 7.6⫾0.8 neurodeficit score, n⫽5). These results demonstrate that chronic SEH inhibition is protective against cerebral ischemia in a model of hypertension, and this protection is associated with a reduction in pathological vascular remodeling and a reduction in the area at risk to ischemia. The ability of SEH inhibition to protect against cerebral ischemia during hypertension indicates that SEH inhibition should be further investigated for its ability to pharmacologically manage ischemic stroke. 541 (pio), reduces the incidence of stroke and myocardial infarction in diabetics, making their neuroprotective actions clinically important. TZDs anti-inflammatory actions are believed to mediate their neuroprotective actions. Since inflammation contributes to reperfusion injury, we hypothesized that reperfusion influences the timewindow for TZD neuroprotection. First, we established the importance of reperfusion using pretreatment. Pio (1mg/kg, IP) was given to rats 24 hrs before and again at the time of 2 hr middle cerebral artery occlusion (MCAO) or permanent MCAO using the suture model. Infarct volume was measured 24 hrs later and expressed as the % of the contralateral hemisphere volume ⫹/- SEM. Pio treated rats receiving 2 hr MCAO had significantly reduced infarct volume (17 ⫹/- 4%;n⫽7) compared with pio treated rats undergoing permanent MCAO (50 ⫹/- 8%;n⫽3), or vehicle treated rats undergoing 2 hr MCAO (48 ⫹/- 4%;n⫽7; p⬎0.05). Using a 2 hr MCAO model, we determined the timewindow for TZD neuroprotection and found that post-MCAO treatment was effective only when pio was given before reperfusion (18 ⫹/- 6%; n⫽4 as opposed to 50 ⫹/- 2%, n⫽6; p⬍0.005). Finally, we altered the time of reperfusion and asked if the timewindow for protection could be extended. All rats were treated with pio 3 hrs after the onset of ischemia. Rats exposed to 3.25 hr MCAO experienced a 47% reduction in infarct volume relative to those exposed to 2 hr MCAO (26 ⫹/-5%, n⫽7 for 3.25 hr MCAO; 50 ⫹/- 2%,n⫽ 3 for 2 hr MCAO; p⬍0.005). Importantly, this protection occurred despite an increased duration of ischemia. Similar results were also found for another TZD, rosiglitazone (0.1mg/kg, IP; 53% infarct volume reduction; p⬍0.005, 18 ⫹/-7, n⫽5 for 3.25 hr MCAO; 38 ⫹/-7%, n⫽ 7 for 2 hr MCAO). Furthermore, we find that leukocyte infiltration is reduced by over 50% in the brains of rats receiving TZD prior to reperfusion relative to rats receiving TZD after reperfusion (p⬍0.001; n⬎200HPF and 3 rats for all treatments) and both TZDs reduce intracellular adhesion molecule (ICAM) mRNA, which contributes to leukocyte infiltration, by 50% relative that seen in vehicle injected rats (p⬍0.05;n⫽3 for rosiglitazone; n⫽5 pio; n⫽4 vehicle). Activated leukocytes gain access to ICAM at the time of reperfusion. If TZD mediated suppression of ICAM expression has been initiated at the time of reperfusion, it is more likely to result in a reduced infiltrate. Physicians increasingly control the timing of reperfusion through the use of thrombolytics and other strategies. These data indicate that TZDs will be most effective when given prior to implementing reperfusion strategies. 56 HSP27 Protects Against Neuronal Ischemia via Attenuation of Mitochondrial Signaling Pathways. R A Stetler, Guodong Cao, Zhongfang Wang, Feng Zhang, Univ of Pittsburgh, Pittsburgh, PA; Yanqin Gao, Fudan Univ, Shanghai, China; Jun Chen; Univ of Pittsburgh, Pittsburgh, PA Background: HSP27 is a member of the small heat shock protein family. In addition to its function as a protein chaperone, HSP27 has shown potent anti-apoptotic effects in various cell types, but the precise mechanism underlying such effects is widely debated. The expression of HSP27 is induced after cerebral ischemia, and may have a neuroprotective role in ischemic neurons. Therefore, the current study was conducted to determine the mechanism by which HSP27 exerts neuroprotective effects following ischemic neuronal injury. Methods: HSP27 transgenic mice (Tg-HSP27) were created on the C57/B6 background using the human HSP27 cDNA under the control of cytomegalovirus enhancer and a chicken -actin promotor. Adult male mice were subjected to 60 min of middle cerebral artery occlusion (MCAO), during which core temperature, blood pressure and blood gases were maintained within normal ranges. Cortical CBF was measured using laser Doppler flowmetry. Mice were sacrificed 24 h after MCAO, and infarct volume was measured on TTC-stained brain sections. For in vitro studies, primary cortical cultures were infected with AAV-HSP27 or AAV-EGFP at 15 DIV for 3 d and then subjected to 60 min of oxygen-glucose deprivation (OGD). Cell viability was measured in cultures 24 h after OGD using Alamar blue flowmetry. Results: Tg-HSP27 mice had significantly smaller infarct volumes than their wild-type littermates 24 h following 60 min of MCAO (18.1 ⫾ 6.6 vs. 47.8 ⫾ 9.2 mm3, p⬍0.0001), as well as improved functional recovery as assessed by neurobehavioral testing. Overexpression of HSP27 in vitro attenuated OGD-induced cell death, caspase-3 and -9 activation, and mitochondrial cytochrome c release. However, no evidence of physical interaction between HSP27 and members of the apoptosome was detectable using co-immunoprecipitation, suggesting that HSP27 may target signaling pathways upstream of apoptosome formation. In support of this, we found that overexpression of HSP27 inhibited the MKK4/JNK signaling pathway following OGD. Conclusion: We have demonstrated that transgenic overexpression of HSP27 efficiently protects against focal ischemic brain injury, leading to improved functional recovery. Contrary to nonneuronal systems reported in the literature, the neuroprotective effect of HSP27 occurs upstream of the mitochondrial pro-death signaling pathway, probably by inhibiting MKK4/JNK-dependent signaling events. 57 Ipsilateral Subventricular Zone is Activated After Acute Ischemic Stroke. 55 Extended Timewindow For Neuroprotection By Thiazolidinediones Is Dependent On Time Of Reperfusion. Jorge Gamboa, Univ of Kentucky, Lexington, OH; Nicole Victor, Gary Landreth, Sophia Sundararajan; Case Western Reserve Univ, Cleveland, OH Thiazolidinediones (TZDs) reduce infarction volume and improve long term neurologic function in rats after focal ischemia. TZDs are used to treat type 2 diabetes and one TZD, pioglitazone Joan Martı́-Fàbregas, Hosp de la Santa Creu i Sant Pau, Barcelona, Spain; José Manuel Garcı́a-Verdugo, Miriam Romaguera-Ros, Ulises Gómez-Pinedo, Unidad Mixta CIPF-UVEG, Valencia, Spain; Isidre Ferrer, Hosp de Bellvitge, L’Hospet de Llobregat, Spain; Sergi Martı́nez-Ramı́rez, Marta Marquié, Luis Antonio Querol, Marc Suárez-Calvet, Daniel Alcolea, Josep-Lluis Martı́-Vilalta; Hosp de la Santa Creu i Sant Pau, Barcelona, Spain INTRODUCTION Recent animal models have shown that repair mechanisms are activated after an ischemic stroke. One of these is the activation of the subventricular zone (SVZ) where the astrocytes behave as stem cells and may generate new neurons. We analyzed the morphologic Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 542 Stroke Vol 39, No 2 February 2008 changes that occurred in the SVZ in patients who died after an acute ischemic stroke. METHODS In patients with a first-ever cerebral non-lacunar infarction in the middle cerebral artery territory, we evaluated the ipsilateral and contralateral SVZ with light and electron microscopy. Immunochemistry with Ki-67 was used to detect cell proliferation and the evaluation was done with imaging techniques (software MethaMorph 7, Molecular Devices). We studied changes in the cyto-architecture with the aid of electron microscopy in the ependymal, gap (hypocellular) and ribbon (astrocytes) layers. RESULTS The study included 5 patients with a mean age of 77 ⫾ 10.4 years, 4 were men. They died after a mean of 8.4 ⫾ 7.8 days (range 2 to 21) after the ischemic stroke. Brain samples were obtained a mean of 4.7 ⫾ 2.4 hours after death (range 2.5 a 8.5). In comparison with the contralateral SVZ, the following changes were observed in the ipsilateral SVZ: widening of the gap layer, increased number of cells in the gap and ribbon layers, a greater cytoplasmatic volume of the astrocytes and an increase of cells positive for Ki-67. CONCLUSION The ipsilateral activation of the subventricular zone is a common phenomenon after an acute ischemic stroke. 58 Improving Motor Function In Chronic Stroke Patients Using Simultaneous Occupational Therapy And TDCS. Dinesh Nair, Vijay Renga, Scott Hamelin, Alvaro Pascual-Leone, Gottfried Schlaug; Beth Israel Deaconess Med Cntr, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: In the current study, we aimed to understand the magnitude and duration of the rehabilitative effects and the neural correlates of multiple simultaneous sessions of occupational therapy and tDCS (sham-controlled) in chronic stroke patients. Methods: Ten chronic stroke patients (⬎ 6 months post-stroke) with moderate to severe upper extremity disability (mean FM of 28) were randomly assigned to the treatment (receiving real-TDCS and occupational therapy (OT) for 5 consecutive days) or sham-control (receiving sham-TDCS and OT for 5 consecutive days) group and crossed-over after one week of assessments. Each subject underwent 2 fMRI (performing auditorially paced flexion and extension movements of wrist and/or elbow) and Transcranial Magnetic Stimulation (TMS) sessions (examining the presence of motor evoked potentials, resting motor thresholds), and several motor assessments (active and passive range of motion (ROM), Fugl-Meyer scores, Wolf-Motor-Function Tests) pre- and post-therapy. During the real-tDCS⫹OT sessions, subjects received OT (60min) along with cathodal TDCS to the contralesional M1 under the assumption that the contralesional M1 exerts an unmatched inhibitory influence on the lesional hemisphere which might interfere with the recovery process. Two primary outcome measures: 1) average percentage improvement of ROM (active*100/passive) across three different joints (shoulder abduction, elbow extension and wrist extension), and 2) Fugl-Meyer score comparing pre with post therapy (real versus sham). Results: The mean change in ROM after real-tDCS⫹OT (7.0%) was significantly higher (p⬍0.05) than after sham-tDCS⫹OT (2.5%). The mean improvement in Fugl-Meyer scores was 5 points in the real-tDCS⫹OT group versus 1.2 points in the sham-tDCS⫹OT group (p⬍0.05). These effects lasted at least 1 week. As an effect of the intervention, the mean activation in the contralesional M1 decreased significantly comparing post with pre, while that in the ipsilesional M1 increased. The improvement score in ROM was inversely correlated with a decrease in the motor activation score (beta value) in the contralesional M1 (which is the hemisphere that was treated with cathodal tDCS). Conclusions: A five consecutive-daytreatment protocol using real TDCS (cathodal) and simultaneous occupational therapy is an effective way to enhance motor recovery in severely impaired chronic stroke patients with effects that outlast the intervention period by at least one week. Imaging evidence indicates that cathodal TDCS might exert its facilitating effect on motor recovery by reducing the transcallosal inhibitory influence exerted by the contralesional, unaffected hemisphere onto the lesional hemisphere. treatment assignment (time X group interaction non-significant), for example: gait velocity increase from baseline to week 9 went from 0.54 ⫹/- 0.37 to 0.72 ⫹/- 0.46 (ROP⫹PT) vs. from 0.49 ⫹/- 0.28 to 0.69 ⫹/- 0.40 (PLAC⫹PT, p⫽0.88); and SIS-16, from 56 ⫹/- 10 to 66 ⫹/- 9 vs. from 58 ⫹/- 11 to 65 ⫹/- 9 (p⫽0.72). None of the 5 serious adverse events was attributable to drug effects. Outside therapy during the study was common, e.g., 61% patients received outside PT (mean 12 sessions). Of patients who received ROP, 93% accurately guessed treatment assignment. Results of serial functional MRI testing will be presented. CONCLUSIONS: PT improves motor function in patients with chronic stroke. PT was also commonly prescribed as standard of care outside of study-related interventions. At the doses achieved in this trial, ROP was safe but did not show any improvement over and above the favorable effects of PT. CLINICALTRIALS.GOV IDENTIFIER: NCT00221390 60 Prevalence And Characteristics Of Potential Subjects For Clinical Trials Of Early Post-stroke Upper Extremity Restoration. Alexander W Dromerick, Georgetown Univ and National Rehabilitation Hosp, Washington, DC; Lucy E Morris, Holly Hollingsworth, Washington Univ, St. Louis, MO; Dorothy F Edwards, Univ of Wisconsin, Madison, WI; M C Baum; Washington Univ, St. Louis, MO Introduction: Stroke lesion location is thought to influence recovery and response to restorative treatments; there is great interest in lesion-driven treatment strategies for motor restoration. The utility of this approach will be limited by the number of patients who have a specific lesion. The prevalence of any single lesion has not been well investigated, nor has the frequency of coexisting brain lesions. We determined the prevalence of potential subjects for a hypothetical upper extremity (UE) intervention trial, and examined clinical and neuroimaging characteristics of that population. Methods: All patients evaluated by the Washington University stroke service from 7/1/04 –3/31/05 meeting ICD-9 acute stroke criteria were studied (n⫽513). Clinical data were obtained from the Cognitive Rehabilitation Research Group stroke registry. Inclusion criteria for a hypothetical trial were applied; these included pre-stroke Barthel Index ⬎95, discharged alive, unilateral UE extremity motor impairment with minimal or no neglect or sensory loss (NIHSS items: UE motor⬎1; Consciousness⬍1, Sensory⬍1, Neglect⫽0, Aphasia ⬍1). CT was routinely obtained; additional MRI’s were performed if indicated. Lesion characteristics were recorded from the MRI; otherwise, the last CT was used. Vascular templates(Damasio) were used for major arterial territories; deep structures were scored individually. Results: 88(17.1%) patients met clinical criteria for this hypothetical trial. The clinical trial population was younger (60.2 ⫹ 13.6 yr.), less severely affected (NIHSS 5.7⫹0.4), more female(56.8%) and more frequently discharged to acute rehabilitation(56.8%) than the overall stroke registry population. MRI was available on 38 of the 88 meeting criteria, 43 has CT only, and 7 had no imaging available. 90% of lesions were ischemic. Acute lesions were visualized in 53 subjects; 42 had a single new lesion, 11 had ⬎2 acute lesions. Of the 42 with single acute lesions, only 13 did not have an additional old stroke or other intra-axial pathology, typically white matter changes. Of the 42 single acute lesions, 16/42 were deep subcortical, 13/42 were superficial cortical only, 5/42 involved both deep and superficial, 7/42 affected brainstem, and 1 affected cerebellum. Oxfordshire scores for those without visualized acute lesions showed lacunar syndromes (66%) and partial anterior syndromes(20%). Conclusion: Our study has two important implications. Restorative treatments for the UE predicated on single lesions in pristine brains in cognitively intact patients will have very limited clinical application; only a small group of registry participants met such criteria in our hypothetical trial. Further, to accurately model the clinical disease of stroke, animal recovery models should incorporate multiple lesions and chronic lesions. 61 59 Ropinirole In The Treatment Of Motor Deficits After Stroke: A Randomized, Placebo-Controlled, Double-Blind Study. Steven C Cramer, Univ of California, Irvine, Orange, CA; Bruce H Dobkin, UCLA, L.A., CA; Elizabeth A Noser, Univ of Texas, Houston, Houston, TX; Rachelle W Rodriguez, Univ of California, Irvine, Orange, CA; Lori A Enney; GlaxoSmithKline, Rsch Triangle Park, NC INTRODUCTION: Several studies suggest the potential to improve motor status in patients with stroke by modifying the function of brain catecholamine receptors. Dopamine receptors are an attractive target given the importance of this neurotransmitter to a multitude of processes including attention, learning, motivation, and motor function. The current study hypothesized that a 9-week course of the dopamine agonist Ropinirole plus physical therapy (PT) would be a safe and effective way to increase gait velocity. METHODS: Entry criteria included stroke 1–12 mo prior, no depression (HAM-D score ⬍ 17), moderate motor deficits (arm/leg Fugl-Meyer score 23– 83/100), and 50 foot walk ⬎ 15 sec. Patients were randomized (double-blinded, stratified for time post-stroke) to 9 weeks of Ropinirole (ROP) or placebo (PLAC), with doses (0.25mg - 4mg QD) titrated weekly as tolerated. All subjects received 8 PT sessions focused on gait, leg, and arm, in weeks 5–9. Assessments extended to week 12, i.e., 3 weeks after drug washout. The primary endpoint, gait velocity, was analyzed using repeated measures ANOVA to examine differences in treatment groups over the 9 weeks of therapy. RESULTS: At 3 U.S. sites, 744 patients were screened and 33 enrolled (age 61 ⫹/- 14 yr; time post-stroke, 30 ⫹/- 15 wks; mean ⫹/- SD). Of these, 16 were randomized to PLAC⫹PT and 17 to ROP⫹PT (mean final daily ROP dose, 2.6 mg). Across all patients, significant gains were found over time for the primary endpoint, gait velocity at week 9 (p⫽0.0001), and for most secondary endpoints, with gains still significant at week 12. However, gains did not differ by The Role Of The Right Hemisphere In Post-Stroke Language Recovery. Gottfried Schlaug, Andrea Norton, Sarah Marchina; Beth Israel Deaconess Med Cntr, Boston, MA Introduction: The neural processes that underlie post-stroke language recovery remain largely unknown and thus, have not been specifically targeted by aphasia therapies. Two possible pathways to recovery may be through reactivation of perilesional areas in the left hemisphere and/or homologous language regions in the right. Because of its potential to engage/unmask language-capable brain regions in the unaffected right hemisphere, Melodic Intonation Therapy (MIT), is well-suited for facilitating language recovery in non-fluent aphasic patients, particularly those with left-hemisphere lesions encompassing large portions of the left frontal and superior temporal lobes. In the current study, we examined the behavioral and neural correlates of speech output after an intensive course of Melodic Intonation Therapy. Methods: Ten patients with left-hemisphere lesions, who were at least 12 months from their first ischemic stroke and had already received at least one course of traditional speech therapy, have participated our Melodic Intonation Therapy trial (75 intensive MIT treatments). Assessments consisting of speech production measures (propositional speech, standardized confrontation naming, and automatic speech) and custom-designed fMRI-experiments using overt speech and singing tasks, were performed twice prior to therapy to establish a stable baseline, and repeated at specific intervals during- and post-treatment. Experimental fMRI tasks required patients to listen to a series of spoken/melodically-intoned, bi-syllabic words/phrases that they were capable of repeating prior to therapy, then overtly repeat each word/phrase after an auditory cue. Experimental tasks were contrasted with control tasks and used to assess potential changes in neural activation/speech output after therapy. Gains in propositional speech scores were correlated with activation changes comparing post- vs. pre-treatment fMRI studies. Results: Across all patients, post-treatment evaluations showed Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations significant improvement (p⬍0.001) in behavioral measures of speech output (e.g., more meaningful words/min and increased phrase length) that correlated significantly with functional imaging changes found in a right-hemispheric fronto-temporal network during overt speech in post- vs. pre-treatment fMRI comparisons. Conclusion: These data suggest that intensive MIT treatment leads to significant gains in speech production that can be maintained after therapy. And further, that these gains are supported by functional brain changes involving primarily right-hemispheric, language-capable brain regions. We hypothesize that MIT’s unique elements (melodic intonation, rhythmic tapping, and continuous voicing) play a critical role in facilitating recovery from non-fluent aphasia. 543 carefully been followed for 3 months. RESULTS: Human bone marrow-derived MSCs were successfully isolated from bone marrow aspirate from all 5 stroke patients, and all were successfully culture-expanded. Serial evaluations showed no adverse cell-related, serological, or imaging-defined effects. CONCLUSIONS: In patients with cerebral infarcts, the intravenous administration of autologous MSCs appears to be feasible and safe, and merits further study as a therapy that may improve functional recovery. 64 Hypertension is Associated with Hippocampal Sclerosis. 62 Brief Psychosocial/Behavioral Intervention With Antidepressant Reduces Post-Stroke Depression Significantly More Than Antidepressant Alone. Pamela H Mitchell, Kyra J Becker, Ann Buzaitis, Kevin C Cain, Michael Fruin, Ruth Kohen, Linda Teri, David Tirschwell, Richard Veith; Univ of Washington, Seattle, WA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objective: To evaluate the short and long-term efficacy of a new brief psychosocial/behavioral intervention adjunctive to antidepressant treatment in reducing post-stroke depression (PSD). This paper reports short term efficacy in reducing depression. Methods: One hundred one patients with ischemic stroke who were clinically depressed (DSM IV criteria) and within four months of index stroke were randomly assigned to receive a 9 session, 8 week brief psychosocial/behavioral intervention plus selective serotonin reuptake inhibitor (SSRI) antidepressant or usual care, including SSRI antidepressants. Reduction in depressive symptom severity was measured by the Hamilton Depression Rating Scale (HDRS) at 9 weeks following entry to the study. The psychosocial/behavioral intervention was adapted from the “Seattle Protocols”, shown to reduce the disability associated with Alzheimer’s Disease. Our adaptation used language pertinent to stroke and taught participants to view depressive symptoms as observable and modifiable behaviors that are initiated and maintained by person-environment interactions. Treatment goal was to increase the level of pleasant social and physical activity in order to improve mood. Participants learned to use behavioral strategies to reduce or prevent behavioral and mood disturbances characteristic of stroke. Specific problem-solving approaches were taught to participants, and solutions to behavioral challenges were individualized to meet the needs of each person. Findings: HDRS in the intervention group was significantly lower immediately post-treatment when compared to the control group (p ⫽ ⬍.001). The mean percent decrease (49% ⫹ 23% intervention versus 19% ⫹ 30% control) and the mean absolute decrease in HDRS (9.8 ⫹ 4.9 intervention vs. 3.6 ⫹ 5.8 control) were both clinically important and statistically significant in the intervention group compared to control (p ⫽ ⬍.001). Responsiveness to treatment may be moderated by serotonin transporter genotype. In 61 of the 101 participants we genotyped the 5-HTTLPR, rs25531 and STin2 VNTR polymorphisms of the serotonin transporter. Treatment success, defined as 50% or greater reduction in HDRS was strongest in the intervention group for those with one or two short (s) alleles of the 5-HTTLPR polymorphism (interaction, p ⫽ .035). The interaction with STin2 VNTR was not significant. Conclusion: A brief psychosocial/behavioral intervention is highly effective in reducing depression in the short term and may be moderated by SERT genotype, particularly 5-HTTLPR polymorphisms. 63 Intravenous Transplantation Of Autologous Mesenchymal Stem Cells Derived From Bone Marrow Into Stroke Patients. Osamu Honmou, Kiyohiro Houkin, Dept. of Neurosurgery, Sapporo Med Univ, Sapporo, Japan; Takuya Matsunaga, Forth Dept. of Internal Medicine, Sapporo Med Univ, Sapporo, Japan; Yoshiro Niitsu, Forth Dept. of Interanl Medicine, Sapporo Med Univ, Sapporo, Japan; Sumio Ishiai, Dept. of Rehabilitation, Sapporo Med Univ, Sapporo, Japan; Stephen G Waxman, Jeffery D Kocsis; Dept. of Neurology, Yale Univ. Sch. of Med, New Haven, CT BACKGROUND: Intravenous injection of mesenchymal stem cells (MSCs) prepared from adult bone marrow has been reported to ameliorate functional deficits in several CNS diseases in experimental animal models. Bone marrow cells can be enriched in MSCs by selecting for plastic-adherent cells. MSCs will grow to confluency in appropriate culture conditions as flattened fibroblast-like cells. Although MSCs may be present in different proportions in the stromal cell fraction of various species, MSCs have a distinct cell surface antigen pattern including SH2⫹, SH3⫹, and CD34-, and methodologies have been established to culture human MSCs in very high purity. Although human MSCs have been clinically used for several diseases, it is still uncertain whether MSCs may have therapeutic benefits on stroke patients. OBJECTIVES: The objectives of this study were to examine feasibility and safety of cell therapy using culture-expanded autologous MSCs in five stroke patients. This study was a phase I clinical trial. METHODS: Five (male and female) patients aged ⬎/⫽50 years with stroke were enrolled. Bone marrows from the stroke patients were obtained by aspiration from the posterior iliac crest after informed consent was obtained; the subject’s consent was obtained according to the Declaration of Helsinki, and this study was approved by the Institutional Review Board at Sapporo Med. Sch. where the cells were isolated and transplanted. Bone marrow was plated in plastic tissue culture flasks, and the adherent cells were cultured in appropriate medium in a humidified atmosphere of 5% CO2 at 37°C. After reaching confluency, they were harvested and cryopreserved until use. On the day of infusion cryopreserved units were thawed at the bedside in a 37°C water bath and injected intravenously into patients over 30 min. All patients were monitored closely during and within 48 h of MSC injections. Oxygen saturation, temperature, blood pressure, pulse and respiratory rate were carefully monitored before and after injection. Patients also had chest films before and after MSC injection. Patients had Amytis Towfighi, Ling Zheng, Univ of Southern California, Los Angeles, CA; William Ellis, Univ of California, Davis, CA; Wendy Mack, Univ of Southern California, Los Angeles, CA; Harry V Vinters, Univ of California, Los Angeles, CA; Helena C Chui, Chris Zarow; Univ of Southern California, Los Angeles, CA Background: Hippocampal sclerosis (HS), severe neuronal loss and gliosis in the CA1 sector of the hippocampus and subiculum, has been reported in 7.4% to 26% of elderly demented individuals. The pathophysiology of HS remains controversial; the prevailing theories are vascular and neurodegenerative. The aim of this study was to use clinical and pathological data to further evaluate the etiology of HS. Methods: 104 autopsy cases drawn from a longitudinal study of subjects with a clinical diagnosis of subcortical ischemic vascular dementia (SIVD), Alzheimer’s disease (AD), and cognitively normal elderly subjects were reviewed pathologically for Braak and Braak stage, CERAD-neuritic plaques score, Lewy Body score, cerebral amyloid angiopathy, atherosclerosis, arteriosclerosis, and severity of cerebrovascular pathology. In all cases, the rostral-caudal extent of both hippocampi were examined; HS was defined as presence of focal neuronal loss with gliosis in the CA1 sector of the hippocampus, not attributable to neurofibrillary tangles. Univariate and multivariate analyses were performed to determine if the following historical and clinical factors correlated with HS: age at death, apoe4 genotype, hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, peripheral vascular disease, alcohol use, smoking, cerebrovascular disease, systolic blood pressure ⱖ 140, diastolic blood pressure ⱖ 90, total cholesterol ⱖ 200, high density lipoprotein ⱕ 40, low density lipoprotein ⱖ 100, triglycerides ⱖ 200, and body mass index ⱖ 25. Results: Of 104 subjects reviewed, 29 subjects (28%) had evidence of HS. On univariate analysis, age at death and history of hypertension were the only factors that were significantly associated with HS (OR 1.1, p⫽0.01 and OR 2.94, p⫽0.021). On multivariate analysis adjusted for age, diastolic blood pressure ⬎90 and history of hypertension were associated with HS (OR 3.34, p⫽0.064 and OR 4.72, p⫽0.004). Conclusion: In this study of 104 elderly patients, hypertension, a key marker of cerebrovascular disease, was significantly associated with HS, supporting a vascular etiology of HS. Supported by grant P01 AG12435. 65 Morphological Changes of Cortical Sulci in Cerebral Small Vessel Diseases: a 3D MRI Study in CADASIL. Eric Jouvent, Dept of neurology, Hopital Lariboisiere, Paris, France; Jean-Francois Mangin, Neurospin, I2BM, Saclay, France; Raphael Porcher, Dept of Biostatistics, Hopital Saint-Louis, Paris, France; Anand Viswanathan, Dept of neurology and Clinical Trials Unit, Massachussets General Hosp and Harvard Med Sch, Boston, MA; Mike O’Sullivan, Dept of neurology, Klinikum Grosshadern, Ludwig-Maximilians-Univ, Munich, Germany; Jean-Pierre Guichard, Dept of radiology, Hopital Lariboisiere, Paris, France; Martin Dichgans, Dept of neurology, Klinikum Grosshadern, Ludwig-Maximilians-Univ, Munich, Germany; Marie-Germaine Bousser, Hugues Chabriat; Dept of neurology, Hopital Lariboisiere, Paris, France Background and purpose: In cerebrovascular disorders, brain atrophy may represent a key marker of clinical severity as reported in neurodegenerative diseases. The cortical morphological changes observed during the course of small vessel diseases remain unknown. In this study, the depth and surface of different cortical sulci were investigated using new imaging tools in a cohort of patients with CADASIL, a genetic model of small vessel disease. Methods: MRI data were obtained from 54 CADASIL patients. Post-processing 3D tools were used to identify automatically and then, calculate the depth and surface of four cortical sulci (cingular, superior frontal, superior temporal and central). The ratio of brain to intracranial cavity volumes (brain parenchymal fraction - BPF), volume of lacunar lesions and of white matter hyperintensities, number of cerebral microhemorrhages, and mean apparent diffusion coefficient were also measured. Association between the depth and surface of the cortical sulci and BPF, clinical status and subcortical MRI lesions were tested Results: The mean depth of the four sulci was strongly related to that of BPF (p⬍0.0001), as was their mean surface (p⬍0.0001). In multivariate analyses, the mean depth was strongly related to the Mattis Dementia Rating Scale (p⫽0.003), and modified Rankin’s Scale (mRS) (p⬍0.0001), as was the mean surface (MDRS : p⫽0.06, mRS: p⫽0.0002). In multivariate analyses, the depth of the different sulci was related to the extent of subcortical lesion, whereas the surface of sulci was only related to age. In additional analyses, the depth of the cingular sulcus was independently associated with the volume of lacunar lesions (p⫽0.01), and the superior frontal sulcus with the mean apparent diffusion coefficient (p⫽0.03). Conclusion: In CADASIL, important morphological changes of cortical sulci occur in association with the progression of global cerebral atrophy. These changes are strongly related to the clinical severity and to the extent of subcortical tissue damage.These results suggest that the examination of cortical morphology may be of high clinical relevance in small vessel diseases. Further studies are needed to better understand the exact mechanisms underlying this process. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 544 Stroke Vol 39, No 2 February 2008 66 Association Between Increased Diastolic Blood Pressure Levels And Cognitive Impairment: The Reasons For Geographic And Racial Differences In Stroke (REGARDS) Study. Georgios Tsivgoulis, Andrei V Alexandrov, Comprehensive Stroke Cntr, Univ of Alabama at Birmingham Hosp, Birmingham, AL; Virginia V Wadley, Dept of Medicine, Univ of Alabama at Birmingham, Birmingham, AL; Frederick V Unverzagt, Dept of Psychiatry, Indiana Univ Sch of Medicine, Indianapolis, IN; Rodney C Go, Dept of Epidemiology, Univ of Alabama at Birmingham, Birmingham, AL; Claudia S Moy, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Brett Kissela, Dept of Neurology, Univ of Cincinnati, Cincinnati, OH; George Howard; Dept of Biostatistics, Univ of Alabama at Birmingham, Birmingham, AL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and purpose: Cross-sectional and prospective studies have shown variable and inconsistent findings regarding the association of blood pressure (BP) levels with impaired cognitive status. This study evaluated relationships of BP components with cognitive impairment after adjusting for potential confounders. Methods: REGARDS is a national, longitudinal population cohort evaluating stroke risk with telephone interviews and in-home physicals in black and white men and women ⱖ45 years of age. Cognitive status and depressive symptoms are being assessed using Six-Item Screener and Center for Epidemiological Studies-Depression-4-Item respectively. During the in-home visit, BP measurements are taken as the average of two measurements using a standard aneroid sphygmomanometer. The present analysis included 27,427 participants with complete baseline physical and cognitive evaluations. Incremental logistic models examined baseline relationships between BP components [systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP)] and impaired cognitive status (score of ⱕ4 on Six-Item Screener) after adjusting for demographic (age, gender, race, region) and environmental (educational level, alcohol use, smoking and exercise habits) characteristics, cardiovascular risk factors (diabetes, hypercholesterolemia, obesity) and depressive symptoms. Results: Increased DBP levels were associated with impaired cognitive status after adjusting for demographic and environmental characteristics, risk factors and depressive symptoms. An increment of 10mmHg in DBP was associated with an 8% (95%CI: 2%–15%; p⫽0.008) higher odds of cognitive impairment. No independent association was identified between impaired cognitive status and SBP (OR: 1.02; 95%CI: 0.99 –1.06) or PP (OR 0.99; 95%CI: 0.95–1.03). There was no evidence of non-linear relationships between any of the BP components and impaired cognitive status. There was no interaction between age and the relationship of impaired cognitive status with SBP (p⫽0.827), DBP (p⫽0.133), or PP (p⫽0.827) levels. Conclusions: That the association between cognitive function was stronger for DBP than for SBP was counter to our hypothesized relationships. The linear cross-sectional association between higher DBP and impaired cognitive status suggests that careful monitoring and control of elevated BP may contribute to the preservation of cognitive function. 68 Tissue Microstructural Changes Are Independently Associated with Pre-Index Cognitive Impairment in Survivors of Lobar Intracerebral Hemorrhage. Anand Viswanathan, Pratik Patel, Rosanna Rahman, R. N Nandigam, Catherine Kinnecom, Massachusetts General Hosp, Boston, MA; Luc Bracoud, Bio-Imaging Technologies SAS, Lyon, France; Jonathan Rosand, Massachusetts General Hosp, Boston, MA; Hugues Chabriat, Dept of Neurology, CHU Lariboisière, Assistance Publique des Hôpitaux de Paris, Paris, France; Steven M Greenberg, Eric E Smith; Massachusetts General Hosp, Boston, MA ABSTRACT Background and Purpose: Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage(ICH) and cognitive impairment and is associated with white matter hyperintensities (WMH) and cerebral microbleeds (MB). MRI diffusion tensor imaging detects microstructural tissue damage in advanced CAA even in areas that appear normal on conventional MRI. We hypothesized that higher global mean apparent diffusion coefficient (mean-ADC), reflecting a higher amount of chronic tissue disruption caused by CAA, and would be independently associated with CAA-related cognitive impairment. Methods: Pre-ICH cognitive impairment (PICI) was systematically assessed using a standardized questionnaire (IQCODE) in 49 patients with CAA according to the Boston Criteria. Volume of WMH, number of MB and mean-ADC were determined from MRIs obtained within 14.0 ⫾ 22.5 days of ICH. Cortical atrophy was graded using a validated scale. WMH and mean-ADC were measured in the hemisphere uninvolved by ICH to avoid confounding. Results: PICI was present in 10/49 subjects. Mean-ADC was the only variable associated with PICI and was elevated in those with PICI compared to those without (12.4x10-4 versus 11.7x10-4 mm2/s; p⫽0.03) (Figure). Mean-ADC positively correlated with age (p⫽0.0002) and cortical atrophy grade (p⫽0.004) but not WMH or number of MB. In logistic regression controlling for age, ICH volume and amount of cortical atrophy, only mean-ADC was independently associated with PICI (OR (per 1x10-4mm2/s increase)⫽2.45, 95%CI 1.115.40, p⫽0.04). Other MRI markers such as nWMH, number of MB, and amount of cortical atrophy were not independently associated with PICI. Conclusions: Mean-ADC is independently associated with pre-ICH cognitive impairment in CAA. The lack of correlation with other MRI markers of CAA suggests that mean-ADC may be sensitive to distinct aspects of CAA pathology and its tissue consequences. These results suggest that global MRI diffusion changes are sensitive to clinically-relevant microstructural alterations, and may be a useful marker of CAA-related tissue damage. 67 Heterogeneity In The Relationships Between Blood Pressure, White Matter Lesion Volume And Cognitive Function In Patients With Small Vessel Disease. Jonathan Birns, King’s College London Sch of Medicine, London, United Kingdom; Jozef Jarosz, King’s College Hosp, London, United Kingdom; Robin Morris, Institute of Psychiatry, London, United Kingdom; Hugh Markus, St George’s, Univ of London, London, United Kingdom; Lalit Kalra; King’s College London Sch of Medicine, London, United Kingdom Background The inter-relationships between dynamic changes in blood pressure (BP), white matter disease and cognitive performance have not previously been investigated in a small vessel disease patient population whose white matter lesion (WML) volume has been quantified. Methods 88 patients (54 male, mean age 65 years) attending a neurovascular clinic with leukoaraiosis on T2 and FLAIR MRI brain scanning were recruited. Exclusion criteria included BPⱖ160/100 mm Hg, cortical infarct or intracranial pathology other than leukoaraiosis on MRI, or stenosis of ⬎50% of extracranial or intracranial arteries on Doppler ultrasound. 24-hour ambulatory BP monitoring, quantitative volumetric MRI analysis of leukoaraiosis and cognitive assessment, including tests sensitive to attentional capacity and executive function, was undertaken. Results Subjects had a mean 24-hour BP of 133/76 (SD13/9) mm Hg, median WML volume of 8464 (IQR 20544) mm3, mean National Adult Reading Test (NART) error score of 25.6 (SD12.3) and mean MMSE score of 27.3 (SD 2.5). After controlling for age and premorbid intellectual functioning, impaired perceptual processing and attentional capacity correlated with frontal and parietooccipital WML volumes (r⫽0.3– 0.4, p⫽0.002– 0.006), impairments of executive function and phonemic verbal fluency correlated with parietooccipital WML volumes (r⫽0.3, p⫽0.007– 0.009) and impairments of phonemic verbal fluency and choice reaction time correlated significantly with infratentorial WML volumes (r⫽0.5– 0.7, p⬍0.001– 0.005). There were significant correlations between daytime mean BP and improved working memory, and between 24-hour pulse pressures and worse executive function, which were independent of aging and premorbid intellectual functioning (r⫽0.3, p⫽0.004 – 0.009) Conclusion In patients with small vessel disease, heterogeneous relationships existed between BP, WML volumes and cognitive function. The neuroanatomical location of white matter tract disruption may influence specific cognitive domains and dynamic changes in BP may affect perfusion within the internal watershed areas differently causing diverse effects on brain structure and function. 69 The Metabolic Syndrome and Cognitive Function in Healthy Middle-Aged and Older Adults without Diabetes. Nicole M Gatto, USC, Los Angeles, CA; Victor W Henderson, Stanford, Stanford, CA; Jan A St. John, Carol McCleary, Howard N Hodis, Wendy J Mack; USC, Los Angeles, CA Recent attention has been directed towards the metabolic syndrome (MetS), a summary measure of major cardiovascular and metabolic risk factors associated with increased risk of heart disease and stroke. Few studies have addressed whether the metabolic syndrome and its individual components are associated with reduced cognitive function in middle-aged and older populations, as well as whether specific areas of cognition are more affected than others. We examined the cross-sectional association between MetS and six areas of cognitive function in healthy cognitively intact men and women without diabetes (n⫽853) randomized in two interventional trials. The National Cholesterol Education Program (NCEP) criteria were used to identify subjects with MetS. Cognitive function was assessed with a neuropsychological battery. A principal components analysis was used to extract five uncorrelated factors interpreted to represent five areas of cognition, and a measure of global cognition was calculated. MetS was weakly associated with decreases in verbal memory and conceptual abilities ( ⫽ -0.16 [SE() ⫽ 0.09], p ⫽ 0.08). As the number of MetS criteria increased, global cognition and verbal memory and conceptual abilities decreased (p-trend both ⫽ 0.01). Hypertension was the only MetS risk factor that was independently correlated with decreased verbal memory and conceptual abilities ( ⫽ -0.26 [SE() ⫽ 0.07], p ⫽ 0.0004), semantic memory and visuospatial abilities ( ⫽ -0.15 [SE() ⫽ 0.07], p ⫽ 0.03) and global Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations cognition ( ⫽ -0.12 [SE() ⫽ 0.06], p ⫽ 0.06). This study provides evidence of an association between MetS and reduced cognitive function among healthy middle aged and older adults without CVD and diabetes, as well as confirms the association between hypertension and reduced cognitive function. TABLE 1 FIA 70 Cortical Grey Matter Volume is Reduced in Patients at High-Risk for Vascular Events. ANEURYSMS Nerses Sanossian, Ling Zheng, Wendy Mack, Univ of Southern California, Los Angeles, CA; Michael W Weiner, Univ of California San Fransisco, San Fransisco, CA; William J Jagust, Univ of California, Berkely, Berkeley, CA; Charles C DeCarli, Dan Mungas, Univ of California, Davis, Sacramento, CA; Bruce R Reed, Univ of California, Davis, Martinez, CA; Joel H Kramer, Univ of California San Fransisco, San Fransisco, CA; Helena C Chui; Univ of Southern California, Los Angeles, CA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Vascular cognitive impairment is a process by which vascular risk factors (VRFs) cause permanent effects on brain function. There are multiple mechanisms by which VRFs affect cognition; however the mediators of this relationship are poorly understood and likely include changes in cortical grey matter (CGM). Objective: To determine if increased vascular risk, as measured by the Framingham Coronary Risk Profile (FCRP), is associated with reduction of relative CGM volume in a group of community-dwelling older persons participating in an observational study. We hypothesize that increasing FCRP scores will be independently associated with decreased CGM volume via ischemic, inflammatory and other mechanisms. Methods: Participants were recruited from a multicenter collaborative study of the contributions of subcortical ischemic vascular disease and AD to cognitive impairment and dementia. All participants received a comprehensive clinical evaluation and a standardized MRI scan of the brain at recruitment. Voxel based morphometry followed by hand editing was used to classify brain MRI pixels into CGM, , white matter hyperintensities (WMH), and CSF (expressed as % intracranial volume). Number and volume of lacunes were drawn by hand. Hippocampal volume was determined using a semi-automated method using surgical navigation technology. Results were adjusted for subject age. Results: 128 subjects had baseline FCRP and MRI available. Mean age was 75.6 (SD ⫾7.2), 42% female, 84% white, and 9% Asian. The clinical diagnosis was normal in 49%, cognitively impaired in 22%, Subcortical ischemic vascular dementia (SIVD) in 5%, Alzheimer’s Disease in 17% and Mixed AD/SIVD in 7%. The mean FCRP was 21.8 (⫾13.9) and the mean percent CGM volume was 37.9 (⫾3.24). FCRP was inversely related to percent CGM volume (r⫽ -0.209, p⫽0.018). Other MRI markers significantly associated with FCRP were number of lacunes (r⫽.250, p⫽0.0048) and lacune volume (r⫽0.283, p⫽0.0014). Hippocampal volume showed a trend towards an inverse relationship to FCRP(r⫽ -0.165, p⫽0.074). White matter hyperintensity volume was not associated with FCRP (r⫽0.127, p⫽0.15). The inverse relationship of CGM and FCRP remained significant after adjusting for age. Discussion: The cognitive effects of vascular risk factors may be mediated by loss of CGM volume. This may have implications in the relationship of VRFs with cognitive performance in vascular and Alzheimer disease. 71 Neurovascular Phenotypes in Children with Familial Intracranial Arterial Aneurysms. Todd Abruzzo, Univ of Cincinnati Med Ctr, Cincinnati, OH; L. Seranno, Cincinnati Children’s Hosp Med Cntr, Cincinnati, OH; D. Kleindorfer, B. Jones, Univ of Cincinnati Med Ctr, Cincinnati, OH; F. Mangano, L. Sauerbeck, Cincinnati Children’s Hosp Med Cntr, Cincinnati, OH; A. Greely, Univ of Cincinnati Med Ctr, Cincinnati, OH; N. Zumberge, Columbus Children’s Hosp, Columbus, OH; K. Crone, Cincinnati Children’s Hosp Med Cntr, Cincinnati, OH; J. Broderick; Univ of Cincinnati Med Ctr, Cincinnati, OH OBJECTIVE: Case series of intracranial arterial aneurysms (IAA) in children have shown significant differences in phenotype as compared with adults. The formation of an IAA in the first two decades of life suggests a more potent biological phenotype, perhaps representing the effect of strong genetic influences. We examined the IAA phenotype in children with Familial Intracranial Aneurysms (FIA), where strong genetic influences are known to exist. MATERIALS AND METHODS: FIA patients under age 19 years (y) were identified by query of the FIA study database. The FIA study is a multi-national study of families with saccular IAA in a sibling pair or ⱖ 3 first degree relatives. In this study, IAA in children were discovered when they ruptured or when neuroimaging of a sibling to a child with a ruptured IAA was pursued by parents. Only children with saccular aneurysms confirmed by surgery or neuroimaging were included. An age matched cohort with non-familial, idiopathic saccular IAA were identified by searching clinical databases at 3 tertiary referral hospitals. We queried radiology reports, clinic registries and angiography logs from 01/93 to 11/06 using the search term “aneurysm”. Medical records were reviewed to confirm each case. Traumatic, infectious, neoplastic, inflammatory and flow related aneurysms were excluded. Phenotypic traits were recorded by medical record review and compared. Differences were tested for significance using the Fisher Exact Test. RESULTS: 8 of 441pedigrees yielded 10 FIA children with 12 IAA. In the Non-familial cohort, there were 13 children with 16 IAA. No genetic condition or family history of IAA was reported for any child in this cohort. Data are presented in Table 1. Analysis of children presenting with hemorrhage showed a decreased frequency of posterior circulation aneurysms in the FIA cohort as compared with the non-familial cohort (p ⫽ 0.03). CONCLUSIONS: The pediatric FIA phenotype is characterized by presentation in adolescence, female predominance and small, proximal anterior circulation aneurysms. In children presenting with hemorrhage, non-familial IAA are commonly in the posterior circulation, while familial IAA are not. Differences between Non-familial and Familial IAA may reflect the differential importance of environmental and genetic factors in determining vascular segment specific vulnerability to aneurysm formation. 545 >7 < 7 mm Size unknown Posterior circulation Anterior circulation Within or proximal to circle of Willis Distal to circle of Willis CHILDREN Average age in years (std. dev.) Male: Female ratio Caucasian ethnicity Multiple aneurysms Non-familial All Children Children presenting with hemorrhage All Children Children presenting with hemorrhage N⫽12 aneurysms 2 8 3 1 11 7 N⫽8 aneurysms 2 3 3 0 8 4 N⫽16 aneurysms 6 10 0 6 10 10 N⫽10 aneurysms 3 7 0 5 5 8 4 4 6 2 N⫽10 children 15 (⫹/- 3) N⫽7 children 15 (⫹/- 4) N⫽13 children 16 (⫹/- 2) N⫽8 children 15 (⫹/- 1) 0.7 10 3 0.7 7 1 1.6 11 3 1.0 7 2 72 Bilateral Corticospinal Tract Degeneration After Unilateral Stroke in Hemiparetic Children: A TMS and MRI Study. Adam Kirton, Alberta Children’s Hosp, Calgary, Canada; Trish Domi, Hosp for Sick Children, Toronto, Canada; Robert Chen, Toronto Western Rsch Institute, Toronto, Canada; Manohar Shroff, Elizabeth Kouzmitcheva, Hosp for Sick Children, Toronto, Canada; Carolyn Gunraj, Toronto Western Rsch Institute, Toronto, Canada; Gabrielle deVeber; Hosp for Sick Children, Toronto, Canada Background: Hemiparesis after childhood stroke is predicted by acute diffusion signal in the descending corticospinal tracts (DCST-DWI), termed “pre” Wallerian degeneration (WD). Newly described contralesional DCST-DWI appears to predict severe hemiparesis but its pathophysiology is unstudied. Methods: We hypothesized that contralesional DCST-DWI represents acute recruitment (and chronic enhancement) of uncrossed DCST from the unlesioned hemisphere to the weak hand and investigated this using: (1) Bilateral transcranial magnetic stimulation (TMS) in children with contralesional DCST-DWI to evaluate for enhanced ipsilateral motor evoked potentials (iMEP), and (2) A novel method measuring bilateral DCST areas from 29 children with chronic, unilateral middle cerebral artery stroke to detect changes in one or both DCST areas using the ratio of ispi (I) and contra (C) cerebral peduncle areas to a standardized brainstem area (S). Results: All children had normal MEP contralateral to the unlesioned side. iMEP were normal for age (absent in 2, small in 2/80 trials from other 2). Peduncle area in children with no acute DCST-DWI showed only mild ipsilesional atrophy (C/S:I/S⫽1.38/1.26; Figure left). Children with acute ipsilesional DCST-DWI showed marked ipsilesional DCST atrophy and the largest difference between sides (C/S:I/ S⫽1.55:1.21; middle). In contrast, those with acute contralesional signal showed evidence of bilateral DCST atrophy with an intermediate difference between sides (C/S:I/S⫽1.36:1.10; right). Differences between these three groups was highly significant (Kruskal-Wallis ANOVA p⫽0.004). Conclusion: Acute DCST-DWI predicts chronic WD. Bilateral corticospinal tracts may be adversely affected after unilateral stroke with loss of contralesional DCST associated with severe outcome. Such novel reorganization merits further study. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 546 Stroke Vol 39, No 2 February 2008 73 Childhood Ischemic Stroke Is More Common in Boys: Findings from the International Paediatric Stroke Study. Male sex Birth weight, mean (SD), g Birth weight ⬍2500g Birth weight ⬎4000g Apgar score, 5 min, mean (range) Meredith Golomb, Riley Hosp, Indianapolis, IN; Heather Fullerton, Univ of California San Francisco, San Francisco, CA; Gabrielle deVeber, The Hosp for Sick Children, Toronto, Canada; and members of the International Paediatric StrokeStudy Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Several studies have suggested a male predominance in childhood ischemic stroke, mirroring well-described gender differences in adult stroke, but were limited by small sample sizes or non-validated diagnoses. The International Pediatric Stroke Study (IPSS)–a multi-centre, multi-national prospective study of pediatric ischemic stroke initiated in 2003–provides a new opportunity to examine this issue. Objective: To determine if a male predominance exists in children with ischemic stroke within a large international study, and whether this gender difference is specific to a certain stroke sub-type, age group, or underlying etiology. Methods: From 1/2003–2/2007, the IPSS prospectively enrolled children (0 –18 years of age) with arterial ischemic stroke (AIS) or cerebral sinovenous thrombosis (CSVT) at 30 hospitals in 10 countries. Investigators abstracted clinical data onto standardized data collection forms. Proportions of boys were calculated for the whole group and for subgroups defined by age (neonatal defined as first 28 days of life), stroke sub-type (AIS versus CSVT), and etiology (as determined by the enrolling investigator using standardized etiologic criteria). Assuming a 1:1 ratio of boys to girls in the general population, we used chi-square tests to compare the observed proportion of boys with stroke to the expected proportion of 50% Results: Among 965 children with ischemic stroke, 582 were boys (60%, p⬍0.001). Male predominance persisted after stratification by age (59% for neonates N⫽289, p⫽0.038; 61% for later childhood, N⫽676, p⬍0.001) and stroke sub-type (59% for AIS, N⫽741, p⬍0.001; 63% for CSVT, N⫽224, p⫽0.003). It also persisted for the different etiologic subgroups: 61% for underlying cardiac disease (N⫽204, p⫽0.03); 59% for vasculopathy (N⫽185, p⫽0.09); 61% for underlying chronic disease, such as pro-thrombotic states, sickle cell anemia, and hematological malignancies (N⫽322, p⫽0.003); and 66% for head and neck disease, such as otitis media, pharyngitis, and head and neck trauma (N⫽205, p⫽0.001). There were no gender differences in case fatality or deficits at discharge. Conclusion: In a large international cohort, childhood ischemic stroke appears to be more common in boys than girls, regardless of stroke sub-type, age group, or etiology. Further exploration of this gender difference could shed light on stroke mechanisms in both children and adults, where a similar difference has been observed. 74 Prevalence and Predictors of Perinatal Hemorrhagic Stroke. Jennifer Armstrong-Wells, S Claiborne Johnston, Yvonne W Wu, UC San Francisco, San Francisco, CA; Steven Sidney, Kaiser Permanente Med Cntr, Oakland, CA; Heather J Fullerton; UC San Francisco, San Francisco, CA Background: Predictors for perinatal arterial ischemic stroke (PAS) include maternal factors such as preeclampsia, prolonged rupture of membranes, and chorioamnionitis, and also intrapartum factors, such as fetal distress and emergent cesarean delivery. Prevalence and predictors of perinatal hemorrhagic stroke (PHS) have not been studied. Methods: We performed a case-control study nested within the cohort of all infants born from 1993–2002 in the Northern California Kaiser Permanente Medical Care Program, a health maintenance organization providing care for more than 3 million members. Cases of symptomatic PHS and PAS in neonates (28 weeks gestational age through 28 days of life) were confirmed by review of medical records. Three controls per case were randomly selected and matched on birth year and facility. This analysis included cases of PHS (intracerebral hemorrhage [ICH] and subarachnoid hemorrhage [SAH], excluding pure intraventricular hemorrhage) and all controls. Predictors of PHS were assessed using logistic regression techniques, adjusting for the matching criteria. Results: The population prevalence of PHS diagnoses was 6.2 per 100,000 live births, compared to 28 per 100,000 for PAS. There were 19 cases of ICH and 1 SAH. Cases commonly presented with altered mental status (100%) and seizures (65%). PHS was typically unifocal (74%), unilateral (83%), and seen in the parietal (47%), frontal (37%), and less commonly, temporal regions (17%). Underlying etiologies included thrombocytopenia (n⫽3) and cavernous malformation (n⫽1); 16 (80%) were idiopathic. Univariate predictors of PHS included fetal distress, birth by emergent cesarean delivery, and preterm or post-dates gestational age (Table). Because of colinearity, we did not enter these predictors into a multivariate model. Conclusions: Similar to PAS, predictors of PHS include intrapartum factors such as fetal distress and emergent cesarean delivery. However, we found no evidence to suggest that maternal factors predict PHS, suggesting that underlying mechanisms of PAS and PHS may differ. UNIVARIATE PREDICTORS OF NEONATAL HEMORRHAGIC STROKE Cases Controls (n⫽20) (n⫽317) Maternal age, mean (SD) 28.3(5.4) 28.5(6.0) Primiparity 11/20 (55%) 149/317 (47%) Preeclampsia 0/18 3/255 (12%) Chorioamnionitis 0/11 3/54 (6%) Maternal fever 1/14 (7%) 12/173 (7%) Prolonged rupture of membranes 1/19 (5%) 16/296 (5%) Prolonged second stage of labor 1/17 (6%) 17/204 (8%) Gestational age, mean (SD) 38.4(3.5) 38.9(2.0) Preterm (<36wks) 3/20 (15%) 16/312 (5%) Post-dates (>40wks) 5/20 (25%) 39/317 (12%) Fetal distress 7/20 (35%) 22/292 (7.5%) Vacuum delivery 1/20 (5%) 36/312 (12%) Emergency cesarean delivery 6/20 (30%) 35/313 (11%) OR (95% CI) P value – 0.62 1.3 (0.5–3.4) 0.49 – 0.64* – 0.44* 0.86(0.08–8.9) 0.91 1.1 (0.1–10.2) 0.86 0.7 (0.06–7.9) 0.77 – 0.89** 5.2 (1.04–25.4) 0.044 3.7 (1.08–12.5) 0.036 9.7 (2.8–33.5) <0.001 0.4 (0.05–3.1) 0.38 3.6 (1.1–12.0) 0.03 – Cases Controls OR (95% CI) P value 13/20 (65%) 3145 (934) 3/20 (15%) 3/20 (15%) 8.7(6–9) 158/317 (50%) 3377 (594) 19/316 (6%) 36/316 (11%) 9.1(5–10) 1.9 (0.7–4.8) – 2.5 (0.59–10.8) 1.92(0.47–7.8) – 0.2 0.95** 0.21 0.36 0.69** Adjusted for birth year and facility of birth. P-value calculated by chi-square* or t-test** 75 Expanded Case Identification Methods Yield a Higher Incidence of Pediatric Stroke. Nidhi Agrawal, S. C Johnston, Yvonne W Wu, UCSF, San Francisco, CA; Stephen Sidney, Kaiser Permanente, San Francisco, CA; Heather J Fullerton; UCSF, San Francisco, CA Background: Prior annualized estimates of pediatric ischemic stroke incidence have ranged from 0.5–1.2 per 100,000 U.S. children, but these studies relied purely on diagnostic code searches to identify potential cases. We sought to estimate the incidence of pediatric ischemic stroke using not only diagnostic code searches, but also searches of radiology reports, and to assess the relative value of these two search strategies. Methods: Using the population of 2.3 million children (ages 0 –20 years) enrolled in a Northern California managed care plan (1/1993–12/2003), we performed electronic searches of (1) in-patient and out-patient diagnoses for ICD-9 codes suggestive of ischemic stroke (433– 436, 437.6) and cerebral palsy (CP; 342–344) and (2) radiology reports for keywords suggestive of infarction. Cases were confirmed through independent chart review by two neurologists, with adjudication by a third. Positive predictive value (PPV) and sensitivities were calculated and stratified by etiology and age at diagnosis. Neonatal strokes were defined as those occurring within the first 28 days of life. Results: We identified 280 potential cases from the stroke ICD-9 code search, 863 from the CP ICD-9 code search, and 439 from the radiology search. A total of 217 childhood ischemic stroke cases were confirmed during 8.9 million person-years of follow-up, yielding an annual incidence rate of 2.4 per 100,000 children. The radiology search had a higher sensitivity than the ICD-9 code search, although both strategies had low PPVs (Table). The sensitivity of ICD-9 codes for neonatal strokes (15%) was significantly lower than that for later childhood strokes (53%, p⬍0.0001), as was the sensitivity of ICD-9 codes for idiopathic strokes (27%) compared to strokes with an identified etiology (45%, p⬍ 0.006). Conclusions: Our estimate of childhood ischemic stroke incidence is double that of prior reports, a difference at least partially explained by our use of both ICD-9 code and radiology searches for case identification. Studies relying purely on ICD-9 code searches may underestimate childhood stroke rates, particularly for neonatal and idiopathic strokes. TABLE. SENSITIVITY AND PPV BY SEARCH STRATEGY FOR ISCHEMIC STROKES Search Strategy Stroke ICD-9 alone Inpatient Diagnoses Outpatient Diagnoses Sensitivity (%) 95% CI PPV (%) 95% CI 34 21 13 26–42 14–29 5–15 29 18 11 23–34 14–23 7–15 Stroke ICD-9 ⫹ CP ICD-9 39 31–47 9 7–10 Radiology alone Radiology ⫹ Stroke ICD-9 83 95 75–89 90–98 26 30 22–31 26–35 76 Nitrative Stress Induces Cerebral Microvascular Degeneration Via The Production Of Trans-Arachidonic Acids: Role Of Hypercapnia. Jean-Claude Honore, Amna Kooli, Elsa Kermorvant-Duchemin, Sainte-Justine Rsch Cntr, Montreal, Canada; Florian Sennlaub, INSERM U598 - Cntr des Cordeliers, Paris, France; Michael Balazy, Dept of Pharmacology - New York Med College, Valhala, NY; Sylvain Chemtob; Sainte-Justine Rsch Cntr, Montreal, Canada Nitrative stress is importantly involved in microvascular degeneration notably through the isomerisation of arachidonic acid which leads to the formation of trans-arachidonic acids (TAA). Carbon dioxide (CO2) enhances nitration by catalyzing the conversion of peroxynitrite into the unstable, more efficient nitrating agent nitrosoperoxocarbonate (ONOOCO2-). On the other hand, preterm infants brain is particularly sensitive to oxidative and nitrative stress due to deficient antioxidant defenses and polyunsaturated fatty acids enriched-cellular membranes. We thus hypothesized that in rat pup models, increased local and/or systemic CO2 levels could favor production of TAA and subsequent cerebral microvascular degeneration. In the cerebral hypoxia/ischemia (HI) rat pups model (postnatal day 7; P7), our results indicate that ipsilateral brain TAA levels are significantly increased 18 hours post-HI as compared to the contralateral side. This phenomenon is associated with a significant decrease of the ipsilateral brain microvascular density. Interestingly, when TAA are directly injected into cerebral lateral ventricles, a similar decrease of microvascular density is observed. The mechanism involved is blood pressure-independent since vascular density is also decreased in ex vivo TAA-treated brain explants. Furthermore, using newborn rat pups directly exposed to 10% CO2 levels from P1 to P3, we observed an increased endothelial cell nitric oxide synthase (eNOS) expression, an increased endothelial cell 3-nitrotyrosine staining; a marker of increased nitrative stress, and a decreased cerebrovascular density. Finally, in microvascular endothelial cells cultured in a 10% CO2 atmosphere, a NO donor DETA NONOate (0.01 mM) enhances 3-nitrotyrosine Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations positive cells and cell mortality. Mechanistically, we have determined that TAA triggers endothelial cell apoptosis through an ERK1/2 activation, and a subsequent upregulation of the antiangiogenic factor thrombospondin-1. In conclusion, our data suggest that CO2 favors nitrative stress and could trigger encephalopathy by eliciting production of trans-arachidonic acids and ensuing cerebral microvascular degeneration in preterm infants. 77 Secretory Phospholipase A2 is Involved in Hypoxic Cerebrovascular Injury in the Newborn Piglet. Ferenc Bari, Aliz Zimmermann, Univ of Szeged, Szeged, Hungary; Jana Pardeike, Free Univ, Berlin, Germany; Eszter Farkas, Ferenc Domoki; Univ of Szeged, Szeged, Hungary Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Phospholipase A2 enzymes including secretory PLA2 (sPLA2) hydrolyze membrane phospholipids and release arachidonic acid. Arachidonic acid is metabolised by cyclooxygenases (COX) producing prostanoids that are key regulators in the newborn cerebral circulation. However, the specific involvement of sPLA2 in prostanoid production is unknown. Cerebral ischemia/ reperfusion (I/R), often occurring during the neonatal period, enhances sPLA2 activity, production of prostanoids and free redical formation. Secretory PLA2 has been implicated in ischemic neuronal damage, but its function in cerebrovascular injury has not been addressed. We used the novel sPLA2 inhibitor PX-18 to examine the role of the enzyme in: 1) the hemodynamics of the systemic and cerebral circulation; 2) COX-dependent cerebrovascular dilatory responses as hypercapnia and pituitary adenylate cyclase-activating polypeptide (PACAP)-38, and 3) the mechanism of I/R-induced cerebrovascular dysfunction. Newborn piglets (1–2-day old, n⫽44) were studied. The animals were anesthetized, ventilated, equipped with arterial and venous catheters and closed cranial window. Pial arteriolar diameter was measured by intravital microscopy. Pial arterioles were significantly dilated (16⫾5%, mean⫾SEM) by PX-18 (10-4M) administered topically onto the brain surface, but not by lower concentrations (10-8-10-5M). Intravenous (iv) bolus of PX-18 (6 mg/kg) transiently decreased the mean arterial blood pressure (from 62⫾7 mmHg to 40⫾5 mmHg) and dilated pial arterioles (32⫾1%) which both normalized in 4 – 6 min. Cerebrovascular dilation to hypercapnia was unaffected by topical (40⫾6% vs. 50⫾7%) or iv PX-18 (51⫾5% vs. 64⫾11%). Pial arteriolar responses to PACAP-38 (10-6M) were significantly reduced by topical PX-18 (10-5M, 67⫾11 vs. 24⫾6), but did not change after iv PX-18 (6 mg/kg in 20 min, 71⫾13 vs. 70⫾8). I/R diminished pial arteriolar reactivity to endothelium-dependent (hypercapnia: from 44⫾4 to 25⫾7, bradykinin 10-6M: from 65⫾7 to 38⫾6) and -independent (NMDA 10-4M: from 57⫾5 to 19⫾7) vasodilators and was rescued by iv PX-18 (responses were 35⫾5%, 59⫾8% and 50⫾10%, respectively). We conclude that sPLA2 1) contributes to basal vascular tone in the cerebral and systemic circulation; 2) may participate in COX-dependent cerebral vasodilation and 3) is significantly involved in I/R-induced cerebrovascular injury. Therefore, PX-18 could be the basis of novel protective pharmacological tools against I/R-induced cerebrovascular injury. 78 Single Center Experience With Combined (Thrombolytics and Mechanical Thrombectomy) Intra-arterial Intervention In 112 Consecutive Patients With Angiographically Confirmed Large Vessel Thromboembolic Ischemic Stroke (1–6 hours post symptom onset) from 2003 to 2007. Michael T Madison, James K Goddard, III., Jeffrey P Lassig, Mark E Myers; St. Paul Radiology, Saint Paul, MN Background: Intra-arterial thrombolytics and mechanical intervention have been shown to recanalize acute ischemic strokes at high rates. Less data has been presented on use of these interventions in community based settings. We wanted to see if results from our group of 4 neuro- interventionalists covering acute stroke at 5 hospitals in the Minneapolis-St. Paul area were consistent with outcomes presented in other trials. Methods: We retrospectively reviewed 112 consecutive angiographically confirmed large vessel thromboembolic ischemic stroke patients treated with intra-arterial intervention in under 6 hours between 2003 to 2007. We generally load the patients with 10 –20 mg of IA tPA. If this fails to recanalize the vessel, we utilize mechanical thrombectomy, and may optionally use additional IA thrombolytics or eptifibatide during procedure. We reviewed baseline demographics, procedural outcomes, hemorrhage rates, and clinical outcomes. Results: The average baseline NIHSS in the cohort was 14.2 (Range 8 –29). Average time of symptom onset to intervention 4 hours and 5 minutes (Range 1–5.5 hours). Intra-arterial Thrombolytics were used in 101 patients (90%). Average dose of IA tPA was 24.6 mg (Range 9 – 42 mg). Average dose of I.A. eptifibatide was 4.6 mg (Range 0 –9.5 mg). The Merci Retriever was used in 54 patients (48%); the immediate post-retriever recanalization was 52%. Final angiographic vessel recanalization (TIMI 2–3 Flow) for the overall cohort was 72%. Average NIHSS (24 – 48 hours) post treatment was 7.5 (Range 0 –30). Positive clinical outcomes were observed in 59% (66/112) of the patients,and in 82% of patients with successful vessel recanalization. In the cohort with improved outcome, the average NIHSS prior to treatment was 13.5 (Range 8 –24) and post treatment was 4.8 (Range 0 –18). In the cohort without vessel recanalization post treatment NIHSS was 14.6 (Range 8 –30). Parenchymal contrast staining at 24 hours was observed in 29%, and symptomatic hemorrhage was observed in 13%. Only 2 patients with complete recanalization had symptomatic hemorrhage. Conclusions: Results from trials done at academic centers can be successfully replicated in a private practice group of 4 neuro-interventionalists covering 5 community hospitals. High rates of final recanalization and good clinical outcomes were observed. Further analysis of our cohort is ongoing. 547 79 Pre-ischemic Upregulation of TNF-␣ induced by Physical Exercise Reduces Brain Inflammation via ERK1/2 Signaling in Stroke. Alecia Curry, Brandon Leibelt, Ryan Rogers, Will Davis, Shane Sprague, David F Jimenez, Yuchuan Ding; Univ Texas Health Science Cntr, San Antonio, TX It has been shown that pre- ischemic physical exercise chronically upregulates TNF-␣. The increase in TNF-␣ prior to I/R injury is associated with a decrease in MMP-9 activity and a subsequent neuroprotective effect in rat stroke models. In this study we sought to test the hypothesis that reduced cerebral inflammation in ischemic rats is caused by the neuroprotective action of TNF-␣ reduced matrix metalloproteinase-9 (MMP-9) activity and suppressed adhesion molecule (ICAM-1) expression via ERK 1/2 phosphorylation. Adult male Sprague Dawley rats were subjected to 30 minutes of exercise on a treadmill 6 days a week for 3 weeks. Stroke was induced by a 2 hour middle cerebral artery (MCA) occlusion using an intraluminal filament. The animals in the 3 week exercised group were treated before MCA occlusion and at reperfusion with UO126 (ERK1/2 inhibitor), TNF-␣ antibody, or both UO126 and doxycycline (MMP-9 inhibitor). Brain infarct volume was assessed using Nissl staining. Leukocyte infiltration was evaluated using myeloperoxidase (MPO) immunostaining in cortex and striatum. I-CAM levels were determined by real time PCR and Western blot and MMP-9 expression was evaluated using RT-PCR, Western Blot, and Zymography to evaluate mRNA levels, protein, and enzyme activity. In exercise group, there was a significant decrease in brain infarct volume as well as MMP-9 activity, leukocyte infiltration, and ICAM-1 expression. In the animals treated with either TNF-␣ antibody or with UO126, an increase in the levels of the same four parameters was observed, which neared the level detected in the non-exercise stroke group. Furthermore, a decrease in the above mentioned parameters was seen in the animals treated with both UO126 and doxycycline. As expected, the decrease in these parameters was near the levels obtained in exercise ischemic rats. The results suggest that phosphorylation of ERK 1/2 plays a major role in the decrease in brain inflammation and subsequent neuroprotective effects seen after exercise induced upregulation of TNF-␣ prior to I/R injury by decreasing MMP-9 activity. 80 Optimal tPA Concentration for 120 kHz Ultrasound Enhanced Thrombolysis. George J Shaw, Jason M Meunier, Christopher J Lindsell, Christy K Holland; Univ of Cincinnati, Cincinnati, OH Introduction: Contraindications to tPA use for acute ischemic stroke and potential side effects such as intra-cerebral hemorrhage (ICH) have led to interest in potential therapies such as ultrasound enhanced thrombolysis (UET). Recently 2 MHz transcranial UET was found to increase the recanalization rate in acute ischemic stroke patients compared with standard tPA therapy. Lower frequency ultrasound (⬃ kHz) is of potential interest for UET as there are studies suggesting better skull penetration and lytic efficacy than higher frequency (⬃MHz) UET. However, a 300 kHz UET trial showed no difference in outcome and a higher ICH rate compared with tPA alone. Clearly, the optimal UET therapy is unknown. Here, the tPA concentration dependence of 120 kHz UET lytic efficacy is determined in an in-vitro human clot model. We hypothesize that there is a range of tPA concentrations for which 120 kHz UET lytic efficacy is maximal. Methods: Blood was drawn from 10 subjects after IRB approval. Clots were made in 20 l pipettes, and placed in a water tank for microscopic imaging during ultrasound (US) and tPA treatment. All treatments were at 37o C for 30 minutes. Clots were treated with tPA (tPA), or tPA and 120 kHz US (UET) in plasma at one of 7 concentrations: 0 (control), 0.25, 0.50, 1.00, 3.15, 6 and 10 (g/ml). Each treatment used an average 18 clots (range 6 –31), from 4 donors (range 3 to 10). Clot lysis was imaged and clot diameter measured over time using a previously developed method. Average initial lytic rate, defined as the percent decrease in clot width per minute (LR) and fractional clot loss at 30 minutes (FCL) was determined for each group. Data are shown as mean ⫾ SEM. Results: The figure shows lytic rate vs.tPA concentration ([tPA]) for tPA and UET treated clots. There is a maximum in LR for the UET group for [tPA] ⬇ 1–3 g/ml. FCL (data not shown) for UET and tPA treated clots increases with [tPA] up to 1 g/ml; and is constant for larger values of [tPA] in both groups. Conclusions: LR for 120 kHz UET treated clots exhibits a maximum for [tPA]⫽1–3 g/ml, and greater FCL at all [tPA] values compared with tPA treated clots. It may be possible to optimize UET therapy for increased lytic efficacy while minimizing tPA dose. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 548 Stroke Vol 39, No 2 February 2008 81 Cerebral Ischemia Results In A Varying Degree Of Reduction Of Cerebral Blood Flow In Gray And White Matter. Quan Zhu, Duke Univ, Durham, NC; Jin-Moo Lee, Katie Vo, Washington Univ, St. Louis, MO; Weili Lin; Univ of North Carolina, Chapel Hill, NC Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Purpose The extent to which cerebral blood flow (CBF) is reduced in relationship to the normal CBF values has been utilized as an indicator to discern ischemic injury. However, despite the well known difference in CBF between gray and white matter, relatively little attention has been given as to how CBF may be differently altered in gray and white matter during ischemia. The lack of attention is most likely attributed by the inability to accurately separate gray and white matter particularly during the hyperacute phase. To this end, we propose a new approach capable of accurately segmenting gray (GM) and white (WM) matter separately in perfusionweighed MR images, allowing a direct and rapid assessment of CBF values in GM and WM separately during acute cerebral ischemia. Materials and Methods MR PWI images were obtained from 10 acute stroke patients using an EPI sequence (TR/TE/ FOV/Mat⫽2s/54ms/ 220mm2/128). A model-based segmentation using unsupervised Bayes classifier with the expectation-maximization (EM) algorithm and a mixture of multivariate Gaussians (MoMG) based on robust principal components analysis (PCA) was developed. Specifically, the matrix X(t⫻N) denotes the perfusion data, where N is the total voxel number in the brain. For each time series xn (t⫻1), n⫽1,…,N, the Bayes classifier is defined as p(i| xn,i,⌺i i)⫽p(i)p(xn|i)/ ⌺ {p(i)p(xn|i)}⫽ i gxn [i,⌺i ]/ ⌺{ i gxn [i,⌺i ]}. Here i{1,…,K} represents a tissue class label. The parameters i,⌺ i and i were estimated by fitting the MoMG to maximize the posterior probability using the EM algorithm. Robust PCA, which is less influenced by outliers, was applied to reduce the data size prior to the clustering process. Results The proposed approach successfully segments the entire brain into multiple components, including not only CSF, normal GM and WM, but also abnormal GM and WM for all patients. Mean CBF values were obtained from normal/abnormal GM and WM, separately. The ratio of normal GM/WM is 2.02⫾0.31 while this ratio is reduced to 1.63⫾0.18 for abnormal GM/WM. In addition, the ratio between normal and abnormal gray is 1.72⫾0.31 and between normal and abnormal white is 1.38⫾0.13, respectively. Conclusions Consistent with the reported results in the literature, the normal GM/WM CBF ratio is ⬃2. However, this ratio is significantly reduced during cerebral ischemia, suggesting that ischemia leads to preferential reduction of CBF in GM. Specifically, the CBF in normal GM is about 1.72 times higher than that in the abnormal GM, while the normal WM is only 1.38 times higher than the abnormal WM. Finally, our results may suggest that the CBF threshold values for infarction may be different between GM and WM. 82 Electrical Stimulation of the Cervical Spinal Cord Resolves Cerebral Vasospasm following Subarachnoid Hemorrhage in Rats. Jin-Yul Lee, Dah-Luen Huang, Richard Keep, Oren Sagher; Crosby Neurosurgical Laboratories, Ann Arbor, MI OBJECTIVE. Cerebral vasospasm following subarachnoid hemorrhage (SAH) remains one of the most serious complications of aneurysmal rupture. Although the delayed cerebral vasospasm is clinically well described, its pathogenesis is still not fully understood, and it remains difficult to treat. Recently, increased global cerebral blood flow (CBF) ameliorating cerebral ischemia was shown through cervical spinal cord stimulation (SCS) in a number of experimental models as well as in anecdotal reports in humans. However, it has not been applied systematically for use in cerebral vasospasm. The aim of this experimental study is to assess the effect of cervical SCS during cerebral vasospasm in a double hemorrhage rat model which causes a significant CBF reduction due to marked vasoconstriction on Day 5 after second SAH induction. METHODS. SAH induction was performed using a double hemorrhage injection method through an indwelling catheter in the cisterna magna. SCS was performed on Day 5 after second SAH induction using standardized technique (unipolar stimulation with 50 Hz, pulse width of 0.2 msec, and current of 0.6 mA). Regional CBF was measured using laser Doppler flowmetry (LDF) and 14C-IMP (14C-radiolabeled N-isopropyl-p-iodoamphetamine hydrochloride) and compared to a SAH group on Day 5 and a sham operated control group without SCS (n⫽25). Additionally, the effect of SCS was assessed microscopically by cross-sectional area of basilar artery (BA) at different points (n⫽15). RESULTS. SCS caused an immediate increase in LDF values to ⬃ 150% of baseline within 10 sec during delayed vasospasm. Thereafter, LDF values progressively dropped reaching values 50% over baseline at 90 sec. and then remained constant. Furthermore, SCS resulted in significant increase in global CBF from ⬃ 60 - 70 to ⬃ 90 - 120 % of control as assessed using 14C-IMP. CBF increase was more pronounced in cerebral regions supplied by the middle cerebral artery (MCA) to that seen in regions supplied by the BA. Microscopically, a significant increase in cross-sectional area of BA (43% ⫾ 19 of baseline) could be found after SCS. CONCLUSIONS. The results of this study show that cervical SCS leads to marked vasodilation and improves significantly the regional CBF during delayed vasospasm in a double-hemorrhage rat model. SCS may represent a useful adjunct in the treatment of vasospasm. delayed and sustained narrowing of the cerebral arteries that typically occurs 4 –21 days after a SAH. Following SAH, patients fall into one of three categories: (1) approximately 30% develop angiographic vasospasm with clinical symptoms of ischemia; (2) 50% develop angiographic vasospasm without clinical symptoms; and (3) 20% have neither angiographic nor clinical evidence of vasospasm. The patients who develop symptomatic vasospasm after SAH may possess a genotypic predisposition. Since inflammation and, more specifically, leukocyteendothelial cell interactions are critical to vasospasm development, and haptoglobin (Hp) modulates inflammation following hemorrhage, we hypothesized that an individual’s Hp genotype may influence their risk for vasospasm. Humans, unlike other mammals, possess two alleles for the Hp gene (Hp1 and Hp2), resulting in three possible genotypes: Hp1–1, Hp1–2, or Hp2–2. The linear Hp1–1 protein more effectively suppresses inflammation induced by extracorpuscular hemoglobin as compared to the cyclical Hp2–2 protein. This functional difference may predispose Hp2–2 individuals to more severe inflammation and thus more severe vasospasm following aneurysmal SAH. Methods: Wild-type Hp1–1 C57Bl/6J mice (n⫽45) and genetically-modified Hp2–2 C57Bl/6J mice (n⫽45), underwent injection of either autologous blood or normal saline solution into the cisterna magna. The animals were sacrificed 24 hours after SAH (time of peak vasospasm in this model) and basilar artery lumen patency and macrophage/neutrophil concentrations in the subarachnoid space were determined histologically and immunohistochemically, respectively. Activity levels were also quantified prior to sacrifice using a 3-point scale. Results were analyzed by Kruskal-Wallis/ Student-Newman-Keuls ANOVA. Results: Hp 2–2mice, as compared to Hp1–1 mice, had significantly lower basilar artery lumen patencies (52.9⫹1.9%vs.82.3⫹1.3% (mean⫹SEM), p⬍0.001), higher macrophage/neutrophil concentrations (31.2⫹6.3vs.8.8⫹1.7 cells/hpf, p⫽0.009), and lower activity scores (0.8⫹0.3vs.2.4⫹0.2, p⬍0.001). Hp2–2 mice not only had more severe vasospasm, but also were markedly symptomatic following experimental SAH. Conclusion: These findings suggest that the Hp2–2 genotype may predispose individuals to the development of severe vasospasm, and that Hp2–2 may serve as a molecular marker to prospectively identify individuals who are at increased risk for this condition. These findings also may explain why only 30% of patients develop severe, symptomatic vasospasm with ischemic deficits, and why current animal models of SAH (exclusively Hp1–1) have asymptomatic and typically mild vasospasm. 84 Early Inflammation after TIA or Ischemic Stroke: Different MMP-9 Time Courses predict Stroke Severity. Hans Worthmann, Anita B Tryc, Argyro Tountopoulou, Annemarie Goldbecker, Reinhard Dengler, Ralf Lichtinghagen, Karin Weissenborn; Med Sch Hannover, Hannover, Germany INTRODUCTION: The early time course of inflammatory reaction immediately following cerebral ischemia has not been investigated in detail. Particularly a correlation with important biomarkers of inflammation like MMP-9, TIMP-1, MCP-1 is still lacking. HYPOTHESIS: Innate inflammation has been identified as one of the factors contributing to bad prognosis in vascular disease. Extent and time course of inflammation as determined by circulating levels of MMP-9, TIMP-1, S-100, IL-6, CRP and MCP-1 is correlated with stroke severity and negatively correlated with functional outcome. METHODS: Blood samples of 87 patients with ischemic stroke were taken at admission and 6h, 12h, 24h, 3d, 7d after symptom onset. Plasma concentrations of biomarkers were measured by commercially available immunoassays. Functional scores mRS (modified Rankin Scale) and NIHSS were taken at each timepoint. RESULTS: Here we present the results of the first 51 patients. Plasma/ serum values of MMP-9, TIMP-1, S-100, IL-6, CRP and MCP-1 show an increase which is significantly correlated with clinical severity. Remarkably different time courses for MMP-9 levels depending on stroke severity are detected. Patients with poor clinical outcome at day 7 show a massive increase of MMP-9 levels as early as 3 to 6h after symptom onset followed by a progressive decline over time (median: 6h: 119.3ng/ml; 12h: 68.2ng/ml; 24h: 80.5ng/ml). In severe stroke cases MMP-9 levels remain elevated for the days to follow. For patients with good recovery we found an increase of MMP-9 levels as early as 3 to 6h followed by a fast decrease at 12h and 24h followed by low and stable plasma levels at 3d and 7d (median: 6h: 68.6ng/ml; 12h: 49.1ng/ml; 24h: 38.9ng/ml). In ROC analysis for comparison of light and severe clinic with biomarkerlevels at 24 hours after symptom onset the area under the curve for MMP-9 is 0.7429. Increase of MMP-9 levels correlates with S-100 (MMP-9 24h: r⫽0.497, p⬍0.001). Extent of tissue damage as measured by S-100 at each time point but particularly as early as at admission strongly correlates with worsening of functional scores at day 1 and day 7 (day1: r⫽0.795; p⬍0.001; day7: r⫽0.586, p⫽0.022). In time course of IL-6, TIMP-1 and MCP-1 levels we detected a rapid increase as early as 6 hours after symptom onset whereas elevation of CRP levels is delayed with a maximum at 24 hours and 3 days after symptom onset. CONCLUSION: Our data show important differences in early time course of inflammation after ischemia depending on stroke severity. Strokes with full recovery in functional scores (mRS, NIHSS) compared to completed strokes with poor clinical outcome show a different time course of biomarkers in particular MMP-9. Further exploration of dynamics of inflammatory biomarkers such as MMP-9 is warranted given the shown negative correlation with functional outcome. 83 The Role of the Haptoglobin Genotype in the Development of Chronic Vasospasm After Experimental Subarachnoid Hemorrhage. 85 Neuroanatomical Basis of Swallowing Disorders after Stroke. Kaisorn L Chaichana, Johns Hopkins Sch of Medicine, Baltimore, MD; Andrew P Levy, Rachel Lotan-Miller, Technion-Israel Institute of Technology, Haifa, Israel; Sophia Shakur, Rafael Tamargo; Johns Hopkins Sch of Medicine, Baltimore, MD Marlis Gonzalez-Fernandez, Jonathan T Kleinman, Paul Ky, Jeffrey B Palmer, Argye E Hillis; Johns Hopkins Univ Sch of Medicine, Baltimore, MD Introduction: The leading cause of morbidity and mortality following aneurysmal subarachnoid hemorrhage (SAH) is chronic cerebral arterial vasospasm. Chronic cerebral vasospasm is the Background: Dysphagia is a common problem after stroke associated with significant morbidity and mortality. Except for patients with brain stem strokes, particularly lateral medullary strokes, Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations it is difficult to predict which cases are likely to develop swallowing dysfunction based on their neuroimaging. Clear models of swallowing control and integration of cortico-bulbar input have not been defined and the role of subcortical structures is still unclear. Objective: To identify regions of interest (ROIs) that might be related to dysphagia in acute stroke patients, with a focus on subcortical structures. Methods: We studied 29 acute stroke cases admitted to our institution between 2001 and 2005 with a diagnosis of a first ischemic stroke and without history of swallowing dysfunction. Subjects had MRI within 24 hours. Cases were defined as those subjects who were diagnosed as dysphagic after clinical evaluation by a speech language pathologist and whose dysphagia was considered significant requiring treatment by diet consistency modification. Controls were defined as those patients who: (1) had passed the stroke unit’s dysphagia screening, (2) had a Clinical evaluation by a SLP that did not result in a diagnosis of dysphagia or diet modifications, or (3) had no documented evidence of dysphagia evaluation or treatment through their medical stay and were discharged home on a regular diet. A trained technician, blinded to case-control status, examined 12 ROIs for dysfunctional tissue in DWI and PWI images. The odds ratio (OR) of dysphagia was calculated for each ROI. Logistic regression models were used to adjust for stroke severity (NIHSS) and stroke volume. Results: Analysis of data on 14 cases and 15 controls demonstrated significant differences in the odds of dysphagia in the following ROIs: 1) primary somatosensory, motor and motor supplementary areas (PSSM) (OR⫽8.8, p⫽0.009); 2) orbitofrontal cortex (OFC)(OR⫽6.5, p⫽0.04); 3) putamen, caudate, basal ganglia (PCBG)(OR⫽5.33, 0.047); and 4) internal capsule (IC)(OR⫽26; p⫽0.005). Non-significant differences were found in the insula and temporopolar cortex. Adjusted odds ratios for the PSSM, OFC, and PCBG were not statistically significant. Adjusted OR of dysphagia for subjects with strokes affecting the IC was 17.8 (p⫽0.03). Conclusion: Significantly increased odds of dysphagia were found in subjects with IC involvement. Other areas that may play an important role include the PSSM, OFC, and PCBG. Analysis of additional areas was limited by the number of subjects in our sample. Further studies with larger sample size can help elucidate the swallowing control mechanism and move toward developing a full swallowing control model. 549 limb. Results: A significant difference was found for blood flow velocity (F ⫽ 53.18, p ⫽ 0.002) between the hemiparetic and less affected limbs. In addition, arterial diameter for the hemiparetic limb was significantly smaller than the less affected limb (F ⫽ 475.58, p ⫽ 0.004); see Figure 1. Conclusion: These findings suggest individuals post-stroke have vascular changes in blood flow velocity and arterial diameter that reduce overall blood flow to the muscle. This may influence muscle performance during exercise. . Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 86 The Plasticity of Swallowing Center in the Brain. Jing Zhang, Xingquan Zhao, Chunxue Wang, Yongjun Wang; BeijingTiantan Hosp Affiliated to Capital Med Univ, Beijing, China Background and objective: There had no study focus on the plasticity of swallowing centers in the brain using fMRI methods. We hypothesis that the volume of swallowing centers would enlarged after recovery of swallowing function. Methods: Total 8 dysphagia patients after stroke were examined under videofuloroscopy swallowing study. Then they had the fMRI study to identify the activation situation during swallowing tasks. After treatment and the recovery of swallowing function, the patients accepted the second fMRI study and six patients had the second videofluoroscopy study. The fMRI were studied utilizing blood oxygenation leveldependent (BOLD) technique on a 3.0 T magnetic resonance scanner (seimens). The parameters were TR 2620ms,TE 30ms, Flip angle 90,FOV 240⫻240cm,Slices of 36,slice thick of 3mm,scanning time is 374s. Subjects were swallow 1 ml water boluses after it was infused into their oral cavity through a plastic catheter placed in the midline in different interval time from 20s⬃35s and total 12 boluses were injected. Matlab7.0 and Statistical Parametric Mapping (SPM2) were used to postmanagement. Results: Dysphagia patients had no activation in 4/6, ACC, parietal lobe, but brainstem, frontal lobe of 8,44,46,47, insula, temporal lobe of 21,22, occipital lobe of 18,19, post cingulate and left cerebellum were activated. After treatment, Brodmann 4,6,3,1,2 areas had larger activation volume. Activation volume in insula enlarged from less than 10 voxels to 56 voxels. The secondary motor areas such as BA 8,9,11 and BA 7 in the parietal lobe, PCC, puteman, brainstem and cerebellum were activated after therapy. Conclusions: The higher centers of swallowing had plasticity. The activation volume in the sensomotor area and insular were enlarged. The activation in ACC, parietal lobe, brainstem and cerebellum were presented. This suggested that these areas were envolved in the modulation of swallowing. 87 Femoral Artery Blood Flow Velocity and Diameter Changes in the Hemiparetic Limb in Chronic Stroke. Sandra A Billinger, Benjamin Y Tseng, Patricia M Kluding; Univ of Kansas Med Cntr, Kansas City, KS Purpose/Hypothesis: Physical activity levels may play a primary role in blood flow regulation. For people post-stroke, a reduction in physical activity and a decreased demand for leg oxygen consumption may affect blood flow to the hemiparetic lower extremity. Decreased blood flow to the hemiparetic muscles may limit performance during functional tasks or exercise. The purpose of this study was to characterize differences in femoral artery blood flow velocity and arterial diameter between the hemiparetic and less affected limb. Subjects: Twelve individuals (69.0 ⫹ 17.0 yeas of age; 8 male) with chronic stroke (6.0 ⫹ 5.0 years post-stroke; 10 with right-side hemiparesis) participated in the study. Methods: Doppler ultrasound was used to characterize resting femoral artery blood flow velocity and diameter between the hemiparetic and less affected lower extremity. Femoral artery blood flow velocity was measured at a 60° inclination angle, with the velocity gate open wide to obtain the average blood flow velocity in the arterial wall. With the ultrasound image frozen on the screen, arterial diameter measurements were taken just above the bifurcation of the common femoral artery at peak systole. Repeated measures ANOVA (␣ ⬍ 0.05) was used to assess differences between femoral artery blood flow velocity and diameter between the hemiparetic and less affected 88 One Year Follow-up Of Patients Who Are Using The Ness L300 Neuroprosthesis: Effects On Gait Performance. Gad Alon, Univ of Maryland, Sch of M, Baltimore, MD; Jeffery M Hausdorff, Harvard Med Sch, Boston, MA; Haim Ring; Sackler Faculty of Medicine, Tel-Aviv Univ, Tel-Aviv, Israel OBJECTIVE: Foot drop is a common impairment that adversely affects the ability of patients with chronic stroke to walk normally. The aim of the present study was to assess patients’ ambulation performance after one year of daily use of the NESS L300 neuroprosthesis - a radio frequency controlled, self-administered stimulation system. SUBJECTS: Sixteen patients (mean age: 55.7⫾14.0) with chronic hemiparesis (6.3⫾4.7yrs) and foot drop . METHODS: Gait was evaluated at baseline without the neuroprosthesis and in four testing sessions with the neuroprosthesis at the initial fitting, after one month, after two months and after one year. At each testing session, subjects walked for 6 minutes wearing force-sensitive insoles. Swing and stride durations were measured while walking speed, gait asymmetry index and stride time variability were calculated. Gait speed was also measured during a 10 meter walk on an obstacle course. A repeated measures model was used to analyze the neuroprosthetic effect on each outcome measure over time. Hotelling’s T2 test compared the one year gait results with baseline (p⬍0.05). RESULTS: Improvement over time was significant for all tested variables. Walking speed improved from 0.62⫾0.22 m/sec to 0.91⫾0.21 m/sec (p⬍0.001). Walking time over an obstacle course improved by 58% (from 0.40⫾0.15 m/sec to 0.63⫾0.19 m/sec; p⬍0.001). Single limb stance (SLS) over the paretic limb increased by 25.6% (from 26.2% to 32.9%; p⫽0.02). The gait asymmetry index, a marker of inter-limb coordination, improved by 96% (from 0.51⫾0.33 to 0.26⫾0.10; p⫽0.006). Stride time variability, an indicator of gait rhythm, decreased from 5.32⫾3.31 to 3.79⫾1.64 (p⫽0.01). Compared to the gains achieved at 2 months, gait speed (with or without obstacle course) improved further at one year, (Figure 1) while the improvements in gait stability at 2 months were preserved at one year. CONCLUSIONS: Daily use of the NESS L300 neuroprosthesis over 12 months enabled patients with chronic foot drop to improve their walking ability . The self-administered stimulation system seems to offer a favorable alternative option to over come foot drop in patients with chronic hemiparesis. . Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 550 Stroke Vol 39, No 2 February 2008 89 Efficacious Affected Arm Rehabilitation Via the Internet; Using Inexpensive, Remote Technology to Deliver Electrical Stimulation. Stephen Page, Valerie Hill, Peter Levine, Univ of Cincinnati, Cincinnati, OH; Amanda Herzog, Rachel Jordan, Maura Hoefner; Xavier Univ, Cincinnati, OH Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Stroke-induced hemiparesis is problematic given its impact on activities of daily living (ADLs). Although affected arm rehabilitation is important, patients are often limited in their ability to attend rehabilitation sessions due to limited transportation. Conventional telemedicine efforts are also often impractical, and can require extensive and expensive technologies that are not available to many stroke patients or rehabilitative clinics. Given the above limitations, the current study examined the feasibility and efficacy of an Internet-based affected arm rehabilitation program. A 62 year old male exhibiting arm hemiparesis and nonuse from an ischemic stroke occurring 3 years before study entry was enrolled. He was administered The Fugl-Meyer Assessment of Impairment (FM) and Action Research Arm Test (ARA) during a single, in-person testing session. During the same session, the subject also received an electrical stimulation machine and instructions on its use, as well as a PC-mounted videocamera to affix to his home computer. Instructions included donning and doffing the stimulation system, and turning the stimulation device on and off. The participant was deemed competent with using the electrical stimulation and camera by the end of the session, by demonstrating all aspects of the application and use of the systems independently. During the next 4 weeks, the subject then used the system for two, 30 minute sessions per weekday. During these times, he logged onto the PC camera at a predetermined time, and was guided through specific exercises with the aid of the stimulation, and with guidance by a member of the therapy team, via the Internet. After 4 weeks, he returned to the laboratory, where the outcome measures were again administered and the devices were returned. Testing revealed a ⫹ 8.0 increase in FM score, indicative of reduced affected arm impairment in the wrist and fingers, and a ⫹ 4.0 increase in ARA score, indicative of new movement in the fingers during fine movements, such as picking up a marble. Functionally, the subject exhibited new ability to write and manipulate small objects (e.g., a zipper). These data suggest feasibility and efficacy of this noninvasive, home-based protocol for electrical stimulation. Importantly, the entire protocol required only two, in person visits by the subject, who lived ⬎ 100 miles away from our rehabilitatation center. 90 Stroke Caregiver Outcomes from the Telephone Assessment and Skill-Building Kit (TASK). Tamilyn Bakas, Indiana Univ Sch of Nursing, Indianapolis, IN; Carol J Farran, Rush Univ Sch of Nursing, Chicago, IL; Joan K Austin, Indiana Univ Sch of Nursing, Indianapolis, IN; Barbara A Given, Michigan State Univ College of Nursing, East Lansing, MI; Susan M Perkins, Indiana Univ Sch of Medicine, Indianapolis, IN; Elizabeth A Johnson, Indiana Univ Sch of Nursing, Indianapolis, IN; Linda S Williams; Indiana Univ Sch of Medicine; Regenstrief Institute; Roudebush Veterans Administration Med Cntr, Indianapolis, IN Background and Purpose: Family caregivers of stroke survivors can experience depression, social inactivity, and poor health as a result of providing care. Furthermore, stroke caregivers often express needs for information about stroke, assistance with stroke-related care, and follow-up after discharge. The Telephone Assessment and Skill-Building Kit (TASK) is an 8-week follow-up program based on individualized assessment of caregiver needs. The purpose of this study was to determine the efficacy of the TASK program in improving stroke caregiver outcomes and to estimate effect sizes for a larger study. Methods: Guided by a conceptual model derived from Lazarus’ transactional theory of stress, 6 stroke caregiver outcomes (optimism, task difficulty, threat appraisal, depressive symptoms, life changes, general health perceptions) were measured in 40 family caregivers randomized to the TASK program (n⫽21) or an attention control group (n⫽19). Data were analyzed using repeated measures ANCOVA, controlling for baseline scores and number of minutes spent with the nurse, with the 4-week and 8-week outcome scores as the dependent variables for each analysis. Partial 2 was used to estimate effect sizes (⬍ .08 small, .09-.24 medium, ⬎.25 large). Results: Significant improvements in caregiver optimism [F(1,36) ⫽ 6.51, p⫽.015, 2 ⫽.153] and task difficulty [F(1,36) ⫽ 5.29, p⫽.027, 2 ⫽.128] were found with medium effect sizes for the TASK group relative to the control group. Although not significant in this small sample, medium size improvements in threat appraisal [F(1,36) ⫽ 3.70, p⫽.062, 2 ⫽.093] and depressive symptoms [F(1,36) ⫽ 3.59, p⫽.066, 2 ⫽.091] were also found. Small, non-significant improvements were noted in life changes [F(1,36) ⫽ 2.794, p⫽.103, 2 ⫽.072] and general health perceptions [F(1,36) ⫽ 1.96, p⫽.170, 2 ⫽.052]. Conclusions: The TASK program showed improvement in caregiver optimism, task difficulty, threat appraisal, and depressive symptoms in this small sample. Further testing of the TASK program in a larger randomized controlled clinical trial is warranted, with attention in subsequent studies directed toward more distal caregiver health outcomes. 91 Costs and Rehabilitation Utilization of Stroke Patients: A Retrospective Study of Medicare Beneficiaries. Richard D Zorowitz, Johns Hopkins Bayview Med Cntr, Baltimore, MD; Er Chen, Kuo B Tong; Quorum Consulting, Inc., San Francisco, CA Objective: Long-term economic impact of stroke and stroke-related hemiparesis has not been well characterized. Utilization of physical therapy and rehabilitation (PTR) among these patients is not well understood. The aim of our study is to examine the costs and PTR utilization in patients with stroke and stroke-related hemiparesis during a 3-year period following their first stroke onset. Methods: Patients with newly diagnosed stroke who were discharged from hospital were identified from a 5% national random sample of all Medicare beneficiaries. These patients were followed from 2003 to 2005, and their Medicare claims were linked from different claims databases. Patients were classified with regard to development of hemiparesis during the study period. In-hospital mortality rate, overall Medicare reimbursements, and PTR utilization and reimbursements were analyzed in each year. Findings: We identified 1,849 patients with newly developed stroke in the first quarter of 2003. Among them, 1,070 subsequently developed hemiparesis and 779 did not. The in-hospital mortality rate of these stroke patients was 30.2%, 8.1% and 7.6% in 2003, 2004 and 2005, respectively. Average Medicare payments were $75,793 for the hemiparesis cohort and $44,544 for the nonhemiparesis cohort during these 3 years. The hemiparesis cohort incurred significantly higher costs than the non-hemiparesis cohort in the 3-year study period, and across nearly all care settings. Hospital inpatient care incurred the highest costs, followed by physician care and skilled nursing care. Significantly more patients in the hemiparesis cohort received some form of PTR than those in the non-hemiparesis cohort during the 3 years. While most costs of PTR incurred in a hospital inpatient setting in 2003 for the hemiparesis cohort, the costs of PTR shifted to skilled nursing facilities and home health agencies in 2004 and 2005. Conclusions: Long-term care and rehabilitation services, especially for stroke patients suffering from hemiparesis, constitute a significant proportion of total medical costs. Costs other than those incurred in hospital inpatient setting must be taken into account when organizing management of post-stroke patients. 92 Insulin Resistance and Risk of Ischemic Stroke among Non-Diabetic Individuals from the Northern Manhattan Study. Tatjana Rundek, Dept of Neurology, Miller Sch of Medicine, Univ of Miami, Miami, FL; Qiang Xu, Dept of Biostatistics, Joseph Miallman Sch of Public Health, Columbia Univ, New York, NY; Ronald B Goldberg, Dept of Medicine, Miller Sch of Medicine, Univ of Miami, Miami, FL; Bernadette Boden-Albala, Dept of Neurology and SocioMed Sciences, Mailman Sch of Public Health, Columbia Univ, New York, NY; Norbelina Disla, Dept of Neurology, Columbia Univ, New York, NY; Myunghee C Paik, Dept of Biostatistics, Joseph Mailman Sch of Public Health, Columbia Univ, New York, NY; Mitchell S Elkind, Dept of Neurology, Columbia Univ, New York, NY; Ralph L Sacco; Dept of Neurology, Epidemiology and Human Genetics, Miller Sch of Medicine, Univ of Miami, Miami, FL Objective: To determine the association between insulin resistance and risk of first ischemic stroke in a multiethnic, stroke-free cohort without diagnosis of diabetes. Background: Insulin resistance is an important underlying mechanism of metabolic syndrome, type 2 diabetes and cardiovascular disease. Insulin resistance may affect as many as 30 – 40% of apparently healthy subjects. Data on insulin resistance and stroke risk is controversial and limited. Methods: The association between insulin resistance and vascular outcomes was analyzed among 1,735 non-diabetic participants with serum available from the Northern Manhattan Study (mean age 68.0⫾10.4 years; 63 % women; 61% Hispanics; 19% black; 19% white). Insulin sensitivity was expressed by the Homeostatic Model Assessment of Insulin Sensitivity (HOMA index ⫽ [fasting insulin (U/ml] [fasting glucose (mmol/L)] 22.5). Insulin resistance was defined by a HOMA index ⬎3. Cox proportional hazard models were used to determine the effect of insulin resistance on (1) the risk of first ischemic stroke and (2) the risk of combined vascular events (MI, stroke, or vascular death). The final models were adjusted for demographics (age, sex, race-ethnicity, education), traditional vascular risk factors (hypertension, diabetes, LDL, HDL), anthropometric (waist, BMI) and lifestyle factors (physical activity, alcohol consumption). Results: The mean HOMA index was 2.76 ⫾ 7.42; 25% of subjects had a HOMA index over 3 (insulin resistance). After a mean follow-up of 6.9 years, vascular events occurred among 188 subjects; 38 had fatal or non-fatal ischemic stroke, 74 had fatal or non-fatal MI, and 116 died of vascular causes. A HOMA index ⬎3 independently predicted the risk of ischemic stroke [adjusted HR 2.2; 95% CI 1.2– 4.0] as well as the risk of combined vascular events [adjusted HR 1.5; 95% CI 1.1–2.1]. This effect was independent of waist circumference, BMI, and other components of the metabolic syndrome. Conclusion: Insulin resistance is an important marker of increased risk of incident stroke and other vascular events among non-diabetics. These findings emphasize the need to better characterize individuals at increased risk of stroke, and the potential role for preventive therapies targeted at diabetes and insulin resistance. 93 C-Reactive Protein Predicts Recurrent Stroke and Death in a Hyperhomocyst(e)inemic Population. Karen L Furie, Massachusetts General Hosp, Boston, MA; Annie G Howard, Lloyd E Chambless, Stephen Campbell, Univ of North Carolina at Chapel Hill, Chapel Hill, NC; James F Toole, Wake Forest Univ, Winston-Salem, NC; Mitchell S Elkind; Columbia Univ, New York, NY Background: Inflammation, measured by high sensitivity C-reactive protein (hsCRP), has been shown to be a predictor of initial stroke and post-stroke mortality. Although both are associated with atherosclerosis, there are conflicting data regarding the correlation between hsCRP and homocyst(e)ine (Hcy). This study was designed to explore the association between hsCRP and Hcy and determine the utility of hsCRP level in predicting outcome events in an ischemic stroke population with an atherosclerotic mechanism of infarction. Methods: We analyzed data on Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 2230 subjects with recent non-cardioembolic ischemic stroke and mild-moderate hyperhomocyst(e)inemia aged 35– 89 enrolled in the Vitamin Intervention for Stroke Prevention (VISP) trial for whom baseline randomization hsCRP and post-methionine load levels of Hcy were available. Baseline values (demographics, medical comorbidities, medications, stroke characteristics) were recorded within 120 days of stroke onset. A Cox Proportional Hazards model to predict outcomes analyzed hsCRP as a categorical variable defined by quartiles, using hsCRP ⬍ 3 mg/L (lowest quartile) as the reference group. Results: The mean duration between stroke onset and baseline measurement of Hcy and hsCRP was 72 days, range 9 –171 days. Mean age was 67 years (sd 10.7). Vascular risk factors such as hypertension (73.5%), hypercholesterolemia (41.8%), diabetes (28.5%), and coronary artery disease (24.6%) were highly prevalent. For each 4.90 umol/L higher Hcy level, hsCRP was higher by 0.27 mg/L (95% CI .076, 0.27) after adjusting for age, gender, and race. There were 192 strokes, 133 deaths, and 383 stroke/death or coronary events during a mean follow-up of approximately 21 months. The highest quartile of hsCRP (relative to the lowest) was predictive of recurrent stroke (p⫽.04), death (p⫽.002), and the combined endpoint of stroke/death/coronary event (p⫽.0002) after adjustment for age, sex, and race. Relative to the lowest quartile (⬍3 mg/L), the highest quartile of hsCRP (⬎ 15.8 mg/L), had hazard ratios of 1.50 (95% CI 1.01, 2.23) for stroke, 2.01(95% CI 1.26, 3.21) for death, and 1.63 (95% CI 1.23, 2.15) for stroke/death/coronary event after adjustment for age, sex, and race. Conclusion: There is an association between level of Hcy and hsCRP in patients with predominantly atherosclerotic subtypes of ischemic stroke. The finding that hsCRP is a strong predictor of post-stroke mortality is consistent with other studies, however, in this population, hsCRP was also predictive of recurrent stroke and the combined endpoint of stroke/death/coronary event. This study illustrates the importance of inflammation as a marker of risk after atherosclerotic stroke, and provides a rationale for exploring inflammation as a target to improve outcomes. 94 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Daytime Sleepiness and Risk of Stroke and Vascular Disease: Findings from the Northern Manhattan Study (NOMAS). Bernadette Boden-Albala, Carl Bazil, Yeseon Moon, Janet De Rosa, Mitchell S Elkind, Myunghee C Paik, Columbia Univ, New York, NY; Ralph L Sacco; Universoty of Miami, Miami, FL Objective: The aim of this study was to explore the relationship between daytime sleepiness as a measure of an underlying sleep disorder and the risk of stroke and vascular events in a multi-ethnic prospective cohort. Background: Sleep is an important modulator of cardiovascular function. Recent studies have suggested poor quality and diminished quantity of sleep may be independently linked to vascular events, though prospective studies are limited. The role of sleep as a risk factor for stroke needs further exploration. Methods: As part of the Northern Manhattan Study (NOMAS), the Epworth Sleepiness Scale (ESS) was collected during the 2004 annual follow-up on stroke-free community residents, identified initially through random digit dialing. The ESS measures daytime sleepiness, which has been correlated with numerous sleep disorders, including sleep apnea. Daytime sleepiness was trichotomized using previously reported cut points of “no dozing” (ref), “some dozing,” and “significant dozing”. Subjects were followed annually for a mean of 2.3 years. Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for total stroke, and all vascular events (stroke, MI and vascular death). Results: We obtained the ESS on 2153 community residents. The mean age was 73 ⫾9 yrs; 64% were women; 18% white, 20% black and 60% Hispanic. Over 44% of the cohort reported no dozing, while 47% reported “some dozing” and 9% “significant dozing.” We detected 40 strokes and 127 vascular events. In a multivariable Cox model with “no dozing” as the reference, “some dozing” [HR 2.6, 95% CI 1.1- 6.0] and “significant dozing” [HR 4.5, 95% 95% C.I 1.5 - 13.?] were both associated with increased risk of stroke, adjusting for age, race-ethnicity, sex, education, systolic blood pressure, diabetes, obesity, and physical activity. A similar dose response relationship existed for occurrence of any vascular events: HR 1.6, 95% CI 1.0 - 2.4 for “some dozing” and HR 2.6, 95% CI 1.4- 4.8 for “significant dozing.” The impact of sleepiness did not significantly differ by gender or race-ethnicity. Conclusions: Findings from this prospective cohort study demonstrate that daytime sleepiness, as measured by the ESS, is an independent risk factor for stroke as well as all vascular events. Further, the elevated risk in the highly prevalent “some dozing” group suggests that the impact of this novel risk factor may be quite important, and further studies of the relationship between sleep and stroke are warranted 95 Stroke in Women - Gender Differences in Stroke Incidence and Post-stroke Disability in the Framingham Heart Study. Rodica E Petrea, Dept of Neurology, Boston Univ Sch of Medicine, Boston, MA; Alexa S Beiser, Sudha Seshadri, Margaret Kelly-Hayes, Carlos S Kase, Philip A Wolf; Dept of Neurology, Boston Univ Sch of Medicine, Public Health and Framingham Heart Study, Boston, MA Objective: To examine gender differences in stroke incidence, severity and post-stroke disability in the Framingham Heart Study. Background: Stroke, once considered primarily a disease of men, is now emerging as the third cause of death and the main cause of disability in both men and women in the US. Controversy exists regarding gender-specific rates of stroke incidence and post-stroke outcome. Methods: Framingham Original (N⫽ 5,119, 2,829 women) and Offspring participants (N⫽ 4,957, 2,565 women) ⬎45 years and stroke-free were followed to first incident stroke. We compared sex-specific stroke incidence, age at first stroke, stroke severity, and 30-day and 6-month case fatality rate. We also examined sex-specific post-stroke 551 disability, dementia prevalence and institutionalization rate in the acute phase and at 3 to 6 months post-stroke. Outcomes were adjusted for age, systolic blood pressure, antihypertensive treatment, atrial fibrillation, current smoking, prevalent cardiovascular disease and diabetes mellitus. Post-stroke disability analyses were also adjusted for pre-stroke disability (using the Katz activities of daily living [ADL] scale). Results: After up to 50 years of follow-up, (249,992 person-years) we observed 1120 incident strokes (625 in women). Results are summarized in Table 1. Conclusions: In the Framingham Heart Study women were older at initial stroke, had a lower incidence of stroke at all age categories ⬍85 years of age and a higher incidence of stroke above that. Women were more disabled in the acute phase of stroke, as disabled as men at 3 to 6 months but more than 4 times as likely to be institutionalized than men. Social and medical factors explaining these gender differences need to be explored. All Incident Strokes Women Men Age N strokes Incidence/1000PY N strokes Incidence/1000PY 45–54 55– 64 65–74 75– 84 85–94 34 76 161 223 128 0.82 1.76 5.04 12.09 21.57 41 93 182 145 34 1.16 2.58 7.59 13.40 15.51 Crude 625 4.42 495 4.56 4.07 4.96 Age-adjusted Baseline characteristics and Outcome measures Prior to or within 72 hrs of acute stroke 6 months post-stroke Women Men OR, p value Women Men OR, p value Age at first stroke 76ⴞ11 71ⴞ10 4.6, <0.001 Severe or fatal strokes vs. mild or moderate 29% 23% 1.33,NS Death in 30 days post-stroke 22% 18% 1.48, NS 30% 27% 1.29, NS Death in 180 days post-stroke Living at home independently prior to stroke 77% Prevalent dementia 92% 0.31, 0.007 11% 7% 0.97, NS 12% 7% 0.68, NS Katz scale Eating Dressing Grooming Bed to chair transfer Walking 42% 60% 56% 60% 65% 30% 41% 36% 39% 52% 1.65, NS 1.88, 0.008 2.12, 0.002 2.29,⬍0.001 1.58, NS 17% 37% 34% 34% 39% 10% 23% 19% 17% 20% 0.93,NS 1.45,NS 1.84,NS 2.30,NS 1.64,NS Institutionalized 88 84 1.09, NS 37 13 4.56,0.004 96 National Utilization of, and Outcomes following, Craniectomy for Space Occupying Cerebral Infarction in the United States. Mustapha A Ezzeddine, Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN; Praveen R Baimeedi, Dept of Neurosurgery, Univ of Minnesota, Minneapolis, MN; Abu Nasar, M. Fareed K Suri, Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN OBJECTIVE: A recent meta-analysis of clinical trials suggests some therapeutic benefit with craniectomy for space occupying cerebral infarction. However, national estimates of the utilization of craniectomy for cerebral infarction are not available. We performed this study to determine the frequency of craniectomy among patients with ischemic stroke in the United States and associated in-hospital outcomes. METHODS: National estimates of craniectomy, associated in-hospital outcomes, and hospitalization charges were obtained from Nationwide In-patient Sample data from 2002 to 2004. Patient numbers and frequency distributions were calculated for a nationally representative sample of patients hospitalized with a primary diagnosis of ischemic stroke. We also determined the predictors of in-hospital mortality among patients who underwent craniectomy. RESULTS: There were 1,470,944 admissions for ischemic stroke between 2002 and 2004. Of these admitted patients, 682 (4.6 per 10,000 admissions) underwent craniectomy. The procedure was performed on either the first day of admission (15%), the second day (24%), third day (16%), fourth day (9%), or later (36%). Craniectomy was more likely to be performed in urban teaching hospitals than in urban non-teaching or rural hospitals (p⬍0.001). The rate of death or discharge to long-term facility was significantly higher for those patients who underwent craniectomy (86% versus 45%). The mean days of hospitalization and total hospitalization charges were significantly higher for patients who underwent craniectomy: 20 days (⫾16 standard deviation) versus 5 days (⫾6), and $127,300 (⫾4234) versus $22,400 (⫾24). No significant relationship was observed between the age of the patients treated or day of craniectomy and in-hospital mortality. CONCLUSION: The present study provides national estimates of patients undergoing craniectomy for space occupying cerebral infarction. Considerable variations in practice patterns and high rates of poor outcomes mandate a more standardized approach for this procedure in the United States. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 552 Stroke Vol 39, No 2 February 2008 97 Gene Variants Previously Associated With Coronary Heart Disease: Association With Incident Ischemic Stroke in the Cardiovascular Health Study. May M Luke, CELERA, Alameda, CA; Ellen S O’Meara, Univ of Washington, Seattle, WA; Charles M Rowland, Lance A Bare, Dov Shiffman, CELERA, Alameda, CA; Thomas Lumley, Kenneth Rice, Univ of Washington, Seattle, WA; Andre R Arellano, CELERA, Alameda, CA; Russell P Tracy, Univ of Vermont, Colchester, VT; James J Devlin, CELERA, Alameda, CA; Bruce M Psaty; Univ of Washington, Seattle, WA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objective: To determine whether 74 single nucleotide polymorphisms (SNPs), which had been associated with coronary heart disease (CHD), are associated with incident ischemic stroke. Method: Based on antecedent studies of CHD, we prespecified the risk allele for each of the 74 SNPs. We used Cox proportional hazards models to estimate associations with incident ischemic stroke during 13 years of follow-up in 4522 white and African American men and women age 65 years and older in the Cardiovascular Health Study (CHS), a population-based cohort study. Models were adjusted for age, sex, body mass index, smoking, diabetes, impaired fasting glucose, hypertension, LDL-cholesterol, and HDL-cholesterol. Results: In white CHS participants, the prespecified risk alleles of 7 of 74 SNPs (in HPS1, ITGAE, ABCG2, MYH15, FSTL4, CALM1, and BAT2) were nominally associated with increased risk of incident ischemic stroke (one-sided P⬍0.05) and the false discovery rate (FDR) for these 7 SNPs was 0.42. In African Americans, the prespecified risk alleles of 5 SNPs (in KRT5, LY6G5B, EDG1, DMXL2, and ABCG2) were nominally associated with increased risk of incident ischemic stroke and the FDR for these 5 SNPs was 0.55. The FDRs of 0.42 and 0.55 suggest that some of these associations may be true positives. The Val12Met SNP in ABCG2 was associated in a log additive model with incident ischemic stroke in both whites (hazard ratio 1.46, 90% CI 1.05, 2.03) and African Americans (hazard ratio 3.59, 90% CI 1.11, 11.6). Kaplan-Meier estimates of the 10 year cumulative incidence of stroke were lower among carriers of the Met allele than among homozygotes of the Val allele in both whites (6% versus 10% respectively) and African Americans (3% versus 12% respectively). Conclusion: The Val allele of the Val12Met SNP in ABCG2 (which encodes a transporter of sterols, protoporphyrin, and anticancer drugs) was associated with increased risk of incident ischemic stroke in both white and African American participants of CHS. 98 99 Timing and Type of Neurologic Events prior to Carotid Artery Stenting are Predictors of Stroke. Seemant Chaturvedi, Wayne State Univ, Detroit, MI; Richard Atkinson, Sutter Health, Sacramento, CA; for the CAPTURE and EXACT Executive Committees Background: Carotid stenting with embolic protection (CAS) in patients at high surgical risk has demonstrated comparable outcomes to endarterectomy (CEA). We sought to determine the effect of symptom type and timing on the post-CAS stroke (S) risk. We examined this relationship via the CAPTURE (C) Post-Market Study (PMS) and two contemporary studies, CAPTURE 2 (C2) and EXACT (E). Methods: The study cohort includes the final patient cohort of 4225 patients enrolled in C between October 2004 and December 2006; 2070 patients in C2 (March 2006-June 2007) and 2239 patients in E (November 2005-April 2007). All patients in whom treatment is attempted with the carotid stent with or without the embolic protection device are included in this analysis. Neurological status is independently assessed at pre-procedure, 24-hours and 30-days post-procedure. Baseline demographics, vessel characteristics and occurrence of S are recorded. Possible stroke events are reviewed by an Independent Adjudication Committee. Symptomatic patients were defined as S, TIA, or amaurosis fugax if the symptoms occurred within 180 days of the CAS. Logistic Regression analysis was performed on timing and type of neurological event to determine predictors of stroke for symptomatic patients. Limitations: These prospective PMS trials were run independently and were not designed to be compared directly. Results: The 30 day endpoint of S for all patients in C, C2 and E is 4.6%, 3.3%, and 3.5%, respectively. In C 13.8% of all enrolled patients are symptomatic, in C2 9.9%, and in E 9.9%. For symptomatic patients the 30 day endpoint frequency of S in C (n⫽573) is 8.4%, for C2 (n⫽197) 7.1%, and for E (n⫽204) 5.9%. Data of the symptomatic patients from all three studies were combined (n⫽ 974). Logistic regression analysis revealed that a neurological event occurring within 2 weeks prior to the procedure is a predictor of stroke within 30 days post- procedure. Evaluation of the type of neurologic event shows that stroke alone, TIA alone, and stroke or TIA within 2 weeks of the procedure increases the risk for stroke in the 30 days post procedure. In this analysis there is no evidence that amaurosis fugax alone is a predictor of stroke. The S rate for all symptomatic patients combined (n⫽ 974) is 7.6%. Removing the recently symptomatic patients (neurological event within 2 weeks of CAS) resulted in S rate of 5.7% and a stroke and death (SD) rate of 6.7% for the combined symptomatic cohort of C, C2 and E (n⫽720). The S rate for the recently symptomatic patients (n⫽254) is 13.0% and the SD rate is 15.7% for the combined symptomatic cohort. Conclusions: In general, carotid stenting is performed safely in symptomatic patients with severe stenosis at high surgical risk. However, recent history of a neurological event is associated with worse outcomes at 30 days. Proper patient selection for CAS should be based on the potential risk of stenting versus the anticipated benefit. Analysis of the Age-at-Onset Phenotype in a Pilot Genome-Wide Association Study of Ischemic Stroke. Bradford B Worrall, Univ of Virginia, Charlottesville, VA; W M Brown, Wake Forest Sch of Medicine, Winston-Salem, NC; Thomas G Brott, Mayo Clinic, Jacksonville, FL; Robert D Brown, Jr, Mayo Clinic, Rochester, MN; John Hardy, Queen Square, London, United Kingdom; Mar Matarin, National Institute of Aging, Bethesda, MD; Stephen S Rich, Univ of Virginia, Charlottesville, VA; Andrew Singleton, National Institute of Aging, Bethesda, MD; James F Meschia, Mayo Clinic, Jacksonville, FL; for the Ischemic Stroke Genetics Study (ISGS) Investigators Our recent genome-wide association study (GWAS) in the Ischemic Stroke Genetics Study (ISGS) identified several single nucleotide polymorphisms (SNPs) associated with ischemic stroke and underscored the potential of this powerful tool to identify genetic stroke risk factors. Linkage and association studies have typically treated stroke as a qualitative (affected/ unaffected) trait. However, the apoplectic and precisely identifiable onset of ischemic stroke provides an opportunity to study “stroke latency” as a quantitative trait. Such an analysis in the Siblings With Ischemic Stroke Study (SWISS) found incident ischemic stroke latencies correlated significantly among siblings overall and among siblings concordant for key vascular risk factors, consistent with genetic factors contributing to stroke latency. In a case-only analysis from ISGS, we tested the hypothesis that there are SNPs that correlate with age at onset of first-ever ischemic stroke, independent of known risk factors. The underlying principle is that a gene controls when a stroke may occur, and that the age at onset of stroke is dependent upon genotype at a SNP in that gene. Significance of association between the SNP and age at onset was determined by the Cochran-Armitage trend test under an additive genetic model. A series of generalized estimating equations was computed that included relevant covariates (sex, history of hypertension, smoking status, diabetes mellitus, and coronary heart disease) to permit estimation of the independent effect of the SNP on age at onset. Significance was determined if P ⬍ 10 –5, a conservative threshold to account for multiple statistical tests in the GWAS. Eighty-two SNPs met the threshold of significance. Eleven percent (9/82) of the SNPs were significant in the unadjusted model only; 51% (42/82) were significant in the adjusted model only, and 42% (31/82) reached significance in both the adjusted and unadjusted models. None of these SNPs were significant in the earlier adjusted case-control analysis of ischemic stroke risk. In summary, a case-only analysis identified 82 candidate SNPs governing variation in age at onset of stroke in our GWAS. These SNPs differed from those observed for stroke risk. Recent data suggest that, in addition to contributing to stroke risk per se, genetic factors may play a role in determining specific phenotypic characteristics of ischemic stroke such as severity, case fatality, recovery, and response to therapy. Using age at onset as a continuous variable rather than dichotomizing stroke into early and late onset may retain statistical power and facilitate the identification of key genetic factors contributing to the burden of cerebrovascular disease. 100 Neuropsychological Changes After Carotid Stenting With Cerebral Protection. Francisco Moniche, Paloma Gonzalez-Perez, Myrta O’Valle, Jose Ramon Gonzalez-Marcos, Alejandro Gonzalez, Aurelio Cayuela, Antonio Mayol, Alberto Gil-Peralta; Hosp. Univ. Virgen del Rocio, Seville, Spain Introduction: Carotid angioplasty and stenting (CAS) is an alternative to endarterectomy (CEA) in severe carotid stenosis. Although previous studies have showed subtle neurocognitive deficits after CEA, in up to 25% of patients, results after CAS are not well known. After CAS, 20 – 40% of patients showed new diffusion-weighted imaging lesions clinically asymptomatic. The significance of these silent embolizations has not yet been established, but there is a potential that they may be associated with cognitive decline. Our aim is to evaluate cognitive and psychiatric changes after CAS. Methods: CAS with cerebral protection device was performed in 50 consecutive patients with severe carotid stenosis. All patients were evaluated with a battery of neuropsychological tests before and 1 and 3 months after CAS. Psychiatric symptoms were investigated by the Neuropsychiatric Inventory (NPI). Basic and instrumental (BADL, IADL) activities of daily living (ADL) were evaluated. Results: Apart from 4 TIA, there was no other morbidity in 30 days after CAS. Global neuropsychological assessment significantly improved after CAS, evaluated by Mini Mental State Examination (MMSE), Blessed Dementia Rating Scale, and Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE). Most patients showed better results in visuoconstructive function, attention-concentration and memory measured by Block Design test, Digit Symbol Coding from the Weschler Adult Intelligence Scale III (WAIS III) and Weschler Memory Scale III (WMS III) respectively. No changes were observed in problem solving (Matrix Reasoning, WAIS III) and language functions. Psychiatric symptoms were scarce before CAS. Anxiety, irritability, and night-time behaviour disturbances significantly improved after the procedure. We also found a slight improvement in the IADL in patients after CAS. Conclusion: After CAS, neuropsychological tests showed clear improvement in cognitive function, especially in executive function and memory, possibly related to increased cerebral blood flow. The improvement in the quality of life of the patients could be correlated with those changes. RESULTS OF THE NEUROPSYCHOLOGICAL TESTS TEST MMSE BLESSED IQ-CODE BASAL 1ST MONTH 3RD MONTH p 24.5[21–28] 1.00[0.0–2.5] 80[78–83] 25.5[21–29] 0.50[0.0–1.5] 79.0[78–83] 26.5[22–29] 0.25[0.0–1.0] 78.0[78–81] ⬍0.0001 ⬍0.0001 ⬍0.0001 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations TEST WAIS-III Digit Symbol Coding WAIS-III Block Design Scale WAIS-III Matriz Reasoning Barcelona verbal subtest Wechsler Memory Scale III Depression Anxiety Apathy Disinhibition Irritability Nigth-time disturbances IDDD BADL IADL BASAL 1ST MONTH 13[6–33] 18[6–35] 18.5[10–28] 18.5[10–29] 3RD MONTH 16[8.5–37.5] 18.0[12–25] p 0.001 0.003 6.0[4–10] 5.0[4–9] 6.0[5–12] NS 11.0[10–12] 11.0[11–12] 11.0[11–12] NS 18.0[16–23] 20.0[16–24] 21.0[18–25] 0.002 0.0[0.0–1.0] 1.0[0.0–1.0] 0.0[0.0–1.0] 0.0[0.0–0.0] 0.0[0.0–3.0] 0.0[0.0–1.0] 33.0[33–35] 16.0[16–16] 17.0[14–18] 0.0[0.0–1.0] 0.0[0.0–1.0] 0.0[0.0–0.0] 0.0[0.0–0.0] 0.0[0.0–2.0] 0.0[0.0–0.0] 33.0[33–35] 16.0[16–16] 17.0[14–17] 0.0[0.0–1.0] 0.0[0.0–1.0] 0.0[0.0–1.0] 0.0[0.0–0.0] 0.0[0.0–1.0] 0.0[0.0–0.0] 33.0[33–35] 16.0[16–16 16.5[14–17] NS 0.001 NS NS 0.03 0.01 553 dyslipemic and 30.2% diabetic. Univariate analysis showed a history of diabetes (p⫽0.002), administration of statins (p⫽0.015) and stroke subtype diagnosis (atherothrombotic and undetermined vs. lacunar, p⫽0.036) as the only significantly different variables among those with vascular disease extension. Baseline plasma levels of IL-6, VCAM-1 and cFn were significantly higher in patients whith extension of their atherothrombotic disease. However, only an increase in MMP-9 and cFn at one-year follow-up was observed among patients who presented disease extension. In fact, an increase in MMP-9 levels ⬎26.4 ng/mL was associated with an 8-fold increase in the risk of atherothrombotic disease extension, and that risk increased 5-fold in patients with a cFn level increase ⬎3.1 g/mL. Conclusion: The extension of atherothrombotic disease to extracerebral territories following stroke is a frequent vascular complication. Among those high risk patients we identified increased levels of several cytokines, adhesion molecules and metalloproteinases suggesting that the vascular extension process might be mediated by both inflammatory and vascular wall remodeling-related mechanisms. NS NS 0.02 Values expressed in P50 [P25-P75]. IDDD indicates Interview for daily living deterioration in dementia. 101 High Volume Centers Have Lower Complication Rates After Cea And Cas In The Space Study. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Peter A Ringleb, Univ clinic of Heidelberg, Heidelberg, Germany; H. H Eckstein, Clinic Rechts der Isar, Munich, Germany; Marius Hartmann, Werner Hacke, Univ clinic of Heidelberg, Heidelberg, Germany; SPACE Investigators Background: As a multicenter, prospective, randomized trial SPACE failed to demonstrate that carotid artery stenting (CAS) is not inferior to carotid endarterectomy (CEA) in treating patients with severe symptomatic carotid artery stenosis. 33 centers took part in this large trial, recruiting together 1,214 patients. We analyzed whether the per-center complication rate was influenced by the amount of patients included per center. Methods: Primary endpoint events of the ITT were analyzed. A receiver operating characteristic (ROC) was done to calculate optimal cut-off points between low- and high risk centers based on the event-rate per year. Groups were compared with a Fisher’s exact test. Results: The number of patients included per center ranged from 7 to 139, the rate of patients included per center and year ranged from 0.5 to 27.8. A ROC-analysis revealed a threshold of 7 interventions per year in both arms. Centers including at least 7 CAS-patients per year (n⫽4) had a complication rate of 4.0% in this arm, as compared to a rate of 8.7% in lower-volume centers (P⫽0.031). Centers including at least 7 CEA-patients per year (n⫽5) had a complication rate of 3.3% in the CEA-arm, opposed to 8.7% in lower-volume centers (Fisher’s exact test; P⫽0.008). Interpretation: In the situation of a randomized trial the center size is of significant influence for the 30-day complication rate both in patients treated with CAS and CEA. Centers recruiting at least 7 patients per arm and year have lower complication rates. 103 Inflammatory Markers Predicts Future Cardiovascular and Neurological Events In Patient Undergoing Carotid Stent Implantation. Francesco Versaci, Costantino Del Giudice, Tor Vergata Univ, Roma, Italy; Achille Gaspardone, Sant’Eugenio Hosp, Roma, Italy; Gian Luigi Condorelli, Istituto di Ricovero e Cura a Carattere Scientifico Multimedica, Roma, Italy; Antonio Pellegrino, Alessandro Mauriello, Laura Liberatoscioli, Igino Proietti, Giovanni Simonetti, Claudio Cortese, Luigi Chiariello; Tor Vergata Univ, Roma, Italy Background. C-Reactive protein predicts cardiovascular events after coronary stenting implantation. The aim of this study was to assess whether baseline inflammatory markers predicts future neurological and cardiovascular events after carotid stenting and to correlate systemic inflammation and histomorphometric analysis of the carotid plaque evaluated from the filters utilized as protective devices during the procedure. Methods. Eighty consecutive patients (mean age 70,8⫾8,32, 55 men) with stable severe carotid stenosis were treated with stent implantation with distal filter devices. Levels of high-sensivity C-reactive protein (hs-CRP) and Interleukin-6 (IL-6) levels were measured before the procedure. Histomorphometric analysis of the debris from the filters was performed in all patients. All patients were followed-up for 5 years and major cardiovascular events (death, myocardial infarction and stroke) were recorded. Results. Procedural success was 98.75%. The incidence of cumulative disabling stroke, myocardial infarction and death at the follow-up was 19%. Higher pre-procedural levels of hs-PCR and IL-6 were associated with clinical events at follow-up (p⫽0.0044 and 0.04 respectively). Furthermore, a significant correlation was found between preprocedural hs-CRP and IL-6 and both the total number of particles (respectively p⫽0.03; r⫽0.3 and p ⫽ 0.02 , r⫽ 0,3) and the mean debris area per filter (respectively p⫽0.04; R⫽0.3 and p⫽0.02, r⫽0,3). Finally mean debris area per filter was significantly associated with a higher incidence of events at follow-up (p⫽0,048). Conclusions. Preprocedural levels of hs-CRP and IL-6 are predictive of neurological and cardiovascular events at follow-up. Patients with higher levels of hs-CRP and IL-6 presents a greater number of debris embolizing particles suggesting that systemic inflammation is associated with a higher plaque instability. 102 Extension Of Atherothrombotic Disease To Extracerebral Territories Following Stroke: Inflammation Or Vascular Remodeling Mechanisms? Tomás Sobrino, Miguel Blanco, Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain; Joan Montaner, Neurovascular Rsch Laboratory, Neurovascular Unit, Vall d’Hebron Univ Hosp, Barcelona, Spain; Marı́a M Freijó, Dept of Neurology, Hosp de Basurto, Bilbao, Spain; Miguel A Llaneza, Dept of Neurology, Hosp Clı́nico Universitario de Salamanca, Salamanca, Spain; Enrique Corredera, Dept of Neurology, Hosp Meixoeiro, Vigo, Spain; Blanca Fuentes, Dept of Neurology, Hosp Universitario La Paz, Madrid, Spain; Javier Tejada, Dept of Neurology, Hosp de León, León, Spain; David Cánovas, Dept of Neurology, Consorci Hospari del Parc Taulı́, Barcelona, Spain; José Castillo, Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain; for the MITICO Study Investigators Background and purpose: Atherothrombotic disease has an irregular and little predictable course and its progression to other vascular territories is not well-understood. Therefore, we aimed to study the rates and clinical profile of extension of atherothrombotic disease to extracerebral territories following stroke as well as its possible association with an increase of inflammatory molecular markers. Methods: Non-anticoagulated ischemic stroke patients, recruited within 1–3 months from stroke onset were included in a multicentric prospective study (MITICO study). Blood samples were obtained at baseline and final one-year follow-up visit for further determination of hsCRP, IL-6, IL-10, ICAM-1, VCAM-1, MMP-9 and cellular fibronectin (cFn). Extension of atherothrombotic disease over one year follow-up was defined as recurrence in a different vascular territory than the cerebrovascular, in patients without history of symptoms in other vascular territories. Results: From 742 patients with monovascular disease at the time of inclusion, 53 showed a new cerebrovascular event, 15 a coronary event and 14 a peripheral event; therefore, 29 patients were considered to have had vascular disease extension (3.4% of the total sample). Regarding disease extension, 18% of patients were smokers, 34.2% ex-smokers, 19.2% alcohol users, 59.8% hypertensive, 44.5% 104 Plaque Characterization by Virtual Histology TM Intravascular Ultrasound Analysis in Symptomatic Internal Carotid Artery Stenosis. Shoji Matsumoto, Ichiro Nakahara, Toshio Higashi, Yasushi Iwamuro, Yoshihiko Watanabe, Kenji Takahashi, Tetsuhiro Kikuchi, Mitsushige Ando, Masahiro Takezawa, Masahiro Takezawa; Kokura Memorial Hosp, Kitakyushu-shi ,Fukuoka, Japan Purpose The purpose of this study was to evaluate the in-vivo plaque composition and characteristics in symptomatic internal carotid artery lesions using Virtual HistologyTM intravascular ultrasound (VH -IVUS). Methods and Results In 27 patients with symptomatic extracranial internal carotid artery stenosis in carotid artery stenting, 27 target plaque were studied and plaque components were analyzed. Patients were divided into two groups by history; symptomatic group (11vessels) and asymptomatic group (16 vessels). There was no significant difference of degree of stenosis in angiography between the two groups.The plaque volume and the fibro-fatty volume were significantly greater in the symptomatic group compared with the asymptomatic group [Plaque volume: 595.0 mm3 (interquartile range (IQR) 548.6 ⬃641.4 mm3) vs. 389.0 mm3 (IQR:357.7⬃420.3 mm3), P⫽0.034; Fibro-fatty volume:225.3 mm3 (IQR:204.3⬃246.4 mm3) vs. 123.4 mm3(IQR:111.3⬃135. 5mm3), P⫽0.006]. There was no significant difference between both groups in regard to the ratio of fibrous, fibro-fatty, dense calcium and necrotic core which were occupied in each plaque. Conclusions In this series of subjects with significant internal carotid artery stenosis, both plaque volume and fibro-fatty volume were significantly greater in symptomatic carotid plaque than asymptomatic. VH- IVUS has a role in the evaluation of carotid artery disease beyond examining luminal stenosis. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 554 Stroke Vol 39, No 2 February 2008 105 High-Resolution CT Imaging of Carotid Artery Atherosclerotic Plaques. Max Wintermark, Univ California, San Francisco, CA; Sumayya S Jawadi, Univ of Missouri, Kansas City, KS; Joseph H Rapp, San Francisco VA Med Cntr, San Francisco, CA; Tarik Tihan, Elizabeth Tong, David Glidden, Univ California, San Francisco, CA; Sami Abedin, Univ of Missouri, Kansas City, KS; Sarah Schaeffer, Gabriel Acevedo-Bolton, Univ California, San Francisco, CA; Benjamin Boudignon, Univ of California, San Francisco, CA; Benjamin Orwoll, Univ California, San Francisco, CA; XianMang Pan, San Francisco VA Med Cntr, San Francisco, CA; David Saloner; Univ California, San Francisco, CA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 PURPOSE: To evaluate the ability of multidetector-row CT-angiography (CTA) to assess the composition and characteristics of carotid artery atherosclerotic plaques, using histology as the gold standard. METHODS: Eight patients with transient ischemic attacks who underwent carotid CTA and “en bloc” endarterectomy were enrolled in a prospective study. An ex-vivo micro-CT study of each endarterectomy specimen was obtained, followed by histological examination. A systematic comparison of CTA images with histological sections and micro-CT images was performed to determine the CT density associated with each component of the atherosclerotic plaques. A computer algorithm was subsequently developed that automatically identifies the components of the carotid atherosclerotic plaques, based on the signal intensity of each pixel. A neuroradiologist’s reading of this computer analysis was compared to the interpretation of the histological slides by a pathologist with respect to the types and characteristics of the carotid plaques. RESULTS: There was a 72.6% agreement between CTA and histology in terms of carotid plaque characterization. CTA showed perfect concordance for calcifications. A significant overlap between densities associated with lipid-rich necrotic core, connective tissue and hemorrhage limited the reliability of individual pixel readings to identify these components. However, CTA showed good correlation with histology for large lipid cores (kappa ⫽ 0.796, p⬍0.001) and wide hemorrhages (kappa ⫽ 0.712, p⫽0.102). CTA performed well in detecting ulcerations (kappa ⫽ 0.855) and in measuring the fibrous cap thickness (R2 ⫽ 0.77, p⬍0.001). CONCLUSION: The composition of carotid atherosclerotic plaques determined by CTA accurately reflects plaque composition defined by histology. 106 Natural History of Dural Arteriovenous Shunts. Tommy Andersson, Karolinska Hosp, Stockholm, Sweden; Ladislav Pavic, Univ Hosp Dubrava, Zagreb, Croatia; Göran Edner, Staffan Holmin, Michael Söderman; Karolinska Hosp, Stockholm, Sweden Background Dural arteriovenous shunts with cortical venous reflux or drainage (CVD) may cause neurological symptoms and death, with or without intracranial hemorrhage. Present knowledge about the natural history of these lesions is however limited. We investigated the incidences of intracranial hemorrhage, progressive dementia syndrome and death in patients diagnosed in our neurovascular center. Material and methods We evaluated the medical records of 163 patients with dural arteriovenous shunts hospitalized in our institution from 1976 to 2007. Eighy-five of the patients had a lesion with CVD. They all had their first angiography performed in our neurovascular unit and were included in the study. The annual incidences of intracranial hemorrhage, progressive dementia syndrome and death were calculated. Findings 53 patients did not have an intracranial hemorrhage as the presenting event. One of these patients bled after diagnosis. 32 patients had an intracranial hemorrhage as the presenting event. Three patients bled after diagnosis. One of these patients died. Apart from deficits caused by hemorrhage, no patient reported aggravated neurological symptoms. Conclusion The risk for hemorrhage from a dural arteriovenous shunt with cortical venous drainage is most likely less than previously proposed and it differs between ruptured and unruptured shunts. In patients presenting with an intracranial hemorrhage the annual risk is about 7.4%. In patients not presenting with a hemorrhage the annual risk is about 1.5%. The risks to develop neurological symptoms not related to hemorrhage are in all probability lower than previously reported. In view of these novel data current management algorithms may have to be revised. presentation with pulsatile tinnitus, headache, or no symptoms. The time of definitive diagnosis was recorded for each patient. The occurrence of any new hemorrhage or new or worsening NHND from the time of diagnosis to definitive treatment (complete disconnection), if any, was recorded. The incidence of these events was compared between groups using Fisher’s exact test. RESULTS: Of the 12 patients with aggressive presentation, 8 were cured with surgical or endovascular procedures that eliminated cortical venous reflux (CVR). Three received partial treatment, with persistent CVR, and one declined treatment. For this group, the mean follow-up from diagnosis to definitive treatment, if any, or from diagnosis to most recent follow-up, was 3.3 years. Over the follow-up period, 3 patients (25%) experienced intracranial hemorrhage; 2 (17%) experienced new or worsened NHND, which manifested as memory loss or dementia in both patients. Four events occurred in patients with persistent CVR; one occurred before complete treatment was achieved. In the benign presentation group, 7 patients received full treatment, 3 received partial treatment, and 2 declined treatment. Over the mean follow-up time of 1.8 years, there was no incidence of new hemorrhage or NHND. The observed difference in the incidence of either hemorrhage or new or worsening NHND between aggressive and benign presentation groups was statistically significant (Fisher’s exact test, p⫽0.02). CONCLUSION: A hemorrhagic or NHND presentation indicates a very high risk for further events, while the absence of these symptoms in patients with Borden type 2 or 3 dAVFs may indicate a benign clinical course. 108 Multimodality Care of Occipital Lobe AVMs: Neurological Outcomes of A Prospective Series of 134 Patients. Amir R. Dehdashti, Laurent Thines, Toronto Western Hosp, Neurosurge, Toronto, Canada; Robert Willinsky, Toronto Western Hosp, Radiology, Toronto, Canada; Michael L. Schwartz, SunnyBrooke Hosp, Neurosurge, Toronto, Canada; Karel TerBrugge, Toronto Western Hosp, Radiology, Toronto, Canada; Michael Tymianski, M.Christopher Wallace; Toronto Western Hosp, Neurosurge, Toronto, Canada Objective: The proximity of the occipital AVMs to the visual cortex and optic radiations makes their management challenging. We studied the neurological outcomes of patients with occipital AVMs and evaluated the role of multimodality management. Methods: A prospective analysis was conducted for 134 patients with occipital AVMs who were managed by the Toronto vascular malformation group between 1985 and 2007. The decision was based on the patients’ characteristics, mode of presentation and morphology of the AVM. The management modalities were correlated with their neurological outcomes. Results: One hundred-twenty-five patients presented with one or more symptoms, including headache in 50, seizure in 43, visual deficit in 33 and hemorrhage in 32. Visual deficit was more common in the group of ruptured AVMs(p ⬍ 0.002). Mean follow-up period was 4.78 years and 12 patients were lost to follow-up. Forty-seven patients did not receive any treatment. Among the 14 patients in this group with visual deficit at presentation, two showed improvement(14%) and two had worsening(14%). Three patients presented with hemorrhage(6%)during follow-up with two new visual deficits (4.2%). The two deaths in this group were unrelated to the AVM. Eighty-seven patients were treated with embolization,surgery,radiosurgery or a combination of treatment modalities.The final cure rate was 67%. Visual deficit at presentation improved in 7 of 32 patients(22%)and worsened in 2(9%).There were 14 new neurological deficits(16%),the majority of which were minor. Two patients rebled after partial treatment of their AVMs. There were three deaths (3%) related to the AVM treatment.Neurological morbidity was higher in the treatment group(p ⬍ 0.005), but the difference in mortality did not reach statistical significance. The visual deficit improvement was more common in the treatment group(p⬍ 0.02). Among the subgroup of unruptured AVMs with treatment(45 patients), there were seven new neurological deficits(16%) including only three new visual deficits(6.7%) and no mortality. Conclusions:Management of occipital AVMs must be based on their natural history. Treatment as opposed to conservative approach results in a better visual outcome in patients with visual symptoms. There is however, a substantial risk of new but minor neurological deficit. Selected patients with unruptured occipital AVM might be offered treatment with a low risk of new visual deficit. The multimodality care of occipital AVMs with appropriate patient selection for each therapeutic arm can aim for a good neurological outcome. 107 109 Benign Course of Borden Type 2 and 3 Dural Arteriovenous Fistulas Presenting Without Neurological Symptoms. Brainstem Arteriovenous Malformations: Natural History, Multimodality Management And Long Term Follow-up. James A Botros, Russell G Strom, Daniel Refai, Dept of Neurosurgery, Washington Univ Sch of Medicine, Saint Louis, MO; Colin P Derdeyn, Depts of Neurosurgery and Neurology and the Mallinckrodt Institute of Radiology, Washington Univ Sch of Medicine, Saint Louis, MO; Gregory J Zipfel; Depts of Neurosurgery and Neurology, Washington Univ Sch of Medicine, Saint Louis, MO Laurent Thines, Amir R Dehdashti, Michael Tymianski, Karel G TerBrugge, Robert A Willinsky, Toronto Western Hosp, Toronto, Canada; Michael Schwartz, Sunnybrook Health Sciences Cntr, Toronto, Canada; M. C Wallace, Toronto Western Hosp, Toronto, Canada; Univ of Toronto Brain Vascular MalformationStudy Group INTRODUCTION: Cranial dural arteriovenous fistulas (dAVFs) with cortical venous reflux (Borden type 2 and 3) are considered to have an aggressive clinical course. The reported risk of hemorrhage or non-hemorrhagic neurological deficit (NHND) is high, with an annual event rate up to 15%. The purpose of the present study is to compare the clinical course of patients with type 2 or 3 dAVFs with benign presentation versus those presenting with hemorrhage or NHND. METHODS: A consecutive cohort of 108 patients at our institution who presented with dAVFs between 1997 and 2007 were evaluated and classified using the Borden scale. Twenty-four patients with type 2 or 3 dAVFs were identified. They were divided into two groups according to their presentation; 12 patients presented aggressively, with hemorrhage or NHND, including seizures, ataxia, and mental status changes. The remaining 12 patients had a benign Background and purpose: The high functional eloquence of the brain stem (BS) makes the management of arteriovenous malformations (AVM) in this location very challenging. Our objective was to review the results of the therapeutic management compared to the long term outcome of BSAVM. Methods: We reviewed from our data base, a prospective series of 26 patients managed for a BSAVM between 1989 and 2007. We analyzed the demographic data, mode of presentation, initial symptoms and early outcome. We assessed the rate of rebleeding, the treatment results and the clinical outcome with the modified Rankin Scale (mRS). Results: The average follow-up duration was 6.3 years. The sex ratio was 0.86 and the median age 37 years. The BSAVM was symptomatic in 92% of cases and bleeding was the revealing factor in 61%. Onset symptoms included: headache in 73%, neurological deficit in 65%, seizure in 4%. Locations in the BS were: midbrain 8, pons 4, medulla oblongata 2, mixed 12. The initial clinical Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 555 examination was abnormal in 69% including: coordination and gait deficit in 48%, cranial nerves deficit in 44%, motor or sensitive deficits in 32%, visual deficit in 16% and the initial mRS values were: 0 to 2 in 86% and 3 to 5 in 14%. The management was conservative in 7 cases and treatment options included radiosurgery alone in 10, embolization with intent to cure in 6, or a multimodality treatment (embolization ⫹ radiosurgery or embolization ⫹ surgery) in 5. The overall rate of rebleeding was 20%. At the end of the follow-up, the mRS values were: 0 to 2 in 78% and 3 to 6 in 22%. Among the 40% of the patients who worsened, 70% of the complications were related to the treatment. The overall rate of occlusion was 53% after the treatment. Conclusions: BS is a rare location of brain AVM. Their natural history doesn’t seem so bad since most of the patients have a good early outcome after the onset of the symptoms, 60 % remained stable or improved spontaneously and only 20% presented a rebleeding. The management, usually aiming to decrease the rebleeding risk, requires a multidisciplinary expertise to precisely select the patients for each therapeutic option and reduce the treatment morbidity compared with the natural course of the disease. comparisons not significant. Log transformation gave the same result that CCMs with venous anomaly had more B cells (FDR adjusted p⫽0.046) and clumps of B cells, and that more clumps of anti-CD3-stained T cells/area were found in single lesions than from CCMs from subjects with multiple lesions (p⫽0.007). Regression analysis gave a negative correlation between numbers of clumps of T cells/area and the age at diagnosis. In conclusion, (1) inflammatory cells within a CCM are present in all lesion types, and are not more prevalent in lesions with recent hemorrhage or lesion growth, (2) more B cells and clumps are correlated with associated venous anomaly and (3) more T cell clumps/area were found in single lesions than in CCMs from multiple lesions. The specific triggers of inflammatory activity in CCM lesions require elucidation to better explain their potential role in lesion maintenance. 110 Plasma Levels of Matrix Metalloproteinases after Treatment for Cerebral Arteriovenous Malformations. Helen Kim, Ludmila Pawlikowska, Charles E McCulloch, Pui-Yan Kwok, William L Young; UCSF, San Francisco, CA Robert M Starke, Ricardo J Komotar, Columbia Univ, New York, NY; Marc L Otten, Brian Y Hwang, David K Hahn, Laura E Fischer, Grace H Kim, Zachary L Hickman, Mathew C Garrett, Maxwell B Merkow, Michal A Rynkowski, Robert A Solomon, E S Connolly; Columbia Univ, New york, NY Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: Abnormal angiogenesis is thought to play a key role in the formation and progression of cerebral arteriovenous malformations (AVMs). Previous studies have demonstrated increased local expression of angiogenic growth factors, such as matrix metalloproteinases (MMP), in resected AVM specimens. In this study, we sought to further investigate the role of MMP-9 and abnormal angiogenesis in AVM pathogenesis by examining changes in plasma MMP-9 levels in patients undergoing treatment for AVMs. Methods: Serial blood samples were obtained from 15 AVM patients undergoing treatment of their AVMs at three time points: (1) prior to embolization, (2) 24 hours post-resection, and (3) 30 days post-resection. Blood samples were also obtained from 29 patients undergoing lumbar laminectomy surgery who served as controls. Plasma MMP-9 concentrations were measured via commercially available enzyme-linked immunosorbent assay (ELISA). The assay exhibits no significant cross-reactivity with other angiogenic factors and has a sensitivity of 0.156 ng/ml. Data are expressed as mean ⫾ SEM. Results: The mean plasma MMP-9 level in AVM patients at baseline was 108.04⫾16.11 ng/ml, which was not significantly different than that of the control group 104.56⫾ 12.97 ng/ml, p⫽0.872). One day after resection, plasma MMP-9 levels increased to 230.97⫾51.00 ng/ml, which was significantly different from pre-treatment levels (p⫽0.029). The mean plasma MMP-9 concentrations 30 days after resection decreased to 132.78⫾42.45 ng/ml which was not significantly different from control or AVM pretreatment mean plasma MMP-9 levels (p⫽0.427 and p⫽0.590) respectively). Plasma MMP-9 levels did not correlate with patient sex, age, AVM size, or patient presentation. Conclusions: There was no significant difference between plasma levels of MMP-9 in our AVM patients and controls. Plasma MMP-9 levels increased significantly after surgery and then decreased to normal levels. These results indicate that MMP-9 levels rise during vascular surgery for AVMs rather than play a pre-operative role in their formation. Previous studies, which found increased levels of MMP-9 in resected AVMs, may have falsely concluded that increased MMP-9 may result in AVM growth. 112 Transforming Growth Factor-beta1 Polymorphisms and Risk of Intracranial Hemorrhage in Brain Arteriovenous Malformation Patients. Background: Transforming growth factor-beta1 (TGFB1) is a pleiotropic cytokine, which plays an important role in inflammatory response, and may be involved in brain arteriovenous malformation (BAVM) pathogenesis. We investigated whether polymorphisms in the TGFB1 gene were associated with increased risk of intracranial hemorrhage (ICH) in the natural course of BAVM patients. Method: Three common TGFB1 polymorphisms (-509C⬎T, Leu10Pro, and Arg25Pro) were genotyped in 334 BAVM patients. Kaplan-Meier survival analysis of time to new ICH after diagnosis, censoring cases at first treatment, death or last follow-up was performed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using multivariate Cox regression analysis to adjust for covariates. Results: A total of 21 ICH events occurred during 867 person-years at risk, with a mean (standard deviation) follow-up of 2.6 (7.2) years. Genotypes were in Hardy-Weinberg equilibrium. The Leu10Pro (⫹858C⬎T) polymorphism was associated with risk of time to new ICH in BAVM patients (Figure). The risk of new ICH was 3.35-fold higher (95% CI⫽1.18 –9.49, P⫽0.023) in patients with the Leu10Pro TT vs. CT⫹CC genotypes, after adjusting for age, gender and white race. Further adjustments for venous drainage and size decreased the HR to 3.15 (95% CI⫽1.09 –9.09, P⫽0.034). The Arg25Pro and -509C⬎T polymorphisms were not associated with ICH risk. Conclusion: A common functional TGFB1 polymorphism (Leu10Pro) may be associated with increased risk of new ICH in the clinical course of BAVM patients. 111 Inflammatory Cell Infiltration in Cerebral Cavernous Malformations and Lesion Phenotype and Clinical Manifestations. Robert Shenkar, Evanston Northwestern, Evanston, IL; Harish Raja, Duke Univ, Durham, NC; Hongyan Du, Evanston Northwestern, Evanston, IL; Changbin Shi, Northwestern Universtiy, Chicago, IL; H. H Batjer, Northwestern Univ, Chicago, IL; Issam Awad; Evanston Northwestern, Evanston, IL Introduction: Cerebral cavernous malformations (CCMs), a cause of hemorrhagic stroke, were studied systematically for inflammatory cells. Hypothesis: We assessed the hypothesis that the amount of inflammatory cells within CCMs correlates with specific CCM phenotype and clinical manifestations. Methods: Formalin fixed paraffin embedded archival CCM lesions, surgically excised from 23 subjects, were stained for plasma cells (CD138), B cells (CD20/CD79a), T cells (CD3/CD45RO) and antigen presenting cells (HLA-DR). The number of clumps of cells/area and total cells/area were determined for each specimen and analyzed for associations with clinical manifestations including subject ages at surgery, first symptom and diagnosis; gender; familial history; lesion multiplicity; seizure presence; lesion location and size; recent hemorrhage; recent growth and venous anomaly presence. Spearman correlations were computed between outcomes. Log transformation was applied for skew-distributed variables. Wilcoxon two-sample test, independent two-sample t test, and linear regression were used in univariate analyses. Multivariate analyses were performed using mixed models. Two-sided p ⬍ 0.05 was considered significant, FDR (False Discovery Rate) adjusted p values from multivariate models were reported. Results and Conclusions: There was a wide range of clumps/area and cells/area of B, T, plasma and antigen presenting cells within the CCMs and the data for these were skew-distributed. B cell infiltration was correlated with T and plasma cells in the same lesions. Recent bleeding and clinical proliferation did not correlate with inflammatory activity. In univariate analysis, CCMs with associated venous anomaly had a larger median of clumps/sq cm (21.4 vs 5.3, p⫽0.034) and cells/sq cm (349 vs 117, p⫽0.041) of B cells stained with anti-CD20 antibody than in CCMs without this anomaly, with other 113 Gender Differences In The Management Of Cerebrovascular Disease: The Challenge Of Secondary Prevention. Gustavo Saposnik, Univ of Toronto and Mobility Program Clinical Rsch Unit, Toronto, Canada; Andrew Yan, Univ of Toronto and Canadian Heart Rsch Cntr, Toronto, Canada; Amparo Casanova, Canadian Heart Rsch Cntr, Toronto, Canada; Anatoly Langer, Univ of Toronto and Canadian Heart Rsch Cntr, Toronto, Canada; Shaun Goodman, Univ of Toronto and Canadian Heart Rsch Cntr, Toronto, Canada; for the Stroke Outcome Rsch Canada (SORCan) Working Group Background: Female sex has been associated with poorer vascular outcomes. Limited information is available on the achievement of guideline recommendations for lipid and blood pressure for secondary prevention. Our goal was to analyze gender differences in attaining the optimal LDL-cholesterol (LDL-C) and blood pressure targets among ambulatory patients with cerebrovascular disease (CVD). Methods: We analyzed 1097 ambulatory patients with CVD enrolled in the prospective Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries from December 2001 to December 2004. Demographic, blood pressure, current medications, and a complete lipid profile were recorded. We examined gender differences in the use of antithrombotic and lipid-modifying agents, and in the attainment of blood pressure (BP) (⬍140/90 mmHg) and lipid (LDL-C ⬍ 2.5 mmol/L) targets. Results: Among 1097 patients with CVD, 679 (62%) were male; mean (⫾SD) age was 69⫾10 years. Women had slightly higher mean baseline systolic BP (2.8 mmHg), diastolic BP (0.66 mmHg) and LDL-C (0.19 mmol/L) than their counterparts. Despite similar use of antithrombotics, antihypertensive and lipid modifying agents, women were less likely to achieve the BP and lipid target and be on optimal care therapy (LDL ⬍2.5 mmol/L and BP ⬍ 140/90 mmHg and on antithrombotic therapy) (table). Conclusions: Ambulatory women with history of CVD Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 556 Stroke Vol 39, No 2 February 2008 were less likely to attain contemporary guideline-recommended BP and lipid targets when compared with men. Our study reveals the existence of important gender gaps in secondary prevention of CVD. Quality improvement strategies should be implemented to optimize care in women with CVD. CVD patients Outcome measures Male N⫽679 Female N⫽415 p-value Statin use (%) 78 79 0.60 Use of any lipid-modifying agent (%) 80 81 0.40 Antithrombotic therapy (%) 91 93 0.22 Use of any anti-hypertensive agent (%) 87 89 0.41 Achieved LDL-C ⬍2.5 mmol/L (%) 49 42 0.01 Achieved BP ⬍140/90 mmHg (%) 78 70 0.003 Optimized care (%) (LDL-C ⬍2.5, BP 36 30 0.01 ⬍ 140/90 and on antithrombotic therapy) TC⫽ total cholesterol, LDL-C⫽ LDL cholesterol Recommended target in the Canadian Dyslipidemia guidelines LDL-C ⬍2.5 mmol/L equivalent to LDL-C 97mg/dL (similar to ATP III -National Cholesterol Education Program (NCEP) Expert Panel LDL-C ⬍100 mg/dL). Results: 1,477 patients were enrolled in AVAIL, 910 had 3 month interviews, and 663 had these data linked to baseline medication lists and GWTG_Stroke information (mean age 67 yrs [std 13 yrs], 83% white, 12% African American, 3% Hispanic, and 2% other). With medication class prescribed at discharge as the denominator, adherence rates at 3 months were 95% (610 of 642) for antithrombotic, 92% (475 of 516) for anti-hypertensive, and 84.5% (437 of 517) for lipid-lowering medications. 413 of 663 (62%) subjects were discharged on all 3 secondary prevention medications regardless of the “qualifying” status and 322 (78%) remained on these medications at 3 months. Of 277 “qualifying” subjects on all 3 medications, 231 (84%) were adherent. Adherent patients were more likely to use a pill box or other reminder tool (61% vs. 35% of non-adherent; p⫽0.0002). Adherence rates did not vary by age, race, education, household income, financial hardship, understanding how or why medications are taken, or provider type. In a logistic regression model adjusted for 3 month modified Rankin scores, female gender (OR 2.26; 95% CI 1.10 – 4.615), dyslipidemia (2.52; 1.27– 4.98), lack of visual deficits (2.50; 1.23–5.26) and use of a pill box/reminders (2.70; 1.34 –5.44) were all independently associated with adherence. Conclusions: Patient adherence to prescribed secondary stroke prevention medications was quite high in this cohort, but about 20% were non-adherent at 3 months. Stroke related deficits such as visual problems may be a barrier to adherence. However, use of simple interventions such as a patient pill box or reminder tool appears to facilitate adherence. 116 114 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Does Differential Prophylactic Aspirin Use Contribute to Racial and Geographic Disparities in Stroke? Atorvastatin is Similarly Effective in All Ischemic Stroke Subtypes: Secondary Analysis of the SPARCL Trial. Stephen P Glasser, Univ of Alabama Birmingham, Birmingham, AL; Mary Cushman, Univ of Vermont, Burlington, VT; Ronald J Prineas, Wake Forest Univ, Winston-Salem, NC; Dawn Kleindorfer, Univ of Cincinnati College of Medicine, Cincinnati, OH; Valerie Prince, Samford Univ McWhorter Sch of Pharmacy, Birmingham, AL; Zhiying You, Virginia J Howard, George Howard, Univ of Alabama Birmingham, Birmingham, AL; for the REGARDS Investigators Pierre Amarenco, Denis Diderot Univ, Paris, France; Oscar Benavente, Univ of Texas Health Science Cntr, San Antonio, TX; Larry B Goldstein, Duke Univ Med Cntr, Durham, NC; Alfred Callahan, III, Saint Thomas Hosp, Nashville, TN; Michael G Hennerici, Universitat Heidelberg, Mannheim, Germany; Henrik Sillesen, Univ of Copenhagen, Copenhagen, Denmark; K M Welch, Rosalind Franklin Univ of Medicine and Science, Chicago, IL; Justin Zivin, Univ of California, San Diego, San Diego, CA; on behalf of the SPARCL Investigators Context. Aspirin use may reduce the risk of stroke and coronary heart disease (CHD). Differential use for vascular prophylaxis may contribute to racial and geographic disparities in stroke and CHD morbidity or mortality. Design and Setting. Cross-sectional analysis of 16,908 participants from a population-based national cohort study (REasons for Geographic And Racial Differences in Stroke) enrolled from February 2003-August 2006 with oversampling from the southeastern Stroke Belt and African Americans. Individuals with a prior stroke or CHD, or regular use of aspirin for pain relief were excluded from analyses. Main Outcome Measures. Aspirin use and reasons for use were assessed using a computer-assisted telephone interview. Results. Prophylactic aspirin use was substantially higher among whites (34.7%) than African Americans (27.2%; p ⬍ 0.0001). There was a higher prevalence of aspirin use for prophylaxis in the Stroke Belt (32.1%) than in the rest of the nation (30.8%; p⫽0.07). After adjustment for measures of socio-economic status, the odds ratio of aspirin use in the rest of the nation compared to Stroke Belt was 0.90 (95% CI 0.84,0.97). There was a higher likelihood of prophylactic aspirin use among participants who were white, male, older, past cigarette smokers, or of higher socioeconomic status (higher income or education). Participants who had hypertension, diabetes, or a higher Framingham Coronary Risk Score or higher Framingham Stroke Risk Score also had a higher likelihood of prophylactic aspirin use. Among aspirin users, white participants were more likely to be taking low dose aspirin (⬍180 mg daily) than African Americans (77.3% versus 70.8%), and there was no evident difference in aspirin dose between regions (p ⫽ 0.79). Conclusions. In this study, aspirin use to prevent stroke and CHD was higher among whites than African Americans, raising the possibility that differential aspirin use could contribute to the racial disparities in vascular disease mortality. Counter to our hypothesis, aspirin use was more common in the Stroke Belt than the rest of the country, so differential aspirin use in the Stroke Belt is unlikely to contribute to geographic disparities in stroke. Background: The Stroke Prevention by Aggressive Reduction in Cholesterol Level (SPARCL) trial showed that atorvastatin 80 mg/day reduced the risk of stroke and other cardiovascular events in patients with recent stroke or TIA. In this post hoc analysis, we tested the hypothesis that the benefit of treatment varied based on the type of index event. Methods: Subjects with stroke or TIA within the prior 1– 6 months and LDL-C of 100 –190 mg/dL without known CHD (n⫽4731) were randomized to atorvastatin 80 mg/d or placebo. Those with prosthetic heart valves, a history of atrial fibrillation, or significant mitral stenosis were excluded. The type of index event and outcome stroke subtype were classified by investigators based on their clinical judgement without independent adjudication. The primary end point was occurrence of a first fatal or non-fatal stroke. Secondary endpoints included major cardiovascular events (stroke plus major coronary events) and revascularization procedures. Potential differences in efficacy based on type of entry event were assessed by testing for an interaction with treatment assignment using Cox regression models. Results: Among 4,731 participants, 15.8% were classified as having large vessel disease (LVD) (reference category), 29.8% small vessel disease (SVD), 21.5% ischemic stroke of unknown cause, 30.9% TIA, and 2% as hemorrhagic stroke (HS) at baseline. There was no difference in the efficacy of treatment for either the SPARCL primary (LVD HR: 0.70 [0.49 –1.02], TIA HR: 0.81 [0.57–1.17], SVD HR: 0.85 [0.64 –1.12], unknown cause HR: 0.87 [0.61–1.24]) or secondary endpoints based on entry event except for patients randomized with a HS (HR⫽ 3.24 [1.01–10.4]). Patients with SVD strokes on atorvastatin had a higher incidence of outcome hemorrhage than those with SVD on placebo (0.61 vs. 0.12/100 p-y, p⫽0.0031). As compared to subjects with LVD strokes, those with SVD had similar major coronary event rates (4.1 vs. 5.1% over the course of the trial, p⫽0.569), and similar overall reductions in stroke (p⫽0.493) and major coronary events (p⫽0.322). Conclusion: Atorvastatin 80 mg/d is effective in preventing strokes and other cardiovascular events, irrespective of baseline ischemic stroke subtype. 115 Adherence eValuation After Ischemic stroke Longitudinal (AVAIL): Identifying Facilitators of Adherence to Stroke Prevention Medications. 117 Assessing the Net Clinical Benefit of Warfarin by Ischemic Stroke Risk in Atrial Fibrillation: The ATRIA Study. Cheryl Bushnell, Wake Forest Univ Health Sciences, Winston-Salem, NC; Mark Alberts, Northwestern Univ, Chicago, IL; Michael Frankel, Emory Univ, Atlanta, GA; Larry B Goldstein, Duke Univ, Durham, NC; Philip Gorelick, Univ of Illinois at Chicago, Chicago, IL; S. Claiborne Johnston, Univ of California at San Francisco, San Francisco, CA; Chelsea Kidwell, Georgetown Univ, Washington, DC; Lee Schwamm, Harvard Univ, Boston, MA; Linda Williams, Indiana Univ, Indianapolis, IN; Eric Peterson; Duke Univ, Durham, NC Daniel E Singer, Yuchiao Chang, Massachusetts General Hosp, Boston, MA; Margaret C Fang, Univ of California, San Francisco, CA; Leila H Borowsky, Massachusetts General Hosp, Boston, MA; Niela K Pomernacki, Kaiser Permanente of Northern California Div of Rsch, Oakland, CA; Natalia Udaltsova, Alan S Go; Kaiser Permanente of Northern California Div of Rsch, Oakland, CA Background: There are only limited data available related to adherence to secondary stroke prevention medications after hospital discharge. As a result, potential barriers and facilitators of adherence are poorly understood. Methods: AVAIL is a multi-center, longitudinal registry of 101 U.S. hospitals participating in the AHA’s Get With The Guidelines - Stroke (GWTG_Stroke) program, and was designed to evaluate 3 month and 1 year adherence to stroke prevention medications. For this first interim analysis, we assessed 3 month adherence to antithrombotic, antihypertensive, and lipid-lowering medications among ischemic stroke and TIA patients enrolled from July 1, 2006 through August 1, 2007 (follow-up rates 97% complete). Patients were contacted via telephone questionnaires administered by trained centralized interviewers. Self-reported adherence was defined as the use of antithrombotic, anti-hypertensive and lipid-lowering therapy in all subjects and also among “qualifying” subjects (i.e. those with hypertension and hypercholesterolemia or an LDL ⬎ 100) at 3 months. Logistic regression modeling was used to identify the major clinical predictors of 3 month composite adherence. INTRODUCTION: Warfarin anticoagulation is highly effective in preventing stroke and systemic thromboembolism in patients with atrial fibrillation (AF). However, current anticoagulation guidelines are (1) based solely on risk of thromboembolism off warfarin therapy, (2) do not incorporate the increased risk of intracranial hemorrhage (ICH) due to warfarin therapy, and (3) rely on stroke rate data from older studies. We examined the net clinical benefit of warfarin in a contemporary cohort of patients with AF. METHODS: The ATRIA cohort consists of 13,559 patients with nonvalvular AF enrolled in an integrated healthcare delivery system with 66,754 person-years of follow-up accumulated between 1996 and 2003. Warfarin exposure was determined using algorithms based on warfarin prescriptions and outpatient international normalized ratio (INR) values. Patient characteristics and outcome events (ischemic stroke, systemic embolism and ICH) were ascertained from health plan databases. Outcome events were validated by chart review. We defined the net clinical benefit of warfarin therapy as ischemic strokes and systemic emboli prevented versus ICH induced (since ICH is the only Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations bleeding complication comparable in clinical impact to ischemic stroke). Net clinical benefit was assessed according to standard stroke risk factors in AF and the CHADS2 stroke risk scheme. Anticoagulation quality was good with an aggregate time in therapeutic INR range of 65%. RESULTS: Overall, the annual rate of thromboembolic events was 1.27% on warfarin therapy compared to 2.1% off warfarin therapy. The annual rate of ICH on warfarin therapy was 0.58% as compared to 0.32% off warfarin therapy. For the entire cohort over the entire observation period, the net clinical benefit of warfarin (thromboembolism prevented vs. ICH induced), was 0.58% per year (95% CI, 0.28 – 0.90). The point estimate of net clinical benefit was negative in patients ⬍ 60 years old, close to zero in those 60 – 69, and increased to ⬎2% per year for those ⬎ 80. Among those with prior ischemic stroke, the net clinical benefit was 3.7% per year vs. 0.57% per year among those without a prior stroke. The net clinical benefit of warfarin increased from a negative value in CHADS2 category 0 to 2.34% in combined CHADS2 categories 4 – 6. These findings were largely unchanged after multivariable analysis including all stroke and ICH risk factors. CONCLUSIONS: In this large cohort of AF patients, we provide a model for evaluating the net clinical benefit of warfarin therapy, taking into account the increased absolute risk of ICH on warfarin and the lower absolute risk of stroke in recent years. Net clinical benefit increases with age and is higher in the presence of any of the established stroke risk factors. Risk assessment incorporating both risk of thromboembolism and risk of ICH provides a more quantitatively informed basis for the anticoagulation decision in AF patients. 118 Closure of the Lead-in Phase of CREST (Carotid Revascularization Endarterectomy Vs. Stenting Trial): 30-day And One Year Analyses. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Robert W Hobson, II, Univ. Medicine & Dentistry of New Jersey/ NJ Med Sch, Newark, NJ; Thomas G Brott, Mayo Clinic, Jacksonville, FL; Gary S Roubin, Krishna Kathir, Lenox Hill, New York, NY; Alice J Sheffet, Univ. Medicine & Dentistry of New Jersey/ NJ Med Sch, Newark, NJ; Pierre Leimgruber, Deaconess Med Cntr, Spokane, WA; Christopher White, Ochsner Clinic, New Orleans, LA; Munier Nazzal, Univ of Toledo, Toledo, OH; Elie Chakhtoura, St. Michael’s Med Cntr, Newark, NJ; B. K Lal, Univ. of Medicine & Dentistry of New Jersey/ NJ Med Sch, Newark, NJ; MeeLee Tom, Susan E Hughes, Univ. Medicine & Dentistry of New Jersey/ NJ Med Sch, Newark, NJ; Mary Longbottom, Mayo Clinic, Jacksonville, FL; George Howard, Univ. of Alabama at Birmingham, Birmingham, AL; Stephanie Martin, Univ. of Alabama at Brimingham, Birmingham, AL; Jenifer H Voeks; Univ. of Alabama at Birmingham, Birmingham, AL BACKGROUND AND PURPOSE: The benefit of carotid endarterectomy (CEA) or stenting (CAS) is dependent upon periprocedural risk and the incidence of subsequent neurological events. Safety and clinical results for CAS have varied. Closure of the CREST lead-in registry (2007) provides an opportunity for comparison of data with published randomized clinical trial (RCT) CEA results at 30-days and one year. METHODS: Interventionalists were CREST approved based on low morbidity and mortality of audited cases by a multi-specialty Interventional Management Committee. Prior to randomization approval, interventionalists performed up to 20 CAS for symptomatic (⬎50%) and asymptomatic (⬎70%) stenosis in patients at conventional or higher risk using the ACCULINKTM Carotid Stent and ACCUNETTM Embolic Protection Systems. Patients were pretreated with aspirin and clopidogrel, continued for at least 30-days post-procedurally. Neurological examinations and NIH Stroke Scales were performed by CREST neurologists pre-procedure, 24-hours and 30-days post CAS. Study primary endpoints were any stroke, death or MI within 30-days and ipsilateral stroke after 30-days, as reviewed by an independent clinical events committee. RESULTS: Completion of the lead-in registry of CREST (n⫽1552 CAS procedures) resulted in analysis of 30-day and one year event rates for all patients as well as symptomatic and asymptomatic patients. Within the first 30 days, 67 (4.3%) patients had a stroke (60 (3.9%) ischemic infarcts and 7 hemorrhagic), 13 (⬍1%) had an MI and 5 (⬍1%) died. The combined 30-day event rate was 4.4% (95% CI: 3.4%–5.4%) with 6.0% (95% CI: 3.7%– 8.4%) for symptomatic patients and 3.8% (95% CI: 2.6%–5.0%) for asymptomatic patients. The one-year event rate was 5.0% (95% CI: 3.8%– 6.2%) and 6.9% (95% CI: 4.4%–9.5%) for symptomatic patients and 4.2% (95% CI: 3.0%–5.4%) for asymptomatic patients. CONCLUSIONS: The 30-day and one year event rates for symptomatic patients were similar to rates reported for CEA in symptomatic RCTs. For asymptomatic patients, despite inclusion of higher risk subsets (⬎80y/o) the 30-day and one year event rates for CAS approached rates reported for CEA in asymptomatic RCTs. Data from this registry confirm that most events occur within the first 30 days, while subsequent ipsilateral stroke rates (⬍1%) suggest durability of CAS to at least one year after the procedure. 557 of women and men in the Aerobics Center Longitudinal Study. Methods - 46,405 men and 15,282 women without known CVD at baseline completed a maximal treadmill exercise test between 1970 and 2001. CRF was grouped as quartiles of the sex-specific distribution of maximal metabolic equivalents (METs) achieved. Mortality follow-up was through December 31, 2003 using the National Death Index. Nonfatal stroke, defined as physician-diagnosed stroke, was ascertained from surveys during 1982–2004. Cox regression models quantified the pattern and magnitude of association between CRF and stroke. Results - Over 18 years of follow-up there were 692 strokes during 813,944 man-years of exposure and 171 strokes during 248,902 woman-years of exposure. In men, age-adjusted rates of total stroke decreased across quartiles representing increasing CRF (Ptrend ⬍0.0001). This negative association remained significant after further adjusting for examination year, smoking, alcohol intake, family history of CVD, and abnormal exercise ECG responses (P trend ⬍0.0001). Further adjustment for BMI, HTN, diabetes, and hypercholesterolemia did not materially change the association (P trend ⫽ 0.003). Similar inverse patterns of association also were seen between CRF and both nonfatal and fatal stroke. In women, total stroke rates were also inversely associated with CRF (P trend ⫽0.006). The inverse association remained significant after adjusting for the covariates (Ptrend ⫽ 0.001). Further adjustment for risk factors did not significantly alter the association (Ptrend ⫽ 0.007). A similar pattern and magnitude of the association was observed between CRF and nonfatal stroke. There was some evidence that the risk of fatal strokes for women may have decreased across increasing quartiles of CRF, although this trend was not statistically significant in either multivariate model (P trend ⬎.05) Lack of statistical significance may be attributable to relatively few fatal strokes in women (N⫽55). A CRF threshold of 7– 8 METs was associated with a substantially reduced rate of total stroke in both men and women. Conclusions - These findings suggest that CRF is an independent determinant of stroke incidence in initially asymptomatic and CVD-free adults, and the strength and pattern of the association is similar for men and women. It also appears that a modest level of CRF confers significant reduction in the risk of stroke for both men and women. 120 Americans Have Higher Prevalence Of Stroke Than Europeans: Results From An International Study. Mauricio Avendano, Dr.; Erasmus MC -Public Health, Rotterdam, The Netherlands Introduction and hypothesis: Stroke mortality varies across countries, but no studies have examined cross-national variations in stroke prevalence. The prevalence of many stroke risk factors is higher in the US than in Europe. Therefore, we hypothesized that the prevalence of stroke is higher in the US as compared to European countries. Methods: Data came from recent nationally representative and fully comparable surveys of adults ages ⬎50 in the United States (n⫽13,667) and 11 European countries (n⫽30,120). Comparable data were collected on stroke prevalence, demographics, socioeconomic status, and major risk factors for stroke including smoking, obesity, diabetes, physical activity and alcohol consumption. Stroke prevalence was modeled as a function of country, demographics and conventional risk factors using logistic regression. Results: Women had a lower prevalence of stroke as compared to men (OR⫽0.73, 95%CI 0.67, 0.80). The age adjusted prevalence of stroke varied considerably across countries (figure) and was highest in the US (7.4, 95%CI 6.9 –7.9 in men; 6.5, 95%CI 6.0 –7.0 in women), and lowest in Southern Mediterranean European countries (Spain, Italy, Greece) and Switzerland. As compared to European men, US men had higher odds of stroke (OR⫽1.61, 95%CI 1.41, 1.83). Similarly, US women had about twice the odds of stroke than European women (OR⫽1.98, 95%CI 1.74, 2.25). Higher stroke prevalence was associated with lower socioeconomic status as measured by wealth, income and education, but these associations were stronger in the US as compared to most European countries. Risk factors explained only a small fraction of the higher prevalence of stroke in the US as compared to European populations. Conclusion: Adults in the US have a higher prevalence of stroke and larger stroke disparities as compared to adults in Europe. Risk factors do not account for these differences, which points at the role of broader healthcare and structural policies in determining stroke prevalence. 119 Cardiorespiratory Fitness as a Predictor of Fatal and Nonfatal Stroke in Asymptomatic Women and Men. Steven P Hooker, Prevention Rsch Cntr, Univ of South Carolina, Columbia, SC; Xuemei Sui, Dept of Exercise Science, Univ of South Carolina, Columbia, SC; Natalie Colabianchi, Dept of Epidemiology and Biostatistics and Prevention Rsch Cntr, Univ of South Carolina, Columbia, SC; John Vena, James Laditka, Dept of Epidemiology and Biostatistics, Univ of South Carolina, Columbia, SC; Michael J LaMonte, Dept of Social and Preventive Medicine, Univ at Buffalo, Buffalo, NY; Steven N Blair; Depts of Exercise Science and Epidemiology and Biostatistics, Univ of South Carolina, Columbia, SC Purpose - Prospective data on the association between cardiorespiratory fitness (CRF) and stroke are largely limited to studies in men, or do not separately examine risks for fatal and nonfatal stroke. This study examined the association between CRF and fatal and nonfatal stroke in a large cohort Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 558 Stroke Vol 39, No 2 February 2008 121 Left Atrial Diameter Predicts Atrial Fibrillation in Ischemic Stroke Patients. Fabricio Lima, Massachusetts General Hosp, Boston, MA; Michael K Parides, Columbia Univ, New York, NY; David M Greer, Massachusetts General Hosp, Boston, MA; Peter J Kelly, Mater Misericordiae Univ Hosp, Dublin, Ireland; Karen L Furie; Massachusetts General Hosp, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Stroke of undetermined etiology, which accounts for 30 – 40% of all ischemic stroke, remains a diagnostic conundrum despite widespread use of sophisticated imaging and physiologic studies. A proportion of these “cryptogenic” stroke patients may have undetected paroxysmal atrial fibrillation, a hypothesis supported by a trend toward a beneficial effect of warfarin in the cryptogenic subgroup in the Warfarin Aspirin Recurrent Stroke Study. It is well established that left atrial (LA) size is associated with risk of atrial fibrillation (AF), a condition which warrants anticoagulation for stroke prevention. We sought to determine whether LA diameter at the time of stroke could be a useful predictor of subsequent AF in stroke patients presenting without a known history of AF. Methods: Using a prospective database collected on consecutive ischemic stroke patients at the Massachusetts General Hospital, patients with no history of atrial fibrillation on admission were identified, and all subsequent parenchymal and cerebrovascular imaging, electrocardiography (ECG), transthoracic echocardiography, and Holter monitoring data analyzed. All echocardiograms were performed in a single laboratory. LA diameter was analyzed as a dichotomous variable (⬍ or ⬎ 38 mm), based on the upper limit of normal for the laboratory. All stroke subytyping was performed by a single stroke neurologist using the TOAST classification. Final determination of AF was based on analysis of aggregate cardiac monitoring data available at 6 months. Results: Data on 645 patients with no previous history of atrial fibrillation were analyzed. Of these, 66 (10.2%) were discovered to have atrial fibrillation within 6 months of stroke onset. The mean age was 67.0 (⫹/-12.1) and 32% were female. All patients had at least 24-hour cardiac monitoring in addition to an admission ECG. LA diameter⬎ 38 mm was present in 31% of “cryptogenic” strokes and 69% of those with documented AF. Patients with an LA diameter ⬎ 38 mm had an OR of 3.0 [95%CI 1.8, 5.1] for being diagnosed with AF at 6-months compared to those with LA diameter ⬍ 38 mm. Every one millimeter increase in LA diameter was associated with a 10% higher risk of being diagnosed with atrial fibrillation. Conclusion: In patients without a clear high risk cardioembolic source at time of presentation, left atrial enlargement (⬎ 38 mm diameter) identified a population with a 3-fold higher rate of atrial fibrillation. In cases of cryptogenic stroke, even in the absence of AF on ECG, left atrial enlargement may identify a subset of patients with PAF who would benefit from more extensive cardiac monitoring and consideration of warfarin therapy for secondary stroke prevention. 123 Validation of a Swallow Screening Tool in Acute Neuroscience Patients. Tessa Goldsmith, Elizabeth Cadogan, Karen L Furie, Lee H Schwamm, Aneesh B Singhal, Carmen Vega-Barachowitz, Hang Lee, Audrey Kurash Cohen; Massachusetts General Hosp, Boston, MA Introduction: Early identification of aspiration risk before administration of oral intake (food, fluids or medications) in acute stroke patients is an initiative to reduce morbidity from aspiration pneumonia that is shared by all the national stroke quality improvement programs (JCAHO, CDC, AHA). There is a paucity of validated, simple screening tools that permit detection of aspiration risk and suspected oropharyngeal dysphagia. Methods: We developed the Massachusetts General Hospital-Swallow Screening Tool (MGH-SST), a weighted 6-item test of dysphagia using factors known to predict aspiration risk with high sensitivity (tongue mobility, vocal quality, pharyngeal sensation, cough and water swallow). The MGH-SST, which requires less than 5 minutes to perform and score, was administered by trained research nurses. Results were compared to a reference standard of dysphagia assessment, namely fiberoptic endoscopic evaluation of swallowing (FEES) performed within 1 hour of MGH-SST by a speech-language pathologist (SLP). Three SLPs reviewed each FEES video-recording and classified subjects by consensus as either “safe” or “unsafe” to eat according to pre-specified criteria. Both the nurses and the SLPs were blinded to the patient’s diagnosis and each others test results during testing and interpretation. Intraclass coefficients (ICC) were calculated for Nurse interrater reliability on 30 independent, non-study patients. Results: Of 1868 consecutive admissions to the neurological and neurosurgical services screened from 8/06 – 4/07, 253 patients who had acute neurological injury with risk for dysphagia and were appropriate to undergo FEES were approached. Of 124 who consented to participate, 100 subjects were able to fully cooperate with FEES. They were 37% male, aged 23– 88 yr, 38% neurosurgical. There were no significant differences between raters for MGH-SST, and the level of concordance was high (ICC, 0.92; analysis of variance F⫽1.3). The MGH-SST performed with high rates of sensitivity among the stroke subjects and the entire subject population. Discussion: The MGH-SST is an easy-to-use, reliable and effective screening tool for dysphagia when done by trained nurses. It rapidly identifies patients who are safe to eat, and protects those with questionable swallowing function so that limited SLP resources can be devoted to those in most need of further assessment and treatment. Further validation is needed in larger cohorts and at other centers. All Patients (n⫽100) Dysphagia FEES- (FEES) ⫹ FEES- 41 5 21 33 24 3 10 17 (MGH-SST) Positive (MGH-SST) negative 122 Ability of the ABCD2 Clinical Prediction Rule to Identify Low-Risk TIA Cases in Community-Based Emergency Departments. Mathew J Reeves, Julia Warner Gargano, Susan Wehner, Michigan State Univ, East Lansing, MI; Michael Brown, MERC, Michigan State Univ, Grand Rapids, MI; Ted Glynn, Mary Hughes, Arshad Majid, Michigan State Univ, East Lansing, MI; Rashmi Kothari; Michigan State Univ, Kalamazoo, MI Introduction: The ABCD2 clinical prediction rule was developed to risk stratify TIA patients in order to inform treatment and management decisions. In the emergency department (ED) setting, the ability to identify the sub-group of patients who are at low-risk of stroke and other adverse events has the most potential clinical utility. Our objective was to prospectively validate the ABCD2 rule in 4 community-based EDs and determine its ability to identify low-risk TIA cases. Methods: Over a 12 month period TIA cases were prospectively identified by trained research staff in 4 universityaffiliated community-based EDs. Eligible cases had to have an ED-based diagnosis of TIA or an acceptable equivalent label (i.e., rule out TIA or stroke, or description of acute onset focal unilateral symptoms), a total duration of symptoms of ⬍24 hours, and no alternative final discharge diagnosis. Data required to calculate the ABCD2 score (i.e., age, blood pressure, clinical feature of unilateral weakness or speech impairment, duration of symptoms, and diabetes) were abstracted from the charts. Cases were categorized into 2 risk groups based on their ABCD2 score i.e., moderate-high risk (ABCD2 ⫽ 4 –7) or low risk (ABCD2 ⱕ 3). All eligible cases consented to provide follow-up information 90-days post discharge. The sensitivity, specificity and predictive values of the dichotomized risk score (moderate-high risk versus low risk) were estimated based on a composite 90-day outcome measure of stroke, recurrent TIA, other cardiovascular hospitalization, or death. Results: A total of 358 eligible cases were enrolled, and 90-day outcomes data were available for 338 subjects (94%). Overall, 32% of the cases were under 60 years of age, 54% were women, and 31% were non-white. The overall composite 90-day event rate was 14.5% (n⫽ 49), while the 90-day event rates for stroke, recurrent TIA, cardiovascular hospitalization, and death were 2.4%, 10.4%, 2.7%, and 1.2%, respectively. The sensitivity, specificity, positive and negative predictive values for the composite event were 84% (95% confidence interval (95% CI) ⫽ 71–92%), 30% (95% CI⫽ 25–35%), 17% (95% CI⫽ 12–22%), and 92% (95% CI⫽ 86 –97%), respectively. Among the 95 subjects (28%) who were categorized into the low risk group, there were no stroke events and only 8 (8.4%) other relevant end points during follow-up. Conclusions: In this series of TIA cases prospectively enrolled in 4 community-based EDs, the ABCD2 prediction rule was able to accurately identify the sub-set of cases that were at low risk of clinical events over a 90-day follow-up period. The ABCD2 rule has potential utility in identifying low risk TIA cases that could be considered for expedited outpatient management. All Subjects Stroke pts. Stroke Subjects (n⫽54) FEES ⫹ Sensitivity [95% CI] Specificity [95% CI] Pos Predict Val [95% CI] Neg Predict Val [95% CI] 0.89[0.80,0.95] 0.89[0.77,0.96] 0.61[0.53,0.66] 0.63[0.51,0.70] 0.66[0.59,0.70] 0.71[0.61,0.76] 0.87[0.76,0.94] 0.85[0.69,0.94] 124 Neurovascular Phenotypes Among Children with Ruptured Idiopathic Intracranial Arterial Aneurysms, and Comparison with the Adult Phenotype. Todd Abruzzo, Univ of Cincinnati Med Cntr, Cincinnati, OH; Lynn Serrano, Cincinnati Children’s Med Cntr, Cincinnati, OH; H Kocaeli, Univ of Cincinnati Med Cntr, Cincinnati, OH; B Jones, Cincinnati Children’s Med Cntr, Cincinnati, OH; N Zumberge, Columbus Children’s Hosp, Columbus, OH; F Mangano, Cincinnati Children’s Med Cntr, Cincinnati, OH; M Zuccarello; Univ of Cincinnati Med Cntr, Cincinnati, OH INTRODUCTION: The vascular pathology literature conceptualizes intracranial arterial aneurysms (IAA) as chronic degenerative lesions that develop over decades due to hemodynamic wear and tear. Although IAA of childhood are a rare entity, they are a contradiction to this model and may represent the product of a different pathogenetic process. To address this possibility, we investigated whether ruptured IAA phenotypes seen in childhood differ from those in adults. MATERIALS AND METHODS: Part 1Patients under age 19 years (y) with ruptured IAA were retrospectively identified by searching clinical registries and databases from 01/93 to 11/06 at 3 tertiary referral hospitals We queried hospital radiology reports, clinic and angiography logs using the search term “aneurysm. Patients with traumatic, infectious, neoplastic, inflammatory and flow related aneurysms were excluded from analysis. Pathogenetic risk factors were documented. Part 2- A published study of 5358 adult patients with ruptured IAA was reviewed. Epidemiological data, as well as, IAA anatomical and metric characteristics were available for 3521 patients in this study. Aneurysm morphology was available for all 5358 adult patients. We compared these adult patients to the pediatric patients. RESULTS: 33 children with 40 idiopathic IAA were initially confirmed. Among these, 16 children with 21 IAA presented with rupture. Comparison data for the pediatric and adult cohorts are presented in Table 1. Pediatric patients are subcategorized: 19 school age children ⬍ age 13y (subgroup A) and 15 adolescents ⱖ 13 y (subgroup B). Fusiform lesions accounted for 4/10 IAA in subgroup A, 2/11 IAA in subgroup B and 59/5358 IAA in the adult group. CONCLUSIONS: Unique characteristics of the ruptured idiopathic IAA phenotype seen in children include increased male predominance, predilection for the posterior circulation, and greater frequency of giant and fusiform aneurysms. Comparison of IAA phenotypes between adults, adolescents and school age children demonstrates a stepwise trend toward increasing multiplicity, and decreasing frequency of giant and fusiform aneurysms with advancing age. Although IAA in children may represent a unique biological phenotype, it is possible that absence of traditional vascular risk factors such as smoking, and long-term cumulative exposure to hemodynamic stress, select more potent forms of the same Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations functional variants in vessel wall biology for clinical expression. References for Adult Study Series Kassell, NF. The International Cooperative Study on the Timing of Aneurysm Surgery. J Neurosurg 73:37– 47, 1990. TABLE 1 Age, Gender, Size & Location Average Age (y) Male/Female Ratio Multiplicity Giant ⬎25mm Large 13–24mm Sm/Med ⬍12mm Anterior Cerebral Circulation Posterior Circulation Totals N⫽ 16 n⫽21 School age children (Subgroup A) N⫽ 7 n⫽10 Adolescents (Subgroup B) N⫽ 9 n⫽11 Adult n⫽3521 N⫽3521 10.4 1.3 3 (.13) 3 (.14) 5 (.24) 13 (.62) 13 (.62) 8 (.38) 5.3 1.3 1 (.10) 2 (0.20) 1 (0.10) 7 (0.70) 7 (.70) 3 (.30) 15.4 1.3 2 (.18) 1 (.09) 4 (.36) 6 (.54) 6 (.55) 5 (.45) 50.4 .6 668 (.19) 70 (.02) 703 (.20) 2748 (.78) 3211 (.92) 266 (.08) n ⫽ number of aneurysms, N⫽ number of patients. 125 Stroke Risk Factors Are Predictive of Cognitive Decline in the Absence of Clinically Diagnosed Incident Stroke. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 George Howard, Virginia G Wadley, Univ Alabama Birmingham, Birmingham, AL; Frederick W Unverzagt, Indiana Univ Sch of Medicine, Indianapolis, IN; Nancy Jenny, Univ of Vermont, Burlington, VT; Rodney C Go, Univ Alabama Birmingham, Birmingham, AL; Mary Cushman, Univ of Vermont, Burlington, VT; Claudia S Moy, National Institute of Neurological Disorders and Stroke, Bethesda, MD; for the REasons for Geographic and Racial Differences in Stroke (REGARDS) Investigators Introduction: While it is reasonable to hypothesize that stroke risk factors contribute to cognitive decline, the literature to date is inconsistent. In order to direct prevention efforts, it is important to identify which stroke risk factors are most closely associated with cognitive decline. Methods: We assessed these relationships in REGARDS, a national longitudinal cohort study currently recruiting 30,000 African American and white participants aged 45 and older from the 48 contiguous states. Cognitive function is being assessed by several scales, including the Six-Item Screener of global cognitive status, conducted by telephone at baseline and annually during follow-up. 17,626 participants (mean baseline age 65.7) were stroke free at baseline and had at least two cognitive function assessments (9,256 with two, 7,034 with three, and 1,336 with four). Observation time was censored after a suspected stroke during follow-up (censoring 524 assessments in 369 participants). Relationships between “traditional” Framingham stroke risk factors (see table) and change in cognitive status were assessed using a mixed model statistical approach. The difference in the annual change in the age-race-sex adjusted number of items correctly answered on the Six-Item Screener (0 - 6) between those with and without each risk factor were estimated. Results: The average age, race, sex adjusted annual change in cognitive score (number of items correctly answered) was -0.059 items. Participants at higher risk for subsequent stroke as indexed by the Framingham Stroke Risk Score (FSRS) had significantly (p ⬍ 0.0001) more rapid decline in cognitive performance, with a 10% higher FSRS associated with an annual change of -0.028 ⫹ 0.004 (see Table), a difference approximately a 50% as great as the annual average rate of decline in cognitive scores (-0.059). Individual FSRS components of left ventricular hypertrophy (LVH) (0.036 ⫹ 0.014 larger annual decline for those with LVH; p ⫽ 0.01), diabetes (0.019 ⫹ 0.009 larger annual decline for those with diabetes; p ⫽ 0.03), and higher systolic blood pressure (0.008 ⫹ 0.003 larger decline for each 10 mmHg; p ⫽ 0.01) were associated with more rapid declines in cognitive function. Discussion: Even in the absence of clinically diagnosed incident stroke, in a general population stroke risk factors were strongly related to more rapid cognitive decline. Further study is needed on whether interventions for stroke risk factors, in particular LVH, hypertension and diabetes, may decrease rates of cognitive decline. DIFFERENCE IN THE ANNUAL CHANGE IN AVERAGE SIX-ITEM SCORE ATTRIBUTABLE TO THE RISK FACTOR Risk Factor Framingham Stroke Risk Function (1 SD difference) SBP (1 SD change) Current BP Medications Diabetes Current Smoking Hx Heart Disease Atrial Fibrillation Left Ventricular Hypertrophy Estimate Standard Error p-Value -0.028 0.004 ⬍0.0001 -0.008 -0.005 -0.019 0.018 -0.011 -0.021 -0.036 0.003 0.007 0.009 0.010 0.008 0.013 0.014 0.015 0.49 0.033 0.077 0.20 0.11 0.0090 For the FSRS and each component individually, the table provides the age, race and sex adjusted estimated difference in the annual change in the number of questions in the 6-item screener correctly answered. 126 Variants in The Monocyte Chemoattractant Protein-1 (MCP-1) and Chemokine Receptor-2 (CCR2) Genes Act Synergistically to Increase the Risk of Carotid Atherosclerosis. Paul A Nyquist, Johns Hopkins, Baltimore, MD; Cherie A winkler, National Cancer Institute, Frederick, MD; Louise M McKenzie, National Cancer Institute, Baltimore, MD; Lisa R Yanek, Lewis C Becker, Diane M Becker; Johns Hopkins, Baltimore, MD Background: MCP-1 mediates recruitment of macrophages into atherosclerotic plaque. CCR2 is its receptor. Recently an independent association has been noted between the single nucleotide 559 polymorphism (SNP) in the MCP-1 promoter region rs1024611 with myocardial infarction. A Similar relationship has been observed for the biologically active SNP in CCR2 known as CCR2 V64I. Because MCP-1 is important in the development of atherosclerosis, we explored the region around the MCP-1 gene and its receptor CCR2, to identify synergy between the two regions in the development of carotid atherosclerosis. Methods: Five SNPs were genotyped around the MCP-1 region: rs1024611, rs1024610, rs2857656, rs2857657, rs4586. One SNP in CCR2 was genotyped: CCR2 V64I. All SNPs were characterized using Taqman. The study population included 465 healthy brothers (37%) and sisters (63%) (mean age, 46 ⫾ 7 years) of 280 probands with premature CAD (⬍ 60 years of age). Carotid artery duplex ultrasonography demonstrated echogenic evidence of carotid plaque (densities ⬎1mm) in 95 subjects (20%). Using unadjusted 2 analyses, we examined associations between each chosen individual SNP and the presence of carotid plaque. We then constructed a multivariable logistic model adjusting for age, sex, race, education, diabetes, smoking, hypertension, obesity, LDL-cholesterol, and non-independence within families. We incorporated SNPs that were associated with carotid atherosclerosis in the unadjusted analysis into the model. This was done individually and in combination to identify individual as well as synergistic associations between genes. Results: In the unadjusted analyses, only the MCP-1 rs2857656 SNP and the CCR2 V64I were individually associated with carotid plaque (P⫽0.05 and P⫽0.03, respectively). In the multivariable adjusted analysis two associations were identified. The homozygous CC genotype at rs2857656 was independently associated with carotid artery plaque, O.R. 2.02 (95% CI 1.02– 4.03, P⫽ 0.04) (N⫽14). In addition we observed a significant epistatic interaction between MCP1 and CCR2. Patients with a combination of homozygous MCP1 CC rs2857656 and heterozygous CCR2 V64I had a significantly higher risk of carotid atherosclerosis OR⫽7.21, (95% CI⫽1.83–28.33, P⫽0.0048) (N⫽13). Conclusion: The homozygous MCP1 CC rs2857656 genotype independently predicts the risk for the development of carotid plaque. The combination of a homozygous (MCP1 CC rs2857656) genotype in the ligand and a heterozygous (CCR2 V64I) genotype in the receptor act synergistically to predict the risk of preclinical carotid artery plaque. 127 Timing Of Microbubble-enhanced Sonothrombolysis Strongly Predicts Intracranial Hemorrhage In Acute Ischemic Stroke. Lavinia Dinia, Marta Rubiera, Marc Ribo, Estevo Santamarina, Olga Maisterra, Raquel Delgado-Mederos, Jorge Pagola, Jose Alvarez-Sabin, Joan Montaner, Carlos A Molina; Hosp Vall D Hebron, Barcelona, Spain Background. Although ultrasound-activated microbubbles (MB) accelerates clot lysis, MB activation has shown to promote blood barrier disruption and hemorrhagic transformation in animal models. We conducted a case-control study aimed to investigate the risk of HT after MB-enhanced sonothrombolysis in acute stroke. Patients and Methods We prospectively evaluated 188 patients with acute stroke related to MCA occlusion and treated with i.v. tPA ⬍ 6 hours of stroke onset. Patients received continuous 2-hour TCD monitoring plus 3 doses of 2.5 g of galactose-based MBs given at 2, 20, and 40 minutes after tPA bolus (MB group). These patients were compared with 98 historical stroke patients treated with tPA plus 2-hour TCD monitoring (control group). Both timing and degree of recanalization during first 12 hours of tPA bolus were recorded. Presence and extend of HT on 24-h CT was blinded assessed as HI1,HI2, PH1 and PH2. Results: Median baseline NIHSS was 17. Age, baseline NIHSS, clot location, early CT findings, stroke subtype and time to treatment were similar between MB and control group. Recanalization rates at 1h (32.2% vs 21%) , 2h (50.0% vs 36.7%), 6 h (63.8%/ 44.5%)and 12 h (74.3%/56.2%) were significantly higher in the MB compared to the control group (p⬍0.05). MB administration was significantly associated with an increased risk of HI1-H2 ( 21% vs 12% , p⫽0.026 OR 5.8 95% IC 2.1– 65 ), and higher degree of clinical improvement at 24 h (54.9% / 31.1%, p⫽0.004). PH1-PH2 (3.3% vs 3.8%; p⫽0.8) and symptomatic ICH rates (2.9% / 2.1%, p⫽0.580) were comparable in both groups. Moreover, the extend of bleeding after MB-enhanced sonothrombolysis was linked to the time-toreperfusion. Early (⬍6h) recanalization independently predicted HI in the MB group (OR 6.3 95% IC 2.3–56) but not in the control group. Delayed (⬎6h) or no recanalization (⬎6h) was significantly associated with PH1-PH2 in both MB ( p⫽ 0.024) and control group (p⫽ 0.045)), respectively. Conclusion: The extend of bleeding after MB-enhanced sonothrombolysis is linked to the time-to-reperfusion. MB administration is associated with early recanalization and high rate of HI1-HI2 , but it does not increase the risk of symptomatic ICH. 128 The Clinical Effect of Mild Hemorrhagic Transformation after Acute Intra-arterial Revascularization Therapy: An Exploratory Analysis. Pooja Khatri, Univ of Cincinnati, Cincinnati, OH; Renee’ Martin, Med Univ of South Carolina, Charleston, SC; Thomas A Tomsick, Univ of Cincinnati, Cincinnati, OH; Yuko Y Palesch, Med Univ of South Carolina, Charleston, SC; Michael D Hill, Univ of Calgary, Calgary, Canada; Joseph P Broderick, Univ of Cincinnati, Cincinnati, OH; for the IMS I and II Investigators BACKGROUND: Recent intra-arterial (IA) trials have reported higher rates of mild hemorrhagic transformation (HT) compared to IV trials. In addition, acute stroke trials have varied in their assessment and recording of asymptomatic hemorrhage subtypes. To our knowledge, the clinical effects of mild HT have not been addressed in the context of IA or combined IV/IA stroke therapy. We hypothesized that patients with mild HT after IV/IA therapy would have similar rates of poor clinical outcome (modified Rankin Score 3– 6 at 3 months) compared to those with no HT. METHODS: The Interventional Management (IMS) I and II trials used low-dose IV tPA (0.6 mg/kg), followed by IA tPA (up to 22 mg), for large ischemic strokes (NIHSSⱖ10) within 3 hours of onset (n⫽161). In IMS II, low-energy ultrasound via the EKOS MicroLysus® Catheter was also used whenever possible. Routine CT was done at 24 ⫾ 6 hours. Varied definitions of mild ICH (using ECASS criteria) were considered in this analysis: (1) hemorrhagic infarction (HI)-1, (2) combined HI-1 and HI-2, and (3) asymptomatic ICH, defined as not associated with clinical deterioration per the Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 560 Stroke Vol 39, No 2 February 2008 local investigator. Stepwise logistic regression models were developed. Age, baseline NIHSS score, sex, history of prior stroke, diabetes, baseline glucose, baseline systolic blood pressure, time to IV treatment, and infarct volume were tested as covariates. RESULTS: Mild HT cases consisted of 60 asymptomatic ICHs (20 HI-1, 19 HI-2, 19 PH-1, and 2 PH-2), and 1 symptomatic HI-2. In unadjusted analysis, all three definitions (HI-1, combined HI-1 and HI-2, and asymptomatic) were significantly associated with poor clinical outcome (OR 4.08, 95% CI 1.43–11.67; OR 4.61, 95% CI 2.04 –10.46; 4.92, 95% CI 2.40 –10.08, respectively), compared to cases with no HT. In adjusted analyses, we saw no association between HI-1 or combined HI-1 and HI-2 with clinical outcome. However, asymptomatic HT was associated with poor clinical outcome (OR 2.57; 95% CI 1.07– 6.19), as were gender (OR 2.72; 95% CI 1.16 – 6.45), baseline glucose (OR 1.01; 95% CI 1.00 –1.02; p⫽0.03), and infarct volume (OR 1.02; 95% CI 1.01–1.03). CONCLUSIONS: We did not show an independent association between HI-1 and HI-2 after IA therapy and clinical outcome. Whether this is due to a lack of association or the small sample size cannot be determined from this exploratory analysis. This analysis also suggests that the broad definition of asymptomatic HT, which includes PH-1 and PH-2, may be independently associated with poor outcome. Our data indicate that trials should continue to monitor asymptomatic HT, particularly PH-1 and PH-2, as a secondary safety endpoint based on routine 24-hour imaging. PH-1 and PH-2 may affect outcome and be missed by monitoring only variably defined “symptomatic” HT. The hypothesis that subtypes of asymptomatic HT after IA revascularization are relevant to clinical outcome will be tested in the IMS III trial. baseline NIHSS score, sex, and baseline glucose– using stepwise logistic regression. RESULTS: Fifty-four cases were identified with ICA-T (n⫽8) and M1 (n⫽46) occlusions and reperfusion. ⌬TReperfuse ranged from 208 to 395 minutes. Mean baseline NIHSS scores were 18.6 (range 10 –28) for these 54 cases, compared to 19.9 (range 10 –27) for the 38 cases without reperfusion (TICI 0 –1). Only ⌬TReperfuse (OR 0.981; 95% 0.967– 0.995) and age (OR 0.949; 95% CI 0.903– 0.998) independently predicted good clinical outcome after reperfusion. Both adjusted and unadjusted analyses showed that the probability of good clinical outcome decreased as ⌬TReperfuse increased (p⫽0.009 and p⫽0.02, respectively). The graph below shows the probability of a good clinical outcome over time (with 95% prediction bands) for cases with reperfusion, and a horizontal line depicting the rate of good clinical outcome for cases without reperfusion as a reference: CONCLUSIONS: We provide the first angiographic evidence in a clinical trial that good clinical outcome following reperfusion with IA therapy is strongly time-dependent. Opening an artery is not enough; time matters. At later times, reperfusion may be associated with a poor risk-benefit ratio. 129 Implant For Augmentation Of Cerebral Blood Flow Clinical Trial-(ImpACT-1). An Interim Analysis Of Safety And Effectiveness Of The Neuropath Is System In The Treatment Of Acute Ischemic Stroke. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Subhash Kaul, Nizam’s Institute of Med Sciences, Nizam, India; Dheraj Khurana, Postgraduate Institute of Med Education & Rsch, Chandigarh, India; Attila Csáni, Petz Hosp, Gyor, Hungary; Nasli Ichaporia, Jehangir Hosp, Pune, India; Dietmar Schneider, Univ of Leipzig, Leipzig, Germany; Christoph Lichy, Heidelberg Univ Clinic, Heidelberg, Germany; Sagit Weiss, David Katz, Avinoam Dayan, BrainsGate LTD, Caesarea, Israel; Yoram Solberg, Brainsgate LTD, Caesarea, Israel; Menashe Levy, BrainsGate LTD, Caesarea, Israel; David Tanne, Chaim Sheba Med Cntr, Tel-Hashomer, Israel; David Yarnitsky, Rambam Hosp, Haifa, Israel; Marc Fisher, Univ of Massachusetts Med Sch, Worcester, MA; Werner Hacke, Heidelberg Univ Clinic, Heideleberg, Germany; Natan Bornstein; Tel Aviv Med Cntr, Tel Aviv, Israel Background: In rat stroke models, sphenopalatine ganglion (SPG) stimulation up to 24 hours after stroke onset augments cerebral blood flow, reduces the infarct volume and improves neurological deficits. We present preliminary safety and effectiveness data of SPG stimulation with the NeuroPath IS System in patients with acute ischemic stroke (AIS). Design: This is an ongoing multi-national open label study recruiting 70 patients with AIS, age 18 – 85 years, NIHSS 7–20, treatment initiated within 24 hours following stroke onset. The NeuroPath IS System is implanted adjacent to the SPG via the greater palatine canal by a minimally invasive surgery (20 min., local anesthesia). The therapeutic regimen consists of 3hr/d of stimulation over 7 days. The primary endpoint is the incidence of AE and SAE, the secondary endpoint is the effectiveness of SPG stimulation as measured by NIHSS, mRS and BI at day 90. Results: To date 48 patients have been enrolled. Among the 23 who completed the study, mean age is 53 yrs, mean time to treatment is 17.7 hr, mean baseline NIHSS 11.7 with a mean baseline motor score of 6.1. Twenty-three patients having completed treatment per protocol and having the 60 day and 90 day follow-up data were compared to NINDS tPA control patients (with a baseline NIHSS 7–20): 57% of patients had a favorable outcome (mRS: 0 –2) compared to 29% among the NINDS control patients (p⫽0.0087). When the range of mRS distributions were compared, the SPG group also had a significantly better outcome (p⫽ 0.0135, CMH test). In the whole population (n⫽48), there were 7 deaths; none was related to study treatment: among them, one patient had no system implanted, 3 patients had massive stroke, 2 died during follow-up and 1 patient had his treatment interrupted after 4 days. There was an additional SAE, (recurrent stroke with hemorrhagic transformation) and 5 AE’s (1 brain edema associated with a 1 point worsening on NIHSS; 2 wound dehiscence and 2 mal-positioning). Conclusion: This interim analysis suggests that SPG stimulation appears to be safe and potentially promising for the treatment of AIS when initiated within 24hours after symptom onset. In this pilot study the NeuroPath IS System was easily and safely implanted. Further recruitment is ongoing. 130 Good Outcome after Technically Successful Intra-Arterial Therapy is Time-Dependent. Pooja Khatri, Todd Abruzzo, Univ of Cincinnati, Cincinnati, OH; Sharon D Yeatts, Med Univ of South Carolina, Charleston, SC; Joseph P Broderick, Thomas A Tomsick, Univ of Cincinnati, Cincinnati, OH; for the IMS I and II Investigators BACKGROUND: IV thrombolysis trials have taught us that “time is brain,” specifically the time from stroke onset to the initiation of therapy. Transcranial doppler studies support the importance of timing. We sought to determine how time from stroke onset to technically successful reperfusion (⌬TReperfuse) affects clinical outcome in the context of intra-arterial (IA) treatment and angiographic assessment in the Interventional Management of Stroke (IMS) I and II trials. METHODS: The IMS trials used low-dose IV rt-PA (0.6 mg/kg), followed by IA rt-PA (up to 22 mg), for large ischemic strokes (NIHSSⱖ10) within 3 hours of onset. In IMS II, low-energy ultrasound via the EKOS MicroLysus姞 Catheter was also used whenever possible. To isolate the effect of ⌬TReperfuse, we only analyzed angiographic M1 and ICA-T occlusions reperfused (TICI 2–3) during the interventional procedure (ⱕ7 hours). ⌬TReperfuse was defined as time from stroke onset to procedure termination. Good clinical outcome was defined as modified Rankin Score 0 –2 at 3 months. Adjustments were made for known predictors of clinical outcome–age, 131 Number Needed To Treat Estimates For tPA Per 90-minute Time Interval. Maarten G Lansberg, Stanford Univ, Palo Alto, CA; Erich Bluhmki, Boehringer Ingelheim, Ingelheim, Germany; Jeffrey L Saver; UCLA, Los Angeles, CA Introduction: Number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) estimates provide physicians and patients with a statistically valid summary measure that they may use intuitively to determine if a treatment effect is clinically worthwhile. When NNT estimates are based on a dichotomization of an ordinal outcome scale, they may underestimate the true treatment effect size. Objective: The aim of this study was to determine, using the entire range of the modified Rankin Scale (mRS) as the outcome variable, NNTB and NNTH estimates for tPA therapy administered within 90 minutes of symptom onset, between 91–180 minutes, between 181–270 minutes, and between 271 and 360 minutes. Methods: Data from the pooled analysis of the NINDS Part 1 and 2, ECASS I and II, and ATLANTIS A and B trials were used. Two experts generated for each 90-minute treatment time window joint distribution outcome tables in model samples of 1000 patients assigned to placebo and tPA therapy. Results: Average NNTB estimates for patients treated in the 0 –90 minute time-window, the 91–180 minute time-window, the 181–270 time-window, and the 271–360 minute time-window were 3.6, 4.7, 6.0, and 16.5. NNTH estimates for these timewindows were 69, 43, 27 and 14. When the mRS was condensed to six strata (combining mRS scores 5– 6) or five strata (combining mRS scores 4 – 6) NNTB estimates did not change, whereas NNTH estimates increased. With the mRS reduced to five strata the NNTH estimates for the four 90-minute time-windows were 167, 97, 68 and 25 respectively. Conclusions: When 100 patients are treated with intravenous tPA within 90 minutes of symptom onset 28 experience a treatment benefit and one is harmed. With longer time-to-treatment windows the benefit gradually declines and the potential for harm increases. In the 271–360 minute time-window, out of 100 patients treated with tPA, only six experience a benefit and seven are harmed. 132 Quality Indicators For Primary Stroke Centers. Anna Bersano, Monica Gattinoni, Dept of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Milan, Italy; Alberto Morabito, Cattedra di Statistica medica, Univ of Milan, Milan, Italy; Roberto Sterzi, SC Neurologia, Ospedale Niguarda Ca’ Granda, Milan, Italy; Giuseppe Micieli, UO Neurologia I/Stroke unit, Istituto Clinico Humanitas,Rozzano, Milan, Italy; Pierluigi Baron, Livia Candelise; Dept of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Milan, Italy Background/Objective: The creation of Primary Stroke Center (PSCs) is strongly recommended (Class I, Level of Evidence B) by the recent AHA guidelines (Stroke2007;38:1655– 711.). Brain Attack Coalition (BAC) group identified six qualifying major elements for PSC: stroke unit, acute stroke team, written protocol, emergency medical service, emergency department and neurosurgery service (JAMA 2000;283:3102–3109). We aim to assess the prognostic value of these six quality indicators for acute stroke care. Methods: We evaluated 11572 stroke Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations patients hospitalised within 48 h of symptoms onset recruited in the PROSIT study (Lancet 2007;369:299 –305). Multifactorial logistic regression analysis was performed to assess the association between the six quality indicators and long term outcome (two year death or disability condition) adjusting for patients characteristics (age, sex, time from stroke onset, intracranial haemorrhage, atrial fibrillation, level of consciousness). Results: Overall 6723 patients were dead or disabled at the two years follow-up. Stroke unit care was associated with a reduced probability of unfavourable outcome [OR 0.81 (95%CI: 0.72– 0.91; p⫽0.0001)]. None of the other five PSCs qualifying elements was statistically significant associated with stroke outcome: acute stroke team [OR 0.76 (95%CI 0.47–1.22)], written protocol [OR 0.82 (95%CI 0.51–1.31], emergency medical service [OR 0.99 (95%CI 0.65–1.52)], emergency department [OR 1.06 (95%CI 0.49 –2.29)] and neurosurgery service [OR 1.27(95%CI 0.84 –1.89]. Moreover any specific element of setting, staffing, process of care and diagnostic exams availability was associated with outcome except for MRI scan 24 h a day, 7 days a week [OR 0.69 (95%CI 0.51– 0.89]. Conclusion: These results should be considered before beginning a formal process of PSCs certification. 561 white women. F1.2 and TAT were highly correlated with each other (r⫽0.652, p⬍0.0001). With the exception of PAI-1 (no relationship), markers of thrombin generation and fibrinolysis were associated with the 90-day NIHSS in AA women (TAT: r⫽0.58, p⫽0.0002; F1.2: r⫽0.332; p⫽0.045; D-dimer: r ⫽ 0.545, p⫽0.001). There were no relationships between any of these markers and outcome in white women (TAT: r ⫽ 0.02, p⫽0.9; F1.2: r ⫽ -0.263, p⫽0.146; D-dimer: r ⫽ 0.28, p ⫽ 0.13). The correlation coefficients were different between AA and white women for TAT (z score ⫽ 2.50, p⫽0.012), but not F1.2 or D-dimer. In AA women (n⫽37), atrial fibrillation (p⫽ 0.035), TAT (p⫽0.058) and D-dimer (p⫽0.053) were independently associated with 90-day NIHSS (model R2 ⫽ 0.67 with adjustment for initial NIHSS). An otherwise identical model including F1.2 instead of TAT yielded similar results. In white women (n⫽32), increasing age (p⫽0.001) and the presence of coronary heart disease (p⫽0.026) were independently associated with 90-day NIHSS (model R2 ⫽ 0.76). Conclusions: Factors associated with greater stroke severity at 90 days differed between African American and white women with ischemic stroke. Elevated markers of thrombin generation and fibrinolysis were associated with outcome in African American but not white women. Differences in thrombin generation and fibrinolysis may in part explain race-ethnic differences in outcome in women after ischemic stroke. 133 AX200 (G-CSF) for the Treatment of Acute Ischemic Stroke (AXIS). Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Wolf R Schäbitz, Dept of Neurology, Univ, Münster, Germany; Rico Laage, Sygnis Bioscience, Heidelberg, Germany; Stefan Schwab, Dept of Neurology, Univ, Erlangen, Germany; Dietmar Schneider, Dept of Neurology, Univ, Leipzig, Germany; Gerhard Hamann, Dept of Neurology, Wiesbaden, Germany; Michael Rosenkranz, Dept of Neurology, Univ, Hamburg, Germany; Roland Veltkamp, Dept of Neurology, Univ, Heidelberg, Germany; Marc Fisher, Dept of Neurology, Univ, Massachusetts, Worcester, MA; Jim Grotta, Dept of Neurology, Univ, Texas, Houston, TX; Werner Hacke, Dept of Neurology, Univ, Heidelberg, Germany; Armin Schneider, Sygnis Bioscience, Heidelberg, Germany; for the AXIS study group Background: The hematopoietic factor G-CSF (AX200) inhibits apoptotic cell death and stimulates neural progenitor differentiation in the ischemic brain. In a number of different animal stroke models G-CSF (AX200) robustly decreased infarct volume and enhanced functional recovery. To date, more than a dozen animal stroke studies have been published that show efficacy of G-CSF in experimental ischemia. To translate these experimental results into the clinic, a national, multicenter, randomized, placebo-controlled phase IIa trial (AXIS) was initiated in December 2004. Methods: G-CSF (AX200) was administered in 4 increasing doses (30, 90, 135, 180 g/kg bodyweight over 72 h) as i.v. infusion (30 patients) and compared to placebo (14 patients). Inclusion criteria included onset of stroke symptoms within the last 12 hours, and presence of DWI/PWI mismatch on MRI. Primary endpoints assessed potential thromboembolic complications and distribution of serious adverse events. Secondary endpoints included occurrence of severe infections, intracranial hemorrhage, or changes in hematocrit and thrombocyte count. Exploratory efficacy analyses aimed at clinical outcome (NIHSS, mRS, BI), and ischemic lesion volume based on MRI. Results: Baseline characteristics (age, gender, neurological deficit) were similar between verum and placebo groups. As expected, G-CSF (AX200) dose-dependently increased white blood cell count with levels not exceeding 85.000/l even in the highest dose group. WBC count dropped rapidly 24 h after end of treatment. The primary and secondary endpoints were reached. G-CSF (AX200) was generally well tolerated with no increase in serious adverse events. Importantly, stenoses of extra- and intracranial arteries were not negatively affected by G-CSF (AX200) treatment. Simple comparison of clinical or imaging outcome variables did not yield differences between placebo and verum groups. However, using age, NIHSS and diffusion volume at baseline as factors in an exploratory multiple regression model, we detected a positive influence of AX200 on all clinical outcome parameters in patients with larger strokes. Conclusion: We have conducted a randomized and controlled dose-escalation study on G-CSF, a novel stroke drug with multimodal modes of action. Intravenous G-CSF (AX200) even at high doses is well tolerated in stroke patients. Exploratory efficacy analyses suggest a beneficial effect on neurological outcome in patients with larger strokes. The results of the AXIS study will serve as a valuable basis for the further clinical development of G-CSF (AX200) in ischemic stroke. 134 Elevated Levels of Thrombin-Antithrombin (TAT) are Associated with Greater Stroke Severity in African American but not White Women. Cheryl Bushnell, Wake Forest Univ Health Sciences, Winston-Salem, NC; Thomas Ortel, Larry Goldstein; Duke Univ, Durham, NC Background/Objective: African American women have poorer outcomes after stroke than white women. We prospectively examined stroke the relationships between markers of thrombin generation and fibrinolysis and stroke severity in African American and white women with ischemic stroke. Methods: Women presenting within 24 hours of an acute ischemic stroke presenting within 24 hours of onset were prospectively enrolled. NIH Stroke Scale (NIHSS) scores were obtained acutely and after 90 days. Markers of coagulation thrombin generation (thrombin antithrombin III [TAT], prothrombin F1.2) and fibrinolysis (plasminogen activator inhibitor-1 [PAI-1] , and D-dimer) were measured after 90 days in subjects from whom blood could be obtained. Results: A total of 133 women were enrolled, 67 (50%) white, 65 (49%) African American (AA), and 1 (1%) Hispanic.Markers were obtained for 70 (53%) women at 90 days. Hypertension was more common in AA women (83% vs. white 64%; p ⫽ 0.01), and atrial fibrillation was less common (6% vs. white 18%; p⫽0.04). The numbers of recurrent strokes, MIs, or venous thromboses during follow-up were similar. There were no differences in initial or 90-day NIHSS scores, or median levels of TAT, F1.2, D-dimer, or PAI-1 at 90 days in AA vs. 135 Higher Inflammatory Status in Patients with Posterior Circulation Stroke than in Those with Anterior Circulation Stroke. A-Hyun Cho, Catholic Univ, St.Mary’s Hosp, Seoul, Republic of Korea; Sang Beom Jeon, Hyun-Sook Chi, Seongsoo Jang, Young-Uk Cho, Eugene Lee, Jong S. Kim; Asan Med Cntr, Seoul, Republic of Korea Background: It has been shown that pathogenesis and stroke mechanisms are different between anterior circulation stroke and posterior circulation stroke. We hypothesized that the role of inflammation might be different between anterior circulation stroke and posterior circulation stroke. Methods: We studied consecutive, ischemic stroke patients in their chronic (⬎3 months) stage and classified stroke subtypes according to modified TOAST classification. Anterior circulation stroke included infarction in the territories of middle cerebral artery and anterior cerebral artery, while posterior circulation stroke included infarctions occurring in the territories of posterior cerebral artery, basilar artery, and vertebral artery. Patients with uncertain territorial infarction (e.g. multiple territories) were excluded. For comparison, 107 age and sex matched controls were included. Levels of high-sensitivity C-reactive protein (hsCRP), intercellular adhesion molecule, vascular cell adhesion molecule, and E-selectin were measured in all included patients and controls. Results: Of 238 patients, 81 patients (34%) had posterior circulation stroke. Regarding the stroke subtype, large vessel disease tended to occur more frequently in posterior circulation stroke than in anterior circulation stroke (64.2% vs. 45.9%, p⫽0.057). Stroke risk factors were similarly present between the two groups. The hsCRP level was higher in posterior circulation stroke patients than in anterior circulation stroke patients (0.26 ⫾ 0.49 mg/dl vs. 0.16 ⫾ 0.11 mg/dl, p⫽0.024). The hsCRP level was also marginally higher in posterior circulation stroke patients than in control subjects (p⫽0.054). After adjusting other factors including age, sex, hypertension, diabetes, hyperlipidemia, smoking, TOAST classification and the use of statin, the level of hsCRP in posterior circulation stroke patients was still higher than those that in anterior circulation stroke (OR 3.26, 95% CI 1.20 to 8.83, p⫽0.02). There was no significant difference in the levels of intercellular adhesion molecule, vascular cell adhesion molecule, and E-selectin between anterior and posterior circulation strokes. Conclusion: The hsCRP level was higher in patients with posterior circulation stroke than that in patients with anterior circulation stroke. The high inflammatory status may play a more significant role in the development of posterior circulation stroke. 136 Cerebral Autoregulation And CO2 Reactivity In Small Vessel Disease Is Affected By Blood Pressure And Not By White Matter Disease Load. Jonathan Birns, King’s College London Sch of Medicine, London, United Kingdom; Jozef Jarosz, King’s College Hosp, London, United Kingdom; Hugh Markus, St George’s, Univ of London, London, United Kingdom; Lalit Kalra; King’s College London Sch of Medicine, London, United Kingdom Background Adequate perfusion of the deep white matter of the brain depends on the relationships between blood pressure (BP), cerebral vasoreactivity and autoregulation. It has been suggested that cerebral vasoreactivity and autoregulation may be impaired in patients with white matter disease and the purpose of this study was to investigate the interrelationships between these variables. Methods 64 patients (41 male, mean age 64 years) attending a hypertension clinic with leukoaraiosis on T2 and FLAIR MRI brain scanning were recruited. Exclusion criteria included BPⱖ160/100 mm Hg, cortical infarct or intracranial pathology other than leukoaraiosis on MRI, or stenosis of ⬎50% of extracranial or intracranial arteries on Doppler ultrasound. 24-hour ambulatory BP monitoring and quantitative volumetric MRI analysis of leukoaraiosis was undertaken. Transcranial Doppler ultrasound techniques were used to calculate CO2 reactivity and dynamic cerebral autoregulatory index (ARI). Results Subjects had a mean 24-hour BP of 133/76 mmHg (SD 13/9), median white matter lesion (WML) volume of 7169 (IQR 20497) mm3, mean CO2 reactivity of 83.6 (SD 37.4) % and mean ARI of 5.6 (SD 1.4) (range 0 –9). ARI correlated significantly with 24-hour systolic BP (r⫽0.327, p⫽0.030) and mean BP (r⫽0.350, p⫽0.020) but not with diastolic BP, pulse pressure, or WML volume. In those individuals with a history of hypertension for more than 10 years, ARI also correlated significantly with nocturnal BP dipping (r⫽0.806, p⫽0.002). CO2 reactivity was not affected by patients’ BP levels or WML volume but correlated negatively with duration of Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 562 Stroke Vol 39, No 2 February 2008 hypertension (r⫽-0.292, p⫽0.027). No significant relationships existed between ARI and CO2 reactivity. Conclusion Cerebral autoregulation and CO2 reactivity are two distinct processes which are not related to WML volume but are related to BP levels and duration of hypertension respectively. Greater nocturnal dipping was associated with higher ARI values, suggesting the possibility of adaptive changes in patients with increased vulnerability to reduced cerebral perfusion. 137 Vulnerability Of Infratentorial White Matter To Nocturnal Decreases In Blood Pressure. Jonathan Birns, King’s College London Sch of Medicine, London, United Kingdom; Jozef Jarosz, King’s College Hosp, London, United Kingdom; Hugh Markus, St George’s, Univ of London, London, United Kingdom; Lalit Kalra; King’s College London Sch of Medicine, London, United Kingdom Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background Cerebral hypoperfusion has been shown to correlate with severity of leukoaraiosis and increased progression of leukoaraiosis has been associated with lower night-time blood pressure (BP). Regional heterogeneity of the relationships between BP and cerebral blood flow has been demonstrated previously. We investigated the relationships between regional white matter disease load and 24-hour BP levels. Methods 88 patients (54 male, mean age 65 years) attending a hypertension clinic with leukoaraiosis on T2 and FLAIR MRI brain scanning were recruited. Exclusion criteria included BPⱖ160/100 mm Hg, cortical infarct or intracranial pathology other than leukoaraiosis on MRI, or stenosis of ⬎50% of extracranial or intracranial arteries on Doppler ultrasound. BP was assessed with 24-hour ambulatory monitoring. Location of white matter lesions (WMLs) (frontal, pariteooccipital, temporal, basal ganglia, infratentorial) was defined according to the Age-Related White Matter Changes rating scale (Wahlund et al., 2001) and quantitative volumetric analysis of WMLs was undertaken. Results Subjects had a mean 24-hour BP of 133/76 (SD13/9) mm Hg and median WML volume of 8464 (IQR 20544) mm3. 25 patients had evidence of ‘nocturnal dipping’ (nocturnal reduction of BP by ⬎10% of daytime BP) and 5 patients had evidence of ‘extreme dipping’ (nocturnal reduction of BP by ⬎20% of daytime BP). Infratentorial WML volume increased with dipper status (F⫽3.57, p⫽0.04). After controlling for age and gender, infratentorial WML volume correlated negatively with night-time BP and positively with nocturnal dipping (r⫽0.6, p⬍0.01). Regression analyses demonstrated reduced night-time BP to be an independent predictor of infratentorial WML load (t⫽2.9, p⬍0.01). No such relationships existed for supratentorial WMLs. Conclusion Infratentorial white matter is particularly vulnerable to nocturnal decreases in BP. This may be related to metabolic activity, vascularisation and circadian rhythm of cerebral blood flow velocity. Reference Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjutti T, Scheltens P; on behalf of the European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001; 32: 1318 –22 139 Albumin Treatment Improves Microvascular Hemodynamics and Augments the Effect of Thrombolytic Therapy in Arteriolar Thrombosis: a Two-Photon Microscopy Study. Myron D Ginsberg, Hee-Pyoung Park, Anitha Nimmagadda, Richard A DeFazio, Raul Busto, Ricardo Prado; Univ Miami Sch of Medicine, Miami, FL High-dose human albumin is robustly neuroprotective in preclinical models of ischemic stroke. The results of the recent ALIAS (Albumin in Acute Stroke) pilot clinical trial suggest that the efficacy of thrombolytic therapy in acute ischemic stroke may be enhanced by the co-administration of high-dose albumin. This result guided the design of the ALIAS phase III multicenter clinical trial, currently in progress. Here, we explored the intravascular component of albumin’s protective effect by studying microvascular hemodynamics in a model of laser-induced cortical arteriolar thrombosis, and we assessed combined therapy with albumin and the thrombolytic agent, reteplase. The cortical microcirculation of anesthetized, physiologically monitored Sprague-Dawley rats was studied in vivo via a fronto-parietal cranial window by two-photon laser-scanning microscopy (TPLSM) after plasma labeling with fluorescein-dextran. Focal thrombosis was produced in 30 –50 m cortical arterioles by laser irradiation. Arteriolar flow velocity was measured repeatedly by line-scanning. At 30 min after thrombus induction, rats of Series #1 received either human albumin, 2.5 g/kg (n⫽8), or saline control (n⫽6), and rats of Series #2 received reteplase (1.84 –3.68 g/kg) co-administered with either albumin (2.5 g/kg, n⫽12) or saline (n⫽9). Baseline arteriolar flow velocity, which averaged 3.6 ⫾ 1.0 mm/sec, was reduced to 10 –25% of control by thrombosis, which also led to focal vasodilatation. In Series #1, saline treatment at 30 min failed to influence arteriolar flow velocity, which remained depressed at 10 –22% of control throughout the 60 –90 min observation period. By contrast, albumin treatment induced a prompt rise in median flow velocity to 38% of control by 10 min post-treatment, and to 61– 67% of control by 50 – 60 min (p⬍0.05 vs. saline). In Series #2, sub-thrombolytic doses of reteplase combined with saline led to a median increase in flow velocity to 37% of control distal to the thrombus (p⫽NS vs. pre-treatment). By contrast, reteplase combined with albumin therapy resulted in a prompt, highly significant increase of median flow velocity to 58% of control levels (p ⫽ 0.013 vs. reteplase ⫹ saline), which remained significantly higher than the reteplase ⫹ saline group at multiple time-points over the subsequent hour. We conclude that albumin, administered alone, induces a prompt, sustained improvement in microvascular hemodynamics distal to arteriolar thrombosis, and when co-administered with a thrombolytic agent, markedly enhances the latter’s beneficial hemodynamic effect. These results support an important intravascular component to albumin’s anti-ischemic effect and have important clinical implications for the management of acute ischemic stroke. 140 Scanning Electron Microscopy Analysis of Thromboembolic Material Retrieved from Cerebral and Cervical Arteries of Patients with Acute Ischemic Stroke. 138 Magnitude And Time Course Of Platelet Inhibition With Extended Release Dipyridamole With Or Without Aspirin In Healthy Japanese Volunteers: The Japanese Aggrenox Versus Aspirin Therapy Evaluation (JAGATE). Victor L Serebruany, Alex Malinin, Osler Med Cntr, Towson, MD; Dan Hanley; Johns Hopkins Univ, Baltimore, MD Background: Randomized trials showed greater stroke prevention with extended release dipyridamole in combination with low dose aspirin than either with aspirin or dipyridamole alone. However, most studies with this formulation (Aggrenox) were done in Europe and North America. Considering potential inter-racial differences in drug response, we conducted a small randomized study in healthy Japanese volunteers to compare antiplatelet regimens with regard to the changes in the platelet biomarkers. Methods: Thirty healthy volunteers (18 – 40 years old, 15 male and 15 female) of Japanese descend were randomized to Aggrenox (n⫽17) or aspirin 81 mg (n⫽13 volunteers) for 30 days. Platelet function was assessed at baseline, and days 15, and 30 by conventional aggregometry, whole blood flow cytometry, and cartridge-based analyzer. Results: Both Aggrenox and aspirin provided sustained platelet inhibition at Day 15 and Day 30. Therapy with Aggrenox, however, was associated with more prominent and significant inhibition of collagen-induced aggregation (p⫽0.08, Day 15), as well as prolongation of the closure time (p⫽0.001, Day 30); diminished expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) (p⫽0.02, Day 30), glycoprotein IIb (GPIIb) antigen (p⫽0.001 and 0.024 for Day 15 and Day 30), and GPIIb/IIIa activity by PAC-1 antibody (p ⫽ 0.014 and 0.03), CD62 (P-selectin) (p ⫽ 0.03 for Day 15 and Day 30), as well as inhibition of protease activated receptors (PAR-1) associated with intact WEDE-15 (p ⫽ 0.002 and 0.003) and SPAN-12 (p ⫽ 0.002 and 0.04) thrombin receptors when compared with aspirin. Conclusion: The magnitude and durability of platelet response after Aggrenox in healthy Japanese is similar to those effects observed in Caucasians and African-Americans. Larger study to assess drug efficacy and safety in the Japanese post-stroke patients is warranted. Raul G Nogueira, Massachusetts General Hosp, Boston, MA; Sivaprasad Sukavaneshvar, Med Device Evaluation Cntr, Salt Lake City, UT; James D Rabinov, Guilherme Dabus, Albert J Yoo, Ferdinando S Buonanno, Johnny C Pryor, Lee H Schwamm, Joshua A Hirsch; Massachusetts General Hosp, Boston, MA BACKGROUND: Greater knowledge about the composition of thromboembolic material underlying the vascular occlusion in stroke patients may provide the means for developing new treatments. Previous studies have given important insights about the histology of these lesions. However, these studies were limited by their inability to analyze the ultra-structure of the thrombus. We report on the scanning electron microscopy (SEM) analysis of thrombi retrieved from 18 stroke patients. METHODS: Thrombi were fixed in either Karnovsky’s fixative or formalin and processed intact for SEM by dehydration with graded ethyl-alcohol. The samples were then sputter coated with gold, and examined in a JEOL-35 Scanning Electron Microscope (set at 25KeV with working distance of 39). RESULTS: Samples were retrieved with the Merci device (n⫽16), Accunet device (n⫽1), or by direct tromboaspiration with a guide catheter (n⫽1). The occlusion sites included the ICA (cervical: n⫽2; intracranial: n⫽7; both n⫽1), MCA (n⫽5), and basilar artery (n⫽3). The samples were diverse in size, morphology, and fragmentation. Most thrombi had some regions that were predominantly red and other regions that were predominantly white, which was suggestive of the exposure of those regions to shear flow or to stasis. The organization of the thrombotic elements, i.e. fibrin, platelets, and red cells was also diverse both within each thrombus and across the various thrombi. Two distinct structural patterns could be recognized: (1) thrombus exhibiting advanced maturity where all the thrombotic elements were so densely integrated that individual entities were not clearly discernible (Fig.1) suggesting a well aged and stable location that had sustained exposure to shear flow; (2) thrombus displaying distinct fibrin strands and trapped red cells suggestive relatively loose cross-linking characteristic of an active region where the thrombus is still in the process of maturing and possibly of formation in regions of stasis and recirculation (Fig.2). These patterns were seen at different proportions in different patients. CONCLUSION: Different ultra-structural patterns can be recognized in thrombi causing cerebrovascular occlusion in acute stroke patients. Correlation of such patterns with the presumed etiology underlying the stroke is currently under way. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 563 600 –1200J sonications were delivered to the clot, 90% of which, was liquefied with 10 seconds of pulsed sonication. The treatment produced no heat at the target. There was a direct, non-linear correlation between clot liquefication and power of sonication. These parameters were successfully applied using the 220KHz HIFU system - a single 750J, 10% duty cycle pulse sonication resulted in clot liquefication. Conclusion In this pilot study, we have demonstrated an efficient way to liquefy a blood clot utilizing a MR guided clinical HIFU system. Further studies will be necessary to explore potential clinical application of this novel technique, such as the treatment of ICH. 143 Stent Or Surgery In Symptomatic Carotid Artery Stenosis - Age Is An Important Factor To Consider. Robert Stingele, Karsten Alfke, UKSH Kiel, Kiel, Germany; The SPACE Study Group 141 TNK Induces Faster MCA Recanalization and leads to Better Short- and Long-term Clinical Outcome Than Native tPA. The TNK-TPA Reperfusion Stroke Study. Carlos A Molina, Marc Ribo, Marta Rubiera, Estevo Santamarina, Raquel Delgado-Mederos, Olga Maisterra, Pilar Delgado, Lavinia Dinia, Octavio Pontes, Joan Montaner, José Alvarez-Sabin; Hosp Vall d’Hebron, Barcelona, Spain Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Aim Tenecteplase (TNK) is a modified form of tPA, with longer half-life and greater fibrin specificity. Although an open-label, dose-escalation study of TNK showed that doses of 0.1 to 0.4 mg/kg are safe in ischemic stroke, comparative safety and efficacy data of TNK and native tPA is needed. We aimed to compare the effects of two thrombolytic regimen (TNK vs standard tPA) on MCA recanalization, early clinical course and long-term outcome. Methods We evaluated 122 consecutive stroke patients due to MCA occlusion who fulfilled criteria for iv thrombolysis. Patients were allocated to receive standard iv tPA 0.9mg/Kg (10% bolus, 90% 1-h infusion) or iv TNK 0.4 mg/Kg (bolus), All patients underwent multiparametric MRI studies including diffusion (DWI), perfusion (PWI), and MRA before treatment. All patients included showed a DWI/PWI mismatch ⬎ 20% of DWI lesion. Site of arterial occlusion before treatment and 2-hour recanalization was assessed by TCD. NIHSS scores were obtained at baseline and 24h. Symptomatic and asymptomatic ICH were assessed on CT scan performed at 24 –36h.The mRS score was used to assess outcome at 3 months. Results Median baseline NIHSS score was 17 points. Eighty-five (69%) patients had a proximal and 37 (31%) a distal MCA occlusion on TCD. Eighty (66%) patients received tPA and 42 (33%) were treated with TNK. Stroke severity, time to treatment, location of MCA occlusion, extend of initial DWI lesion and percentage of DWI/PWI mismatch were similar in both groups. At 2h of treatment, recanalization was significantly (p⫽0.028) higher in TNK group (n⫽29/69%) as compared to tPA (n⫽43/53%) group. Complete recanalization at 2h was seen in 18 (42.4%) and 27 (33.4%) patients treated with TNK and tPA, respectively (p⫽0.014). The time to beginning of recanalization after bolus was comparable in TNK (27⫾19 min) and tPA (35⫾24 min) groups (p⫽0.11). SICH occurred in one (2.3%) and 3 (3.7%) TNK and tPA patients, respectively. Asymptomatic ICH on 24 –36h CT was seen in 28% of TNK and 21% of tPA treated patients (p⫽0.089). At 24h, 63% and 51% of TNK and tPA improved ⬎ 4 points in the NHSS score (p⫽0.041). TNK increased in 2.5-fold the rate of dramatic clinical recovery at 24h as compared to tPA (24.5% vs 11%). At 3 months, 66% and 52% (p⫽0.039) of TNK and tPA patients, respectively, became independent (mRS score ⬍ 2). Conclusion Compared to native tPA, TNK (0.4 mg/Kg) administration is associated with faster and more complete MCA recanalization, and better short-and long-term outcome without increasing the risk of SICH. 142 Mr Guided Focused Ultrasound Surgery For The Treatment Of Intra Cerebral Hemorrhage: In Vitro Proof Of Concept. Sagi Harnof, Univ of Virginia, Charlottesville, VA; Arik Hananel, Gilat Schiff, Javier Grinfeld, Eyal Zadicario, Insightec, Haifa, Israel; Neal Kassell; Univ of Virginia, Charlottesville, VA Introduction Intracranial hemorrhage (ICH) is the most lethal type of stroke with a mortality rate of up to 50%. Surgical evacuation of the hematoma in order to reduce mass effect and secondary insult has failed to be of proven benefit, probably due to the effects of the surgical insult. However, minimally invasive approaches such stereotactic guided and endoscopic evacuations have shown initial encouraging results. MR Guided High Intensity Focused Ultrasound (MRgHIFU) is an evolving and promising non invasive technology which enables the delivery of high energy in the form of thermal or mechanical forces to a precise point defined by high resolution MRI imaging. We have conducted a series of in vitro, phantom based studies to evaluate the feasibility of lysing ICH utilizing MRgHIFU, and to establish appropriate sonication parameters. Methods All sonications were done utilizing Insightec MRgHIFU clinic system (both the FDA approved body unit and the experimental brain unit). Phantoms consisted of customized gel filled with clotted procaine blood. Each sonication was followed by T2 imaging. 10 cc clots were treated with escalating doses of power starting at 600w up to 1200w of pulsed sonication for 1 to 20 seconds using a 10%–20% duty cycle, with and without electrical steering mode. Volume analysis was done using 500 –1200 w pulsed sonication of a 1 sec 10% duty cycle. Volumes were measured from the T2 images. 500 to 1000 w of 10% duty cycle pulsed sonications were preformed utilizing the head system. Results A total of Introduction: Carotid artery stenting (CAS) and carotid thrombarterectomy (CEA) are therapeutic options for symptomatic carotid artery stenoses. Populations at a high procedural risk might be different for CAS or CEA due to technical differences between these methods. We therefore identified risk factors associated with a high procedural risk in patients treated within the ‘Stent-supported angioplasty versus carotid endarterectomy’ (SPACE)-trial. SPACE to date is the largest randomized clinical trial comparing CAS and CEA in 1214 patients with symptomatic carotid artery stenosis. Methods: Multivariate statistical methods and regression tree analysis were used to identify risk factors for a high incidence of the primary study endpoint of the SPACE-study (ipsilateral stroke or death within 30 days of randomization). The covariates under investigation were defined pre-hoc in the study protocol of SPACE and consisted of age, sex, type of qualifying event (ocular, TIA, stroke), side of intervention, degree of stenosis and presence of relevant contralateral stenosis. Results: 1) Age: There was an age-dependent increase of the periprocedural risk in patients treated by CAS (p ⫽ 0.008) but not with CEA (p ⫽ 0.446). The optimal separator-age between low and high procedural risk was 68 years for CAS patients. For CEA patients, such a separator could not be identified. 2) Contralateral carotid stenosis or occlusion was present in 7.1% of CAS patients and 7.5% of CEA patients. CAS patients with and without contralateral stenosis had similar event rates (5 vs. 7.1%), in CEA-treated patients there was an increased risk if contralateral stenosis was present (13 vs. 5.9%). There was a trend for interaction between type of therapy and presence of contralateral sternosis or occlusion (ITT: p⫽0.1, PP: p⫽0.042) 3) For the other covariates (sex, type of qualifying event, side of intervention, degree of stenosis), no between-group differences could be detected. Conclusions:In younger patients (⬍68 years), CAS had a lower procedure related risk for stroke and death than CEA whereas older patients had a lower risk if treated with CEA. In patients with contralateral stenosis, there was a trend for a lower risk in CAS patients. 144 VECTORS (Very Early Constraint Therapy for Recovery from Stroke) Phase II RCT: Results of Secondary Analyses. Dorothy F Edwards, Univ of Wisconsin, Madison, WI; Catherine E Lang, Rebecca Birkenmeier, Washington Univ, Saint Louis, MO; William J Powers, Univ of North Carolina, Chapel Hill, NC; Alexander W Dromerick; Georgetown Univ and National Rehabilitation Hosp, Washington, DC Introduction: Results from VECTORS have called into question the superiority of ConstraintInduced Therapy (CIT) over traditional therapy in promoting upper extremity (UE) recovery after stroke. The primary analyses of VECTORS found no difference between dose-matched CIT and control groups during acute rehabilitation. The purpose of this study was to confirm the primary result using secondary efficacy measures from the Phase II RCT. Methods: Subjects were assigned using adaptive randomization into control (2 hrs traditional OT), dose matched CIT (2 hrs shaping, 6h day constraint), or high intensity CIT (3 hrs shaping, 90 % waking hrs constraint) groups at inpatient rehabilitation admission. Inclusion criteria included ischemic or hemorrhagic stroke within 28 days of onset; no prior stroke-related neurologic impairment; need for inpatient rehabilitation; NIH Stroke Scale (NIHSS) aphasia, command, consciousness and sensory items ⱕ 1; NIHSS neglect ⫽ 0; and persistently hemiparetic UE with some residual voluntary movement. Blinded raters evaluated subjects at randomization, end of treatment (14d), and the primary endpoint (90d). Prespecified secondary measures were the Wolf Motor Function Test (WMFT) Function and Time scores and the Motor Activity Log (MAL) for the affected UE. Mixed model analyses were performed. Results: 52 participants (mean age 63.9⫾14 yrs) were randomized 9.65⫾4.5 days after onset. Mean NIHSS was 5.3⫾1.8; 77 % had ischemic stroke. Groups were equivalent at baseline on all randomization and dependent variables. As expected, all groups improved over time on the WMFT- Function scale(p⬍.0001), WMFT-Time scale (p⬍.0001) and MAL (p⬍.0001). Significant Time x Group interactions were found for WMFT Function (F⫽3.29; p⬍.008), and MAL (F⫽2.21; p⬍.05), such that the high intensity CIT group had significantly worse function scores at Day 90. No significant Time x Group interaction in timed motor performance (WMFT-Time) was found, indicating that the three groups had equivalent time scores at Day 90. Further, no significant differences were found between the dose-matched CIT and control groups at Day 90 on any of the three measures. Conclusions: Analyses of secondary efficacy measures are consistent with our previous finding that CIT was not superior to equal doses of conventional therapy in the acute inpatient rehabilitation setting. We again observed an inverse dose response relationship, where a higher dose was associated with lower function assessed by both objective (WMFT) and subjective measures (MAL). Our results support the need for controlled clinical trial designs examining the effects of timing and dose on motor recovery during acute rehabilitation. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 564 Stroke Vol 39, No 2 February 2008 145 Withdrawn min-reperfusion ischemia model, r (rat) ASCs were isolated from fresh subcutaneous fat tissue of each rat, and incubated under endothelial growth medium for seven days. At 8 days, autologous rASCs (0.5 million cells in 0.5 cc PBS) or vehicle were intravenously administered. Behavioral recovery, cerebral perfusion, brain atrophy, and angiogenesis were assessed till 35 days. Results: hASCs expressed VEGF, BDNF, CXCR4, Flk1, Flt1, vimentin, and nestin. When cultured in hypoxic condition (1% oxygen) for 72 hours, hASCs increased the expressions of GM-CSF, BDNF, FGF, p75, and Flt1. Intravenous transplantation of hypoxia-treated hASCs enhanced cerebral endothelial proliferation (BrdU⫹ endothelial cells), and cerebral perfusion state in rats with cerebral ischemia. Rats transplanted with hASCs showed better neurologic recovery and also revealed lesser lesion volume. Conditioned media of hASCs protected cerebral neuronal cells from hypoxic and oxidative injury. In the autologous transplantation, the yield of rASCs in each animal was about 5 million cells per 1g fat. Autologous rASCstransplanted rats showed better functional outcome measured by modified limb placing test compared to the vehicle group. Autologous ASCs increased angiogenesis after cerebral ischemia. Conclusion: In summary, ASCs expressed multiple growth factors and growth factor receptors, especially in hypoxic condition, and enhanced angiogenesis and neurologic recovery in a cerebral ischemia model. Autologous ASCs were easily obtained and exerted functional recovery. Neuroprotective and regenerative effects induced by intravenous hASCs seem to be results of the orchestration of secretary and bystander effects. 148 18 FDG-PET Imaging Of Human Carotid Arteries Prior To Endarterectomy Confirms It Is A Bilateral Disease. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 146 High Resolution Copy Number Variation Analysis of Sporadic and Familial CCM Patients. Yasar Bayri, Winson S Ho, Kaya Bilguvar, Michael DiLuna, Mohamad Bydon, Lindsay A Collins, Fatih Bayrakli, Christopher E Mason, Matthew W State, Murat Gunel; Yale Univ Sch of Medicine, New Haven, CT Introduction: Cerebral Cavernous Malformations (CCM) are a central nervous system vascular disorder characterized by abnormally dilated vascular channels lined by a single layer of endothelium, that are prone to cerebral hemorrhage. Three causative genes have been identified to date that, when mutated, lead to the severe genetic phenotype of this disease. To identify whether genetic aberrations other than the three known loci may underlie the sporadic and familial form of this disease, single nucleotide polymorphism (SNP) based high resolution genotyping and copy number variation (CNV) analysis of 30 sporadic and familial patients with CCM (for whom linkage excluded the three known loci) were performed. Methods: Patient DNA was analyzed using 250K Sty SNP chips (Affymetrix). The Affymetrix Chromosome Copy Number Analysis Tool (CNAT) and Circular Binary Segmentation (CBS) were used to identify significant CNVs based on derived Log2 ratios using 270 HapMap control. Results: Out of 30 patients, 23 loci with large numbers of consecutive probes demonstrating statistically significant Log2 ratios consistent with either heterozygous or homozygous deletions not within known CNV-rich intervals. One deletion in a sporadic case included the CCM2 interval. Excluding the X chromosome, the two algorithms called a total number of 376 CNVs, with NegLog10PValue larger than 2.6, that are not observed in 30 separate controls. Of the putative CNVs, 160 and 216 are deletions and amplifications respectively. These putative CNVs are to be validated with qPCR. Conclusions: Additional genes other than Krit1, malcavernin and PDCD10 may account for the CCM phenotype as de-novo mutations in sporadic patients or additional linkage loci in familial cases. The further characterization of the genes within these loci may provide further insight into the CCM pathway and lesion pathogenesis. 147 Transplantation Of Adipose Tissue-derived Stem Cells In Cerebral Ischemia: Enhanced Angiogenesis By Functional Stem Cells And Feasibility Of Autologous Transplantation. Kon Chu, Soon-Tae Lee, Keun-Hwa Jung, Eun-Cheol Song, Hee-Kwon Park, Jeong-Min Kim, Jin-Hee Kim, Jae-Sung Lim, Kyung-Mook Kang, Nan-Hyung Hong, Jun-Young Chang, Sang Kun Lee, Manho Kim, Jae-Kyu Roh; Seoul National Univ Hosp, Seoul, Republic of Korea Background: Adipose-derived stem cell (ASC) is a multipotent mesenchymal stem cell population with easy accessibility, and known to secrete multiple growth factors, thereby showing cytoprotective effects in ischemic injury. Given the feasibility of ASCs transplantation in cerebral ischemia, we investigated the “bystander” protection and neuro-regenerative effect induced by ASCs in a rodent cerebral ischemia model. Methods: In the first experiment, we cultured human ASCs (hASCs) from subcutaneous adipose tissue which was acquired from elective surgery with patients’ consent. We investigated the cytokine transcription levels between normoxia and hypoxia culture conditions. hASCs (3 million cells per animal) or vehicle (PBS) were intravenously injected at 24 hours after the induction of middle cerebral artery occlusion in rats (90 minutes, ischemia-reperfusion model), and BrdU was injected for next 14 days. Behavioral recovery, cerebral perfusion, brain atrophy, and angiogenesis were assessed till 35 days. Conditioned media of hASCs were tested for neuroprotective effects. In the second experiment, we tested the feasibility of autologous ASCs transplantation. On the next day of 90 M.Angels Font, Hosp Universitari de Bellvitge, Barcelona, Spain; Alex Fernandez, Cristina Gamez, Hosp Universitari de Bellvitge, IDI, Barcelona, Spain; Mark Slevin, Manchester Metropolitan Univ, Manchester, United Kingdom; Ramon Vila, Elena Iborra, Hosp Universitari de Bellvitge, ACV, Barcelona, Spain; Francisco Rubio, Jerzy Krupinski; Hosp Universitari de Bellvitge, Barcelona, Spain Introduction: It is still unclear whether patients with unilateral carotid disease are at higher risk of contralateral carotid artery progression. Both carotid vulnerability to rupture and asymptomatic progression is linked to plaque inflammatory cells which can be detected in vivo with 18-FDG-PET imaging. Hypothesis: Our hypothesis was that 18FDG-PET imaging can identify inflammation in contralateral carotids with low to moderate stenosis. Methods: We studied 15 patients with symptomatic or asymptomatic unilateral carotid artery stenosis (i.e. contralateral carotid stenosis less than 50%) scheduled for carotid endarterectomy (CEA). 18-FDG-PET was performed prior to CEA and 116 ⫾ 22 days following surgery. All patients received an integrated FDG-PET/CT using a Discovery ST scanner. Two-centimeter circular regions of interest were drawn on CT images around the area including carotids in each slice, and then transferred onto the corresponding co-registered PET image to enable FDG-uptake values based on maximum standardized uptake value. The analysis included a vascular region 56 mm over and below the level of the carotid bifurcation, and slice-activity curves were calculated in order to visualize plaque and basal metabolism. Results: Carotid plaques with inflammatory infiltrates had the highest 18-FDG uptake (p⬍0.05). We found significant correlation between the degree of FDG accumulation in the ipsilateral carotids scheduled for CEA and contralateral asymptomatic carotids (R⫽0,9 p⬍0.001). The FDG uptake rates in the contralateral arteries remained increased on the follow-up imaging (1.15⫾ 0.2 vs. 1.14⫾0.1; R⫽0,7 p⫽0,006). No significant correlation was found between the degree of 18-FDG uptake and time from symptoms to PET imaging, symptomatic or asymptomatic patients and degree of carotid stenosis. Diabetic patients, although normoglycemic, had lower FDG uptakes (p⬍0,01). Statin treatment was associated with a more pronounced decrease in 18-FDG-uptake on second PET (p⬍0.05). Conclusions This is the first in vivo study using 18-FDG-PET imaging demonstrating that carotid atherosclerosis is a bilateral disease. Identification of inflammatory regions in the contralateral carotids has the potential to offer early aggressive medical treatment to these patients. 149 CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke. David S Liebeskind, William H Yong, Nerses Sanossian, Sidney Starkman, Michael P Tsang, Antonio L Moya, David D Zheng, Doojin Kim, Latisha K Ali, Samir H Shah, Amytis Towfighi, Bruce Ovbiagele, UCLA, Los Angeles, CA; Chelsea S Kidwell, Georgetown Univ, Washington, DC; Satoshi Tateshima, Reza Jahan, Gary R Duckwiler, Fernando Vinuela, Noriko Salamon, J P Villablanca, Victor J Marder, Jeffrey L Saver; UCLA, Los Angeles, CA Background: Noncontrast CT depicts some MCA occlusions as linear increased density, the hyperdense MCA sign (HMCAS). Gradient echo (GRE) MRI may also delineate some MCA occlusions as ovoid regions of hypointensity or blooming artifact (BA), often extending beyond vessel margins. Prior studies of the HMCAS and BA have analyzed their prognostic significance and prediction of response to thrombolysis, but not their pathologic substrate. Methods: Noncontrast CT and GRE MRI studies performed immediately prior to mechanical thrombectomy in consecutive cases of acute MCA ischemic stroke were reviewed by 2 readers, blinded to clinical and pathology data. Presence and density (HU) of the HMCAS, and presence or absence of BA were assessed. Occlusions subsequently retrieved by embolectomy underwent histopathologic analysis, including automated quantitative and qualitative rating of proportion composed of red blood cells (RBC), white blood cells, and fibrin based on microscopy of sectioned thrombi. Results: Among 51 patients, mean age was 65 years and 49% were female. Across all retrieved thrombi, mean (SD) proportion that was RBC was 33% (⫾23) RBC, WBC 6% (⫾14), and fibrin 62% (⫾23). Of the retrieved clots, 22 (43%) were fibrin dominant, Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations 12 (24%) RBC dominant and 17 (33%) mixed. HMCAS was noted in 10/20 MCA stroke cases with CT, with a mean HU of 61 (SD⫾8). BA was noted in 18/34 cases with GRE MRI. HMCAS was more commonly seen with RBC dominant and mixed than fibrin dominant clot pathology (100% vs. 62.5% vs. 22%, p⫽0.043). Mean percent RBC composition was higher in clots with HMCAS (45% vs. 19%, p⫽0.030), although HU density was not correlated with clot composition. BA was also more common in RBC dominant and mixed clots compared to fibrin dominant clots (100% vs. 60% vs. 37%, p⫽0.020). Mean percent RBC was greater with BA (43% vs. 22%, p⫽0.011). Conclusions: The CT HMCAS and GRE MRI BA reflect the pathology Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 of the occlusive thrombus. Strong correlation with RBC content suggests that RBC x-ray density is a principal factor of the HMCAS and RBC hemoglobin deoxygenation an influential determinant of BA. Absence of HMCAS or BA may indicate the presence of fibrin predominant clots. 150 Evaluation Of Patients With Suspected Cardioembolic Stroke Using Cardiovascular Mri - A Comparative Study With Echocardiography. John J Sheehan, Northwestern Memorial Hosp, Chicago, IL; George Lin, Northwestern Univ, Chicago, IL; Jim Connors, Mark J Alberts, Karin Dill, Reed A Omary, Richard Bernstein, James C Carr; Northwestern Memorial Hosp, Chicago, IL Introduction: The aim of our study was to compare Cardiovascular MRI (CVMR) and Echocardiography (TTE and TEE) used in the detection of intracardiac thrombi in patients with suspected cardioembolic stroke (CES). This study examined the utility of CVMR for the detection of non-thrombotic additional findings. Methods: Over a 12 month period between September 2005 and September 2006, 106 consecutive patients with a suspected CES had CVMR for the detection of intracardiac thrombi. All CVMR examinations were performed on a 1.5T MR scanner using CINE trueFISP, contrast enhanced MR angiography, delayed enhanced inversion recovery trueFISP and first pass imaging. The clinical information and study reports of echocardiography, CVMR, MR Brain and Carotids was retrospectively reviewed. Results & Discussion: Of the 106 patients who had a CVMR study for suspected CES, CVMR revealed 10 thrombi in n⫽9 (9.7%) patients. The thrombi were located in the LAA (n⫽3), left ventricle (n⫽4) and right atrial appendage (n⫽3). Of these 9 patients echocardiography was positive in n⫽2 (22%), indeterminate in n⫽2 (22%) and negative in n⫽5 (56%) (Fig. 7). One of the 5 patients with an negative echocardiograms was obese leading to technical difficulties during the TTE. TTE and TEE was performed in 3 of the 5 negative echocardiographic studies. No thombi were detected echocargraphy that were not seen on CVMR. CVMR reported 103 non thrombotic additional findings in n⫽53 (57%) of patients compared to echocardiography. Sixty of these were considered significant in n⫽38 (40.9%) of patients. When all significant findings including thrombi were calculated there were 67 additional significant findings in n⫽42 (45%). Additional findings associated with thrombus formation (acute infarction, scarring and LV aneurysms) were n⫽19(20%) for CVMR and n⫽7(7%) for echocardiography. Conclusion: CVMR is a non invasive, reproducible method for the detection of intracardiac thrombi and is clinically advantageous in the detection of important non thrombotic findings, including prothrombotic conditions. CVMR should be considered as part of the routine evaluative framework along with echocardiography in the assessment of patients with suspected CES. 565 151 Prognostic Value of a Qualitative MRI Scoring System for Neurologic Outcome of Comatose Survivors After Cardiac Arrest. Sofie Jansen, Dept of Neurology and Neurological Sciences, Stanford Stroke Ctr, Stanford Univ Med Ctr, Stanford, CA; Nancy J Fischbein, Michael V Krasnokutsky, Dept of Radiology, Stanford Univ Med Ctr, Stanford, CA; Michael Mlynash, Irina Eyngorn, Christine A Wijman; Dept of Neurology and Neurological Sciences, Stanford Stroke Ctr, Stanford Univ Med Ctr, Stanford, CA Background Identification of comatose survivors after cardiac arrest with an unfavorable neurologic outcome remains challenging, especially in those who do not meet conventional prognostic criteria for poor outcome. Methods In this AHA funded study, 68 (85%) of 80 prospectively enrolled comatose survivors of cardiac arrest underwent brain MRI at a median of 90 hours (range 2–718 hours) after the arrest. Five brain regions (cortical grey and white matter, deep grey nuclei, hippocampus, brainstem and cerebellum) were assigned 1– 4 points based on the severity of signal abnormalities on FLAIR and diffusion-weighted MRI (DWI) by 2 independent and blinded raters. Outcome was assessed at 3 months as favorable (Glasgow Outcome Scale (GOS) 3–5) and unfavorable (GOS 1–2). Gold standard non-survivors met any of the following conventional prognostic criteria: absent pupillary reflexes at ⬎⫽ 24 hours, myoclonus status epilepticus, absent SSEPs or motor response absent or extensor at 72 hours in the absence of sedating medications. Sensitivity and specificity of the MRI scoring system were estimated using ROC analysis. Results Eighty-seven MRIs of 67 patients with a mean age of 56⫾15 years and mean arrest duration of 22⫾12 minutes were included. Thirty-four MRIs were in patients with a favorable neurological outcome and 53 in patients with an unfavorable neurological outcome. Of these, 28 scans were in patients with gold standard unfavorable outcome. The mean summation score of the 2 raters of the cortical grey and white matter on both DWI and FLAIR sequences best predicted unfavorable neurologic outcome with an overall specificity of 100% (95% CI 90 –100%) and a sensitivity of 86% (95% CI 67–96%). Inter-rater agreement of this ‘cortex score’ was excellent (ICC⫽ 0.905). The optimal time window to predict unfavorable outcome appeared to be ⬎ 24 hours, as 3 patients with unfavorable neurological outcome who underwent MRI ⬍ 24 hours had minimal cortical abnormalities. Sensitivity of the ‘cortex score’ in ‘gold standard’ patients ⬎ 24 hours was 92% (95% CI 75–99%). Applying the cortex score cutoff to ‘non-gold standard’ non-survivors identified an additional 8 patients (32%) with unfavorable outcome resulting in an overall sensitivity of 60% (95% CI 47–74%). Conclusion A qualitative MR scoring system involving the cortical grey and white matter appears to accurately identify comatose post-cardiac arrest patients with an unfavorable neurological outcome after 24 hours and may be particularly useful in patients who do not meet conventional prognostic criteria for poor outcome. 152 CT Angiography Source Images Predict Functional Outcome In Basilar Artery Occlusion: The Posterior Circulation Acute Stroke Prognosis Early CT Score. Volker Puetz, Univ of Calgary, Calgary, Canada; P.N. Sylaja, Ananthapuri Hosps and Rsch Institute, Trivandrum, India; Michael D. Hill, Shelagh B. Coutts, Univ of Calgary, Calgary, Canada; Imanuel Dzialowski, Pia Mueller, Ulf Becker, Technical Univ Dresden, Dresden, Germany; Philip A. Barber, Mayank Goyal, Pranshu Sharma, Univ of Calgary, Calgary, Canada; Georg Gahn, Ruediger von Kummer, Technical Univ Dresden, Dresden, Germany; Andrew M. Demchuk; Univ of Calgary, Calgary, Canada Introduction: Quantification of early ischemic changes (EIC) on non-contrast CT (NCCT) or CT angiography (CTA) source images (CTA-SI) may predict functional outcome and treatment response in patients with posterior circulation stroke. We tested the validity and reliability of a novel CT score, the posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS). Methods: Pc-ASPECTS allots the posterior circulation 10 points. One point each is subtracted for EIC in left or right: thalamus, cerebellum or PCA territory, respectively and two points each for EIC in any part of the midbrain or pons. We retrospectively studied 2 different patient populations: 1) patients with clinically suspected vertebrobasilar ischemia; 2) patients with basilar artery occlusion (BAO). In both groups, patients had CTA done within 24 hours from symptom onset. We independently applied pc-ASPECTS to baseline NCCT, CTA-SI and follow-up image by 3-reader consensus. For BAO, we defined TIMI 2 or 3 flow on acutely performed angiogram as recanalization. Assuming follow-up image as the gold standard we calculated sensitivity for early ischemic changes. We analyzed the prognostic value of the pc-ASPECTS score for independent (modified Rankin Scale [mRS] score 0 –2), favourable (mRS 0 –3) and fatal outcome. Results: Of 130 patients with clinically suspected vertebrobasilar ischemia, final diagnosis was posterior circulation stroke in 72% (94), TIA in 8% (10) and nonischemic in 20% (26). Sensitivity for any ischemic change was improved with CTA-SI compared to NCCT (65% [CI95 57%–73%] vs. 46% [CI95 37%–55%], respectively). Inter-rater reliability for pc-ASPECTS on CTA-SI was moderate (ICC 0.72; lower CI95 0.54). The CTA-SI pc-ASPECTS score but not the NCCT pc-ASPECTS score predicted independent functional outcome in this population (ORs 1.58; p⫽0.005 vs. 1.22; p⫽0.42 per point pc-ASPECTS score increase, respectively). Of 46 patients with BAO, 52% (12/23) with a CTA-SI pc-ASPECTS score ⬎8 but only 4% (1/23) with a score ⬍8 had a favourable functional outcome (risk ratio [RR] 12.1; CI95 1.7– 84.9). Similarly, patients with a CTA-SI pc-ASPECTS score ⬍8 were more likely to die (RR 2.5; CI95 1.2–5.3). Of 23 patients with basilar artery recanalization, 75% (9/12) with a CTA-SI pc-ASPECTS score ⬎8 but only 9% (1/11) with a score ⬍8 had a favourable functional outcome (RR 8.3; CI95 1.2–55.0). Conclusion: Compared with NCCT, CTA-SI provide added information for patients with supected vertebrobasilar ischemia. In basilar artery Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 566 Stroke Vol 39, No 2 February 2008 occlusion, extensive hypocontrastation indicated by a CTA-SI pc-ASPECTS score ⬍8 identifies patients unlikely to have a favourable functional outcome despite early recanalization. 153 Cervicocepharic Arterial Dissections in Japan: Analysis of 454 patients in the Spontaneous Cervicocephalic Arterial Dissections Study I (SCADS-I). Kazuo Minematsu, Hideki Matsuoka, Junji Kasuya, National Cardiovascular Cntr, Suita, Osaka, Japan; SCADS-I collaborators Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: Recent studies have suggested that clinical features of spontaneous cervicocepharic arterial dissections (SCADs) in Japan are different from those in Western countries. The aim of the present study is to confirm this suggestion. Methods: This is a retrospective multicenter registration study with 82 hospitals all over Japan. We collected and analyzed the clinical data of patients with SCADs who were admitted to registration hospitals between April 2003 and March 2006. The diagnosis of SCADs was made principally based on findings of angiographic studies. Results: A total of 454 patients (320 men) with SCADs were enrolled. Age ranged from 13 to 88 (54 in median) years old, including 179 patients (39%) of ⱕ50 years. Cerebral arterial lesions were examined with conventional angiography in 383 patients (84%), magnetic resonance angiography in 288 (63%), or computed tomographic angiography in 95 (21%). The dissections were identified in intracranial arteries for 419 patients (92%), and in the vertebrobasilar arteries (VA) for 374 patients (82%). Only 11 patients (2.4%) had the extracranial internal carotid artery (ICA) dissections. The most common site of SCADs was the intracranial VAs (288 patients, 63%), followed by the anterior cerebral artery (8%), posterior inferior cerebellar artery (6%), basilar artery (5%), and others. Stroke occurred in 389 patients (86%); 234 ischemic, 126 hemorrhagic, and 29 both. Headache developed at the day of or several days before the stroke onset in 291 (75%). Patient’s family had a history of SCADs in 9 patients (2%), of cerebral aneurysms in 18 (4%), and of aortic dissections in 4 (1%). As vascular risk factors, hypertension was present in 226 patients (50%), hypercholesterolemia in 73 (16%), impaired glucose tolerance in 45 (10%), and smoking habit in 157 (35%). These factors were more common in patients developing ischemic stroke than in those with hemorrhagic one. Patients with ischemic stroke were treated with antiplatelets agents in 166 patients (71%) or with anticoaglants in 122 (52%) at least for several weeks after stroke onset. As compared to patients with hemorrhagic stroke, ischemic stroke patients had symptom progression or early stroke recurrence within the first 7 days less frequently (19% vs. 9%, p⬍0.0001), and obtained more often favorable outcome at discharge (modified Rankin scale 0 –1, 67% vs. 51%, p⬍0.005). Conclusion: We confirmed that SCADs occurred mainly in intracranial arteries, especially at VA in Japanese patients; being contrast to their predominant occurrence in extracranial ICA in Western countries. Ischemic stroke with SCADs was more common and associated with better outcome as compared to hemorrhagic one. 154 Emergent Echocardiography Is Associated With A High Rate Of Detection Of Mobile Aortic Arch Thrombi In Acute Ischemic Stroke. Estevo Santamarina, M Teresa Gonzalez-Alujas, Andrea Pacchioni, Marc Ribo, Marta Rubiera, Olga Maisterra, Raquel Delgado-Mederos, Pilar Delgado, Jose Alvarez Sabin, Carlos A Molina; Hosp Vall Hebron, Barcelona, Spain AIM: Fast-track emergent echocardiography within the first few hours of stroke onset may increase the accuracy in the detection of fresh thrombi into the cardiac cavities or the aortic arch. We conducted a case-control study aimed to evaluate the yield of second harmonic transthoracic echocardiography (SHTTE) within the first hours of acute ischemic stroke. METHODS: We study consecutive non-lacunar ischemic stroke patients evaluated between November 2006 and April 2007. It included patients with a known cardioembolic source (atrial fribrillation, ischemic cardiopathy, valve prothesis and dilated miocardiopathy) and patients with an undetermined origin. Emergent SHTTE was performed during the first hours (⬍24h) of admission (early SHTTE group) These data were compared with age- and sex- matched historical controls (delayed SHTTE group) who underwent SHTTE as part of the standard diagnostic work-up (⬎24h) RESULTS: A total of 350 patients underwent SHTTE. One-hundred and sixty-five patients were evaluated in the early SHTTE and 185 patients in the delayed SHTTE group. Mean time from stroke onset to SHTTE evaluation was 14⫾9 hours and 1076⫾168 hours in the early and delayed SHTTE, respectively. Among patients with stroke of undetermined origin, detection of a cardioembolic source of emboli was significantly higher in patients who underwent early (n⫽52;48%) compared to those who received delayed (n⫽16;23%) SHTTE (p⫽0.001). Main findings included severe aortic atheromatosis 24(22.2%) vs. 3(3.5%), akynesia/hypokynesia 15(14%) vs. 9(11%), PFO 8(7.4%) vs. 8(9.5%), valvulpathy 6(5.6%) vs. 2(2.4%) and dilated miocardiopathy 3(2.8%) vs. 1(1.2%). The greater diagnostic accuracy of early compared to delayed SHTTE was mainly due to a higher detection of aortic arch atheroma with mobile thrombus. Early (⬍24h) SHTTE evaluation increased in 7-fold the likelihood of detection of a mobile thrombus in the aortic arch as compared with delayed (⬎24h) SHTTE exam (22.2% vs. 3.2%; p⫽0.001). CONCLUSION: The yield of SHTTE is markedly increased when performed during the first hours of acute stroke. Early SHTTE provides a higher detection of a cardioembolic source of emboli, mainly mobile thrombi engrafted in an aortic atheroma. These findings have an important impact on therapeutic decisions. 155 The Balance Between The Expression Of Cd36 And Abca1 Favors Lipid Accumulation In Ulcerated Carotid Plaques. Pia M Isoviita, Krista Nuotio, Riitta Turunen, Jani Saksi, Petra Ijäs, Biomedicum Helsinki, Helsinki, Finland; Petri Kovanen, Wihuri Rsch Institute, Helsinki, Finland; Markku Kaste, Perttu J Lindsberg; Dept of Neurology, Helsinki, Finland BACKGROUND The development of a lipid core is a key event in the progression of an atherosclerotic plaque to a vulnerable one that causes thromboembolic strokes. CD36 is an important scavenger receptor that accumulates lipids within macrophages, whereas ABCA1 protein counteracts this effect by removing lipids from cells. Based on DNA microarray, we previously found that the genes encoding CD36 and ABCA1 were overexpressed in symptomatic carotid plaques (CPs) compared to asymptomatic CPs. Here we evaluated their role in CP destabilization by studying the localization of lipid within CPs, the expression of CD36 mRNA, as well as CD36 and ABCA1 protein expressions in ulcerated and non-ulcerated CPs and their colocalization with intraplaque red blood cell (RBC) extravasation. METHODS 92 high-grade (⬎70%) CPs obtained from carotid endarterectomy were stained with the Oil-red-O method to visualize lipids. A subgroup of asymptomatic and stroke-causing CPs (n⫽44) were used in further analyses. The relative expression of CD36 mRNA was measured by quantitative real-time RT-PCR. Adjacent sections of CP specimens were immunostained against CD36 and ABCA1, and analysed microscopically in detail and correlated topographically with the presence of extravasated RBCs. RESULTS There were more extracellular lipid deposits in the ulcerated CPs as compared to non-ulcerated CPs (P⫽0.038). The amount of CD36 mRNA associated with CD36 protein expression (rs⫽0.551, P⫽0.001). In ulcerated CPs, the expression of both CD36 mRNA (P⫽0.010) and protein (P⬍0.001) were increased as compared to non-ulcerated CPs. Moreover, there was more expression of CD36 than ABCA1 protein (P⬍0.001) in ulcerated CPs, while the opposite was true in non-ulcerated CPs. CD36 and ABCA1 proteins co-localized with each other (P⬍0.001), and with the presence of extravasated RBCs (P⫽0.007 and P⬍0.01 respectively). CONCLUSIONS Our results suggest that the balance between lipid influx (CD36) and efflux (ABCA1) favor lipid accumulation in macrophages in ulcerated CPs, contributing to the growth of lipid core and consequent plaque destabilization. Furthermore, co-localization of CD36 and ABCA1 proteins with RBCs suggests that intraplaque hemorrhages may contribute to the lipid load of CPs, and may induce the expression of lipid scavenger receptors. 156 C-reactive Protein Exerts Potent Angiogenic Effects On Vascular Endothelial Cells. Jerzy Krupinski, Marta M Turu, Hosp Universitari de Bellvitge,, Barcelona, Spain; Sabine Matou, Manchester Metropolitan Univ, Manchester, United Kingdom; Cristina Rodriguez, Jose Martinez-Gonzalez, Lina Badimon, CSIC-ICCC, Barcelona, Spain; Ana Luque, Hosp Universitari de Bellvitge,, Barcelona, Spain; Mark Slevin; Manchester Metropolitan Univ, Manchester, United Kingdom Introduction: Formation of neovessels in the developing atherosclerotic plaques is thought to contribute significantly to intra-plaque haemorrhage and instability resulting in thrombosis. C-reactive protein (CRP) is an acute phase reactant whose expression is increased in both the tissue and circulation of patients with inflammatory disease, in particular, in reactive plaque regions. Although CRP is known to induce a pro-inflammatory phenotype on endothelial cells (EC) for instance, by inducing expression of adhesion molecules, a direct role on modulation of angiogenesis has not been identified. Hypothesis: Our hypothesis was that CRP exerts a potent pro-angiogeneic effects on vascular endothelial cells. Methods: Angiogenic effects i.e. proliferation, migration and tube formation of purified endotoxin-free CRP was studied in vascular EC (Bovine aortic EC {BAEC} and human coronary artery EC {HCAEC}). Furthermore, using a specifically targeted TaqMan gene microarrays we studied CRP-induction of pro-angiogenic genes. Results: Addition of CRP induced a significant increase in proliferation, migration and tube-like structure formation in vitro and stimulated blood vessel formation in the chick chorioallantoic membrane assay. We identified CRP-induction of several key pro-angiogenic genes: vascular EC growth factor (VEGF) receptor (KDR), NOTCH (1, 3), platelet-derived growth factor (PDGF[[Unsupported Character - ]] and cysteine-rich angiogenic inducer 61 (CYR61). Western blotting showed increased expression of phosphorylated early response kinase (ERK) 1/2, a key protein involved in EC mitogenesis, in CRP treated cells. Conclusions: This data suggests an important role for CRP in direct stimulation of angiogenesis and therefore may be an important mediator of neovessel formation in the intima of vulnerable plaques. 157 Early Blood Brain Barrier Disruption Is Associated With Plasma Matrix Metalloproteinase-9 Concentration In Acute Stroke Patients. Taura L Barr, National Institutes of Neurological Disorders and Stroke, National Institute of Nursing Rsch, National Institutes of Health, Bethesda, MD; Lawrence L Latour, Kyung-Yul Lee, Timothy J Schaewe, Marie Luby, George Chang, Ziad El-Zammar, Shaista Alam, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Chelsea S Kidwell, Georgetown Univ, Washington, DC; Steven Warach, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; for the NIH Natural History of Stroke Investigators Background: Matrix metalloproteinases (MMP’s) may play a critical role in blood brain barrier (BBB) disruption and ischemia/reperfusion injury following ischemic stroke. Hyperintense Acute Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Oral Presentations Reperfusion injuRy Marker (HARM) is a novel magnetic resonance imaging (MRI) marker of BBB disruption characterized by gadolinium enhancement of cerebrospinal fluid on fluid attenuated inversion recovery (FLAIR) images. HARM has been associated with reperfusion, hemorrhagic transformation, and poor clinical outcome in acute stroke patients. We hypothesized that plasma concentration of MMP-9 would be associated with HARM. Methods: This is a prospective study of acute stroke referrals enrolled in a natural history research protocol between May 2006 and June 2007. Patients underwent gadolinium-enhanced MRI on presentation and approximately 24 hours later. The presence of severe HARM on post-contrast FLAIR images was assessed by blinded expert readers. Lesion volume was measured on acute diffusion weighted imaging (DWI). Blood samples were obtained during the initial evaluation. MMP-9 concentration was measured by ELISA. A logistic regression model tested for predictors of severe HARM on acute and follow-up scans using MMP-9 concentration and covariates with known or suspected associations with HARM. Results: Sixty-eight patients were enrolled. Diagnoses were acute ischemic cerebrovascular syndrome (n⫽52), intracerebral hemorrhage (n⫽7) and stroke mimic (n⫽9). Thirteen patients were treated with tPA. Mean (SD) time from symptom onset to acute imaging was 9.6 h (10.9); to acute blood draw (MMP-9 sampling) 16.2 h (27.6); to follow-up imaging 33.0 h (11.4) in 43 patients. Severe HARM was present on post-contrast scans in 13% of the patients acutely and in 41% on the follow-up scan. Severe HARM on acute scan was associated with MMP-9 concentration (p⫽0.023) and time to acute MMP-9 sampling (p⫽0.006). Severe HARM on follow-up scan was associated with MMP-9 concentration (p⫽0.030), time to acute MMP-9 sampling (p⫽0.038), age (p⫽0.007), and tPA treatment (p⫽0.017). In both models, higher MMP-9 concentrations were associated with the presence of severe HARM. Conclusions: Plasma MMP-9 concentration was found to be an independent predictor of HARM on acute and follow-up scans, supporting the hypothesis that HARM reflects early blood brain barrier disruption. If the association between plasma MMP-9 concentration and HARM is confirmed in future studies, HARM may be useful as an imaging marker to evaluate MMP-9 inhibition in ischemic stroke and other pathologies associated with blood brain barrier disruption. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 158 Regional Differences In CO2 Vasoreactivity After Stroke Using CASL MRI. Peng Zhao, David Alsop, Magdy Selim, Beth Israel Deaconess Med Cntr, Harvard Med Sch, Boston, MA; Amir Abduljalil, The Ohio State Univ, Columbus, OH; Peter Novak, Univ of Massachusetts, Boston, MA; Lewis Lipsitz, Kun Hu, Sarah LaRose, Vera Novak; Beth Israel Deaconess Med Cntr, Harvard Med Sch, Boston, MA Redistribution of perfusion to ischemic areas with increased metabolic demands is essential for neuronal recovery after ischemic stroke. We aimed to investigate the regional differences in CO2 vasoreactivity (CO2VR) and their relationships to chronic infarct volume, persistent infarct hyperintensities (PIHs) and clinical outcomes. We studied 27 subjects with chronic large vessel infarcts in the middle cerebral artery (MCA) territory (age 65.4⫾8.9 yrs) and 43 controls (68.4⫾5.8 yrs), matched for age, sex and history of hypertension. MRI with FLAIR, MP-RAGE, and continuous arterial spin labeling (CASL) perfusion images were acquired with a GE 3-Tesla scanner. We measured cerebral blood flow in regions surrounding the infarct and adjacent vascular territories using CASL during baseline, hypocapnic and hypercapnic conditions, and assessed its relationship to the infarct volume and NIHSS of neurologic impairment. Image segmentation and registration were used to quantify CO2VR in major anatomical lobes and vascular territories. Data were analyzed using repeated measures MANOVA adjusted for age, gender and brain volume. The CO2VR was lower in the stroke group than control across several anatomical regions (p⬍0.0001) (Fig 1) and vascular territories (p⬍0.0001) bilaterally. The CO2VR was significantly lower in insular cortex than other regions (Fig 1). There were regional differences in CO2VR between stroke and non-stroke sides (p⫽0.0004). In MCA territory, perfusion during hypercapnia was reduced on the stroke side compared to the non-stroke side (p⫽0.03) and to the control group (p⫽0.01). In the stroke group, the CO2VR in the MCA was negatively associated with PIHs volume (p⬍0.0001), infarct volume (p⬍0.0001) and the systolic BP increase from hyperventilation to CO2 breathing (p⬍0.0002). The same relationship was found for CO2VR in the entire anatomical lobe and peri-infarct regions. Lower CO2VR was associated with higher NIHSS (p⬍0.003). Impairment of CO2VR after stroke extends into 567 various brain regions and vascular territories distant from the infarct site. Neurological status, assessed by NIHSS, correlates with CO2VR. Regional differences in CO2VR may play an important role in recovery from ischemic stroke. These results may be of therapeutic significance to improve the outcome of stroke patients. 159 Granulocyte-Macrophage Colony-Stimulating Factor Treatment after Common Carotid Artery Occlusion Enhances Leptomeningeal Collateral Growth and Reduces Infarct Size after Focal Cerebral Ischemia. Kenichi Todo, Kazuo Kitagawa, Tsutomu Sasaki, Emi Omura-Matsuoka, Yasukazu Terasaki, Naoki Oyama, Yoshiki Yagita, Masatsugu Hori; Osaka Univ, Osaka, Japan Background and purpose: We have reported that chronic reduction of cerebral perfusion induced by unilateral common carotid artery (CCA) occlusion resulted in attenuation in infarct size after ipsilateral permanent middle cerebral artery (MCA) occlusion. These results suggested that chronic unilateral CCA occlusion in mice may induce collateral growth at distal leptomengeal anastomosis. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to accelerate the collateral growth (arteriogenesis) at the circle of Willis in rat. However, the effect of GM-CSF on leptomeningeal collateral growth has not been established. In this study, we examined the effect of GM-CSF treatment after CCA occlusion on leptomeningeal collateral growth and infarct size after permanent MCA occlusion. Methods: Adult mice were assigned to unilateral CCA occlusion or sham operation and followed by alternate-day regimen with GM-CSF (20 g/kg) or saline injection. After the CCA operation, latex perfusion was performed to visualize the leptomeningeal vessels. In another set of mice, after the CCA operation, permanent ipsilateral MCA occlusion was performed and the infarct volume was measured. Results: The diameter of leptomeningeal collateral vessels 14 days after CCA occlusion was larger than that without CCA occlusion (31.0 ⫾ 9.4 m, n⫽4, 64 vessels vs. 25.6 ⫾ 4.5 m, n⫽4, 64 vessels, P⬍0.01) whereas the diameter 7 days after CCA occlusion (25.9 ⫾ 7.7 m, n⫽4, 65 vessels) did not enlarge. However, with GM-CSF treatment, 7 days after CCA occlusion, the diameter was larger than that without GM-CSF treatment (32.0 ⫾ 8.8 m, n⫽8, 127 vessels vs. 25.9 ⫾ 8.1 m, n⫽8, 126 vessels, p⬍0.01). The infarct volume due to MCA occlusion 14 days after CCA occlusion was smaller than that without CCA occlusion (25.5 ⫾ 7.8 mm3, n⫽6, vs. 50.5 ⫾ 12.8 mm3, n⫽6, P⬍0.01) whereas, 7 days after CCA occlusion, that did not diminish (46.7 ⫾ 13.1 mm3, n⫽6). However, with GM-CSF treatment, 7 days after CCA occlusion, the infarct volume due to MCA occlusion was reduced (35.4 ⫾ 12.2 mm3, n⫽9 vs. 48.0 ⫾ 14.8 mm3, n⫽9, P⬍0.05). Conclusion: We could reveal for the first time that, after CCA occlusion in mice, GM-CSF treatment enhanced the leptomeningeal colalteral growth and reduced the infarct volume after MCA occlusion. 160 Interference with Peroxisome Proliferator-activated Receptor Gamma Signaling Causes Cerebral Vascular Hypertrophy and Remodeling. Gary L Baumbach, Carmen M Halabi, Andreas M Beyer, Curt D Sigmund, Frank M Faraci; Univ of Iowa, Iowa City, IA The transcription factor peroxisome proliferator activated receptor-␥ (PPAR␥) exerts antiinflammatory and anti-oxidant effects and is expressed in endothelium and vascular muscle. Its role in regulating vascular growth, however, remains undefined. To test the hypothesis that PPAR␥ plays a protective role in the cerebral vasculature, we studied cerebral arterioles in two groups of genetically altered mice: 1) heterozygous knockin mice expressing the P465L dominant negative mutation in PPAR␥ (L/⫹)(equivalent to the human P467L mutation), and 2) transgenic mice expressing the human P467L PPAR␥ mutation under the control of the smooth muscle myosin heavy chain promoter to restrict expression to smooth muscle (SM-P467L). Unanesthetized systemic arterial pressure was measured using a carotid indwelling catheter in L/⫹ (n⫽15) and non-transgenic wild-type littermates (⫹/⫹, n⫽19) and radiotelemetry in SM-P467L (n⫽7) and ⫹/⫹ (n⫽6). Whereas systolic pressure was slightly elevated in both groups of mice with altered PPAR␥ signaling (L/⫹: 147⫾3 vs. 140⫾2 mmHg in ⫹/⫹, p⬍0.05; SM-P467L: 128⫾2 vs. 121⫾2 mmHg in ⫹/⫹, p⬍0.05), diastolic pressure was not significantly (p⬎0.05) altered in either L/⫹ (125⫾2 vs. 122⫾2 mmHg in ⫹/⫹) or SM-P467L (92⫾3 vs. 89⫾2 mmHg in ⫹/⫹). External diameter (ED) of maximally dilated cerebral arterioles was reduced and cross-sectional area of the arteriolar wall (CSA, measured histologically) was increased in both L/⫹ (ED ⫽ 54⫾2 vs. 64⫾2 m in ⫹/⫹, p⬍0.05; CSA ⫽ 473⫾21 vs. 378⫾18 m2 in ⫹/⫹, p⬍0.05) and SM-P467L (ED ⫽ 52⫾3 vs. 61⫾3 m in ⫹/⫹, p⬍0.05; CSA ⫽ 549⫾27 vs. 365⫾22 m2 in ⫹/⫹, p⬍0.05) mice. Thus, interference with PPAR␥ signaling, whether induced systemically or restricted in a cell-specific manner to vascular muscle, produced cerebral arteriolar remodeling and hypertrophy. These findings indicate that PPAR␥ normally has profound effects in the cerebral circulation and provide the first direct evidence that PPAR␥ plays a critical role in regulating vascular structure in any vascular bed. Furthermore, cerebral vascular remodeling and hypertrophy induced by altered signaling of PPAR␥ may impact regulation of cerebral blood flow and/or predispose to greater levels of brain injury during ischemia. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 568 Stroke Vol 39, No 2 February 2008 161 Genome Wide Association Study of Intracranial Aneurysms in the Finnish Population. arrays enabled the detection of very small CNVs that account for disease states as well as genome-wide association studies. Observed CNVs unique to patient group and loci that show association with the disease can contribute to our understanding of IA pathogenesis. Kaya Bilguvar, Yasar Bayri, Michael DiLuna, Fatih Bayrakli, Christopher E Mason, Mohamad Bydon, Yale Univ Sch of Medicine, New Haven, CT; Mika Niemela, Aki Laakso, Juha Hernesniemi, Helsinki Univ Sch of Medicine, Helsinki, Finland; Juha E Jaaskelainen, Univ of Kuipio, Kuipio, Finland; Aarno Palotie, Helsinki Univ Sch of Medicine, Helsinki, Finland; Jaakko Rinne, Univ of Kuopio, Kuopio, Finland; Matthew W State, Murat Gunel; Yale Univ Sch of Medicine, New Haven, CT 162 Cortical Stimulation for Upper-Extremity Hemiparesis from Ischemic Stroke: Everest Study Primary Endpoint Results Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: Previously published parametric and nonparametric linkage studies have established multiple genetic loci that may contribute to the formation of intracranial aneurysms (IAs). While there have been several reports of loci associated with IAs, including 1p34.3–36.13, 2p13, 7q22.1, 11q25, 14q22, and 19q13.3, no causative gene has been found to date. High throughput genotyping arrays have made large scale association studies feasible for common diseases such as rheumatoid arthritis, coronary artery disease (Nature, June 2007). We sought to employ a genome-wide association study for intracranial aneurysms using the Finnish population. Finland was established by a relatively small number of settlers followed by small waves of immigration, creating a genetic bottleneck effect. This gives the advantage of decreased population stratification, which is a common cause of false positive results in large association studies. Additionally, Finland has a high rate of subarachnoid hemorrhage (incidence of 19.7/100,000 person - years compared to a global average of 9/100,000 person - years). A genome-wide association study of IAs in the Finnish population has the potential to contribute significantly to our understanding of IAs and their pathogenesis. Methods: We have performed classical parametric linkage analysis as well as genome-wide association study. Illumina Human CNV 370-Duo chips will be used to genotype 500 familial index cases, 500 sporadic cases and 1,000 controls from Finland. These chips utilize 318,000 tagged single-nucleotide polymorphisms (SNPs) and 52,167 copy number variation (CNV) markers. Genotyping data derived from these arrays will be used for whole-genome association studies as well as copy number variation analysis. Results: Our and other groups‘ previous parametric and non-parametric linkage analysis demonstrated linkage to multiple loci, showing strong evidence for genetic heterogeneity for IAs. Thus far, we have genotyped 250 index cases and 200 controls out of the Finnish cohort. Our preliminary results indicate the presence of many chromosomal regions showing CNVs. Some of these CNVs overlap with previously reported CNVs. Other novel regions that tend to cluster in the patient group need to be further analyzed in comparison with the control group. Preliminary association study results also show evidence of association of novel loci with IAs. The completion of genotyping of patient and control groups will provide statistically significant p values. Conclusions: The advent of very high density genotyping Robert M. Levy, Northwestern Univ, Chicago, IL; Randall R. Benson, Wayne State Univ, Detroit, MI; Carolee J. Winstein, Univ of Southern Calif, Los Angeles, CA; Everest Study Investigators Objectives: To determine if subthreshold epidural motor cortex stimulation (CS) is 1) safe and 2) improves hand/arm motor function of hemiparetic chronic stroke patients. Methods: Subjects at least 4 months post ischemic stroke with an Upper Extremity Fugl-Meyer (UEFM) score between 28 and 50 points were enrolled into a 21 center prospective, randomized, single-blind, longitudinal study assessing cortical stimulation (using an investigational device) for enhancing hand/arm motor function. Subjects were randomized into an investigational group or control group. Subjects in both groups were given equal amounts of focused rehabilitation therapy during a 6-week treatment phase. Investigational subjects were implanted with an epidural electrode over the hand/arm area of motor strip of the ipsilesional hemisphere (targeted by fMRI) and were given subthreshold electrical stimulation concurrently with rehabilitation therapy. Primary outcome measures compared the UEFM, which provides an index of subjects’ neurological and motor function, and the Arm Motor Ability Test (AMAT), a measure of activities of daily living, obtained at 4-weeks post rehabilitation to values obtained during baseline. Clinically meaningful improvement was defined as a change of at least 4.5 points in UEFM and 0.21 points in AMAT. CS therapy would be classed as effective if the percentage of investigational subjects achieving clinically meaningful improvements in the combined endpoint of the UEFM and AMAT is 20 percentage points greater than the combined data for control subjects. Findings: A total of 104 investigational subjects and 60 control subjects were randomized. There have been no serious device related complications. The 4-week primary endpoint data collection has been completed. Due to the requirement that investigators remain blinded to the results throughout the 24-week study secondary endpoint, unblinded analysis of the primary endpoint data cannot be performed until January, 2008. The primary endpoint data will be analyzed and presented. Conclusions: The primary endpoint results of this prospective, randomized, single-blinded 164-subject study on the safety and efficacy of subthreshold epidural motor cortex stimulation in hemiparetic stroke patients will be presented and discussed. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations 569 International Stroke Conference Poster Presentations Diagnosis P1 MRI-Based Diagnostic Evaluation has Substantial Impact on Final Stroke Diagnosis. Monisha A Kumar, Dennis M Campbell, Stanford Univ, Palo Alto, CA; Hema L Vangala, Regional Med Cntr, San Jose, CA; Irina Eyngorn, Jean Marc Olivot, Anne Sophie Beraud, Amit Belgude, Maarten G Lansberg, Ingela Schnittger, Christine A Wijman, Stanford Univ, Palo Alto, CA; David C Tong, California Pacific Med Cntr, San Francisco, CA; Michael Mlynash, Michael Moseley, Gregory W Albers; Stanford Univ, Palo Alto, CA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose - Identification of stroke etiology currently relies on clinical evaluation supported by a multitude of diagnostic tests. However, the diagnostic yield of these tests is unclear. We sought to determine how often an MRI-based diagnostic algorithm altered the final diagnosis in a large consecutive series of unselected patients presenting with signs and symptoms of stroke. Methods - In this prospective NIH funded study, 273 consecutive patients admitted to the Stanford Stroke Service underwent CT, MRI, intracranial and cervical MRA and echocardiography, in this pre-specified order. All patients over the age of 18 years, within 48 hours of symptom onset, and able to comply with MRI and echocardiography were included in the study. TOAST classification was determined by a stroke neurologist both after review of the initial history/physical and CT, and on hospital discharge, after review of all diagnostic studies. Results - Correspondence between the initial and final TOAST classification is shown in the Table below. Only 53.1% of the patients had the same TOAST classification on discharge as they did after the initial (CT-based) diagnostic evaluation. Of the remaining 128 patients, MRI findings led to a change in the diagnosis in 36.7% of the patients, MRA led to a change in diagnosis in 18.8%, and echocardiography led to a change in diagnosis in 16.4% of the patients. The overall prevalence of large artery atherosclerosis was correctly estimated; however, the initial diagnosis was accurate only 46% of the time. The initial diagnosis was correct in only 17/46 patients (37.0%) discharged with a final diagnosis of cardioembolism; many were initially diagnosed as having large artery atherosclerosis or small vessel disease. Though the initial diagnosis of small vessel disease had high sensitivity (92.3%), the positive predictive value was poor (58.4%). Conclusions - The positive predictive value of the initial CT-based stroke assessment is poor, even among fellowship-trained vascular neurologists. An MRI-based diagnostic evaluation led to a change in final diagnosis in about half of the patients in this consecutive series. COMPARISON OF TOAST STROKE CLASSIFICATION BEFORE AND AFTER MRI-BASED DIAGNOSTIC ALGORITHM. FINAL INITIAL DIAGNOSIS (N) Large Artery Atherosclerosis (65) Cardioembolic (29) Small Vessel Disease (101) Other Determined (8) Stroke, Undetermined (41) Not Stroke (11) Uncertain (18) Total ⫽ 273 Patients as embolic (artery-to artery or cardiac), small vessel, or undetermined. Cervical MRA was considered positive if there was a ⬎50% stenosis (NASCET criteria) ipsilateral to a symptomatic hemisphere. The ‘diagnostic utility’ of TEE was determined based on whether the TEE findings led to a change in the final diagnosis. Results - MRI, MRA and TEE were obtained in 154 patients. A DWI pattern suggestive of acute artery-to-artery or cardiac embolism occurred in (55.8%). MRI evidence of a small vessel (lacunar) lesion was present in 29.9% and in 14.3% the MRI was negative or non-specific. Among patients with an MRI pattern suggestive of artery-to-artery or cardiac embolism, the diagnostic yield of TEE was 15.1% vs. 6.5% for the small vessel group and 4.5% for the undetermined group (p⫽0.04). Among patients with the combination of an embolic pattern on MRI and a negative cervical MRA, the diagnostic yield of TEE was 17.8% in the embolic group, 6.8% in the small vessel disease group and 4.5% in the undetermined group (Figure). Conclusions - The diagnostic utility of TEE varies substantially based on MRI/MRA patterns. Diagnostic utility is highest in patients with an embolic MRI pattern and a negative cervical MRA. An MRI-based diagnostic approach allows the clinician to selectively obtain TEE examinations in patients who are most likely to benefit. DIAGNOSIS Positive Large Predictive Artery Small Other Stroke, Not Value Atherosclerosis Cardioembolic Vessel Determined Undetermined Stroke Uncertain (%) 31 11 2 1 18 1 2 47.7 3 17 1 0 5 3 0 58.6 9 8 60 0 18 2 5 58.4 0 0 1 5 0 1 1 62.5 6 8 0 2 18 3 3 43.9 1 3 51 0 1 46 0 1 65 0 0 9 5 1 64 5 3 18 0 9 20 45.5 50.0 P2 MRI/MRA Patterns Predict the Diagnostic Utility of Transesophageal Echocardiography in Patients with Acute Stroke. Monisha A Kumar, Stanford Univ, Palo Alto, CA; Hema L Vangala, Regional Med Cntr, San Jose, CA; Dennis M Campbell, Irina Eyngorn, Amit Belgude, Jean Marc Olivot, Anne Sophie Beraud, Maarten G Lansberg, Ingela Schnittger, Christine A Wijman, Stanford Univ, Palo Alto, CA; David C Tong, California Pacific Med Cntr, San Francisco, CA; Michael Mlynash, Michael Moseley, Gregory W Albers; Stanford Univ, Palo Alto, CA Background and Purpose - Transesophageal Echocardiography (TEE) is a valuable tool for the evaluation of ischemic stroke patients, but its diagnostic yield is much debated. We sought to determine whether magnetic resonance imaging (MRI) can be used to predict which subgroups of patients presenting with signs or symptoms of acute ischemic stroke are most likely to have clinically relevant findings on TEE. Methods - In this prospective NIH-sponsored study, consecutive patients admitted to the Stanford Stroke Service underwent CT, MRI, cervical MRA and TEE, in this pre-specified order. After acquisition of the MRI, DWI patterns were classified P3 Multimodal CT in Acute Ischemic Stroke: Predictive Value for Early Infarct Extension. Kristian Barlinn, Imanuel Dzialowski, Jasmin Renger, Andrei Khomenko, Dept. Neurology, Univ of Dresden, Dresden, Germany; Olaf Wunderlich, Dept. Neuroradiology, Univ of Dresden, Dresden, Germany; Georg Gahn, Dept. Neurology, Univ of Dresden, Dresden, Germany; Rüdiger von Kummer; Dept. Neuroradiology, Univ of Dresden, Dresden, Germany Background: In acute ischemic stroke, specificity of non-contrast CT (NCCT) for ischemic damage at baseline is high, but sensitivity is not optimal. We sought to determine whether multimodal CT might improve prediction of early infarct extension. Methods: We prospectively studied anterior circulation ischemic stroke patients presenting within 12 hrs of symptom onset and with a National Institute of Health Stroke Scale (NIHSS) score ⬎ 2. We examined all patients with cranial NCCT, CT angiography and CT perfusion imaging and generated parameter maps of TTP, CBV and CBF. Patients could be treated with IV, IA, or combined IV/IA thrombolysis according to current guidelines. We applied the Alberta Stroke Program Early CT Score (ASPECTS) to all NCCT, CTA-source images (CTA-SI) scans and CTP parameter maps. We scored hypoattenuation (NCCT), diminished contrast enhancement (CTA-SI) and qualitative reduction in CBF and CBV and prolonged TTP as abnormal. We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), using 24 hr NCCT or MRI diffusion- weighted images as reference. We determined predictive values for any (ASPECTS ⬍ 10) and for extensive (ASPECTS ⱕ 7) ischemic lesions for all and for thrombolysed and non-thrombolysed patients separately. Results: We studied 33 patients (mean age 70.2 ⫾ 13.0 yrs, 46 % male, 17/33 (52%) thrombolysed, time-to-presentation 171 ⫾ 137 min, median NIHSS score 7, NCCT-ASPECTS 9 (range 2–10)). In this unselected population, predictive values for any and extensive ischemic lesions did not differ among the different CT-modalities. In thrombolysed patients, sensitivity of NCCT and CTA-SI for any ischemic lesion was significantly higher compared to non-thrombolysed patients (predictive values are presented in table 1 and 2), but we did not find differences in prediction of extensive ischemic lesions. Among non-thrombolysed patients, sensitivity for CBV trended to be the best predictor for both any and extensive lesion (57% and 100%). Among thrombolysed patients, predictive values did not differ. Conclusions: In our study, multimodal CT does not seem to significantly improve prediction of early infarct extension using ASPECTS. Sensitivity of NCCT and CTA-SI seems to be excellent in thrombolysed but poor in non-thrombolysed patients. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 570 Stroke Vol 39, No 2 February 2008 TABLE 1. THROMBOLYSIS (Nⴝ17; ASPECTS<10) NCCT Sensitivity Specificity PPV NPV CTA-SI TTP CBF CBV 82(0.59–0.93) 88(0.64–0.97) 76(0.53–0.90) 76(0.53–0.90) 71(0.45–0.88) / / / / / 100(0.78–1.0) 100(0.78–1.0) 100(0.77–1.0) 100(0.77–1.0) 100(0.72–1.0) 0(0–0.56) 0(0–0.66) 0(0–0.49) 0(0–0.49) 0(0–0.49) TABLE 2. NON-THROMBOLYSIS (Nⴝ16; ASPECTS<10) NCCT Sensitivity Specificity PPV NPV CTA-SI TTP CBF CBV 21(0.08–0.48) 29(0.13–0.55) 54(0.29–0.77) 57(0.33–0.79) 57(0.45–0.88) 100(0.34–1.0) 100(0.34–1.0) 100(0.34–1.0) 100(0.34–1.0) 100(0.34–1.0) 100(0.44–1.0) 100(0.51–1.0) 100(0.65–1.0) 100(0.68–1.0) 100(0.68–1.0) 15(0.04–0.42) 17(0.05–0.45) 25(0.07–0.59) 25(0.07–0.59) 25(0.07–0.59) rated as mild-moderate in 51.6% (49/95), severe in 8.4% (8/95), and as none in 40% (38/95) of patients on immediate post-contrast FLAIR. There was a trend between time from onset to detection and HARM, median of 4.84 hrs for mild-moderate and 8.64 hrs for severe, (p⫽0.084). Delayed enhancement on first follow-up FLAIR, rated as mild in 44.3% (42/95) and severe in 41.1% (39/95) of patients, was significantly associated with HARM on acute exam, (p⫽0.036). Acute imaging was performed prior to t-PA in 22 patients and HARM was rated as mild-moderate in 45.5% (10/22), severe in 4.5% (1/22), and as none in 50% (11/22). Median time between stroke onset to detection of any HARM was 1.38 hrs in t-PA treated patients. On follow-up, HARM was rated as mild-moderate in 31.8% (7/22), severe in 59.1% (13/22), and as none in 9.1% (2/22). Treatment with t-PA was associated with HARM on follow-up MRI (p⫽0.035) but not HARM on the pre-treatment scan (p⫽0.60). . Conclusions: It is possible to detect HARM on immediate post-contrast FLAIR imaging performed during the acute exam and prior to treatment with t-PA. The ability to detect BBB disruption prior to thrombolytic therapy and the high prevalence of HARM following treatment may aid in the development of new therapies to protect the barrier and minimize further injury. Values are presented as % (95% CI). P4 Neuroanatomic Representation of NIHSS Sub-items Employing Acute Diffusion Imaging: Developing a Predictive Atlas of Clinical Outcome. Chelsea S Kidwell, Georgetown Univ, Washington, DC; Kyle W Singleton, Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Timothy J Schaewe, UCLA, Los Angeles, CA; Marie Luby, Steven Warach, Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Jeffry Alger, UCLA, Los Angeles, CA; for the NIH Natural History of Stroke Investigators Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: To date, predictive models employing acute imaging data have been focused on prediction of final infarct volume. However, the clinical utility of predictive models would be greatly enhanced if these models were able to predict not only infarct volume and anatomical location, but also acute and long-term clinical outcome. This information could then be used to guide treatment decisions. Methods: As part of a global project aimed at creating a large scale stroke-specific predictive brain atlas, we correlated acute DWI lesion location with the presence of individual sub-item scores from the NIHSS. Inclusion criteria were: acute ischemic stroke; brain MRI (including DWI) performed within 24 hours of symptom onset; and baseline NIHSS score available. Acute DWI images from all subjects were aligned to a common neuroanatomic coordinate system. Chi square images were calculated on a voxel-by-voxel basis. Results: A total of 163 patients met inclusion criteria. Mean age was 70, range 21–97. Baseline NIHSS was median 4, mean 6, range 0 –27. The figure shows representative axial slices from the atlas. The images show color-coded chi square values, using a false discovery rate of 5%, for anatomic regions in which there was a significant correlation between symptom presence and DWI hyperintensity. Item 5b (motor arm) is shown on the top row, illustrating that the voxels significant for this subitem correspond anatomically to the corticospinal tract. The bottom row shows slices from item 9 (language), now with the significant regions corresponding to primary language areas. Conclusions: This is the first voxel-based stroke atlas correlating NIHSS sub-items employing DWI data. The maps illustrate the neuroanatomic representation of the NIHSS in standardized space. The ultimate goal is to build an atlas that uses acute diffusion and perfusion MR imaging to predict long-term outcome for two scenarios: untreated vs. treated with recanalization therapy. This information may then be used to influence treatment decisions. P5 Blood Brain Barrier Disruption in Acute Stroke Prior to Therapy is Evident on Immediate Post-Contrast FLAIR MRI. Lawrence L Latour, NINDS, Bethesda, MD; Chelsea S Kidwell, Georgetown Univ, Washington, DC; Kyung-Yul Lee, NINDS, Bethesda, MD; Timothy J Schaewe, UCLA, Los Angeles, CA; Jose G Merino, Steven Warach, NINDS, Bethesda, MD; for the NIH Natural History of Stroke Investigators Introduction: Hyperintense Acute Reperfusion injuRy Marker (HARM) is a novel magnetic resonance imaging (MRI) marker of early blood brain barrier (BBB) disruption. HARM has previously been reported as appearing on follow-up imaging but not on the acute scan immediately after administration of contrast agent. We hypothesized that it is possible to detect HARM on the acute scan within 5 min of first contrast injection. . Methods: 95 patients with ischemic stroke (17 month period) presenting within 24 hrs of symptom onset, having pre- and post-contrast FLAIR on acute MRI, and FLAIR on first follow-up occurring within 48 hrs, were included. Two expert readers evaluated FLAIR images for evidence of HARM, blinded to identifiers, order of exam, and pre vs post contrast imaging. HARM was graded as none, mild-moderate, and severe. Chi-square statistics were used to test associations between HARM on acute and follow-up imaging. . Results: HARM was P6 Early Clinical Improvement From Complete Recanalization Predicted By Extent And Degree Of CTA Source Image Abnormality. Nikolai Steffenhagen, Volker Puetz, Michael Hill, Univ of Calgary, Calgary, Canada; Imanuel Dzialowski, Univ of Dresden, Dresden, Germany; Christine O’Reilly, Mayank Goyal, Andrew Demchuk; Univ of Calgary, Calgary, Canada Background: Mismatch on perfusion CT or MRI is thought to identify patients with benefit from thrombolysis. CT angiography (CTA) source images (CTASI) may indicate irreversibly infarcted tissue and the presence of an intracranial occlusion on CTA may indicate perfusion status. Hypothesis: We sought to determine if CTA can identify patients with middle cerebral artery (MCA) occlusion who will respond to early recanalization. Methods: We retrospectively studied patients with CTA for acute ischemic stroke. We only selected patients with MCA mainstem (M1) occlusion on CTA who had complete recanalization (defined as TIMI 3 flow) on digital subtraction angiography within 8 hours from onset. We independently applied an expanded Acute Stroke Prognosis Early CT Score (e-ASPECTS) to areas with hypoattenuation on CTA-SI in a 3-readers consensus setting. e-ASPECTS separately rates grey and white matter for 5 cortical ASPECTS regions (M1, M3, M4, M5, M6) thus adding 5 points to conventional ASPECTS. One point each is given for normal, 0.5 points for decreased and 0 points for absent contrastation. An e-ASPECTS value⫽15 indicates a normal scan, e-ASPECTS⫽0 indicates complete MCA stroke. For analysis, we categorized patients into 3 CTA-SI e-ASPECTS groups where 15 is best and 0 is worst: ⬎⫽12; ⬎⫽9 to ⬍12; ⬍9. Primary outcome was early clinical improvement defined as 10-point improvement in NIHSS score or NIHSS score ⱕ2 at 24 hours. Secondary outcomes were median 24-hours NIHSS improvement and percentage independent functional outcome (modified Rankin Scale [mRS] score ⱕ2) at 3 months. Results: From a CTA database with 985 patients, 129 (13%) had M1 occlusion. 25 of these had complete early recanalization on DSA. Results for categorized CTA-SI e-ASPECTS groups are given in the table. With higher CTA-SI e-ASPECTS values, patients were more likely to have early clinical improvement with early recanalization. Also, median improvement in 24-hours NIHSS score was higher in patients with high compared to patients with low CTA-SI e-ASPECTS scores (p⫽0.23). Patients with a CTA-SI e-ASPECTS score ⬍9 were unlikely to have early clinical improvement with MCA recanalization. This trend translated into higher percentage functional independence at 3 months (p⫽0.35). Given small numbers in the this highly selected population, none of these findings reached statistical significance. Conclusion: Simple CTA with CTA-SI indicating irreversibly infarcted tissue and MCA occlusion indicating perfusion impairment may identify patients likely to respond to recanalizing therapy. e-ASPECTS on CTA-SI (n) ⬎⫽12 (9) 9–11 (10) ⬍9 (6) Baseline NIHSS (median, [iqr]) 15 15 20 NIHSS improvement ⬎⫽10 points or NIHSS ⱕ2 at 24hrs (14to18) (11to20) (18to22) 56% 50% 0% 24hrs NIHSS improvement (median, [iqr]) 8.0 6.5 -1.0 3 month mRS of 0 2 (1 to10) (-1to11) (-3to 4) 56% 50% 17% Outcome by CTA-SI e-ASPECTS category. P7 Cardiac Multidetector Computed Tomography Accurately Detects Embolic Sources In Acute Ischemic Stroke Patients. Sang-Bae Ko, Yong Chai Ko, Jung-Hyun Park, Hee-Joon Bae; SNU Bundang Hosp, Seong-nam, Republic of Korea Background: Screening the embolic sources is an important process in acute stroke patient evaluation. Transesophageal echocardiography (TEE), which is superior to transthoracic Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations echocardiography (TTE), is very sensitive in detecting intracardiac thrombi (ICT) and atheromatous plaque (AP) in the ascending aorta (AsA) and aortic arch (AA). However, due to blind spot at the distal part of AsA, only limited evaluation is possible using TEE. With good image resolution and no blind spot, cardiac multidetector computed tomography (MDCT) can be used as an alternative tool to TEE in detecting ICT and AP in the AsA and AA. Methods: One hundred and seventy four consecutive patients with acute ischemic stroke and transient ischemic attack (TIA) were included in this study. Because lacunar infarction is unlikely to be related with ICT, forty patients were excluded, and a total of 134 patients underwent TTE, TEE, and cardiac MDCT scans. We compared the diagnostic yield of TEE in detecting ICT and AP with that of cardiac MDCT. Results: Demographic data of study population as follows, (Male, 55.2% with mean age, 66.1 ⫹/- 12.9). 1) ICT detection. TEE showed possible cardiac embolic sources in 23 patients (23/134, 16.5%), and which were mitral stenosis, mitral valve prolapse, patent foramen ovale, dilated cardiomyopathy, congestive heart failure, and spontaneous echo contrast. ICT was seen in only one patient using TEE. Cardiac MDCT showed embolic sources in 27 patients, and ICT was seen in 5 patients, and average size of ICT was 5.2 mm X 3.2 mm. One patient only showed ICT with TEE, not with MDCT. Excluding 63 patients with a stroke mechanism of large artery disease (LAD), TEE and cardiac MDCT detected ICT with a probability of 1.4% (1/71) and 7.0% (5/71), respectively. 2) AP detection. Complex AP, composed of thickness of ⱖ4 mm, ulceration, pedunculation, or mobile elements, was seen on TEE in 3 patients. Cardiac MDCT showed high risk AP (low Hounsefield index with ulceration) in 10 patients. Excluding patients with cardioembolism and LAD, TEE and MDCT showed another possible embolic source at AsA and AA with a probability of 6.3% (3/48) and 22.7% (10/44). Conclusion: Cardiac MDCT identified more patients with ICT and AP than TEE. Combined with TEE, Cardiac MDCT can provide more accurate information regarding embolic sources in acute ischemic stroke patient. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P8 The Neurocardiovascular CT Protocol: A Comprehensive Analysis of Stroke Etiology and Ischemic Penumbra Using 64-slice Multi-Detector CT in Patients with Acute Ischemic Stroke. Raul G Nogueira, Ricardo Cury, Stuart Pomerantz, Joshua A Hirsch, Ferdinando S Buonanno, Lee H Schwamm, Suhny Abbara, Ramon G Gonzalez, Michael H Lev; Massachusetts General Hosp, Boston, MA 571 scores showed similar patterns, but with less significance. Discussion: Use of VLSM produced anatomically specific results demonstrating a subcortical area leading into the CST appears to be critical for motor performance after a stroke. This area may represent an important integration site for the main motor fibers from surrounding cortex. It might also represent the joining of parallel redundant tracts that when damaged, would inhibit plasticity that would otherwise occur. Acknowledgements: This study was funded by the investigational study sponsor, Northstar Neuroscience, Inc. Figure: The critical anatomic region determined by VLSM analysis (blue) was used as a seed for DTI tractography (red/yellow). The crosshairs are centered over M1. Background and Significance: The underlying cardiac-cervico-cranial vascular lesion determines the optimal treatment and the clinical outcomes in acute stroke patients. The use of transthoracic echocardiography is limited by its poor evaluation of the left atrium (LA), in particular the LA appendage (LAA). The use of transesophageal echocardiography is limited by its degree of invasiveness, required expertise, costs, and time-consumption. We have developed a new CT protocol that provides detailed anatomic information about the heart and aortic arch as well as the cervical and cranial vessels in addition to tissue perfusion data while using limited amounts of contrast material and time. Methods: Fifteen acute stroke patients were examined by 64-slice MDCT. Scan protocol included: (1) Non-contrast Head; (2) First Perfusion slab; (3) CTA Head and Neck; (4) Cardiac Group; (5) Cardiac Delay; (6) Second Perfusion slab; (7) Post Processing MIPS and CTP data. Results: The image quality of the cervico-cranial CTA (Figs. 1 & 2) and CT perfusion (Fig. 3) was similar to our previous protocol. In all cases, there was adequate evaluation of the aortic arch and the heart (Fig. 4). No cases of poor opacification of the LAA were seen, presumably due to the addition of the delayed cardiac phase. This is of essential importance since in previous studies the specificity of MDCT for the detection of LAA thrombus was limited by its inability to distinguish blood stasis or low-velocity blood flow (e.g. TEE spontaneous echo contrast) from thrombus. The total imaging acquisition time was less than 3 minutes. The total amount of injected contrast was 150 mL. Conclusion: Advanced imaging employing 64-slice MDCT scanning allows for optimal anatomic imaging of the heart, aortic arch, and cervico-cranial vasculature while providing functional data about tissue perfusion. This protocol may diminish the overall costs and time spent on the investigation of stroke etiology. In comparison to our standard acute stroke protocol, this is accomplished by using only an extra 15 mL of iodine contrast and minimal additional scanning time. P9 Identification Of Critical Areas For Motor Function Recovery In Chronic Stroke Subjects Using Voxel-based Lesion-symptom Mapping. Ryan Lo, Darren Gitelman, Robert Levy, Northwestern Univ, Chicago, IL; Justin Hulvershorn, Northstar Neuroscience, Seattle, WA; Todd Parrish; Northwestern Univ, Chicago, IL Introduction: Previous stroke studies using fMRI or lesion-based methods to predict residual motor function have been limited in defining critical anatomic structures. This study uses a new method of analysis, voxel-based lesion symptom mapping (VLSM) to overcome the limitations of previous studies. Methods: Forty-two stroke subjects with moderate to moderately severe motor impairment (AMFM ⬎28, AMAT ⬎ 1.25) participating in an investigational study were imaged using a 3T Siemens TIM Trio magnet. High resolution 1 mm isotropic 3D T1 weighted volumetric images were collected. All subjects’ motor performance was assessed by three different behavioral measures (AMFM, AMAT, Box & Block). All T1 volume images were normalized using SPM5 to a symmetric template using SPM5 and oriented so that lesions appeared in the left hemisphere. The lesioned areas were identified using both the T1 image and the non-diffusion T2 weighted scans obtained during DTI acquisition. The 3D lesion maps were entered into the VLSM analysis. Areas showing significant correlations with performance measures (AMFM, AMAT and Box & Block) were identified using the false discovery rate corrected at p ⱕ 0.05. Results: The area most correlated with decreased AMAT scores was the junction of the corona radiata leading into the corticospinal tract (CST). AMFM and Box & Block P10 A 30-Day Cardiac Event Monitor Belt for Recording Paroxysmal Atrial Fibrillation After a Cerebral Ischemic Event: The EMBRACE Pilot Study. Melanie Spring, Dept of Medicine, Univ of Toronto, Toronto, Canada; Paul Dorian, Div of Cardiology, St. Michael’s Hosp, Univ of Toronto, Toronto, Canada; Beth Fry, Brian Buck, Demetrios J Sahlas, Julia Hopyan, Regional Stroke Cntr, Sunnybrook Health Sciences Cntr, Univ of Toronto, Toronto, Canada; Victoria Korley, Div of Cardiology, St. Michael’s Hosp, Univ of Toronto, Toronto, Canada; Sandra E Black, David J Gladstone; Regional Stroke Cntr, Sunnybrook Health Sciences Cntr, Univ of Toronto, Toronto, Canada Background - Atrial fibrillation (AF) is a major preventable cause of stroke. Improved methods for detecting AF are needed, as it is frequently paroxysmal and asymptomatic, and routine Holter monitoring (24 –72 hours) detects AF in only 5% of patients after stroke/TIA. Few studies have investigated extended duration ambulatory monitoring after stroke/TIA. This study evaluates the yield of 30-day monitoring. We hypothesize that some cases of “cryptogenic” stroke result from cardioembolism due to (undiagnosed) paroxysmal AF. Methods - This prospective observational study employs a soft, lightweight elastic belt (Accuheart Electrode Belt, Advanced Bioelectric Inc.), a new technology using high resistance non-adhesive electrodes without the need for pregelled adhesive skin contact electrodes. The belt is attached to a programmable, event-triggered device (Braemar Inc., ER910AF) that records episodes of Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 572 Stroke Vol 39, No 2 February 2008 asymptomatic AF by automated detection of R-R variability after 30 beats. It can detect up to 6 events of 5 min. each (memory storage capacity 30 min.). Patients are recruited from an outpatient stroke clinic in Toronto. Inclusion criteria are a recent (⬍6 months) ischemic stroke or TIA of undetermined etiology (TOAST criteria) diagnosed by a stroke neurologist after complete etiological work-up (12-lead ECG, 24 or 48 hour Holter, echocardiography, brain MRI, vascular imaging with MR or CT angiography, bloodwork). Exclusions are any previous documentation of AF by history, ECG, telemetry, or Holter. The monitor is worn for 30 days or until 6 events are recorded. Data are transmitted transtelephonically for central reading by the study cardiologist. Main outcomes are the proportion of patients for whom the study monitor records one or more episodes of: (1) AF ⬎30 seconds; (2) non-sustained (⬎ 3 beats) irregular atrial tachyarrhythmia ⬍30 seconds (including brief runs of AF); or (3) atrial flutter; and the proportion who are anticoagulated based on the monitor results. Results - The study monitor identified new AF in 3/15 (20%) of patients with cryptogenic stroke/TIA enrolled to date. Patient 1 (age 79) had a 3-minute episode of AF; patient 2 (age 65) had a 30-beat run of AF; patient 3 (age 89) had 14 brief episodes of irregular tachycardia. None had left atrial enlargement. All were anticoagulated based on the results. Study recruitment is ongoing. Conclusions - These preliminary results suggest that a simple intervention of extended duration ambulatory cardiac monitoring is feasible, improves the detection of occult AF, and results in more patients being anticoagulated for secondary stroke prevention. If confirmed in a larger sample, these findings may have implications for clinical practice. P11 Telemedicine Evaluation For Acute Stroke Treatment Is Faster And Achieves Better Protocol Adherence Than Phone Consultation. Syed F Zaidi, Ridwan Lin, Lori Massaro, Vivek Reddy, Maxim Hammer, Lawrence R Wechsler, Ken Uchino; Univ of Pittsburgh Med Ctr, Pittsburgh, PA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Two-way video telemedicine and telephone consultations between community hospitals and stroke centers are increasingly used to provide more optimal acute stroke care. We sought to compare their efficiency, diagnostic accuracy, and intravenous tissue plasminogen activator (IV tPA) protocol adherence. Methods: We performed a retrospective chart review of consecutive patients receiving IV tPA through telemedicine (TM) consultations at three community hospitals between March 2006 and June 2007. Comparisons were made to consecutive patients who received IV tPA at community hospitals following telephone (TP) consultations and randomly selected patients at the university stroke center (SC) who received IV tPA from January 2002 to October 2005. From chart review, we extracted the door-to-CT and door-to-tPA treatment times, IV-tPA protocol violations, and the final discharge diagnoses. Comparisons were made with Mann-Whitney U test for numerical and Fisher’s exact test for categorical variables. Results: Thirty-three patients evaluated using telemedicine consultation were compared to 128 patients with telephone consultation and 50 patients evaluated at the stroke center. The door-to-TPA time was shorter in the TM group when compared to the TP group (median 70 vs 89 minutes, p⬍0.001). The door-to-CT time was also shorter in the TM group compared to the TP group (median 16 vs 25 minutes, p⬍0.001). The rate of IV-tPA protocol deviations was significantly lower in the TM and SC groups compared to the TP group (6.1%, 6.0% and 37.5%, p⬍0.001 for comparison to TP group). We also noted a trend toward fewer rates of eventual stroke misdiagnoses in the TM group when compared to the TP group, (3% vs 6%, p⫽0.68). When compared with the SC group, the TM group also had a significantly shorter time to the CT scan (median 16 vs 23 mins, p⫽0.016), but the overall door to tPA time was not significantly different (70 vs 77 mins, p⫽0.25). Conclusion: Diagnosing acute stroke for IV-TPA therapy is faster, more accurate, and has fewer protocol violations compared to phone consultations.Telemedicine treatment might be as efficient as on-site treatment at stroke center. P12 Transesophageal Echocardiography Findings Change Secondary Prevention Strategies in Stroke Patients. Guido Falcone, Josefina H Prebble, Dario Colombero, Juan P Guerchi, Candelaria Leiguarda, Sebastian F Ameriso; FLENI, Buenos Aires, Argentina Transesophageal echocardiography (TEE) was recently introduced in clinical practice for the evaluation of the heart and aortic arch. This diagnostic modality is routinely recommended for young stroke patients and for those with suspected embolic infarcts. Aortic arch atheromas and patent foramen ovale (PFO) with or without atrial septum aneurysm (ASA), among other conditions are often associated with cerebrovascular disease and are best demonstrated by TEE. However, data are limited regarding the role of routine use of TEE in non selected stroke patients. In clinical practice, antiplatelet agents are frequently replaced by anticoagulation in subjects with mural left auricular/ventricular thrombi, complex aortic arch plaques, or PFO with atrial septum aneurysm in subjects without vascular risk factors. We assessed the hypothesis that TEE findings can modify therapeutic strategies in a substantial number of patients and should be routinely employed in patients with stroke. We prospectively performed TEE in every patient admitted with diagnosis of recent ischemic stroke or TIA. We excluded patients with contraindications for anticoagulation, those who should receive anticoagulation despite TEE findings (i.e., atrial fibrillation, valve disease, prothrombotic conditions), and those who did not tolerate the procedure. The incidence of complex aortic arch atheromas was high but the incidence of PFO with and without associated ASA was lower than previously reported. Five percent of the patients had PFO without vascular risk factors. TEE detected a condition that supported a change of initial secondary prevention measures in 65 subjects (21.5%). In conclusion, TEE contributes to the implementation of secondary prevention strategies in a substantial number of non selected stroke patients. These findings support a recommendation for routine use of this modality in the diagnostic work-up of subjects with ischemic cerebrovascular disease. PATIENT DATA AND TEE FINDINGS n 303 Females/males (%) Age (mean ⫾SEM,years) Comorbid conditions (%) 28/72 62.8⫾0.8 Hypertension Hypercholesterolemia Smoking Diabetes Coronary artery disease Prior stroke/TIA Neoplasia Migraine 64 47 38 14 16 PFO PFO⫹ASA Complex aortic arch plaques Mural left cavity thrombus 10 4 16 Patients without vascular risk factors (%) TEE Findings (%) 22 6 4 17 3 P13 The Influence Of Ischemic Stroke Subtype On Infarct Expansion, Penumbral Fate And Reperfusion. Jane F Prosser, Louise Allport, Ken Butcher, Mark Parsons, Patricia Desmond, Brian Tress, Stephen M Davis; Royal Melbourne Hosp, Melbourne, Australia Background: Tissue outcome in acute ischemic stroke is imperfectly predicted by the extent of PWI-DWI mismatch. Other physiologic characteristics may also influence the eventual extent of infarction by altering tissue susceptibility to ischemia. Cardioembolic ischemic strokes are more likely to be fatal and are associated with greater degrees of initial neurologic impairment. Embolus size/site of vessel occlusion, relative cerebral hypoperfusion related to cardiac failure, haematologic or endothelial abnormalities and increased susceptibility to reperfusion injury have been suggested to explain this. The potential of stroke etiology to influence infarct evolution has not been rigorously studied. Aims: We hypothesised that acute stroke associated with a cardioembolic source would be associated with greater infarct expansion, increased percentage mismatch lost (PML) and greater percentage reperfusion compared to strokes of other types. Methods: Ninety eight patients with acute ischemic stroke and a non-lacunar clinical syndrome were included. MRI was performed within 24 hours of symptom onset, on day 3–5 and day 90 from stroke onset. Fifty five patients had a region of DWI-Tmax⫹2 mismatch that was greater than 20% of the initial DWI volume. We examined the effects of stroke subtype (SSS-TOAST classification determined independently by two raters blinded to quantitative imaging data), presence of atrial fibrillation or other potential cardioembolic source, presence of ipsilateral large artery stenosis⬎50%, acute blood glucose, acute hematocrit, age, history of diabetes mellitus and use of tPA on infarct growth, penumbral outcome (percentage mismatch lost) and reperfusion. Results: SSS-TOAST classifications were as follows: cardioembolism 57, large artery atherosclerosis 14, undetermined 25 (including 6 large artery and cardioembolism combined, and 8 undetermined unclassified) and other determined causes 2. Independent predictors of subacute infarct expansion included acute blood glucose(P⫽0.009), ipsilateral large artery stenosis ⬎50%(P⫽0.013), and mismatch volume(P⫽0.028). The only independent predictor of percentage mismatch lost was increasing blood glucose (P⫽0.002). Cardioembolic stroke was positively associated with reperfusion (P⫽0.013), while increasing blood glucose was negatively associated with reperfusion (P⫽0.041). Conclusions: Ipsilateral large artery stenosis is independently associated with increased subacute infarct expansion, but stroke subtype does not influence penumbral fate. Cardioembolism is associated with greater reperfusion; this adds weight to suspicions that cardioembolic stroke could be associated with reperfusion injury. Acute blood glucose remains strongly associated with adverse MRI outcomes. P14 In-vivo Optical Imaging of Cerebral Blood Perfusion During Focal Ischemia in Mice. Sawan Hurst, Wenjie Huang, Wenri Zhang, Nabil J Alkayed, Andras Gruber, Ruikang K Wang; Oregon Health & Science Univ, Portland, OR Introduction: We have developed a new optical micro-angiography (OMAG) imaging technique that is capable of resolving 3D distribution of dynamic blood perfusion at a capillary level resolution within microcirculatory beds in vivo. The imaging contrast of blood perfusion is based on endogenous light scattering from moving blood cells within vessels, thus no exogenous contrast agents are necessary. The purpose of this study is to validate this method and assess its potential application in the studies of cerebrovascular perfusion during and after induced stroke in mouse models in vivo. Methods: We used an OMAG imaging system operated at 1300 nm wavelength that delivered a 3D spatial resolution of 10 microns for this study. Temporal Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations resolutions for 2D and 3D imaging were 0.1s and 50s, respectively. Cortical blood perfusion under normal and induced stroke conditions was monitored using OMAG through the intact cranium of mice. Results from OMAG imaging under baseline conditions were correlated with cerebral blood flow rates measured in the same regions using [14C]iodoantipyribe (IAP) autoradiography. Ischemic stroke was induced by middle cerebral artery occlusion (MCAO) using the intraluminal filament technique, and OMAG imaging was used to obtain 3D dynamic perfusion images before, during and after MCAO for up to 24 hours. Results: OMAG imaging provided real-time volumetric measurements of blood perfusion in 2 mm depth down to the capillary level through the intact skull without the need for dye injection, contrast agents, or surgical craniotomy. Detailed 3D superficial vascular architecture images obtained by OMAG had an excellent agreement with that from direct photographing of blood vessels on the surface of the cerebral cortex. Quantitative assessment of blood flow rates using OMAG imaging was within 20% of CBF rates measured in the same region postmortem using IAP autoradiography. Repeated OMAG imaging captured progressive cessation of cortical perfusion during MCAO in the ipsilateral hemisphere and revealed significant progressive changes in the perfusion pattern of the contralateral hemisphere. Following filament withdrawal, blood perfusion resumed in some but not all blood vessels even after 24r hrs. Conclusions: OMAG provides a novel dynamic image of cortical perfusion in real time and allows for repeated, non-invasive assessment of blood flow rates in all patent vessels without the need for injecting dyes or contrast agents. P15 Withdrawn 573 P16 Therapeutic Impact of Cardiac MRI in Patients with Ischemic Stroke. Richard A Bernstein, James Conners, John J Sheehan, George Lin, Karin Dill, Reed A Omary, Mark J Alberts, James C Carr; Northwestern Univ, Chicago, IL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: Cardiac MRI (cMRI) identifies clinically relevant cardiac findings in stroke patients that may not be visible by transesophageal (TEE) or transthoracic (TTE) echocardiogram. Prior work from our group has described the diagnostic impact of cMRI (1). In a cohort of stroke patients who underwent echocardiography, cardiac MRI identified intracardiac thrombi in 10% of patients. In 75% of these patients, echocardiograms were either normal or ambiguous. We now describe the effect on therapy of the detection of intracardiac thrombus by cMRI in patients with ischemic stroke. Methods We reviewed the records of patients with ischemic stroke who underwent cMRI between October 2005 and October 2006. cMRI was ordered by a vascular neurologist (RAB or MJA) during in-patient evaluation; all patients had TTE, TEE, or both, prior to cMRI. Echocardiograms and cMRI were read with clinical information available. We identified changes in presumed stroke mechanism (using TOAST criteria) and anti-thrombotic therapy by review of the medical records. Results Our cohort of 93 patients has been described previously (1); 52% were male, and the mean age was 65 years (range 18 –92). TTE was performed in 89%, TEE in 41%, and both studies were performed in 32%. cMRI identified intracardiac thrombus in 9/93 patients (9.7%); all 9 patients had echocardiography performed prior to cMRI. In 5 out of these 9 patients the echocardiograms showed no thrombus; 3 out of these 5 had TTE and TEE performed prior to cMRI. Secondary preventive therapy changed from antiplatelet agents to anticoagulants (warfarin or heparin) in 4 out of 9 (44%) patients; the other 5 out of 9 were already prescribed anticoagulants for a presumed, but unproven, cardioembolic source. Presumed stroke mechanism changed in 3/9 patients (33%), in all cases from “unknown” to “cardioembolic”. Conclusion Cardiac MRI identified intracardiac thrombi in a significant percentage of patients with cryptogenic strokes. This led to a change in secondary preventive therapy for almost half of these patients. CMRI should be considered as part of the evaluation for patients with cryptogenic stroke. (1) Evaluation of patients with suspected cardioembolic stroke using Cardiovascular MRI - A comparative study with echocardiography. JJ Sheehan, AR Hitchell, RA Bernstein, K Dill, RA Omary, JC Carr. SIR, Seattle, Journal of Vascular and Interventional Radiology February 2007 (Suppl.) P17 Diagnosis Of Vertebral Artery Dissection At CTA With A Normal Luminal Diameter-Are we Missing Cases? Cheemun Lum, Ravi Mohan, The Ottawa Hosp, Ottawa, Canada; Sridhar Panugpath, NIMHANS, Bangalore, India; Marlise Santos, Mukul Sharma, Michael Schlossmacher, Santanu Chakraborty; The Ottawa Hosp, Ottawa, Canada Introduction: CTA for suspected dissections has complemented or even replaced catheter angiography and may be the only imaging study performed. We present a series of acute vertebral artery dissection (VAD) where there is normal vertebral artery (VA) luminal diameter and characteristic thickening of the wall of the vertebral artery (VA) along its suboccipital course(V3). We coin this the “suboccipital rind-sign” (SORS). Subsequent MRI’s demonstrated the intramural hematoma or the imaging findings resolved at CTA follow-up. Knowledge of the SORS may aid in detection of VAD in cases where the lumen is normal or minimally reduced in caliber. Materials & Methods: We reviewed our prospectively collected database of patients demonstrating the SORS. The clinical presentation and imaging findings were identified. We subdivided the V3 portion of the VA into 5 segments. The luminal diameter at each segment was compared to the overall corresponding vessel diameter. A comparison between the arteries demonstrating the SORS and 50 normal patients was performed. Results: Between November 2005 and July 2006 (9 mos.), there were 6 patients with the SORS identified. Two of 6 had bilateral rind signs accounting for a total of 8 abnormal arteries. Of these 8 arteries, in only 1, was there significant narrowing of the artery noted prospectively. 4/8 arteries had normal appearing lumens, 3/8 had subtle areas of narrowing that were only noted in retrospect after identifiying the rind sign. There was no evidence of luminal tapering in both dissected and normal vessels. The average wall thickness of the dissection group was 2.96 mm greater for the control group. This difference was significant by a separate variances t test, t(19.6) ⫽ 6.44, p ⬍ .001. A 95% confidence interval for the difference between means was 2.6 mm to 3.32 mm. Conclusion: We describe a previously undescribed characteristic imaging sign of VAD in the V3 portion where the imaging plane is parallel to the course of the VA. Our study revealed absence of vessel tapering in the abnormal vessels emphasizing the importance of recognition of wall thickening, the SORS. We caution using only lumen-opacifying techniques to exclude VAD as they are limited in evaluating for mural hematoma. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 574 Stroke Vol 39, No 2 February 2008 P18 Flow Heterogeneity MRI Reveals Compensatory Changes in the Microcirculation during Acute Ischemic Stroke. David S Liebeskind, Jeffry R Alger, Brian H Buck, Tim Schaewe, Oh Y Bang, Sidney Starkman, Doojin Kim, Latisha K Ali, Bruce Ovbiagele, Noriko Salamon, J P Villablanca, Jeffrey L Saver; UCLA, Los Angeles, CA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Perfusion MRI may demonstrate changes in the flow distributions of the microcirculation as derangements of the normal flow heterogeneity (FH) within a voxel of the ischemic brain. Such FH abnormalities have been used to predict final infarct evolution. We used FH MRI to explore the specific microcirculatory derangements associated with collateral perfusion in acute MCA ischemia. Methods: FH MRI measures were derived in 75 consecutive cases of acute ischemic stroke with complete occlusion of the MCA on conventional angiography. Separate maps were generated reflecting the width or standard deviation (FHD), skewness (FHS), and kurtosis (FHK) of flow distributions in the microcirculation. In addition standard perfusion MR images were obtained of CBF, CBV, MTT and CPP. Region of interest analyses were performed to compare values of FHD, FHS, and FHK in the ischemic territory with homologous regions of the contralateral hemisphere. Collateral circulation evident on catheter angiography was graded with the ASITN/SIR scale. Results: Pretreatment FH MRI revealed microcirculatory flow abnormalities in all 75 cases. FHD or the width of the flow distribution was increased in all cases (p⬍0.001). FHS images revealed redistribution of flow within slower routes of the microcirculation (p⬍0.001). FHK images demonstrated the predominance of particular flow routes in all cases (p⬍0.001). Topographic features of the FH abnormalities correlated with the degree of collateral flow noted at angiography. Conclusions: Multiparametric FH MRI reveals consistent changes in the microcirculation associated with collateral perfusion in acute ischemic stroke due to MCA occlusion. Flow redistribution may involve recruitment of specific preferential routes with slower flow to enhance oxygen extraction. FH images can be rapidly generated and provide unique insights into tissue state that may help guide management. characteristics can guide EMS system planners in implementing stroke inventories for prehospital use. STROKE IDENTIFICATION PERFORMANCE PPV NPV Sensitivity Specificity Accuracy LAPSS CPSS ELAPSS 100 98.4 86.4 100 98.6 37.7 98.7 90.9 82.5 83.4 62.5 98.9 90.9 93.7 93.4 P20 Comparison of Computed Tomography Angiography to Trans-Esophageal Echocardiography for Evaluation of Aortic Arch Disease. Nobl Barazangi, Max Wintermark, Katy Lease, Wade Smith, S. Andrew Josephson; Univ of California, San Francisco, CA Aortic arch (AA) atheromas are a common source of artery-to-artery embolism, and identification of disease in the AA is an important component of embolic stroke workup. Trans-esophageal echocardiography (TEE) has served as the gold standard for evaluation of the AA; however, this technique is invasive, time-consuming, and may carry a substantial morbidity in high-risk patients. Computed tomography angiography (CTA) is used regularly to evaluate acute stroke patients upon initial presentation to the Emergency Department (ED). This imaging modality can include angiography of the AA, allowing for rapid, non-invasive evaluation. We sought to determine the sensitivity and specificity of CTA for detecting AA disease compared to TEE. We performed a retrospective review of 250 patients at a tertiary stroke center who received both a TEE and CTA within 90 days; however, 72% of the studies were conducted within one week of each other. We compared the presence and characteristics of AA plaques using a blinded neuroradiologist and cardiologist. A pre-determined grading system for AA plaques in the ascending, transverse, and descending arch was used for both modalities (Grades 1– 4). Out of the 250 patients in which the AA could be visualized by both CTA and TEE, a total of 497 studies, with the ascending, transverse, and descending arch each considered a separate study, were available for analysis. The sensitivity for CTA to detect plaque as compared to TEE was 39.3% with a positive predictive value of 67.1 (59 –74), while the specificity was 77.6%, with a negative predictive value of 47.6 (42–53). If only Grade 3 and 4 plaques were selected, the sensitivity of CTA dropped to 8.1% but the specificity increased to 98.7%. A weighted kappa test comparing the plaque grade in CTA versus TEE was 0.0169 (95% confidence interval -0.1048 to 0.1387), reflecting a poor correlation. Based on these results, CTA may not be a sensitive diagnostic tool for detecting AA plaques, but may be specific for detecting high-grade plaques. Furthermore, these data may demonstrate the potential limitations of TEE in detecting plaque in all sectors of the AA, indicating a complementary role of CTA for improved detection of AA plaques. Further analysis of the false positive (CTA positive, TEE negative) studies may help elucidate the role of both modalities in detecting AA disease. P21 Biopsy Proven Isolated CNS Vasculitis, Much-Vaunted but Rarely Seen: 20 Year Retrospective Review of Brain Biopsies. P19 The Accuracy of Prehospital Stroke Identification Instruments: Prospective Comparison of the LAPSS, CPSS, and ELAPSS. Parham Moftakhar, Daniel Colby, Sidney Starkman, Jeffrey L Saver, Geffen Sch of Medicine UCLA, Los Angeles, CA; UCLA Student Stroke Team Background: The Los Angeles Prehospital Stroke Screen (LAPSS), the Cincinnati Prehospital Stroke Scale (CPSS), and the Expanded LAPSS (ELAPSS) are brief inventories employed by prehospital personnel worldwide to identify stroke patients in ambulances and in the Emergency Department. However, their relative sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy have not been well characterized in the same study population. Methods: Consecutive patients transported by 911 ambulances during a 7 month study period were assessed for possible stroke. Paramedics first identified whether patients harbored neurologic complaints or signs. The presence of any of seven neurologically-relevant complaints/signs triggered formal stroke screening inventory assessment, and included: 1) altered level of consciousness, 2) local neurological signs, 3) seizure, 4) syncope, 5) head pain, 6) nausea/vomiting, 7) weak/dizzy. (Examples of non-neurologic complaints include chest pain, allergic reaction, and shortness of breath.) Patients with neurologic complaints were evaluated with the LAPSS, CPSS, and ELAPSS. The ELAPSS is a 9 item inventory that adds to the 8 items of the LAPSS the speech/language item of the CPSS. Results: Among 211 consecutive, ambulance-transported patients with neurologic complaints, mean age was 63 and 47% were female. Twenty-two patients (10.4%) had a final ED diagnosis of acute cerebrovascular disease (ischemic stroke, intracranial hemorrhage, still symptomatic TIA). Syncope, seizure, and toxic-metabolic encephalopathy were the most common final non-stroke diagnoses. The accompanying table shows inventory stroke identification performance compared with final diagnoses. Conclusion: While all three standard prehospital stroke recognition inventories show good to excellent sensitivity, the LAPSS is superior in distinguishing stroke mimics from true strokes, yielding a higher positive predictive value. These performance James Castle, Stanford Univ, Palo Alto, CA; Rafael Llinas, Robert Wityk; Johns Hopkins Univ, Baltimore, MD Background and Purpose: Biopsy of brain and meningeal are generally considered to be the gold standard diagnostic test for CNS vasculitis short of autopsy. Sensitivity and specificity for brain and meningeal biopsy are felt to be as high as 80% and 100% respectively. We reviewed all cases of biopsy when CNS vasculitis was considered with the intent of evaluating which elements of the history, physical, laboratory, and radiologic assessment were most accurate for diagnosing vasculitis. Methods: We reviewed all cases at Johns Hopkins Hospital between 1986 and 2006 for which a brain and/or meningeal biopsy was performed when vasculitis was considered a diagnostic possibility. We screened the pathology database by searching for all pathology reports in which the word “brain” and one of the words, “vasculitis”, “angiitis”, or “arteritis” were used. Using those criteria, 41 cases were isolated and all charts were reviewed. Results: Of the 41 cases where the CNS vasculitis diagnosis was considered and a brain biopsy was performed, not a single case of vasculitis found on biopsy. In 7 of the 41 cases, a diagnosis was found on biopsy: 3 Alzheimer’s, 2 CJD, 1 amyloid angiopathy, 1 intravascular lymphoma. In the remaining 34 cases, the physician diagnosed 14 patients as having biopsy negative vasculitis. Of those, 5 eventually had autopsy or other diagnostic biopsy. All showed an alternative diagnosis: 2 atherosclerosis, 1 metastatic renal cell carcinoma with possible hypercoaguable state, 1 CNS lymphoma, and 1 idiopathic basement membrane disease on kidney biopsy. 25% (7/28) of the patients in this series who had a conventional angiogram were thought to have definite vasculitis by the reviewing radiologist. Only 32% (9/28) of these patients who had conventional angiogram were felt not to have vasculitis by the reviewing radiologist. Conclusions: Based on our retrospective series over 20 years and 41 patients, isolated CNS vasculitis was often considered but rarely proven. In fact, was never responsible for the clinical picture in patients who went on to have CNS biopsy. Biopsy and autopsy not-infrequently revealed other diagnosis. Angiogram frequently identified “vasculitis” which was later not confirmed by biopsy. The authors feel that clinicians should avoid being cavalier regarding the diagnosis of Isolated CNS Vasculitis as it is a rare disorder. In our series more common diagnosis were found later to be the true diagnosis when CNS vasculitis was considered. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations P22 Predicting Stroke Deficit From Infarct Topography. Thanh G Phan, Jian Chen, Monash Med Cntr, Clayton VIC, Australia; Geoffrey A Donnan, National Stroke Rsch Institute, Heidelberg, Australia; Velandai Srikanth, Amanda Wood, David C Reutens; Monash Med Cntr, Clayton VIC, Australia Background & Aims: Improving the ability to predict potential stroke deficit may aid the selection of patients most likely to benefit from acute stroke therapies. Current methods, based on ischaemic volumes or initial neurological condition do not predict neurological outcome adequately. On the basis that there is a close relationship between anatomy and function in the brain, we developed and validated a predictive tool for stroke outcome incorporating information on infarct location. Methods: A prospective study of 60 patients with ischaemic stroke (38 in the training set and 22 in the validation set), using a novel implementation of partial least squares with penalised logistic regression (PLS-PLR), was performed. The method yielded a predictive model relating location of infarction (on a voxel-by-voxel basis) and neurological deficits. Results: In the validation phase, this model accurately predicted the presence of neglect (3 errors in 22, 86% correct), aphasia (4 errors in 22, 82% correct), right-arm motor deficit (1 error in 22, 95% correct), right-leg motor deficit (1 error in 22, 95% correct), left-arm motor deficit (10 errors in 22, 55% correct) and left-leg motor deficit (6 errors in 22, 73% correct). The model accurately predicted no to mild disability (Rankin ⱕ2) versus moderate to severe disability (Rankin⬎2) in 73% (16 errors in 22). Conclusion: The model has moderately high accuracy for predicting different neurological deficits and its severity following stroke. This study provides proof of the concept that a model based on imaging data can be used to predict the outcome of the individual patient following stroke. 575 9%). Age, female, AF, and NIHSS score ⬎7 on admission were significantly higher in CE than in other stroke subtypes. The mean plasma BNP level of the CE group was significantly higher than that of the other 3 subtypes (409.6 pg/ml for CE, 94.0 pg/ml for LVD, 37.4 pg/ml for SVD, and 156.9 pg/ml for others, p⬍0.001). The optimal cut-off values, sensitivity, and specificity of the plasma BNP levels to distinguish CE from other ischemic stroke subtypes were 140.0 pg/ml, 80.5% and 80.5%, respectively. Conclusions The plasma BNP level appears to be significantly highest in CE patients among stroke subtypes. Furthermore, BNP should be a good biological marker to differentiate cardioembolic stroke from the other ischemic stroke subtypes. We should strongly consider cardioembolic stroke when the plasma BNP level is over 140.0 pg/ml in acute ischemic stroke patients. P24 Integrity Of The Left Arcuate Fasciculus May Predict The Prognosis Of Aphasia In Patients With Left Middle Cerebral Artery Infarct. Akiko Hosomi; Dept of Neurology Graduate Sch of Med Science, Kyoto Prefectural Univ of Medicine, Kyoto, Japan Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose: It is often clinically difficult to assess the severity of aphasia in the earliest stage of cerebral infarction. A method enabling objective assessment of verbal function is needed for this purpose. We examined whether diffusion-tensor (DT) tractography is of clinical value in assessing aphasia. Methods: Thirteen right-handed patients with left middle cerebral artery territorial infarcts who were scanned within 2 days after stroke onset were enrolled in this study. MR data of 10 healthy controls were also examined by DT tractography. Based on the severity of aphasia at discharge, patients were divided into 2 groups: 6 patients in an aphasia group and 7 in a non-aphasia group. Fractional anisotropy (FA) and number of arcuate fasciculus fibers were evaluated. Asymmetry index was calculated for both FA and number of fibers. Results: FA values for the arcuate fasciculus fibers significantly differed between hemispheres in neither the patient groups nor in the controls. In the control subjects, the mean FA value was 0.44⫾0.028 for the right AF (range, 0.39 to 0.47) and 0.44⫾0.047 for the left AF (range, 0.35 to 0.51). There was no asymmetry in FA value (mean FA ratio, -0.02⫾0.057). In the non-aphasia group, the measured FA values also exhibited no asymmetry. The measured FA values of the non-aphasia group tended to be lower on the left side, and the FA ratio was for the majority of patients slightly negative (indicating rightward asymmetry). However, none of these differences was statistically significant. Number of arcuate fasciculus fibers exhibited a significant leftward asymmetry in the controls and the non-aphasia group, but not in the aphasia group. The number ratio of AF fibers was significantly smaller (indicating rightward asymmetry) in patients with aphasia than in patients without aphasia and controls; both of these differences were significant (P ⫽ 0.014 and 0.002, respectively). There was no significant difference in number of AF fibers between patients without aphasia and controls. Loss of leftward asymmetry in number of AF fibers predicted aphasia at discharge with a sensitivity of 0.83 and specificity of 0.86. Conclusions: We found in this study that in left MCA stroke patients, loss of leftward asymmetry of AF fibers predicted persistent aphasia with high sensitivity and specificity. DT tractography of arcuate fasciculus fibers may be useful for predicting the fate of vascular aphasia. P25 Yield of Transesophageal Echocardiography in Ischemic Stroke Patients by Age and Lesion Pattern on Diffusion-Weighted MRI. Dennis M Campbell, Stanford Stroke Cntr, Stanford, CA; Anne-Sophia Beraud, Stanford Sch of Medicine Dept of Cardiovascular Medicine, Stanford, CA; Michael Mlynash, Stanford Stroke Cntr, Stanford, CA; Ingela Schnittger, Stanford Sch of Medicine Dept of Cardiovascular Medicine, Stanford, CA; Irina Eyngorn, Monisha A Kumar, Stanford Stroke Cntr, Stanford, CA; David C Tong, Stanford Sch of Medicine, Stanford, CA; Michael Moseley, Stanford Sch of Medicine Dept of Radiology, Stanford, CA; Gregory W Albers, Christine A Wijman; Stanford Stroke Cntr, Stanford, CA P23 Plasma Brain Natriuremic Peptide Should Be A Good Biological Marker For Cardioembolic Stroke. Kensaku Shibazaki, Kazumi Kimura, Yasuyuki Iguchi, Yoko Okada, Takeshi Inoue; Kawasaki Med Sch, Kurashiki Okayama, Japan Background and Purpose Plasma brain natriuremic peptide (BNP) is used as a marker of heart failure. In acute ischemic stroke, we hypothesized that plasma BNP level was highest in patients with cardioembolic stroke compared with other stroke subtypes, and could be a biological marker to differentiate cardioembolic stroke from the other ischemic stroke subtypes. Methods Consecutive patients with acute ischemic stroke within 24 hours of onset were prospectively enrolled. We measured plasma BNP on admission. Patients were divided into four groups according to the TOAST classification: large-vessel disease (LVD), cardioembolism (CE), small-vessel disease (SVD), and other stroke. We examined relation between plasma BNP level and stroke subtypes. Results Total 200 patients (124 male; mean age, 71.4 ⫹ 12.8 years) were enrolled into the present study. Cardioembolism (n⫽82, 41%) was the most frequent stroke subtype, followed by other stroke (n⫽68, 34%), SVD (n⫽32, 16%), and LVD (n⫽18, Introduction: Ischemic stroke is a major cause of death and disability, and up to 30% of these are attributed to cardioembolism. The most common approach of detecting subtle cardiac lesions is transesophageal echocardiography (TEE); however, due to its invasiveness, it is typically used in a subset of ischemic stroke patients. We sought to determine the yield of TEE in a consecutive series of unselected patients presenting with symptoms of ischemic stroke who underwent diffusion weighted MRI (DWI). Methods: In this prospective NIH funded study, TEE and DWI were obtained in 194 consecutively admitted patients with symptoms suggestive of ischemic stroke. TEE results were categorized into high-risk (left atrial thrombus, left atrial appendage thrombus, left ventricular thrombus, left-sided cardiac mass, mitral valve vegetation, aortic valve vegetation, patent foramen ovale (PFO) with an atrial septal aneurysm (ASA), and large (⬎4 mm) or mobile aortic plaque) and moderate-risk (left atrial spontaneous echo-contrast, ASA alone, PFO alone, and moderate sized (3– 4 mm) aortic plaque) lesions. The distribution of diffusion deficits on DWI were categorized into the following categories: single lesion, multiple lesions in a single vascular territory, and multiple lesions in multiple vascular territories. TEE yield was determined by age (⬎65 years vs. ⬍65 years) and DWI pattern. Results: Overall, the yield of TEE was 21.6% for detecting a high risk lesion and 28.4% for detecting one or more moderate risk lesions, for an overall yield of 50.0%. A lesion within the heart or aortic arch was detected more commonly in older (⬎65) vs younger (⬍65) patients (66.1% vs 29.4%; p⫽⬍0.001). Overall, positive TEE occurred more commonly in patients with multiple DWI lesions than in those with a single lesion identified on DWI (66.7% vs 44.6%; p⫽0.0221). This difference remained significant when comparing patients with multiple MRI lesions confined to a single vascular territory and positive TEE with those with single MRI lesions (p⫽0.003); however, the difference between multiple DWI lesions scattered over multiple vascular territories Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 576 Stroke Vol 39, No 2 February 2008 and positive TEE vs those with single MRI lesions was not significant. Conclusion: The yield for detecting a moderate or high risk lesion on TEE in unselected ischemic stroke patients is substantial, and is particularly high in elderly patients (age ⬎ 65 years) and in those with multiple acute DWI lesions. How often the detection of these lesions influences final diagnosis of stroke subtype and treatment decisions is under investigation. This study was funded by the NIH: RO1 NS34866, PI Mike Moseley. P27 Blood Flow Measurement In A Canine Carotid Stenosis Model Using Quantitative Magnetic Resonance Angiography. Mateo Calderon-Arnulphi, Sepideh Amin-Hanjani, Ali Alaraj, Meide Zhao, Univ of Illinoins, Chicago, IL; Lauren Ostergren, VasSol, Inc, Chicago, IL; Sean Ruland, William Ashley, Xinjian Du, Fady T Charbel; Univ of Illinoins, Chicago, IL analysis was performed to define the threshold for infarct growth that has the highest sensitivity and specificity for predicting clinical response. Results: Lesion growth was significantly associated with clinical outcomes in patients with a Mismatch. Median (IQR) lesion growth was ⫹2cc (-2, ⫹10) in Mismatch patients with favorable clinical response, vs. ⫹29cc (⫹6, ⫹52) in Mismatch patients who did not have favorable response (p⫽0.004) independent of age, baseline NIHSS and baseline DWI volume. There was no association between lesion growth and clinical outcomes in the No mismatch group [⫹1cc (-3, ⫹6) vs. ⫹1cc (-1, ⫹11), p⫽0.755]. The ROC analysis demonstrated that for Mismatch patients, lesion growth of less than 7 cc is highly predictive of a favorable clinical response (odds ratio, 13.5; p⫽0.006, sensitivity 82%, specificity 75%). Conclusion: There is a strong relationship between ischemic lesion growth and clinical outcomes in patients with a perfusion/diffusion mismatch; no relationship could be demonstrated in patients who did not have a mismatch. Infarct growth may be a suitable surrogate outcome measure for Mismatch patients P29 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction The hemodynamic effects of cerebrovascular stenosis may have implications for stroke risk. Direct large vessel flow measurement has traditionally only been available in the intraoperative setting with flow probes. Quantitative magnetic resonance angiography (QMRA), however, allows non-invasive measurement of vessel flows utilizing phase contrast techniques. To evaluate the accuracy of blood flow quantification related to progressive arterial stenosis, we measured flows in a canine carotid artery model with QMRA in comparison to an ultrasonic flow probe, the gold standard in direct flow measurement. Methods Hound dogs (n⫽6) were placed under general endotracheal anesthesia, and an ultrasonic flow probe (Transonic Systems, Inc.) implanted around the canine common carotid artery (CCA) for measurement of mean blood flow. Arterial pressure was continuously recorded via a femoral arterial line. A vascular tourniquet was applied around the CCA to produce varying degrees of stenosis. QMRA was performed using NOVA software (VasSol, Inc.). CCA flows were measured simultaneously using QMRA and the flow probe. Statistical comparisons were made using Pearson correlation coefficient, and Bland Altman plots. Results A total of 48 paired CCA flow measurements were performed. Stable mean arterial pressure was maintained during each paired measurement. Using pharmacological blood pressure manipulation and progressive tourniquet stenosis, CCA blood flows ranging between 10 to 700 ml/min were generated. The correlation coefficient between the QMRA measurements and the flow probe was 0.99 (p⬍0.0001). The average difference between the two techniques was 16.5 ml/min (SE ⫹/- 2.20 ml/min), and the average proportional difference (PD) was 5.9% (SE⫹/- 0.75). PD increased at higher degrees of stenosis and lower flow: PD⫽ 12.9% SE ⫹/- 2.17 at ⬍80ml/min compared to PD⫽ 3.38% SE⫹/- 0.55 at flow rates ⬎350ml/min (NOVA higher than flow probe). ConclusionsCCA flow measurement using QMRA is accurate in vivo compared to direct flow probe measurement in a canine arterial stenosis model. QMRA is a promising modality for the evaluation of the hemodynamic effects of cerebrovascular atherostenosis. Etiology of Ischemic Stroke Determined Using Blood Gene Expression Profiling. Huichun Xu, Jeffrey P Gregg, Univ of California at Davis, Sacramento, CA; Arthur Pancioli, Edward C Jauch, Univ of Cincinnati, Cincinnati, OH; Piero Verro, Univ of California at Davis, Sacramento, CA; Joseph P Broderick, Univ of Cinicnnati, Cincinnati, OH; Frank R Sharp; Univ of California at Davis, Sacramento, CA Determining the etiology of ischemic stroke is critical for developing the most appropriate treatment to prevent stroke recurrence. Though imaging of the carotid and heart are very specific, they are not very sensitive for detecting cardiac and large vessel atherosclerotic causes of stroke. Recently we and other groups demonstrated gene expression changes in blood cells following ischemic stroke as early as 2–3hr after onset. The expression of as few as 18 genes can correctly classify most stroke patients. We reasoned that different etiologies of stroke would be associated with different RNA expression profiles in peripheral blood. Forty -five peripheral blood samples were taken at ⬍3, 5 and 24 hours from 15 patients who had either cardioembolic, large vessel atherosclerotic or ischemic stroke of undetermined etiology. Sixteen peripheral blood samples were taken from healthy controls. RNA was purified, labeled and hybridized to Affymetrix Human U133 Plus 2.0 Arrays. Seventy five genes were significantly different between cardioembolic and large vessel atherosclerotic stroke and controls (⬎ 1.5 fold change, ANOVA with Benjamini-Hochberg false discovery rate ⬍ 0.05, Student-Newman-Keuls post hoc test). Functional analyses show that atherosclerotic stroke-specific genes regulate hemostasis and cytokine activities and are expressed mainly in platelets and monocytes. In contrast, cardioembolism-specific genes are involved in the immune response to pathogens and are expressed mainly in polymorphonuclear cells (neutrophils). Our results suggest that blood gene expression profiling can be used to determine the etiology of ischemic stroke. It also can offer pathological insights into the molecular mechanisms of ischemic stroke, which will have important implications for the development of novel, etiology-specific treatments. P30 Perfusion Angiography: A Novel Technique for Characterization of Perfusion in Cerebral Ischemia. David S Liebeskind, UCLA, Los Angeles, CA; Gregory Szilagyi, Sandra E Black, Brian H Buck; Sunnybrook Health Sciences Cntr, Univ of Toronto, Toronto, Canada P28 Lesion Growth is Associated with Clinical Outcome in Patients with Mismatch, but not in No Mismatch Patients. Jean-Marc Olivot, Michael Mlynash, Dept of Neurology and Neurological Sciences and the Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA; Vincent N Thijs, Neurology, Univ Hosps, Leuven, Leuven, Belgium; Marteen G Lansberg, Stephanie Kemp, Dept of Neurology and Neurological Sciences and the Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA; Roland Bammer, Dept of Radiology and the Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA; Lawrence Wechsler, UPMC Stroke Institute and Dept of Neurology., Univ of Pittsburgh, PA; Gregory W Albers; Dept of Neurology and Neurological Sciences and the Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA Background: Most perfusion imaging modalities for acute stroke or cerebral ischemia depend on contrast bolus tracking, yet the anatomy of specific flow routes remains obscure. Conversely, conventional angiography is increasingly used for endovascular procedures in acute stroke; however, standard perfusion parameters may be difficult to ascertain. We developed a novel post-processing technique that allows for rapid determination of various perfusion parameters from digital subtraction angiography (DSA). Methods: Angiodensitometry of DSA data acquired in acute stroke was utilized to estimate perfusion. A standalone computer software algorithm was developed to iteratively process temporal changes in contrast intensity, yielding concentration-time curves based on the known arterial inflow within each pixel. Cerebral blood volume (CBV) is calculated at each pixel by numerical integration over the entire corresponding concentration-time curve. Cerebral blood flow (CBF) is determined by deconvolving the tissue concentration-time curve with the arterial input function (AIF) using singular-value decomposition with a block-circulant deconvolution matrix. Subsequent generation of multiparametric perfusion maps allowed for region of interest analyses. Results: Perfusion angiography images were processed in 20 cases of acute ischemic stroke, exhibiting various types of occlusive lesions and degrees of collateral circulation. Perfusion maps were Background and Purpose: Ischemic lesion growth has been proposed as a surrogate measure of stroke outcome. It is hypothesized that patients who have less ischemic lesion growth will have better clinical outcomes. We investigated the association between lesion growth and clinical outcomes in the DEFUSE dataset for patients with a perfusion/diffusion mismatch (Mismatch) as well as for No Mismatch patients. Methods: DEFUSE is an open-label, NIH-funded, multicenter study in which acute stroke patients were treated with intravenous tPA between 3 and 6 hours after symptom onset. A magnetic resonance imaging (MRI) scan was obtained immediately before, 3 to 6 hours and 30 days after thrombolytic treatment. Ischemic lesion growth was defined as the difference between the final infarct volume (measured on 30 day FLAIR) and the baseline DWI volume. Baseline MRI profiles were used to determine which patients had a Mismatch (N⫽23) or No Mismatch (N⫽27). Favorable clinical response was defined as ⱖ8 point improvement in the NIHSS, or a score of 0 –1 at 30 days. An ROC curve Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations 577 generated to display cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT) and cerebral perfusion pressure (CPP). Simultaneous visualization of anatomic structures allowed the user to identify specific flow routes. Perfusion images were generated in frontal, lateral, and oblique planes. Software capability included use of DSA data with variable frame rates and spatial resolution. Validation was performed on multicenter datasets and correlation assessed with noninvasive perfusion imaging modalities. Conclusions: Perfusion angiography provides a novel means to rapidly assess numerous perfusion parameters at the time of endovascular procedures. Serial changes in perfusion associated with treatment may be evaluated with this software in a multicenter setting. P31 Detection Of Right-to-left Shunt In Stroke Satients: Contrast-enhanced Transesophageal Echocardiography At The Bilateral Atria, Aortic Arch, And Descending Aorta. Rieko Suzuki, Kazunori Toyoda, Ryoichi Otsubo, Sohei Yoshimura, Masatoshi Koga, Kuni Konaka, Fumio Miyashita, Masahiro Yasaka, Hiroaki Naritomi, Kazuo Minematsu; Cerebrovascular Div, Dept of Medicine, National Cardiovascular Cntr, Osaka, Japan Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: Because the right-to-left shunt (RLS) is an important cause of paradoxical embolism, it is necessary for patients with cryptogenic stroke to receive screening examinations for RLS. Although monitoring with contrast-enhanced transesophageal echocardiography (cTEE) at the bilateral atria (BA) is commonly used for detecting RLS, the procedure has several limitations. In particular, nonsmoke spontaneous individual contrast (NSSIC) is generated in the atrium just after the Valsalva maneuver without contrast injection, and makes the diagnosis of RLS difficult. To overcome the limitations, we determined the efficacy of monitoring with cTEE at three sites: the BA, aortic arch (AA), and descending aorta (DA). Methods: Between October 2004 and July 2006, 613 patients (414 men, 68⫾12 years) with cerebrovascular diseases underwent cTEE monitoring at the BA, AA, and DA using a real-time two-dimentional echocardiography system equipped with a 5.0-MHz phased array omniplane transducer. In each monitoring site, visualization of contrast much brighter than NSSIC during the respiratory maneuver with administration of the contrast medium was considered to be positive. When the positive finding was proven at least in two sites or when it was reproduced in one site, patients were diagnosed as having RLS. Results: We diagnosed 92 patients (15%) as having RLS; positive findings were obtained at all the three sites for 45 patients, at two sites for 22 patients (9 at the BA and AA, 7 at BA and DA, and 6 at AA and DA), and at one site for 25 patients (13 at the BA, 8 at AA, and 4 at DA). RLS was not the diagnosis for 55 patients who had a positive finding at one site without reproducibility (48 at the BA, 4 at AA, and 5 at DA). The sensitivity, specificity, positive and negative predictive values of the positive finding at BA for the diagnosis of RLS were 80%, 91%, 61%, and 96%, those at AA were 74%, 99%, 89%, and 96%, and those at DA were 67%, 99%, 92%, and 95%, respectively. Conclusions: Among three monitoring sites for cTEE, the BA had the highest sensitivity and AA and DA had almost the perfect specificity for the diagnosis of RLS. Combined monitoring at the BA, AA, and DA may improve the diagnostic accuracy for RLS in stroke patients. P32 Proteomic Identification Of Potential Biomarkers For Ischemic Stroke Subtype. David Brea, Tomás Sobrino, Manuel Rodrı́guez-Yáñez, Iván Cristobo, Raquel Rodrı́guez-González, Octavio Moldes, Rogelio Leira, José Castillo; Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain Background. Accurate classification of ischemic stroke subtype is very important because secondary prevention is subtype-dependent. Nowadays, despite imaging advances, 30 – 40% strokes still remain as “undetermined stroke”. Therefore, we need molecular markers to accurately classify ischemic stroke. In this study, we hypothesise that variations in the serum protein expression from patients with different ischemic stroke subtype may help to find new diagnostic biomarkers. Methods. Serum proteins from 24 patients with ischemic classified according to TOAST criteria (12 atherothrombotic and 12 cardioembolic matched by age, sex, serum glucose, fibrinogen levels and NIHSS socre on admission, infarct volume and modified Rankin Scale at 3 months) were separated by two-dimensional gel electrophoresis. Resulting patterns were compared and founded differences were identified by mass spectrometry. Results. A comparison of protein expression patterns (analyzed with PDQuestTM 2D analysis software) showed that four spots were found to be fourfold or more expressed in atherothrombotic patients than in cardioembolic patients. These spots were identified as haptoglobin ␣1 chain, serum amyloid A (two spots) and haptoglobin related protein (Figure). Conclusions. Haptoglobin ␣1 chain, serum amyloid A and haptoglobin related protein may be potential molecular markers of atherothrombotic ischemic stroke subtype. Figure. Gel fragment including the different expression of spots, between atherothrombotic and cardioembolic patients, in tridimensional view. SAA, Serum Amyloid A. HPTR, Haptoglobin Related Protein. HPT␣1chain, Haptoglobin ␣1chain. P33 Benign Oligemia Reflects Collateral Perfusion: MRI and Angiography of Low Perfusion Hyperemia in Humans. David S Liebeskind, Jeffry R Alger, Oh Y Bang, Brian H Buck, James C Norman, Sidney Starkman, Doojin Kim, Latisha K Ali, Bruce Ovbiagele, Amytis Towfighi, Samir H Shah, Reza Jahan, Gary R Duckwiler, Fernando Vinuela, Noriko Salamon, J P Villablanca, Jeffrey L Saver; UCLA, Los Angeles, CA Background: The basis of benign oligemia, or regions of the ischemic territory not at risk of infarction, remains unknown. Characterization of the vascular pathophysiology in such regions may provide insight regarding hemodynamic vulnerability of the adjacent ischemic penumbra and enhance prediction models of infarct evolution. We utilized concurrent MRI and conventional angiography in a large series of acute ischemic stroke cases to probe the basis of benign oligemia. Methods: Data were analyzed from a consecutive series of acute MCA ischemia cases evaluated with concurrent MRI and conventional angiography. Tmax thresholds of 2, 4, and 6 seconds on perfusion-weighted MRI were used to delineate potential regions of benign oligemia. Volumetric and voxel-based analysis methods were used to correlate cerebral blood volume (CBV) and cerebral perfusion pressure (CPP) values within these regions, using contralateral hemispheric areas to derive ratios of relative CBV and CPP. Angiographic features were scored with the TICI scale for the degree of occlusion and the ASITN/SIR scale for extent of collateral flow. Results: Pretreatment MRI and angiography were analyzed in 50 consecutive cases of acute MCA occlusion. For all Tmax thresholds used to identify potential areas of benign oligemia, marked variability in the extent of such non-penumbral regions was noted despite complete occlusion and cessation of antegrade MCA flow (TICI 0) in all 50 cases. Hyperemia, or increases in relative CBV values, were evident in these regions of “oligemia” in all cases (p⬍0.001). Cerebral perfusion pressure (CPP) was mildly decreased in these areas, yet consistently exhibited a further gradient extending deep from the cortical surface in all cases (p⬍0.001). Although the presence of collateral flow was always evident, the correlation between angiographic collateral grade and the area of hypoperfusion varied with the specific Tmax thresholds employed. Conclusions: Regions of benign oligemia, or non-penumbral areas at the periphery of the ischemic territory, are hyperemic, not oligemic. Perfusion pressure, evident on MRI CPP maps, declines from cortex to deep regions of the ischemic territory, corresponding to progressive slowing of retrograde leptomeningeal collateral flow on angiography. Features of collateral perfusion including an interaction between CBV and CPP, not autoregulation, likely account for determinants of ischemic vulnerability in areas of low perfusion hyperemia. P34 A Pearl In Every Cowslip’s Ear: Pearls on Diffusion-Weighted MRI Predict Large Vessel Stroke. Lisa C Turtzo, Univ of Connecticut, Farmington, CT; Rebecca F Gottesman, Rafael H Llinas; Johns Hopkins Bayview Med Cntr, Baltimore, MD Background Infarct pattern on diffusion-weighted (DWI) MRI may predict stroke etiology. The “string of pearls” pattern has been described as a result of large artery disease, but evidence is lacking to confirm this relationship. Other similar patterns have not been investigated. In this retrospective study, we investigated whether or not “pearls” (DWI-bright lesions) on MRI were predictors of intracranial and/or extracranial arterial stenosis. Methods We reviewed all stroke and TIA admissions to an academic hospital over a 2-year period (495 subjects), excluding patients without DWI, with hemorrhagic strokes, or with non-vascular disease. Two vascular neurologists reviewed patients’ records to classify probable stroke etiology by modified TOAST criteria. Another investigator, blinded to clinical information, reviewed DWI and ADC images from patients’ MRIs. “String of pearls” was classified as 3 or more pearls in a line found unilaterally in the anterior circulation. “Scattered pearls” were defined as 3 or more pearls distributed such that no single line could connect them, also found unilaterally in the anterior circulation. Results After review of exclusion criteria, 370 patients were included in this study, averaging 66.8 years in age. “String of pearls” or “scattered pearls” were found on the MRIs of 6 and 30 patients, respectively. 56% of patients with either “pearls” sign were classified as TOAST 1 or 2, but this classification was only found in 33% of subjects with any other DWI pattern (p⫽0.009). Cases with scattered pearls, in particular, were found to have a TOAST 1 or 2 etiology 53% of the time (versus 33% without this pattern) (p⫽0.027). Four of 6 cases with string of pearls had this mechanism, versus 34% of other cases (p⫽0.187). If either “pearl” sign was seen on MRI, a patient was 2.65 (95% CI 1.32, 5.32) times as likely to have either intracranial or extracranial large vessel stenosis. Conclusion Having either “string of pearls” or “scattered pearls” was associated with an independently determined mechanism of intracranial or extracranial large vessel stenosis. If either type of “pearls” is seen on MRI, these Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 578 Stroke Vol 39, No 2 February 2008 data would suggest that a thorough workup of the intracranial and extracranial vasculature be pursued. P35 P37 Frontal Bone Window Improves Success Rate of Transcranial Color-Coded Ultrasonography in Visualizing Anterior Cerebral Artery in Japanese Stroke Patients. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Higher ABCD2 Score Predicts Patients Most Likely to Have True TIA. Sohei Yoshimura, Masatoshi Koga, Kazunori Toyoda, Boo-Han Hyun, Kazuyuki Nagatsuka, Hiroaki Naritomi, Kazuo Minematsu; National Cardiovascular Cntr, Osaka, Japan S. Andrew Josephson, Univ of California San Francisco, San Francisco, CA; Stephen Sidney, Kaiser-Permanente Northern California, Oakland, CA; Allan L Bernstein, Kaiser-Permanente, Santa Rosa, CA; Trinh N Pham, S. Claiborne Johnston; Univ of California San Francisco, San Francisco, CA Objectives: Proper bone windows for transcranial color-coded ultrasonography (TCCS) are essential to detect intracranial vascular lesions not only for the diagnosis, but also for hyperacute sonothrombolytic therapy. Because Japanese patients do not frequently have the adequate temporal bone window (TBW), the success rate for identification of basal cerebral arteries via TBW, in particular that of the anterior cerebral artery (ACA), is not high enough for the clinical use. Additional examinations via the frontal bone windows (FBW) may overcome the limitations. We hypothesized that the success rate in visualizing the basal cerebral arteries may be improved by the combination of TBW and FBW. Methods: We studied 100 consecutive stroke patients (age, 69⫾12 or 32 to 93; 72 men) who were admitted to our hospital from June to August in 2007. The success rates of visualizing the ACA (A1/A2), M1 segment of the middle cerebral artery (MCA), and the posterior cerebral artery (PCA) through TBW and FBW were evaluated using a unit (Sonos 5500; Philips Medical Systems, Japan, Tokyo) with a 1.0 –3.0 MHz sector scan. FBW consists of a lateral FBW, which is located above the lateral aspect of the eyebrow, and a paramedian FBW, which was slightly lateral of the midline of the forehead. Ultrasound contrast-enhancing agents were not used in this study. Results: Success rates in visualizing the MCA (37.0%) and PCA (23.0%) through FBW were inferior to those through TBW (56.0%; p⬍0.001, 56.0%; p⬍0.001, respectively). The combination of observation via the both windows slightly increased the detection rate of MCA to 63.5% (p⫽0.126) and that of PCA to 62.5% (p⫽0.186). ACA was similarly detected via FBW (42.0%; 50.7% in men, 19.6% in women) and TBW (38.5%; 47.9% in men, 14.3% in women) (p⫽0.475). It was notable that 20.5% of the ACA was detected only via FBW. The combination significantly increased the detection rate of the ACA to 59.0% (69.4% in men, 32.1% in women) as compared to the examination only via TBW (p⬍0.001). Conclusions: Examination of TCCS via FBW in addition to TBW improved the success rate in visualizing the ACA. The compensatory technique appears to be useful for patients having the inadequate TBW. Background: Some patients diagnosed with TIA in the Emergency Department (ED) may actually have alternative diagnoses such as seizure, migraine, or other non-vascular spells. The ABCD2 method has been shown to predict subsequent risk of stroke in patients with TIA diagnosed by emergency physicians, but perhaps high ABCD2 scores simply separate those patients with true TIA from those with alternative diagnoses. We investigated this hypothesis in a cohort of patients with TIA identified in the ED whose charts were reviewed by an expert neurologist. Methods: All patients diagnosed by emergency physicians with TIA in 16 hospitals in the Kaiser-Permanente Medical Care Plan over a 1-year period ending February 1998 (prior to publication of prediction rules) were included (n⫽1707). An expert neurologist blinded to outcome reviewed the charts of 713 of these patients and determined if the spell was likely to represent a true TIA. Subsequent strokes within 90 days were identified in the cohort. ABCD2 scores were calculated for all patients and two-sided Cochran-Armitage Trend tests were used to assess subsequent risk of stroke. Results: Of the 713 patients reviewed by the expert neurologist, 642 (90%) were judged to likely have experienced a true TIA. Ninety-day stroke risk was 24% in the group judged to have experienced a true TIA, and 1.4% in the group judged to not have a true TIA. ABCD2 scores were higher in those judged to have a true TIA compared with those who were not (p⫽0.0001). In the group judged to have a true TIA, 90-day stroke risk increased as ABCD2 score increased (p⬍0.0001); there was no relationship between ABCD2 score and stroke risk in those judged unlikely to have had a TIA (p⫽0.73). Conclusions: In this cohort of patients with TIA, higher ABCD2 score was associated with patients thought to have true TIA on review by an expert neurologist. Risk of subsequent stroke was quite low in patients judged to likely have not experienced a true TIA. Higher ABCD2 scores still remained predictive of 90-day stroke rate in the group of patients judged to have a true TIA by an expert neurologist. The predictive power of the ABCD2 model is therefore partially explained by identification of those patients likely to have experienced a true TIA, an important aspect of the score when used by non-neurologists. P38 Clinical Features Of Patients With Acute Ischemic Stroke Who Had Hyperintense Lesions In The Aortic Arch Plaque On T1-weighted Magnetic Resonance Imaging. Hiroyuki Kawano, Chiaki Yokota, Naoaki Yamada, Kazunori Toyoda, Kazuo Minematsu; National Cardiovascular Cntr, Suita, Japan P36 Real-Time 3D Contrast-Enhanced Transcranial Ultrasound. Daniel T Laskowitz, Heather A Nicoletto, Duke Univ Med Cntr, Durham, NC; Nikolas M Ivancevich, Gianmarco Pinton, Stephen W Smith, Duke Univ BioMed Engineering, Durham, NC; Monica Scism, Ellen Bennett; Duke Univ Med Cntr, Durham, NC Background and Purpose: Contrast enhanced transcranial color-coded duplex sonography (CE-TCCD) and reconstructed 3-dimensional TCCD have shown advantages over traditional TCCD in assessing a variety of cerebrovascular diseases. We tested the feasibility of real-time 3D (RT3D) CE-TCCD in a baseline study of 17 healthy adults Methods: Per an IRB approved protocol, we used the Volumetrics (VMI) 3D ultrasound scanner with a 2.5 MHz matrix array to obtain 3D scans from the temporal and sub-occipital acoustic windows of healthy volunteers given the FDA approved dosage (10 L/kg) of Definity echo contrast agent. The VMI scanner generates a real-time, 65° 3D pyramidal scan displaying three orthogonal planes, spectral and 3D color flow Doppler. Two observers later reviewed the data, identifying cerebral vessels. In addition, we used adaptive imaging to estimate and correct the skull-aberration in the temporal acoustic window, to increase image quality. Color Doppler volumes were then acquired preand post- correction for comparison. Results: In Figure 1, we demonstrate simultaneous axial (A) and coronal (B) scans of a typical subject. In A, we show the circle of Willis. In B, we see the length of the M1 and M2 segments of both middle cerebral arteries. In 82% of subjects, we identified the ipsilateral Circle of Willis, and in 65% we imaged the entire Circle of Willis. Figure 1C shows a coronal scan of the vertebral arteries (VA) merging into the basilar artery (BA) in a typical subject. In the sub-occipital approach, we imaged the entire vertebrobasilar circulation in 22% of subjects. In 50% we imaged the basilar artery. For proof of principle, with the corrected data we visualized an A1 segment that was not present in the uncorrected data. Conclusions: In this study, we present a novel transcranial technique which allows real-time, three dimensional visualization of the Circle of Willis and proximal vasculature. RT3D CE-TCCD increases ease of use compared to 2D imaging; precise and accurate positioning and aiming of the transducer is not necessary to image the vessels, as a whole 3D volume of data is acquired. We also believe that skull-aberration correction will help increase the image quality of RT3D CE-TCCD. Objective: Atherothrombotic diseases in the aortic arch as well as in the carotid artery is known to be a strong and independent risk factor of ischemic stroke. MRI can identify the plaque instability by characterizing plaque components. In the case of the carotid artery, a lipid-rich necrotic core with intraplaque hemorrhage displays a hyperintense signal on T1-weighted MRI (T1WI). Hyperintense lesions in the aortic arch on T1WI may indicate a high risk for future cerebrovascular events. We aimed to clarify the clinical features and transesophageal echocardiography (TEE) findings of acute ischemic strokes with hyperintensity in the aortic arch on T1WI. Methods: Of 345 consecutive patients who were admitted within 7 days after the onset of ischemic stroke between May 2006 and May 2007, 61 patients with either ⬎50% area stenosis of the carotid artery or a plaque ⬎4.0mm of thickness in the aortic arch detected by TEE were enrolled. All patients underwent plaque imaging studies using 3-dimensional inversion-recovery-based T1WI (alternatively known as magnetization- prepared rapid acquisition with gradient-echo or MPRAGE) in the aortic arch. A high signal plaque on MPRAGE was defined as a plaque with the intensity of ⬎200% as compared to that of adjacent muscular tissues. All the patients were followed up until 3 months after the onset. The end-points were cerebrovascular events including ischemic stroke and carotid endarterectomy. Results: Thirty-five patients (57%) had high signals of atheroma in the aortic arch on MPRAGE. Eighteen patients (30%) had cerebrovascular events within 3 months after the onset. Current/former smoking habit was more common in patients with high signals of atheroma on MPRAGE than without (74% vs. 42%, p⫽0.011). Male (83% vs. 62%, p⫽0.061) and larger plaques in the aortic arch (5.6⫾1.7 vs. 4.9⫾1.5 mm, p⫽0.072) tended to be observed more frequently in patients with hyperintensity in the aortic arch on MPRAGE. The optimal cut-off score of the thickness in the aortic arch atheroma for high signals on MPRAGE was ⬎4.5mm (sensitivity, 76%; specificity, 62%). Adjusted for age, gender and smoking habit, high signals on MPRAGE were associated with larger plaques (⬎4.5mm) in the aortic arch (odds ratio 5.20, 95%CI 1.39 –19.53), but not associated with future cerebrovascular events within 3 months after the index stroke. Conclusion: Larger plaques in the aortic arch, in particular ⬎4.5mm thickness, were associated with high signals in the aortic arch on MPRAGE in patients with acute ischemic stroke. P39 Unilateral versus Bilateral Monitoring for Quantitation of Right-to-Left Shunt by Power M-Mode Transcranial Doppler. Jill T Jesurum, Cindy J Fuller, Swedish Med Cntr, Seattle, WA; Mark A Moehring, Merrill P Spencer; Spencer Technologies, Seattle, WA Background: Though technically challenging, bilateral monitoring is the clinically accepted standard for performing transcranial Doppler (TCD) examination despite published guidelines Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations that recommend monitoring at least one temporal bone window to detect right-to-left circulatory shunt (RLS). Insonation of both temporal bone windows may be difficult or impossible in some patients, particularly in elderly females. Systematic comparisons of unilateral and bilateral monitoring are limited; therefore, the purpose of this study was to compare unilateral vs. bilateral monitoring by power M-mode TCD (pmTCD) for quantifying RLS. Methods: Recorded Doppler data from 89 patients referred for transcatheter closure of patent foramen ovale were re-analyzed for embolic track (ET) counts observed from left and right temporal bone windows. Patients were excluded for carotid artery stenosis ⬎70%. Unilateral ET counts were obtained by multiplying each side by two; bilateral ET counts were obtained by summing left- and right-sided ET. Gender and age group subanalyses and inter-rater reliability were performed. Results: The sample consisted of 47 males (53%) and 42 females; 47 (53%) were aged ⬍ 55 years and 42 were aged ⱖ 55 years. Most patients had minimal internal carotid artery (ICA) stenosis, defined as ⬍15% using carotid duplex ultrasound. All patients had adequate bilateral temporal bone windows. ET counts were similar between left and right windows; therefore, the left window was randomly selected for comparison with bilateral windows. No significant differences were found between unilateral (left multiplied by 2) and bilateral ET counts at rest (mean ⫾ SD: left 107 ⫾ 122 vs. bilateral 112 ⫾ 124; p ⫽ 0.054) or following strain (left 211 ⫾ 140 vs. bilateral 214 ⫾ 141, p⫽ 0.164). No differences were found within genders or younger patients for left versus right ET counts. For the group aged ⱖ 55 years, the right side yielded greater ET counts (12% ⫾ 13%; 95% CI, -3% to 28%) than the left side at rest only (Z ⫽ -2.577, p ⫽ 0.010). Inter-rater reliability of ET counts was satisfactory (r ⫽ 0.903). Conclusions: This is the first study to show that, compared to bilateral monitoring, unilateral monitoring of ET counts by pmTCD is sufficient to detect and quantify RLS. This will allow design of more portable and user-friendly equipment to screen for presence of RLS using a single temporal bone window. P40 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Persistence of the Diffusion-Perfusion Mismatch up to 24 Hours: Dependence upon Proximal Arterial Occlusion. William A Copen, Elizabeth R Barak, Lee H Schwamm, Leila Reza-Gharai, Shahmir Kamalian, Ona Wu, R. G Gonzalez, Pamela W Schaefer; Massachusetts General Hosp, Boston, MA 579 Diagnosis II P41 Anatomic Localization of the Hand Motor Area in Chronic Stroke Affected Brains is as Accurate as Functional MRI. Todd Parrish, Robert Levy, Lora Cope, Dan Krainak, Northwestern Univ, Chicago, IL; Justin Hulvershorn; Northstar Neuroscience, Seattle, WA Introduction: Neurosurgical procedures frequently require accurate localization of the precentral gyrus. Yousry (1997) proposed an anatomic technique for locating the precentral gyrus. We determined whether this approach is valid in stroke patients, whose brain injury and resulting neuroplasticity may alter these critical functional/anatomic relationships. Methods: Using the Yousry method, three independent observers located the hand motor area in 46 chronic stroke patients enrolled in a stroke motor recovery investigational trial with an implanted cortical stimulation device (n⫽92 hemispheres; right lesion⫽26, left lesion⫽20). fMRI localized the affected hand in 43 subjects and the non-affected in 14. The fMRI coordinates were the center of mass located in the precentral gyrus. The functional location was compared with the anatomically derived localizations, see figure. Results: The mean Euclidian error between observers was 6.5 mm and 6.2 mm on the stroke and normal hemispheres, respectively. The mean distance between fMRI hand motor localization and anatomic localization was 9.3 mm and 8.2 mm on the stroke and normal hemispheres, respectively. Conclusions: The Euclidian error between the functional and anatomic localization was less than 10 mm, even in the infarcted brain, which is on the order of the typical error in fMRI localization. The acquisition resolution of fMRI is ⬃4mm; processing decreases resolution to 6 – 8mm. Thus, the variability of anatomic localization between trained observers and the difference between fMRI location of motor areas and the anatomically derived localization are essentially equivalent in chronic stroke patients. References: Yousry TA, et.a l. Localization of the motor hand area to a knob on the precentral gyrus: A new landmark. Brain 1997; 120: 141–157. Acknowledgements: This study was funded by Northstar Neuroscience, Inc., the manufacturer of the implanted stimulation device system. Figure: Results from a single patient with a large infarct. The individual localization of motor cortex is well clustered and the functional imaging result is just anterior to the anatomic localization. Background: Ongoing research is investigating the efficacy of intravenous thrombolysis up to 9h after stroke onset in patients with diffusion-perfusion mismatch seen on MRI. In order to assess the potential impact of future studies that might involve thrombolysis even later than 9h, we studied the prevalence of persistent mismatch up to 24 hours after onset, and assessed the relationship of persistent mismatch to the existence of proximal arterial occlusion. Methods: 110 patients underwent diffusion- (DWI) and perfusion-weighted (PWI) MRI, as well as vascular imaging (MR or CT angiography) within 24 hours after they were last seen at neurologic baseline. 86 patients were scanned before (“pre9h”) and 24 patients after (“post9h”) the 9h threshold. 71 had intracranial proximal arterial occlusions (PAO), defined as ICA, M1, M2, A1, or A2 occlusion, and 29 (NPAO) did not. DWI and mean transit time (MTT) lesion volumes were measured, and mismatch size was computed as a percentage of the size of the MTT lesion. Results: 75/86 (87%) of pre9h and 17/24 (71%) of post9h patients had at least a 20% mismatch. Among NPAO patients, the percent mismatch was smaller in post9h than in pre9h patients (p⫽0.02, 2-tailed t-test), with a significant negative correlation between percent mismatch and time as a continuous variable (r⫽-0.37, p⫽0.02). However, among PAO patients, there was no significant correlation between percent mismatch and time (r⫽0.14, p⫽.24), and no significant difference in mean percent mismatch between pre9h and post9h patients (p⫽0.28). The mean percent mismatch at different times is shown below. Conclusion: Most of our patients scanned within 24 hours demonstrated a substantial diffusion-perfusion mismatch. Among patients without proximal arterial occlusion, percent mismatch decreased as a function of the time since the patient was last seen without symptoms. However, no such time-related decrease was seen among patients with proximal arterial occlusive lesions that may be accessible to intra-arterial intervention. This apparent persistent penumbra may reflect prolonged collateral support of larger regions of at-risk tissue. Further study is warranted. P42 Combined Perfusion and Diffusion MR Imaging Can Improve Diagnostic Yield in Hemispheric TIA. Michael Mlynash, Dept of Neurology and Neurological Sciences, Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA; David C Tong, California Pacific Med Cntr, Comprehensive Stroke Care Cntr and Cntr for Stroke Rsch, San Francisco, CA; Maarten G Lansberg, Jean-Marc Olivot, Irina Eyngorn, Stephanie Kemp, Dept of Neurology and Neurological Sciences, Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA; Michael E Moseley, Dept of Radiology, Lucas Magnetic Resonance Spectroscopy and Imaging Cntr, Stanford Univ Med Cntr, Stanford, CA; Gregory W Albers; Dept of Neurology and Neurological Sciences, Stanford Stroke Cntr, Stanford Univ Med Cntr, Stanford, CA Objective Transient ischemic attacks are strong predictors of future stroke. However, current diagnostic criteria for TIA are not sensitive and specific. Acute diffusion weighted imaging (DWI) lesions can be detected in about one third of TIA patients. The yield of MR perfusion imaging (PWI) for detecting ischemic lesions in TIA patients has not been established. Methods In this prospective NIH-funded study, DWI and PWI images were performed within 48 hours of symptom onset in 43 consecutive patients admitted with suspected hemispheric TIAs (symptom duration less than 24 hours). Mean transit time perfusion maps (PWI) and DWI Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 580 Stroke Vol 39, No 2 February 2008 images were assessed for the presence and location of lesions by two independent raters, blinded to clinical features. MRA scans were assessed for the presence of an arterial lesion in the ICA or intracranial vessels by a third reader. Correspondence of the lesions with the suspected clinical localization and baseline characteristics was assessed. Clinical features predictive of a positive PWI lesion were determined in a multivariate logistic regression model. Results PWI and DWI lesions were detected in 33% and 35% patients respectively. An isolated PWI lesion was present in 16%, and both a DWI and a PWI lesion were present in 16%. The combined yield for identification of either a PWI and/or a DWI lesion was 51%. Correspondence with the clinically suspected hemisphere was 93% for DWI and 86% for PWI lesions. Both of the patients who had PWI lesions in a clinically silent hemisphere also had acute DWI lesions in the same region. Both raters agreed on the existence and location of PWI lesions in 81% of the patients (Kappa⫽0.58). Inter-rater agreement regarding the presence and location of DWI lesions occurred in 98% of the cases (Kappa⫽0.95). Fourteen percent of the patients had an MRA lesion in the symptomatic hemisphere or ipsilateral ICA; ipsilateral MRA lesions were present in 36% of the patients with a PWI lesion and 20% of the cases with DWI lesions. Obtaining the MRI scan within 12 hours of symptom resolution and multiple symptomatic episodes were the only clinical features predictive of a positive PWI lesion. There was no statistically significant association of symptom type or duration with presence of a perfusion abnormality. Conclusion DWI in combination with early PWI can detect cerebral ischemic lesions in approximately half of all patients who present with a suspected hemispheric TIA. MR imaging has the potential to substantially improve the accuracy of TIA diagnosis. P43 Sodium MRI Intensity Evolves Over Time in Human Acute Ischemic Stroke. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Muhammad S Hussain, Robert W Stobbe, Yusuf A Bhagat, Derek Emery, Kenneth S Butcher, Dulka Manawadu, Nasir Rizvi, Perkash Maheshwari, Ashfaq Shuaib, Christian Beaulieu; Univ of Alberta, Edmonton, Canada Background: The time of onset of ischemic stroke is a critical determinant for acute therapy. Presently, there are no imaging methods that determine the time of stroke onset within the acute time frame (⬍7 days). Although correlations between relative signal intensity within the ischemic lesion and time of onset have been demonstrated with sodium magnetic resonance imaging (MRI) in animal models, this correlation has not been demonstrated in acute human stroke. The purpose of this study is to determine whether relative signal intensity measured within the ischemic lesion on sodium MRI evolves with time following stroke onset in humans. Methods: Fifteen patients (58 ⫾ 16 years) with clearly defined time of onset were scanned between 4 - 61 hours post symptom onset. Several patients were scanned more than once, yielding 24 time points. A standard stroke imaging protocol was acquired at 1.5 Tesla (T), followed by sodium MRI at 4.7T, where whole brain sodium images were acquired in 10 minutes. Relative signal intensity within each lesion was measured with respect to the contralateral side. Results: Representative sodium MRI images from one patient at two different time points are shown (figure). The sodium image quality was sufficient to elucidate each lesion (lesion volume range 1.7 - 93 mL), and the total imaging protocol was tolerated well by all patients. Relative signal intensity (mean ⫾ 95% CI) measured within the lesion on sodium MRI was increased 5 ⫾ 3 % by 4 - 7 hours (n ⫽ 5), 37 ⫾ 9 % by 13 - 29 hours (n ⫽ 10), and 61 ⫾ 12 % by 36 - 61 hours (n ⫽ 9) (p ⬍ 0.01). Conclusion: Good quality sodium MRI images were acquired from acute stroke patients at 4.7T. The relative signal intensity within the ischemic lesions measured on these images evolved with time following stroke onset. For this reason, sodium MRI may be a useful imaging tool in acutely determining time of onset in ischemic stroke patients. from the extracorporeal circulation circuit, and hypoperfusion of brain. Acute ischemic stroke and cerebral air embolism can be detected on diffusion-weighted imaging (DWI) and T2*-weighted gradient-echo imaging (GRE), respectively. Objectives: In this study, we evaluated the frequency and pattern of air emboli on GRE and acute ischemic stroke on DWI. Moreover, we investigated the factors associated with new lesions on DWI and GRE. Methods: We conducted a prospective study of patients who underwent cardiac valve replacement surgery. We checked baseline characteristics (demographic features, stroke risk factors, National Institutes of Health Stroke Scale (NIHSS) scores, and modified Rankin Scale (mRS) scores), operative factors (atheroma detected on ascending aorta, duration of operation, postoperative atrial fibrillation), and MRI (including DWI, GRE, and MR angiography) before surgery. Three days after operation, we followed up NIHSS, mRS, DWI and GRE. At 3 months after operation, we scored mRS again. We defined any new lesions on DWI as ischemic stroke, and any new low signal lesions on GRE as air emboli. We analyzed the relationship between new lesions on MRI and baseline characteristics, operative factors, and preoperative imaging characteristics. Results: Among 44 consecutive patients who were screened, 40 patients were enrolled and 19 completed all preoperative and postoperative tests. Among 19 patients, 10 patients (52.6%) developed 20 air emboli on postoperative GRE, and 1 patient (5.3%) showed new infarct on postoperative DWI. There were no significant factors associated with development of air embolism. Two patients developed new clinical events after surgery. One patient developed generalized seizure accompanied by confusion and mild facial palsy several hours after surgery. MRI performed 2 days after surgery showed large ischemic cortical lesions on DWI in right middle cerebral artery territory and 8 air emboli lesions on GRE scattered in bilateral supratentorial and infratentorial areas. The other patient developed transient irritability and confusion after surgery. Postoperative DWI did not show any new lesion, but GRE revealed four air emboli in supratentorial and infratentorial areas. Conclusions: Air emboli documented on GRE were more frequent than new ischemic lesions on DWI after cardiac valve replacement surgery. Further studies are needed to reveal the clinical significance of these findings. P45 Complications of Modern Diagnostic Cerebral Angiography in an Academic Medical Center. Johanna T Fifi, Philip M Meyers, Sean D Lavine, Virgnia Cox, Lynn Silverberg, Sundeep Mangla, John Pile-Spellman; Columbia Univ, New York, NY Background: Catheter-based cerebral angiography has steadily improved over the past several decades. Simultaneously, non-invasive imaging of the cerebral vasculature, predominantly using CT and MR, has increased in accuracy and now supplants catheter-based angiography in many circumstances. Catheter-based angiography is now most commonly used for treatment planning, either endovascular or open surgical procedures. To remain a viable diagnostic modality, catheter-based angiography must not represent a significant source of patient morbidity. We report the complication rate of catheter-based cerebral angiography performed by neurointerventional specialists at a major academic medical center. Methods: From July 2001 through June 2007, 3417 catheter-based cerebral arteriograms were performed at a large academic institution. Data were prospectively acquired over a 6 year period according to institutional policy and NYPORT criteria. Data collected included patient age, sex, indication for procedure, operator, and nature of symptomatic or asymptomatic adverse event, including need for treatment. Results: Among 3417 diagnostic cerebral angiograms performed over this 6 year period, there were 11 (0.32%) clinical complications. One (0.03%) patient had MRI detected stroke with no apparent clinical deterioration. Iatrogenic dissections of 5 (0.15%) arteries occurred with one patient requiring immediate stent placement due to angiographic flow impairment. No patient developed neurological symptoms. Non-neurological complications occurred in 5 (0.15%) patients who suffered puncture site related complications: 1 femoral abscess in the setting of repeat angiography through a groin hematoma and use of a arterial closure device, 2 occlusions of the femoral artery with leg ischemia requiring surgical revascularization also associated with groin closure devices, 1 dissection with pseudoaneurysm formation requiring percutaneous thrombin injection, and 1 retroperitoneal hemorrhage requiring transfusion. There were no deaths. Conclusions: Modern catheter-based cerebral angiography performed by experienced neurointerventionalists is associated with a very low complication rate of 0.32% even in a highly complex, frequently symptomatic patient population. Non-neurological complications were associated with the use of arterial closure devices. P46 CT Perfusion Estimation of Penumbra During Acute MCA Strokes in Patients Receiving Thrombolytic Treatment: Does the Perfusion Package Matter? David Clopton, Ansaar T Rai, Jeffrey S Carpenter; West Virginia Univ, Morgantown, WV P44 Cerebral Air Embolism and Acute Ischemic Stroke Detected on MRI after Cardiac Valve Replacement Surgery. Sang-Beom Jeon, Jae Won Lee, Kyoung-Sun Kim, Cheol Hyun Chung, Hyun Song, Suk Jung Choo, Eun-Kyung Kim, Dong-Wha Kang; Asan Med Cntr, Seoul, Republic of Korea Background: Stroke is major neurologic complication after cardiac valve replacement surgery. The etiology of postoperative stroke has been suggested as the macroembolization from the heart or ascending aorta (including air emboli, atheromatous debris, and fat), the microemboli Objective: To compare standard CT perfusion parameters in acute middle cerebral artery strokes as determined by two perfusion analysis packages and to assess the clinical relevance of the estimations of penumbra size. Methods: CT perfusion imaging was performed on 17 patients with documented M1 or M2 MCA occlusions prior to thrombolytic therapy. All strokes were confirmed by follow-up imaging. Infarct core was defined for the purposes of this comparison as the zone of perceptible CBV decrease within a region of CBF decrease as noted on color maps (rainbow type) with dynamic range of 0 to 10 for CBV (ml/100g) and 0 to 100 for CBF (ml/100g/min). Free hand regions of interest were drawn about the region of CBV and CBF decrease compared to the contralateral side. The average of the parametric indices of CBF and CBV were recorded within these regions. The percentage of penumbra remaining was then Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations determined by 1 - (CBVarea / CBFarea) * 100. These steps were performed retrospectively using GE CT Perfusion 2 software (ver. 2.6.6i) and Vital Images’ Vitrea 4.0 CT Perfusion. Results: There are significant differences (p ⬍ 2 x 10 -6) between the mean value of CBV within the infarct core as determined by the GE Perfusion 2 software (0.80 ⫹/- 0.30) and the Vital Perfusion software (1.8 ⫹/- 0.5). The mirrored values in the non-ischemic hemisphere are significantly different (p ⫽ 0.016) with GE value of 2.3 ⫹/- 0.9 and Vital value of 3.6 ⫹/- 1.5. The ratio of CBVcore / CBVmirror differed as well (p ⫽ 0.001). With respect to estimated residual penumbra, the Pearson Coefficient is 0.77 indicating a strong linear correlation between the software. The Vital software uniformly estimates the penumbra to be greater than that estimated by GE Perfusion 2. Conclusions: The two analysis packages differ significantly in their quantitative characterization of the infarct core. Yet when the parametric maps of CBV and CBF are compared and the penumbra estimated, there is a strong linear correlation between the two packages. Of the 17 cases perhaps one patient’s treatment may have differed between the two packages (GE⫽15, Vital⫽84) if basing treatment decisions on physiologic parameters alone assuming thrombolytic treatment for patients with at least 1/3 of the abnormally perfused area estimated as penumbra. Does it matter? It depends. 581 in the general population, effective prevention and treatment of PFO-related stroke requires refining and developing clinical criteria for accurate diagnosis and risk assessment. In this prospective cohort population study, we investigate the association of gender and age with respect to PFO-related strokes. Methods: From 346 consecutive patients who presented to the Cardio-Neurology Clinic specializing in PFO assessment at Massachusetts General Hospital between July 2005 and July 2007, 102 young patients (age 21–55) were determined to have PFO-related strokes. In this group of patients with PFO-related strokes, 96% had positive imaging findings of strokes correlating to the clinical assessment and 100% were determined by 2 vascular neurologists to have had a PFO-related stroke. In this group, 52% were women, equally distributed with respect to age. Men and women had similar baseline risk factors such as hypertension (HTN), diabetes (DM), hyperlipidemia (HL), smoking and alcohol intake (p⫽NS). However, women were more likely than men to have a history of migraine (54% vs. 20% p⬍0.00001), positive pelvic venous abnormalities (20% vs. 8.3% p⬍0.05), and higher ESR at presentation (p⬍0.005), while men had higher percentages of precipitating a stroke with Valsalva maneuvers, such as weight lifting (24% vs. 5% p⬍0.01). When the entire group was dichotomized using the median age into younger (21– 45) vs. older (46 –55) age groups, conventional stroke risk factors (HTN, DM, HL, sedentary lifestyle) increased with age; however, the incidence of migraine and of obesity remained similar in both age groups (p⫽NS). Conclusions: In patients whose strokes are attributable to PFO, women were more likely than men to have migraines, higher ESR, and pelvic venous findings on imaging. While older patients predictably had more conventional risk factors, age did not change the incidence of migraine or obesity in this cohort. These findings suggest that while the modification of certain risk factors (e.g. obesity) is “ageless,” an individualized evaluation and stroke prevention strategy is needed with respect to gender, as the pathophysiology of PFO-related stroke may differ between men and women. Further studies in a larger cohort are underway to confirm these findings. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P49 Dwi-mri Study In Patients With Mild Ischemic Stroke. P47 Stroke Mechanisms Of Intracranial Artery Dissection. Hideki Okatsu, Hideki Matsuoka, Kazunori Toyoda, Junji Kasuya, Hiroaki Naritomi, Kazuo Minematsu; National Cardiovascular Cntr, Suita. Osaka, Japan Objectives: Previous studies indicated that carotid artery dissections produce ischemic stroke mainly by an embolic mechanism, because of a high incidence of microembolic signals on ultrasound in the middle cerebral artery (MCA) distal to the dissection and of the frequent localization of infarcts in the cortex rather than in watershed areas. In Japanese patients, dissections occur more commonly in intracranial arteries than in the extracranial carotid arteries. However, the stroke mechanisms of intracranial artery dissections have not fully been elucidated. The objective of this study was to investigate stroke mechanisms of intracranial artery dissections. Methods: Of 1874 patients who were admitted to our hospital within two weeks after the onset of ischemic stroke between 2001 and 2007, 34 patients were diagnosed as having intracranial artery dissections as a cause of ischemic stroke. Diagnosis of the dissection was principally made based on findings of the digital subtraction angiography. Infarcted lesions were assessed using MRI scans including diffusion weighted imaging (DWI), unless contraindicated, with regard to the anatomical localization (involving the cortex or not), multiplicity, and topographical relationship of the infarcts with the dissections (if the infarct lay close to or remote from the dissected artery). Results: The dissections were identified in the intracranial vertebral artery (VA) for 10 patients, posterior inferior cerebellar artery (PICA) for 3, basilar artery (BA) for 5 (3 patients had VA dissections simultaneously), posterior cerebral artery (PCA) for 5, MCA (M1) for 4, and anterior cerebral artery (ACA) for 7. The patients having PCA dissections were younger than the others (30.8⫾6.6vs.54.2⫾2.8 years, p⫽0.003), and did not have traditional risk factors including hypertension, diabetes mellitus, and dyslipidemia. Cortical infarcts were more common in patients with supratentorial artery dissections (PCA, MCA, ACA, 16 patients, 100%) than in those with infratentorial artery dissections (VA, PICA, BA, 7 patients, 39%, p⬍0.001). Infarcts were multiple in 8 patients (50%) with supratentorial dissections and in 6 (33%, p⫽0.324) with infratentorial dissections. Infarcts were remote from the dissected artery in 11 patients (69%) with supratentorial dissections and in 8 (44%, p⫽0.154) with infratentorial ones. Conclusions: Stroke mechanisms of intracranial artery dissections may vary among the dissected arteries. As compared to infratentorial artery dissections, infarcts with supratentorial dissections are more suggestive of embolic mechanisms. P48 Gender and Age Associated Clinical Characteristics of Young Patients with Patent Foramen Ovale (PFO) Related Strokes. MingMing Ning, Igor F Palacios, Ignacio Inglessis, Mary Ellen McNamara, Mary Lievens, Zareh N Demirjian, Ignacio Cruz-Gonzalez, Massachusetts General Hosp/Harvard Med Sch, Boston, MA; David McMullin, New York Univ, New York, NY; Pablo Rengifo, Ferdinando S Buonanno; Massachusetts General Hosp/Harvard Med Sch, Boston, MA Strokes related to patent foramen ovale (PFO) have been reported to be the etiology for up to 40% of cryptogenic strokes in the young. However, given the high baseline prevalence of PFO Angel Ois, Elisa Cuadrado-Godia, Jordi Jimenez-Conde, Claustra Pont, Gracia Cucurella, Meritxell Gomis, Xavier Perich, Alberto Solano, Jaume Roquer; Hosp del mar, Barcelona, Spain Background The presence of acute ischemic lesion in the diffusion-weighted-imaging (DWI) has been related with a high risk of recurrence in patients with transient ischemic attack. The aim of our study was to determine if the presence of multiple acute lesions in patients with mild stroke are associated with aetiology, vascular risk factors, recurrence rate and outcome at six months. Patients and methods Prospective cohort of patients admitted to stroke unit with first ischemic stroke of mild severity (NIHSS 1–7). The DWI-MRI study was performed during hospitalization by a trained radiologist blind for patient’s data. Stroke severity was measured using NIHSS. Poor outcome was defined as moderate-severe disability or death (modify Rankin Scale (mRS) ⬎2) at six months. The relationship between radiological data stroke severity, vascular risk factors, aetiology, recurrence rate and outcome was analyzed using logistic regression model with 95% CI. Results The final cohort was 218 patients. NIHSS median (q1-q3) 3 (2–5), mean age (SD) 69.9 (12.8). The DWI study showed multiple acute lesions in 64 patients (29.4%). Presence of multiple lesions was independently associated with cardioembolic stroke (adjusted OR⫽12.81; 95%CI 2.96 –55.52), large-vessel disease (adjusted OR⫽8.41; 95%CI 2.80 –25.22), and previous TIA (adjusted OR⫽4.00; 95%CI 1.53–10.51). Stroke recurrence was found in 29 patients (16 patients 55.2% with multiple lesions) whereas 49 patients (22.5%) had poor outcome. The presence of multiple lesions in DWI independently predicted stroke recurrence [adjusted OR⫽2.49; 95%CI (1.04 –5.97)] but not poor outcome [adjusted OR⫽1.49; 95%CI (0.72–3.07)]. Conclusion Multiple acute ischemic strokes in DWI are found in a considerable rate of patients with mild stroke. The presence of multiple acute lesions can help to identify stroke aetiology and also patients with a higher recurrence risk. P50 Diagnostic Accuracy of Transcranial Color Flow Imaging against Magnetic Resonance Angiography in Japanese Patients with Ischemic Stroke. Hidetaka Mitsumura, Kiyoharu Inoue, Dept of Neurology, Jikei Univ, Tokyo, Japan; Hiroshi Furuhata; ME Lab, Jikei Univ, Tokyo, Japan Background and Purpose; In order to increase availability of transcranial color flow imaging (TC-CFI) for ischemic stroke, we aimed to evalate the diagnostic accuracy of TC-CFI compared with magnetic resonance angiography (MRA) in Japanese patients with ischemic stroke. Methods; We examined TC-CFI for one hundred fifty one cases of Japanese patients with ischemic stroke (⬍14 days from onset) from bilateral temporal bone window without echo-contrast agents, and evaluated the rate of recordable CFI focused on middle cerebral artery (MCA; M1 and M2) and posterior cerebral artery (PCA; P1 or P2). We assigned the recordable conditions to three categories (A; all arteries were recordable, B; some arteries were recordable, C; non - recordable), and then analyzed the proportion of category in each age group (20 – 49, 50 –59, 60 – 69, 70 –79, and over 80y.o.) and gendor group separately. In only patients of group A, the findings of TC-CFI were compared with those of MRA. The accuracy was calculated by a paired statistical analysis. Results; The 151 patients (104 man and 47 female, mean age 68.6⫾12.9 y.o.) were separated to 75 cases (49.7%) in group A, 41 cases (27.1%) in group and 35 cases (23.2%) in group. The proportion of group C was significantly higher in females than in males (p⬍0.0001), and increased with age gradually. Particularly, the detectability of the group over 80 y.o. was significantly lower than the other groups. In 71 patients of group A who underwent MRA, the diagnosis of TC-CFI was adequately same enough Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 582 Stroke Vol 39, No 2 February 2008 to those of MRA with the accuracy of 90.7% (sensitivity; 86.7% and specificity; 91.6%). Conclusion; TC-CFI has the same diagnostic ability as MRA in patients with ischemic stroke, who have sufficient bilateral echo windows. However, it is necessary to improve the detectability of TC-CFI in Japanese patients with poor echo windows. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P51 Cardiovascular MRI in Detection and Measurement of Aortic Atheroma in Stroke/TIA Patients. Souvik Sen, Jennifer W Simmons, David Y Huang, Susan E Wilson, James Barnwell, William B Hyslop, Alan L Hinderliter; Univ of North Carolina, Chapel Hill, NC Background: Aortic atheroma (AA; ⱖ4 mm) is an independent risk factor for new and recurrent stroke. AA ulceration and mobility are associated with an increased risk for brain embolism. Transesophageal echocardiography (TEE) is the gold standard for detection and measurement of AA in stroke/TIA patients. Cardiovascular MRI (cMRI) could be an alternative, non-invasive imaging modality for stroke/TIA patients. Objective: To assess the accuracy and correlation of AA detected and measured by cMRI versus TEE in patients with recent stroke/TIA. Methods: Stroke/TIA patients undergoing TEE as a part of their stroke workup consented to a protocol-mandated cMRI performed on a 1.5 T magnet. The protocol included an axial non-breathhold EKG-gated dual-echo spin echo MRI of the thoracic aorta (TR/TE1/TE2⫽900/ 29/69) and a contrast-enhanced breathhold 3D gradient-echo image of the thorax (flip/TR/TE⫽ 12/4.0/1.71). AA was assessed using spin-echo and 3D images. Maximum plaque thickness, ulceration (ⱖ2 mm) and mobility were assessed in the proximal (ascending and proximal arch) and distal (distal arch and descending) segments of thoracic aorta, by a cardiologist (TEE) and a radiologist (cMRI), blinded to one another’s readings. Results: Twenty-two stroke/TIA patients (mean age 68 years, 55% males) had TEE and cMRI assessment for AA. There was good correlation bewteen cMRI and TEE in measurement of plaque thickness in the proximal segments (R⫽0.93, p⬍0.0001) and the distal segments (R⫽0.81, p⬍0.0001) of the AA. cMRI had a high degree of accuracy in detecting measurable AA (ⱖ1 mm) in the proximal segments (sensitivity 90%, specificity 100%), as well as the distal segments (sensitivity 67% , specificity 100%). cMRI also had a high degree of accuracy in detecting significant AA (ⱖ4 mm) in proximal segments (sensitivity 71%, specificity 93%), as well as distal segments (sensitivity 71%, specificity 100%). However, cMRI was able to identify proximal AA ulceration in 89% and in 64% in the distal segments (Figure). AA mobility was not assessed by MRI using this protocol. Conclusions: The study shows a high degree of accuracy and correlation of AA detected and measured by cMRI as compared to TEE in patients with recent stroke/TIA. cMRI has limitations in detection of AA ulceration, and protocols assessing AA mobility need to be developed. P52 Evaluation of the Vertebral Artery Using Transoral Carotid Ultrasonography. Rieko Suzuki, Ryoichi Otsubo, Kazunori Toyoda, Hiroyuki Kawano, Sohei Yoshimura, Kayoko Kawase, Masatoshi Koga, Kazuyuki Nagatsuka, Hiroaki Naritomi, Kazuo Minematsu; Cerebrovascular Div, Dept of Medicine, National Cardiovascular Cntr, Suita, Japan Objectives: The transoral carotid ultrasonography (TOCU) is used to demonstrate the distal internal carotid artery which conventional ultrasonography cannot examine. It has not been clarified whether TOCU can also evaluate the distal vertebral artery (VA). The goal of this study was to solve this question. Methods: The study subjects consisted of 45 patients (64⫾13 years in age, 40 men) with cerebrovascular disease. The VA was visualized using conventional angiography in 29 patients, magnetic resonance angiography in 43, and computed tomographic angiography in 17. TOCU examinations were performed with a color Doppler flow imaging system equipped with the 6-MHz convex array transducers, originally designed for transrectal use. A probe was inserted transorally, touching the tip to the pharyngeal posterolateral wall. We then attempted to detect the VA and measure its diameter and flow velocities using principal images obtained by TOCU. The results were compared with those by conventional ultrasonography using the Student’s t-test and linear-regression analysis. Results: In all 90 VAs, 13 vessels were ineligible for the analysis because of occlusion or stenosis on the angiographic studies. Four VAs could not be examined because of gag reflex. Although TOCU identified the remaining 73 VAs, 6 VAs were excluded from the flow velocity analysis because of improper angles of insonation. On TOCU, VAs were visualized at a depth of 23.9⫾5.9mm from the pharyngeal wall as a vertical linear vessel between almost two transverse processes of the cervical spine, mainly at the height of the C2 level. The diameter was 3.7⫾1.1mm on TOCU and 3.9⫾0.7mm on conventional US. The peak systolic (Vmax), mean (Vm), and end-diastolic flow velocities (Vmin) of the VAs were significantly higher on TOCU than on the conventional US (61.5⫾29.3 vs. 46.8⫾16.9 cm/s, 34.0⫾15.9 vs. 26.0⫾10.6, 21.1⫾11.7 vs. 15.3⫾7.9, respectively, all p⬍0.001). Between the two US techniques, the correlation coefficients of Vmax, Vm and Vmin were 0.91, 0.92 and 0.90, respectively (all p⬍0.001). Conclusions: TOCU can visualize the distal VA mainly at the height of the C2 level. The flow velocities were significantly higher on TOCU than on the conventional US, but their correlations were excellent. TOCU may be useful for the evaluation of morphology and flow dynamics of the distal extracranial VA. P53 Diameter of The Basilar Artery May Be Associated With Neurological Deteriorarion in Acute Pontine Infarction. Junya Aoki, Yasuyuki Iguchi, Takeshi Inoue, Kensaku Shibazaki, Shinji Yamashita, Kazumi Kimura; Kawasaki Med Sch, Kurashiki, Japan Purpose: 20% of patients with acute pontine infaction, especially branch atheromatous disease (BAD), have neurological deterioration at acute phase of stroke. However, it has still unknown about predictors for neurological deterioration in pontine infarction. The aim of present study is to investigate the predictive factors associated with neurological deterioration in pontine infarction. Methods: We consecutively enrolled patients with acute pontine infarction without BA occlusion. We performed diffusion weighted magnetic resonance imaging (DWI) twice, on admission and after 7days of onset and measured the ischemic volume. Magnetic resonance angiography was also examined to identify to measure a diameter of internal carotid artery (ICA) and basilar artery (BA), and BA diameter/ ICA diameter (BA/ICA ratio) were calculated in each patient. When ischemic lesion extended to third ventricle, we diagnosed one as BAD. We defined neurological deterioration as worsening of NIHSS score 2 points or more for one week. All patients were classified based on the presence of neurological deterioration during first 7 day of onset into two groups, deteriorated group (D group) and no deteriorated group (ND group). Clinical characteristics were compared between two groups. Results: 65 patients (age; 71.0 ⫾ 9.9 years, men; 46) were enrolled into the present study. BAD was found in 32 (49.2%) of 65 on initial DWI and 38 (58.4%) of 65 on follow up DWI. Neurological deterioration occurred 11 (16.9%) in 65 patients. Initial infarct volume was 0.44 ⫾ 0.19cm3 in D group and 0.32 ⫾ 0.35cm3 in ND group, respectively (p⫽0.016). In follow-up DWI study, 10 (90.9%) of 11 patients in D group comprised BAD and 29 (53.7%) of 54 patients in ND group had BAD (p⫽0.016). BA/IC ratio was 0.76 ⫾ 0.13 in D group and 0.66 ⫾ 0.17 in ND group (p⫽0.014). Optimal cut-off infarct volume on initial DWI and BA/IC ratio to differentiate D from ND group was 0.37cm3 (sensitivity of 74%and specificity of 73%) and 0.72 (sensitivity of 76% and specificity of 73%), respectively. Multivariate regression analysis demonstrated that initial infarct volume of 0.37cm3 or more (OR 7.78, 95%CI 1.10 –54.78, p⫽0.039) and BA/IC ratio of 0.72 or more (OR 7.98, 95%CI 1.46 – 43.67, p⫽0.017) were independent factors associated with neurological deterioration. Conclusion: Diameter of the basilar artery may be associated with neurological deterioration in acute pontine infarction. P54 Can CT Angiography of Great Vessels and Cervical Carotids Predict Micro-Embolic Signals on Transcranial Doppler? Firosh Khan, Youngbin Choi, Univ of Calgary, Calgary, Canada; Maher Saqqur, Univ of Alberta, Edmonton, Canada; Ali Al-Khathaami, Pranshu Sharma, Eileen Stewart, Caroline Stephenson, Andrew M Demchuk; Univ of Calgary, Calgary, Canada Purpose: Significance of atheromatous disease of great vessels as a potential source of cerebral embolism varies. Though CT Angiography (CTA) delineates structural details, Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Transcranial Doppler (TCD) provides direct information regarding cerebral embolization. We aimed to define the variables in CTA of great vessels predicting micro-embolic signals (MES) in TCD. Methods: We analyzed 1hour TCD emboli-detection monitoring studies of patients with anterior circulation cerebral ischemia in a prospectively maintained CTA database, and correlated MES with great vessel and cervical carotid CTA features. Standard Power M-mode Doppler apparatus with head frame (Spencer Tech, Inc; PMD100 mol/L) was used and bilateral middle cerebral arteries insonated at 55– 65mm depth. Studies from May’02-Dec’06 were reanalyzed jointly by two neurosonologists to count MES in PMD and/or spectrogram. CTAs of aortic arch, great vessels and cervical carotids were done on a 66-slice multi-row-detector CT scanner. Images were analyzed jointly by a stroke-neurologist and a neuroradiologist, to note size/shape/surface/density/calcification of plaques, degree of internal carotid artery (ICA) stenosis and presence of intra-luminal thrombus. MES positivity and count were correlated with CTA features using univariate analysis, and variables found significant tested in a multivariate model. Results: There were 243 emboli-monitoring studies on 198 subjects (151 males; mean age 66.2 years, range 16 –94), done at median of 19 hrs (IQR 12 hrs-4 days) after ischemic event and one day (IQR 0 –3 days) after CTA. Fifty two studies in 45 patients detected MES (median 3 MES/study, range 1– 87). Univariate analysis showed plaque-length/thickness, stenosis degree and intraluminal thrombus in ICA as the CTA features predicting MES. None of the features of common carotid arteries, brachiocephalic artery or aortic arch was significantly related. On multiple-logistic-regression analysis, intra-luminal thrombus [RR 5.4 (CI951.8 – 15.8), p⫽.002] and ICA stenosis remained significant. Ipsilateral 50 –70% and 70 –90% ICA stenoses had odds of 3.6 (CI951.5– 8.7, p⫽.004) and 9.3 (CI953.7–23.3, p⬍.01) respectively for MES, whereas 30 –50% stenosis (p⫽.42) and total occlusion (p⫽.65) had no predictive value. When number of MES was analyzed as dependent variable in stepwise multiple-linearregression, each 1mm increase in ICA plaque-width raised MES count by 0.8 (p⫽.004), while presence of intraluminal thrombus increased the count by 4.5 (p⫽.007). Conclusions: Out of various quantitative and qualitative characteristics of aortic arch, great vessels and cervical carotids in CT Angiography, only intraluminal thrombus in ICA and moderate to severe degrees of ICA stenosis predict TCD-emboli in anterior circulation cerebral ischemia. Intraluminal thrombus and ICA plaque-width are principal determinants of quantity of emboli. P55 Plasma Brain Natriuretic Peptide as a Predictor For Appearance of Atrial Fibrillation in Stroke Patients With Sinus Rhythm on Admission. Yoko Okada, Kensaku Shibazaki, Kenichirou Sakai, Junya Aoki, Yuka Terasawa, Kazuto Kobayashi, Shinji Yamashita, Masao Watanabe, Junnichi Uemura, Noriko Matsumoto, Takeshi Inoue, Yasuyuki Iguchi, Kazumi Kimura; Kurashiki, Okayama, Japan Background Atrial Fibrillation (AF) is a major risk factor for ischemic stroke. Acute stroke patients with sinus rhythm on admission sometimes have appearance of AF after admission. Patients with AF have been reported to have high level of plasma brain natriuretic peptide (BNP). Therefore, we made a hypothesis that high BNP on admission indicated that stroke patients with sinus rhythm on admission had appearance of AF after admission. The aim of the study was to investigate the hypothesis. Methods Between March 2006 and May 2007, consecutive patients with acute ischemic stroke and TIA with sinus rhythm on admission within 24hours of onset were prospectively enrolled. We measured plasma BNP on admission. All patients routinely underwent electrocardiography (ECG) on admission and 24-hour Holter ECG within 7 days after admission. Patients with AF on admission, coronary heart disease, dialysis-dependent chronic renal failure, and mechanical prosthetic valve were excluded from the study because plasma BNP increases in such patients. We divided patients into two groups; AF group had appearance of AF after admission, and Non-AF group had no appearance of AF. Results 173 patients (54 female; mean age, 71⫾12 years) were enrolled into the study. AF was observed in 19 patients (AF group). Age (77 years vs. 70 years, p⫽0.01), female (56% vs. 28% p⫽0.04), NIHSS score on admission (mean 8.5 vs. 4.3, p⫽0.01), modified Rankin Scale on discharge (mean 3.1 vs. 1.8, p⫽0.01), and D-dimer (mean 1.5 vs. 1.4, p⫽ 0.02), were higher in AF group than non-AF group. Mean plasma BNP levels were significantly higher in AF group than non-AF group (306.4 pg/ml vs. 65.6 pg/ml, p⬍0.01). The cut-off value, sensitivity, and specificity of BNP levels to distinguish the AF from the non-AF group were 80 pg/ml, 77.8%, and 76.7%, respectively. Multivariate regression analysis demonstrated that plasma BNP over 80 pg/ml was an only independent factor associated with detection of AF (odds ratio 6.7, 95% CI; 1.86 to 24.1, p⫽0.01) Conclusion Plasma Brain Natriuretic Peptide can predict an appearance of AF in acute stroke patients with sinus rhythm on admission. 583 non-H group did not have. We studied clinical characteristics including the presence of microbleeds between 2 groups. Results ; Hemorrhagic infarction was observed in 111 (30.0%) patients (31 patients in symptomatic and 80 in asymptomatic) on follow up T2* weighted imaging. Microbleeds was more frequently seen in non-H group than H-group (60.2% vs. 45.1%; p⫽0.007). The significant differences between two groups were observed following factors; (hyperlipiemia; 20.4% for H group vs 33.5% for Non-H group, p⫽0.013, age; 75.7⫾12.0 vs 71.3⫾12.9, p⫽0.002, atrial fibrillation (AF); 52.0% vs 26.9%, p⬍ 0.0001, NIHSS on admission; 11.7⫾7.8 vs 6.1⫾6.6, p⬍ 0.0001). There were no differences in following factors; gender, smoking, hypertension, diabetes mellitus, diastolic and systolic blood pressure. Multivariate analysis demonstrated that NIHSS score of 10 or more on admission (OR 2.7, 95%CI 1.5 to 4.8, p⫽0.0006) and AF (OR 1.9, 95%CI 1.1–3.4, p⫽0.02) were independent factors associated with hemorrhagic infarction. However, microbleeds were a negative independent factor associated with hemorrhagic infarction (OR 0.5, 95%CI 0.3 to 0.9, p⫽0.02). Conclusions ; Microbleeds on MRI T2* imaging on admission could not predict hemorrhage infarction in acute ischemic stroke. P57 Robustness of Prognostic Models to Interrater Variability in Delineating Final Infarct Lesion. Lars R Ribe, Kim Mouridsen, Anders Neumann, Niels Hjort, Kristjana Jonsdottir, Leif Østergaard; Cntr of Functionally Integrative Neuroscience, Dept of Neuroradiology, Aarhus Univ Hosp, Aarhus, Denmark Introduction: Perfusion and diffusion MR images are often used in acute stroke to assess salvable tissue. Recently, multiparametric statistical models have been introduced, assessing probability maps of tissue outcome at a voxel level by integrating acute perfusion, diffusion and structural images, based on acute and expert classified follow-up (FU) images from previous patients. The success of predictive algorithms, however, depends on correct delineation of FU in the training data and performance may therefore be influenced by interrater variability. Here we compare the influence of both FU modality (T2 and FLAIR) as well as interrater variability on the predictive performance of the common GLM algorithm. Materials and methods: Data from 14 patients with acute stroke was included. Nine experienced neuroradiologists manually outlined final infarct regions on 3-month follow-up FLAIR and T2 images, respectively. Two algorithms were trained for each observer by using either T2 or FLAIR as FU resulting in a total of 2x9 algorithms. Infarct predictions calculated by an algorithm was compared voxel-wise to the FU outcome outlined by each rater, yielding 9 validations per algorithm. Predictive performance was measured using (a) area under the ROC curve (AUC) and (b) statistical accuracy (SA). Results: Predictive performance on FLAIR (AUC⫽0.82⫾0.01, SA⫽0.74⫾0.02) was significantly higher than T2 (AUC⫽0.81⫾0.02, p⬍0.01, SA⫽0.73⫾0.02, p⬍0.01). Using FLAIR as FU performance was also less influenced by interrater variability (AUC range: 0.79 – 0.85 (FLAIR) and 0.74 – 0.85 (T2)). The lower, right corner of the figure demonstrates AUC performance for all pairs of raters when trained on FLAIR. To visually assess the effect of differences in AUC, the top row of the figure shows an example of probability maps for two observers (number 2 and 3). The FU FLAIR image is shown in the lower, left corner. Conclusion: To maximize performance and robustness of predictive algorithms, FLAIR images should be used for delineating end infarcts. Although some variations in performance are detected for different raters, these are likely too subtle to be appreciated visually in probability maps. P56 Microbleeds on MRI T2* Weighted Imaging Cannot Predict Hemorrhagic Infarction in Acute Ischemic Stroke. Kenichirou Sakai, Kazuto Kobayashi, Noriko Matsumoto, Kensaku Shibazaki, Takeshi Inoue, Yasuyuki Iguchi, Kazumi Kimura; Kawasaki Med Sch, Kurashiki, Japan Background and purpose ; 5–10 % of acute ischemic stroke patients have hemorrhagic infarction. Recently, hemorrhagic lesions including hemorrhagic infarction and microbleeds can be clearly detected by MRI T2* weighted imaging. The aim of this study is to investigate whether microbleeds on MRI T2* weighted imaging on admission could predict hemorrhagic infarction at acute phase of ischemic stroke. Methods ; 370 patients with acute ischemic stroke excepting lacuna stroke within 48 hours of onset were enrolled. We performed twice MRI studies including T2* weighted imaging for all patients on admission and 7th day. Patients were classified into 2 groups, H group had hemorrhagic infarction including asymptomatic and symptomatic (neurological deterioration as worsening of NIHSS score 2 points or more) and Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 584 Stroke Vol 39, No 2 February 2008 P58 Abc/2 Estimation Technique Is Not An Accurate Measurement Of Acute Ischemic Stroke Volume With Diffusion Weighted Imaging. Salvador Pedraza, Josep Puig, Gerard Blasco, Carla Guergue, Jaume Astarloa, Idi. Hosp Dr Josep Trueta, Girona, Spain; Maria Garcia, Hosp Dr Josep Trueta, Girona, Spain; Sebastian Remollo, Ana Quiles, Eva Gomez, Mar Castellanos, Idi. Hosp Dr Josep Trueta, Girona, Spain; Joaquin Serena; Hosp Dr Josep Trueta, Girona, Spain Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction Measurement of infarct volume have been used as a surrogate or auxiliary outcome method in clinical stroke trials. Planimetric method is considered the gold standard technique to measure the infarct volume. However, this method is slow and difficult to apply in the acute setting. On the other hand, ABC/2 is an easier and faster method but to our knowledge, there have not been reported comparative studies about the concordance between both methods. Objective The aims of this study were to compare the level of concordance between the ABC/2 method and the planimetric method in the measurement of infarct volume in DWI sequences. Methods. Infarcts volumes measurements were calculated using DWI images by three independent observers. Each observer performed their analysis blinded to the relevant patient clinical information. The volume measurements were performed in the MR workstation. Observers used two methods to measure infarcts volumes: ABC/2 technique and planimetric method. In both methods, all volumes were calculated three times, and the mean value was taken as definitive. Results We studied Ninety-one patients (mean age, 71.7 years; range, 40 to 89 years). Five patients were excluded because the movement artifacts. Eighty-six stroke patients (mean age, 67,9; range, 40 to 89 years) were enrolled in the study.The patients were studied in the first 12 hours the first 12 hours after the stroke onset (mean, 2.8 hours; range, 0.25 to 9.8 hours) in a period of 3 years. Eighty-six infarct volume of MCA territory were calculated: 52 were located in superficial territory (60.5%), 19 were deep (22.1%), and 15 affected both territories (17.4%). The ABC/2 technique overestimated the infarct volume by median false increase of 8.8 cm3 [2.9, 32.4], an increase over the gold standard value of 182% [148.03, 294.74]. The intraclass correlation coefficient between measurements by ABC technique and planimetric analysis were 0.636, 0.717, 0.722 between different observers. Scatterplots show the ratios between ABC/2 and planimetric measurements with values from 2 to 2.3. In each method the Interrater reliability was excellent with an intraclass correlation of 0.991 and 0.984 for a ABC/2 technique and planimetric method, respectively. Conclusion Our findings indicate that the abc/2 method overestimates the real volume of the infarction. A faster and more reliable volumetric method is needed to allow the measurement of infarct volume in the acute setting. P59 30-Day Event Monitors in Detecting Atrial Fibrillation in Cryptogenic Stroke. P60 MRI Use in TIA Patients: Variations by Joint Commission Stroke Center Certification Status and Implications for a Revised Tissue-Based Definition of TIA. Andrew W Asimos, Carolinas Med Cntr, Charlotte, NC; Wayne D Rosamond, Kathryn M Rose, Annie Green Howard, Carol V Murphy, Univ of North Carolina, Chapel Hill, NC; Charles H Tegeler, Wake Forest Univ Sch of Medicine, Winston-Salem, NC; Sylvia W Coleman; North Carolina Dept of Health and Human Services, Raleigh, NC Background: A tissue based definition of TIA, which includes no evidence of acute infarction, has been proposed, implying that an MRI is necessary for an accurate diagnosis. Data are lacking for the proportion of TIA patients receiving an MRI across hospital settings. Thus, we examined the proportion of presumed TIA cases receiving an MRI and variations by Joint Commission Primary Stroke Center (JCPSC) certification status. Methods: Between January 2005 and July 2007, the North Carolina Collaborative Stroke Registry (NCCSR), a CDC-funded Paul Coverdell National Acute Stroke Registry, tracked MRI use in 3,350 presumptive TIA patients from 39 NC hospitals with access to MRI. We used logistic regression to compare MRI use in patients treated at JCPSCs (n⫽10) and non-JCPSCs (n⫽29). Covariates included age, gender, and hospital type (teaching vs. non-teaching, based on criteria established by the CDC). Due to an interaction between JCPSC and teaching status (p ⬍ 0.0001), analyses were stratified by teaching status. Results: Of patients with a presumed admitting diagnosis of TIA, 64% (n⫽2,149) underwent an MRI during their hospitalization. Patients at JCPSCs were more likely to receive an MRI than were those at non-JCPSCs (72% vs. 55%, p⬍0.0001). At teaching hospitals, MRI use did not vary between JCPSCs and non-JCPSCs (OR ⫽ 0.89, 95% CI ⫽ 0.69 –1.15). In contrast, in non-teaching hospitals, patients treated at JCPSCs were more likely to undergo an MRI than those treated at non-JCPSCs (OR ⫽2.74, 95% CI 2.22–3.40). Final discharge diagnoses, based on ICD-9 discharge codes, included TIA for 48%, ischemic stroke for 25%, and other for 27% of patients admitted with a presumptive diagnosis of TIA. Of patients discharged with a diagnosis of TIA, 61% received an MRI during their admission, while 72% of patients with a final diagnosis of ischemic stroke had an MRI performed. Conclusions: This experience, including a broad range of hospitals in North Carolina with access to MRI, found that over one-third of admitted presumptive TIA patients did not have an MRI during their hospitalization. At non-teaching hospitals, MRIs were more likely to be performed at JCPSCs than non JCPSCs. This suggests that changing to a tissue based definition of TIA would be significantly undermined by lack of MRI performance, especially at non-JCPSC, non-teaching hospitals. P61 Comparison of Regional Perfusion Parameters Derived from Two Perfusion Packages on “Stroke Protocol” Patients without Cerebrovascular Disease or Subsequent Stroke. David Clopton, Ansaar Rai, Jeffrey S Carpenter; West Virginia Univ, Morgantown, WV Lucas Elijovich, S. Andrew Josephson, Gordon L Fung, Wade Smith; UCSF, San Francisco, CA Introduction: A large proportion of cryptogenic stroke may be due to atrial fibrillation. Thirty-day cardiac event monitors may increase the detection rate of atrial fibrillation compared with standard investigations such as EKG, inpatient cardiac telemetry, and short-term Holter monitoring. Methods: We conducted a retrospective study of all patients admitted to a tertiary stroke center or seen in clinic from June 2006 to March 2007 who were diagnosed with a cryptogenic stroke or TIA. Cryptogenic stroke was defined by the attending Neurologist if a thorough workup failed to identify an etiology for a large-vessel stroke. All patients underwent standard investigation for stroke etiology including EKG, 48 hours of inpatient cardiac telemetry, cervical and intracranial vascular imaging, and echocardiogram. In all included patients, there were no pre-exisiting indications for anticoagulation. Two models of 30-day event monitors were used, the AFIB Dual Alert (West Palm Beach, Florida) and LifeStar AF Express 3X (Buffalo Grove, Illinois) that are programmed to automatically detect R-R interval irregularities that may represent malignant arrhythmias. A cardiologist reviewed the study record at the time of each event transmission and upon completion of the 30-day study period. Results: Twenty-six patients were referred for 30-day event monitor, and twenty (76%) completed the study. Inpatients were monitored on cardiac telemetry for an average of 54 hours (range 24 –96) without any episodes of atrial fibrillation. Nineteen of the patients (95%) had an echocardiogram, and five (26%) patients had severe left atrial enlargement. Only one of the 5 patients with severe left atrial enlargement was found to have atrial fibrillation. Five patients (25%) had clinically significant findings on their event monitors. Four (20%) had newly diagnosed atrial fibrillation, and one additional patient had three asymptomatic episodes of ST segment depression associated with tachycardia. Two out of the five patients with clinically significant findings were evaluated as outpatients and both had atrial fibrillation discovered on long-term monitoring Conclusion: Thirty-day event monitors identified a larger proportion of atrial fibrillation in patients with cryptogenic stroke than would be expected with standard investigations. Further prospective studies of extended event monitors in the setting of cryptogenic stroke are warranted. Objective: To demonstrate the significant territorial differences in perfusion parameters derived from perfusion CT and the differences in values generated by two existing perfusion packages. Methods: Standard CT Perfusion of the brain and CT angiographic imaging of the head and neck was performed on 734 patients between 5/1/05 and 5/30/07. No stroke was identified on in 360 of these patients. Exclusions from analysis were made for prior stroke, presence of any detectable arterial stenoses by CTA, excessive motion, inadequate bolus arrival curve or lack of MR or CT follow-up within 30 days. A single operator reprocessed the raw perfusion data on both Vital Images’ Vitrea 4.0 CT Perfusion and GE CT Perfusion 2 software selecting region of interests encompassing both gray and white matter within the ACA, MCA, and PCA bilaterally and of the basal ganglia region on the 80 remaining patients. The same arterial input and venous output source were selected on the level best depicting all vascular territories being evaluated. Regions of interest were evaluated on this level only. Conclusion: All perfusion values generated are significantly different (two tailed student t-test p values less than 0.05) between the two packages with the exception of CBV values in the ACA, BG, and PCA territories. The differences can be due to a number of sources including differences in motion correction, vascular pixel elimination and numerical method differences in calculation of CBV and MTT. These differences may have clinical significance when upgrading or switching packages if treatment decisions are based upon absolute values of these perfusion parameters. Both perfusion packages indicate prolonged mean transit times within the PCA distribution compared with the ACA and MCA values (p value ⬍ 1 x 10-15) with increased variance within this region as well. This may lead to unnecessary concern and further testing of the vertebrobasilar system unless recognized as a “normal” finding of the CT perfusion technique. RESULTS MTT (s) ACA BG MCA PCA CBF (ml/100gm/min) CBV ml/100gm Vital GE V2 Vital GE V2 Vital GE V2 4.0⫹/-0.7 3.4⫹/-0.6 3.8⫹/-0.7 4.8⫹/-1.1 3.4⫹/-0.7 3.0⫹/-0.6 3.4⫹/-0.8 4.4⫹/-1.2 45⫹/-15 50⫹/-17 54⫹/-18 38⫹/-17 57⫹/-27 60⫹/-27 83⫹/-40 58⫹/-37 2.7⫹/-0.9 2.6⫹/-0.9 3.1⫹/-0.9 2.8⫹/-1.2 2.5⫹/-1.0 2.5⫹/-1.0 3.5⫹/-1.4 3.1⫹/-1.6 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations P62 Utility of CT Angiography and MR Angiography in Evalution of Vertebral Artery Origin Stenosis. Mouhammad A Jumaa, Alexandra Popescu, Nirav A Vora, Ajith Thomas, Vivek Reddy, Syed F Zaidi, Ridwan Lin, Maxim D Hammer, Lawrence R Wechsler, Tudor G Jovin, Michael B Horowitz, Jawad Tsay, Ken Uchino; Univ of Pittsburgh Med Cntr Stroke Institute, Pittsburgh, PA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Atherosclerotic disease of the V1 Segment of the vertebral artery is reported to be found in 20% of patients with posterior circulation stroke. Our goal was to determine the sensitivity and specificity of CT angiography (CTA) and MR angiography (MRA) in detecting stenosis of the vertebral artery origin compared to Digital Subtraction Angiography (DSA) as the standard. Methods: With IRB approval, we reviewed medical records of patients evaluated in our center for vertebral artery origin stenosis between 2003 and 2007. Patients were included if they had a noninvasive study (CTA or MRA) and a DSA within a three months period. Data extracted from MRA, CTA and DSA reports included whether the vertebral artery origins were imaged and appropriately visualized and the degree of stenosis (none, ⬍ 50%, ⬎50%, or occlusion). All MRAs and CTAs were independently reviewed by a second Neuro-radiologist blinded to the first interpretation. Interrater agreement was calculated between observers. Sensitivity and specificity were calculated with DSA as the standard for determination of stenosis with thresholds of 50% and 0%. Proportions were compared by Fisher’s exact test. Results: Forty-eight subjects with 23 CTA and 38 MRA studies were included. There were 92 interpretable vertebral arteries on DSA, since 4 right vertebral arteries could not be visualized. Only 15% (7/46) of arteries evaluated by CTA were deemed as not interpretable, whereas 45% (34/75) were not interpretable on MRA (p⬍0.001 by Fisher’s exact test). Interrater agreement of interpretability was moderate for CTA with kappa of 0.43, whereas that for MRA was fair at 0.39. Sensitivity and specificity for ⱖ50% stenosis by CTA was 61.9% and 77.8%. Sensitivity and specificity for ⱖ50% stenosis by MRA was 55.0% and 85.7%. Interrater agreement for ⱖ50% stenosis was fair at kappa of 0.26 for CTA and 0.32 for MRA readings. Conclusions: MRA and CTA have comparable sensitivity and specificity, but CTA has a higher rate of interpretable studies. Further studies are needed to validate our data. The low interrater agreement indicates a need for development of standardization for measurement of vertebral artery origin stenosis. CTA vs. DSA Threshold for stenosis Number of arteries examined Sensitivity % (95% CI) Specificity % (95% CI) ⫹Predictive Value -Predictive Value ⱖ50% MRA vs. DSA ⬎0% ⱖ50% ⬎0% 46 46 75 75 61.9% (40.9–79.3) 77.8% (54.8–91.0) 0.765 91.3% (73.2–97.6) 56.3% (33.2–76.9) 0.750 55.0% (34.2–74.2) 85.7% (65.4–95.0) 0.786 90.9% (72.3–97.5) 47.4% (27.4–68.3) 0.667 0.636 0.818 0.667 0.818 P63 Hyperdense Basilar Artery Sign on Unenhanced CT Predicts Thrombus and Outcome in Acute Posterior Circulation Stroke. Gregory V Goldmakher, Erica C Camargo, Karen L Furie, Wade S Smith, Gordon J Harris, Maggie J Chou, Massachusetts General Hosp, Boston, MA; Trese Biagini, Univ of California, San Francisco, San Francisco, CA; Luca Roccatagliata, Elkan F Halpern, Massachusetts General Hosp, Boston, MA; William P Dillon, Univ of California, San Francisco, San Francisco, CA; R Gilberto Gonzalez, Aneesh B Singhal, Walter J Koroshetz, Michael H Lev; Massachusetts General Hosp, Boston, MA BACKGROUND: In acute stroke patients, the dense MCA sign on unenhanced CT is a specific but insensitive indicator of acute thrombosis. It has been suggested that the dense basilar artery (DBA) sign may have utility in detecting thrombosis and predicting recanalization after thrombolysis. However, it is not known how specific and sensitive this sign is for outcome prediction in suspected posterior circulation stroke. Methods: We reviewed unenhanced CT scans obtained within 24 hours of symptom onset in 95 consecutive patients with suspected posterior circulation stroke. Three blinded neuroimagers rated presence of DBA sign on a 5-point level of certainty scale (1 ⫽ definitely absent; 5 ⫽ definitely present). ROC curve analysis was performed, with concurrent CTA as the reference standard. NIHSS score at discharge was used to measure short-term outcome, and 6-month modified Rankin score (mRS) was used to measure long-term outcome (poor outcome defined as mRS⬎2). Univariate analysis assessed the correlation of the following variables with short and long-term outcome: DBA, age, sex, time from onset to imaging, admission NIHSS, history of stroke/TIA, atrial fibrillation, CAD, HTN, DM, hypercholesterolemia, tobacco use, and thrombolysis. Variables associated with outcomes at p⬍0.1 on univariate analysis were included in multivariate regression models. RESULTS: Using a level of certainty cutoff score of 4 or higher (probable, definite), DBA sign had 71% sensitivity, 98% specificity, 94% accuracy, 83% PPV, and 95% NPV for basilar artery occlusion. In univariate analysis, factors significantly associated with short-term outcome were: admission NIHSS (p⬍0.001, R⫽0.77), DBA (p⫽0.01), and DM (p⫽0.02), with thrombolysis showing a trend (p⫽0.053). Factors significantly associated with poor long-term outcome were age (p⫽0.02), admission NIHSS (p⫽0.007), DBA (OR⫽5.6, 95%CI 1.1–29.3; p⫽0.02), and history of stroke/TIA (p⫽0.007). In multivariate analysis, the 585 only independent predictors of short-term outcome were admission NIHSS (p⬍0.001) and DBA (p⫽0.03). Significant independent predictors of poor long-term outcome were age (p⫽0.02), admission NIHSS (p⫽0.005), history of stroke/TIA (p⫽0.02), and DBA (p⫽0.04). CONCLUSION: In patients with a high pretest probability of posterior circulation stroke, the presence of a DBA sign on unenhanced CT is a specific and accurate predictor of basilar artery thrombosis, and an independent predictor of short and long-term clinical outcome. P64 CT Perfusion Cerebral Blood Volume Can Be Used to Predict Anatomic Collaterals in Acute Stroke Patients Receiving Endovascular Therapy. Nirav Vora, Ridwan Lin, Ajith Thomas, Syed Zaidi, Vivek Reddy, Univ of Pittsburgh, Pittsburgh, PA; Ken Uchino, Univ of Pittsburgh, Pittsburgh, MI; Maxim Hammer, Lawrence Wechsler, Michael Horowitz, Tudor Jovin; Univ of Pittsburgh, Pittsburgh, PA Background: Our aim was to correlate CT perfusion, hemispheric mean cerebral blood volume (CBV) and mean transit time (MTT) values to the presence of collaterals in acute stroke patients treated with endovascular therapy. Methods: We retrospectively reviewed patients who underwent endovascular therapy for anterior circulation stroke and received a pre-treatment CT perfusion. Hemispheric mean CBV and MTT values were obtained using a software which calculates average values within selected regions of interest (ROI). ROI were drawn in both middle cerebral artery (MCA) distributions for both CBV and MTT maps. Additionally, a ratio was generated using hemispheric mean CBV ipsilateral to the stroke divided by the hemispheric mean CBV contralaterally. Angiographic collaterals during intervention were graded based on late angiographic filming of the symptomatic hemisphere. A score of 1 to 5 was ascribed to the collaterals as follows: a score of 1 if collaterals reconstituted any part of the MCA M1 segment, 2 for any reconstitution of the MCA M2 segments, 3 for any reconstitution of the MCA M3 segments, 4 for any reconstitution of the MCA M4 segments, 5 for absent collaterals. Correlation techniques were performed to determine the relationship of hemispheric mean CBV, hemispheric mean CBV ratio, and hemispheric mean MTT to the presence of collaterals. Results: A total of 31 patients were identified with mean age 63⫾13 years and mean NIHSS 16⫾4. Two patients had an internal carotid artery (ICA) origin occlusion; 8 had an ICA terminus occlusion; 9 had a middle cerebral artery (MCA) M1 segment occlusion; 3 had a MCA M2 segment occlusion, and 9 had a tandem occlusion of the ICA origin and intracranial circulation. Both hemispheric mean CBV and hemispheric mean CBV ratio showed a significant correlation to the presence of collaterals (r ⫽ -0.60, z⫽3.17 and r ⫽ -0.63, z⫽3.33, respectively for an ␣⫽0.05). Hemispheric mean MTT statistically did not correlate with the presence of collaterals (r ⫽ -0.18, z⫽0.95 for an ␣⫽0.05). Conclusion: CBV, and not MTT, may be a tool for predicting the presence of anatomical collaterals in acute stroke. Further correlation with stroke outcome is needed to determine if this tool can be used to tailor endovascular strategies prior to treatment. P65 Arterial Input Choice in CTP Map Construction with Acute MCA Thrombus: Does Side Matter? - Not If Delay Correction Software Is Used Proximal to the Occlusion. Rafael M Ferreira, Gregory Goldmakher, Shahmir Kamalian, Pamela W Schaefer, R Gilberto Gonzalez, Michael H Lev; Massachusetts General Hosp, Boston, MA PURPOSE: Using software from two vendors for CT perfusion (CTP) map construction in acute stroke patients, we examined how CBV, CBF, and MTT values vary with the placement of the arterial input function (AIF) region-of-interest (ROI) relative to an arterial occlusion. METHODS: A neuroradiologist constructed CTP maps for 14 acute stroke patients using deconvolutionbased software from two vendors (A: CT Perfusion 4, GE Healthcare; B: Brain Perfusion, Philips Medical Systems). All cases had unilateral proximal MCA clot confirmed by CTA and infarct core confirmed by MR-DWI. CTP maps were generated with the AIF ROI in 4 positions relative to the MCA clot (AIF1 - proximal ipsilateral; AIF2 - distal ipsilateral; AIF3 - proximal contralateral; AIF4 distal contralateral). Other technical parameters were held constant. For each map, CBV, CBF and MTT values were sampled in the infarct core, healthy gray matter and healthy white matter. RESULTS: Using software A, mean CBF and CBV at the infarct core remained ⬍12 mL/100g/min and ⬍2 mL/100g, respectively, for AIF1, 3, and 4. For AIF2, mean CBF and CBV values were 17.3 mL/100g/min and 2.85 mL/100g, respectively. Using software B, mean CBF and CBV at the infarct core remained ⬍12 mL/100g/min and ⬍1.8 mL/100 g, respectively, for AIF1, 3, and 4. For AIF2, mean CBF and CBV values were 19.4 mL/100g/min and 2.5 mL/100g, respectively. For both packages, a significant difference was observed between the CBF and MTT values at the infarct core obtained with AIF2 and those obtained with AIF1, 3, and 4 (p⬍0.05). Using AIF2 led to higher mean CBF (software A: ⫹7 mL/min/100g; software B: ⫹11.3 mL/min/100g) and lower mean MTT (software A: -1.5s; software B: -2.5s). Mean CBV showed a trend towards increase (p⫽0.083) with AIF2 for all tissues sampled (software A: ⫹1.01 mL/100g; software B: ⫹1.32 mL/100g). With AIF2, 43% of cases showed visible differences in the CTP maps, most notably for MTT; time-density curves (TDCs) showed visually depressed peak enhancement. These effects were qualitatively less pronounced with software A. CONCLUSION: For accurate quantitative CTP map construction, laterality of AIF ROI placement is less important than avoiding placement distal to an MCA occlusion. TDCs suggest that decreased AIF peak enhancement distal to a clot may lead to overestimation of CBV and CBF, and underestimation of MTT. This pitfall is less severe with delay-corrected deconvolution software. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 586 Stroke Vol 39, No 2 February 2008 P66 MR Regional Perfusion Values in Hyperacute Ischemic Stroke Treated by Intra-Arterial Thrombolysis are Influenced by Recanalization and Time to Recanalization. Luis A Verduzco, Albert J Yoo, Kit Mui, Michael H Lev, Joshua A Hirsch, Ramon G Gonzalez, Pamela W Schaefer; Massachusetts General Hosp, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Purpose: In the setting of hyperacute ischemic stroke, DWI-PWI mismatch identifies hypoperfused but potentially salvageable brain parenchyma, the ischemic penumbra. We sought to determine regional cerebral blood flow (CBF) values in penumbral tissue that progressed to infarction versus tissue that recovered in hyperacute stroke patients who underwent intra-arterial thrombolysis (IAT). Furthermore, we sought to determine the effect of recanalization status and time to recanalization on these values. Methods: 14 patients with acute MCA and/or ICA terminus occlusion underwent DWI/PWI before IAT followed by post-thrombolysis imaging to ascertain infarct extension. CBF values were obtained from the pre-treatment perfusion scans in three regions: (1) infarct core (abnormal on admission DWI and CBF); (2) penumbra that infarcted (normal on admission DWI, abnormal on admission CBF, abnormal on follow-up); (3) penumbra that survived (normal on admission DWI, abnormal on admission CBF, normal on follow-up). CBF ratios (rCBF) were determined for these regions by dividing by CBF values in mirror-image regions of interest in the non-ischemic hemisphere. Results: In the entire group, mean rCBF values for regions 1–3 were 0.35⫾0.15, 0.53⫾0.16, and 0.61⫾0.17, respectively (p⬍0.0001). Mean rCBF values for region 2 in recanalizers (RC) versus non-recanalizers (NRC) were 0.48⫾0.16 and 0.56⫾0.15 (p⬍0.03), respectively. Mean rCBF values for region 2 in patients with recanalization within 3 hours of imaging versus after 3 hours of imaging were 0.40⫾0.12 and 0.67⫾0.06, respectively (p⬍0.0001). Conclusion: In penumbral tissue that goes on to infarct, mean rCBF values are lower in the setting of RC. Early time to RC also resulted in lower mean rCBF values for this region. These findings support the time dependence of CBF thresholds in the ischemic penumbra. P67 Assessment Of Large Vessel Cerebral Blood Flow In Healthy Subjects Using Quantitative Magnetic Resonance Angiography. Table of Contents 䡠Arteries Arteries TVA TCF TCBF Mean ⫾ 1.96 SD ml/min (95% CI of Lower and Upper bound) 18 – 40 41– 60 ⱖ61 197⫾88(⫾15) 1014⫾211(⫾53) 731⫾210(⫾36) 190⫾77(⫾14) 950⫾265(⫾48) 698⫾195(⫾35) 173⫾78(⫾19) 925⫾309(⫾76) 641⫾198(⫾49) P68 The Assessment of Lesion Volumes in TIA and Minor Stroke Patients. Cynthia R Campos, Young B Choi, Firosh Khan, Dept of Clinical Neurosciences, Foothills Med Cntr, Univ of Calgary, Calgary, Canada; Jayme Kosior, Dept of Electrical and Computer Engineering, Univ of Calgary, Calgary, Calgary, Canada; Michael D Hill, Andrew M Demchuk, Shelagh B Coutts; Dept of Clinical Neurosciences, Foothills Med Cntr, Univ of Calgary, Calgary, Canada Background and Purpose: The risk of disability following TIA or minor stroke is high. Clinical trials are needed for acute treatment options in these patients and reducing the sample size required may improve feasibility. Lesions volumes measurements in disabling stroke have been used in some clinical trials; however the usefulness of this method in TIA or minor stroke patients who generally have smaller lesion volumes is unknown. We sought to see how feasible measuring lesion volumes in TIA and minor stroke patients was and also to assess in what proportion of patients the presenting lesion had disappeared at 30 days and in how many had the initial lesion grown. Methods: Patients with TIA or minor stroke were examined within 12 hours by a stroke neurologist and had a brain MRI within 24 hours of symptom onset and at 30 days. Patients with acute lesions on DWI had the volumes of their lesions measured both on the baseline DWI and on the follow-up FLAIR MRI. When more than one lesion was present, the total volume of the lesions was considered. Volumes of the follow-up FLAIR lesion were compared to the baseline DWI lesion to define lesion growth (increase⬎2mL). Volumes were measured by commercially available software using computer-assisted volumetric analysis. The intrarater reliability for measurement of these lesions was calculated. Results: From 180 patients enrolled, 80 patients had at least one acute lesion on the baseline DWI. The mean volume of the baseline lesion was 2.73mL (range: 0.1–32.95mL). On the follow-up MRI, in 14(17.5%) patients the initial lesion disappeared; in 5(6.2%) the volume decreased; in 14(17.5%) the volume increased, and in 47(58.8%) no change in volume occurred. The intraclass correlation was excellent; ICC⫽0.99, suggesting that although these lesions are small, lesion volume measurements are reproducible. Conclusions: Lesion volume measurements are feasible in minor stroke and TIA patients. Although others have previously reported in TIA and minor stroke patients that the presenting lesions persist, we have found that in a high proportion (17.5%) of these patients the initial lesion disappears by 30 days. We also found a high proportion of patients in whom the lesion increased in volume from baseline. Further studies are required to assess whether this can be used as a surrogate marker for therapeutic trials in TIA and minor stroke. Xinjian Du, Sepideh Amin-Hanjani, Meide Zhao, Sean Ruland, Weihua Gao, Craig Beam, Fady Charbel; UIC, Chicago, IL BACKGROUND AND PURPOSE: Blood flow rate in major cerebral arteries can be measured non-invasively with quantitative magnetic resonance angiography (QMRA). However, normal values have not been previously determined. METHODS: QMRA was performed in 255 subjects18 to 80 years old and free of known disease (124 women, mean age 47⫾15; 131 men, mean age 46⫾16.). Cerebral blood flows were measured in 6 cervical and 9 intracranial arteries in each volunteer. Normal range for each major cerebral artery was established based on sample mean ⫾ 1.96SD, 95%CI for lower and upper bound was also obtained. The mean flow rate of basilar artery (BA) and internal carotid arteries (ICA) was calculated after excluding volunteers with absent first segment of anterior cerebral artery (ACA0, existing fetal posterior cerebral artery (PCA), or posterior communicating artery (PCOM ⱖ 30ml/min. Because anatomic asymmetry in the ACAs and vertebral arteries (VA) is common, we calculated total ACAs (TACA) and total VAs (TVA). We also examined ranges for total cranial flow (TCF), calculated from the sum of both common carotid arteries (CCA) and TVA, and for total cerebral blood flow (TCBF), calculated from the sum of 2 ICAs and 2 VAs. RESULTS: See table1. Table 1. The Range of Blood Flow Rate for Major Cerebral Arteries in Different Age Groups CONCLUSIONS: Non-invasive large vessel cerebral blood flow rates can be determined using QMRA. This is a promising tool for assessing the hemodynamic effects of cerebrovascular disease. Table of Contents 䡠Arteries Arteries BA LICA RICA LMCA RMCA LPCA RPCA TACA LCCA RCCA Mean ⫾ 1.96 SD ml/min (95% CI of Lower and Upper bound) 18 – 40 166⫾54(⫾11) 274⫾87(⫾18) 262⫾95(⫾20) 169⫾68(⫾11) 158⫾62(⫾10) 74⫾33(⫾6) 71⫾32(⫾5) 186⫾75(⫾13) 417⫾140(⫾23) 406⫾157(⫾27) 41– 60 150⫾61(⫾13) 250⫾89(⫾26) 241⫾101(⫾20) 157⫾52(⫾9) 144⫾52(⫾9) 69⫹25(⫾4) 64⫾26(⫾4) 171⫾65(⫾11) 378⫾124(⫾21) 382⫾137(⫾24) ⱖ61 129⫾40(⫾12) 231⫾95(⫾26) 220⫾201(⫾28) 141⫾48(⫾12) 130⫾51(⫾12) 61⫾22(⫾5) 58⫾22(⫾5) 156⫾58(⫾15) 371⫾154(⫾37) 381⫾169(⫾40) P69 Ophthalmic Artery High Flow As The Risk Indicator For The Intracranial Hemorrhage In Moyamoya Disease. Shoichiro Kawaguchi, Dept of Neurosurgery, Nara Prefectural Nara Hosp, Nara, Japan; Toshisuke Sakaki, Dept of Neurosurgery, Nara Med Univ, Kashihara, Japan; Masami Imanishi, Dept of Emergency and Critical Care, Nara Prefectural Nara Hosp, Nara, Japan; Yasunori Sasaoka, Dept of Neurosurgery, Nara Prefectural Nara Hosp, Nara, Japan; Takeshi Matsuyama, Dept of Emergency and Critical Care, Nara Prefectural Nara Hosp, Nara, Japan; Toshikazu Takeshima, Dept of Neurosurgery, Nara Prefectural Nara Hosp, Nara, Japan; Misato Nobayashi; Dept of Emergency and Critical care, Nara Prefectural Nara Hosp, Nara, Japan Introduction: In this paper, the authors analyzed the relationship between the clinical symptoms and the findings of the ophthalmic artery (OA) flow in moyamoya disease. Hypothesis: The authors hypothesized that the OA high flow is the risk indicator for the intracranial hemorrhage in moyamoya disease. Methods: The 43 patients (mean age: 36 years) with moyamoya disease were evaluated. Their clinical symptoms were following; an intracranial hemorrhage in 11 patients, an ischemic event in 28 patients and asymptomatic in 4 patients. OA flow was examined using the OA color Doppler flow imaging (CDFI) revealing the peak systolic flow velocity (Vs), time-averaged maximum flow velocity (TAMX) and pulsatility index (PI)of both side OA. Results: 1) The average Vs was 0.47 m/sec, the average TAMX was 0.30 m/sec. These values were significantly (p⬍0.05) high compared to the normal controls. The average PI was 1.14, which was significantly low compared to the controls. 2) The CDFI findings of the eleven OAs same side to the intracranial hemorrhage showed the significantly (p⬍0.05) high Vs (mean: 0.60 m/sec), high TAMX (mean: 0.39m/sec), and low PI (mean: 0.86) compared to the CDFI findings of the other 75 OAs same side to the ischemic or asymptomatic side. 3) During the follow-up period (mean period: 3.0 years), an intracranial hemorrhage was seen in 2 patients showing the high Vs, TAMX, and low PI. Conclusion: The OA high flow, such as high Vs, high TAMX and low PI, was the significant risk indicator for intracranial hemorrhage in moyamoya disease including the follow-up period. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations P70 Small Cortical Lesions Visible on Acute DWI are not Visible on 90 day FLAIR. Karima Benameur, Jose Merino, NINDS-NIH, Bethesda, MD; Chelsea S Kidwell, Georgetown Univ, Washington, DC; Steven Warach, Lawrence Latour; NINDS-NIH, Bethesda, MD Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 BACKGROUND: Improved diffusion weighted imaging with increased signal-to-noise and resolution results in improve acute lesion conspicuity and an unexpected prevalence of cortical lesions. Lesion seen on high resolution DWI that are not seen on conventional DWI are typically punctuate. The purpose of this study is to determine the fate of such small acute lesion on 90 day follow up FLAIR and T1 imaging. . METHODS: This was a retrospective study of acute stroke patients seen by the NIH stroke team at Suburban hospital between September 2004 and March 2007. Inclusion criteria were; a discharge diagnosis of ischemic stroke, an imaging study within 24 hours of symptom onset including high resolution diffusion weighted imaging (DWI) and FLAIR, a 90 day follow up study including FLAIR and T1 sequences. Ischemic lesions were defined as hyper-intense lesions on DWI, and were verified for their acuity by comparing acute and 90 day FLAIR. Lesions present on both sequences were excluded from the study. Lesion location and volume were recorded on acute DWI. Acute DWI images were co-registered to their corresponding 90 day FLAIR and T1 respectively, lesions were then compared between DWI, 90 day FLAIR, and 90 day T1. . RESULTS: A total of 30 patients were included in the study with a total lesion number of 88 lesions. Categorization of lesions per location on DWI identified 67 (76%) as cortical, 15 (16%) as sub-cortical, 3 (3%) as cortico-subcortical, and 2 (2%) as cerebellar. Follow up of acute DWI lesions on 90 day FLAIR identified 53 (61%) lesions as visible, 34 (39%) as non visible, and 1 (1%) as non readable. A break down per lesion location on 90 day FLAIR identified 32 (45 %) of cortical lesions as non visible as opposed to 4 (25 %) of sub-cortical. Follow up of acute DWI lesions on 90 day T1 identified 38 (43 %) of overall lesions as non visible, 35 (40 %) of lesions as hypo-intense, and 15 (17 %) of lesions as hyper-intense. As many as 83% of non visible lesions on 90 day T1 were cortical on acute DWI, as opposed to 11% of sub-cortical lesions. A break down per lesion location on 90 day T1 identified 32 (48%) of cortical lesions as non-visible, as opposed to 4 (25%) of sub-cortical lesions. . CONCLUSIONS: Almost half the lesions were not visible on 90 day FLAIR. A preponderance for cortical lesions to disappear was observed, with a few cases clear cortical gray matter atrophy on T1 imaging. Small cortical ischemic lesions evident acutely, but not apparent on chronic FLAIR imaging may contribute to diffuse cortical atrophy. P71 Intracranial Aneurysm Formation As An Indirect Consequence Of Traumatic Brain Injury. Jefferson T Miley, Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr Univ of Minnesota, Minneapolis, MN Background: Projectile injury and skull and vertebral fractures result in direct aneurismal injuries to the carotid and vertebral arteries. Recently, it has been observed that vessels can suffer changes due to indirect effect trauma. We report the occurrence of intracranial aneurysms in patients with traumatic brain injury without direct vessel injury. Methods We reviewed all the cerebral angiograms performed in patients with traumatic brain injury at a level I trauma center from January 2006 to July 2007. Vessel injuries are classified as grade I and grade II lesions show less than 25% and greater than 25% luminal narrowing, respectively; grade III pseudoaneurysms; grade IV thrombosis; grade V transections with extravasation. Results A total of 73 cerebral angiograms where performed for the indication of possible vascular injury. In 26 patients a vascular injury was identified as tabulated below. In 22 patients, direct vascular injuries where confirmed by cerebral angiogram. Indirect vascular injury was found in four patients (4 with carotid grade III). These injuries or aneurysms where found in the intracranial segment of the internal carotid (2 supraclinoid, one cavernous and one paraophthalmic) without evidence of a fracture at the exact level of the injury. Two patients where treated with coil embolization, one required further embolization 2 days later due to incomplete endovascular treatment. Another patient had a cerebral angiogram following coil embolization for a vertebral artery occlusion and no change in the morphology of the ICA aneurysm was found. The last patient died as a consequence of severe head trauma. Conclusion: We report the occurrence of intracranial aneurysm as indirect consequence of traumatic brain injury. A low threshold should be maintained to detect these aneurysms in patients with traumatic brain injury. Carotid Vertebral Grade I Grade II Grade III Grade IV Grade IV Fistula 3 5 1 0 5 0 2 7 1 0 2 0 P72 Is Routine CT Scanning Indicated After Neuroendovascular Embolization? Mateo Calderon-Arnulphi, Ali Alaraj, Sepideh Amin-Hanjani, Adam Wallace, Goro Osawa, Soma Sinha Roy, Rajeev Deveshwar, Qasim Bashir, Pawan Singh, Fady T Charbel, Victor Aletich; Univ of Illinoins, Chicago, IL INTRODUCTION Endovascular neurosurgical embolization procedures carry a potential risk for intracranial injury. A post-procedural brain CT scan is indicated when patients have complications during the intervention, or new neurological findings emerge after the procedure. 587 However, the value of routine brain CT scan in patients without peri-procedural complications and no immediate new neurological findings after the intervention is not clear. We sought to assess the need for routine brain CT scan after endovascular neurosurgical procedures in these patients. METHOD Consecutive neuroendovascular embolization procedures performed in the department of Neurosurgery, University of Illinois at Chicago during the period of January 2000 to June 2007 were retrospectively reviewed. Diagnosis, neurological status, and CT finding were noted before and after the procedures. Inclusion criteria: Patients included in the review had normal neurological exams and brain CT scans negative for acute injury. The endovascular procedure was uncomplicated and post procedure neurologic exam was unchanged from baseline. Exclusion criteria: Patients presenting with pre-existing neurological deficit, positive brain CT prior to the intervention, complications during the procedure, or new neurological findings after the procedure. Results A total of 1157 neuroendovascular embolization procedures performed on 880 patients (655 aneurysms, 191 arterio-venous malformations and 34 meningiomas) were reviewed. 580 procedures met the exclusion criteria of the study. For the 577 procedures that met inclusion criteria, 337 had post procedural CT scans. The corresponding brain CT scans post intervention in this subgroup revealed no instances of hemorrhage or new ischemic injury. Conclusions In selected patients with no signs of bleeding in preoperative brain CT scan, no complications during the embolization procedure and no new neurological findings after embolization, there appears to be no value for routine brain CT scan. P73 Ultrasound Velocity Criteria For Vertebral Origin Stenosis. Sebastian Koch, Amir Murtaza, Hannah Park, Jose G Romano, Alejandro Forteza; Univ Miami, Miami, FL Background: The vertebral artery origin (VAo) is commonly affected by atherosclerosis and may be a cause of cerebral embolism. Although this segment is easily insonated by ultrasound, diagnostic criteria for vertebral origin stenosis are not well established. We undertook the present study to compare different ultrasound criteria for diagnosis of vertebral artery stenosis. Methods: We retrospectively reviewed catheter cerebral angiograms and extracranial Duplex ultrasounds in patients undergoing both procedures at a community based teaching hospital. Data collected included the degree of angiographic vertebral artery origin stenosis, peak systolic velocities (PSV) and end diastolic (EDV) flow velocities at the VAo, the proximal vertebral pre-foraminal (V1) segment and intra-foraminal (V2) segment. Angiographic stenosis of ⬎ 50% was confirmed with electronic calipers, utilizing the diameter ratio between VAo and V1. A receiver operator characteristic curve (ROC) was computed for the following diagnostic criteria for VAo stenosis: PSV Vo, PSV ratio VAo/V1 and PSV ratio of VAo/V2. Results: A total of 218 patients met inclusion criteria allowing analysis of 386 vertebral arteries. Angiographic vertebral artery stenosis ⬎ 50% was found in 36 (9 %) vessels of which 31 were insonated by ultrasound. The mean vessel stenosis was 71 ⫾ 15 %. Mean VAo PSV was 175 ⫾ 109 cm/sec in patients with VAo stenosis vs. 64 ⫾ 28 cm/sec in patients with ⬍50% stenosis (p⬍ 0.0001). The ROC area under the curve for PSV VAo was 0.82 (CI: 0.72, 0.92), 0.77 (CI: 0.66, 0.87) for PSV VAo/V2 and 0.73 (CI 0.62, 0.84) for PSV VAo/V1. A threshold PSV of 78 cm/sec resulted in a sensitivity of 80% and specificity of 72% for diagnosing ⬎ 50% VAo stenosis. Conclusion: PSV has the highest diagnostic accuracy among the criteria tested and is useful in identifying vertebral artery origin stenosis. Threshold velocity values for the diagnosis of VAo stenosis will need to be tailored towards the individual needs of ultrasound laboratories and respective patient population. P74 MR-Based Algorithms Combining DWI-PWI More Accurately Predicts Tissue Outcome Than DWI or PWI Individually in a Large Patient Cohort. Ona Wu, Hakan Ay, E. M Arsava, Thomas Benner, Christopher Melinosky, Vicky J Tiglias, Athinoula A Martinos Cntr for BioMed Imaging, MGH, Charlestown, MA; Christian A Holt, Dept of Neurology, Massachusetts General Hosp, Boston, MA; Kiran Garimella, Meiyun Wang, Mingwang Zhu, Athinoula A Martinos Cntr for BioMed Imaging, MGH, Charlestown, MA; William A Copen, Pamela W Schaefer, R. G Gonzalez, Dept of Radiology, Massachusetts General Hosp, Boston, MA; Walter J Koroshetz, Aneesh B Singhal, Dept of Neurology, Massachusetts General Hosp, Boston, MA; A. G Sorensen; Athinoula A Martinos Cntr for BioMed Imaging, MGH, Charlestown, MA Background: Previous studies have shown that MRI-based algorithms combining acute DWI-PWI can accurately predict tissue outcome in acute stroke patients. However, these studies have been performed in relatively small patient data sets (⬍ 20 patients). This study investigates the applicability of these models to a large cohort. Methods: DWI-PWI from patients admitted between 1994 –2007 who were not given thrombolytic or catheter-based therapy or enrolled in clinical trials and who received acute MRI⬍12 h from stroke onset and follow-up imaging (F/u) ⬎⫽5 d were analyzed (n⫽120). Combinations of apparent diffusion coefficient (ADC), T2 (T2WI) and DWI (DWI), CBF, CBV, MTT and Tmax (time of peak of deconvolved residue function) were used as covariates in a generalized linear model (GLM) where the output is infarction risk on a voxel-wise basis. Coefficients were calculated using bootstrapping and jackknifing. Receiver operating characteristic curves were generated. Area under these curves (AUC) were calculated and compared (repeated measures ANOVA followed by Student Newman Keuls (SNK) test). Subset analysis among SSS-TOAST subtypes was performed (ANOVA followed by SNK test). The predicted lesion volumes (PLV) using a threshold Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 588 Stroke Vol 39, No 2 February 2008 of 50% for classifying infarcted tissue were correlated with the measured lesion volumes (MLV) on F/u and acute NIH stroke scale scores (NIHSSS). Results: Median NIHSSS was 6, interquartile range (IQR) 3–11. Onset time to MRI was 6.0⫾2.9 h. Age was 65⫾16 y, and 67% male. Distribution of SSS-TOAST subtypes were cardio-aortic embolism (CE: 41%), large artery atherosclerosis (LAA: 26%), small artery occlusion (SAO: 5%), other (12%) and unknown (17%). F/u lesion volume (MLV) had a median of 14 cm3, IQR⫽3– 49 cm3. AUC of the model combining all 7 imaging parameters (ALL model) (0.85⫾0.13) was significantly higher (P⬍0.01) than models using individually T2 (0.47⫾0.12), ADC (0.74⫾0.13), DWI (0.80⫾0.15), CBF (0.69⫾0.14), CBV (0.59⫾0.13), MTT (0.67⫾0.15), or Tmax (0.70⫾0.15), a combination of T2⫹ADC⫹DWI (0.80⫾0.15), and a combination of CBF⫹CBV⫹MTT⫹Tmax (0.75⫾0.15). The ALL model PLV was significantly correlated with the MLV (R⫽0.79, P⬍0.001) and acute NIHSSS (R⫽0.61, P⬍.001). Subset analysis showed that the AUC for SAO (0.67⫾0.29) was significantly smaller (P⬍0.04) than for CE (0.87⫾0.11), LAA (0.84⫾0.11), Other (0.80⫾0.15) or Unknown (0.89⫾0.10). No correlation between MLV and AUC was found. Conclusion: Predictive algorithms combining multiparametric MRI maps on a voxel-wise basis can more accurately predict tissue outcome than only DWI or PWI parametric maps. The high accuracy of these models in a large patient cohort suggest that these algorithms can be used to predict natural infarct risk in different stroke subtypes and therefore assist in the development of treatment strategies on an individual patient basis. P75 Hemorrhage Detection, Both Acute and Chronic, is Comparable on 1.5 vs 3.0 Tesla Magnet Strength. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Amie W Hsia, Lynn Huang, Washington Hosp Cntr, Washington, DC; Brittany R Copenhaver, Georgetown Univ, Washington, DC; Timothy J Schaewe, UCLA, Los Angeles, CA; Chelsea S Kidwell, Georgetown Univ, Washington, DC; for the NIH Natural History of Stroke Investigators Background: MRI gradient echo (GRE) imaging has been shown to accurately detect both acute and chronic hemorrhage, including cerebral microbleeds. However, the detection rate of hemorrhage by field strength has not been systematically studied. We sought to determine if the two most commonly available field strengths (1.5T and 3.0T) are comparable in the detection of both acute and chronic hemorrhage. Methods: We performed a retrospective analysis of consecutive patients admitted to a single stroke center for evaluation of acute ischemic stroke or intracerebral hemorrhage from October 2004 to April 2007. GRE sequences were designed to have equivalent susceptibility weighting. Only patients who underwent MRI with GRE on both a 1.5T and 3.0T scanner were eligible. Images were resliced to 4 –7 mm to minimize slice thickness as a confounding factor. The number and location of acute and chronic hemorrhages were determined by two experienced independent readers, a neuroradiologist and a stroke neurologist, blinded to clinical and MRI field strength information. Results: Thirty-one patients met inclusion criteria. Mean age was 60 years. Primary diagnosis was ischemic stroke in 27 (87%) patients, and ICH in 2 (6%) patients. Median interval between scans was 3 days with the 1.5T MRI performed first in 81% of cases. The number of microbleeds ranged from 0 to 30 with 35% of cases having 1 or more microbleeds on 1.5T versus 32% on 3.0T (p⫽1.0). Inter-observer reliability was high (Cohen’s kappa ⫽ 0.86). There was no significant difference between the number of microbleeds detected on 1.5T compared to 3.0T MRI (pⱕ0.9 and pⱕ0.8, respectively for the 2 readers). In 10 cases the number of microbleeds was discrepant (range of discrepancies 1– 4) between the scanners. In half, more microbleeds were seen on 3.0T and in the other half more on 1.5T. Acute hemorrhages were detected equally for patients undergoing both scans within 7 days of onset. There was no significant difference in detection rate of chronic hematomas (p⫽1.0 for the both readers). Conclusions: This study demonstrates that, using standard GRE sequences, there is no difference in the detection rate of hemorrhage, including microbleeds, on MRI at 1.5T vs 3.0T magnet strength. This finding has important implications for both clinical diagnostic assessment and for multi-center studies. Our findings support the validity of combining data from different scanner strengths in studies that involve cross-sectional or longitudinal microbleed quantification. P76 Endothelial Progenitor Cells and Leukoaraiosis. Glen Jickling, Muhammad S Hussain, Richard Camicioli, James Scozzafava, Ashfaq Shuaib; Univ of Alberta, Edmonton, Canada Introduction Endothelial progenitor cells (EPC) are proposed to be markers of endothelial function and cardiovascular risk. When vascular endothelium is damage, EPCs are mobilized by cytokines and vascular endothelial growth factor. Patients with atherosclerotic vascular disease, including cerebrovascular disease, have significantly lower numbers of EPC. White Matter Changes (WMC) can be seen on CT scan and correlates pathologically with vascular disease. Here we show that the number of EPC correlate with severity of WMC on CT scan. Methods Twenty-five patients experiencing a transient ischemic attack or ischemic stroke were recruited for analysis. EPC were measured using immunolabelling according to the methods previously described. Severity of WMC was assessed on CT using the Age-Related White Matter Changes rating scale previously described. Briefly, two raters independently scored 25 CT scans obtained at the time of cerebrovascular event for severity of infratentorial and supratentorial WMC. Interrater reliability was evaluated by using k statistics. Results EPC were found to decrease significantly with increasing severity of WMC (R2 ⬎0.97, P⬍0.05). Compared to patients without WMC (mean 12.0, SD 4.8), the number of EPC were 83.3% in those with mild WMC (mean 10.0, SD 7.8), 52.5% in moderate WMC (mean 6.3, SD 3.1), and 17.5% in severe WMC (mean 2.1, SD 0.9). Discussion Compared to patients without evidence of WMC on CT scan, EPC levels were significantly lower with increasing severity of WMC. These preliminary results support the association of EPC with cerebrovascular disease, and the use of EPCs as a surrogate marker for vascular dysfunction in cerebrovascular disease. P77 Parenchymal Enhancement on T1-weighted MRI Predicts Subsequent Hemorrhagic Transformation in Acute Ischemic Stroke. Kyung-Yul Lee, Lawrence L Latour, Jose G Merino, Steven Warach, NINDS, Bethesda, MD; for the NIH Natural History of Stroke Investigators Background and purpose: Parenchymal enhancement (PE) on T1-weighted MRI may be evidence of blood-brain barrier breakdown and it reflects risk of hemorrhagic transformation. In addition to conventional T1-weighted image, T1-weighted MRA source image can also detect PE. We assessed the incidence of early PE on T1-weighted images and Hyperintense Acute reperfusion injuRy Marker (HARM) on fluid attenuated inversion recovery (FLAIR) images and their association with subsequent hemorrhagic transformation (HT) in acute ischemic stroke. Methods: Consecutive patients with ischemic stroke with MRI examination performed within 24 hours after onset were enrolled. Immediate PE was evaluated on T1-weighted post gadolinium images acquired within several minutes after gadolinium injection. The first follow up T1-weighted MRA source images and FLAIR images performed within one day after initial gadolinium injection were used to look for PE and HARM, and gradient echo image or CT which performed at anytime within 10 days after stroke to look for hemorrhagic transformation. Results: Immediate PE on T1-weighted post gadolinium images was found in 11 out of 59 patients (18.6%). HT was present in 5 out of 11 patients with immediate PE and 7 out of 47 without it (OR, 4.76; 95% CI, 1.13–19.96; p⫽0.039). PE on follow up was found in 36 out of 80 (45%). HT was present in 19 of the 36 patients with PE on follow up, but only 6 out of 44 without it (OR, 7.08; 95% CI, 2.4 –20.87; p⬍0.001). PE on follow up was seen before HT in 12 patients, and simultaneously or later in 5 and 2. PE on follow up was significantly correlated with higher initial NIHSS score, non-lacunar infarction and shorter time from gadolinium use to follow up MRI. HARM was found in 61 out of 82 patients and most of patients with PE on follow up also showed HARM. HT occurred in 21 out of 60 patients with HARM and 3 out of 21 without HARM (OR, 3.23; 95% CI, 0.85–12.25; p⫽0.098). Using a composite variable of PE on follow up or severe grade HARM, the association with HT was stronger (OR, 10.35; 95% CI, 2.76 –38.75; p⬍0.001). Conclusions: We found PE more frequently in the first follow up T1-weighted MRA source images than in the immediate T1-weighted post gadolinium images. PE on follow up is better than any other single factor in predicting HT and addition of severe grade HARM to PE can increase its power to predict HT. In conclusion, early PE on MRA source image can be used as surrogate imaging marker to predict subsequent HT in acute ischemic stroke. P78 Neural Network Model for Prediction of Final Infarct Volume in Treated versus Untreated Stroke Patients. Marie Luby, Jennifer L Jothen, José G Merino, Julie L Bykowski, National Institutes of Health, Bethesda, MD; Peter D Schellinger, Neurologische Klinik, Erlangen, Germany; Steven Warach, National Institutes of Health, Bethesda, MD; for the NIH Natural History of Stroke Investigators Background and Purpose: The purpose of this study was to predict final infarct volume in patients treated with IV tPA therapy with a neural network model that combines both clinical and imaging variables and to demonstrate the model’s specificity by applying it to untreated patients. Methods: The model was designed using the generalized regression neural network (GRNN) in Matlab™ (v6.5). The model was trained using the baseline predictors of sex, age, National Institutes of Health Stroke Scale (NIHSS), stroke onset time to MRI scan time and corresponding values for follow-up modified Rankin Score (mRS), follow-up NIHSS, baseline lesion volume on diffusion weighted MRI, baseline hypoperfusion volume (on MTT map), follow-up reperfusion (reduction of MTT volume by at least 30%), and final infarct volume on FLAIR MRI. The model was trained with data from patients (N⫽99) that presented with stroke symptoms within 3 hours of onset and underwent acute MRI scans prior to treatment with IV rt-PA therapy. The model was tested with baseline predictors from 13 different patients in order to predict final infarct volume. In order to assess the model’s specificity for predicting outcome in tPA-treated patients, the model was used to predict final infarct volume in 30 untreated stroke patients from the same hospital. Results: The medians and Wilcoxon signed-ranks test were calculated to compare the predicted versus actual values (SPSS for Windows v14.0). The final infarct volume predicted by the treated model (median⫽26.68 cc) did not significantly differ from the actual measured volume for the tPA-treated patients (median⫽21.16 cc, Z⫽-.734, p⫽.463). In the sample of untreated patients, the final infarct volume predicted by Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations the tPA-treated model (median⫽2.07 cc) was different from the actual measured volume (median⫽14.23 cc, Z⫽-3.075, p⫽.002), indicating that the model was specific for tPAtreatment. Conclusions: The neural network prediction model demonstrated promising results for prediction of final infarct volume in tPA-treated patients and in distinguishing tPA-treated from untreated patients. 589 In-hospital mortality and the proportion of patients discharged home remained stable over time (both p⬎.30). Conclusions: In this nine-year cohort, current physicians are treating strokes of greater severity, with fewer deviations from accepted treatment protocols, compared to earlier time periods. Onset-to-ED arrival and arrival-to-treatment times have not improved over time, suggesting additional work is needed in identifying treatment barriers and potential solutions. Additional attention to meeting post-treatment (inpatient) treatment guidelines appears warranted as well. P79 Lower Presenting Systolic Blood Pressure Is Associated With Cardioembolic Subtype In Ischemic Stroke. William J Meurer, Lynda Lisabeth, Brisa N Sánchez, Melinda Smith, Jennifer J Majersik, Devin Brown, Univ Of Michigan, Ann Arbor, MI; Ken Uchino, Univ of Pittsburgh, Pittsburgh, PA; Lewis B Morgenstern; Univ Of Michigan, Ann Arbor, MI Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Introduction: Readily identifying ischemic stroke subtype is crucial for providing directed secondary stroke prophylaxis. We used data from a population-based stroke surveillance study to test the association between presenting systolic blood pressure (SBP) and the ischemic stroke subtype based on TOAST criteria. We hypothesized that clinicians could use low presenting SBP to predict cardioembolic (CE) stroke. Methods: Active and passive surveillance were used to identify all ischemic strokes in patients ⬎44 years in Nueces County, Texas as part of the Brain Attack Surveillance In Corpus Christi (BASIC) study. Ischemic strokes identified between January 2000-December 2002 were validated by board-certified neurologists using source documentation. Cases were classified into subtype categories according to a published, modified version of the TOAST criteria: large-artery atherosclerosis, CE, lacunar non-lacunar stroke of unknown etiology, stroke of other determined etiology and stroke of undetermined etiology. Multinomial logistic regression was used to examine the association between stroke subtype and first documented SBP in the medical record. Gender, ethnicity, NIHSS, age, and history of hypertension and coronary artery disease (CAD) were examined as potential confounders or additional predictors of stroke subtype. Results There were 402 cases identified with completed ischemic stroke. Subtype could not be determined in 22% and 1.5% had a stroke of other determined etiology, leaving 308 cases for analysis. Presenting SBP was associated with stroke subtype (P⫽0.007) in an unadjusted model. The association was also significant (p⫽0.01) in the final model adjusted for age and history of CAD (see table). A 10 year increase in age increased the odds of CE subtype by 56% (OR⫽ 1.56, 95% CI: 1.13–2.16). Conclusions SBP at ischemic stroke presentation is associated with stroke subtype. Lower initial SBP is associated with the CE subtype. Suspicion of CE stroke should be increased in those presenting with lower SBP. RESULTS OF MULTINOMIAL LOGISTIC MODEL OF INITIAL SBP AND SUBTYPE ADJUSTED FOR AGE AND CAD HISTORY. OR IS FOR 10 MM HG DECREASE IN SBP. Subtype OR CE Non Lacunar Large Artery Small Vessel 1.20 1.12 1.04 1.00 P81 CT Angiography And CT Perfusion Before IV tPA For Acute Ischemic Stroke Within The Window: Are We Delaying tPA Therapy Unnecessarily? Anitha Abraham, Sheryl Martin-Schild, Andrew D Barreto, Hen Hallevi, Miriam Morales, James Grotta, Sean Savitz; Univ of Texas, Houston, TX CTA and CTP before IV t-PA for AIS within the window: Are we delaying t-PA therapy unnecessarily? Background: A noncontrast head CT is the only required neuroimaging test prior to t-PA therapy within the 3 hour window for acute ischemic stroke. Many stroke centers are using rapid CT angiography (CTA) and CT perfusion (CTP). At our institution, these studies are used routinely to evaluate extra- and intracranial large arteries and to provide an approximation of the penumbra in patients presenting beyond 3 hours or with an unknown onset time. In some patients presenting within 3 hours, these studies are performed prior to t-PA administration. We sought to determine if pre-lytic advanced neuroimaging with CTP and/or CTA delays administration of IV t-PA for patients presenting within three hours of stroke onset. Methods: From our prospective stroke registry over the past 3.5 years, we identified 277 patients treated in our emergency department with IV tPA within 3 hours of onset. Of these patients, 13 had CTA alone and 12 had both CTA and CTP prior to IV t-PA. We compared onset to needle time and door to needle time among these three groups. Results: The door-to-needle times and onset-to-needle times were not significantly different in patients that had CTA or both CTA and CTP prior to t-PA. There was no difference in baseline NIHSS among patients that had these studies compared with those that only had a noncontrast CT (p⫽0.19). There were no significant differences in discharge disposition (p⫽0.67) or mRS scores (p⫽0.74). Discussion: Rapid CTA and CTP provide potentially useful information regarding tissue salvagability. In our population, IV t-PA treatment was not delayed in patients that had CTA and CTP studies. This result may be explained in part by a protocol we implemented to obtain rapid serum creatinine within 10 minutes of patient arrival to the ED. Further investigations are necessary to determine whether the results of CTA and CTP have meaningful impact on treatment decisions for patients presenting with ischemic stroke in the 3 hour time window. Noncontrast CT only N⫽252 CTA alone N⫽13 CTA and CTP N⫽12 p-value 129⫾ 34 65⫾23‡† 134⫾ 30 71⫾23‡ 131⫾ 39 77⫾14† 0.78, ANOVA 0.136,ANOVA 95%CI 1.07 1.01 0.92 Referent 1.35 1.25 1.18 Onset to needle time, min, mean ⫾ SD Door to needle time, min, mean ⫾ SD ‡p⫽0.235 †p⫽0.911 P82 Partial Recanalization after Intraarterial Thrombolysis: Angiographic Consequences and Clinical Outcome. Acute Management P80 Gyeong- Moon Kim, Oh Young Bang, Chin-Sang Chung, Kwang Ho Lee; Samsung Med Cntr, Sungkyunkwan Univ Sch of Medicine, Seoul, Republic of Korea Objectives: Tissue-type Plasminogen Activator (tPA) was first introduced over a decade ago. The goal of the present analysis was to examine whether there have been improvements in the frequency of protocol deviations, speed of treatment, hemorrhage rates, or outcomes over time. Methods: Time series analysis of 273 stroke patients treated with tPA from 1/1/1996 to 1/1/2005 (55% male, mean age ⫽ 68) from four hospitals in southeastern MI. Treatment years were stratified into three groups (pre-specified): early (1996 –1998, n⫽62); middle (1999 – 2001, n⫽120) and recent (2002–2004, n⫽91). Descriptive statistics, chi square test and two-sample t-tests were use to examine differences in the variables of interest over time. Results: Patient age, gender proportion, premorbid disability (mRS), and onset-to-ED arrival time remained consistent over time (all p⬎.05). The stroke severity (NIHSS) of tPA-treated patients increased from a median of 11 in the early group to 14 in the recent group (p⬍.01). The number of patients with one or more tPA protocol deviations declined significantly (p⬍.01) over time - from 58% in the early group to 33% in the recent group. The improvement was due primarily to reductions in protocol deviations prior to treatment (p⬍.01) as compared to those occurring after treatment (p⫽.38). The mean time from ED arrival to tPA bolus was 100, 93 and 93 minutes in the early, middle and recent groups, respectively. This change was not significant (p⬎.09). The rate of symptomatic intracranial hemorrhage (sICH) did not improve over time (11%, 8% and 9% for early, middle and recent groups respectively; p⫽.66). Background and Purpose: Recanalization is strongly associated with improved functional outcomes and reduced mortality in acute ischemic stroke. For further understanding of the angiographic and clinical consequences of acute ischemic stroke after intraarterial (IA) thrombolysis, we investigated the follow-up MR angiography and functional outcomes with respect to the degree of immediate recanalization status. Methods: We studied 32 consecutive patients with angiographically proven middle cerebral artery (MCA) or internal carotid artery (ICA) occlusion. IA thrombolytic therapy was administered within 3 to 6 hours of onset of symptoms using mechanical thrombolysis alone or in combination with minimal dosage of recombinant tissue plasminogen activator (20mg⬎) or urokinase (300,000 U⬎) given intra-arterially. Angiographic reperfusion was classified according to thrombolysis in myocardial infarction (TIMI) grades. Serial MR angiography (MRA) and perfusionweighted imaging (PWI) at 1, 7, and 90 days, the NIH Stroke Scale (NIHSS) score, 3-month modified Rankin Scale (mRS) were evaluated and compared among complete recanalization (CR, TIMI flow 3), partial recanalization (PR, TIMI flow 1–2), and no recanalization (NR, TIMI flow 0) groups. Results: Mean scores of baseline NIHSS were not different among 3 groups. Any recanalization after IA thrombolysis was observed in 78% of patients (CR: 41%; PR: 37%). Restenosis or occlusion of corresponding vessel on 7-day MRA was found in 2 of 13 patients (15%) with CR and 2 of 12 patients with PR (17%) compared with the initial TIMI grades after IA therapy. Further improvement of TIMI grade was observed in 25% of PR group on 90-day MRA. Baseline improvement of 1 and 7 day NIHSS scores were not statistically different between CR and PR group. NR was associated with poor functional outcome (mRS 0 –2: 13%, P⫽0.03), but no statistical difference was found between CR and PR group (mRS 0 –2: 66% vs 64%). CR group showed early significant improvement of PWI deficits measured by the PWI lesion volume after immediate IA thrombolysis Use of Tissue-type Plasminogen Activator: Have We Improved? Angela F Caveney, William J Meurer, Zhenzhen Xu, Shirley Frederiksen, Ann B Holden, Robert Silbergleit, Phillip A Scott; Univ of Michigan, Ann Arbor, MI Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 590 Stroke Vol 39, No 2 February 2008 (p⫽0.027), whereas PR group showed less but persistent improvement of perfusion deficits compared to NR group through 1 week after symptom onset (CR vs NR, p⫽0.002; PR vs NR, p⫽0.003). Conclusions: These data suggest that partial recanalization may not be associated with poor angiographic and clinical outcomes after IA thrombolysis. The relatively fair clinical outcome may be associated with delayed but persistent improvement of perfusion deficits during acute period. P83 Safety of Thrombolytics in Patients with Malignancy and Acute Ischemic Stroke. Shihab Masrur, MD, Abdul R Abdullah, Eric E Smith, Renzo Hidalgo, Ahmed El-Ghandour, Guy Rordorf, Lee H Schwamm; Massachusetts General Hosp, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Little is known about the risk of thrombolytic therapy in patients with malignancy, as these patients have been excluded from most clinical trials. We reviewed our single center experience of thrombolytic therapy for safety in patients with acute ischemic stroke (AIS) and malignancy. Methods: Consecutive AIS patients admitted from 1/03 to 12/06 (n⫽2148) were retrospectively analyzed to identify those treated with thrombolysis. Patient data were abstracted per the Get With The Guidelines Stroke definitions, or from medical records, by a trained abstractor. Malignancy was identified based on past history or work-up during the index AIS admission. Logistic regression with backward elimination was used to identify independent predictors of in-hospital mortality controlling for age, NIHSS and malignancy. Results: 308 cases of AIS with thrombolytic therapy were identified: 210 (68%) received IV tPA only, 41 (13%) IV tPA ⫹ intra-arterial therapy (IAT), and 57 (18%) IAT only. There were 44/308 (14%) with malignancy (breast, 21%; lung, 18%; colon, 16%; hematologic, 9%; prostate, 9%; skin, 9%; others, 18%); active malignancy was present in 15/44. In-hospital mortality occurred in 16/44 with malignancy (table 1) including 7/15 with active malignancy. Worsening medical condition contributed to 5/7 deaths among those with active malignancy and 1/9 deaths among those with inactive malignancy (p⫽0.03). Active malignancy, but not inactive malignancy, was independently associated with in-hospital mortality when controlling for other predictors (table 2). Symptomatic intracranial hemorrhage (ICH) did not account for the excess mortality in active malignancy (2/15 vs. 17/293, p⫽0.24). Discussion: Active malignancy, but not history of malignancy, is associated with increased in-hospital mortality following thrombolysis for AIS. Nevertheless we cannot exclude a beneficial effect of thrombolysis in this group despite the high mortality. The mortality in active malignancy is mostly attributed to medical comorbidities, and not ICH. These data suggest that IV and IA thrombolysis can be safely given to patients with active or inactive malignancy that have acceptable medical comorbidities and performance status. Patient Characteristic Age (mean ⫹ SD) Gender (% female) NIHSS initial (mean) CAD/MI (%) Diabetes (%) Hypertension (%) Atrial Fibrillation (%) Dyslipidemia (%) Prior Stroke/TIA (%) Smoking (%) Warfarin Use (%) PT ⬎ 15 (%) Platelet count IV t PA only (%) Serious systemic hemorrhage (%) Symptomatic ICH (%) Any ICH on imaging (%) Ambulatory at discharge (%) Mortality (%) Mortality Age NIHSS HTN Smoking Active Malignancy Inactive Malignancy Malignancy (Active or Inactive) (N⫽44) No malignancy (N⫽264) P value 75.1⫹10.4 52.2 15.8⫹7.4 36.4 14.3 70.5 29.6 18.1 18.2 36.4 9.1 15.9 241,300 72.7 2.3 11.4 29.5 47.7 36.4 69.6⫹14.9 50.8 14.6⫹6.8 23.5 18.9 65.5 26.5 15.9 14.4 31.8 5.3 14.5 253,000 67.4 2.3 5.3 28.8 62.1 19.7 0.02 0.85 0.49 0.07 0.2 0.52 0.67 0.71 0.51 0.55 0.32 0.80 0.001 0.48 1.0 0.12 1.0 0.07 0.01 Adjusted Odds Ratio 95%CI P value 1.01 1.20 2.74 0.39 4.26 1.86 0.98–1.03 1.13–1.27 1.20–6.23 0.19–0.82 1.20–15.09 0.66–5.26 0.59 ⬍0.001 0.02 0.01 0.03 0.24 P84 The Usefulness Of Algorithm Of Dysphagia For Management Of Acute Stroke Patients. Boo-Han Hyun, Kayoko Kawase, Shoichiro Satoh, Kuni Konaka, Hiroaki Naritomi; National Cardiovascular Cntr, Suita, Osaka, Japan Background: Dysphagia is an important manifestation of acute stroke which is often connected with poor prognosis. We produced original algorithm of dysphagia for managing acute stroke patients and studied its usefulness in a retrospective manner. Methods: The algorithm was as follows. Stage1 is the initial step in which patients swallow 5 ml water 3 times. Patients clearing Stage 1 move to Stage 2 and swallow 30 ml water. Patients clearing Stage 2 go to Stage 3 and try Repetitive Saliva Swallowing Test. Patients who can not clear Stage 1 move to Stage 4 and swallow a teaspoon of jelly. On the basis of such algorithm, the type of food to be given is determined, such as normal, hard pasting, soft pasting, or tube feeding. The algorithm was applied to all acute stroke patients within 3 days after admission. To clarify the usefulness of algorithm, the time to start food intake and the prevalence of infection or gastrointestinal symptoms were compared between two groups of patients admitted within 3 days after onset, such as Group A admitted between September 2002 and March 2003 without using algorithm (n⫽94, 70⫾12 years) and Group B admitted between September 2005 and March 2006 with using algorithm (n⫽121: 70⫾12 years). Patients going to Stage 4 and the remainders were classified to high-risk and low-risk patients, respectively. The comparison was made also between these two groups. Results: Baseline characteristics including risk factor, stroke subtype, and NIHSS score on admission were the same in Groups A and B. The mean time to start food intake or tube feeding were significantly shorter in Group B than in Group A (1.6⫾2.2 vs 4.0⫾6.6 days, p⫽0.007). The prevalence of pneumonia was lower in Group B than in Group A (19.2% vs 9.1%, p⫽0.03). The prevalence of gastrointestinal symptoms was significantly lower in Group B than in Group A (24.5% vs 13.2%, p⫽0.03). High-risk patients had higher prevalence of pneumonia or gastrointestinal symptoms than low-risk patients (37.5% vs 4.3% and 25% vs 0%, respectively, p⫽0.045). Conclusions: The use of algorithm shortens the time to start food intake safely and detects high-risk patients consequently reducing complications. The algorithm is considered useful for management of acute stroke. P85 Acute Stroke CT Perfusion Imaging Profiles Predict Outcomes Of Early Intravenous Thrombolytic Therapy. Brian H Buck, David J Gladstone, Gabriella Mallia, Sandra E Black, Demetrios J Sahlas, Julia Hopyan, Jacqueline Pettersen, Sean P Symons, Richard I Aviv; Regional Stroke Cntr, Sunnybrook Health Sciences Cntr, Univ of Toronto, Toronto, Canada Background: Multimodal MRI has been used to identify subgroups of stroke patients most likely to benefit from IV-tPA therapy in the 3– 6 hour window. In the 0 –3 hour time window, imaging markers that predict outcome following IV-tPA therapy are less well defined. On CT imaging, the extent of early ischemic change at best has a modest relationship to prognosis. In this study, we present preliminary results from an ongoing prospective cohort study to determine if CT perfusion (CTP) imaging can improve the prediction of prognosis in IV-tPA treated patients in the 0 –3 hour window. Methods: Consecutive anterior circulation ischemic stroke patients treated with IV-tPA within 3 hours of onset and imaged with multimodal CT prior to therapy were identified in a prospectively maintained database at a regional stroke centre in Toronto. CTP studies consisted of 8 slices covering 20 mm, processed with CT Perfusion 3 software (GE Healthcare) to generate CBF, CBV and MTT maps. Volumetric analysis was performed using a semiautomatic threshold technique. Decreased CBV was used to define infarct core and penumbra was defined by the region of increased MTT. Mismatch was calculated as: 100*(MTT-CBV)/CBV. Patients with no perfusion lesion or lesion volumes of less than 10 ml were excluded. Patients were categorized into three groups based on the DEFUSE criteria: target mismatch (⬎ 20% mismatch and lesion volumes less than 100 mL), matched (less than 20% mismatch) and malignant mismatch (mismatch and lesion volume ⬎ 100 mL). Primary outcome was modified Rankin score (mRS) at 3 months. Results: Thirty-six patients met study inclusion/exclusion criteria, mean age was 68.7 and median (IQR) NIHSS was 18 (13–21). The numbers of patients with matched, target, and malignant lesions were respectively: 6 (16.7%), 15 (41.7%), and 15 (41.7%). 83.3% of patients with malignant mismatch had ASPECT scores ⬍8, compared to 50% in the target mismatch and 40% in the matched group. The proportion of good outcomes (mRS ⬍2) at 90 days in the target (26.7%) and malignant mismatch groups (35.7%) did not differ. There was, however, a significant difference in poor outcomes (mRS 4 – 6) between patients with mismatch compared to those matched lesions. All patients (6/6) in the matched group had poor outcomes at 90 days, which was significantly greater than the proportion of poor outcomes in the target (53.3%) and malignant groups (57.7%) (p⫽0.032). Worse outcomes occurred despite the matched group having smaller baseline MTT volumes than the mismatch group (64.1 mL vs 107.8 mL; p⫽0.007) and similar initial median NIHSS scores (18 vs 19). Conclusions: This study showed that in the 0 –3 hour time window, perfusion CT identifies a subgroup of patients without significant mismatch who do not appear to benefit from IV-tPA therapy. These results, if validated in a larger sample, suggest that perfusion CT may enhance patient selection for early thrombolytic therapy. P86 Breaking Traditional Study Time Barriers: A Descriptive Review of Demographic Variables and Unique Early Observations Seen in a Prehospital Stroke Study. Anna Yanes, Theresa Haley, Brenda Pierce, Miranda Gordon, Bogdan Filip, Mike Lee, Minja Cho, Sidney Starkman, Jeffrey Saver, UCLA, Los Angeles, CA; on behalf of FAST MAG investigators and staff Background Many neuroprotective drugs have proven beneficial in the lab but later failed to demonstrate similar effects in phase III trials with 4 –12 hour time windows. FAST MAG (Field Administration of Stroke Therapy - Magnesium) is the first neuroprotective trial to treat subjects in hyperacute time windows similar to the preclinical models. FAST-MAG is a multi-center, Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations double blind, placebo controlled, Phase III clinical trial designed to determine if fieldadministered intravenous magnesium sulfate, given within two hours of stroke symptom onset, improves patients’ functional outcomes. Methods The study has now enrolled more than one-fourth of the planned 1298 patients, permitting delineation of the features of a prehospital trial population.. Results Among the first 382 enrollments, the average interval from last known well time to start of study drug 44 minutes and 73% have had study drug initiated within the first hour after onset. The mean age is 69 and 39% are female. The median NIHSS on ED arrival is 8. Final diagnoses are ischemic stroke in 58%, TIA in 12%, intracerebral hemorrhage in 26% and other in 4%. Unique study aspects will be discussed, such as early conversation by cell phone with an enrolling stroke physician-investigator, multiple confirmations of symptom onset time, and multi-tiered feedback to the paramedics. Conclusion Successes, pitfalls and pearls of wisdom gained from early enrollments of such a novel study will be offered and may prove beneficial for any researcher and coordinator wishing to incorporate a similar study design. P87 Safety and Early Outcomes of Thrombolysis in Patients Who Wake-up with Stroke. Andrew D Barreto, Sheryl Martin-Schild, Hen Hallevi, Miriam M Morales, M. Rick Sline, Nicole R Gonzales, Kachi Illoh, James C Grotta, Sean I Savitz; Univ of Texas-Houston, Houston, TX Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Approximately 25% of ischemic stroke patients awaken with their deficits. The last-seen-normal (LSN) time is defined as the time the patient went to sleep which usually places these patients outside the window for thrombolysis. Purpose: The purpose of this study was to describe our center’s experience with off-label, compassionate thrombolysis for wake-up stroke (WUS) patients. We sought to determine the safety and rates of early outcomes in WUS patients treated with a compassionate protocol consisting of intravenous (IV) and/or intra-arterial thrombolysis (IAT). Methods: Our prospective stroke database was utilized to identify three cohorts of ischemic stroke patients: a) WUS patients treated with compassionate thrombolysis, b) WUS patients not treated with thrombolysis, and c) 0 –3 hour IV tPA treated patients. Outcome measures were symptomatic intracerebral hemorrhage (sICH), favorable outcome (discharge modified Rankin score, mRS 0 –2) and mortality. Statistical analysis was performed using 2, Fisher’s Exact and t-Tests. Outcome measures were controlled for baseline NIHSS, age, early ischemic changes on CT scan and admission glucose using multivariate logistic regression. Results: Thirty-five WUS patients treated with thrombolysis were identified. Sixty percent (21/35) of the treated WUS patients underwent IV thrombolysis alone while 29% (10/35) were given only IAT. Four patients received both IV and IAT (11%). Nine of the 35 had mismatch on penumbral imaging, however presence of mismatch was not associated with better outcomes compared with non-contrast CT alone (P⫽0.47). Treated WUS were compared to 175 standard-of-care (0 –3 hour) IV-tPA patients. There were no significant differences in rates of sICH or favorable outcome after controlling for baseline NIHSS, age, glucose, and presence of early ischemic changes (Figure). A second comparison controlling for the same baseline variables between treated WUS and 26 non-thrombolysed WUS patients revealed similar safety profile and functional outcomes. Conclusion: Thrombolysis may be safe in wake-up stroke patients. Our center’s experience supports considering compassionate thrombolysis for these patients, but a prospective, randomized trial is needed to validate these results. 591 consecutive patients who underwent intra-arterial thrombolysis using tPA within 6 hours following stroke symptom onset. TPA was delivered at 1mg per minute in all cases, and never exceeded 100 mg tPA. The three methods included: 1) continuous infusion of tPA following microcatheter placement within the offending thrombus; 2) microcatheter infusion within the offending thrombus with “microwire clot maceration” and 3) microcatheter placement within the offending thrombus with periodic gentle microcatheter contrast injections and microcatheter repositioning to insure that tPA surrounded the thrombus during delivery throughout the treatment. The latter method results in more homogenous distribution of the thrombolytic agent within the thrombus. Arteriograms were reviewed to assess reperfusion on the basis of the modified thrombolysis in myocardial ischemia score (Mori score)1. Logistic regression analysis for Mori score was performed. Predictors tested included the following factors previously shown to be associated with higher recanalisation rates: time to treatment, site of occlusion (distal vs. proximal), presence of slow antegrade flow around the clot (SAF) and microcatheter technique. All factors with p⬍.10 were entered into the final model as predictors of clinical outcome using backward selection. Any hemorrhage associated with an increase in National Institutes of Health Stroke Scale score of 4 or more was considered symptomatic. Results: Statistically significant predictors for reperfusion on logistic regression analysis (whole model test: p⬍0.0001; r2⫽ 0.26) included: SAF (p⫽0.0008) and method of recanalisation (p⬍0.0001). Good reperfusion rates (Mori 2 or 3 scores) were present in 80% of patients with SAF (p⫽0.0094; Pearson). Good reperfusion rates were found in 31%, 32% and 78% of cases with methods 1, 2 and 3 described above respectively (p⬍0.0001; Pearson); symptomatic hemorrhage rates with methods 1,2 and 3 were 7.1%, 10.7% and 7.3% respectively (p⫽0.867; Pearson). Conclusion: A more homogenous distribution of tPA throughout the offending thrombus via microcatheter repositioning results in higher reperfusion rates in acute stroke. Reference: 1) Arnold M, Nedeltchev K, Remonda L et al. Recanalisation of middle cerebral artery occlusion after intra-arterial thrombolysis: different recanalisation grading systems and clinical functional outcome. J Neurol Neurosurg Psychiatry. 2005; 76:1373– 6. P89 Mediators Of Symptomatic Penumbral Recruitment In Patients With Acute Ischemic Stroke. Mar Castellanos, Hosp Universitari Dr. Josep Trueta, Girona, Spain; Natalia Pérez de la Ossa, Hosp Univ Germans Trias i Pujol, Badalona, Spain; Salvador Pedraza, MRI Unit-IDI. Radiology Service, Girona, Spain; Manuel Rodrı́guez-Yáñez, Hosp. Clı́nico Univ. Santiago de Compostela, Santiago de Compostela, Spain; Joaquı́n Serena, Yolanda Silva, Hosp Universitari Dr. Josep Trueta, Girona, Spain; José Castillo, Hosp. Clı́nico Univ Santiago de Compostela, Santiago de Compostela, Spain; Antoni Dávalos; Hosp. Univ. Germans Trias i Pujol, Badalona, Spain Background and purpose: Although ischemic lesion enlargement is often associated with early neurological deterioration (END), the recruitment of the penumbral tissue does not always cause neurological worsening. In this study we aimed to investigate those factors that might be associated with the symptomatic penumbral recruitment (SPR) in patients with acute ischemic stroke. Methods: From a total of 200 patients with an acute hemispheric infarction within the first 12 hours of evolution, 104 who had significant (ⱖ20%) perfusion-diffusion mismatch (PDM) on admission and significant DWI lesion volume enlargement (ⱖ20%) between admission and 72 h were studied. NIHSS score was evaluated at the same intervals, and END was defined as an increase ⱖ 4 points between the two examinations. The ultimate infarct volume was calculated on FLAIR-MRI at day 30. SPR was considered when the significant DWI lesion enlargement was accompanied by END. For a secondary analysis of the effect of molecular factors, glutamate, interleukin-6, tumor necrosis factor-␣, matrix metalloproteinase-9, and cellular fibronectin levels were determined in blood samples obtained on admission. Results: SPR occurred in 18 patients (17.3%) and was associated with a higher frequency of diabetes history, lower NIHSS score on admission, higher mean systolic blood pressure (SBP) levels at 48 h of evolution, cortical location of the lesion and higher levels of glutamate. No differences were found regarding PWI, DWI, PDM and FLAIR lesion volumes at any time. After adjustment for potential clinical and radiological confounders lower NIHSS score on admission (OR 0.78; 95% CI, 0.62 to 0.99; p⫽0.041) and high SBP at 48h (OR 1.07; 95% CI, 1.01 to 1.02; p⫽0.024) independently predicted SPR. However, after the inclusion of molecular mediators in the model, only glutamate levels remained independently associated with SPR (OR 1.01; 95% CI, 1.00 to 1.03; p⫽0.046) Conclusions: Among clinical, radiological and biochemical mediators, only glutamate levels are associated with SPR which suggest that excitotoxicity mediates symptomatic penumbral recruitment in patients with acute ischemic stroke. P90 Real-Time Validation of Thrombolysis in Brain Ischemia (TIBI) Flow Grading of Recanalization during Intra-Arterial Rescue for Acute Ischemic Stroke. P88 Does The Method For Intra-arterial TPA Delivery Affect Reperfusion Rate? Gregory Christoforidis, Yousef Mohammad, Marinos Kontzialis, Louis Caragine, Andrew Slivka; Ohio State Univ, Columbus, OH Purpose: Three methods for intra-arterial delivery of tissue plasminogen activator (tPA) for acute stroke were compared to determine whether reperfusion rates differ. More homogenous distribution of tPA throughout the offending thrombus via microcatheter repositioning was hypothesized to result in higher reperfusion rates. Methods: This study reviewed prospectively collected clinical information, arteriograms and CT scans following treatment, from 82 Georgios Tsivgoulis, Comprehensive Stroke Cntr, Univ of Alabama Hosp, Birmingham, AL; Marc Ribo, Dept of Neurology, Hosp Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Mark R Harrigan, Dept of Neurosurgery, Univ of Alabama Hosp, Birmingham, AL; Agniezska A Ardelt, David Brenner, Alice Robinson, Comprehensive Stroke Cntr, Univ of Alabama Hosp, Birmingham, AL; Carlos A Molina, Dept of Neurology, Hosp Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain, Birmingham, AL; Joseph A Horton, Div of Neuroradiology, Dept of Radiology, Univ of Alabama Hosp, Birmingham, AL; Andrei V Alexandrov; Comprehensive Stroke Cntr, Univ of Alabama Hosp, Birmingham, AL Background&Purpose: Recanalization is strongly associated with improved functional outcomes and reduced mortality in acute ischemic stroke (IS). It is considered a marker of Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 592 Stroke Vol 39, No 2 February 2008 therapeutic activity in early phase trials of thrombolytic treatment for IS. Transcranial Doppler (TCD) is a bedside, non-invasive tool for the real-time monitoring of the residual flow at the site of occlusion. However, validation of ultrasonographic criteria for recanalization with contrast angiography is limited. We aimed to determine the diagnostic accuracy of TCD detection of recanalization in real time during intra-arterial rescue in acute IS. Subjects&Methods: Consecutive acute IS patients with proximal intracranial occlusions underwent intra-arterial rescue procedures (IA) including mechanical thrombectomy (MT) with simultaneous real-time TCD-monitoring. Residual flow signals at the site of occlusion were monitored at a constant angle of trans-temporal insonation during IA using a standard head-frame. Recanalization was assessed simultaneously by angiography and ultrasound using TIMI (Thrombolysis in Myocardial Infarction) and TIBI (Thrombolysis in Brain Ischemia) criteria respectively. Independent readers blinded to angiographic findings performed real-time validation of TIBI flow grades. Results: We evaluated time-linked real-time DSA-TCD images from 42 diagnostic DSA runs during 10 IA procedures in consecutive acute IS patients. The mean age was 57⫾24 years; there were 4 men and 6 women; median NIHSS was 18, range 6 –28. Four patients had M1-MCA, 1 M2-MCA, 3 TICA, and 2 distal BA occlusions. IA procedures included rt-PA (n⫽3), MT (n⫽2), and combination of rt-PA and MT (n⫽5). IA procedures started at median time from symptom onset of 180min, range 75– 620min. Compared to angiography, TCD had the following accuracy parameters for detection of complete recanalization (TIBI IV-V vs TIMI III flow grades): sensitivity 91% (95% CI 74%–100%), specificity 97% (91%–100%), PPV 91% (74%–100%), NPV 97% (91%–100%), and overall accuracy 95% (89%–100%). In two cases, TCD-monitoring showed flow changes consistent with re-occlusion and collateralization that were helpful to interventionalists in decision-making during the IA procedures. Conclusions: TCD assessment of recanalization yields excellent agreement with invasive contrast angiography in real-time and provides additional hemodynamic data. The usefulness of TCDmonitoring during IA procedures in acute IS is promising and should be further investigated. after stroke, and proxy vs. pt responder. Results: To date, “waiver” data exist for 124 pts (median age 69 yrs, range 38 –93; 22% black/78% white; 48% female; 39% with ⬎12th grade education; median initial NIHSS of 4, range 0 –25; median mRS of 3 at 30 days post-stroke; 20% by proxy); 6 did not answer the waiver questions, and 118 interviews remain to be done in 2007. See Figure for responses from the cohort. The only predictor of a positive response was pt sex: men were more likely to agree to blood samples (OR 2.7, 95% CI 1.1– 6.8, p⫽0.03) and invasive procedures (OR 2.32, CI 1.01–5.3, p ⫽0.047). Conclusions: Nearly half of the interviewed stroke pts were unsure or had a negative opinion regarding acute stroke research involving medical treatments or invasive strategies without express consent from self or family, even though this cohort had already consented for research. Pt sex as an independent predictor of willingness to participate in waiver of consent studies will be further explored and presented within the full cohort. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P91 Modified ABCD And ABCD2 Scores Appear Safe For TIA Triage. James Castle, Connie Wolford, Gregory Albers; Stanford Univ, Palo Alto, CA Background and Purpose: There is existing uncertainty about the appropriateness of using an outpatient rather than inpatient setting to evaluate TIA patients. The purpose of this study was to assess if the use of a modification of the ABCD and ABCD2 models for triage of acute TIA patients would result in a low rate of early stroke (⬍ 2–3%) in patients referred to an outpatient TIA clinic. Methods: In July 2006 the Stanford Stroke Center began using a modification of the “ABCD score” for TIA patient triage: acute TIA patients with 0 –3 points or 4 points and a favorable stroke risk factor profile were referred to rapid outpatient evaluation (TIA Clinic) rather than inpatient hospital admission. On February 20, 2007, after evidence of an improved stroke risk model was published, a modification of the ABCD2 score was adopted: ‘low-risk” patients with a TIA score of 0 –3 points were referred to TIA clinic as were “moderate-risk” patients with a score of 4 –5 points and unremarkable vascular imaging performed in the Emergency Department (no evidence of large artery stenosis (ⱖ50%), clot, or unstable plaque on CT angiography). All other TIA patients are admitted for inpatient observation and evaluation. We prospectively followed all patients referred from the Emergency Department to the TIA Clinic at Stanford University from July, 2006 to July, 2007 to assess the seven day stroke rate. Seven day stroke data were available for 66/68 patients (2 of the patients were lost to follow-up). Results: Of the 66 patients referred from the emergency room to the TIA clinic for whom follow-up data are avialbe, only one had a stroke within one week of their referral. This patient had been triaged using the initial modified ABCD score criteria, and would have been admitted using the new modified ABCD2 criteria, as a significant stenosis with clot was observed on cerebrovascular imaging of his carotid artery. Our overall stroke rate at one week in the referred population was 1.54% (95% confidence interval of 0.1% to 7.6%). Conclusions: Our data indicates that a modification of the ABCD2 and ABCD scores can likely be used to safely triage acute TIA patients to an outpatient evaluation. Future studies with larger sample sizes will provide greater clarification of the risk of early stroke in these patinets. P92 Stroke Patient Perspective Regarding Waiver of Consent and Acute Stroke Research. Dawn Kleindorfer, Kathleen Alwell, Christopher J Lindsell, Charles J Moomaw, Matthew L Flaherty, Daniel Woo, Jane Eilerman, Pooja Khatri, Opeolu Adeoye, Christopher W Nichols, Simona Ferioli, Joseph P Broderick, Brett M Kissela; Univ of Cincinnati, Cincinnati, OH Introduction: “Waiver of consent” is a rigorous procedure regulated by the FDA that requires community assent but allows enrollment without patient (pt) or family consent. Recently, several acute stroke trials have explored the use of waiver of consent to improve enrollment. We obtained ischemic stroke survivors’ opinions regarding hypothetical enrollment into a clinical trial at the time of their stroke without personal or proxy consent. Methods: During 2005, 502 ischemic stroke pts (or their proxy) were prospectively interviewed. At two years post-stroke, 82 had died, 76 were lost to follow-up, and 96 refused follow-up, leaving 248 pts. Pts were asked to think back to the time of their stroke and indicate whether they would have wished to be enrolled in an acute stroke research study before individual or proxy consent could be obtained, understanding that consent would be sought as soon as possible thereafter. Using a modified Likert scale (Figure), they rated how agreeable they would have been to acute stroke research with different levels of invasiveness. Predictors of a positive opinion regarding the hypothetical research were analyzed using logistic regression. Variables included in the model were age, race, sex, education, initial NIHSS, modified Rankin (mRS) prior to stroke and 30 days P93 Evidence of Clustered Recruitment in Randomized Clinical Trials Pertaining to Cerebrovascular Diseases. Jill M Novitzke, Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr Univ of minnesota, Minneapolis, MN Introduction: As a coordinating center for a number of clinical trials, we observed that recruitment varies considerably among participating sites in multi-center trials, potentially impacting overall performance and even outcome of the trial. Our objective was to report recruitment patterns in randomized clinical trials pertaining to cerebrovascular diseases. This information could be utilized for optimal site selection; thus promoting time management and fiscal responsibility. Hypothesis: We assessed the hypothesis that a minority percentage of clinical sites complete the majority of recruiting in clinical trials pertaining to cerebrovascular diseases. Methods: We analyzed data from randomized clinical trials that provided the number of subjects recruited at participating sites. We determined the number of sites that recruit 10% or greater, 5–9%, 1– 4%, and less than 1% of the total number of subjects recruited. Patterns were compared between trials performed predominantly in United States or abroad. Results: We analyzed a total of 7 randomized trials. Of these, 257 participating centers recruited a total of 6432 subjects. Two trials were conducted in the United States and five were conducted abroad. The results are tabulated below: Conclusions: The analysis suggests that nearly half of the participating sites recruit less than 1% of the subjects in clinical trials, highlighting the importance of more rigorous methods to screen, select, and monitor clinical sites. Inference could be made that sites enrolling the majority of subjects are better equipped clinically and have the necessary infrastructure to conduct trials. These data could ultimately be used as a basis to create budget models that are predictive of a center’s recruiting ability, leading to appropriate fund allocation. In conclusion, the pursuit of further data regarding site-specific recruitment performance may translate into a meaningful resource to assist investigators in trial planning and execution, as well as provide guidance to aspiring centers regarding successful trial management. Proportion of subjects recruited ⬍1% 1–4% 5–9% ⱖ10% Number of centers 120 83 36 18 P94 Transcranial Duplex 24 Hour-monitoring of Acute MCA Occlusions after i.v. t-PA Administration: Prognostic Impact of Time-point and Degree of Arterial Recanalization. Laura Dorado, Juan F Arenillas, Natalia Pérez de la Ossa, Mónica Millán, Cristina Guerrero, Domingo Escudero, Elena López-Cancio, Ana C Ricciardi, Patricio Sandoval, Antoni Dávalos; Neurosciences Dep. Germans Trias i Pujol Universitary Hosp, Barcelona, Spain Background and purpose. Early (⬍300 min) & complete arterial recanalization has been shown to be independently associated with favourable clinical outcomes in acute ischemic stroke patients treated with i.v. t-PA. It remains unclear whether recanalization is still beneficial Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations when occurring at later time points or in a partial manner. We aimed to evaluate the prognostic impact of the degree and time-point of arterial recanalization during the first 24 hours after t-PA administration, in patients with acute middle cerebral artery (MCA) occlusions. Methods. We prospectively studied consecutive ischemic stroke patients treated with i.v. tPA following SITS-MOST criteria, who showed MCA occlusions on pre-bolus transcranial Duplex (TCCD) examinations. TCCD recordings were obtained 1, 2, 6, 12 and 24 hours after t-PA treatment. Thrombolysis in Brain Ischemia criteria were used to define complete, partial or absent MCA recanalization at each time point. Early neurological improvement (ENI) was defined as a decrease in ⱖ4 points in the NIHSS score during the first 24 hours. A modified Rankin scale score ⱕ2 at day 90 was considered indicative of good long-term clinical outcome. Results. A total of 61 patients were included. Median baseline NIHSS score was 13 (interquartile range 9 –18). ENI was observed in 32 (53%) patients. Complete, but not partial, recanalization at any time-point was independently associated with ENI in adjusted logistic regression models. The probability of ENI was maximal for ⬍1h complete recanalization (OR 14.7, 95% CI [1.9 –109.2], p⫽0.009) and gradually decreased with later time-points. Thirty-five (57%) patients showed good long-term outcome. Both partial and complete MCA recanalizations achieved at any time-point during the first 12 hours after t-PA bolus were independently associated with good outcome. Odds ratios for favourable outcome attending time frame of any degree of MCA recanalization were 33.7 [2.2–520] for ⬍1h, 12.9 [1.1–182] for 1– 6 h, and 3.1 [0.3–35] for 6 –24h, using the absence of recanalization at 24 hours as the reference category. Conclusion. Any degree of MCA recanalization observed during the first 12h following t-PA administration predicted good long-term outcome. In contrast, only complete recanalization was associated with early neurological improvement. P95 Combined Therapy of IV t-PA with Caffeinol in Acute Ischemic Stroke. 593 prevalence of CIN in those who had a CTA/CTP upon initial evaluation. We hypothesized that the use of contrast for CTA/CTP prior to the availability of renal function tests is safe in code stroke patients. Methods: We retrospectively analyzed our prospectively collected database. We identified all patients seen in our ED as code stroke, presenting within 9 hours of neurological symptom onset. We collected the clinical data that was available at the time of the code stroke activation and until discharge including: demographics, comorbidites and laboratory results. A baseline Cr level ⬎ 2.0 was considered to be the upper cut-off for administration of contrast. An increase in the Cr of ⬎25% within 72 hours of contrast administration was defined as CIN. We used simple descriptive statistics to report our findings. Results: We identified 131 consecutive code stroke patients from December 2006-June 2007. Mean age was 67.8 (⫹/-17.5) years and 79 (62%) were women. A total of 68 (52%) underwent a CTA of the head and neck and 28 received a CTP in addition to the CTA, prior to availability of BUN/Cr. The mean age of these patients was 71.1 (⫹/- 12.9); 59% were women. Of these patients, only 1 patient (1.5%) had a baseline Cr greater than 2, when the laboratory results became available. This patient was known to have end-stage renal disease on dialysis. There were follow up Cr results, obtained within 72 hours, available for 66 of the 68 patients who received contrast. Two (3%) had an increase in the Cr of greater than 25%. Among the remaining 63 code stroke patients who did not receive contrast, 4 (6.3%) had a baseline Cr greater than 2. Three of these 4 patients (75%) had a known history of renal disease. A GFR⬍60, indicating moderate kidney disease, was present in 34% of our code stroke patients, and was not linked with the development of CIN. A total of 78 patients (59%) had a discharge diagnosis of TIA, infarct or hemorrhage. Conclusion: In this population of code stroke patients, 3.8% would not have received contrast based on a Cr level ⬎ 2 upon initial evaluation. However, 80% of these patients had a known history of renal disease and would have been excluded from consideration for CTA/CTP for this reason alone. Our findings suggest that the use of contrast agents in code stroke patients prior to availability of renal function tests appears safe in patients who do not have a known history of renal disease. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Sheryl Martin-Schild, Miriam M Morales, Andrew D Barreto, Hen Hallevi, Jarek Aronowski, Sean I Savitz, James C Grotta; UT Houston Health Science Cntr, Houston, TX Background: Two different rodent models of transient ischemic stroke in separate laboratories have shown that caffeinol reduces cortical damage and enhances neurological recovery. When tested in conjunction with tPA, caffeinol maintained its efficacy and did not increase hemorrhagic conversion. In this phase 1 study, we tested the dosing, safety, and short term outcome of caffeinol as an adjunctive therapy to IV t-PA in acute stroke patients. Methods: Patients 18 years of age and older who presented with a clinical syndrome compatible with ischemic stroke and clinical signs localizing to the cortex were treated with IV t-PA within 3 hrs and caffeinol within 6hrs from symptom onset. Patients were given a 2hr infusion of caffeinol. The dose of caffeine was 8mg/kg or 9mg/kg and the dose of ethanol varied from 0.3g/kg to 0.4g/kg. Our control group was retrospectively collected from our prospective database and consisted of IV t-PA patients treated from 2004 –2007 in our emergency department within 3 hrs of symptom onset who would have met the inclusion criteria for the caffeinol study. Results: Ten patients received t-PA and caffeinol while 90 patients received t-PA alone. There were no significant differences in age or onset to treatment time. Patients treated with tPA alone had significantly lower baseline glucose levels and a trend towards lower median baseline NIHSS scores compared with patients treated with tPA and caffeinol. The caffeinol group had a non-significant shorter time to t-PA treatment and none had early ischemic changes. There was no difference in the rates of hemorrhagic transformation. A significantly higher percentage of patients achieved a mRS 0 –1 at hospital discharge in the caffeinol group (p⬍.05). Discussion: This study suggests that t-PA followed by caffeinol is safe and may lead to a better outcome in acute stroke patients compared with historical controls. A randomized trial testing the efficacy of caffeinol/t-PA compared with standard t-PA treatment alone has been designed. Age Male Baseline NIHSS (median) Glucose Early ischemic changes Time from onset to tPA Time from onset to caffeinol sICH mRS 0–1 at discharge Caffeinol plasma level Ethanol plasma level tPA ⫹ caffeinol n ⫽ 10 tPA alone n ⫽ 90 60⫹19 [26,90] 3 (30%) 18 [7, 24] 178⫹86 [89,333] 0 113.44⫹32.10 [80,170] 195.80⫹61.51 [125,325] 1 (10%) 6 (60%) 8.5 ⫹/- 2.1 26.2 ⫹/- 18.6 67⫹15 [26,90] 46 (50%) 13 [7,25] 141⫹51 [83,341 ] 14 (16%) 131.51⫹29.10 [47,196] 0.211 0.176 0.128 0.046 0.265 0.287 3 (3%) 23 (26%) 0.348 0.032 p value P96 Reducing The Delay In t-PA Use: Is It Necessary To Await The Results Of Renal Function Tests Before CT Perfusion And Angiography In “Code Stroke” Patients? Manu Mehdiratta, Gottfried Schlaug, Sandeep Kumar, Louis R Caplan, David Searls, Adnan Safdar, Magdy Selim; Beth Israel Deaconess Med Cntr, Boston, MA Background: CT Angiography (CTA) and Perfusion CT (CTP) are becoming increasingly utilized in the diagnosis and management of patients with suspected acute ischemic stroke. There is a risk of contrast induced nephropathy (CIN) with these studies. Awaiting the results of serum creatinine (Cr) and glomerular filtration rate (GFR) can delay these studies and the initiation of thrombolysis. We aimed to determine the percentage of patients presenting as “code stroke” who would be excluded from these studies based on their laboratory results; and the P97 Safety And Efficacy Of Ultrasound-enhanced Thrombolysis: A Meta-analysis Of Randomized And Non-randomized Studies. Georgios Tsivgoulis, Comprehensive Stroke Cntr, Univ of Alabama at Birmingham Hosp, Birmingham, AL; Carlos A Molina, Dept of Neurology, Hosp Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Jürgen Eggers, Neurology, Asklepios Hosp North, Hamburg, Germany; Fabienne Perren, Dept of Neurology, Neurosonology Unit, HUG, Univ Hosp and Med Sch of Geneva, Geneva, Switzerland; Marta Rubiera, Dept of Neurology, Hosp Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Vincent Larrue, Service de Neurologie Vasculaire, Université de Toulouse III, France, Toulouse, France; Andrei V Alexandrov; Comprehensive Stroke Cntr, Univ of Alabama Hosp, Birmingham, AL Background&Purpose: Ultrasound-enhanced thrombolysis (UET) is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, three different ultrasound technologies were used to increase the thrombolytic activity of tPA including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD) and low-frequency ultrasound (LFUS). We performed a meta-analysis to evaluate the safety and efficacy of UET compared to the current standard of care (iv-tPA). Subject&Methods: Through Medline search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication was needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA⫹TCD⫾microspheres (S), tPA⫹TCCD⫾S, and tPA⫹LFUS. Results: A total of 6 randomized (224 patients) and 3 non-randomized (192 patients) studies were identified. The rates of sICH in randomized studies were as follows: TCD 3.8% [95%CI: 0%–11.2%], TCCD 11.1% [0%–28.9%], LFUS 35.7% [16.2%– 61.4%] and TPA alone 2.9% [0%– 8.4%], Table. Complete recanalization rates were higher in patients receiving combination of TCD with TPA 37.2% (26.5%– 47.9%), compared with patients treated with TPA alone 17.2% (9.5%–24.9%) both in randomized and combined trials. Additional data including non-randomized studies are shown in the Table. Conclusions: The present safety and signal-of-efficacy data should be taken into account in the design of randomized controlled trials evaluating ultrasound-enhanced thrombolysis. Table. Recanalization and sICH rates in randomized and non-randomized studies of ultrasound-enhanced thrombolysis. Variable Randomized studies Number of patients sICH (95%CI)* Recanalization (complete) Randomized and nonrandomized studies Number of patients tPA tPA⫹TCD⫾S tPA⫹TCCD⫾S tPA⫹LFUS 105 78 27 14 2.9% (0%–8.4%) 3.8% (0%–11.2%) 11.1% (0%–28.9%)** 17.2% (9.5%–24.9%) 37.2% ¶ (26.5%–47.9%) 26.9% ¶¶ (9.9%–44.0%) 35.7% (16.2%– 61.4%)*** Not available 141 208 53 14 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 594 Stroke Variable sICH (95%CI)* Complete Recanalization (95%CI) Vol 39, No 2 February 2008 tPA tPA⫹TCD⫾S tPA⫹TCCD⫾S tPA⫹LFUS 3.5% (0%–8.3%) 3.8% (0%–7.5%) 18.8% (12.0%–25.5%) 40.9% (34.2%–47.6%)§ 9.7% (0%–20.7%)# 42.3% (28.9%–55.7%)§§ 35.7% (16.2%–61.4%)## Not available *Adjusted Wald **p⫽0.175 vs. TCD (Fisher’s exact test), p⫽0.100 vs. tPA (Fisher’s exact test) ***p⫽0.002 vs. TCD (Fisher’s exact test), p⬍0.001 vs. tPA (Fisher’s exact test) ¶ p⫽0.003 vs. tPA (2-test) ¶¶ p⫽0.267 vs. tPA (2-test) # p⫽0.147 vs. TCD (Fisher’s exact test), p⫽0.140 vs. tPA (Fisher’s exact test) ## p⬍0.001 vs. TCD (Fisher’s exact test), p⬍0.001 vs. tPA (Fisher’s exact test) §p⬍0.001 vs. tPA §§p⫽0.001 vs. tPA P98 Uric Acid Prevents The Early Increase In Endogenous Active MMP-9 Levels In Acute Stroke Patients Receiving tPA. Sergio Amaro, Manuel Gomez-Choco, Xabier Urra, Alvaro Cervera, Victor Obach, Stroke Unit, Hosp Clı́nic and IDIBAPS, Barcelona, Spain; Planas AM, Pharmacology and Toxicology Dept, Consejo Superior de Investigaciones Cientı́ficas (IIBB-CSIC) and IDIBAPS, Barcelona, Spain; Angel Chamorro; Stroke Unit, Hosp Clı́nic and IDIBAPS, Barcelona, Spain Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 INTRODUCTION: In experimental ischemia Uric Acid (UA) administration is neuroprotective. Furthermore, in human stroke the combined treatment with tPA and UA is safe and decreases lipid peroxidation. tPA increases the plasma levels of MMP-9, an enzyme able to degrade the blood-brain barrier and to promote hemorrhage and edema. OBJECTIVES: The aim of this study was to evaluate the effect of the antioxidant agent UA in the temporal profile of total and endogenous active MMP-9 levels in stroke patients receiving tPA. METHODS: Patients were part of the Uricoictus trial, a single center, double-blind, randomized, vehicle-controlled trial of intravenous administration of UA in 24 acute ischemic stroke patients treated with tPA (0,9mg/kg) within 3 hours of onset. At the end of the 1-hour tPA infusion, patients were randomized to receive an intravenous infusion lasting 90 minutes of 500 mg of UA (n⫽8), 1 gr of UA (n⫽8), or vehicle alone (n⫽8). Disability was evaluated at day 90 using the modified Rankin Scale (mRS). The levels of total MMP-9 (tMMP-9) and of endogenous active MMP-9 (eaMMP-9) were assessed in serum samples at baseline (T0), at the end of UA/vehicle infusion (T1), and at 48 hours (T2). RESULTS: The tPA treatment was initiated within mean (SD) 133 (35) minutes of onset and UA/vehicle treatment within 212 (42) minutes. Patients who had good clinical outcome at day 90 (mRS of 0 or 1) had lower baseline eaMMP-9 levels (18.3⫾8.2 ng/ml vs 27.5⫾9.4 ng/ml; p 0.028, t-test) and lower T1 eaMMP-9 levels (18.1⫾10.5 ng/ml vs 27.7⫾8.3 ng/ml; p 0.022, t-test). Baseline tMMP-9 and eaMMP-9 levels were not different between treatment groups. In the whole population tMMP-9 levels increased in the hyperacute phase with a peak observed at T1 (183.1⫾117.5 ng/ml at T1 vs 145.6⫾97.3 at T0; p 0.016, paired t-test). At T1 those patients allocated to vehicle showed an increment in the eaMMP-9 levels, while those allocated to the low dose or to the high dose of UA showed a decrement (⫹19.3% ⫾19.4 for vehicle group, -10.2% ⫾14.8 for 500 mg UA group, and -2.5% ⫾ 21.5 for 1000 mg UA group; p 0.013, ANOVA). CONCLUSIONS: UA administration immediately after tPA prevents the hyperacute increase in eaMMP-9 levels observed in acute stroke patients receiving tPA. In tPA treated patients, high acute levels of eaMMP-9 are related to bad clinical outcome. These findings support the role of oxidative stress in in-vivo regulation of MMP-9 and the potential clinical utility of combined treatment with tPA and antioxidants in acute stroke. findings. The Houston outcome analysis showed that HB, EB and WAR were independently predictive of a favorable outcome (p⫽0.004) while ASA treatment predicted a poor outcome (p⫽0.003). Conclusions: Anticoagulation of CES patients can be safely started with warfarin within the first days after CES. Bridging with a full-dose of either heparin or enoxaparin does not reduce stroke recurrence and may increase the risk of systemic and intracerebral hemorrhage. P100 Feasibility and Safety of Very Mild Hypothermia Therapy Using Oral Non-steroidal Anti-inflammatory Drugs in Acute Embolic Stroke: A Case-Control Study. Hiroshi Moriwaki, Kotaro Miyashita, Kazuyuki Nagatsuka, Kuni Konaka, Buhan Hyon, Hiroaki Naritomi; National Cardiovascular Cntr, Suita, Japan BACKGROUND and PURPOSE: Acute stroke is commonly accompanied by fever, which is an important aggravating factor of clinical outcome. Antipyretic pharmacological intervention using acetaminophen was proposed to be an alternative therapy of moderate hypothermia, which requires general anesthesia. However, the effect of acetaminophen administered as suppositories 6 times daily in acute ischemic stroke has been still controversial. We propose the new concept of more feasible therapy using oral administration of loxoprofen-Na, a novel non-steroidal anti-inflammatory drugs (NSAID) with powerful antipyretic and anti-inflammatory actions accompanied by minimal gastro-intestinal complications, in acute ischemic stroke. METHODS: We prospectively included 20 patients (Group A: 13 males, mean age 72.2 yrs) with cardiogenic embolism of ICA or MCA trunk admitted from 3 to 12 hours after stroke. They were treated with very mild hypothermia therapy using oral NSAID (powdered loxoprofen-Na 60 mg, administered via a stomach-tube 3 times daily for 7 days) and ice-cooling. Historical cohort of similar 60 patients without hypothermia therapy matched for age, and time from stroke onset to admission were evaluated as a control (Group B). Patients with thrombolytic therapy were excluded. Axillary temperature was recorded every 6 hours. Sequential CT examinations were performed at days 1, 2, 4 and 7. Stroke severity was quantified with the National Institutes of Health Stroke Scale (NIHSS), and functional outcome was assessed with the modified Rankin Scale (m-RS) and the Barthel Index (BI) at 3 months. RESULTS: Baseline NIHSS scores, occluded site of major arteries, and body temperature on admission were the same in the two groups. Body temperature from days 2 to 7 was significantly lower in Group A than in Group B (36.4⫹/-0.4 degrees vs. 37.1⫹/-0.6 degrees, p⬍0.05) without noticeable side effects. Ischemic lesions on CT were more distinctly demarcated from the surrounding normal area in Group A. Maximum midline shift on CT was significantly smaller in Group A than in Group B (3.7⫹/-2.9 mm vs. 8.2⫹/-6.4 mm, p⬍0.01), and the frequency of massive hemorrhagic transformation was somewhat smaller in Group A (15% vs. 33%). Reduction of NIHSS score at day 30 as compared with the baseline was significantly larger in Group A than in Group B (8.4 vs. 4.9, p⬍0.05). There were no significant differences in the m-RS at 3 months, however the percentage of patients with good function (BI⬎/⫽ 75 at 3 months) was significantly higher in Group A than in Group B (35% vs. 13%, p⬍0.05). CONCLUSION: Very mild hypothermia therapy using oral NSAID and ice-cooling may be useful for the treatment of acute stroke, because of its feasibility, safety and capability to reduce the extent of brain edema. P99 Starting Warfarin After Cardioembolic Stroke: To Bridge or Not To Bridge? P101 The Use of a Portable CT Scanner is Associated with a 58% Reduction in Request-to-Scan Times for Neuro CT Imaging in the Emergency Room of a 280-Bed Community Hospital. Hen Hallevi, Univ of Texas Houston, Houston, TX; Karen C Albright, Dept of Neuroscience, Univ of California, San Diego, San Diego, CA; Sheryl Martin-Schild, Andrew D Barreto, Sean I Savitz, Miguel A Escobar, Nicole R Gonzales, Elizabeth A Noser, Kachi Illoh, James C Grotta, Univ of Texas Houston, Houston, TX; The VISTA Investigators David B Weinreb, North Shore Med Cntr/Salem Hosp, Salem, MA; Lee H Schwamm; Massachusetts General Hosp, Boston, MA Background: Cardioembolic Stroke (CES) comprises 20% of all ischemic strokes and may carry a higher risk of hemorrhagic transformation. While guidelines do not support acute anticoagulation of CES patients, uncertainty exists regarding the best timing and method of initiating long-term anticoagulation. Methods: We conducted a retrospective review of all patients admitted to our stroke center with CES not treated with tPA. Data was abstracted regarding type of anticoagulation or antiplatelet and adverse events. Clinical outcome was determined using the modified Rankin scale (mRS). Poor outcome was defined as mRS 4 to 6. Patients were grouped into the following treatments treatment: No treatment, aspirin only (ASA), aspirin followed by warfarin (WAR), IV heparin in the acute phase followed by warfarin (heparin bridging- HB), and full-dose enoxaparin combined with warfarin (enoxaparin bridging- EB). The study endpoints were hemorrhagic transformation (HT), systemic bleeding, stroke progression, mortality and the rate of poor outcome on discharge. Pooled data from the Virtual International Stroke Trials Archive (VISTA) project of 402 CES patients that served as control in acute stroke treatment trials was used to validate our adverse events distribution. Results: Two hundred and four patients met inclusion criteria. Recurrent stroke occurred in 2 patients (one in the ASA group and 1 in WAR). Progressive stroke was the most frequent serious adverse event seen in 11 patients (5.4%). Anticoagulation was associated with a reduced rate of stroke progression (1/108 in anticoagulated patients vs 10/96 in patients treated with aspirin or no-treatment; p⬍0.001). HT occurred in a bimodal distribution- an early (day 0 –3 from stroke onset) non-symptomatic HT, and a late (9 –22 days) symptomatic HT. All 3 cases of symptomatic HT cases were in the EB group (10% of the EB group, p⫽0.003 comparing EB and non-EB patients). Systemic bleeding occurred in 2(1%) of patients - all in the HB group (4.5% of the HB group, p⫽0.043 comparing HB to non-HB patients). The VISTA cohort replicated these Background: Our Emergency Department (ED), residing in a 280-bed community hospital, ordered more than one thousand head CT scans within the last year. Many of these patients had presented with signs of acute stroke and rapid neuroimaging is necessary before anti-coagulation or thrombolytic therapy can be initiated. The NIH and American Stroke Association recommend that CT imaging of acute stroke patients be performed with 25 minutes of the patient’s arrival. To facilitate rapid neuroimaging, many large tertiary care centers have installed fixed CT scanners in the ED, although it may be more cost-effective for community hospitals to purchase a portable head/neck CT. We performed a prospective study to determine whether the use of a portable CT scanner reduces request-to-scan times for ED patients. Methods: A portable head/neck CT scanner was purchased for the ED (CereTom® CT, NeuroLogica Corporation, Danvers, MA). The system is a mobile, high-resolution 8-slice CT scanner equipped to perform non-enhanced CT, CT angiography and CT perfusion studies. Request-to-scan times were recorded on all patients requiring neuroimaging for any clinical indication, including acute stroke and trauma. Request-to-scan times are reported as mean⫾standard deviation for the months prior to and following the introduction of the portable scanner. The data was analyzed using a two sample student’s t-test. Results: The use of the portable CT scanner was associated with a 58% reduction in mean request-to-scan times for neuroimaging of ED patients (P ⬍ 0.001, n⫽530). The mean request-to-scan time was 39⫾5.1 minutes (n⫽127) for the month prior to the use of the portable scanner; request-to-scan times for the four consecutive months for which the portable scanner was used were 17⫾2.7 minutes (n⫽121, P ⬍ 0.001), 13⫾1.9 minutes (n⫽92, P ⬍ 0.001) and19⫾1.8 minutes (n⫽120, P ⬍ 0.001) and 13⫾1.3 minutes (n⫽69, P ⬍ 0.001). Image quality was determined to be equivalent to the conventional CT scanner by the interpreting radiologists. Conclusion: A portable head/scanner CT scanner may be a cost-effective Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations approach to reduce time to rapid neuroimaging of patients with acute neurological injury (e.g., suspected stroke, trauma, infection) in the community hospital setting. P102 Safety of Thrombolysis in Stroke Mimics. Georgios Tsivgoulis, Stroke Program, Barrow Neurological Institute, Phoenix, AZ and UAB Comprehensive Stroke Cntr, Birmingham, AL; Steven Hoover, James L Frey, Annabelle Y Lao, Vijay K Sharma, Wei Liu, Murray Flaster, Stroke Program, Barrow Neurological Institute, Phoenix, AZ; Anne W Alexandrov, College of Nursing, Arisona State Univ, Phoenix, AZ and UAB Sch of Nursing, Birmingham, AL; Marc Malkoff, Stroke Program, Barrow Neurological Institute, Phoenix, AZ; Andrei V Alexandrov; Comprehensive Stroke Cntr, Univ of Alabama at Birmingham Hosp, Birmingham, AL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background&Purpose: Efforts to increase the availability of intravenous thrombolysis and to shorten the time for delivery of iv-TPA carry the potential for TPA administration in stroke mimics. Limited data exist regarding the use of thrombolysis in patients erroneously diagnosed as having ischemic stroke (IS) in emergency department (ED). We aimed to determine safety of thrombolysis in stroke mimics and to describe outcomes in these patients. Subjects&Methods: A retrospective cohort design was used to analyze stroke registry data from consecutive IS admissions treated with iv-TPA according to standard indications from January 2002 to December 2005. The National Institutes of Health Stroke Scale (NIHSS) scores on admission, the presence of previous and modified Rankin Scores (mRS) at discharge were documented as standard of care. Ischemic lesions on brain MRI (routinely performed as part of diagnostic work-up 24 –72 hrs from symptom onset) were documented from radiology reports. Decision for administration of thrombolytic treatment was based on baseline brain CT-scan in all cases. Initial stroke diagnosis in ED was compared to the final hospital discharge diagnosis. The diagnosis of stroke mimics was based on the absence of ischemic lesions on DWI sequences in addition to the final diagnosis. Symptomatic intracerebral hemorrhage (sICH) was defined as brain imaging evidence of ICH with clinical worsening by NIHSS score increase of ⱖ4 points. Results: A total of 381 IS patients (216 men; mean age 66⫾14years) received intravenous thrombolysis. Misdiagnosis of IS was documented in 31 cases (8%, 95%CI: 5.4%–10.9%). Conversion disorder (35%) and complicated migraine (19%) were the most common final diagnoses in stroke mimics treated with TPA. Stroke mimics were younger (mean age 56⫾12 years) and had milder stroke severity (median baseline NIHSS: 5 points, interquartile range 5 points) compared to those with confirmed acute IS (mean age 67⫾14 years; NIHSS 10 points, IQR 8 points; p⬍0.001). No sICH occurred in stroke mimics (0%, Adjusted Wald 95% CI: 0%–9.6%). All stroke mimics were functionally independent at hospital discharge (mRS: 0 –1). The length of hospitalization was shorter in stroke mimics (median 3 days, IQR 2 days) compared to confirmed acute IS patients (median 5 days, IQR 4 days; p⬍0.001). Conclusions: Our data indicate that symptomatic hemorrhagic complications did not occur in stroke mimics treated with iv-TPA at our center. Since the number of cases is limited, definitive conclusions regarding safety of thrombolysis cannot be drawn with statistical confidence. Stroke mimics also had a shorter length of hospital stay and they were functionally independent at hospital discharge. P103 Periprocedureal Sedation During Intervention for Acute Stroke. Christopher W Nichols, Pooja Khatri, Univ of Cincinnati, Cincinnati, OH; Sharon Yeatts, Med Univ of South Carolina, Charleston, SC; Janice Carrozzella, Judith Spilker, Thomas Tomsick, Joseph P Broderick, Univ of Cincinnati, Cincinnati, OH; The IMS II Investigators Background: In order to safely perform acute intra-arterial (IA) revascularization procedures, use of sedative medications and paralytics is often necessary. In our experience, the clinical indication and level of sedation can vary greatly, ranging from protocol mandated paralysis of all IA cases to no routine sedation. We sought to identify patient characteristics that would correlate with the need for deeper sedation, and to explore whether levels of sedation relate to patient outcomes. Methods: We studied 75 of 81 patients in the Interventional Management of Stroke (IMS) II Study who had anterior circulation strokes and underwent angiography and/or intervention. We defined “mild sedation” as that which did not affect the patient’s exam, and “heavy sedation” as that which did affect the exam by clinical judgment. We tested for factors potentially associated with four levels of sedation (Table 1), and examined whether dichotomized sedation (no/mild sedation versus heavy sedation/pharmacological paralysis) correlated with 90-day modified Rankin Score (mRS) 0 –2 or death. Results: Among the baseline and treatment factors listed in the Table 1, only baseline NIHSS was significantly associated with level of sedation (p⫽0.01). Sedation (p⫽0.02), baseline NIHSS (p⫽0.03) and baseline systolic blood pressure (p⫽0.04) were associated with death in univariate analysis. Using stepwise logistic regression, only level of sedation was associated with death (p⫽0.02; OR 5.0, 95% CI 1.34, 18.7). Sedation (p⫽0.003), baseline NIHSS (p⫽0.08), baseline aphasia (p⫽0.11), baseline glucose (p⫽0.12), female sex (p⫽0.004), and duration of procedure (p⫽0.13) were associated with poor outcome in univariate analysis. Stepwise regression showed only sedation (p⫽0.002; OR 7.0, 95% CI 2.0, 24.5) and female gender (p⫽0.004; OR 5.5, 95% CI 1.7, 17.2) to be associated with poor clinical outcome. Conclusion: In our analysis, higher baseline NIHSS correlated with use of deeper sedation during or prior to angiography and/or intervention. The clinical indication for the level of sedation confounds the analysis, since higher levels of sedation mark more severe disease. In this small sample, patients not receiving sedation fared better. Further examination of the indications for procedural sedation or paralysis and their effect on outcome is warranted. Table 1. Characteristics and outcomes of patients in each sedation category Number Age Baseline NIHSS Male Gender Non-White Atrial Fibrillation Aphasia Present Left Hemisphere Involved Baseline Glucose Baseline SBP Onset to IV treatment (min) Received IA treatment Onset to IA treatment (min) Duration of procedure (min) Death mRS 0–2 595 No Sedation Mild Sedation Heavy Sedation Pharmacological Paralysis All Groups p-value 40 64.6 17.30 26 (65%) 7 (17.5%) 11 (27.5%) 19 (47.5%) 20 (50%) 9 63.56 19.44 4 (44.4%) 2 (22.2%) 2 (25%) 6 (66.6%) 6 (66.6%) 9 64.00 21.00 3 (33.3%) 1 (11.1%) 2 (22.2%) 6 (66.6%) 8 (88.8%) 17 62.82 21.24 11 (64.7%) 5 (29.4%) 3 (17.6%) 11 (64.7%) 11 (64.7%) 75 64.00 18.89 44 (58.6%) 15 (20%) 18 (24.3%) 44 (58.7%) 45 (60%) 0.98 0.03 0.26 0.68 0.95 0.11 0.17 120.1 ⫾ 42.6 143.8 ⫾ 22.6 141.6 ⫾ 33.5 25 (62.5%) 116.1 ⫾ 19.4 150.1 ⫾ 10.4 127.67 ⫾ 38.3 8 (88.8%) 169.0 ⫾ 104 143.67 ⫾ 20.9 139.11 ⫾ 28.4 8 (88.8%) 125.24 ⫾ 38.8 147.41 ⫾ 21.0 139.00 ⫾ 25.5 12 (70.5%) 126.63 ⫾ 52.5 145.36 ⫾ 20.7 139.05 ⫾ 31.6 53 (70.6%) 231.6 ⫾ 55.3 111.2 ⫾ 59.3 3 (7.5%) 4 (8.2%) 24 (60%) 30(61.2%) 234.63 ⫾ 55 119.89 ⫾ 65.9 1 (11.1%) 236.8 ⫾ 57.7 136.80 ⫾ 65.7 6 (35.2%) 234.3 ⫾ 51.9 123.09 ⫾ 60.5 238.5 ⫾ 35.4 150.89 ⫾ 44.4 2 (22.2%) 8 (30.8%) 6 (66.6%) 2 (22.2%) 6 (23.1%) 0.68 0.83 0.75 0.31 0.99 0.26 12 (16%) 4 (23.5%) 36 (48%) P104 Microcatheter-Guided Intra-Clot Administration of Microbubbles During External Continuous 2-MHz Ultrasound Insonation Safely Enhances Thrombolysis in Acute Stroke. Marc Ribo, Carlos Molina, Marta Rubiera, Beatriz Alvarez, José Alvarez-Sabin, Manel Matas; Hosp Vall d’Hebron, Barcelona, Spain AIM Microbubbles (MBs) and ultrasound have shown to enhance the thrombolytic effect of systemic tPA. We sought to evaluate the safety and efficacy on middle cerebral artery (MCA) recanalization of local microcatheter-guided intra-clot administration of MBs during intraarterial (IA) thrombolysis and external continuous 2-MHz pulsed-wave transcranial Doppler (TCD) monitoring. METHODS. Nine patients with acute stroke due to proximal MCA occlusion were treated with IA tPA (repeated 4 mg doses up to 20 mg or recanalization) and IA galactose based MBs (up to 3 doses of 1 ml (400 mg/dl)). MBs and tPA were infused through a microcatheter directly intra-clot. TCD flow monitoring during the procedure allowed continuous insonation at clot location. Retrieving devices were not used. Recanalization was angiographically assessed according to the TICI reperfusion score and compared to simultaneous online TCD data. In all cases IA procedures were stopped at 6 hours after symptoms onset. Recanalization was re-assessed with TCD at 12 hours after symptoms onset. Hemorrhagic transformation was assessed at 24 hours according to NINDS criteria. In-hospital neurological status was assessed with the NIHSS score. At three months patients were considered independent if mRS was ⱕ2. RESULTS Of the nine included patients (mean age 72 years) 7 received standard iv. tPA treatment (0.9 mg/kg) prior to the IA rescue procedure. Median pre-IA procedure NIHSS score was 20. Median time to IA procedure initiation was: 175 minutes. The mean IA administered doses were: tPA 10 mg, MBs 3 ml. TCD monitoring allowed direct visualization of massive MBs arrival during every dose administration In 7 patients (78%) recanalization was confirmed at the end of MBs infusion: complete-TICI 3: 2 patients (22%), partial-TICI 2: 5 patients (56%). A perfect correlation was observed between TICI and TCD scores. According to TCD, at 12 hours recanalization rate was still 78%, however complete recanalization increased to 56%. One patient (11%) experienced a symptomatic intracranial hemorrhage accounting for the only death in the series. Median NIHSS evolution was: 12 (inter-quartile range 6 –19) at 24 hours and 10 (range 6 –14) at discharge. At three months 44% of patients were independent. CONCLUSION Ultrasound-activated intraclot-delivered MBs in combination with tPA may be a safe strategy to enhance the thrombolytic effect and increase recanalization rates. Ongoing study: presented data will include all future treated patients. P105 Lack Of Association Between Cholesterol Levels And Risk Of Hemorrhagic Transformation After Intravenous Rtpa. Manuel Gomez-Choco, Victor Obach, Xabier Urra, Sergio Amaro, Alvaro Cervera, Martha Vargas, Angel Chamorro; Hosp Clinic, Barcelona, Spain Introduction: Low total cholesterol levels have been associated to hemorrhagic stroke and recently low LDL cholesterol (LDL-c) has been associated to hemorrhagic transformation after thrombolysis. Methods: We prospectively collected the demographic, clinical and radiological data of consecutive patients treated with IV-rtPA within 3 h from symptoms onset at our institution from July 2001 to June 2007. The aim of our study was to asses if there was a relationship between the cholesterol levels and the risk of hemorrhagic transformation after IV-rtPA in our population.Only patients whose cholesterol levels were determined within 48 h from stroke were included in the study. Results: One hundred and twelve out of 192 patients were analyzed (mean age 70.86 SD 12.78, 68 men and 45 women). There were a total of 11 hemorrhagic infarctions and 6 parenchymal hemorrhages. There were not differences in the Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 596 Stroke Vol 39, No 2 February 2008 levels of either total cholesterol or LDL-c between patients with or without hemorrhagic trnasformation (195.29 SD 43.85 vs. 197.45 SD 45.55, p⫽ 0.857 and 127.94 SD 59.94 vs. 123.49 SD 38.52, p⫽0.771). Both total cholesterol and LDL-c levels were also similar among patients with either IH, PH or no bleeding (127.09 SD 66.78 vs. 129.50 SD 50.74 vs. 123.49 SD 38.52; p⫽ 0.918 and 187.45 SD 45.42 vs. 209.66 SD 40.55 vs 197.45 SD 45.55; p⫽ 0.618, respectively). In the multivariate analysis, neither total cholesterol nor LDL-c adjusted for age, glucose, arterial pressure, NIHSS, smoking, early ischemic changes and time to treatment, were associated to hemorrhagic transformation(OR 0.996, IC 95% 0.982–1.011, p⫽ 0.657 and OR 1.003, IC 95% 0.988 –1.019, p⫽ 0.669, respectively). Conclusions: We have not found any relationship between either total cholesterol or LDL-c levels and hemorrhagic transformation after IV-rtPA in our population. Preexistent hypocholesterolemia should not play a role in the treatment decision of stroke patients until more data are available. P106 The HAT Score: A simple Grading Scale for Predicting Hemorrhage After Thrombolysis. Min Lou, The 2nd Affiliated Hosp of Zhejiang Univ, Hangzhou, China; Adnan Safdar, Sandeep Kumar, Gottfried Schlaug, Louis Caplan, Manu Mehdiratta, David Searls, Magdy H Selim; Beth Israel Deaconess Med Ctr, Boston, MA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose: Intracerebral hemorrhage (ICH) is the most feared complication of thrombolytic therapy for acute ischemic stroke (AIS). We aimed to develop a simple grading scale that can be used at the bedside during the hyperacute phase to predict the risk of ICH after treatment with intravenous t-PA. Methods: We identified key factors associated with increased risk for ICH after t-PA in AIS from published literature. We allotted point(s) to each predictor based on its prognostic value, and constructed a 5-point scale, based on the weight of 4 easily-obtainable pre-treatment factors to predict the risk of hemorrhage after t-PA “HAT Score”. We evaluated the predictive ability of this model in 2 independent cohorts of patients; the t-PA treated group in the NINDS study, and consecutive patients treated with IV t-PA at our institution, according to ASA/AHA guidelines. The prognostic ability of the model was evaluated with c-statistics. Results: The HAT score comprised the sum of individual points assigned as follows: pre-treatment NIHSS score ⱕ 15 (⫽0 points), 15 - ⱕ 20 (⫽1), and ⬎ 20 (⫽2); history of diabetes and/or baseline blood glucose ⬎ 200 mg/dl (yes ⫽1; no ⫽0); and the presence of visible hypodensity on initial head CT scan (no ⫽0; ⬍ 1/3 of middle cerebral artery territory ⫽1; and ⱖ 1/3 of MCA territory ⫽2). We evaluated 302 patients in the NINDS trial (age: 68⫾11; 57% women), after excluding 10 with incomplete data elements, and 98 local patients (age: 71⫾17; 51% women). The percentage of patients who developed any ICH after t-PA rose with higher scores in both cohorts. Collectively, the rate of any symptomatic ICH was 2% (0 point), 5% (1 point), 10% (2 points), 15% (3 points), and 44% (ⱖ 4 points). The predictive capability of the model, c statistic, was 0.72 (95% CI 0.65– 0.79; p⬍0.0001) for all hemorrhages; 0.74 (0.63– 0.84; p⬍0.0001) for any symptomatic hemorrhages; and 0.79(0.70 – 0.88; p⬍0.0001) for symptomatic fatal hemorrhages. Similar results were obtained when each of the two cohorts was analyzed separately. Including other variables, such as age, smoking, or concurrent use of antithrombotics, did not improve the model’s predictive ability. Conclusions: The HAT score is a practical, quick, and easy-to-perform scale that allows reasonable risk stratification of ICH after IV t-PA, and could improve standardization of t-PA use in patients with AIS. The prognostic value of this scale needs to be prospectively confirmed in a larger cohort of patients. P107 Lack Of Association Between Neurology Consultation Prior To Administration Of Intravenous Thrombolytics And Prevalence Of Protocol Deviations. William J Meurer, Angela F Caveney, Lingling Zhang, Robert Silbergleit, Phillip A Scott; Univ Of Michigan, Ann Arbor, MI Introduction: It is common practice for emergency physicians to consult a neurologist prior to administering tPA in acute ischemic stroke. It is unclear whether this prevents protocol deviations from published guidelines. We assessed the hypothesis that consultation with neurology would be associated with fewer protocol deviations. Methods: Retrospective analysis of 273 consecutive tPA-treated acute stroke patients at 4 hospitals from 1996 through 2004 was performed. The primary outcome studied was presence of a protocol deviation, including pre and post-treatment. Multivariate binary logistic regression was then used to determine the odds ratios for protocol deviation without consultation compared to patients with consultation. Results: TThere were 119 patients with protocol deviations (52 in ED, 48 inpatient, 19 both.) Patients receiving a consult had protocol deviation rate of 44.4%, whereas those without a consultation had a rate of 40.9% (p ⫽ .614 by chi-square.) The door to drug time was similar with and without consultation (94 and 98 minutes, respectively.) In the adjusted model (see table), the association between obtaining a neurology consultation and protocol deviation did not achieve statistical significance, after controlling for covariates. Treating hospital, history of prior stroke and history of atrial fibrillation were significant predictors and were included in the final model. Stroke severity and patient demographic factors such as age, gender, and race were not significant predictors. Conclusions: Neurological consultation was not found to be associated with decreased protocol deviations in this cohort. The sample size for a clinical trial able to detect the observed 3.5% difference in protocol deviations would require 3134 patients per group, assuming 80% power. This approaches U.S. estimates for the total number of tPA-treated stroke patients annually. A registry or a very large observational study would be the optimal study design to demonstrate such a difference, if present. Method of Consult Neurology Thrombolytic Expert Either/Both Adjusted Odds Ratio For Deviation 1.06 0.62 1.25 95% CI P (0.55,2.06) (0.66,2.01) (0.58,2.68) 0.86 0.62 0.57 P108 Intracranial Volume Adaptation and Complications after Decompressive Hemicraniectomy with Durotomy. Axel J Rosengart, Charity Cordero-Tumangday, Jeffery I Frank, Bahk Yamini, Fernando D Goldenberg; The Univ of Chicago Med Cntr, Chicago, IL Decompressive hemicraniectomy with durotomy (DHwD) is increasingly utilized in patients with expanding, space-occupying hemispheric lesions neuromedically intractable intracranial hypertension, often as a life-saving procedure. However, there is limited information available delineating the intracranial volume changes and operative complications post DHwD. We report a prospective case series of 28 DHwD patients with the following diagnoses: 12 (43%) ischemic stroke, 9 (32%) subarachnoid hemorrhage (SAH), 2 (7%) intracerebral hemorrhage, 5 (18%) non-vascular. Intracranial volume changes on pre- and postoperative head CT were quantified in 15 cases using ANALYZE software. All pre- and postoperative CT images and complications thought to be directly related to the DHwD procedure were evaluated by 2 independent neurointensivists. Mean age of 48 years; 57% females; 57% Non-Caucasian, 43% Caucasian. Hemicraniectomy was performed within an average of 2.6 hours from onset of the clinical herniation syndrome. Mean pre-operative intradural volume was 1353cc which increased to a mean of 1506 cc post-operatively (11%). Postoperative subgaleal volume increased by 10%, while the intraventricular CSF space expanded by 25%. Pre-operative ICP monitoring was available in 57% (n⫽16) of cases with mean ICP of 40 mmHg (range 16 –90 mmHg). Post-operative ICP monitor was utilized in 82% (n⫽23) with mean ICP values of 16 mmHg (range 8 - 30). The average ICP reduction post-operatively was 25 mmHg. Pre-operative mean anteroseptal shift was 10 mm (range 4 - 19), while the mean pre-operative pineal shift was 5 mm (range 0 - 12). Mean reduction was 6 mm and 3 mm, for anteroseptal and pineal midline shift, respectively. Complications included: a) nonsurgical ipsilateral intraparenchymal hemorrhages 4/28 (14%) b) subdural hematoma requiring surgical evacuation (3/28, 11%) c) hydrocephalus 7/28 (25%) d) wound breakdown in 4/28 (14%) e) CSF drainage-related infection in 3/28 (11%). Decompressive hemicraniectomy with durotomy reverses the brain herniation syndrome from acutely expanding hemispheric vascular lesions as demonstrated by ICP normalization and detailed intracranial morphometric analyses. However, DHwD may be associated with clinical complications including subdural and intraparenchymal hemorrhages, hydrocephalus, wound breakdown, and infections. P109 SPECTRM - Stroke Patients Eligible for Clinical Trials - a Regression Model. Alexis M Taylor, Amanda B Castle, NIH, NINDS, Section on Stroke Diagnostics and Therapeutics, Bethesda, MD; Amie W Hsia, Washington Hosp Cntr, Washington, DC; Jose G Merino, NIH, NINDS, Section on Stroke Diagnostics and Therapeutics, Bethesda, MD; Chelsea S Kidwell, Georgetown Univ, Washington, DC; Steven Warach, NIH, NINDS, Section on Stroke Diagnostics and Therapeutics, Bethesda, MD; for the NIH Natural History of Stroke Investigators Objective: To develop a model for estimating the proportion of stroke patients eligible for clinical trials based on the three most influential variables: age, National Institutes of Health Stroke Scale (NIHSS), and onset to triage time (OTT). Methods: This study was a retrospective review of all patients with confirmed acute ischemic cerebrovascular syndromes referred to the stroke team over a 70 month period at two hospitals. Patients were excluded if missing any of the required data points. Onset to treatment time window was assumed to be one hour later Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations than the onset to triage time, which was recorded for each patient. The cumulative proportion of patients over the range of values was plotted for each of the three variables and fit to a regression curve. The regression equations thus generated were used to calculate the proportion of strokes satisfying a given range of trial eligibility criteria (e.g., NIHSS 6 –30). Assuming the correlations among these factors are negligible, the product of the predicted proportions for each of the 3 eligibility criteria is taken as the overall estimate of the proportion of stroke patients meeting these trial eligibility criteria. Results: The model was developed from one half of the total sample of 1323 cases, and confirmed using the second half of the data. Age was fit by a Weibull function, onset to triage time by a third order logarithmic function, and NIHSS by a first order logarithmic function (See figure). When applying this model to a clinical trial, for example the MR RESCUE trial, with inclusion criteria of age 18 – 85, NIHSS 6 –30, and onset to triage time (OTT) 2–7 hours, the probability of patients meeting each of these criteria would be 81 %, 37%, and 27% respectively. The final probability of patients meeting all three criteria is 8.1%. Conclusions: We have demonstrated a simple approach to estimating the proportion of a stroke center’s population that may be eligible for a specific clinical trial based on age, NIHSS, and onset to triage time. Differing demographics across stroke centers and geographies may yield different regression equation parameters, but the approach should be applicable to all stroke centers and additional eligibility criteria. This approach may be valuable for clinical trial planning. P110 Application Of The “Practical” Continual Reassessment Method (CRM) To Two Phase I Dose-finding Studies Of Neuroprotection In Ischemic Stroke. Scott W Miller, Sharon D Yeatts, Med Univ South Carolina, Charleston, SC; Adnan I Qureshi, Univ of Minnesota, Minneapolis, MN; Steven R Messe, Univ of Pennsylvania, Philadelphia, PA; Yuko Y Palesch; Med Univ South Carolina, Charleston, SC Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background - There are no FDA-approved neuroprotective medications for ischemic stroke. However, given the public health implications of an effective neuroprotective agent, it is likely that a large pool of potential agents will continue to be developed and investigated. As a result, methods for improving the efficiency and safety of Phase I dose-finding and safety studies are desirable. The “practical” continual reassessment method (pCRM) is a non-Bayesian approach to dose-finding. It has several modifications to improve safety over the original CRM model, while still retaining statistical advantages over more traditional algorithms, e.g. the commonly used “3⫹3” design. Unlike the “3⫹3” design, the pCRM allows for a continuous dosing range rather than requiring pre-specification of a limited number of arbitrary doses. We evaluated the operating characteristics of the pCRM for Phase I dose-finding studies in the setting of two planned erythropoiesis neuroprotection studies. Methods - We conducted simulation studies using a SAS macro to examine the behavior of the pCRM for these two treatments across a wide range of possible MTDs/MEDs. For the first agent, we modeled a traditional doseresponse curve to identify the maximum tolerated dose (MTD). For the second agent, we used an efficacy response to find the minimally effective dose (MED) worthy of further study. We examined the average sample size required, the average dose recommended, the number of patients exposed to subtherapeutic doses, and the effect of model mis-specification. Results - Based on approximately 1000 simulated datasets per setting examined, the pCRM is efficient, in that it requires a median of 39 subjects (95% CI 25– 45) to reliably estimate the MTD/MED. Few subjects (18%) are treated at sub-therapeutic doses (doses significantly below the MTD/MED), and the majority of these are due to the requirement to start at the lowest dose; excluding these decreases this to only 5%. Less than 3% of the subjects were treated in the upper 10th percentile of the doses under consideration, and none were exposed to doses beyond the pre-specified maximum acceptable dose. 57% of the simulations recommended a dose within 10% of the true dose, and 90% within 20%. Conclusions - Our simulations highlight several of the advantages of the pCRM. The sample size needed for this approach is in a feasible range for a Phase I trial, patient exposure to non-efficacious or toxic doses is minimized, and the model appears to be robust to mis-specification of the underlying dose-response curve. Finally, the pCRM demonstrated excellent accuracy in determining the correct dose established by the simulation. We recommend that this model be considered more routinely for Phase I dose-finding neuroprotectant trials for stroke. P111 Is Mechanical Clot Removal a Cost-Effective Treatment for Acute Stroke? Mai N Nguyen-Huynh, S Claiborne Johnston; UCSF, San Francisco, CA Background Several mechanical clot-retrieval devices have been tested as therapies for acute ischemic stroke and one of these was recently approved by the FDA for the removal of clots causing ischemic strokes. While reported rates of recanalization with mechanical therapies have been promising and would be expected to improve outcomes, it is not known whether the upfront costs and risks would make this option cost effective. We sought to examine whether mechanical clot removal is a cost-effective treatment for acute stroke compared to best medical therapy, using recanalization as an intermediate to derive expected outcomes. Methods We performed a cost-utility analysis of patients with acute stroke due to large intracranial artery occlusion presenting beyond the 3-hour window for intravenous tPA. We compared mechanical clot removal to best medical therapy for secondary stroke prevention. This analysis was done with a societal perspective. Model inputs for the mechanical clot removal arm were derived from raw data from Multi MERCI trial as well as a recent meta-analysis [Stroke 2007;38:967–73], and included rate of recanalization with the device, rates of intracerebral hemorrhage (ICH) for successes and failures, and functional outcomes, as well as costs of the procedure and hospitalization. For the best medical therapy arm, we used 597 rates of spontaneous recanalization [Stroke 2007;38:967–73], intracerebral hemorrhage (ICH), and functional outcomes [JAMA 1999; 282:2003–2011] based on current literature. Discounted QALYs were determined for 65-year-old patients with acute stroke, with 3-month functional outcomes categorized by modified Rankin scores (mRS) of 0 –2, 3–5, and 6. Interventions with cost-effectiveness ratios ⬍$50,000/QALY are generally considered cost-effective. Results For the base case, we modeled a rate of recanalization was 84% for mechanical clot removal with a 6.2% rate of symptomatic ICH. For best medical therapy, we modeled a spontaneous recanalization rate of 24% with a 2% rate of symptomatic ICH. With these inputs mechanical clot removal was associated with a $26,000 net saving and a gain of a 0.21 QALYs for each use, thus dominating medical therapy. In sensitivity analysis, results were highly dependent on the rates of recanalization, symptomatic ICH, and 3-month functional outcomes. Conclusions Based on the published literature, mechanical clot removal in qualified patients presenting with acute stroke who are beyond the 3-hours window appears to be cost-effective compared to best medical therapy. However, results of this analysis are based on a number of assumptions and are sensitive to estimated variables. P112 Barriers to the Emergency Use of Thrombolysis for Acute Ischemic Stroke: the INcreasing Stroke Treatment through INteractive Behavioral Change Tactics (INSTINCT) Trial. William J Meurer, Jennifer J Majersik, Shirley M Frederiksen, Lingling Zhang, Annette Sandretto, Phillip A Scott; Univ Of Michigan, Ann Arbor, MI Introduction: Numerous internal and external barriers exist which inhibit adherence to guidelines recommending tPA delivery in acute stroke. We used qualitative methods to describe and prioritize barriers to the delivery of tPA. Methods: The INSTINCT trial is a multi-center, randomized, controlled study to evaluate a barrier assessment and interactive educational intervention designed to increase appropriate tPA use in stroke. Hospitals were randomly selected from the population of eligible Michigan acute care hospitals and matched into 12 pairs. The intervention sites, randomly assigned within the pairs, underwent qualitative barrier assessment. Focus groups were conducted by trained leaders with representatives from each intervention site using a professionally developed discussion guide. Six groups, of 4 – 6 individuals each, ran concurrently and had verbatim transcriptions made. A prespecified taxonomy was employed to characterize barriers to clinical guideline adherence. Two investigators independently coded the transcripts into themes using a grounded theory approach. Participant responses were coded into 9 main themes: 6 internal barriers (motivation, self-efficacy, outcome expectancy, and lack of awareness, agreement, or familiarity with guidelines) and 3 external barriers (environmental factors such as slow specialist response, patient/family factors such as delayed arrival times, and guideline factors such as contradictory guidelines). A single paragraph (the coding unit) could be assigned 0 –9 themes. Results: There were 30 participants: 10 emergency physicians (EPs), 15 nurses, 3 neurologists, 1 hospitalist, and 1 pharmacist. A total of 605 responses were coded into the 9 themes. The agreement between the coders was 82.1%. Environmental and patient factors were the most frequently cited barriers (37.1% and 16.7% of total coded responses respectively). Other important barriers included familiarity with (13.0%) and motivation to adhere to (10.4%) the guidelines, self-efficacy (the feeling that one could not perform the guideline) (9.7%), and outcome expectancy (the belief that performing the guideline would not lead to the desired outcome) (8.0%). Lack of awareness of the existence of acute stroke guidelines, presence of conflicting guidelines, and lack of agreement with the guidelines were not important barriers (each ⬍5%). Nurses were somewhat more likely to cite lack of familiarity as a barrier (17.3% vs. 8.8%) and less likely to cite lack of agreement (1.4% vs. 5.1%) when compared to EPs. Conclusions: Acute stroke stakeholders perceive environmental and patient factors as the primary barriers to adherence with acute stroke guidelines. Detailed knowledge of these barriers is crucial to designing effective educational interventions to improve guideline adherence. P113 Serum Magnesium And Early Stroke Severity: Influence On Stroke Syndromes. Paolo Milia, Stroke Unit, Univ of Perugia, Perugia, Italy; Ken Lees, Stroke Unit, Glasgow, United Kingdom; Katiuscia Nardi, Neurology, Perugia, Italy; Maurizio Paciaroni, Michele Venti, Valeria Caso, Sergio Biagini, Giancarlo Agnelli; Stroke Unit, Univ of Perugia, Perugia, Italy Background: Magnesium revealed to be benefit in animal models of stroke and recently the IMAGES trial revealed significant benefit of intravenous magnesium in patients with non cortical stroke particularly in lacunars clinical syndromes (LACS) Purpose and methods: We aimed to test whether serum magnesium collected at admission on acute stroke patients can play a role on early neurological clinical pattern and if there is a difference between the various clinical syndromes and/or subtypes of stroke We studied patients consecutively admitted to our Stroke Units. Serum Magnesium was collected at admission: values were divided in four subgroups (Mg⬍1.6, Mg 1.7, Mg 1.8 –1.9, Mg ⬎ 2). Severity of stroke was assessed according to NIHSS, respectively at admission (NIHSS0) and after 72 hours (NIHSS72). Outcome was valuated using mRS. Results: One thousand consecutive acute stroke patients were studied (832 Ischaemics, mean age 75⫾11, 168 Haemorrhagics mean age 73⫾13). Among the overall patients the mean NIHSS score difference between the four Mg groups showed a worst clinical pattern in patient with Mg⬍1.6 at NIHSS0 ( 10⫾7 p 0.01). Focusing on ischemic stroke the same results was obtained for Mg⬍1.6 group at NIHSS0 (10⫾7 p0.02) showing also a less probability to be Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 598 Stroke Vol 39, No 2 February 2008 alive at 72 hours (p 0.02). There were no differences in hemorrhagic strokes. The stroke syndromes had similar frequencies among the four subgroups although LACS showed a worst clinical pattern at NIHSS72 (6⫾5, p0.01) within the Mg⬍1.6 group. After binomial logistic regression analysis Lacs group showed a more probability of bad outcome (mRS⬎2) having a Mg 1.7 at admission (p 0.03 CI 1.07–7.3). Conclusions: Low serum magnesium at admission seems to be related with bad clinical presentation in ischaemic stroke patients rather than haemorrhagics. Particularly LACS syndrome seems to be more sensible to low serum magnesium, thus justifying the recent results of clinical trials and underlying the opportunity of MG treatment in LACS. P114 Mechanical Approaches Combined with Intraarterial Pharmacological Therapy are Superior to Either Intervention Alone in Revascularization of Acute Carotid Terminus Occlusion. Ridwan Lin, Nirav Vora, Sayed Zaidi, Ajith Thomas, Michael Horowitz, Univ of Pittsburgh Med Ctr, Pittsburgh, PA; Rishi Gupta, Michigan State Univ, East Lansing, MI; Susan Kim, Maxim Hammer, Ken Uchino, Lawrence R. Wechsler, Tudor Jovin; Univ of Pittsburgh Med Ctr, Pittsburgh, PA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose: Acute stroke caused by occlusion of the internal carotid artery terminus (TICA) carries a poor prognosis. Intraarterial (IA) pharmacologic thrombolysis is associated with low recanalization rates. We sought to determine whether adjunctive mechanical revascularization achieves better vessel recanalization and functional outcome in acute TICA occlusions. Methods: We retrospectively reviewed 59 consecutive interventional cases of acute stroke due to TICA lesions treated at our center between October 1998 and July 2007 and collected clinical, CT, angiographic and followup outcome data. Mechanical approaches (MERCI retrieval, angioplasty, stent) with or without adjunctive IA pharmacological therapy were compared to intraarterial thrombolysis alone (urokinase (UK) or tissue plasminogen activator (TPA)). Some patients in both groups also received intravenous thrombolysis. Univariate and multivariate analyses were performed to determine predictor(s) of recanalization (Thrombolysis in Myocardial Infarction (TIMI) scores of 2–3) and favorable functional outcome at 3 months (modified Rankin score of 0 –2). Results: Lowest recanalization rates were observed with IA-TPA/UK with or without adjunctive intravenous TPA or glycoprotein IIB-IIIA inhibitor (3/13, 23.1%). MERCI retriever and adjunctive intraarterial TPA/UK therapy was associated with the highest recanalization rates (8/10, 80%, p⫽0.012). Angioplasty and/or stenting with adjunctive IA-TPA/UK achieved 54.6% recanalization (6/11,p⫽0.21). Baseline age, admission NIH stroke score (NIHSS), Alberta Stroke Program Early CT score (ASPECTS) score, time to intervention, and stroke etiologies were not significantly different between these groups. In a multivariate regression analysis, MERCI retriever ⫹ IA-TPA/UK adjunct (OR⫽12.5, CI⫽2.24 –106.2, p⫽0.01) and any mechanical thrombolysis ⫹ IA-TPA/UK adjunct (OR⫽4.71, CI⫽1.2–21.2, p⫽0.031) independently predicted TIMI 2–3 recanalization. No statistically significant difference was observed between the use of mechanical only (1/4), mechanical ⫹IA (3/18), or IA only therapies (3/13) in development of type 2-parenchymal hemorrhages (p⫽0.88). In a stepwise logistic regression model, age (OR⫽0.94, CI⫽0.88 –1.0, p⫽0.045), admit NIHSS (OR⫽0.78, CI⫽0.61–1.0, p⫽0.05), and TIMI 2–3 recanalization (OR⫽5.6, CI⫽0.98 –31.9), p⫽0.052) were associated with favorable functional outcome. Conclusions: Mechanical approaches in combination with adjunctive IA pharmacological therapy are superior to pharmacologic thrombolysis or mechanical intervention alone in revascularization of acute TICA occlusion. P115 Reliability of NIHSS Training and Certification in Across Multiple Venues. Patrick Lyden, Rema Raman, Lin Liu, Karen Rapp, Univ of California, San Diego, CA; Marion Emr, Margo Warren, John Marler; NINDS, Bethesda, MD The AHA/ASA offers web-based training and certification for users of the NIH Stroke Scale, the most widely used certification for participation in modern stroke clinical trials. Users may train and certify from the web, using a DVD individually, or in group settings. We sought to measure inter-rater reliability of the certification video across multiple venues using methodology previously published for NIHSS reliability. We obtained scores from users who certified on the website (n⫽7,419), individually (n⫽379), in small groups (n⫽178) and at large meetings of trial investigators (n⫽238). Demographic data was not available for website raters, but from the other venues we obtained responses from 795 raters: 32.5% of all responses came from nurses, 3.9% from ED physicians, 44.2% from neurologists, and 7.7% from others. One half (50.8%) of raters were previously NIHSS certified. Item responses were tabulated, scoring performed as previously published, and agreement measured with unweighted Kappa Coefficients and an intraclass correlation coefficient. We used bootstrap and jackknife methods to estimate variances and confidence intervals since there were an unequal number of ratings within patients. Kappas ranged from 0.15⫾0.06 (Ataxia) to 0.81⫾0.16 (LOCC questions). Of 15 items, 2 showed poor, 11 moderate, and 2 excellent agreements, based on Kappa scores. The pattern of Kappa scores resembled those obtained in previous studies, with Ataxia, and Face showing poorest agreement, and LOCQ and LOCC shows best agreement. The intraclass correlation coefficient for total score was 0.85 (95% CI 0.80 - 0.90). Reliability scores were not statistically significantly different among all venues although scores for individual use were highest, followed by group settings, followed by website. There were no major differences in agreement between nurses and physicians for non-web users. Kappa scores were similar by previously certification status. These data show that NIHSS certification via the AHA/ASA website does not differ, in terms of reliability, from certification obtained via other venues and is a reasonable alternative to DVD certification. P116 Characteristics of Cardioembolic Stroke in Response to Thrombolytic Treatment. Hyo Suk Nam, Dept of Neurology, Ajou Univ College of Medicine, Suwon, Republic of Korea; Kyung-Yul Lee, Dept of Neurology, Yonsei Univ College of Medicine, Youngdong Severance Hosp, Seoul, Republic of Korea; Seong Hwan Ahn, Dept of Neurology, Chosun Univ College of Medicine, Gwangju, Republic of Korea; Sang Won Han, Dept of Neurology, Inje Univ College of Medicine, Sanggye Paik Hosp, Seoul, Republic of Korea; Jong Yun Lee, Dept of Neurology, National Med Cntr, Seoul, Republic of Korea; Seo Hyun Kim, Dept of Neurology, Yonsei Univ Wonju College of Medicine, Wonju, Republic of Korea; Dong Chul Park, Dept of Neurological sciences, Univ of Nebraska Medicine Cntr, Omaha, NE; Ji Hoe Heo; Dept of Neurology, Yonsei Univ College of Medicine, Seoul, Republic of Korea Objective: Although responses to thrombolytic treatment vary among individual, clinical factors to predict the responses are not well known. A growing body of evidence suggests that stroke patients due to cardioembolism (CE) show poor prognosis and frequent hemorrhagic transformation. However, it is uncertain how patients with CE would respond to the thrombolytic treatment. Methods: This study was conducted by retrospective review of case series from a prospective stroke registry. All the consecutive patients who received the thrombolytic treatment were investigated. Stroke due to CE were defined as the presence of atrial fibrillation, sick sinus syndrome, mechanical valve replacement, mitral stenosis, dilated cardiomyopathy, and congestive heart failure. The recanalization was determined based on the Thrombolysis In Myocardial Infarction (TIMI) grading system. Results: From January 2000 to May 2005, 166 patients received thrombolysis. Among them, 11 (6.6%) patients were excluded due to incomplete data. Finally, data of 155 patients were analyzed for this study. The modality of thrombolytic treatment was IV tissue-type plasminogen activator (tPA) in 73 (47%), intraarterial (IA) urokinase in 32 (21%), combined IV tPA and IA urokinase treatment in 50 patients (32%). Eighty patients (52%) had been identified having one or more than one CE before thrombolytic treatment. The patients with CE were older (p⫽0.007) and of female predominance (p⫽0.003). Onset-to-treatment (159.5 vs. 137 minutes p⫽0.056), and baseline NIHSS scores (18 vs. 14, p⫽0.074) were not different between patients with CE and those without. Although, overall recanalization rate (TIMI 2 or 3) was not different (67% vs. 73% p⫽0.456), complete recanalization (TIMI 3) was less often achieved in patients with CE (22% vs. 44%, p⫽0.01). According to the modality, IV tPA was less effective for achieving complete recanalization against CE clots (19% vs. 58%, p⫽0.013), while responses to IA urokinase (p⫽0.961) and combined treatment (p⫽0.139) were not different between patients with CE and those without. Hemorrhagic transformations were more common in patients with CE (44% vs. 23%, p⫽0.005). Poor outcome (modified Rankin score ⱖ3) at 3 month were frequent (59% vs. 37%, p⫽0.008) in patients with CE. Conclusions: The present study demonstrated that cardioembolic stroke is predictive of incomplete recanalization, a poor response to IV tPA, poor functional outcome, and hemorrhagic transformation. P117 Impact of the Metabolic Syndrome on the Temporal Profile of Arterial Recanalization after Thrombolysis for Acute Middle Cerebral Artery Ischemic Stroke. Juan F Arenillas, Mónica Millán, Natalia Pérez de la Ossa, Cristina Guerrero, Domingo Escudero, Laura Dorado, Elena López-Cancio, Ana C Ricciardi, Patricio Sandoval, Antoni Dávalos; Neurosciences Dep. Germans Trias i Pujol Universitary Hosp, Barcelona, Spain Background and purpose: The metabolic syndrome (MetS) is a cluster of vascular risk factors associated with a prothrombotic state and enhanced inhibition of endogenous fibrinolysis. We aimed to evaluate the impact of MetS on the temporal profile of arterial recanalization after systemic thrombolysis in patients with acute middle cerebral artery (MCA) ischemic stroke. Methods: We prospectively studied 77 consecutive ischemic stroke patients showing an MCA occlusion on prebolus transcranial Duplex (TCCD) examination, who were treated with i.v. t-PA following SITS-MOST criteria. The MetS was diagnosed during admission following AHA/NHLBI2005 criteria. The occluded MCA was monitored by serial TCCD recordings obtained 2, 6, and 24 hours after t-PA treatment. Thrombolysis in Brain Ischemia (TIBI) criteria were used to define complete, partial or absent MCA recanalization at each time point. Arterial recanalization was defined as early when complete or partial recanalization occurred ⬍6h after t-PA bolus. Results: Mean age of included patients was 67.8 ⫾ years. The MetS was diagnosed in 44 (56%) patients. Median baseline NIHSS score was 14 (interquartile range 9 –18). Patients with the MetS showed a temporal profile of MCA recanalization characterized by a lower likelihood of achieving complete or partial recanalization at 2h [16 MetS patients (36%) vs. 19 no-MetS (58%)] and at 6h [22 (50%) vs. 25 (76%)] after t-PA, and by a higher frequency of absent recanalization at 24 hours [16 (36%) vs. 2 (6%)] (p⫽0.021). The differences were more pronounced in the same direction when considering the time profile of complete MCA recanalization (p⫽0.0004). The MetS emerged as independently associated with a lower probability of early MCA recanalization (OR 0.34, 95% CI [0.12– 0.98], p⫽0.046) and with a higher odds of absent MCA recanalization at 24 h (OR 9.8, 95% CI [1.8 –53.5], p⫽0.008), in multivariate logistic regression analyses adjusted for age, sex and baseline glycemia. Conclusion: The temporal profile of t-PA induced MCA recanalization in patients with the MetS appears to be characterized by a lower likelihood of early (⬍6h) MCA recanalization and by a higher risk of persistent (⬎24h) MCA occlusion. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations P118 Rescue Thrombolysis And Beyond ; Usefulness Of Intravenous Tirofiban In Acute, Progressing Cerebral Infarction. Jae H Sung, Seung H Yang, Jae T Hong, Byung C Son, Sang W Lee, Chun K Park; St. Vincent’s Hosp. (Neurosurgery), Suwon, Republic of Korea Introduction The platelet glycoprotein (GP)IIb-IIIa receptor blockers has been accepted for coronary intervention and nowadays, they are increasingly used for thrombolysis of acute occlusive stroke. For powerful blocking of platelet-fibrin aggregation, we applied intravenous (IV) tirofiban to various acute progressing ischemic strokes. Material and Method From March 2006 to Feb 2007, total 18 cases of cerebral infarction were treated using intravenous tirofiban (male 9, mean age 63.2⫾10.7). Progression of infarction was defined as any subjective or objective neurologic deterioration despite of conventional conservative management of acute infarction. Dosage was strictly matched with manufacturer’s recommendation (body weight dependent loading dose for 30 min followed by maintenance dose). Categories of infarction are as follows; acute occlusion of major cerebral arteries (Group 1, n⫽3), progressing infarction of anterior circulation (Group 2, n⫽8) and of posterior circulation (Group 3, n⫽7). During maintenance infusion, the blood pressure was strictly controlled under 160mmHg of systolic pressure. Results Mean interval between admission and onset of progression in group 2 and 3 was 25.3⫾15.1 hrs. Total duration of tirofiban maintenance were 1.1⫾0.9 days in group 1, 3.9⫾1.7 days in group 2 and 5.0⫾3.3 days in group 3. Success rate of progression arrest were 33% (1/3) in group 1, 62.5% (5/8) in group 2 and 85.7% (6/7) in group 3. Most frequent side effect was hematuria (4 cases) followed by rash (1 case). In only one case with gross hematuria, tirofiban was used intermittently. No intracranial hemorrhagic complication occurred. Conclusion Intravenous tirofiban therapy may be effective and promising for arrest of various types of progressing stroke. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P119 Early Ischemic Changes May Be Associated With Symptomatic Hemorrhage in Multi MERCI. Helmi L Lutsep, Oregon Stroke Cntr, Oregon Health & Science Univ, Portland, OR; Tudor G Jovin; Univ of Pittsburgh Med Cntr, Pittsburgh, PA Objective: To investigate whether more marked early ischemic changes, measured using the Alberta Stroke Program Early CT Score (ASPECTS), are associated with the development of symptomatic intracerebral hemorrhage (sICH), poorer outcomes and lower frequency of recanalization in patients treated with mechanical embolectomy in the Multi MERCI study. Background: More significant early ischemic changes, ASPECTS ⱕ 7, have been associated with parenchymal hemorrhages in 6 hour trials of tissue plasminogen activator and pro-urokinase. More severe ischemia has been linked with lower likelihood of vessel recanalization. Methods: Patients with anterior circulation strokes enrolled in Multi MERCI and baseline ASPECTS ⱕ 7 were compared to those with ASPECTS ⬎ 7 as determined by the investigator for development of sICH (4-point National Institutes of Health Stroke Scale (NIHSS) change and any blood on imaging at 24 hours), good outcome (modified Rankin ⱕ 2) and post procedural revascularization success (TIMI 2–3). The groups were compared for age, gender, baseline NIHSS, baseline blood glucose, history of congestive heart failure, use of lytics, lesion location, time to groin stick, procedure duration and number of passes. Results: ASPECTS ⱕ 7 was present in 24 of 147 cases (16%) and baseline characteristics did not differ from the ASPECTS ⬎7 group. Those with ASPECTS ⱕ 7 trended toward higher overall sICH rates (17% (4/24) versus 6.5% (8/123), p⫽0.11) and developed more symptomatic PH2s (dense hemorrhages exceeding 30% of infarct volume) (13% versus 0.8%, p⫽0.014). Good outcomes (29% in low ASPECTS vs. 39% high, p⫽0.49) and mortality (33% in each, p⫽1) did not differ significantly between the 2 groups, despite a tendency toward more revascularization success in those with higher ASPECTS (54% vs. 69%, p⫽0.16). Conclusions: More marked early ischemic changes may be associated with sICH and perhaps less vessel recanalization while not significantly affecting outcomes after mechanical embolectomy. Since only 16% of the cases were reported to show these changes, however, the accuracy of the study investigator’s assessments is uncertain. A blinded panel review of the MERCI and Multi MERCI scans is in progress. P120 Drip-and-Ship Thrombolytics: Is This Approach Safe to Deliver Standard-of-Care Therapy for Acute Ischemic Stroke? Sheryl Martin-Schild, Miriam M Morales, UT Houston Health Science Cntr, Houston, TX; Aslam M Khaja, Univ of Illinois at Chicago, Chicago, IL; Andrew D Barreto, Hen Hallevi, Anitha Abraham, M. Rick Sline, James C Grotta, Sean I Savitz; UT Houston Health Science Cntr, Houston, TX Background: Tissue plasminogen activator within 3 hrs of symptom onset remains the only proven treatment for acute ischemic stroke (AIS), yet national rates of t-PA use among eligible patients remain ⬍5%. Many small hospitals are reluctant to treat with t-PA unless the patients can be rapidly transferred to stroke centers for post-lytic care. While this approach has been shown to increase t-PA delivery, the safety and liability, remain concerns. Our stroke center serves as a hub for emergency departments covering a radius of more than 100 miles. Methods: From our prospective stroke registry, we identified patients over the past 3.5 years who presented to outside hospitals (OSH) with acute stroke symptoms, were treated with t-PA 599 after consultation with our stroke team, and then transferred for further care. We compared the baseline demographics, NIHSS, onset-to-needle and door-to-needle times, adverse events (sICH, PH2, and neurological deterioration), and early outcomes (discharge mRS and disposition) of drip-and-ship patients with patients treated within 3 hours of onset with IV t-PA in our emergency department. Pearson’s Chi-Square (for categorical measures) and t-Test (for continuous measures) explored potential differences between transfer patients and patients treated at our stroke center. Results: We accepted 93 patients after treatment with IV t-PA at outside hospitals. Only 67 (72%) were treated within 3 hrs of onset. When these patients treated within 3 hrs were compared with the 319 patients treated directly at our institution over the same period, we found no difference in age or gender, but a significantly higher proportion of transfers were white. The baseline NIHSS was lower in patients treated at OSH (p⫽0.043). The door-to-needle time was significantly prolonged at OSH (p⬍0.0001), but there was no difference in adverse events. Patients treated at OSH had a trend to more favorable early outcomes. The inclusion of patients treated beyond 3 hrs at OSH yielded a mean onset to needle of 160 minutes, which did not affect the incidence of adverse events or good outcomes (mRS 0 –1). Discussion: The drip-and-ship strategy for delivering standard of care for AIS has similar safety profiles and discharge outcomes compared with patients treated at our institution. This approach likely increases the number of treated patients which translates into improved outcome. The trend to higher rate of good outcomes in the transfer population may be due to lower baseline NIHSS scores. Treated MHH ⬍3hrs from onset N⫽319 Age, years, mean ⫾ SD Race, % White Black Hispanic Other Male, % Time from onset (or last seen normal) to tPA bolus, min Door to needle time, min NIHSS pre-tPA, mean ⫾ SD, median (range) Adjuvant IAT rate, % Complications, % PH2 sICH neurological deterioration Discharge mRS 0–2, % Discharge mRS 0–1, % Discharge disposition, % Good (home or inpatient rehab) Treated OSH ⬍3hrs from onset N⫽67 p-value 64.9 ⫾ 14.5 45.8 37.9 14.4 1.9 65.5 ⫾ 14.4 76.1 10.4 13.4 0 0.77 ⬍0.0001 44.2 129.1 44.8 138.0 0.52 0.051 65.1 N⫽306 13 ⫾ 7 12 (0–38) N⫽312 ⬍0.0001 0.043 15.4 5.7 4.4 23.7 85.2 N⫽46 11 ⫾ 6 10 (3–28) N⫽56 7.5 4.5 6.1 18.2 41 26.5 66.3 43.9 28.5 77.0 0.06 0.50 0.38 0.21 0.195 0.404 0.066 P121 Predictors of Recanalization with Mechanical Thrombectomy for Acute Ischemic Stroke. Kwang Deog Jo, Gangneug Asan Hosp, Gangneung, Republic of Korea; Jeffrey L Saver, Sidney Starkman, Doojin Kim, Latisha K Ali, Bruce Ovbiagele, Oh Young Bang, Susan Yun, Amytis Towfighi, Samir H Shah, Paul M Vespa, Chad Miller, Satoshi Tateshima, Reza Jahan, Fernando Vinuela, Gary R Duckwiler, David S Liebeskind; UCLA, Los Angeles, CA Background and Purpose— Arterial recanalization significantly improves functional outcomes and reduces mortality in patients with acute ischemic stroke. The MERCI® Retriever System (MERCI) was recently cleared by the FDA for use in acute stroke patients based on technical efficacy. The purpose of this study was to determine predictors of recanalizaton in acute ischemic stroke patients treated with the MERCI device. Methods—We analyzed a prospectively maintained database of consecutive patients treated with the MERCI Retriever device for acute ischemic stroke at a single center from May 2001 to June 2007. Demographic, clinical, radiological and detailed angiographic features, and therapeutic variables were analyzed. We compared these variables between patients with successful recanalization (Thrombolysis in Cerebral [TICI] grades 2 or 3) and those with unsuccessful recanalization (TICI grades 0 or 1). Predictors of recanalization were determined based on multivariate logistic regression model. Results—One-hundred fourteen acute stroke patients were treated with mechanical thrombectomy using the MERCI device. Mean age was 65⫾19 years, and median baseline National Institutes of Health Stroke Scale (NIHSS) score was 19. Recanalization was achieved in 75 (66%) patients (48 TICI 2; 27 TICI 3). On multivariate analysis, independent predictors of recanalization were prior antiplatelets use (odds ratio [OR], 3.19 [95% CI, 1.03 to 9.85]; P⫽0.044) and good collateral flow (P⫽0.009) defined using the graded ASITN /SIR scale. Other demographic and clinical features, including time from onset to treatment, baseline NIHSS score, comorbidities, stroke mechanism, and vital parameters on admission, did not predict recanalization. Laboratory results, routine CT/MRI findings, angiographic occlusion site, and adjunctive therapeutic modalities were also not significant predictors of recanalization after MERCI Retriever thrombectomy. Conclusions—Prior antiplatelets use and greater degree of collateral circulation evident on pretreatment angiography are associated with successful recanalization with mechanical thrombectomy using the MERCI Retriever device. These observations suggest that antiplatelet and collateral enhancement therapies are worthy of study as concomitant treatments in patients undergoing mechanical thrombectomy. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 600 Stroke Vol 39, No 2 February 2008 P122 Impact of Timing of Recanalization after Intra-arterial Thrombolysis on Clinical Outcome. Kyung-Hee Cho, Eun Kyung Kim, A-Hyun Cho, Sun U. Kwon, Deok Hee Lee, Choong Gon Choi, Sang Joon Kim, Dae-Chul Suh, Jong S. Kim, Dong-Wha Kang; Asan Med Cntr, Seoul, Republic of Korea Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Purpose: Thrombolytic therapy is based on the “recanalization hypothesis”, i.e., that reopening of occluded vessels improves clinical outcome through reperfusion and salvage of threatened tissues. Intra-arterial (IA) thrombolysis is considered to be effective for treatment of acute ischemic stroke attributable to large artery occlusion. We examined the relationship between timing of recanalization and functional outcome after IA thrombolysis. Methods: We retrospectively reviewed 98 acute ischemic stroke patients treated with IA urokinase (⫾ intravenous (IV) tissue plasminogen activator (tPA)) between March 2004 and February 2007. The angiogram immediately after completion of IA thrombolysis was used for the assessment of immediate recanalization, and follow-up CT angiography or MR angiography within a week were used for the assessment of delayed recanalization. The patients were excluded for the analysis: 1) if they received concomitant stent insertion (n⫽10), or 2) if they did not undergo follow-up vascular imaging despite the lack of recanalization immediately after IA thrombolysis (n⫽13). Patents were divided into 3 groups: immediate; delayed; and no recanalization. Clinical outcome was evaluated using the modified Rankin Scale (mRS) at 7-day and at 3-month after onset. Factors related to each recanalization group were also explored, Results: Of the 75 patients, recanalization was observed in 53 (70.6%): immediate in 28 (37.3%) and delayed in 25 (33.3%). The proportion of functionally independent patients (mRS ⱕ 2) at 7-day were 53.6% (15/28) in immediate, 28.0% (7/25) in delayed, and 22.7% (5/22) in no recanalization group (p⫽0.047). At 3-month, it was 64.3% (18/28), 40.0% (10/25), and 27.3% (6/22), respectively (p⫽0.027). Multivariate analysis showed that cardioembolism (odds ratio (OR), 3.74; 95% confidence interval (CI), 1.15–12.19) and middle cerebral artery occlusion (OR, 3.23; 95% CI, 1.04 –10.04) were independent predictors of any recanalization (either immediate or delayed) and that IV tPA prior to IA therapy was an independent predictor of immediate recanalization (OR, 3.91; 95% CI, 1.09 –14.00). Conclusions: Our results show that the timing of recanalization after IA thrombolysis is significantly associated with clinical outcome. Stroke mechanism and site of occlusion may be factors discriminating between recanalization and non-recanalization. The fact that delayed recanalization group has similar baseline characteristics to immediate recanalization group suggests that more efficient thrombolytic strategies are needed in this group. SD ⫽ standard deviation, NIHSSS ⫽ NIH Stroke Scale Score, IQR ⫽ Interquartile range, GOS ⫽ Glasgow Outcome Scale, mRS ⫽ modified Rankin Scale *Small numbers of subjects were missing outcome data for each measure. These subjects were assigned a negative outcome. ^Within 36 hours of study drug administration. Each group includes both placebo and rt-PA treated patients. P124 Hypointense Leptomeningeal Vessels on T2*-weighted Gradient Echo Imaging in Acute Ischemic Stroke: A Correlation with Angiographic Findings. Sam-Yeol Ha, Sang-Hyuck Seo, Gyeong-Moon Kim, Chin-Sang Chung, Kwang-Ho Lee; Samsung Med Cntr, Sungkyunkwan Univ Sch of Medicine, seoul, Republic of Korea Background and purpose: T2*-weighted gradient echo (GRE) imaging is sensitive to changes in blood oxygenation. The oxygen extraction fraction (OEF) increases when decreased perfusion pressure cannot be compensated by increment of cerebral blood volume. Hypointense leptomeningeal vessels (HLV) draining hypoperfused regions on GRE imaging may indicate the presence of tissue with increased OEF and deoxyhemoglobin in the vessels. Thus, we analyzed the correlation between HLV, angiographic findings, and clinical improvement in patients with acute ischemic stroke who received thrombolytic therapy. Methods: From Samsung Acute Stroke Registry 22 patients with middle cerebral artery stroke were included, who were treated by combined intravenous and intra-arterial thrombolysis or intra-arterial thrombolysis within 6 hours of symptom onset. Brain MRI including GRE, diffusion-weighted and perfusion-weighted imaging was performed with a 3.0-T imager just before digital subtraction angiography. Results: The small to medium sized HLV on GRE corresponded to the veins in the zone of delayed wash-out of capillary stain in the delayed venous phase of angiography. These veins drained into venous sinuses through superior cerebral veins, vein of Labbe, and/or superficial/ deep middle cerebral veins. HLV on GRE imaging may mainly indicate the venous system from small veins before draining into venous sinuses. Group I with extensive small to medium sized HLV (n⫽7) which drained into all the superior cerebral veins, vein of Labbe, and superficial/ deep middle cerebral veins (see figures) had the initial NIHSS score from 11 to 22 (mean 16.9⫾3.4) and the group II with less extensive or no HLV (n⫽15) from 6 to 21 (mean 11.7⫾5.3). Major neurologic improvement (defined by a ⱖ8-point improvement in NIHSS score at 24 hours) was observed in 6/7 patients in group I and 2/15 patients in group II. Conclusions: The extensive small to medium sized HLV on GRE imaging may predict major neurologic improvement following thrombolytic treatment in acute ischemic stroke. Figure legend: The extensive zone of delayed wash-out of capillary stain in the delayed venous phase of angiography and small to medium sized hypointense leptomeningeal vessels on gradient echo imaging in a patient with acute right MCA stroke. P123 How Important is Surrogate Consent for Stroke Research? Matthew L Flaherty, Jane C Khoury, Dawn Kleindorfer, Joseph P Broderick; Univ Cincinnati, Cincinnati, OH Background: Many patients with stroke are unable to provide informed consent for research studies because of aphasia, neglect, or reduced level of consciousness. In several states current legal interpretations do not allow surrogate consent for research studies except when consent is provided by a medical power of attorney or court-appointed guardian. We explored the importance of surrogate consent in the NINDS rt-PA Stroke Trial, the study that led to the only FDA-approved treatment for acute ischemic stroke. Methods: Utilizing the NINDS rt-PA Stroke Trial database we determined which subjects provided their own consent and which subjects were enrolled by surrogate consent. We compared the baseline characteristics of these groups and their clinical outcomes in univariable and multivariable analyses. Results: The NINDS rt-PA Stroke Trial enrolled subjects from 2/4/1991 to 10/30/1994. Of 624 participating subjects, 439 (70%) were enrolled by surrogate consent. Comparisons of subjects providing their own consent and those enrolled by surrogate consent are provided in the table. Subjects enrolled by surrogate consent were older, had more severe strokes, and were less likely to make a good recovery than subjects who provided their own consent. In multivariable modeling there was no interaction between method of consent and response to rt-PA. If the NINDS rt-PA Stroke Trial had used the same sample size and recruited at the same rate but excluded subjects who could not provide their own consent, it would have taken approximately 12.5 years to complete. Conclusions: The NINDS rt-PA Stroke Trial would not have been completed in a timely fashion without the participation of subjects enrolled by surrogate consent. Furthermore, exclusion of subjects who could not provide their own consent would have severely limited the generalizability of trial results and may have produced misleading estimates of treatment effects if attempts were made to generalize such results. Surrogate consent is essential to acute stroke research. Self Consent (%) Subjects Age Time to treatment (hours) Baseline NIHSSS 90-day NIHSSS ⱕ 1* 90-day Barthel ⱖ 95* 90-day GOS ⫽ 1* 90-day mRS score 0–1* 90-day mortality Symptomatic intracranial hemorrhage^ 185 63.4 2.0 9 76 113 106 98 14 7 (30) 439 (SD12) 68.5 (SD0.62) 1.99 (IQR6–14)17 (41.1) 93 (61.1) 165 (57.3) 131 (53.0) 116 (7.6) 104 (3.8) 15 Surrogate Consent (%) (70) (SD11.3) (SD0.61) (IQR11–22) (21.1) (37.6) (29.8) (26.4) (23.7) (3.4) p-value ⬍0.001 0.88 ⬍0.0001 ⬍0.0001 ⬍0.0001 ⬍0.0001 ⬍0.0001 ⬍0.0001 0.82 Acute Management II P125 Short-term Clinical Outcome Following Gastro-intestinal Tube Feeding By Immunonutrition-oriented Or Protein-oriented Food In Acute Stroke Management:Preliminary Results. Hiroyuki Tajiri, Takahisa Mori, Tomonori Iwata; Shonan Kamakura General Hosp, Kamakura City, Japan [Backgrounds/Purpose] Most of acute stroke patients who can not take food orally due to serious neurological symptoms undertake gastro-intestinal tube feeding (GITF). However, some of them are led to protein-energy malnutrition (PEM) state, secondary complications occur and result in longer hospitalization and worse clinical outcome. The purpose of our prospective study is to investigate whether or not there are any differences between costly immunonutrition-oriented IMPACTTM and not costly protein-oriented PEMVestTM for GITF on short-term clinical outcome. [Objects and Methods] Included were patients as follows, 1) who were admitted to our institution from 1st January 2007 to 15th August 2007, 2) who undertook GITF during the study period and were assigned randomly to PEMVestTM (P) and IMPACTTM (I) group. Excluded were patients as follows, 1) who suffered from gastro-intestinal bleeding on admission or on the second day, 2) who suffered from serious pneumonia on admission or on the second day, and 3) who presented coma state of 3 in Glasgow coma scale on admission or on the second day. Evaluation items were age, man(%), NIHSS score on admission, NIHSS score on the 10th day, change of NIHSS score, albumin value (AV) on admission, AV on the 10th day, change of AV, and in-hospitalization period. [Results] During the study period, 266 acute stroke patients were admitted to our institution. Forty-one of them undertook GITF and were assigned randomly to P group in 15 patients and I group in 26 patients. In P and I groups, an average age was 78 and 76 years, man (%) was 40 and 61.5, an average NIHSS score on admission was16.9 and 17.7, median NIHSS score on the 10th day was 16 and 15.5, median change of NIHSS score was 0 and -0.5, an average albumin value (AV) on admission was 3.86 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations and 3.94, an average AV on the 10th day was 3.17 and 3.20, an average change of AV was -0.69 and -0.74, and median in-hospitalization period was 10 and 11.5 days, respectively. Although there were no significant differences between two groups (Student’s t test, chi square test, and M-W test), albumin value decreased significantly in P group (p⬍0.005, Wilcoxon test) and in I group (p⬍0.001, Wilcoxon test). [Conclusions] Although protein-oriented PEMVestTM was not costly compared to immunonutrition-oriented IMPACTTM, it had the same effect on short-term clinical outcome and in-hospitalization period in management of serious state of acute stroke patients. P126 Does Application of Radio Contrast Media Prior to Thrombolysis Impact Thrombolytic effect in Acute Ischemic Stroke? Imanuel Dzialowski, Univ of Dresden, Dept Neurology, Dresden, Germany; Volker Puetz, Andrew M Demchuk, Univ of Calgary, Dept of Clinical Neurosciences, Stroke Program, Calgary, Canada; Alastair M Buchan, Univ of Oxford, Dept. Geratology, Oxford, United Kingdom; Michael D Hill, Univ of Calgary, Dept of Neurosciences, Stroke Program, Calgary, Canada; for the Calgary CTA Study Group Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: Experimental data suggests a negative interaction between radio contrast media (RCM) and the fibrinolytic effect of rt-PA. We studied the hypothesis that application of RCM prior to thrombolysis reduces the response to intravenous thrombolysis with rt-PA. Methods: We retrospectively studied consecutive ischemic stroke patients receiving CT Angiography (CTA) prior to IV treatment with rt-PA within 6 hrs from symptom onset and compared functional outcome to a historical control group NOT receiving CTA before standard thrombolysis with rt-PA: the Canadian Alteplase for Stroke Effectiveness Study (CASES). Exclusion criteria were pre-morbid modified Rankin Scale Score (mRS) ⬎ 3 and any intra-arterial intervention. Our primary endpoint was favourable functional outcome at 90 days defined as modified Rankin Scale (mRS) scores 0 –2 (if not available score at discharge carried forward). We performed logistic regression analysis including the variables age, gender, history of diabetes, baseline NIHSS score, onset-to-treatment-time (OTT), and baseline Alberta Stroke Program Early CT Score (ASPECTS). Results: For the CTA group, we identified 111 patients (mean age 68 ⫾ 16, 51% male, OTT 155 ⫾ 63 min, median NIHSS score 12), the control group included 1119 patients (mean age 70 ⫾ 13, 55% male, OTT 150 ⫾ 38 min, median NIHSS score 14). Apart from a higher proportion of pre-thrombolysis anti-platelet therapy in the control group, baseline characteristics did not differ among groups. Proportions of favourable functional outcome were 47.8% for the CTA and 49.5% for the control group (p⫽0.4). In our logistic regression model, performance of CTA prior to thrombolysis was an independent negative predictor of favourable functional outcome (OR 0.62, CI95 0.39 – 0.99, p⫽0.049). Adjusted probabilities for favourable outcome were 0.48 (CI95 0.37– 0.58) and 0.51 (CI95 0.47– 0.54) for CTA and control group, respectively. Conclusion: Our retrospective study suggests that performing a CTA prior to IV thrombolysis with rt-PA might reduce response to thrombolysis. This effect might be caused by a negative interaction between RCM and rt-PA. These results need to be confirmed, however, in a prospective fashion. Further basic and clinical research is needed to study possible interactions between CT and MR contrast media and thrombolytic agents. P127 Clinical Research Coordinator Turnover: Impact on NIH Funded Clinical Trials and Potential Solutions. Edward C Jauch, Judith Spilker, Pooja Khatri, Rose Beckmann, Univ of Cincinnati, Cincinnati, OH; Michael Hill, Univ of Calgary, Calgary, Canada; Renee Martin, Med Univ of South Carolina, Charleston, SC; Joseph Broderick; Univ of Cincinnati, Cincinnati, OH Introduction: With clinical trials growing in complexity and regulatory oversight, clinical research coordinators (CRC) play an increasingly pivotal role in clinical trials; CRC described as “the glue that holds the study together”. Recent studies illustrate a growing concern: half of all CRC leave their positions within 3 years, at the same time the overall CRC experience level is declining. Locally, CRC loss causes delays in study initiation and regulatory material submission, and interruptions in recruitment. CRC loss in a multicenter study causes repeat site initiation visits and orientation, reduced patient recruitment rates, delays in study completion, and increased study costs. For these reasons, CRC retention is a concern in ongoing clinical stroke trials. The Interventional Management of Stroke (IMS) III trial is a multicenter phase III trial investigating new treatment strategies for ischemic stroke. The IMS3 study design is complex, incorporating IV tPA administration followed by potential intra-arterial strategies, often necessitating transfer to tertiary care centers. The high-dose human albumin therapy for neuroprotection in acute stroke (ALIAS) trial is a phase III multicenter study, and while less complex, faces similar CRC challenges. We investigated the impact of CRC loss on these studies and began an investigation into ways to improve CRC retention. Methods: We reviewed IMS3 study initiation data and personnel turnover. A similar review is underway for the ALIAS trial. We constructed a confidential survey instrument related to CRC turnover and retention issues. After IRB approval, the survey was sent to all CRC involved in the IMS3 study and ALIAS trial. The survey data will be presented using descriptive statistics. Results: Funding for the NINDS sponsored IMS3 study was awarded in 09/05 and first patient recruited in 08/06. IMS3 will utilize 50 clinical sites in the US and Canada, and will enroll 900 patients over a 5 year period. As of 08/14/07, 32 sites have been visited and reviewed by study executive committee members, 32 centers are authorized to receive study supplies, 27 are screening, 4 are on hold, and an additional 21 invited to participate. Since first contact or re-contact after funding was assured, 37 CRC, 9 principal investigators, and 7 principal interventionalists have resigned or sought reassignment. 73 patients have been enrolled in IMS3 out of a projected 900 patients. 601 CRC survey results from the IMS3 study and ALIAS trial will be presented at the 2008 ISC. Conclusions: Clinical research coordinator retention is a growing concern and threatens clinical trial success. The operational and fiscal impact of CRC loss warrants efforts to improve CRC retention and preempt their loss P128 Routine Transthoracic Echocardiography May Be Of Limited Value In Ischemic Stroke Patients Who Have Normal Electrocardiograms And Normal Troponin And Brain Naturitic Peptide Levels. Sanjay Gill, Seema Bansal, D A Shoham, John T Barron, Rima Dafer, Michael Schneck; Loyola Univ Med Cntr, Chicago, IL INTRODUCTION The utility of TTE in acute ischemic stroke (AIS) patients is mainly in identifying wall motion abnormalities, low ejection fractions (EF) or valvular anomalies that may be source markers for thrombus. Transthoracic echocardiography (TTE) is of limited utility in identifying intracardiac thrombus yet TTE is routinely performed at most institutions following an acute ischemic stroke (AIS); some patients may then undergo transesophageal echocardiography (TEE) thereafter. We hypothesized that a panel consisting of normal troponin and brain naturitic peptide serum levels along with a normal electrocardiogram (ECG) would preclude the need for TTE in the overwhelming majority of stroke patients. METHODS One hundred and thirty eight consecutive patients admitted with the diagnosis of AIS were grouped according to whether or not they had normal values for troponin (ⱕ0.1 ng/ml), BNP (ⱕ100 pg/ml) as well as a normal ECG. A normal ECG was defined as absence of the following findings: old infarcts, possible current ischemia/MI, atrial fibrillation, atrial flutter, left bundle branch block, right bundle branch block, second degree heart block, third degree heart block, premature ventricular contractions, left ventricular hypertrophy, left atrial enlargement, or peaked T-waves. The ‘normal values’ (NL) group with normal BNP, troponin, and ECG was compared with the ‘abnormal values’ (ABNL) group for which there was an abnormality in at least one of the three variables. These two groups were compared with respect to the presence of any wall motion abnormalities, valvular defects (as defined as moderate or severe stenosis or regurgitation), or an ejection fraction less that 50% as measured by TTE. RESULTS The average age of the patients was 70 years with a range of 39 to 92. There were 30 patients in the NL group, and 108 patients in the ABNL group. The NL group had a significantly reduced rate of wall motion abnormalities (3.3% vs. 28.7%, p ⫽ 0.0036) and a significantly reduced rate of any valvular defects (6.7% vs. 23.2%, p ⫽ 0.0441) as compared with the ABNL group. Furthermore, there were no patients in the NL group who had an EF less than 50%; however there were 24 patients in the ABNL group (0.00% vs. 22.2%, p ⫽ 0.0045) with a reduced EF. CONCLUSION These results suggest that a normal ECG on admission coupled with normal values for BNP and troponin in patients admitted for AIS may mitigate the need for a TTE with respect to assessment of wall motion abnormalities, valvular defects and reduced EFs. For those AIS patients for whom intracardiac thrombus or interatrial anomalies continue to be clinically suspected, direct assessment with TEE can then be considered. P129 Predictors of Outcome Following Local Intra-arterial Fibrinolysis for Central Retinal Artery Occlusion. Eric M Aldrich, Johns Hopkins Hosp, Baltimore, MD; Andrew W Lee, Celia S Chen, Flinders Univ Med Cntr, Bedford Park, Australia; Rebecca F Gottesman, Johns Hopkins Hosp, Baltimore, MD; Mona N Bahouth, Univ of Maryland Med Cntr, Baltimore, MD; Robert J Wityk, Phillipe Gailloud, Kieran J Murphy, Neil R Miller; Johns Hopkins Hosp, Baltimore, MD Introduction: Local intra-arterial fibrinolytic therapy (LIF) for central retinal artery occlusion (CRAO) was developed over ten years ago, but has not become widespread. There is significant debate in the literature regarding its efficacy, safety and practicality. Understanding what factors are predictive of either good or bad outcomes would be of significant value in determining which subjects should be offered this therapy. Methods: Consecutive subjects with CRAO referred to the Johns Hopkins Hospital Stroke Service from 2001 to 2007 were reviewed. Twenty-three subjects were identified who received LIF. Clinical characteristics including stroke risk factors were collected as well as diagnostic test information. In addition, the characteristics of the diagnostic cerebral angiogram and the subsequent intervention were collected. The individuals who collected the angiographic data were blinded as to clinical presentation and outcome. The primary outcome measure was a one line improvement in visual acuity as tested on a Snellen chart. The secondary outcome was a three line improvement in visual acuity. Results: Regarding clinical characteristics a prior history of hypercholesterolemia or stroke showed a trend toward significance, predicting negatively on final visual(OR ⫽ 0.15, p⫽0.09 for each). No predictive effect was seen from routine diagnostic tests such as EKG, carotid ultrasound, echocardiography or brain imaging. Diagnostic cerebral angiograms revealed no significant incidence of concurrent ipsilateral carotid stenosis. One interesting effect was that in approximately half the subjects super-selective cannulation of the ophthalmic artery was possible prior to LIF, whereas in the other cases the tip of the catheter could only by positioned just adjacent to the origin of the ophthalmic artery. Despite this difference in technique, super-selective vs. non-selective, there was no difference in the primary or secondary outcome measures. Conclusion: A prior history of hypercholesterolemia or stroke showed a trend toward significance as negative predictors for outcome following LIF for CRAO. All other clinical characteristics, including visual acuity at presentation, showed no predictive effect. However, due to small sample size the statistical power was limited. In addition, both super-selective and non-selective cannulation of the ophthalmic artery resulted in similar efficacy of LIF for CRAO. A prospective randomized clinical trial with a larger number of subjects Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 602 Stroke Vol 39, No 2 February 2008 is needed to further investigate safety, efficacy and clinical predictors of outcome for this treatment. P130 Improving Acute Stroke Care in a Community Hospital Utilizing Neurohospitalists. Stanley N Cohen, Kyle Malone, Glenn M Fischberg, Donna Delaney, Rob Phoenix, Scott L Selco; Sunrise Hosp and Med Cntr, Las Vegas, NV Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: Administration of tPA to acute stroke patients is underutilized in community hospitals. We studied the effect of having two stroke-fellowship trained neurohospitalists on tPA utilization in a community hospital with no academic affiliation. Methods: Data on all stroke admissions were collected using the ASA Get with the Guidelines worksheet. We analyzed information gathered on all stroke admissions for 2006, the first complete year in which our hospital had stroke protocols and order sets with 2 stroke neurologists working full time as neurohospitalists in one hospital with 24/7 availability. Results: Of 1025 patients admitted with a diagnosis of cerebrovascular disease during the study period, 970 (95%) were seen by the neurohospitalists; 502 acute ischemic strokes, 225 TIAs, 141 ICHs, 63 SAHs, 39 uncertain. Of the ischemic stroke patients, 100 (20%) received any type of lytic treatment; IV tPA (N⫽67), IA tPA (N⫽18), IV/IA tPA (N⫽7), experimental drug (N⫽3), and IV tPA started at an outside hospital prior to transfer (N⫽5). Mean symptom onset to arrival at the ER was 1.1 and 5.4 hours for IV and IA tPA treated patients, respectively. Mean door-to-CT time was 24 and 30 mins for IV and IA tPA patients, respectively. Mean door-to-treatment time was 74 and 225 mins for IV and IA tPA administration, respectively. Patients receiving IV tPA had a mean age of 66 years and 54% were male. The IV tPA patients arrived by ambulance from the scene (84%), by private transport (10%), and by hospital transfer (5%). At least 86% of eligible patients with no exclusions received tPA. Of patients receiving IV tPA, 6 (9%) died during the hospitalization, 1 as a complication of drug administration. Of those surviving to discharge, 41% were able to ambulate without assistance, 21% ambulated with assistance, and 33% were unable to ambulate. Of the 402 patients not receiving thrombolysis, the most common reasons were arrival ⬎3 hrs after onset (34%), stroke severity too mild (31%) or too severe (11%) and active internal bleeding (16%). Conclusions: In a community hospital, creation of a neurohospitalist service with two stroke neurologists, responsible for ER coverage 24/7 but no outpatient services, resulted in successful administration of lytic therapy to 100 appropriate acute ischemic stroke patients in one year. P132 Comparison of Intravenous and Intra-arterial with tPA within 3–6 Hours Guided by Multi-MRI: Randomised Study of 36 Patients. Yilong Wang, Weijian Jiang, Xiaoling Liao, Bin Du, Xingquan Zhao, Kehui Dong, Jing Xue, Peiyi Gao, Liping Liu, Yongjun Wang; Beijing Tiantan Hosp, Capital Med Univ, Beijing, China Objective To compare the efficacy and safety of intravenous and intra-arterial with rt-PA within 3– 6 hours of acute ischemic stroke with PWI/DWI mismatch guided by multi-MRI. Methods All acute ischemic stroke patients within 6 hours of symptom onset were recruited from 7 centers in China between 2005 and 2006 for this prospective, clinical trial. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN69163448. Within 3 hours, patients were treated according to NINDS criteria. After 3 to 6 hours, treatment with randomized intravenously or intra-arterial rt-PA was performed based on multi-MRI findings. Favorable outcome was assessed after 90 days using a dichotomized modified Rankin scale score of 0 to 1. Intracerebral bleeding complications were assessed on follow-up MRI or computed tomography. Data were compared with the pooled placebo and pooled tPA patients of the ATLANTIS, ECASS, and NINDS tPA trials. Results Favorable outcome was trend to more frequent but non-significantly in 36 patients (20.3%) be performed with randomized intravenously (n⫽18) or intra-arterial (n⫽18) rt-PA based on multi-MRI findings (50%) compared with pooled placebo (35.9%; P⫽0.088) and pooled rt-PA patients (37.7%; P⫽0.068). Among those patients, the rate of good outcome in MRI-selected intra-arterial rt-PA group was 55.6%, but the intravenous group only was 44.4% (p⫽0.739). The rate of sICH in intra-arterial rt-PA group was 3/18 (16.7%), the intravenous group was 1/18 example (5.6%), but difference showed no significance (p⫽0.603). Patients given intravenous rt-PA were treated significantly earlier than intra-arterial (300 minutes vs 265 minutes; p⫽0.005). The direct cost of intra-arterial treatment was significantly more expensive than intravenous by RMB 9,000 Yuan (p⫽0.005). Conclusions To compared with intravenous rt-PA within 3– 6 hours of acute ischemic stroke with PWI/DWI mismatch guided by multi-MRI. The intra-arterial approach shows the trend to more effective, but need to enlarge the sample to further study. P133 Effectiveness of Establishing Critical Pathway and Emergency CT Room in Thrombolytic Treatment. Hee Young Park, Jung Han Yoon, Jun Young Choi, Ji Hye Shin, Hye Gyeong Lee, In Ok Han, Mi Suuk Bog, Hyo Suk Nam; Dept of Neurology, Ajou Univ Sch of Medicine, Suwon, Republic of Korea P131 Angiographic Scales in Acute Ischemic Stroke: The MERCI/Multi MERCI Experience. David S Liebeskind, UCLA, Los Angeles, CA; Raul G Nogueira; Massachusetts General Hosp, Boston, MA Purpose: Angiographic characterization of occlusive lesions and compensatory collateral flow in acute ischemic stroke may be standardized with the use of various scales. As endovascular therapy for acute stroke rapidly expands in both investigational studies and routine clinical practice, familiarity with scale terminology and implementation is critical. We describe the methodology utilized for the application of angiographic scales employed in the central review of angiography studies obtained in the MERCI and Multi MERCI studies. Methods: The angiographic scales used in central readings of baseline and postprocedural angiograms obtained as part of MERCI and Multi MERCI were analyzed in detail. Scales incorporated various aspects relating to arterial patency, distal perfusion, and extent of collaterals. Application of these scales by 2 blinded, central readers was compared, resulting in a standardized algorithm that allows for routine use and addresses discrepancies or unusual patterns that may impede standard definitions. A subset of angiograms was selected to underscore distinctive features of scale performance and consensus definitions. Results: Seven scales were employed by 2 independent reviewers to generate central readings on baseline and post-procedural angiograms in MERCI and Multi MERCI. Two scales were heavily weighted on arterial patency, 4 scales focused mainly on perfusion of the distal territory, and 2 scales assessed collateral flow at a different level of detail. Considerable agreement occurred on review of baseline angiograms, whereas greater discrepancies were noted on post-procedural views. Discriminant ability varied across scales, with subtle and potentially subjective distinctions frequently noted. Scale performance was influenced by site of vascular occlusion on both initial and posttreatment angiograms. Specific criteria were needed to define extent of the ischemic bed, incomplete filling or rate of distal opacification. Scale use on hard copies or films was distinguished from cases where electronic copies allowed for detailed evaluation of temporal resolution. Recanalization and reperfusion were often, yet not universally, coincident. Posttreatment embolism was underestimated by most scales. Particular advantages and disadvantages of each scale were noted and lack of prior validation identified. Conclusion: Although commonly used scales utilize seemingly discrete grades or patterns to define angiographic views, considerable variation may be noted without elaboration of a standardized algorithm for implementation. Scales that neglect to address antegrade or retrograde flow to the distal ischemic bed may have poorer correlation with clinical outcomes. Advantages and disadvantages, including lack of prior validation, of each scale may influence future use in clinical trials and routine care. Objective: The need for rapid evaluation and treatment of acute stroke patients has been well-documented. To reduce time intervals from emergency department (ED) arrival to treatment, making critical pathway and reducing physical distance from ED to CT room could be an effective strategy. The present study investigated whether moving CT room into the ED can reduce more time delay in the thrombolytic treatment. Methods: To reduce the time from a patient’s arrival at the ED to thrombolysis, multidisciplinary team approach program was developed and named the Fast Acute Stroke Therapy (FAST). To develop FAST program, delay factors were analyzed, and roles of stroke team members were assigned. Cellular phones and interphones were used for rapid communication between team members, and written protocol was made. The FAST program was initiated from August 2006, and a CT room was located in the ED at March 2007. The study period was divided into pre FAST and post FAST, the post FAST period was subdivided into pre EDCT, and post EDCT. Efficacy was investigated by comparing time intervals from arrival to evaluation and IV tissue type plasminogen activator (tPA) treatment before and after FAST or EDCT. Results: From January 2000 to July 2007, 99 patients were received IV tPA. Among them, 14 patients were excluded, because of 4 patients suffered in-hospital attack, and remaining 11 patients were performed the CT image from the other hospitals. According to FAST program, 61 patients were classified in pre FAST, 24 patients in post FAST (15 pre EDCT, and 9 post EDCT). Median onset-to-door time was not different before and after FAST (60 vs. 60 minutes, p⫽0.366). After FAST program implementation, door-to-CT time was reduced from 30 to 17 minutes ( p⬍0.001). Finally, door-to-needle time was markedly reduced by 34 minutes (from 75 to 41 minutes, p⬍0.001). After moving CT room in the ED, both door-to-CT (16 vs. 17 minutes, p⫽0.42) and door-to-needle (40 vs. 42 minutes, p⫽0.609) time were not improved. Conclusions: In the thrombolytic treatment, no additional reduction of in-hospital delay was observed. Making a critical pathway might be a more effective and cost saving strategy than moving CT room in the ED. P134 Prospective Study of Stroke Subtype and Anti-inflammatory Cytokine in Relation to Risk of Early Progression. Satoshi Takaishi, Bunta Katou, Kouji Yamada, Toshikazu Hirayama, Yasuhiro Hasegawa; Dept of Neurology St. Marianna Univ Sch of Medicine, Kawasaki, Japan Background and Purpose: In more than 10% of patients with ischemic stroke, early neurological deterioration occurs after admission, and is associated with increased risk of dependency. Early progression is a potential therapeutic target. Several studies demonstrated an important role of inflammation in the pathophysiology. We aimed to identify the clinical Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations significance of early diagnosis of stroke subtype and measurements of several biomarkers for the prediction of early clinical progression. Subjects and Methods:Patients admitted within 24 hours after ischemic stroke onset were prospectively enrolled from Jan 2006 to Jun 2007. On admission, routine blood chemistry, blood cell count, PT, APTT, D-dimer, fibrinogen, and high sensitivity CRP were measured. Blood samples were stored at -80°C and plasma levels of interleukin-10 (IL-10) were measured using commercially available ELISA kit. Occlusive lesions of major cerebral arteries were evaluated by 3D-CT angiography, MR angiography or carotid ultrasonography immediately after admission. Then the stroke subtype was determined according to the TOAST classification. Neurological deficits were serially evaluated by NIH Stroke Scale (NIHSS) on admission, Day-3, Day-7 and at discharge. Early clinical progression was defined when the NIHSS score increased at least 1 point during the first 48 hours after admission. Logistic regression analysis was used to determine predictive values of early diagnosis of stroke subtype and levels of biomarkers on admission by adjusting age, sex, initial NIHSS score, and co-morbidity. Results:A total of 127 ischemic stroke patients with mean age of 72.5 (SD 11.0) years old were enrolled. Early progression was demonstrated in 32 patients (25.2%). Mean value of plasma IL-10 levels in these patients was significantly higher than that in patients without progression (9.7 ⫾ 10.4 Pg/ml vs. 16.77 ⫾ 14.95 Pg/ml, P⬍0.05). Major cerebral artery occlusion was demonstrated in 41 patients on admission and 16 of them (39.0%) demonstrated early progression. Logistic regression analysis demonstrated that initial assessment of major cerebral artery occlusion (OR 2.26, 95%CI 0.013 - 0.841), plasma level of IL-10 on admission (OR 0.067, 95%CI 0.888 - 0.985) were significantly associated with early progression. Stroke subtype according to the TOAST classification, CRP, and fibrinogen were not associated with early progression. Conclusions: Major cerebral artery occlusion, and low plasma level of anti-inflammatory cytokine IL-10 are found to be important predictors for the early clinical progression within 48 hrs after admission in patients with ischemic stroke. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 P135 Role Of Contralateral Flow In Predicting Symptomatic Vasospasm With Tcd. Carol Derksen, Maher Saqqur, Mohamed Ibrahim, Michael Chow, Jim Kutsogiannis, Ashfaq Shuaib, Khurshid Khan; Univ of Alberta Hosps, Edmonton, Canada Background: TCD correlation of symptomatic vasospasm is poor when the mean flow velocities (MFVs) are in the intermediate range, (150 –200cm/s). We evaluated the changes in MFVs on the aneurysmal side versus the contralateral in predicting clinical or angiographic vasospasm (CA-VSP). Method: Forty patients with aneurysmal subarachnoid hemorrhage (aSAH) were assessed between October 2006 and August 2007. Daily TCD started on day 3 until clinical improvement or death. Correlation was made with cerebral angiogram (CA). MFVs were defined as intermediate (150 - 199 cm/s) and severe ⬎ 200 cm/s in MCA, ACA or terminal ICA. Result: Transcranial Doppler, cerebral angiogram and clinical data from 28 patients was analyzed. Twelve patients were excluded due to early death or poor insonating window. Interpretation: These results indicate that all the patients developed CA-VSP if the MFV increased to ⬎ 150 m/s (intermediate range) on the contralateral side prior to Ispsilataral. Three (75%) among those who developed high MFV (intermediate range) first on the ipsilateral but later accompanied by an increased MFV on contralateral side also developed CA-VSP. Only one (17%) among those who showed MFV increase (intermediate range) on the Ispsilataral side alone developed CA-VSP. None of the ten patients developed CA-VSP with MFV ⬍ 150cm/s on either side. This proportion was statistical highly significant with P-value of ⬍0.0001. Conclusion: Hemodynamic changes with MFVs ⬎150 cm/s on the contralateral side of the ruptured aneurysm may predict the onset of clinical or angiographic vasospasm. This likely reflects hemispheric dys-autoregulation. RELATIONSHIP BETWEEN CA-VSP AND TCD FLOW. TCD CA-VSP developed Yes Contralateral side prior to ipsilateral increase (150 - 199cm/s) Ipsilateral side prior to contralateral increase (150 -199cm/s) Ipsilateral side only increase (150 - 199 cm/s) Both sides ⬍ 150 cm/s No 8(100%) 0 3(75%) 1(25%) 1(17%) 5(83%) 0 10(100%) P136 Initial Results From The Michigan Stroke Network. Richard D Fessler, John Whapham, Connie Parliament, Robert Fisher, St. Joseph Mercy Oakland, Pontiac, MI; Michigan Stroke Network Participants INTRODUCTION: The Michigan Stroke Network (MSN) is a collaborative network of hospitals linked by a common website (www.michiganstrokenetwork.com) and wireless remote presence robots (RPRs). Network members, regardless of location, size, or resources, have access to treatment algorithms and stroke specialists 24/7. Creation of the MSN was based on the presumption that improving member hospital access to stroke specialists would increase the delivery of tPA to eligible patients. METHODOLOGY: The MSN was created by Trinity Health Corporation as a mission-driven initiative to enhance the delivery of stroke care within the state of Michigan. As the 9th hospital in the United States with primary stroke center certification, St. Joseph Mercy Oakland Hospital received a capital investment over several years to recruit neuro-critical care specialists, stroke fellowship trained neurologists, neuroendovascular specialists, and to create a dedicated website. RPRs are stationed at member hospitals in 603 emergency rooms. A 1– 800 number alerts the MSN on call physician. Wireless laptops allow the MSN stroke specialist access to RPRs for 2-way audio-video communication. MSN stroke specialists assist in patient evaluation, answer questions regarding treatment options, and help determine suitability for intravenous tPA administration. The MSN contracts with statewide medical helicoptor services in the event that transfer to a tertiary facility is warranted. Incoming calls, response times, robot utilization, as well as patient interactions/interventions are tracked. RESULTS: During the first nine months of the program, 18 hospitals joined the MSN. An additional 6 are undergoing RPR installation, and 6 are in process of joining the MSN. To date, 90 RPR consultations involving patients from 20 Michigan counties have been performed. All consults were initiated within 9 –12 minutes. Approximately 70% of all patients eligible for intravenous tPA (3 hours) were treated (16/23). An additional 3 patients were transferred for embolectomy. Twelve doses of tPA were administered at institutions in which tPA had never been given. Twenty-seven patients were transferred to a tertiary center. CONCLUSION: The MSN allows member hospitals rapid access to stroke specialists on a case-by-case basis. To date, the majority of intravenous tPA eligible patients evaluated via the MSN have received tPA. Improved access to stroke specialists through RPRs enhances the rate of tPA delivery to eligible stroke patients. P137 Platelet Aggregation Unit Inhibition to Guide Abciximab Therapy in Acute Ischemic Stroke: Preliminary Results. Pitchaiah Mandava, Jane Anderson, Perumal Thiagarajan, Thomas A Kent; MEDVAMC/BCM, Houston, TX Background: Glycoprotein (GP) IIb/IIIa inhibitors are employed in stroke patients as adjunct in intra-arterial (IA) and intravenous (IV) protocols and post-angioplasty/stenting. Experimental data indicate that thrombosis is abolished at ⬎80% inhibition of GP IIb/IIIa receptors while clinical data indicate that bleeding complications are limited to patients with ⬎ 90 % inhibition [Tambarella et al, Am J Card 2002]. While not reported in ischemic stroke, therapy guided by platelet aggregation inhibition has been utilized in the setting of coronary syndromes. AbESTT-II, a randomized trial of intravenous abciximab in stroke, utilized the usual cardiac dosage, but this phase III trial was abandoned due to an unfavorable risk/benefit ratio. The dose of abciximab used in AbESTT-II produced 95⫾4% and 96⫾10% platelet aggregation unit (PAU) inhibition respectively in cardiac trials [Steinhubl et al, Circ 1999 & 2001]. We previously hypothesized a lower dose of abciximab would result in less PAU inhibition than the usual cardiac dose but still sufficient for clinical efficacy and initiated a case series of acute ischemic stroke patients treated with a lower dose of abciximab potentiated by the simultaneous use of heparin. Methods: A lower dose of abciximab (bolus: 0.20 mg/kg, max of 16 mg; and a 12 hr infusion of 0.05 ug/kg/min, max of 2.9 mg) and time-limited heparin to patients has been offered to 35 patients with large vessel or cardioembolic stroke. This dose is approximately 30% lower than standard. PAU was measured at baseline and 10 –20 minutes after the bolus. Baseline and 24 hour follow-up CT of the head and bleeding complications were monitored, and 3 month mortality and mRS obtained. Results: PAU was obtained on 15 of the 35 patients. Mean baseline NIHSS of these patients was 16.2 (Range: 6 –36), mean age was 69. Mean PAU inhibition post bolus was 90.8% (SD: 5.88; 95% CI: ⫾3.5; Range: 78 –100; p⫽.001 vs Steinhubl 1999). There was one symptomatic intra-cerebral hemorrhage in protocol patients (2.9%), occurring in a patient treated for basilar artery thrombosis 23.5 hours after onset. There were no serious systemic hemorrhages and a 11% incidence of asymptomatic hemorrhage. The determination of the relationship of PAU with efficacy awaits completion of 3 month follow up in all subjects, but this IV protocol has already suggested comparable efficacy to published IA series with similar baseline stroke severity [Mandava and Kent, 2005]. Conclusion: Adequate platelet inhibition was found at this lower dose of abciximab. This finding could explain lack of serious symptomatic hemorrhagic events in our patients despite severity of NIHSS and use of heparin. The higher dose of abciximab used in AbESTT-II likely produced excess PAU inhibition leading to increased hemorrhagic risk without improved efficacy. We suggest PAU measurement may guide abciximab treatment in stroke. P138 Intracerebral Haemorrhage and Haemorrhagic Transformation in Patients Treated with Tinzaparin Versus Aspirin for Acute Ischaemic Stroke: Data From the “Tinzaparin in Acute Ischaemic Stroke Trial” (TAIST). Timothy England, Gray J Laura, Gillian M Sare, Chamilla Geeganage, Philip M Bath, Univ of Nottingham, Nottingham, United Kingdom; on behalf of the TAIST Investigators Background: The incidence of haemorrhagic transformation of infarcts is unclear (with quoted rates between 6% and 60%), including in-patients taking aspirin early after ischaemic stroke. Methods: TAIST was a randomised, controlled trial assessing the safety and efficacy of tinzaparin (a low molecular weight heparin, LMWH) at two doses (medium 100 IU/kg and high 175 IU/kg) versus aspirin (300 mg) in 1,484 patients with acute ischaemic stroke. CT head scans were performed at baseline and after a treatment period of 10 days. The scans were independently adjudicated for presence of haemorrhage, haemorrhagic transformation, intrainfarct haematoma, mass effect and midline shift. The relationships between treatment group and these parameters were assessed with adjustment for age, sex, baseline stroke severity, and systolic blood pressure. Results: At 10 days, the frequency of haemorrhagic infarction did not differ between aspirin (32.7%) and medium dose tinzaparin (35.9%, odds ratio [OR] 1.18, 95% confidence interval [CI] 0.86 - 1.62) or high dose tinzaparin (32%, OR 0.95, 95% CI 0.69 –1.32). Asymptomatic haemorrhage also did not differ between aspirin and medium and high dose tinzaparin (OR 2.68, 95% CI 0.51–13.99, and OR 3.10, 95% CI 0.62–15.58 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 604 Stroke Vol 39, No 2 February 2008 respectively). Similarly, there were no differences in size of haemorrhagic transformation, presence of intra-infarct haematoma, mass effect, or midline shift at day 10. In contrast, symptomatic intracranial haemorrhage was increased with LMWH in a dose dependent manner (medium dose: OR 2.91, 95%CI 0.31–77.0; high dose: OR 7.15, 95% CI 1.10 –163 [Bath et al, Lancet 2001]). Conclusion: Approximately one third of patients with acute ischaemic stroke treated with early aspirin have asymptomatic haemorrhagic transformation of the infarct. The incidence does not appear to increase with LMWH, a finding that has also been seen with intravenous thrombolysis. P139 AIRDOC: A Randomized Acute Stroke Intervention Trial During The Novel Setting Of Early Helicopter Evacuation To A Comprehensive Stroke Center. Enrique C Leira, Azeemuddin Ahmed, Diane L Lamb, Richard C Callison, Heena Maiseri, James C Torner, Harold P Adams, Jr.; Univ of Iowa, Iowa City, IA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Stroke patients in remote or rural areas are often initially evaluated at small community hospital emergency departments (ED), and then evacuated by medical helicopter to a stroke care center. Currently, enrollment in clinical trials is delayed until the patient reaches the receiving hospital. If acute stroke trials could be initiated at the outside community hospital or en-route to the stroke center, patients could be enrolled and treated sooner after stroke. However, the feasibility and safety of such an approach needs to be tested. Objectives: 1) To test if an intervention trial could be safely implemented during early medical helicopter evacuation of stroke patients using flight crews as co-investigators , and 2) If a strategy of a co-investigator calling the subject and faxing the consent form while flying to pick up the patient facilitates subsequent consent among patients and their surrogates in this timeconstrained setting. Methods: We implemented the AIRDOC trial (Antiacids In-flight Reduce Disability and Overcome Complications) as a vehicle to test our hypothesis. AIRDOC was a randomized placebo-controlled trial of a low-risk intervention (ranitidine 50 mg IV) aimed to prevent aspiration pneumonitis. Eligible patients were subjects with ischemic or hemorrhagic stroke who were about to be transferred by the air medical helicopter service of the University of Iowa Hospitals and Clinics for further care. The outbound flight-crew investigator first randomized the potential subject or surrogate to either receive advanced information about AIRDOC (through an explanatory radio phone call and faxed consent form) versus no advanced information. Upon arrival at the ED, the flight crew approached the patient or surrogate about entry into AIRDOC. Those who consented were screened, and if eligible, were randomly assigned to a single dose IV ranitidine vs. placebo that was administered during the helicopter flight. The primary outcome measures are the number of subjects or surrogates that provided informed consent for AIRDOC as affected by advanced notification status. Secondary outcomes include number of mis-randomizations, protocol violations, complications, and the rate of aspiration pneumonitis by AIRDOC treatment assignment. Results: At the time of this preliminary report 67 of the targeted 100 patients had enrolled (34 to advanced notification, and 33 to no advanced notification). Informed consent for AIRDOC was obtained from 56% patients with advance notification and 44% without such early notification. Of those 36, 18 were eligible for AIRDOC and received the study infusion in flight. Conclusions: It is feasible and safe to conduct an acute stroke intervention trial during early helicopter evacuation to a comprehensive stroke center. The trial is expected to be completed by February 2008. P140 ⱕ2 (p⬍0.0013).Conclusion. As compared with an NIHSS ⱖ1, the two percent of acute ischemic stroke patients with an NIHSS of zero much more frequently have posterior circulation strokes, normal acute CTs, absence of significant arterial pathology, and excellent short term outcome. These findings confirm the favorable prognostic value of low NIHSS scores and suggest insufficient sensibility of the NIHSS for posterior circulation strokes. P141 Efficacy and Limitations of Intravenous Low-Dose Alteplase Therapy at 0.6 mg/kg for Hyperacute Ischemic Stroke. Takahiro Nakashima, Kazunori Toyoda, Masatoshi Koga, Hideki Matsuoka, Kazuyuki Nagatsuka, Tatsuro Takada, Shoichiro Sato, Hiroyuki Kawano, Sohei Yoshimura, Hiroaki Naritomi, Kazuo Minematsu; National Cardiovascular Cntr, Suita, Osaka, Japan Objectives: The internationally approved dosage of 0.9 mg/kg may not be the optimum for intravenous alteplase therapy in hyperacute ischemic stroke. In Japan, intravenous alteplase therapy with a 0.6 mg/kg dose was approved in October 2005, being based on the results by Japan Alteplase Clinical Trial (Stroke 2006;37:1810 –1815). We determined the efficacy and limitations of the low-dose alteplase therapy. Methods: A prospective observational study in a single stroke center. Fifty six consecutive patients (46 men, 55 - 94 years) who received intravenous alteplase at 0.6mg/kg for hyperacute stroke between October, 2005 and April, 2007 were enrolled. Ischemic changes and vascular lesions were identified using diffusionweighted MRI, MRA (unless contraindicated), and ultrasound as well as CT. Occlusion at the common or internal carotid artery or at the origin of the middle cerebral artery trunk on MRA or ultrasound was defined as the carotid trunk occlusion. Results: The median National Institutes of Health Stroke Scale (NIHSS) score declined from 12 at baseline to 8 at 24 hours, and 3 at 3 weeks. At 24 hours, the NIHSS score of 26 patients (46%) improved by ⱖ4 points. After adjustment for underlying features, absence of the carotid trunk occlusion (odds ratio 2.63, 95% CI 1.28 - 6.03) and lower systolic blood pressure on admission (odds ratio 1.02, 95% CI 1.00 - 1.04, per increase by 1 mmHg) were independently predictive of the improvement. Two patients (4%) had symptomatic intracranial hemorrhage within the initial 36 hours. At 90 days, all the patients survived; overall, 27 of 55 patients (49%: excluding one patient who needed a wheelchair before the onset from the analysis) had a favorable functional outcome corresponding to the modified Rankin Scale (mRS) score ⱕ1. However, only 2 of 15 patients (13%) with the carotid trunk occlusion on admission had the favorable outcome. After adjustment for underlying features, lower NIHSS score on admission (odds ratio 1.23, 95% CI 1.05 - 1.53, per decrease by 1 point) and absence of the carotid trunk occlusion (odds ratio 3.12, 95% CI 1.23 - 10.35) were independent predictors of the favorable outcome at 90 days. Conclusions: Intravenous alteplase therapy at 0.6 mg/kg in our stroke center resulted in better efficacy and safety as compared with the results of previous studies using 0.9 mg/kg of alteplase, including STARS, CASES, and SITS-MOST. The low-dose alteplase, however, may not be effective for the patients with the carotid trunk occlusion. P142 Use of Quantitative Multimodal Magnetic Resonance Imaging Following Intravenous Thrombolytic Therapy in Predicting Outcomes. Mahmut E Gurol, Harold P Adams Jr., Patricia H Davis; Univ of Iowa, Iowa City, IA Nihss Zero Strokes: Are localization, imaging and outcome different? Mitra Houchmand-zadeh, Vancianne Rey, Neurology Service Univ and Institute of Social and Preventive Medicine. Cntr Hospier Universitaire Vaudois and Univ of Lausanne, Switzerland, Lausanne, Switzerland; Mohamed Faouzi, Institute of Social and Preventive Medicine. Cntr Hospier Universitaire Vaudois and Univ of Lausanne, Switzerland, Lausanne, Switzerland; Patrik Michel; Neurology Service Univ and Institute of Social and Preventive Medicine. Cntr Hospier Universitaire Vaudois and Univ of Lausanne, Switzerland, Lausanne, Switzerland Background. The NIHSS is widely used to measure stroke severity and is a strong predictor of outcome. Patients may have zero points on this scale despite a clinical stroke, given that some neurological deficits are not counted in the NIHSS. We sought to determine whether these patients differ from NIHSS ⱖ1 patients Methods. Between 1/2003 - 4/2007, all consecutive ischemic stroke patients admitted within 24 hours after symptom onset to a single stroke unit were entered prospectively in a registry. Patients who had persistent signs or symptoms ⬎ 24 hours were considered to have a stroke. Demographic data, time to hospital arrival since last well time, arterial territory of stroke, pathogenesis using modified TOAST criteria, early ischemic signs on acute parenchymal imaging (mostly CT), ⱖ50% stenosis on extra- or intracranial arterial imaging (mostly CT-angiography), and short term prognosis (modified Rankin scale at 7 days) were determined. Patients with an NIHSS of zero on admission (Z) were compared with patients whose NIHSS was above zero (A), using univariate non parametric tests for statistical analysis (Wilcoxon1, chi-square2, and Fisher’s exact test3). Results. Of 1’254 acute ischemic stroke patients (mean age 68.8 years -sd⫽15.8-, 54.3% male, median delay to admission 222.5 min.). The A group had a median NIHSS score of 6. Of the 25 (2.0 %), Z patients 14 (56%) had pure vestibulo-ocular signs and 7 (28%) pure mild corticospinal signs. The Z and A groups did not differ in gender2, age1 or delay to hospital arrival1. The proportion of posterior circulation strokes was clearly higher in Z than A (71.4% vs. 27.9%, p⬍0.0013), but stroke causes were not different3. Acute imaging (92 % CT) showed the acute ischemic lesion in 8.7% in Z and in 34.7% in A (p⫽0.0073). Similarly, acute arterial imaging (81 % CT-angiography) showed significant pathology only in 5.0% in Z but in 49.0% in A (p⬍0.0013). All Z patients had a mRS ⱕ2 at 7 days (21 had mRS ⱕ1), whereas only 54.4% of A had a mRS Background/Purpose: Despite its established efficacy in the first 3 hours, intravenous tissue plasminogen activator (IV t-PA) is not effective in all cases and rescue reperfusion strategies may need to be considered in the acute phase. We aimed to evaluate the accuracy of quantitative MRI/MRA analysis to predict outcome, as this might improve selection of patients for endovascular interventions. Methods: Over the last 1.5 years, 30 out of 50 consecutive stroke patients admitted to a tertiary care center after receiving IV t-PA had brain MRI in the first 8 hours. The volume of the infarction on diffusion weighted imaging (DWI) and perfusion deficit on TTP (time to peak) maps (PWI) were segmented using computer assisted techniques by a neurologist blinded to clinical data and mismatch was noted when PWI/DWI⬎1.4. Another outcome predictor was the modified TIMI (Thrombolysis in Myocardial Ischemia) grade that shows the recanalization status of arteries supplying the ischemic areas. Outcome measures were the volume of the infarction on a CT obtained 24 hour after IV t-PA, modified Rankin Scale (mRS) on discharge and neurologic worsening over the first 48 hours. All predictive models were further adjusted for age and for performance of endovascular intervention (5 patients). Results: MRA TIMI grade 1 was found in 38% (total occlusion, no anterograde distal flow), 35% had grade 2 (partial recanalization, decreased distal flow) and 27% grade 3 (complete recanalization, unimpeded distal flow). The mean volume of lesion on DWI was 37.3 cc (range 0 –198), on PWI was 101.2 cc (range 0 – 416), and the mean final infarct volume was 46.2 cc (range 0 –291). A PWI/DWI mismatch was found in half of the patients. In univariate analyses, DWI lesion volume (r⫽0.93, p⬍0.001), PWI volume(r⫽0.86, p⬍0.001), and MRA TIMI grade (r⫽-0.6, p⫽0.001) were strongly correlated with final infarct volume; DWI volume (p⫽0.001) and PWI volume (p⫽0.05) remained as independent predictors in multivariate analysis. At discharge, 40% of patients had a mRS score of 0 –2. MRA TIMI grade (r⫽-0.66, p⬍0.001) and DWI infarct volume (r⫽0.47, p⫽0.002) were correlated with mRS on discharge; only MRA TIMI score (p⫽0.004) was an independent predictor on multivariate analysis. Neurological worsening was noted in 23% of patients. Higher DWI volumes were independently associated with risk of early deterioration (p⬍0.001). Presence of mismatch was not associated with any of the outcome measures. Conclusions: A combination of quantitatively measured DWI and PWI lesions and MRA TIMI grade may improve the accuracy of outcome prediction immediately after IV t-PA. The association of MRA TIMI score to the outcome may be important as the Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations presence of persistent arterial stenosis and distal flow compromise are potential targets for endovascular interventions. P143 Combined Extracranial and Intracranial Interventions as a Revascularization Strategy for Anterior Circulation Tandem Occlusions. Nirav Vora, Ridwan Lin, Ajith Thomas, Rishi Gupta, Syed Zaidi, Vivek Reddy, Maxim Hammer, Ken Uchino, Lawrence Wechsler, Michael Horowitz, Tudor Jovin; Univ of Pittsburgh, Pittsburgh, PA Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Acute anterior circulation tandem occlusions (TO) of the internal carotid artery (ICA) origin and intracranial ICA or middle cerebral artery (MCA) have been poorly studied. Our aim is to evaluate our intra-arterial (IA) strategy for these lesions. Methods: We retrospectively reviewed case records of patients presenting to our center with an acute anterior circulation TO. Data collected included stroke risk factors, baseline National Institutes of Health Stroke Scale (NIHSS), intracranial site of occlusion, and IA treatments implemented. All patients first received angioplasty and stenting of the proximal ICA origin occlusion with emboli protection. Subsequent intracranial interventions if required included IA tPA, urokinase, angioplasty, stenting, or mechanical embolectomy. Our study had 3 endpoints: successful reperfusion defined as Thrombolysis in Myocardial Infarction (TIMI) score ⱖ 2 post-procedure, incidence of post-procedure parenchymal hematomas (PH), and good functional outcome defined as hospitalization discharge to home or an acute rehabilitation facility. Multivariate analysis was performed to determine predictors of successful reperfusion and good functional outcome. Results: We identified 40 patients with mean age 64⫾10 years and mean NIHSS 15⫾5. Mean time to reperfusion was 593⫾454 minutes after clinical symptom onset. Intracranial occlusions included the following: 10 ICA terminus, 23 MCA M1, 5 MCA M2. Twenty-one patients (52.5%) achieved successful reperfusion. Fifteen patients were treated with proximal ICA stenting only with 10 achieving successful reperfusion. Nine patients (22.5%) sustained a PH with 8 occurring in the 25 patients treated with proximal stenting and an intracranial intervention. Two patients had distal embolization during their procedure; one of these recanalized spontaneously. Twenty-two patients (55%) achieved good functional outcomes. Combination intracranial pharmacologic and mechanical interventions (OR 50.4, 3.98 –2035 95% CI, p ⫽0.01) and intracranial occlusion distal to the ICA terminus (OR 22.9, 2.2– 607 95% CI, p⫽0.02) were statistical predictors of successful recanalization. Baseline NIHSS was the only statistically significant predictor for functional outcome (OR 0.00004, 1.4x10-9-0.02 95% CI, p⫽0.01). Conclusions: Endovascular therapy can be safely performed in the setting of an anterior circulation TO particularly when proximal ICA stenting is performed initially. This approach requires further prospective study. 605 P145 Staged Versus Single Stage Treatment Of Intracranial Aneurysm Using Neuroform Stent. Yahia (former Abutah M Lodi (former Yahia), Upstate Med Univ, Syracuse, NY; Vickie Gordon, John Whapham, Ali Malek, Richadr Fessler; Dept of Neursurgery, Providence Hosp, Southfield, MI Background: Neuroform stent facilitates endovascular treatment of difficult intracranial aneurysm. Complications associated with neurofm stent have been described previously. The effects of multi-staged versus single stage procedure on the rate of complications associated with Neuroform stent-assisted coiling of intracranial aneurysm are not known. Objectives: To compare the incidence of complications between single stage and staged neuroform stent-assisted coiling of intracranial aneurysms. Methods: Consecutive patients undergoing treatment of intracranial aneurysm using Neuroform, either single stage or staged procedure, from January 2003 to November 2006 are enrolled. Information of patient demographics, aneurysm size, location, and complications events are gathered. Additionally, clinical outcomes are measured using Glasgow Outcome Scale (GOS) and National Institute of Health Stroke Scale (NIHSS) at 90 days. Results: Neuroform stents are successfully implanted in 66/68 (97%) patient. Patient mean age is 50.5 ⫾ 13.7 years and 57/68 (83.8%) are woman. There are 6 complication events; five in single stage and one in staged procedure. Complications in the single stage are ruptured of aneurysm in two (both basilar artery bifurcation aneurysms required Y-neck reconstruction), thromboembolic event in two (stroke in one on day 14, transient ischemic event in other on day 6) and herniation of stent into aneurysm in one. In the staged procedure, the only event is an ischemic stroke on day 7, after a second stent to reconstruct a middle cerebral artery bifurcation aneurysm. The event is not associated with patient’s age, gender, cerebrovascular risk factors, size or location of the aneurysm. But, three of six events have been observed on patients, who require Y-stent neck reconstruction. Most of the patient have good outcome (GOS 1 or NIHSS 0 was observed in 63/67 (94%) cases. GOS 2 or NIHSS 2, GOS 3 or NIHSS 4 was observed in another 3). Conclusion: Higher rate of complications are observed in single than staged endovascular treatment of intracranial aneurysms using neuroform stent. These are intraoperative rupture of aneurysm and thromboembolic event. Therefore, caution should be made during single stage coiling of the aneurysm using neuroform stent. Further study is warranted. P146 Relationship Between Inaccurate Thrombolytic Dosing and Hemorrhagic Complications in Acute Stroke. P144 Changes in Triage Stroke Panel Correlate with Outcome in Ischemic Stroke Patients Treated with Thrombolysis. Byron R Spencer, Jr., Molly A Smith, Maria I Aguilar, Mayo Clinic Hosp, Phoenix, AZ; Bentley J Bobrow, Mayo Clinic Hosp and Arizona Dept of Health Services, Phoenix, AZ; Timothy J Ingall, David W Dodick, Nadine F Lendzion, Patricia H Miller, Bart M Demaerschalk; Mayo Clinic Hosp, Phoenix, AZ Raf Brouns, Rishi Sheorajpanday, Jan Kunnen, Didier De Surgeloose, Peter Paul De Deyn; ZNA Middelheim, Antwerp, Belgium Background: Hemorrhagic complications are the major adverse events associated with thrombolytic therapy. The dose of thrombolytic used is based upon body weight. Incorrect dosing of thrombolytic therapy occurs in approximately 5–12% of cases and has been associated with major hemorrhage and increased mortality. Since body weight may not be accurately determined in the emergency department in the setting of acute ischemic stroke, the incorrect dosing of tissue plasminogen activator (t-PA) may occur more frequently than previously recognized. Hypothesis: The overdosing of t-PA based on estimated versus (vs.) actual patient weight in the setting of acute ischemic stroke is associated with a higher rate of hemorrhagic complications. Methods: We used a registry of ischemic stroke patients receiving t-PA to conduct a retrospective study of the estimated (patient, family, or healthcare provider best estimate) and actual (admission bed measured) weight of 122 consecutive patients who presented to our Joint Commission certified Primary Stroke Center (JC PSC) emergency department between Jan 2004 and Aug 2007 and received intravenous (IV) t-PA for ischemic stroke. Overdosing (OD) or under dosing (UD) were defined arbitrarily in the instances when the difference between estimated and actual weight was ⱖ 1kg (equivalent to 0.9mg dose of t-PA). The cohort was divided in two categories: Overdose group versus correct dose (CD) and under dose (CD⫹UD) group. Hemorrhagic complications were defined as follows: Asymptomatic intracranial hemorrhage (ASICH), symptomatic intracranial hemorrhage (SICH), fatal symptomatic intracranial hemorrhage (FSICH), and major systemic hemorrhage (MSH). Proportions of hemorrhagic complications were compared between the two groups with chi square statistics. Results: Baseline characteristics (mean age, gender, stroke severity) of the OD group did not significantly differ from the CD⫹UD group. OD group 32/122 (26.2%) and CD⫹UD group 36/122 (29.5%) and 54/122 (44.3%) respectively. ASICH occurred in 12.5 % (OD) versus 17.8% (CD⫹UD) [OR 0.66 (0.00 to 1.84)]. SICH occurred in 9.4% (OD) vs. 7.8% (CD⫹UD) [OR 1.23 (0.00 to 2.64). FSICH occurred in 3.1% (OD) vs. 5.6% (CD⫹UD) [OR 0.55 (0.00 to 2.73)]. MSH occurred in 0% (OD) vs. 4.4% (CD⫹UD) [OR 0 (not significant)]. Any hemorrhage occurred in 21.9% (OD) vs. 30.0% (CD⫹UD) [OR 0.65 (0.30 to 1.61)]. Conclusion: In this retrospective study of 122 patients with acute ischemic stroke who received IV t-PA, the incidence of excessive dosing was 26.2%, higher than previously recognized. There was no statistically significant association between overdosing of t-PA based on estimated vs. actual patient weight and hemorrhagic complications. Introduction: Identification of easily accessible markers for short-term and long-term prognosis after thrombolysis for ischemic stroke may be of use. Hypothesis: We investigated the possible added value of the bedside biomarker assay Triage® Stroke Panel over clinical evaluation and infarct volume for prediction of both short-term and long-term outcome after thrombolysis. Methods: We evaluated sixteen consecutive ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator (n⫽12) or intra-arterial administration of urokinase (n⫽4) by means of the National Institutes of Health Stroke Scale (NIHSS) and the multimarker index MMX (Triage姞 Stroke Panel) before thrombolysis and 72 hours after stroke onset. The Triage姞 Stroke Panel measures brain natriuretic peptide, D-dimer, matrix metalloproteinase-9 and S100 and calculates the composite multimarker index MMX based on the single biomarker concentrations. Standardized infarct volumetry after thrombolysis was obtained in every patient. The predictive value of infarct volume, change in NIHSS score and Triage® Stroke Panel results for stroke outcome at 7 days and 3 months (modified Rankin Scale, mRS) was evaluated. Results: Changes in MMX results and NIHSS scores before thrombolysis and 72 hours after stroke onset were significantly correlated with stroke outcome both at 7 days and at 3 months after stroke onset (⫽0.67 and 0.75 for change in MMX (P⫽.004 and .001); ⫽0.58 and 0.60 for change in NIHSS (P⫽.019 and .013)). These findings indicate that decreases in MMX and NIHSS are correlated with good outcome. Increases in MMX and NIHSS are correlated with poor outcome. Using cut point 0.0 for change in MMX and 0 for change in NIHSS, the overall accuracy for predicting good outcome (mRS 0 to 2) at 7 days after stroke was 81% for both parameters. For prediction of good outcome at 3 months, the overall predictive accuracy was 88% and 75% respectively. Infarct volume was not significantly correlated with and had poor predictive accuracy for outcome. In a multivariate stepwise regression analysis only change in MMX and change in NIHSS emerged as an outcome predictor that was independent of age, gender, stroke severity, stroke etiology, vascular risk factors, blood pressure before thrombolysis, blood glucose, type of thrombolysis, and time between onset of symptoms and start of thrombolysis. Conclusions: The use of the Triage® Stroke Panel before thrombolysis and 72 hours after stroke onset may be of more predictive value for short-term and long-term outcome than change in NIHSS score or infarct volume. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 606 Stroke Vol 39, No 2 February 2008 P147 Frequent Anti-hypertensive Treatment During Revascularization Therapy Is Associated With Intracerebral Hemorrhage In The First 24 Hours. Rakesh Khatri, Pooja Khatri, Jane Khoury, Joseph Broderick, Thomas Tomsick, Dawn Kleindorfer, Daniel Woo; Univ of Cincinnati, Cincinnati, OH Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Intracerebral hemorrhage (ICH) may occur as a consequence of ischemic stroke and its risk is increased in the setting of thrombolytic therapy. Some patients receiving thrombolysis require multiple treatments with anti-hypertensive medications to maintain blood pressure parameters. We hypothesized that an increased number of anti-hypertensive treatments would be associated with ICH after thrombolytic treatment for ischemic stroke. Methods: We examined a registry of patients treated with IV/IA or IA-only rtPA for ICA-terminus, M1, or M2 occlusions (n⫽64). The number and type of anti-hypertensive treatments before, during and after revascularization therapy were recorded. Post-procedure follow up CTs of patients at 24 hours (⫹/- 6 hours) after symptom onset were reviewed for ICH, including symptomatic and asymptomatic ICH. We categorized ICH by ECASS criteria. We tested the association between the number of anti-hypertensive drug treatments and ICH after adjusting for significant covariates. Covariates considered were sex, race, baseline NIHSSS, type of thrombolysis (IA vs IVIA), lytic dose, atrial fibrillation, history of diabetes, history of hypertension, antiplatelet use and serum glucose. Anti-hypertensive treatments included labetolol, hydralazine, sodium nitroprusside, nitroglycerine and enalapril. Results: Of 64 patients included between 1999 and 2005, the average age was 63 years, 41 (64%) were female, 12 (19%) were black, the median baseline NIHSS score was 19 and 52 (81%) proceeded to have IA therapy (12 required only the original 0.6 mg/kg IV dose). ICH occurred in 30 (47%) cases, including 5 (8%) PH1s and 7 (11 %) PH2s. Anti-hypertensive treatment was administered in 25 (39%) cases (range 1–10 doses). In bivariate analysis, use of any anti-hypertensive treatment was associated with increased risk of ICH (p⫽0.02). When examined by the number of treatments, use of 1–2 treatments was not significantly associated with ICH at 24 hours (OR⫽3.1; 95% CI 0.5–17.8) while ⱖ 3 treatments was associated with increased risk of ICH (OR⫽9.6; 95% CI 1.5– 60.4) after adjustment for significant covariates of lytic dose (p⫽0.007), diabetes (p⫽0.03), and serum glucose (p⫽0.04). Considering only anti-hypertensive treatments before and during revascularization therapy, treatment was also associated with increased risk of ICH (p⫽ 0.01). Conclusions: Hypertension requiring more than two treatments during revascularization therapy is an important risk factor for ICH at 24 hours. Excessive antihypertensive treatment may be a surrogate marker for uncontrolled hypertension or a consequence of ICH. Our results suggest that the need for 3 or more treatments of hypertension should raise clinical suspicion for ICH. P148 Predictors For Good Pial Collateral Formation In Acute Ischemic Stroke. Gregory Christoforidis, Yousef Mohammad, Marinos Kontzialis, Louis Caragine, Andrew Slivka; Ohio State Univ, Columbus, OH Purpose: The extent of pial collateral formation to an ischemic territory during acute stroke influences outcomes. This study sought to identify clinical factors which can be predictive of good pial collateral formation prior to intra-arterial thrombolyitic treatment for acute ischemic stroke. Methods: This study reviewed prospectively collected clinical information and arteriograms from 79 consecutive patients with anterior circulation infarctions involving either the horizantal portion of the middle ceerebral artery (MCA), or the terminal internal carotid artery (ICA) in patients who underwent intra-arterial thrombolysis within 6 hours following symptom onset. Pial collaterals were assessed on the basis of anatomic extent. Good pial collaterals in this study were equivalent to grades 3 and 4 described by Higashida (1). Logistic regression analysis for good pial collateral formation used the following predictors: pretreatment National Institutes of Health Stroke Scale Score (NIHSSS), age, time to treatment, sex, presenting systolic and diastolic blood pressure (DBP), admitting glucose level, admitting platelet level and site of occlusion (ICA vs. MCA). All factors with p⬍.10, were entered into the final model as predictors of clinical outcome using backward selection. Results: Logistic regression analysis (whole model test: p⬍0.0001; r2 ⫽0.13) identified clot location within the MCA versus the ICA terminus (p ⬍.0001), lower presenting NIHSSS (p⫽0.0449) and lower presenting DBP (p⫽0.0497) to be associated with better pial collateral formation. The median presenting NIHSSS for patients with good versus poor pial collateral formation was 15 versus 18.5 respectively (p⫽0.0070; 2-sample Wilcoxan rank sums test). The mean DBP was 81mmHg versus 89mmHg respectively (p⫽0.0396; analysis of variance).Good pial collateral formation was associated with 35.3% of patients with carotid terminus occlusions versus 79.4% of patients with m1 segment occlusions (p⫽0.0004; Pearson). Conclusion: Clinical predictors for good pial collateral formation in the setting of anterior circulation acute ischemic stroke include: MCA location versus carotid terminus location, lower presenting NIHSSS and lower DBP. References: 1) Higashida RT, Furlan AJ. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34:109 –137. P149 Absence of Atrial Fibrillation is A Risk of Neurological Deterioration in Ischemic Stroke Patients Who are Excluded from Intravenous Tissue Plasminogen Activator Treatment Because of Mild or Improving Symptoms. Kuniyasu Wada, Yasuyuki Hara, Tadashi Terasaki, Daisuke Higashi, Japanese Red Cross Kumamoto Hosp, Kumamoto, Japan; Teruyuki Hirano, Makoto Uchino; Kumamoto Univ, Kumamoto, Japan Background and Purpose: Acute ischemic stroke patients with mild or improving neurological symptoms are excluded from intravenous tissue plasminogen actibator (tPA) treatment. Occasionally, after the decision on eligibility of tPA treatment, neurological deterioration (ND) is observed in the patients who are regarded as “mild to treat with tPA” (MTT). The purpose of this study is to find the predictors of poor outcomes in the data that was obtained before tPA decision in emergency rooms. Methods: One hundred and seven consecutive patients presenting at our hospital within 3 hours of stroke onset between October 2005 and April 2007 were entered the analysis. We defined early rapid improvement (ERI) as a 4-point NIHSS score improvement from the time of initial evaluation to the time of tPA decision, minor symptom (MS) as NIHSS score⬍/⫽4 at the time of tPA decision and ND as 2-point worsening in NIHSS score from the time of tPA decision to the time of hospital discharge. MTT patients were regarded those with ERI or MS. To find predictors of poor outcomes, the data obtained before tPA decision were compared between MTT patients with and without ND. Stroke pathophysiology was determined at hospital discharge. Results: Fifty (48%) of all were MTT patients (35 men and 15 women, 70⫾12 years old). (Twenty-six (24%) patients were treated with tPA.) The average NIHSS score of MTT patients at the time of initial evaluation was 4.7 and at the time of tPA decision was 1.8. Nine MTT patients had ND. Thirteen of 41 MTT patients without ND had atrial fibrillation on admission, while none of the patients with ND had atrial fibrillation (31% vs. 0; p⬍0.05). Eighty-nine percent of patients with ND were diagnosed as large-artery atherosclerosis (LAA) at discharge. The percentage of LAA in MTT patient with ND was higher than in that without ND (p⬍0.05). Conclusion: Absence of atrial fibrillation on admission is a risk of ND in MTT patients. This may reflect that stroke pathophysiology is LAA in most of the MTT patient with ND. P150 Telestroke Shortens Onset to Treatment Times for Intravenous tissue Plasminogen Activator in Acute Ischemic Stroke. Jeffrey A Switzer, Hartmut Gross, Christiana E Hall, Robert J Adams, Fenwick T Nichols, David C Hess; Med College of Georgia, Augusta, GA Introduction More than half of the over 5000 hospitals in the U.S. have less than 100 beds. These hospitals seldom have stroke specialists available to provide acute consultations and guide the administration of tPA. At the Medical College of Georgia (MCG), we have developed a web-based telestroke (REACH) system to facilitate intravenous (IV) tissue plasminogen activator (tPA) administration in rural emergency departments. Early treatment with tPA is associated with better outcomes. We report our treatment times in the first 94 patients treated with tPA and compare the results to the published literature. Our hypothesis was that the use of REACH would shorten onset-to-treatment time (OTT). Methods Using the REACH system, six stroke specialists at MCG provide 24 hour per day, 7 day per week acute stroke consultations to 9 rural emergency departments in hospitals with 10 –75 beds. Video and CT transmission across the internet allows for real time neurologic assessment and determination of the appropriateness of tPA use. A systematic review of the literature was conducted to examine IV tPA use in other stroke care delivery systems. We excluded studies that did not document OTT, included treatments beyond three hours or intra-arterial tPA, required MRI prior to treatment, included only MCA occlusions, or enrolled less than twenty patients. We compared the treatment times using REACH with these systems. Results To date 94 patients have received IV tPA using REACH. Ten patients were treated beyond three hours from time of onset. These patients were excluded from further analysis. The mean OTT was 121.2 and door-to-needle was 75.9 minutes. 18 (21%) and 45 (54%) of the 84 patients were treated within 90 and 120 minutes respectively. There have been 4 symptomatic intracerebral hemorrhages (NINDS criteria), but no type 2 parenychymal hematomas (ECASS criteria). Fourteen studies were identified that fulfilled our search criteria. OTT using REACH was significantly shorter than all other published systems with the exception of a single center study from Cologne, Germany (Grond et al). Conclusions The REACH system facilitates rapid treatment of acute ischemic stroke patients within a rural telestroke network. Using REACH, OTT was shorter than in community and academic centers that relied on an “in-person” recommendation for administration. Telestroke could be used to speed treatment in urban communities as well. Study Grond et al. Stroke 1998;29:1544 –9 Chiu et al. Stroke 1998;29:18–22 Wang et al. Stroke 2000;31:77–81 Chapman et al. Stroke 2000;31:2920–4 Albers et al. JAMA 2000;283:1145–50 Grotta et al. Arch Neurol 2001;58:2009–13 Koennecke et al. Stroke 2001;32:1074–8 Merino et al. Stroke 2002;33:141–6 Walters et al. Cerebrovasc Dis 2005;20:438–42 Dick et al. Neurologist 2005;11:305–8 Sims et al. Ajnr 2005;26:246–51 Mouradian et al. JNNP 2005;76:1234–7 # treated OTT p-value ⬍90 minutes 100 126 0.1755 26% 30 157 ⬍.0001 57 148 ⬍.0001 11% 46 165 ⬍.0001 389 164 ⬍.0001 269 137 ⬍.0001 75 144 ⬍.0001 9% 4% 82 148 ⬍.0001 120 139 ⬍.0001 101 130 0.0143 47 132 0.0029 65 145 ⬍.0001 ⬍120 minutes 4% 28% Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations Study Hill et al. CMAJ 2005;172: 1307–12 Sattin et al. Stroke 2006;37:2935–9 # treated OTT p-value 1135 155 ⬍.0001 45 133 0.0012 ⬍90 minutes ⬍120 minutes 44% P151 Matrix Metalloproteinase-9 And Early CT Changes In Patients With Thrombolytic Treatment. Hye-Yeon Choi, Young Dae Kim, Hye Sun Koh, Hyun Ji Cho, Eung Yeop Kim, Ji Hoe Heo; Yonsei Univ, Seoul, Republic of Korea Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and objectives The Alberta Stroke program early CT score (ASPECTS), which is CT-based grades of early ischemic changes, and the plasma MMP-9 levels are known as surrogate markers to predict hemorrhage after thrombolytic treatment in stroke. This study was aimed at determining whether the MMP-9 levels are associated with ASPECTS. We also investigated their predictabilities of initial neurologic severity and outcomes. Methods Among patients who received thrombolytic treatment, those whose blood samples could be obtained before the treatment and who had a stroke in the anterior circulation were included. ASPECTS was scored from baseline CT scans by consensus approach of two neurologists. Plasma MMP-9 levels were measured by using a commercially available enzyme-linked immunosorbent assays kit. National Institutes of Health Stroke Scale (NIHSS) score was used to determine the severity of neurologic deficits at baseline, 24 hours and 7 days. The early or late improvement ratio (IR) was defined as [(initial NIHSS scores - 24 hours (early) or 7 days (late) NIHSS scores) X 100/ baseline NIHSS scores]. Results Forty three patients were included (27 men, mean age 69 years). ASPECTS values were dichotomized into ⱕ8 (moderate/severe change, 22 patients) and ⬎8 (mild/no change, 21 patients). Mean NIHSS scores were 15 at baseline, 12 at 24 hours, and 10 at 7 days. Mean early IR was 24.4% and late IR was 41.3%. Hemorrhagic transformation occurred in 23 patients (symptomatic in ten). Hemorrhage was common in patients with ASPECTS ⱕ8 (p⬍0.05). Patients with symptomatic hemorrhage showed a tendency of higher MMP-9 levels (52.40 ⫾ 32.40 vs. 70.52 ⫾ 36.98). However, plasma MMP-9 levels were not different between patients with ASPECTS ⱕ8 and ⬎8. NIHSS scores and mortality were higher in the patients with ASPECTS ⱕ8 than those with ⬎8 (p⬍0.05). Early and late IRs were higher in the patients ASPECTS ⬎8 (early 45.0 vs 1.9%; late 53.2 vs 17.3%; p⬍0.05). In contrast, plasma MMP-9 levels showed no association with initial NIHSS or ealry and late IR. Conclusions Plasma MMP-9 levels were not predictive of neurologic severity or degree of neurologic improvement, while ASPECTS was associated with them. Although both plasma MMP-9 levels and ASPECTS may be markers to predict hemorrhagic transformation after thrombolysis, there was no direct relationship between them. Plasma MMP-9 levels and ASPECTS seem to be surrogate markers, which reflect different aspects of mechanisms leading to hemorrhagic transformation. 607 P153 The Impact of Improved Hospital Reimbursement on National Rates of Rt-PA Use. Dawn Kleindorfer, Univ of Cincinnati, Cincinnati, OH; Irene Katzan, Cleveland Clinic, Cleveland, OH; Dilib Pandey, Univ of Illinois, Chicago, IL; Richard Hornung, Joseph P Broderick; Univ of Cincinnati, Cincinnati, OH Introduction: We have shown that national rates of rt-PA use were not increasing between fiscal years (FY) 2001– 04. In FY 2006, a new hospital reimbursement diagnosis related group (DRG) code 559 was introduced, which more than doubled the reimbursement for stroke patients treated with thrombolytic therapy. We hypothesized that the new DRG would be associated with a significant increase in the use of rt-PA for ischemic stroke. Methods: The Premier database is currently partnered with the FDA to study drug utilization in hospitalized patients and contains approx. one out of every six inpatient discharges in the U.S, has no age exclusion, and has the ability to access pharmacy billing records. All stroke-related (ICD-9 codes 430 – 436) admissions were queried using the DRG codes 14, 15, 524, and 559 for FY 2001– 06. Rt-PA administration was described using the ICD-9 code 99.1 (cerebral thrombolysis), and rt-PA utilization documented in pharmacy records. Differences in proportions were tested using the Chi-square statistic. Results: The rates of rt-PA use increased in FY 2006 when compared to the pooled treatment rate of FY 2001–2005 (3.0% vs. 1.8%, p⬍0.0002). However, there was a also significant increase between FY 2004 vs 2005, and FY2005 vs. 2006 (p⬍0.001 for both). See table for rt-PA rates among patients with ischemic stroke ICD-9 codes over a six year period. Patients given thrombolytic, yet coded with hemorrhagic stroke or TIA ICD-9 codes represented 12% of rt-PA treats in both FY 2005 and 2006, and 5% of DRG 559 discharges in FY 2006. Within the DRG 559 discharges, 13% did not administer thrombolytic therapy according to pharmacy records. Discussion: In contrast to 2001– 04, we found that the rates of rt-PA use in the U.S. increased in FY 2005 and 2006, a relative increase of more than 60% over two years. However, the new DRG 559 was not introduced until FY 2006, so likely other factors were influencing this increase, such as JCAHO stroke center certification and other quality improvement programs. Patients receiving rt-PA are often miscoded by billing personnel, which makes interpretation of national statistics problematic. The “drip and ship” model of care may explain the 13% of DRG 559 discharges that did not bill for thrombolytic, since the patients are transferred after receiving thrombolytic at an outside hospital. However, the DRG 559 is not supposed to not be billable to either the receiving or transferring institution, an issue which has yet to be addressed by the Centers for Medicare and Medicaid Services (CMS). total number of cases, DRG 12/15/524/559 # with ICD-9 code 99.1 (%) # with pharmacy billing for thrombolytic (%) FY 2001 FY 2002 FY 2003 FY 2004 FY 2005 FY 2006 ALL DRGs 54,772 59,893 58,570 56,129 54,012 59,334 572 (1.04) 875 (1.60) 632 (1.06) 1002 (1.67) 616 (1.05) 956 (1.63) 646 (1.20) 1021 (1.82) 811 (1.50) 1332 (2.47) 1447 (2.44) 1781 (3.0) FY 2006 DRG 559 Only 1,437 1437(100) 1256 (87.4) P152 Does Hyperacute Diffusion and Perfusion Weighted Imaging Predict Outcome in Acute Ischemic Stroke? Elizabeth Barak, Javier Romero, Shahmir Kamalian, Leila R Gharai, Ramon G Gonzalez, Pamela Schaefer; Massachusetts General Hosp, Boston, MA Purpose: To evaluate whether initial lesion volume on diffusion weighted imaging(DWI) and perfusion weighted imaging(PWI) in acute ischemic stroke is associated with clinical outcome. Material and Methods: 54 patients with acute strokes who underwent DWI and PWI within 9 hours of symptom onset were evaluated. Visually detected DWI and mean transit time(MTT) abnormalities were segmented with a commercial analysis program and volumes were calculated. Clinical outcomes, abstracted from medical records, were considered good if the modified Rankin scale(mRS) was 0 to 2 and poor if the mRS was 3– 6. T Test was used to analyze DWI and MTT volumes relative to good versus poor outcome and Receiver Operating Characteristic(ROC) curves were calculated. Results: 33/54 (61%) patients had a good clinical outcome. Mean DWI lesion size was 54cc. Patients with good clinical outcomes had significantly smaller initial DWI lesion volumes (mean 15cc) versus patients with poor outcomes (115cc)(p⫽0.0001). Mean MTT lesion volume was 126cc. Patients with good clinical outcomes had significantly smaller MTT lesion volumes (65cc) versus patients with poor outcomes (218cc)(p⬍0.0001). ROC curves for DWI and MTT relative to poor outcome, had areas under the curve of 0.896 and 0.894, respectively. To maximize the specificity of DWI lesion volume, (all patients above the cutpoint have a poor outcome) we chose a cut-off point of 72cc with 97% specificity and 62% sensitivity for poor outcome. 13/13 (100%) patients with DWI lesion size ⬎ 72cc and 8/41 (20%) patients with DWI lesion size ⬍ 72cc had a poor outcome. To maximize the sensitivity of MTT lesion volume (no patients below the cut-off point have a poor outcome), we chose a cut-off point of 47cc with 49% specificity and 96% sensitivity for poor outcome.0/16 (0%) of patients with MTT lesion size ⬍47cc and 21/47 (47%) patients with MTT lesion size ⬎ 47cc had a poor outcome. Conclusion: Patients with good clinical outcome had smaller DWI and MTT lesion size on admission MRI. An initial DWI lesion size ⬎ 72cc is highly specific for poor outcome (all patients with a large DWI have a poor outcome) and a MTT lesion size ⬍ 47cc is highly sensitive for poor outcome (no patients with MTT ⬍ 47cc have a poor outcome, ie: all have good outcome). DWI and PWI in acute ischemic stroke can help choose candidates most likely to benefit from thrombolysis without taking unnecessary risk. P154 Increasing ThrombolyticTreatment Rates: Results Utilizing Revised Treatment Criteria And A Multidisciplinary Stroke Education Program. David C Tong, Jack Rose, Jeffrey Thomas, Jackie Phan, Ann Bedenk, Jerome Barakos, Dan A McDermott; California Pacific Med Cntr, San Francisco, CA Stroke treatment with rt-PA remains dismally low. We hypothesized that a rapid stroke triage system using revised criteria reported to permit safe thrombolysis, coupled with a comprehensive education program could substantially increase thrombolysis treatment rates even without the presence of a stroke network. METHODS: A rapid triage stroke code system was implemented where patients are considered for treatment with revised criteria that have been reported to permit safe thrombolysis. Clinical factors such as recent surgery or possible seizure at symptom onset are considered relative rather than absolute contraindications to treatment. Patients of any age are eligible for treatment. Complete reporting of laboratory values is not necessary prior to the initiation of therapy if there is no reason to suspect a clinically relevant abnormality. Patients are treated if the neurological deficit is considered disabling, but without a specific NIHSS score cut off. All stroke codes alert the CT technologist to facilitate rapid imaging. Intra-arterial therapy is used in patients with contraindications to IV treatment such as recent surgery or anticoagulation with a significantly elevated PTT or INR. A comprehensive hospital wide educational program was instituted with emphasis on early recognition of stroke-like symptoms. Our stroke code system permits any health care provider to initiate a stroke code. RESULTS: After implementation of the new system, on average 23.8% of all acute ischemic stroke patients were treated. Monthly treatment rates ranged from 13–38%. The mean age was 73 ⫾ 16 years. 51% were male, 39% (16/41) were ⱖ 80 years old. Median door to needle time was 67 minutes (95% CI 28 –152), and median symptom onset time to treatment was 130 minutes (95% CI 87–290). 13/41 (32%) received IA treatment, primarily due to a post surgical state (n⫽6; 46%) or anticoagulation at the time of symptoms (n⫽3; 23%). Symptomatic intracerebral hemorrhage rate was 7%, and mortality was 18%. At discharge, 52% (21/41) of patients had good outcome (mRS 0 –2), despite the older population treated. CONCLUSION: A system of rapid triage, revised treatment criteria, and education can result in a substantial increase in the rate of thrombolytic treatment and outcomes comparable to Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 608 Stroke Vol 39, No 2 February 2008 published series. Outcomes were comparable to those in clinical trials, despite the significantly older population treated. Widespread adoption of these techniques could greatly increase the safe and effective use of thrombolysis for acute stroke. P157 The Role of Stroke Severity in Transfer and Treatment Decisions. Marilyn M Rymer, Duane Thrutchley, Saint Luke’s Hosp, Kansas City, MO; Saint Luke’s Hosp Stroke Team P155 Timing And Delivery Of Acute Stroke Therapy: Does Place Or Day Of The Week Matter? Rakesh Khatri, Dawn Kleindorfer, Jane C Khoury, Pam Schmit, Irene Ewing, Edward Jauch, Pooja Khatri, Arthur Pancioli, Brett Kissela, Daniel Woo, Matthew L Flaherty, Brian A Stettler, Christopher W Nichols, Opeolu Adeoye, Joseph P Broderick; Univ of Cincinnati, Cincinnati, OH Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: There remains a concern whether the timing and delivery of tissue plasminogen activator (t-PA) and potential study interventions are similar in Community Hospitals (CH) compared with Academic Centers (AC). Methods: We collected data from our local SPOTRIAS registry about academic centers and community hospitals in the Greater Cincinnati- Northern Kentucky area about stroke onset-to -treatment time, percentage of t-PA treatments and study enrollment rates. Our multidisciplinary stroke team provides rapid consultation to a total of 31 hospitals (3 AC and 28 CH) either by phone (N ⫽ 31) and/or in person (N ⫽ 16) to evaluate acute stroke patients 24 hours a day and seven days a week. We compared stroke symptom onset to treatment time between ACs and CHs. We also compared rates of study enrollment and percentage of treatments on weekdays and weekends. Results: Our stroke team evaluated a total of 2556 cases (including phone calls without an in-person evaluation) from a period of January 2005 to June 2007. A total of 807 cases (296 at ACs and 574 at CHs) were evaluated by a stroke team physician in person. From a total of 292 thrombolytic treatments, 127 cases (60 arriving directly and 67 transferred from CHs) were eventually treated at an AC and 185 cases were treated at a CH. Time-to-treatment at CHs was 145 minutes (range 120, 170) compared to 132 minutes at AC for 60 cases arriving directly (range 114, 162) with p⫽ 0.07 . On combined analysis of both AC and CH, time-to-treatment on weekdays was 140 minutes (range 115, 167) compared to weekend time of 146 minutes (range 119, 170) with p⫽ 0.49. The distribution of 292 patients treated with t-PA on any day of the week was not statistically different with most treats occurring on Friday (43%) and fewest on Thursday (26%). Study enrollment rates of these 292 patients were comparable during any day of the week with maximum on Saturday 25 (23%) and minimum on Thursday 16 (12%) for a total of 144 cases. Conclusion:Rapid evaluation by on-call regional stroke team physicians at both community and academic hospitals was associated with similar time-to-treatment at both types of institutions with a trend toward longer times at CHs. The proportion of thrombolytic treatments and study enrollment are comparable on weekdays and weekends if there is continuous on-call support by stroke team physicians. P156 Rates and Predictors of Clinical and Radiological Outcomes in Acute Ischemic Stroke Patients without Angiographic Occlusion. A Multicenter Review. Background: The National Institutes of Health Stroke Scale (NIHSS) score is a strong predictor of clinical outcome, and a score ⬎10 is highly correlated with large artery occlusions that may be more difficult to treat successfully with intravenous (IV) thrombolysis alone. As a regional referral center for acute ischemic stroke (AIS) we sought to analyze the spectrum of stroke severity in our cases as measured by the NIHSS score at presentation, determine whether the case was transferred in, and analyze treatment patterns within the NIHSS severity spectrum. Methods: All AIS cases from 1/2000 to 7/2007 were reviewed for presenting NIHSS scores using 5 point groupings, transfer status and whether treatment with IV or intra-arterial (IA) tissue plasminogen activator (tPA) and/or mechanical embolectomy was used.The data was then dichotomized into cases with NIHSS ⬍ 10 and cases with NIHSS ⬎10 and analyzed for significant differences in transfer status and treatment decisions. Results: NIHSS scores were available for 1791(71%) of 2518 ischemic stroke cases. Overall, 36.6% (655/1791) received acute therapy with lytic and/or mechanical embolectomy and 49.4% (855/1791) were transferred. Of the treated cases 67.9% (445/655) were transferred to our center.Significant differences were found in transfer and treatment decisions in milder (NIHSS ⬍ 10) vs more severe strokes (NIHSS ⬎10) Conclusions: The distribution of NIHSS scores indicate that milder strokes occur more frequently than severe strokes.Severe strokes are significantly more likely to be transferred to a comprehensive stroke center, to receive acute treatment, and to receive intra-arterial tPA and/or mechanical embolectomy rather than IV tPA alone. NIHSS SCORES OF TRANSFERRED AND TREATED CASES OF AIS Baseline NIHSS Score Number of Cases Transferred Cases Treated Cases IV tPA only Transferred Treated IV tPA only 0 –5 754 (42.1%) 322/ 754 (42.7%) 100/ 754 (13.3%) 69/ 100 (69.0%) 6 –10 364 (20.3%) 181/ 364 (49.7%) 123/ 364 (33.8%) 75/ 123 (61.0%) 11– 15 16 – 20 21– 15 235 206 138 (13.1%) (11.5%) (7.7%) 132/ 122/ 78/ 235 206 138 (56.0%) (59%) (56.5%) 141/ 129/ 98/ 235 206 138 (60.0%) (62.6%) (71.0%) 42/ 14/ 13/ 141 129 98 (29.8%) (10.9%) (13.3%) 26 –30 >30 Total 68 (3.8%) 26 (1.5%) 1791 34/68 (50.0%) 16/26 (61.5%) 46/68 (67.6%) 18/26 (69.2%) 2/68 (4.3%) 3/18 (1.7%) 885/ 1791 (49.4%) 6551791 (36.6%) 218/ 655 (33.3%) ⱕ10 NIHSS Score N⫽1118 ⬎10 NIHSS Score N⫽673 p-value 503(45%) 233(20%) 144(65%) 382(57%) 432(64%) 74(17%) ⬍0.0001 ⬍0.0001 ⬍0.0001 Qaisar A Shah, M. Fareed K Suri, Haitham M Hussein, Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN; Yousef M Mohammad, Dept of Neurology, Ohio State Univ, Columbus, OH; Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Minneapolis, MN Background: Approximately 15% of the patients with acute ischemic stroke do not have any occlusion demonstrated on initial angiography. The optimal management strategy in these patients is not known. Objective: To determine the rates and predictors of clinical and radiological outcome of the acute ischemic stroke patients without an angiographic occlusion. Methods: Patients were identified from a multiple single-center registries and a literature search of MEDLINE, PubMed, and Cochrane databases supplemented by a review of bibliographies of relevant articles and personal files. All patients underwent serial neurological assessment with National Institutes of Health Stroke Scale (NIHSS) score and modified Rankin Scale (mRS). Radiological assessment was performed with computed tomography scan (CT) and magnetic resonance imaging (MRI) obtained at 24 –72 hours. Predictors of favorable clinical outcome and radiological cerebral infarction were determined using multivariate analysis. Results: A total of 85 patients were analyzed (mean age 63 years; 31 were women) with acute ischemic stroke patients without an angiographically demonstrated occlusion. The median NIHSS score was 8 (range 2–25). A total of 10 patients received intravenous tissue plasminogen activator (t-PA) prior to angiography. Neurological improvement (defined by ⱖ4 points reduction in NIHSS score) was observed in 26 (48%) of the 54 patients with serial examinations. Favorable outcome defined by mRS 0 –2 ascertained at follow-up was seen in 47 (57%) of the 85 patients. After adjusting for confounding variables, patients with diabetes mellitus have a trend towards higher risk (odds ratio [OR] 3.7, 95% confidence interval [CI] 0.93 - 17.07) of poor functional outcome. Cerebral infarction was detected in 64 (77%) of the 83 patients with CT or MRI located in cortical (n⫽48) or sub-cortical (n⫽15) distribution. There were (n⫽44) anterior circulation strokes, (n⫽20) posterior circulation stroke, and (n⫽19) normal; CT data on two patients were not available. After adjusting for confounding variables, the risk of cerebral infarction was higher in patients aged more than 65 years (OR 23, 95% CI 1.9 - 357) and in men (OR 7.3, 95% CI 1.9 - 33). Conclusion: High rates of new infarcts in follow-up radiological assessment, and disability or death subsequent to the ischemic event are observed, particularly among older patients, men, and patients with diabetes. P158 Early Clinical Experiences With A New Thrombectomy Device For The Treatment Of Ischemic Stroke. Thomas Liebig, Kinikum rechts der Isar - TUM, Munich, Germany; Joerg Reinartz, Robert Janker Klinik, Bonn, Germany; Thomas Guethe, Katharinen Hosp, Stuttgart, Germany; Christian Roth, Universitätsklinikum des Saarlandes, Homburg/Saaar, Germany; Elina Miloslavski, Hans Henkes; Katharinen Hosp, Stuttgart, Germany A new flexible micro filament device for intraarterial thrombectomy, the phenox Clot Retriever (pCR) has become available for use in patients experiencing acute ischemic stroke in Europe since October 2006. The device consists of an array of radially circumferential oriented polyamid microfilaments on a highly flexible nitinol/platinum-alloy compound core wire. It is available in three sizes that range from 3 to 1mm proximally and 5 to 2mm distally and it can be deployed through a standard microcatheter. The smallest version is capable of recanalizing Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations vessel diameters well below 2mm such as the distal MCA branches. In three centers, 48 treatments in 45 patients with ischemic stroke were performed with one or more PCRs so far. The distribution of vascular territories was as follows: ICA (terminal and bifurcation) 13, MCA 18, vertebrobasilar 13, ACA and PCA 4. Recanalization was achieved in 33/48 treatments (68,8%) whereas in 12/48 no recanalization was possible. There were 3 failed attempts were the device and/or microcatheter could not be deployed. Of all 33 recanalizations, 27 were TIMI scores II or III (56,3%). In 11 treatments the vessel diameter was 2mm or less. The average number of devices needed was 2,6. Apart from a recanalization of more than 70% (failed attempts excluded), it was most remarkable that there was no device related morbidity and mortality recorded during these 48 treatments which is most likely attributable to the highly flexible and atraumatic design together with a simple application. From our experience we conclude that the pCR is a potentially useful supplement to the repertoire of currently available devices for endovascular intracranial thrombectomy. P159 Multimodal CT to Define a Tissue Window for Thrombolysis in Acute Ischemic Stroke. Imanuel Dzialowski, Jasmin Renger, Dept. Neurology, Univ of Dresden, Dresden, Germany; Olaf Wunderlich, Dept. Neuroradiology, Univ of Dresden, Dresden, Germany; Kristian Barlinn, Ulf Becker, Hjordis Hentschel, Katja E Wartenberg, Dept. Neurology, Univ of Dresden, Dresden, Germany; Ernst Klotz, Siemens Med Solutions, Forchheim, Germany; Georg Gahn, Dept. Neurology, Univ of Dresden, Dresden, Germany; Ruediger von Kummer; Dept. Neuroradiology, Univ of Dresden, Dresden, Germany Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: To date, thrombolysis in acute ischemic stroke has been restricted to a three-hour time window. We sought to define a CT-based tissue window for thrombolysis instead of a time window. Methods: We prospectively studied patients presenting with anterior circulation ischemic stroke within 12 hours of symptom onset and a National Institute of Health Stroke Scale (NIHSS) score ⱖ 3. All patients underwent cranial non-contrast computed tomography (NCCT), CT angiography (CTA), and CT perfusion imaging (CTP). Parameter maps of time-to-peak (TTP), cerebral blood volume (CBV) and cerebral blood flow (CBF) were generated. Patients were treated with IV, IA, or combined IV/IA thrombolysis according to current guidelines. We determined intracranial occlusion status and applied the Alberta Stroke Program Early CT Score (ASPECTS) to all NCCT scans and CTP parameter maps. A normal scan scored 10, a complete middle cerebral artery (MCA) lesion scored 0. We defined three different types of tissue windows in this population: 1) good NCCT scan (ASPECTS ⬎ 7), 2) favorable NCCT scan (ASPECTS ⬎ 5) in the presence of a MCA occlusion, and 3) CBV-ASPECTS minus CBF-ASPECTS ⱖ 2. We analysed feasibility, incidence and prognosis with and without thrombolysis for each tissue window. We defined favorable outcome as modified Rankin Scale scores 0 –2 at 3 months. Results: From 12/06 to 06/07, we screened a total of 138 patients, of which 46 fulfilled inclusion criteria. Mean age was 70 years, 48% were male, time-topresentation was 204 min, median NIHSS score 7 (range 3–31), ASPECTS 9 (range 2–10), 20/46 (43%) of patients had occlusions within the MCA territory, 23/46 (50%) received thrombolysis. Tissue windows 1 and 2 could be assessed in all, tissue window 3 in 33/46 (72%) of patients, mostly due to motion artefacts (5/13). Incidence was 27/46 (58%), 14/46 (30%) and 7/46 (15%) for tissue window 1,2, and 3, respectively. Tissue window 1 characterized less severely affected patients (median NIHSS score ⫽ 5, ASPECTS ⫽ 10, 6/27 (22%) MCA occlusions) compared to tissue window 2 (NIHSS score ⫽ 13.5, ASPECTS ⫽7, 14/14 occlusions) and 3 (NIHSS score ⫽ 14, ASPECTS ⫽ 6, 6/7 (86%) occlusions). We observed favorable outcome without thrombolysis in 6/15 (40%), 1/7 (14%) and 0/2 patients with tissue window 1,2, and 3, respectively. With thrombolysis, proportions for favourable outcome were 6/12 (50%), 2/7 (28%) and 1/5 (20%) for tissue window 1,2, and 3, respectively. Conclusion: Performing multimodal CT in patients with anterior circulation ischemic stroke presenting within 12 hours from symptom-onset might help to define a tissue window for thrombolysis. Feasibility of a CTP-based tissue window might be limited. Patients with a favourable NCCT scan and a MCA occlusion might be a target group for thrombolysis within a tissue window. However, the number of patients in this ongoing study is a limit to draw definite conclusions. 609 patients (age; 73.8 ⫾ 8.9 years, male; 14, median NIHSS; 15.3 ⫾6.6) into the present study. MRA immediately after t-PA therapy showed early recanalization in 14 of 31 (45.2%) patients. Before IV t-PA therapy, median infarct volume was 5.6 cm3 in non-recanalization group and 10.7 cm3 in recanalization (p⫽0.93) and mean NIHSS score was 16 in occlusion group and 16 in recanalization group (p⫽0.95). Immediately after IV t-PA, median infarct volume was 32 cm3 in non-recanalization group and 10.8 cm3 in recanalization (p⫽0.93) and NIHSS score was 17 in occlusion group and 14 in recanalization group (p⫽0.35). However, at 24 h of onset, infarct volume was larger in non-recanalization group than recanalization group (65.4 cm3 vs. 12.1, p⫽0.02) and NIHSS score more elevated in non-recanalization group than recanalization group (19 vs. 12, p⫽0.02). After 7 days of onset, similar tendency was observed between non-recanalization and recanalization groups (infarct volume; 133.6 cm3 vs. 19 cm3, p⫽0.01, and NIHSS score; 19 vs. 11, p⫽0.01). Conclusion: Early recanalization immediately after IV t-PA infusion in acute ischemic stroke can avoid the enlargement of ischemic volume. P161 Orolingual Angioedema After Thrombolysis For Acute Stroke. Maria I Aguilar, Bart M Demaerschalk, David W Dodick, Timothy J Ingall, Nadine F Lendzion, Patricia H Miller, Mayo Clinic Arizona, Phoenix, AZ; William D Freeman, Nancy L O’Keefe, Mayo Clinic Jacksonville, Jacksonville, FL; Gustavo Saposnik, Univ of Toronto, Toronto, Canada; Brian Silver, Panayiotis D Mitsias, Wayne State Univ, Detroit, MI; Vladimir Hachinski; Univ of Western Ontario, London, Canada Background: Orolingual angioedema, which can be a life-threatening emergency, occurs in up to 5% of patients with ischemic stroke who receive IV recombinant tissue plasminogen activator (rtPA). It has been postulated that the incidence may increase with the concomitant use of angiotensin-aonverting-anzyme inhibitors (ACE-I). No information is available regarding the risk when re-exposed to rtPA. The exact pathophysiologic mechanism is unknown, but it is believed to be due to increased production of bradykinin by rtPA and inhibited degredation of bradykinin by ACE-I (figure). Bradykinin facilitates inflammatory and allergic reactions. Objective: Identify common characteristics among subjects who develop angioedema after or during the administration of rtPA for acute ischemic stroke, which could serve as risk factors for this entity. Methods: Acute stroke databases for Mayo Clinic Arizona, Mayo Clinic Jacksonville and London Health Sciences Centre, Canada were searched for the development of this complication. (Table 1) Results: We found 6 cases of angioedema among 447 subjects treated with rtPA for acute ischemic stroke (table 2). This is lower (1.3%) than previously reported (5%). The use of ACE-I was common (4/6 or 5/6). Four of six strokes were located on the right hemisphere and with cortical involvement. The mean NIHSS prior to treatment was 11. Only 1 of the 6 subject had been exposed to rtPA before. Five subjects were alive upon discharge. Conclusions: Angioedema due to use of rtPA for acute ischemic stroke is a rare complication. The prior or concomitant use of ACE-I may be a risk factor. Stroke location in the right hemisphere and with cortical involvement was common in these cases. Only one of the 6 subjects had been exposed to rtPA in the past. Severity of stroke symptoms (NIHSS) does not seem to influence the development of angioedema. P160 Early Recanalization Immediately After IV rt-PA in Acute Ischemic Stroke Can Avoid The Enlargement of Infarct Volume. Kazuto Kobayashi, Yasuyuki Iguchi, Kenichirou Sakai, Junya Aoki, Yoko Okada, Yuka Terasawa, Junichi Uemura, Shinji Yamashita, Masao Watanabe, Kensaku Shibazaki, Noriko Matsumoto, Takeshi Inoue, Kazumi Kimura; Kawasaki Med Sch, Kurashiki, Japan Purpose: Intravenous administration of tissue plasminogen activator (t-PA) dissolves the clot and can improve clinical outcome in patients with acute ischemic stroke. Sveral studies have reported that neurological improvement is caused by early recanalization after IV t-PA. Our aim of the present study is to investigate whether early recanalization immediately after IV t-PA can avoid the enlargement of infarct volume during 7days of onset. Materials and Methods: Acute ischemic stroke patients treated with IV t-PA were prospectively registered in the present study. In order to measure infarct volume and assess early recanalization, MRI studies including DWI, MRA and FLAIR were performed four times (on admission, immediately after IV t-PA, 24 h of onset and 7 days). We evaluated neurological symptoms by National Institute of Health stroke scale (NIHSS) score in accordance with each MRI studies. We divided patients into two groups; early recanalization and no-recanalization groups, and compared serial infarct volume and NIHSS score between two groups. Results: We had consecutive 49 patients treated with IV t-PA. We excluded 18 patients without occluded arteries on initial MRA, and enrolled 31 P162 Reported Stroke Onset Times are Clustered and Imprecise. Don B Smith, Chris V Fanale, Colorado Neurological Institute, Englewood, CO; Christy L Casper, Kathryn A Leonard, Swedish Med Cntr, Englewood, CO; Judith A Hinchey; St Elizabeth’s Med Cntr, Brighton, MA Introduction: Time is an important factor in the decision to administer intravenous tissue thromboplastin activator (TPA) for stroke. Guidelines recommend that TPA be started within Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 610 Stroke Vol 39, No 2 February 2008 three hours of symptom onset, and “strict adherence” to guidelines is generally advocated. Yet, time of onset can be difficult to establish. Different sources may report notably different times for same event. Hypothesis: Onset time is an imprecise variable. It may be imprecise enough to call into question onset-to-treatment calculations. Methods: We sought to determine the precision of onset time (and several other timed variables). We queried two stroke databases, containing 6733 patients, for whom time of onset was reported in 3234. We assumed that these values, if precise, would be distributed randomly among the possible values of 0 to 59, when expressed as minutes-after-the-hour. We compared database values with a set of computer-generated random values for minutes-after-the-hour. Results: Nearly 75% of the database values were on the hour or the half-hour. The time of onset was factorable by 5 in 98% of database values. In contrast, the random data were evenly distributed across the allowable range, with no single minute occurring more 2.6% of the time. The odds ratios (95% CI) –when compared to random data– that a database onset value would be 5-factorable in the two databases were: 252.6 (141– 453) and 151.9 (113–204), respectively. The 5-factorability of times for Hospital-Arrival and Starting-TPA were also significantly different from the random values, but these showed no clustering on the hour or half hour. Discussion: Calculated onset-to-treatment times for stroke have been assumed to be fairly reliable. In some reports, values up to 185 minutes are not considered protocol violations, but anything higher is a violation. In our study stroke onset times were strongly clustered on the hour or the half hour. If onset is typically measured in half-hour increments, it is unlikely that onset-to-treatment times are accurate to within five minutes. The precision of time of onset might be improved if, in addition to encouraging a call to 911, we encourage a look at the clock as soon as stroke symptoms are recognized. It likely, however, that time of onset will remain inexact. This limitation adds weight to the argument for relying less on the history and more on physiologic measures of tissue viability in determining when acute stroke treatment would be “too late”. P163 Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Initial Experience With Combined 64-slice Ct Perfusion (ctp) And Ct Angiography (cta) In Routine Practice. Potential And Pitfalls. David Tong, Jack Rose, Jerome Barakos, Jeffrey Thomas, Ann Bedenk, Jackie Phan, Dan A McDermott; California Pacific Med Cntr, San Francisco, CA Few data are available on the utility of 64 slice CT in stroke evaluation. This technique covers 2– 4x more brain than prior methods. We evaluated the utility of 64 slice CTA/CTP in routine practice. We hypothesized that 64 slice CTP would be feasible and add value to the management of patients with acute ischemic neurological symptoms. Methods: We reviewed our experience with 64 slice CTA/CTP in patients with acute neurological symptoms ⱕ6h after symptom onset. Patients with cerebral hemorrhage were excluded. Follow up MRI including DWI and MRA was routinely performed in patients when clinically appropriate. Results: From 5/06 to 7/07, 70 ⱕ 6h patients received CT/CTP/CTA. CTA/CTP was successful in 60/70 (86%). Mean age was 70 (range 32–93). There were 35 strokes and 12 TIAs (47/70;67%). Median NIHSS of stroke patients was 12 ⫾ 9. CTP detected reduced perfusion in 24/31 (77%) acute stroke patients, and in 2/11 (18%) TIA patients. DWI was negative in 2/4 (40%) stroke patients with a negative CTP who received an MRI. Median NIHSS was 3.5 in these cases, and outcome was excellent, with no major neurological sequelae on follow up. All of the non-stroke/TIA patients (n⫽22) had negative CTP/CTA, and experienced a good outcome. Eighteen patients received rt-PA (4 intra-arterial). CTA was negative in 8/25 (32%) patients with acute stroke and abnormal CTP. 4 of these received rt-PA (2 intra-arterial) with good recovery in 75% (3/4). CTP also revealed focal hypo perfusion in 1/4 (25%) seizure patients, and elevated perfusion in one brain tumor patient. No patients with a negative CTP/CTA experienced subsequent stroke or deterioration within the next 48h. Conclusions: 64-slice CTP/CTA is feasible and practical in acute stroke evaluation. It detects abnormalities in many patients (32%) in which no occlusion is identified on CTA, and that respond to thrombolytic therapy. A negative CTP/CTA predicts a good outcome in most patients, particularly those with a questionable diagnosis of stroke/TIA. However, despite its greater brain coverage it can still miss some smaller lesions in a minority of patients (14%), although most of these patients do not experience early recurrence or significant persistent deficits. The combination of CTA and CTP using 64 slice technology is a practical and useful addition to the evaluation and management of patients with acute neurological symptoms, especially those patients who may respond to thrombolytic therapy. P164 Ultrasound Energy Levels in the CLOTBUST Trial: A Step towards Optimization of Clinical Sonothrombolysis. Rajan Ramaswami, Yufeng Zhou, ImaRx Therapeutics, Inc, Tucson, AZ; Mark Schafer, Sonic Tech Inc, Philadelphia, PA; Reena Zutshi, ImaRx Therapeutics, Inc.,, Tucson, AZ; Andrei V Alexandrov; Comprehensive Stroke Cntr,Univ of Alabama at Birmingham, Birmingham, AL Background and Purpose: Low intensity ultrasound augments arterial recanalization with systemic TPA therapy for stroke. However, the optimal intensity and other parameters of patient exposure to ultrasound remain unknown. As a step towards development of an operatorindependent device for sonothrombolysis, we aimed to determine acoustic output parameters of the commercially available transcranial Doppler (TCD) devices used in the CLOTBUST trial. Materials and Methods: Standard diagnostic 2 MHz TCD equipment, with pulsed wave single element transducers, were evaluated in a water tank with a calibrated hydrophone and acoustic output data acquisition equipment and data analysis software. Energy parameters of the emitted ultrasound beams were measured at the maximum power output produced by TCD equipment. Beam attenuation caused by the temporal bone was measured in an in-vitro water tank model, again using a hydrophone. Results: 2 MHz TCD units emitted pulsed wave ultrasound beams at a Mechanical Index range of 0.19 - 0.24. The range of spatial peak temporal average intensities (ISPTA) was 125 - 467 mW/cm2 at pulse repetition frequencies of 8 - 11.5 kHz. Beam attenuation was measured at 5 cm depth after its passage through the temporal bone. The presence of bone reduced ISPTA by 16 - 94%, depending upon the exact beam path through the temporal window. The peak rarefactional acoustic pressure after passage through the bone was 128 - 247 kPA at the depth of 5 cm. Conclusions: We measured the output parameters of standard diagnostic ultrasound units to understand the levels of patient exposure achieved in the CLOTBUST trial. Even in the presence of the temporal bone, a substantial amount of energy can be delivered by a single element 2 MHz transducer. These data will be used in development and optimization of an operator-independent device for sonothrombolysis. P165 The Relationship Between Baseline Blood Pressure and CT Findings in Acute Stroke: Data from the “Tinzaparin in Acute Ischaemic Stroke Trial”(TAIST). Gillian M Sare, Laura J Gray, Timothy England, Chamilla Geeganage, Philip M Bath, Univ of Nottingham, Nottingham, United Kingdom; on behalf of the TAIST Investigators Introduction: High blood pressure (BP) is present in ⬃80% of patients with acute ischaemic stroke; high and low BP are associated independently with poor outcome. The relationship between BP and acute, and subacute CT findings in patients with stroke has yet to be examined. Data from the TAIST trial has previously shown hypertension to be related to poor outcome. Methods: TAIST was a randomised controlled trial assessing the safety and efficacy of tinzaparin (a low molecular weight heparin) at two doses (medium and high,100 and175 IU/kg) versus aspirin (300 mg) in 1,484 patients with acute ischaemic stroke (⬍48h). Systolic BP (SBP) was measured at baseline. CT head scans were performed at baseline and after a treatment period of 10 days; scans were independently adjudicated for the presence of infarction, dense MCA signs, mass effect, cerebral oedema, haemorrhagic transformation, leukoariosis, and old infarctions. The relationships between BP and CT findings were adjusted for age, sex, baseline severity, time to randomisation, and treatment assignment. Results: High SBP was associated with a normal baseline CT, the presence of leukoariosis (odds ratio [OR] 1.011, 95% confidence interval [CI] 1.005–1.016) and old infarcts (OR 1.011, 95% CI 1.006 –1.016). A lower baseline SBP was associated with signs of early infarction (OR 1.01, 95% CI 1.00 –1.01), and a higher baseline SBP was associated with visible infarction at day 10 (OR 1.008, 95% CI 1.003–1.013) in both univariate and adjusted analyses. There was no association between BP and haemorrhagic transformation. Conclusions: In acute stroke, lower BP is more likely to have CT signs of early infarction. High BP is associated with visible infarctions on late CT and is not associated with an increased risk of haemorrhagic transformation. The relationship between BP and poor outcome appears to be related to factors which may be detected in CT findings. P166 Prognostic Factors In Patients With Acute Basilar Artery Occlusion Treated With Multi-modal Reperfusion Therapy. Ronen R Leker, Guy Raphaeli, Ronie Eichel, Tamir Ben-Hur, Jose Cohen; Hebrew Univ Hadassah Med Cntr, Jerusalem, Israel Background: Acute basilar artery occlusion (ABAO) is associated with poor outcome when treated conservatively. Intra-arterial thrombolysis (IAT) has been advocated for treatment of ABAO and several prognostic factors were identified in these patients. To date this approach is replaced by multi-modal endovascular treatments that includes intra-arterial infusion of thrombolytics and/or antiplatelet agents, mechanical clot disruption with microguidewires, microcatheters and balloon angioplasty with stent placement. Objectives: We aimed to identify prognostic factors in patients with ABAO that underwent multi-modal endovascular treatment. Methods: Clinical and radiological data from consecutive BAO patients treated at our center over the last 2 years were analyzed. In all, BAO was documented by CT or MR angiography and by plain angiography. All patients presented with acute basilar stroke and underwent multi-modal endovascular treatment on an emergency basis. Stroke subtypes were categorized according to TOAST criteria. Good outcome was defined as a modified Rankin score (mRS) ⬍2 and poor outcome as a mRS⬎2 at 30 days post-stroke. The results were compared to those observed historically in patients that were treated conservatively or with IA treatment alone. Results: Twenty four patients were included (21 male) with a mean age of 54.7 (range 26 –70). Eight patients died (33%) and 6 of the surviving 16 (37.5%) patients achieved a mRS ⬍2 at 30 days. We could not identify any clinical or radiological variable that were associated with a greater likelihood of good or poor outcome at 30 days. Specifically, age, presenting symptoms and signs, risk factor profile, acute vs. progressive stroke onset, stroke subtype, time from onset to treatment and time from onset to reperfusion as well as lesion location within the BA, lesion length, lesion irregularity on the angiography and the presence of collateral flow did not significantly differ between the groups. All patients with mRS⬍2 had reperfused with TIMI 2 or 3 scores but so did also 8/10 patients with MRS⬎2. Conclusions: Multi-modal endovascular treatment resulted in higher than expected survival and good outcome rates when compared with patients treated conservatively or with IA therapy alone. We couldn’t identify prognostic factors in patients with ABAO treated with multi-modal endovascular approach. Our results imply that patients should not be excluded from treatment based on clinical or radiological parameters and that all patients with ABAO should be given the chance to benefit from therapy. P167 Approaching Stroke Similar to Trauma Improves Door to Needle Time for IV tPA. Batya R Radzik, Rebecca F Gottesman, Peter M Hill, Rafael H Llinas, Cathleen Carlen-Lindauer, Eric M Aldrich; Johns Hopkins Hosp, Baltimore, MD Introduction: Eleven years after its introduction IV tPA continues to be the only FDA approved treatment for acute ischemic stroke. However, less than 5% of stroke patients nationwide Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations receive it. There are a number of factors identified that contribute to this low percentage. Some of these factors are community based. Others are intrinsic to the hospital system. These include hesitancy on the part of the physician to administer tPA and failure to triage strokes in a rapid and timely fashion. Furthermore, an efficient tPA program requires healthcare providers from multiple disciplines and departments to coordinate efforts to provide optimal care. Our hypothesis was that adopting the clinical care process for trauma would improve tPA administration and door to needle time. Methods: In 2004 a workgroup consisting of representatives from Neurology and Emergency Medicine was created to review and revise our tPA program. The national goals of door to needle time (DTN) of less than 1 hour were targeted. The following changes were instituted: acute strokes are triaged similarly to trauma and treated in critical care areas, pre-printed tPA related documentation is kept in a specified location, and the ED physicians perform an exam and call the brain attack team. Data for all patients who received tPA in the ED at our institution from 2000 –2006 were entered into a database. Time specific data included symptom onset to ED arrival, door to CT time, door to needle time, and total time to treat. A t-test was used to compare mean time intervals from 2000 –2004 before the changes and 2004 –2006 after the changes. A linear regression model was used to determine the linear effect of time (year) on the chronology intervals in tPA administration. Results: From 2000 –2004, our primary target of door to needle time averaged 93 minutes. After these changes were instituted, our DTN decreased to 68 minutes (p⫽0.0002). The proportion of patients who met the goal of DTN⬍ 60 minutes was only 16% prior to 2004 and 43% (p⫽0.04) afterward. Conclusion: Door to needle time significantly improved since 2004. Adopting the clinical care processes used for trauma patients to improve an IV tPA program demonstrated consistent results over a two year time period. P168 Withdrawn 611 reperfusion injury. In this study, we attempted to examine the time window of nitrite effect in the experimental stroke, and to develop the preventive therapy for potential oxidative stress. Methods: Solutions of sodium nitrite (480 nanomol) were infused intravenously in the ischemia-reperfusion (90 minutes MCA occlusion) and permanent occlusion models of the adult male SD rats, at the various injection time points (90 min-12 hr). Also, nitrite (480, 4800 nmol) were infused with alpha-lipoic acid (␣-LA, 100mg/kg), an anti-oxidant for preventing the potential toxicity. Infarct volumes and functional outcomes were measured. Results: Nitrite infusion reduced infarction volume, and enhanced functional recovery at the time of reperfusion, and 90 minutes and 3 hours after reperfusion, but not 6 hours after. However, the nitrite treatment in permanent model was less effective with a shorter time window. The potential oxidative toxicity of high dose of nitrite was inhibited significantly by the combinational treatment of ␣-LA. Conclusions: Nitrite exerted profound neuroprotective effects in the ischemic brains up to 3 hours after reperfusion, and the potential nitrite toxicity could be attenuated by an anti-oxidant combinatorial treatment. These results suggest that nitrite may be a safe and effective therapeutic agent in the setting of acute ischemic stroke. In-hospital Treatment P170 Comparison of Primary Angioplasty and Stent Placement for Intracranial Atherosclerosis. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Farhan Siddiq, M. Fareed K Suri, Robert A Taylor, Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Mineapolis, MN; John C Chaloupka, Interventional Neuroradiology, Univ of Iowa, Iowa City, IA; Adnan I Qureshi; Zeenat Qureshi Stroke Rsch Cntr, Univ of Minnesota, Mineapolis, MN Objective: To determine and compare the rate of short and long-term out-comes of primary angioplasty and stent placement for intracranial atherosclerosis. Background: Primary angioplasty and stent placement has been used to treat intracranial atherosclerosis refractory to best medical treatment. There are no large studies to compare the clinical outcomes of these two procedures. Methods: We analyzed the clinical and angiographic data of 190 patients treated with 98 intracranial stents and 95 angioplasty procedures in three tertiary care centers. Only patients with adequate clinical follow-up were included in the analysis. Rates of one month stroke and/or death were compared for angioplasty and stenting. Stroke rates and combined stroke and death rates were identified as clinical endpoints during follow-up. The effect of angioplasty and stenting on clinical outcome was evaluated using Cox proportional hazards analysis to adjust for potential confounders (age, sex, location, and severity of post-procedure stenosis). Results: The mean age (⫾standard deviation) of the treated patients was 61.9 (⫾ 12.6) years. Three patients suffered fatal peri-procedural complications (1 in angioplasty and 2 in stent treated group). There were 14 stroke events in the peri-procedure period (10 in angioplasty and 4 in stent treated group) (Relative Risk [RR] 1.06, 95%, confidence interval [CI] 0.97–1.16, p⫽0.182). The mean follow-up time (⫾standard deviation) for 187 patients (excluding 3 peri-procedure deaths) was 20.8 ⫾20.5 months. Eight patients suffered stroke during follow-up period (4 each in the angioplasty and stent treated groups). In the Cox proportional hazard analysis, stroke event rate was not significantly different between the two groups (RR 1.7, 95% CI 0.13–10.02, p⫽0.83), but there appears to be a trend towards increased risk of combined endpoints of stroke and death in the stent treated group (8 in angioplasty and 10 in stent treated group, RR 2.4, 95% CI 0.8 – 6.7, p⫽0.09) after adjusting for age, sex, location and post-procedure stenosis. Conclusion: Primary angioplasty appears to have trend towards a lower rate of stroke and death than stent placement for intracranial atherosclerosis. P171 Predictors of Infection following Ischemic Stroke. Angela Kalil, Patricia Tanzi, J. M Gee, Kevin Cain, Kyra Becker; Univ of Washington Sch of Medicine, Seattle, WA P169 Optimal Treatment Of Sodium Nitrite In The Acute Ischemic Stroke: Time Window Study And Combination With Anti-oxidants. Keun-hwa Jung, Kon Chu, Soon-Tae Lee, Hee-Kwon Park, Seoul National Univ Hosp, Seoul, Republic of Korea; Eun-Cheol Song, Inha Univ Hosp, Incheon, Republic of Korea; Sang Kun Lee, Jae-Kyu Roh; Seoul National Univ Hosp, Seoul, Republic of Korea Backgrounds: The rate of NO generation from sodium nitrite is linearly dependent on reductions in oxygen and pH levels. We recently reported that nitrite-derived nitric oxide (NO) has been reported to exert a profound protection against transient focal cerebral ischemia- Background: Infection following stroke is common and associated with worse outcome, yet prophylactic antibiotics have not been shown to improve outcome in large cohorts of patients with stroke. If one could identify patients at the highest risk for developing infection, it might allow for more selective prophylaxis. The goal of this study was to test whether clinical and immunological variables from the first 72 hours post-stroke were predictive of subsequent infection. Methods: The study was approved by the local IRB. Patients with ischemic stroke were enrolled within 72 hours of stroke onset and followed prospectively. Infection was diagnosed by the constellation of clinical signs, symptoms, imaging findings and culture results. A number of clinical and immunological variables were assessed at 72 hours and their association with the occurrence of infection by day 14 determined. To ensure that the 72 hour biomarkers were not affected by concurrent infection, patients diagnosed with infection in the first 5 days after stroke onset were excluded from analysis. Results: Among 55 consecutive patients enrolled in the study, 2 died within 1 week and are excluded from further analysis. Of the remaining 53 patients, 65% were male with a mean age 55 (SD 14); the median NIHSSS was 13. Among these 53 patients, 18 (34.0%) developed infection within 14 days of stroke onset; 6 of these infections were noted within the first 5 days and these patients are excluded from analysis. Of the 12 remaining patients with infections, 4 developed pneumonia (PNA), 8 Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 612 Stroke Vol 39, No 2 February 2008 developed urinary tract infection (2 of whom also had PNA) and 2 developed other non-severe infections. Increased risk of infection on days 6 –14 was associated with higher NIHSSS (OR⫽1.22, 1.08 –1.37), older age (OR⫽1.07, 1.00 –1.14), intubation (OR⫽22.5, 2.2–229.4), and elevated levels of hsCRP (OR⫽1.77, 1.14 –2.74), IL-6 (OR⫽2.19, 1.04 – 4.64), and TNF␣ (OR⫽4.45, 1.14 –17.43) at 72 hours. Weaker and not quite significant associations were seen with total leukocyte count, lymphocyte count and IL10 levels. After controlling for the NIHSSS, only age (OR⫽1.10, 1.01–1.20) and TNF␣ levels (OR⫽7.70, 1.16 –51.22) remain predictive of infection. Conclusions: Infection following stroke is common. The risk of infection appears to be related primarily to stroke severity, as assessed by NIHSS, and age. A strong early inflammatory response, as measured by plasma levels of TNF␣, also appears to predict infection within the first 14 days after stroke onset. Further analyses with a larger sample are needed to confirm this association. P172 Efficacy Of A Free Radical Scavenger, Edaravone, On Acute Lacunar Infarction. Yasuyuki Ohta, Ota Memorial Hosp, Fukuyama, Japan; Tomoko Fukushima, Fukuyama Transporting Shibuya Longevity Health Foundation, Fukuyama, Japan; Kazuhiro Takamatsu, Satomi Ikegami, Ikuko Takeda, Taisei Ota, katsuya Goto; Ota Memorial Hosp, Fukuyama, Japan Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 [Preface] Free radicals are thought to be important in the occurrence of neural damage during cerebral infarction. There are many in vitro and in vivo studies showing that a free radical scavenger, edaravone, inhibited brain edema after ischemia, tissue injury, delayed neuronal death and vascular endothelial cell injury. Though there is a randomized, placebo-controlled, double blind study at multiple centers in Japan showing the effect of edaravone on acute cerebral infarction, clinical studies are scanty yet. This study investigated the effect of edaravone on the outcome of patients with acute lacunar infarction. [Materials and Methods] We retrospectively evaluated 124 consecutive patients with first-ever acute lacunar infarction who were admitted to our hospital within 24 hours after the onset between January 2004 and June 2007. Of these, 59 patients underwent both edaravone and conventional therapy (edaravone group), and other 65 patients underwent conventional therapy only (non-edaravone group). The clinical outcome was assessed by the National Institutes of Health Stroke Scale (NIHSS) scale. [Results] 1. There was no significant difference in patients’ baseline characteristics and the incidence of administration of conventional therapy for acute lacunar infarction between the two groups. 2. The reduction of NIHSS scale during hospitalization (1.51⫾1.01 vs. 1.03⫾1.08; p⫽0.007) and the percentage of patients with favorable outcome (NIHSS at dischargeⱕ1) (91.5% vs. 78.5%; p⫽0.044) was significantly larger in edaravone group than non-edaravone group. [Conclusion] This study showed that edaravone improves the outcomes of patients with acute lacunar infarction irrelevant to the different conventional therapy concomitantly performed. CLINICAL CHARACTERISTICS AND OUTCOME OF STUDY SUBJECTS Edaravone group (n⫽59) Age / years, mean⫾SD Men, n (%) History, n (%) Hypertension Diabetic mellitus Hyperlipidemia Coronary heart disease Smoking Drinking NIHSS on admission, mean⫾SD Time to treatment after stroke onset / hour, mean⫾SD Conventional therapy, n (%) Ozagrel sodium Argatroban Heparine Oral antiplatelet drugs Duration of hospitalization / day, mean⫾SD NIHSS at discharge, mean⫾SD Reduction of NIHSS scale during hospitalization, mean⫾SD Favorable outcome (NIHSS at dischargeⱕ1), n (%) Non-edaravone group (n⫽65) Hsiang-Kuo Yuan, Ping-Huang Tsai, Kun-Ping Lin, Neurological Institute, Taipei Veterans General Hosp, Taipei, Taiwan; Chen Lin, Dept of Physiology, National Yang Ming Univ, Taipei, Taiwan; Meng-Tzung Lo; Rsch Cntr for Adaptive Data Analysis, National Central Univ, Tao-Yuan, Taiwan Introduction: The influence of angioplasty on central autonomic system remains largely unknown. Although angioplasty, such as carotid artery stent (CAS) implantation and carotid endarterectomy has been increasingly utilized as a stroke-preventing therapy for patients with carotid artery stenosis, its effect on the carotid body function or the intracranial vascular auto-regulation requires further understanding. Heart rate variability provides a non-invasive analysis of the autonomic modulation whereas a newly-developed non-linear HRV technique, approximate entropy (ApEn), will be adopted in our study to assess the complex interaction of autonomic and central nervous system in the acute phase after CAS. Patients and Methods: During the study period, thirteen male patients (mean age 70⫹-9.5 years), who visited Neurological Institute at Taipei Veterans General Hospital for stroke prevention, were enrolled in this study. Each candidate for CAS was thoroughly evaluated by the experienced neurologist and neuro-radiologist followed by a 30-minute electrocardiograph (ECG) recording at 3 intervals: before CAS, 1-hr and 24-hour after CAS. In addition to conventional spectral analysis of HRV, ApEn was used to quantify the irregularity in heart rate complex dynamics. Repeated measure ANOVA and Wilcoxon signed ranks test were prescribed for statistical analysis. Results: Within-subject differences at 3 intervals were found significant on the non-linear analysis ApEn (1.07⫹-0.27 -⬎ 1.25⫹-0.24 -⬎ 1.26⫹-0.24, p⫽0.03) but not on other linear analyses: mean RR interval (905.5⫹-163.2 -⬎ 937.2⫹-152.8 -⬎ 883.8⫹-150.9 ms, p⫽0.37), low frequency power (176.0⫹-143.7 -⬎ 214.5⫹-141.9 -⬎ 141.2⫹-112.8 ms2, p⫽0.11), high frequency power (65.5⫹-54.4 -⬎ 110.1⫹-101.0 -⬎ 95.7⫹-84.8 ms2, p⫽0.18) and low/high frequency ratio (3.5⫹-3.3 -⬎ 2.9⫹-1.8 -⬎ 2.0⫹-1.3, p⫽0.25). ApEn increased significantly at 1-hr (p⫽0.04) and 24-hr (p⫽0.03) post-stent-implantation. Conclusion According to our study, CAS could enhance the dynamic complexity of HRV whereas conventional spectral analysis of HRV remained unchanged. This is for the first time to reveal the active modulation of human autonomic system during the acute recovery phase of CAS by means of the non-linear ApEn technique. Thus, we presume that conventional HRV indexes fail to fully characterize the quick autonomic response within 24 hours after the stent implantation. Furthermore, while reduction of ApEn has been related to aging and pathology, it is likely that CAS may potentially improve the survival by means of autonomic modulation. More future studies are worthy to further clarify the underlying mechanism in the response of the autonomic nervous system induced by stent. P174 Weekends are Worse for Stroke Care in the United States. p value 63.4⫾7.0 64.1⫾7.7 0.189† 40 (67.8) 46 (70.8) 0.720‡ 42 (72.4) 17 (22.8) 37 (62.7) 5 (8.5) 39 (60.0) 22 (33.8) 40 (61.5) 7 (10.8) 0.147‡ 0.547‡ 0.893‡ 0.350‡ 28 (47.5) 15 (25.9) 2.2⫾1.0 29 (46.8) 19 (30.6) 2.0⫾1.3 0.940‡ 0.561‡ 0.058† 9.2⫾5.8 9.8⫾7.0 0.900† 39 (66.1) 14 (23.7) 5 (8.5) 47 (79.7) 53 (81.5) 11 (16.9) 2 (3.1) 58 (89.2) 0.065‡ 0.345‡ 0.193‡ 0.140‡ 9.4⫾2.6 8.5⫾2.7 0.080† 0.7⫾0.7 1.0⫾1.2 0.525† 1.5⫾1.0 1.0⫾1.1 0.007† 54 (91.5) 51 (78.5) 0.044‡ †Mann-Whitney test, ‡chi-square test. NIHSS: National Institutes of Health Stroke Scale. P173 Enhancement in Dynamic Complexity of the Heart Rate Variability following Carotid Artery Stent Implantation. Darrin J Lee, David S Liebeskind; UCLA, Los Angeles, CA Objective: To characterize inpatient stroke care in the United States over a broad time span based upon admission on the weekday versus the weekend. Background: Previous studies in Canada and Europe have suggested that patients admitted for stroke on the weekends have poorer care and a higher risk-adjusted mortality. This study aims at describing the outcomes and factors associated with stroke care in the United States based upon weekday and weekend admissions. Methods: A comprehensive analysis of the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (Releases 1–13, 1988 –2004) based on ICD-9-CM codes 430 – 438 was performed. Ischemic stroke was defined as a primary diagnosis categorized as ICD-9-CM codes of 433– 434 and 436. Annual percentages and trends analyses were conducted for demographic variables, admission characteristics, procedures and outcomes. Results: 2,409,043 admissions of stroke cases were analyzed (1,397,883 ischemic stroke cases). These cases were reported across a wide geographic distribution throughout the United States. Age at admission was not statistically significant between the weekday (mean 71.49 years, SD 13.86) and weekend groups (mean 71.90 years, SD 14.32). In addition, stroke admissions were consistent across the 12 months. Race, gender and socioeconomic variables did not differ significantly between the two cohorts. Patients admitted on the weekend versus weekday were admitted more often emergently (70.2% versus 53.5%), although hospital stay did not differ dramatically in the overall stroke population (6.0 days, weekends versus 5.9 days, weekdays) or the ischemic stroke subpopulation (6.51 days, weekends versus 6.45 days, weekdays). The mortality rate for weekday admissions was remarkably lower than weekend admissions (7.9% versus 10.1%, p⬍0.001). A similar finding was noted in the ischemic stroke cases (7.3% versus 8.2%, p⬍0.001). Furthermore, patients were more likely to be routinely discharged if they were admitted on weekdays versus weekends (53.2% versus 43.8%, p⬍0.001). Patients admitted for ischemic stroke were more likely to be routinely discharged if they were admitted on the weekday (43.1% versus 38.9%, p⬍0.001). Based upon the years 1998 –2004, the 2 cohorts had a similar number of procedures done; however, those patients in the weekend cohort did not undergo their first procedure as soon (2.65 ⫹/- 4.31 days versus 1.76 ⫹/- 3.98 days). Conclusions: Weekend admissions for stroke in the United States from 1988 –2004 were associated with a higher mortality rate compared with weekday admissions. Other measures of patient care, including discharge type also suggested a weekday admission benefit. This phenomenon may be due to the apparent delay in procedures and other staffing differences. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations P175 Impact of the Approval of Intravenous Recombinant Tissue Plasminogen Activator Therapy on the Processes of Acute Stroke Management: The Stroke Unit Multicenter Observational (SUMO) Study. Shoichiro Sato, Toshiyuki Uehara, Kazunori Toyoda, Hiroaki Naritomi, National Cardiovascular Cntr, Osaka, Japan; Yasuhiro Hasegawa, St. Marianna Univ, Kawasaki, Japan; Kazuo Minematsu, National Cardiovascular Cntr, Osaka, Japan; The Stroke Unit MultiCntr Observational (SUMO) Study Group Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Objectives: The Ministry of Health, Labor and Welfare, Japan approved the use of recombinant tissue-type plasminogen activator (rt-PA) for the treatment of acute ischemic stroke in October, 2005. We evaluated an impact of the regulatory approval of rt-PA on the processes of acute stroke management. Methods: A prospective, multicenter, observational study was conducted between December 2004 and December 2005 in 84 Japanese institutes, including 24 institutes where the stroke unit (SU) was placed. We enrolled 4662 consecutive patients who were hospitalized within 72 hours after the onset of completed ischemic stroke; 1099 of them were hospitalized after the rt-PA approval. Patient characteristics and processes of stroke management were compared between the periods before and after the rt-PA approval. Results: Age, sex, stroke subtype, time from onset to hospital visit, and National Institutes of Health Stroke Scale score on admission were similar between the two periods. According to the approval, the rate of intravenous rt-PA therapy increased from 0.7% to 2.5% (p⬍0.001). The rate increased from 0.9% to 5.1% in the institutes with SU (p⬍0.001), but did not increase in the others (p⫽0.583). Within 24 hours of stroke onset, conventional MRI (p⫽0.002), diffusion weighted MRI (p⬍0.001), MRA (p⫽0.001), carotid ultrasound (p⫽0.005), blood coagulation tests (p⫽0.042), and evaluation for swallowing functions (p⫽0.022) were performed more frequently after the rt-PA approval. Conclusion: The present results indicate that the approval of intravenous rt-PA therapy resulted in dramatic changes in the processes of management for acute stroke patients, particularly in the institutes having SU. P176 Inpatient Acute Ischemic Stroke: Patient Characteristics, Process Measures and Thrombolytic Rates. Soojin Park, Shihab Masrur, Abdul R Abdullah, Ahmed El-Ghandour, Renzo Hidalgo, Lee H Schwamm; Massachusetts General Hosp, Boston, MA Introduction Little is known about the frequency or severity of acute ischemic stroke (AIS) among hospitalized patients. We sought to analyze patient characteristics, in-hospital delays and acute stroke process measures in this population compared to the population presenting to our emergency department (ED). Methods We obtained IRB approval to retrospectively review prospectively collected cases (1/1/05–12/31/06) in our web-enabled Acute Stroke Log (ASL), including initial NIHSS and key process measures. Patient characteristics were abstracted per Get With the Guidelines-Stroke. We identified a cohort of patients who required rapid evaluation (Rapid Eval) for thrombolytic therapy based on stroke severity and time from symptom discovery by healthcare team minus last seen well (SxD-LSW). To compare hospital-based acute stroke response for patients in hospital (INPT) vs. in ED, we defined time of symptom discovery for patients arriving via the ED (contact with healthcare provider or HCP) as the earliest of either the triage time or the time of a pre-arrival stroke team notification. Rapid Eval for IV tPA was NIHSS ⬎ 4 and SxD-LSW ⬍ 2 hr; for intra-arterial therapy (IAT), NIHSS ⬎ 8 and HCP-LSW ⬍ 4.5 hr. Results From 1/05–12/06, 548 /1025 (53.4%) calls entered in the ASL were from our hospital (INPT, 136; ED, 412). Stroke was the diagnosis in 284/548 (45.3%), evenly split between INPT and ED calls (51.5% vs. 51.9%, p⫽NS). Patient characteristics and treatment rates are shown below. INPT strokes were more likely than ED patients to require rapid evaluation for IV tPA based solely on severity of stroke and time of discovery, but were also more likely to have a reason for non-treatment with IV tPA; especially increased risk of bleeding (68.4% vs. 23.3%, p⬍.001). They received IV tPA less frequently. They had much longer times for key inhospital process measures. INPT strokes were more likely than ED patients to require rapid evaluation for IAT based solely on severity of stroke and time of discovery, but were equally likely to have a reason for non-treatment with IAT and received IAT equally often. Overall treatment with IV tPA or IAT at our hospital, regardless of NIHSS or time criteria, was more likely in ED patients. Discussion Inpatient Stroke calls made up ⬃25% of all stroke consults to our service. Despite shorter times from LSW to symptom discovery, the evaluation times are longer and the number of patients actually eligible for intervention remains low. However, for those inpatients who are eligible for treatment, more work is needed in symptom detection and in reducing time to imaging and time to treatment. Characteristic of stroke patients Age (mean) NIHSS Female (%) AF (%) DM (%) HTN (%) HL (%) CAD/prior MI (%) Prior Stroke/TIA (%) PVD (%) IV tPA Rapid Eval (%) INPT (nⴝ70) 70.1⫹15.9 10.9 ⫹ 8.2 64.3 34.3 30 55.7 51.4 38.6 18.6 14.3 54.3 ED (nⴝ214) p 72.3 ⫹ 14.1 10.6⫹8.4 0.28 0.84 47.2 33.2 25.2 77.1 57.5 27.1 24.8 6.5 36.5 0.01 0.86 0.43 0.001 0.38 0.07 0.29 0.04 0.008 Characteristic of stroke patients Medical reason for no IV tPA (%) Rapid Eval who received IV tPA (%) IAT Rapid Eval (%) Medical reason for no IAT (%) Rapid Eval who received IAT (%) Overall treatment IV or IAT for any NIHSS or LSW Mean Time Intervals for Rapid Eval Patients SxD-LSW (min) AST Consult-SxD (min) CT-SxD (min) tPA-SxD (min) INPT (nⴝ70) 94.3 613 ED (nⴝ214) 51.9 p ⬍.001 10.5 56.2 ⬍.001 37.1 73.4 22.9 72.9 0.02 0.93 34.6 32.7 1.0 17.1 29.4 0.04 INPT (nⴝ64) 27.6 49.8 129.7 97 82.6 6.2 36.8 71.9 ED (nⴝ122) ⬍0.001 ⬍0.001 ⬍0.001 0.046 P177 Temporal Trends and Predictors of rt-PA Use Among All Florida Acute Ischemic Stroke Patients, 2001–2005. Elizabeth Barnett, USF College of Public Health, Tampa, FL; Michael Sloan; USF College of Medicine, Tampa, FL Background: Clinical guidelines recommend intravenous tissue plasminogen activator (rt-PA) for the treatment of appropriate ischemic stroke patients who present to hospital within 3 hours of symptom onset. However, previous research has shown significant variation in rt-PA utilization across the U.S.A. In this study of Florida stroke patients, we asked: 1) Were there important patient-level predictors of rt-PA use? and 2) After controlling for patient factors, did rt-PA use increase significantly over time? Methods: We studied all acute ischemic stroke patients aged ⬎18 years who were admitted to Florida hospitals through the emergency department during 2001–2005. We examined hospital discharge data, with up to 10 detailed ICD-9-CM diagnosis and procedure codes per patient. Any mention of code 99.10 defined rt-PA use. Logistic regression models estimated the odds of receiving rt-PA for potential predictors, including demographics [age, gender, ethnicity, SES], stroke risk factors [hypertension, diabetes, smoking or COPD, obesity, hyperlipidemia, alcohol abuse], and co-morbid medical conditions [congestive heart failure (CHF), and end-stage renal disease (ESRD)]. We also included dummy variables for year to assess temporal trends in rt-PA use. Results: Among 111,836 patients, we found a crude rate of rt-PA use of 1.78%. After control for all other factors, there was no evidence of an upward trend in rt-PA use for 2001–2004, but patients admitted in 2005 were significantly more likely to receive rt-PA than those admitted earlier (OR 1.5, 95%CI 1.3–1.7; p⬍0.0001). Most of the demographic factors were significant predictors of rt-PA use in the full model, with patients who were male, white, and younger than age 75 all significantly more likely to receive rt-PA than the referent groups (p⬍0.0001 for each). Among stroke risk factors, patients with hypertension were significantly less likely to receive rt-PA (OR 0.8, 95%CI 0.7– 0.9; p⫽0.0002). Similar results were found for diabetes (OR 0.6, 95%CI 0.5– 0.7 p⬍0.0001). Patients with co-morbid ESRD were less likely to receive rt-PA (OR 0.7, 95%CI 0.6 – 0.9 p⫽0.003). However, CHF was a significant predictor of receiving rt-PA (OR 1.4, 95%CI 1.3–1.7; p⬍0.0001). Conclusion: We found a 50% increase in rt-PA use in Florida ischemic stroke patients between 2001 and 2005. In this population, use of rt-PA varied significantly by patient demographic characteristics and co-morbid medical conditions. P178 Ampulla (Tako-Tsubo) Cardiomyopathy Associated with Acute Ischemic Stroke. Sohei Yoshimura, Kazunori Toyoda, Tomoyuki Ohara, Noriko Ohtani, Hikaru Nagasawa, Takahiro Kuwashiro, Hiroaki Naritomi, Kazuo Minematsu; National Cardiovascular Cntr, Osaka, Japan Objectives: Ampulla (tako-tsubo) cardiomyopathy is characterized by transient left ventricular apical ballooning which resembles the Japanese octopus catcher pot (tako-tsubo). It is a known complication of subarachnoid hemorrhage, while the association with ischemic stroke is not clarified. We determined the clinical characteristics of ampulla cardiomyopathy associated with acute ischemic stroke. Methods: All the acute ischemic stroke patients, who were hospitalized between 2005 and 2006, underwent ECG monitoring during the initial several days. We studied the patients who did not have ECG abnormality on admission, but showed changes in ECG and abnormal echocardiographic findings which indicated ampulla cardiomyopathy during the acute stage. Results: Seven patients were diagnosed as developing ampulla cardiomyopathy. They were all women, and mostly aged (75 - 90 years) except for a 47-year-old young woman. Initial National Institutes of Health Stroke Scale score ranged between 3 and 28 (9 in median). Four patients had embolic infarcts (cardiogenic embolism in 3 and aortogenic embolism in 1) which expanded to the insular cortex; their ECG showed negative giant T wave within 10 hours after the stroke onset. Two patients developed progressing stroke (branch atheromatous disease) in the basal ganglia which finally expanded close to the insular area; ECG changes appeared within 5 hour in a patient and on day 6 in the other. The remaining young patient developed severe cerebellar and pontine infarcts with the basilar artery occlusion possibly due to the dissection; her ECG showed negative giant T on day 12. In all the 7 patients, echocardiography Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 614 Stroke Vol 39, No 2 February 2008 showed localized left ventricular hypokinesis around the apical area, which improved within 1 month except for a patient who dropped out of the follow-up. The peak creatine kinase level ranged 53 - 308 IU/L, and the brain natriuretic peptide level increased to 266 - 1182 pg/ml, although the level of troponin-T was normal. Four patients did not complain cardiac symptoms or show changes in vital signs even when ECG showed the abnormal findings. All patients received anticoagulant therapy after detecting the cardiomyopathy to prevent the embolic events from the hypokinetic wall. Five patients needed the wheelchair for the daily living at discharge. Conclusions: The ampulla cardiomyopathy can occur during acute ischemic stroke, in particular for aged women, and patients were often asymptomatic. Monitoring of long-term ECG is useful to detect the cardiomyopathy. In-hospital Treatment II patients, 119 (43.6%) had 150 protocol violations (89 with one, 30 with two or more). Patient characteristics (age, stroke severity, time from onset to arrival) did not predict violations (all p⬎.4). Pre-treatment deviations included: exceeding 3h time limit (46; median 3.25 hr); BP ⬎ 185/110 (8); platelet count ⬍100k; glucose ⬍50 or ⬎400, and history of seizure (5 each); recent history of MI (2); prior ICH/SAH, recent major surgery, mild stroke severity and abnormal aPTT (1 each). Post-treatment deviations included: early (⬍24h) antiplatelet use (30), early (⬍24h) anticoagulant use (19) and failure to maintain BP within guidelines (28). Overall, patients with protocol violations had slightly more sICHs (OR 1.10, 95% CI 0.48 –2.60) than those without violations. Multiple violations increased this risk (OR 1.21). There were insufficient data to determine risk by each type of violation. Deviations occurring only after treatment with tPA, however, conveyed the highest risk of sICH (OR 3.57, 95% CI 0.67–18.27) as compared to violations occurring only prior to treatment. Conclusions: In these data, protocol deviations were common but were not generally associated with significantly increased risk of sICH. Focusing quality improvement efforts on reducing protocol violations after tPA is given may have the highest yield in minimizing patient risk. P179 P181 Is Reflex Cough Protective in Stroke Patients with Dysphagia and at Increased Aspiration Risk? Reactivation of Old Stroke Symptoms. Defining a Clinical Entity. Katie Ward, John Seymour, Caroline Jolley, Joerg Steier, King’s College London, London, United Kingdom; Michael Polkey, National Heart and Lung Institute, Imperial College, London, United Kingdom; Kerry Mills, John Moxham, Lalit Kalra; King’s College London, London, United Kingdom Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and Objectives: Nearly 50% of acute stroke patients have dysphagia and are at increased aspiration risk. Although several studies have shown weak voluntary cough (VC) in these patients, reflex cough (RC), a brainstem reflex, may be preserved and is assumed to be protective against aspiration. We tested the validity of this assumption by studying the physiological characteristics of VC and RC in 15 acute stroke patients (5 female) and 17 controls (5 female). To do this, we performed volitional and non-volitional expiratory muscle tests on all subjects. Methods: Patients with first ever middle cerebral artery infarcts (median NIH score ⫽ 6) were included within the first 14 days of stroke onset (median ⫽ 6 days). RC was induced using suprathreshold concentrations of nebulised tartaric acid. The following measurements were made under standardised laboratory conditions: VC and RC: maximum cough flow rate (CFR); maximum cough gastric pressure (Pgas); cough expired volume (exp vol). Volitional expiratory muscle test: maximum expiratory mouth pressure (PE max); Non-volitional expiratory muscle test: maximum gastric pressure achieved after magnetic stimulation of the T10 nerve roots (Tw T10 Pgas). Unpaired t-tests were used to compare means of groups. Results: see Table 1. Conclusion: Reflex and voluntary cough flow rates and volumes are both impaired after acute stroke and hence, reflex cough may not be protective in acute stroke patients. Muscle strength (as measured by Pgas ) is not impaired for reflex cough suggesting that the reflex may be modulated by cortical inputs which are affected by stroke. TABLE 1: RESULTS Age VC CFR VC exp vol VC Pgas RC CFR RC exp vol RC Pgas PE max TwT10Pgas normal value stroke patients (n⫽15) mean (sd) controls (n⫽17) mean (sd) p-value ⬎130 ⬎130 ⬎80 ⬎16 59.9 (14.5) 239.4 (147.0) 2.345 (1.419) 103.0 (83.7) 199.9 (124.6) 1.197 (0.626) 193.0 (85.4) 71.4 (51.3) 29.4 (6.8) 49.9 (16.6) 516.3 (124.1) 4.681 (1.596) 206.6 (55.5) 397.4 (90.7) 2.060 (1.091) 204.8 (79.5) 119.2 (33.6) 34.6 (15.4) 0.083 ⬍0.001 0.001 ⬍0.001 ⬍0.001 0.044 0.719 0.005 0.447 Jose A Cardenas, Dion F Graybeal, Mark D Johnson; Univ of Texas Southwestern Med Cntr, Dallas, TX Background and Purpose: There is a subgroup of stroke patients presenting to the Emergency Department (ED) with similar complains to those they experienced with a previous stroke. These patients have sometimes been diagnosed as having a “stroke reactivation” and either are discharged home or are admitted to the hospital for further evaluation. The evaluation of these patients varies widely between institutions and there is no standardized clinical protocol. We sought to analyze the clinical characteristics of this group of patients in an attempt to better characterize and explain this phenomenon. Methods: From Aug 2005 through March 2006, we conducted a prospective observational study. 323 patients were evaluated by the UTSW Stroke Service and 16 (5%) of them were diagnosed as “Stroke Reactivation”. Charts were reviewed and 14 patients included in the study according to determined inclusion/exclusion criteria. Patient information was collected into a de-identified database. Results: Data on 16 patients was available for analysis, 2 patients were excluded. Of the 14 patients, 4 were male and 10 female. All MRI’s failed to show restricted diffusion supporting the absence of a new ischemic infarct. Every patient had previous imaging studies and clinical notes to document the existence of a chronic ischemic infarct with symptoms very similar or even identical to the latest presentation. In all cases, we were able to identify a medical condition other than Stroke, and after treatment the symptoms resolved. The most common triggers for the “Reactivation of Stroke” were urinary tract infections, Hypo/Hyper glycemia, and dehydration. Some patients had more than 1 medical condition that may have played a role into the pathogenesis of their symptoms. Conclusion: “Reactivation of Old Stroke Symptoms” is a commonly used clinical term, however not well defined in the literature. To our knowledge there are no prospective trials in the literature describing this event. In our case series, we were able to identify medical conditions other than stroke, causing the reappearance of previous symptoms and once treated, these previous stroke symptoms resolved. Further investigation is needed to clarify the pathophysiology of this phenomenon. A proposed mechanism could be a metabolic or neurochemical stressor triggering a dysfunction within recently formed or recruited neural networks, causing the reemergence of previous stroke signs and symptoms. More information is needed to determine the correct treatment for this syndrome and the appropriate diagnostic testing necessary when these patients present to an ED. Furthermore, clarification is needed to formalize a definition of this clinical entity and determine clinical guidelines to aid in its recognition, diagnosis, and management. P182 Transfusion of Blood Products Predicts Poor Clinical Outcome Independent of Stroke Severity in Acute Ischemic Stroke Patients. Units: pressure in cm H2O; flow in litres/minute; volume in litres. P180 Patterns and Importance of Protocol Deviations in use of Tissue-type Plasminogen Activator in Stroke. Angela F Caveney, William J Meurer, Zhenzhen Xu, Shirley Frederiksen, Annette Sandretto, Robert Silbergleit, Phillip A Scott,; Univ of Michigan, Ann Arbor, MI Objectives: Limited data suggest deviation from tPA-treatment guidelines may increase hemorrhage risk in stroke, however few data are available on what deviations are most common and when they are most likely to occur. This study characterizes protocol deviations, and their timing and association with symptomatic intracranial hemorrhage (sICH) in a large regional sample of tPA treated stroke patients. Methods: All ED stroke patients treated with IV tPA in 4 hospitals, without dedicated acute stroke teams, serving a single region over 9 years were retrospectively analyzed. Protocol deviations and outcomes in this previously described dataset were determined by rigorous explicit chart review with 20% dual abstraction, re-interpretation of brain imaging by two neuroradiologists blinded to clinical history, and formal adjudication of disagreements. The number and distribution of violations, whether they occurred prior to or after tPA treatment, and the associated risk of sICH were analyzed with descriptive statistics. Odds ratios were calculated to compare risks. Results: Among 273 Kachi Illoh, Miriam Morales, James Grotta, Orieji Illoh; UTHSC, Houston, TX Background: Acute ischemic stroke (AIS) patients often receive blood products to correct anemia or bleeding disorders. However, blood transfusion through inflammatory and prothrombotic mechanisms has been associated with poor outcome in a variety of disease conditions. There is paucity of data establishing benefit of blood transfusion in AIS patients. We sought to determine whether transfusion of blood products predicted clinical outcome after AIS. Our hypothesis was that outcome differs between transfused and non-transfused AIS patients independent of stroke severity. Methods: We studied AIS patients consecutively admitted to the stroke service of a 900-bed tertiary care center. Transfusion history for each patient was verified from the Blood Bank records. Poor clinical outcome was defined as a modified Rankin Scale of ⬎3. We examined the characteristics of the patients who received blood products (packed red blood cells, fresh frozen plasma, platelets and cryoprecipitate) and compared their clinical outcome to the non-transfused using t tests and chi-squared tests as appropriate. Logistic regression was used to examine the association between transfusion and outcome while adjusting for age, length of stay, NIH Stroke Scale (NIHSS), laboratory tests (hematocrit, creatinine level, platelet count and total cholesterol), and medications (antiplatelets, statins, and thrombolytics). All tests were two-sided with P values ⬍0.05 considered statistically significant. Results: A total of 1,213 AIS patients with a mean age of 65 ⫹ 16 years (51% males) were enrolled; 13% (152/1,213) received blood products. Transfusion of blood products Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations was an independent predictor of clinical outcome, such that transfused patients after adjusting for covariates were 2 times (OR ⫽ 2; 95% CI ⫽1.02 - 3.91; p⫽0.043) more likely to have a poor outcome than the non-transfused (70% versus 25%). Similarly, mortality during hospitalization was 6 times more likely to occur in the transfused group compared to the non-transfused (23% versus 4%; p⬍0.0001). The transfused patients had 8 days longer hospital stay and more severe strokes by 6 points on NIHSS score than the non-transfused (p⬍0.0001). Among the 106 patients who received packed red blood cell (pRBC) units, the higher the number of units transfused the worse the outcome, as 88% (22/25) transfused with more than 6 units had poor outcome compared to 64% (52/81) who got less than 6 units (p⫽0.026). Conclusion: In patients hospitalized for AIS, transfusion therapy predicted poor clinical outcome independent of stroke severity and is associated with longer hospital stays. This information warrants further scrutiny of the inflammatory properties of blood products and the liberal use of transfusion in stroke patients. P183 The Lombardia Stroke Unit Registry: Study Protocol and Preliminary Data. Giuseppe Micieli, IRCCS Istituto Clinico Humanitas, Rozzano (MI), Italy; Anna Cavallini, IRCCS Istituto Neurologico C. Mondino, Pavia, Italy; Silvana Quaglini, Dipartimento di Informatica e Statistica, Università di Pavia, Pavia, Italy; SUN Lombardia Collaborators Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Stroke Unit care represents the major advancement in stroke management and it is applicable to all stroke patients. The development of stroke registries has been recognised as a critical step to document treatment pathways, procedures and use of resources to objectively guide improvements in the quality of stroke care. In 2006 on the behalf of the Lombardia Stroke Unit Network (SUN) a web-based registry has been developed with the aim of improving the quality of hospital stroke care. At to-day 36 departments have joined the SUN registry. Its first objective is to verify adherence of units to Italian Guideline (IG) SPREAD recommendations and to evaluate their impact on stroke outcome. Methods The registry has been developed, validated and implemented in the second part of 2006. At the 1st of January 2007 the first Centre started data collection. The recruitment will stop at the 31st of December 2007. The registry includes information of the acute stroke episode from onset through treatment to follow-up (3⫹1 months) and of the adherences to IG’s recommendations (RCs). The RCs considered are: grade A: 10.2⫽t-PA considered, 10.5⫽antithrombotics within 24 hours of hospitalization, 11.35⫽FKT within 48 hours of hospitalization, 12.2–12.4⫽discharged on antithrombotics, 12.10⫽patients with AF discharged on anticoagulation therapy; grade B: 5.11⫽carotid duplex scan, 10.10⫽patients with AF receiving anticoagulation therapy during hospitalization, 10.18⫽DVT prophylaxis, 12.1⫽Smoke cessation/diet education, 12.7–12.8⫽ discharged on anti-hypertensive and/or statin therapy if indicated; grade D: 9.1⫽quickly and standardized neurological evaluation, 9.7–9.10⫽CT scan or MRI on admission and within 7 days of hospitalization, 10.19⫽early mobilization, 11.1⫽monitoring of vital signs during the first 48 hours, 11.20⫽screen for dysphagia. Results At the 30th June 2007 1681 cases have been enrolled and 647 completed the follow-up at three months. The percentage of adherences to IG RCs were: 10.1⫽100%, 10.2⫽ 90%, 10.5⫽65%, 11.35⫽ 48%, 12.2–12.4⫽77%, 12.10⫽61%, 5.11⫽78%, 10.10⫽57%, 10.18⫽49%, 12.1⫽ 46%, 12.7⫽ 71%, 12.8⫽ 54%, 9.1⫽ 99%, 9.7⫽87%, 10.19⫽65%, 11.1⫽77%, 11.20⫽46%. A significant correlation between Rankin scale score at discharge and number of non-compliance (NNC) has been detected (Spearman test, p⬍0.0006). At the follow-up visit the NNC was slightly higher for dead patients and significantly higher (Wilcoxon test p⬍0.008) for those with stroke recurrence. Conclusions Our data support the usefulness and adequacy of registry to describe and monitor process of care and implementation of guidelines. It can identify system criticity, such as the underused of diagnostic techniques and/or therapeutical procedures which can significantly influence outcome and recurrences. 615 of hospitalization, and prognosis before and after the implementation of new program. Results: One-hundred ninety eight (Season 1) and 44 patients (Season 2) were eligible for stroke critical pathway, respectively. Among them, 164 and 39 patients had ischemic infarction. After program implementation, time from arrival to acceptance of thrombosis panel was shortened from 52 to 27 min (p⬍0.001), and time from arrival to CT scan was slightly reduced from 31 to 24 min (p⫽0.21). There was little difference of thrombolysis rate by 26.8%(44/164) and 30.8%(12/39) (p⫽0.69). Times from arrival to injection of intravenous rtPA and intraarterial urokinase were reduced by 19 min (from 65 to 46 min;p⫽0.03) and 52 min (from 136 to 84 min;p⫽0.08), respectively. In addition, some trends suggesting good prognosis were observed that the duration of hospitalization was shortened by 6 days(from 21 to 15 days;p⫽0.09), and discharge NIHSS score was lowered by 2.1(from 6.1 to 4.0;p⫽0.17) after revised critical pathway. Conclusions: Our results indicate that powerful critical pathway shortened the door-to-lab time, door-to-needle time, and hospitalization period than previous ordinary critical pathway. Moreover, some tendencies were observed that it shortened door-to-CT time and improved stroke scale at discharge. Not only the presence of critical pathway but also fast communication network of related departments promotes the quality of critical pathway of stroke. P185 Hyperosmolar Hypothermic Normoglycemia (H2N) for Preventing Cerebral Edema after Large Hemispheric Infarction - a Pilot Study. Katja E Wartenberg, Carl Gustav Carus Univ Dresden, Dresden, Germany; Sheetal J Sheth, Columbia Univ, New York, NY; Jennifer A Frontera, Mount Sinai Med Cntr, New York, NY; Noeleen D Ostapkovich, Neeraj Badjatia, Columbia Univ, New York, NY; Stephan A Mayer; Columbia Univ, New, NY Background and Purpose: Large hemispheric infarction carries a mortality rate of 40 – 80%. Despite the introduction of decompressive hemicraniectomy, the medical management of brain swelling after large hemispheric infarction is still not satisfactory. Methods: We treated 22 patients with large hemispheric infarctions between July 2004 and February 2006 with the combination of insulin infusion (target glucose 100 –120 mg/dl), mild hypothermia (35.5°C) using a surface cooling or intravascular heat exchange device, and hypertonic saline (3% sodium acetate) at a rate 1ml/kg (goal osmolarity 310 –320 mosmol/l) within 72 hours of symptom onset. Primary outcome was progression or evolution of the midline shift on computed tomography (CT). Secondary outcome measures were Glasgow Coma Scale (GCS) at hospital discharge, modified Rankin Scale (mRS) at 3 months, and complications. Results: Of the 22 patients 13 had right-sided infarctions and median age was 64.5 (range 41– 84) years. Baseline NIHSS was 19 (6 –26). H2N was started on average one day (range 0 –5 days) after symptom onset; median duration of treatment was 9.5 (range 4 –20) days. Mean septal midline shift was 2.1⫾2.8 mm on admission; peaked at 8.9⫾5.9 mm, and was 5.1⫾3.7 mm on discontinuation of the protocol. The median GCS of the patients alive at time of discharge was 11 (range 4 –15). At 3 months, ten patients had died (45%); support had been actively withdrawn in six cases. The mRS was 2 in one patient, 3 in three patients, 4 in two patients, and 5 in four patients. Complications included pulmonary edema (n⫽10), aspiration and ventilator-acquired pneumonia (n⫽5), blood stream infection (n⫽3), urinary tract infection (n⫽3), atrial fibrillation with rapid ventricular response (n⫽3), bradycardia (n⫽2), acute renal failure (n⫽2), coagulopathy (n⫽2), septic shock (n⫽1), cerebral edema and herniation after discontinuing H2N (n⫽1), while receiving H2N (n⫽2), and before H2N therapy was maximized (n⫽1), thrombocytopenia (n⫽1), upper extremity deep vein thrombosis (n⫽1), and upper extremity ischemia (n⫽1). Conclusions: The combination of mild hypothermia (35.5°C), infusion of hypertonic saline, and insulin infusion offers a feasible alternative strategy to minimize massive cerebral edema after large hemispheric infarction and needs to be studied in a standardized trial. P184 Wireless Dispatch Call System Promotes Quality of Critical Pathway in Stroke. Sung Hyuk Heo, Kyusik Kang, Dept of Neurology, Clinical Rsch Cntr for Stroke, Seoul National Univ Hosp, Seoul, Republic of Korea; Hee-Kwon Park, Seoul National Univ Hosp, Seoul, Republic of Korea; Seung-Hoon Lee, Dept of Neurology, Clinical Rsch Cntr for Stroke, Seoul National Univ Hosp, Seoul, Republic of Korea; Jae-Kyu Roh, Seoul National Univ Hosp, Seoul, Republic of Korea; Kyung Cheon Chung, Kyung Hee Univ College of Medicine, Seoul, Republic of Korea; Byung-Woo Yoon; Dept of Neurology, Clinical Rsch Cntr for Stroke, Seoul National Univ Hosp, Seoul, Republic of Korea Background: It is widely known that time factor in acute stroke patients is very important. To reduce in-hospital time delay, it has been reported that critical pathway is useful. Because it is team approach, how fast the communication process will be is most important for effective critical pathway. Methods: The stroke critical pathway in our hospital was started on the September of 2005. Our emergency center adopted Korea Telecom Powertel service, wireless dispatch call service by using integrated digital enhanced network system, because it is possible to call specified group simultaneously. We revised the stroke critical pathway by using Powertel service, and updated critical pathway was started on the late March, 2007. If the patients who arrived at emergency room within 6 hours from when their symptoms or signs were detected for the first time are suspicious of stroke, critical pathway is started on broadcasting simultaneously to laboratory room, CT & MRI room, neurologist, radiologist, and intervention doctor. We selected 2 periods, one initial critical pathway program [Season 1: 2005/9 –2007/2] and the other revised critical pathway program [Season 2: 2007/3/22– 6/21], and efficacy was investigated by comparing time factors of diagnosis and treatment, duration P186 Lack of Impact of EMS Training and Use of the Cincinnati Prehospital Stroke Scale. Daniel M Frendl, David G Strauss, Duke Univ, Durham, NC; Kevin Underhill, Durham County EMS, Durham, NC; Larry B Goldstein; Duke Univ, Durham, NC Background: The Cincinnati Prehospital Stroke Scale (CPSS) evaluates facial droop, arm drift, and speech clarity. Its use by Emergency Medical Service (EMS) responders is recommended for identifying stroke patients for rapid hospital transport. There are only limited data assessing its performance outside of the research setting. Purpose: Our aim was to assess the impact of routine training and use of the CPSS on the accuracy of paramedics’ stroke diagnosis and on-scene time. Methods: A 1-hour long interactive educational presentation for paramedics providing emergency transport services to an academic center’s emergency department focusing on stroke recognition and the use of the CPSS was conducted in November 2004. Transported patients diagnosed with stroke were identified retrospectively by review of computerized and paper-based paramedic records and the academic center’s prospective stroke registry for the year before and after the training. Patients identified by EMS as being “unresponsive” were excluded from the assessment of the CPSS. The paramedic’s stroke diagnosis was compared to the final diagnosis after physician evaluation. Results: Of the 184 patients identified, 57% were women, 52% white and 46% African American (mean age of 68⫹/-6 years); 30 patients were noted by EMS as being “unresponsive.” There was no difference in paramedics’ use of the CPSS (37.5% vs. 23.8%, p⫽0.123), on-scene time (18⫹/-6 vs. 17⫹/-7 min, p⫽0.140), or the accuracy of the paramedic stroke diagnosis (40.5% vs. 38.9%, p⫽0.859) before and after training. Of responsive patients with a paramedic Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 616 Stroke Vol 39, No 2 February 2008 diagnosis of stroke, 57% had an abnormality in at least one CPSS item with no effect on on-scene time (17⫹/-1 min with a normal CPSS vs. 18⫹/-1 min, p⫽0.492). Those with a final diagnosis of stroke (n⫽61, 40%) more frequently had at least one abnormal CPSS item (49% vs. 27% with no CPSS abnormality, p⫽0.008; sensitivity 0.30, 95% CI 0.20 to 0.42; specificity 0.52, 95% CI 0.42 to 0.62). Conclusions: Simple EMS training in the CPSS, or its use, had no impact on paramedic’s stroke diagnostic accuracy or on scene time. Only half of patients with a final diagnosis of stroke had at least one noted CPSS abnormality. Whether improvements can be achieved with more extensive training or through ongoing performance improvement programs requires further study. histological examinations suggest an enhanced EPO-induced dendritogenesis. Gene expression profiles will be presented at the conference. Developing a hematopoietic factor therapy such as EPO with multimodality concentrated in 1 compound appears to be fundamental to improve future stroke treatment. Interestingly, a small pilot study demonstrated beneficial effects for the treatment in acute human stroke (2). A randomized, multicenter, placebo-controlled phase II trial with EPO is currently ongoing to assess the safety in acute stroke patients and is expected to conclude in September 2007. REFERENCES: (1) Wang, L. et al. (2004). Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats. Stroke 35:1732–7. (2) Ehrenreich H. et al. (2002). Erythropoietin therapy for acute stroke is both safe and beneficial. Mol.Med. 8:495–505. P187 The Prevalence of Positional Sleep Apnea Among Patients with Acute Ischemic Stroke and Transient Ischemic Attacks. Dawn M Bravata, Indiana Univ; VAMC, Indianapolis, IN; John Concato, Terri Fried, Noshene Ranjbar, Tanesh Sadarangani, Frederick Struve, Yale Univ; VAMC, New Haven, CT; Mark Gorman, Univ of Vermont, Burlington, VT; Vincent McClain, Albert Lo, George B Richerson, Yale Univ; VAMC, New Haven, CT; Linda S Williams, Indiana Univ; VAMC, Indianapolis, IN; Joseph Agostini, Henry K Yaggi; Yale Univ; VAMC, New Haven, CT Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background Sleep apnea is an independent risk factor for cerebrovascular disease and is associated with poor outcomes following an acute stroke or transient ischemic attack (TIA). Given both the high prevalence of sleep apnea among patients with cerebrovascular disease and the association between sleep apnea and adverse events, the treatment of sleep apnea in the acute stroke or TIA period may improve clinical outcomes. Continuous positive airway pressure (CPAP) is the first-line treatment for sleep apnea, however, CPAP is difficult to implement in acute cerebrovascular disease patients. Positional therapy (having a patient sleep in the lateral position) is a simple and effective treatment for positional sleep apnea. The objective of this study was to determine the prevalence of positional apnea and positional sleep apnea among acute cerebrovascular disease patients. Methods This was a secondary analysis of data from two on-going randomized controlled clinical trials that are evaluating the efficacy of a strategy of diagnosing and treating sleep apnea in acute ischemic stroke and TIA patients. Unattended polysomnography was performed within 48 hours of symptom onset in acute stroke and TIA patients. The apnea-hypopnea index (AHI) is the total number of apneas and hypopneas per hour of sleep. Sleep apnea was defined as an AHI of ⱖ5. The positional AHI was calculated for the supine position (supine-AHI) and for the combination of all of the non-supine positions (non-supine-AHI). Positional apnea was defined by a supine-AHI ⱖ2 times the non-supine-AHI. Positional sleep apnea was defined by a supine-AHI ⱖ2 times the non-supine-AHI and where the total-AHI was ⱖ5. Results Among 28 patients (13 stroke and 15 TIA) with baseline polysomnographic data, 17 had sleep apnea (prevalence of 61%; 95%CI 42–76%). The prevalence of positional apnea was 9/28 (32%, 95%CI 18 –51%). Overall positional sleep apnea was present in 8/28 (29%, 95%CI 15– 47%). Prevalence rates were similar between stroke and TIA patients. Discussion New therapies are needed to improve clinical outcomes for post-stroke and post-TIA patients. Positional apnea appears to be common among patients with acute ischemic stroke and TIA. Cerebrovascular disease patients who have positional sleep apnea and who do not tolerate CPAP therapy may benefit from sleeping in the lateral position. Recovery P188 Erythropoietin Improves Motor Skill Learning In An Accelerated Training Paradigm After Focal Ischemia. Andreas Rogalewski, Jens Minnerup, Kai Diederich, Wolf R Schäbitz; Univ of Muenster, Muenster, Germany BACKGROUND AND PURPOSE: Erythropoietin (EPO) promotes proliferation and differentiation of erythroid progenitors and the survival of maturing erythroid cells. EPO enhances neurogenesis and angiogenesis after stroke, which could contribute to functional recovery (1). The present investigation explored beneficial effects of EPO on improvement of motor skill learning in an accelerated rotarod training paradigm after focal ischemia. METHODS: 28 Wistar rats were randomly treated with either recombinant human EPO or saline daily for 7 days starting at 24 hours after photothrombotic stroke of sensory-motor cortex. Rats were trained on an accelerated rotarod over ten consecutive days each with ten trials beginning at day 3 after stroke. At day 7 and 14 after ending of the rotarod task, we examined the consolidation of motor skill. Postmortem Golgi-Cox staining was performed to examine neurite growth (dendritogenesis). Furthermore, for gene expression changes samples was taken from the ipsiand contralateral cortex. The complete available rat Genome chip was used (rat 230 A and B), encompassing all known genes and expressed sequence tags (EST) for the rat. RESULTS: Therapy with EPO significantly improves motor skill learning in the accelerated rotarod training paradigm after focal ischemia. After 7 and 14 days of pause, the enhancement of the rotarod skill was retained indicating an improved consolidation. Preliminary data of histological examinations revealed an enhanced dendritogenesis after EPO treatment. We currently analyze gene expression profiles to evaluate the precise mechanism of EPO-induced neurogenesis. CONCLUSIONS: Our data demonstrate that EPO significantly and permanently improves functional recovery after stroke as a result of enhanced neurogenesis. Futhermore, preliminary P189 Neuronal Predictors Of Stroke Recovery. Carmen Cirstea, Cary Savage, Hoglund Brain Imaging Cntr, Kansas Univ Med Cntr, Kansas City, KS; Randolph Nudo, Landon Cntr on Aging, Kansas Univ Med Cntr, Kansas City, KS; William Brooks; Hoglund Brain Imaging Cntr, Kansas Univ Med Cntr, Kansas City, KS Stroke is the leading cause of long-term motor disability worldwide and identifying predictors of motor recovery following stroke is the objective of considerable research. Although, functional neuroimaging biomarkers might be helpful in understanding the neural systems level, to date, no valid functional biomarker has been found accurate enough to predict gain in individual stroke survivors. It is clear that a complete understanding of brain plasticity and prognosis of intervention response following stroke requires an understanding at two neural levels, system and cellular. However, research focused on cellular biomarkers has received limited attention in this stage of stroke The goal of this study was to determine the predictive values of two neuroimaging biomarkers for further functional improvement following an arm-focused intervention in late stroke. The neuroimaging biomarkers are: (i) N-acetylaspartate, as a metabolic neuronal biomarker (NAA, a compound localized exclusively in neurons and their dendritic and axonal processes, measured on MRS in radiologically normal-appearing primary motor cortex, M1), and (ii) spatial extent of M1 motor-related activation on fMRI as a functional biomarker. Subcortical stroke survivors participated in a repetitive practice of a reach-to-grasp task with the impaired arm (90 repetitions on each of 12 days over four weeks). Each participant underwent kinematic (trunk movement) and neuroimaging (magnetic resonance spectroscopy, MRS; functional MRI, fMRI) testing on three separate occasions: one month (Baseline) and immediately prior to (PRE), and immediately after (POST) the motor practice. Functional recovery was evaluated by decreased compensatory trunk use based on the correlations between this variable and other movement variables, such as angular motions and interjoint coordination. For the proposed study, the changes PRE vs. Baseline were used to examine whether the patients are at their stable behavioral/neural status while the changes POST vs. PRE to study the intervention effects. The preliminary results suggest that the intervention-related changes of NAA in bilateral M1 seem to be better correlated with the rate of functional recovery than changes in spatial extent of motor-related M1 activation. The results of the present study might be especially useful for the design of randomized clinical trials by estimating sample size and define inclusion criteria. In addition, this information might be useful for enabling clinicians to set realistic therapeutic goals, by selection of individualized rehabilitation strategies based on the prediction of functional potential. P190 Effect Of Forced Arm Use And Voluntary Exercise On Functional Motor Recovery And Gene Expression Profiles After Focal Ischemia. Andreas Rogalewski, Univ of Muenster, Muenster, Germany; Rico Laage, SYGNIS Bioscience, Heidelberg, Germany; Katharina Kuhnert, Jens Minnerup, Univ of Muenster, Muenster, Germany; Armin Schneider, SYGNIS Bioscience, Heidelberg, Germany; Wolf R Schäbitz; Univ of Muenster, Muenster, Germany BACKGROUND AND PURPOSE: Both the immobilization of the unaffected arm combined with physical therapy (forced arm use, FAU) and voluntary exercise (VE) as model for enriched environment are promising approaches to enhance recovery after stroke. The genomic mechanisms involved in long-term plasticity changes after different means of rehabilitative training post-stroke are largely unexplored. The present investigation explored the effects of these physical therapies on behavioral recovery and molecular markers of regeneration after experimental ischemia. METHODS: 42 Wistar rats were randomly treated with either FAU (1-sleeve plaster cast onto unaffected limb at 8/10 days), VE (connection of a freely accessible running wheel to cage), or a cage control condition for 10 days starting at 48 hours after photothrombotic stroke of sensory-motor cortex. Functional outcome was measured using a battery of sensory-motor tests at baseline before ischemia, after ischemia, after the training period of 10 days, and at 3 and 4 weeks after ischemia by an investigator blinded to the experimental groups. For gene expression changes samples was taken from the ipsi- and contralateral cortex. The complete available rat Genome chip was used (rat 230 A and B), encompassing all known genes and expressed sequence tags (EST) for the rat. RESULTS: Therapy with both FAU and VE compared to cage control condition significantly improved functional recovery after focal ischemia. The enhancement of functional outcome was retained over 4 weeks after ischemia. Furthermore, FAU-treated animals had significant better functional recovery compared to the VE-treated group. A number of genes were detected as induced in the ipsi- and contralateral cortex due to treatment conditions. CONCLUSIONS: Our data demonstrate that physical training modeled by FAU and VE treatment for 10 days initiated 48 hours after photothrombotic stroke significantly and permanently improve functional Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations recovery after stroke. Furthermore, we suggest that FAU is superior to voluntary physical activity after small ischemia. Effects of FAU treatment on functional outcome are not completely understood. Although human studies indicate that FAU in the chronic phase after stroke improves functional recovery, experimental studies are more controversial. Here we can substantiate the positive effect of FAU on functional recovery after small ischemia. Moreover, we highlight the degree of transcriptional changes in the cortex after post-stroke physical training, and provide insight into functional pathways of relevance for compensatory recovery mechanisms in neural networks. P191 Nitric Oxide Mediates Proliferation Of Endothelial Progenitor Cells In Human Ischemic Stroke. Tomás Sobrino, Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain; Marı́a A Moro, Dept of Pharmacology, Sch of Medicine, Univ Complutense, Madrid, Spain; Miguel Blanco, Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain; Juan F Arenillas, Dept of Neurosciences, Hosp Germans Trias i Pujol, Badalona, Spain; Mar Castellanos, Dept of Neurology, Hosp Doctor Josep Trueta, Girona, Spain; David Brea, Octavio Moldes, Pedro Ramos-Cabrer, Rogelio Leira, Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain; Antonio Dávalos, Dept of Neurosciences, Hosp Germans Trias i Pujol, Badalona, Spain; José Castillo; Dept of Neurology, Clinical Neuroscience Rsch Laboratory, Hosp Clı́nico Universitario, Univ of Santiago de Compostela, Santiago de Compostela, Spain Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background and purpose: The increase in circulating Endothelial Progenitor Cells (EPCs) number after acute ischemic stroke is associated with good functional outcome, reduced infarct growth and neurological improvement. In experimental models, it has been suggested that vascular endothelial growth factor (VEGF), which mediates EPC proliferation, up-regulates nitric oxide (NO) through the activation of endothelial nitric oxide synthase (eNOS). Likewise, EPC migration is mediated by active metalloproteinase 9 (MMP-9). On the other hand, statins are known to enhance vascular expression of endothelial (eNOS), inducible (iNOS) and neuronal nitric oxide synthase (nNOS). Therefore, as vascular repair and angiogenesis may be therapeutic targets in cerebral ischemia, our aim was to study the role of these molecular factors as well as statin treatment in the proliferation of EPCs in human ischemic stroke. Patients and methods: Forty-eight patients (24 males, average 70.9⫾10.1 years) with a first-ever episode of non-lacunar ischemic stroke (⬍12 hours from onset) were prospectively studied. EPC colonies were quantified as early outgrowth colony forming unit-endothelial cell (CFU-EC). We defined the increment of EPC colonies during the first week as the difference in the number of CFU-EC between day 7 and admission. Serum levels of VEGF and active MMP-9 (determined by ELISA) and nitric oxide metabolites (NOx)(determined by HPLC) were measured at admission, 24 and 72 hours, and at day 7. Atorvastatin (20 mg) was administered during the acute phase of stroke in 16 patients. ROC analysis was used to select the best cut off value for CFU-EC increment as predictor of good outcome due to a lack of linearity. Results: Patients with EPC increment ⱖ4 CFU-EC (n⫽22) showed higher serum levels of VEGF, active MMP-9 and NOx at 24 hours in comparison with the patients with EPC increment ⬍4 CFU-EC during the first week (all p⬍0.0001). Likewise, patients treated with statins showed higher serum levels of VEGF (p⫽0.004), active MMP-9 (p⫽0.002) and NOx (p⬍0.0001). Serum levels of NOx ⱖ990 M was the only variable associated with EPC Increment ⱖ4 CFU-EC (OR, 47.1; CI95%, 2.9 –778.1, p⫽0.007) after adjustment for baseline stroke severity, body temperature, glucose levels, the presence ⬎ 2 vascular risk factors and statin treatment. Conclusion: High serum levels of NOx at 24h from stroke onset are associated with an EPC increment ⱖ4 CFU-EC during the first week in acute ischemic stroke. 617 was 29 ⫹/- 2 cc. Aspiration was well tolerated, with Visual Analog Pain scores of 2.4 ⫹/- 1.4 (out of 10). Specimen cooler temperatures remained in the target range during round-trip transportation between the marrow donor center and the marrow processing lab. A median of 40 (range 20 –225) x 10^6 MNC were available for plating from the marrow. The MSC yield at 21 d was median 2.1 (range, 0.9 – 4.4) x 10^6 MSC/kg. Median cell viability was 98.5%. All samples were formally cleared for release within the allotted time period, and post-release bacterial and fungal cultures were furthermore negative. Viability of MSC was well maintained in saline at 1 x 10^6 MSC/mL for 24 h at 4 C, but not after 48 h or if stored at room temperature. Subject age correlated with number of marrow nuclear cells (p⬍.05) but not with yield of MSC. CONCLUSIONS: This study suggests the feasibility of a two-hospital, GTPcompliant system for use of autologous MSC to treat subjects with a time-sensitive condition such as subacute stroke. Sufficient MSC that are suitable for human therapy can be rapidly and reliably generated, and the resultant MSC may be preserved for up to 24 h. P193 An Active and Repetitive Robot Assissted Training Improves Functional Motor Recovery of the Arm in Sub-acute Stroke Patients. Samuel Faran, Institute for Med Psychology and Behavioral Neurobiology, Univ of Tübingen, Tübingen, Germany; Stefanie van Kaick, Christel Eickhoff, Charité- Berlin Universitaetsmedizin, Dept of Neurological Rehabilitation, Clinic Berlin, Berlin, Germany; Richard Mahoney, Motorika USA, Mount Laurel, NJ; Karl-Heinz Mauritz; Charité- Berlin Universitaetsmedizin, Dept of Neurological Rehabilitation, Clinic Berlin, Berlin, Germany Background and Propose: Loss of arm function is one of the most devastating consequences of stroke and the affected limb may cause severe disability. During the last years many studies have described the contribution of robotic devices in improving upper-extremity functions in chronic patients with hemiparesis following stroke. The purpose of this study was to test the hypothesis that a robot-assisted repetitive unilateral movement training effects upper limb motor function in sub-acute stroke patients. Methods: A single blinded, randomized controlled study in twenty (20) sub-acute stroke patients with a first ischemic stroke between 3 weeks and 3 months prior to study entry, and with a upper limb muscle strength grades between 2 to 3 on the Medical Research Council (MRC) motor power scale. In addition to daily common physiotherapy and occupational therapy sessions patients received during 4 weeks of treatment 20 sessions of one hour each an upper extremity treatment with either the Reo Therapy System robotic device (group A) or an air splint therapy (group B). The robot-assistance was provided by the Reo Therapy System (Motorika USA Inc. New Jersey, USA), that interacts with the patient in real-time and applies forces to the affected forearm during goal-directed movements. The primary outcome measures were the blindly assessed Fugl-Meyer, Motor Power Score (MP), and the Motor status score for shoulder and elbow (MS-SE). As secondary endpoints we assessed the Action Research Arm Test (ARAT), the point-to-point (PtP) reach performance measured automatically by the Reo Therapy System, and the Barthel Index. Assessments were performed at baseline, one day after the 4 week training period and at follow up 3 months later. Adverse effects were continuously monitored. Results: Patients in the experimental group performed better on the Fugl-Meyer and ARAT tests than those in the control group with significant differences at the end of the study (P⬍.05). The effect of the robotic therapy was attributed to the intensive and repetitive reach movements which led to increased muscle activity. The treatment was most effective in patients with a moderate motor deficit of the upper-extremity (20⬍FM⬍ 60). No adverse effects due to the intervention were found. Conclusions: The ReoTM Therapy System produced a superior improvement in upper limb motor control and power compared with air splint therapy in subacute stroke patients. Future studies should address different variables of the treatment effects in subacute stroke patients and determine the optimum treatment intensity and motion modus for an individual patient. P194 P192 Feasibility of Autologous Marrow Stromal Cell Therapy in Human Stroke. Safety And Behavioral Effects Of A Single Session Of High Frequency Repetitive Transcranial Magnetic Stimulation In Chronic Stroke. Steven C Cramer, Univ of California, Irvine, Orange, CA; Davina Garls, Sanjivan S Kohli, Ellen Mackintosh, UCSD, La Jolla, CA; Randall Holcombe, Univ of California, Irvine, Orange, CA; Murat Digicaylioglu, Thomas A Lane; UCSD, La Jolla, CA Nuray Yozbatiran, Univ of California, Irvine, Orange, CA; Miguel Alonso-Alonso, Beth Israel Deaconess Med Cntr, Boston, MA; Jill See, Univ of California, Irvine, Orange, CA; Asli Demirtas-Tatlidede, Alvaro Pascual-Leone, Beth Israel Deaconess Med Cntr, Boston, MA; Steven C Cramer; Univ of California, Irvine, Orange, CA INTRODUCTION: Prior studies suggest the potential for autologous marrow stromal cell (MSC) therapy to improve outcome after stroke. The purpose of this study was to evaluate a system to obtain human bone marrow at one institution (UCI), culture MSC at a second institution (UCSD), and returning MSC to the first institution for infusion, under Good Tissues Practice (GTP) conditions. No subjects were treated–this report describes the feasibility of the approach. METHODS: A bone marrow sample was aspirated from the iliac crest of healthy subjects, then transported 82 miles under sterile, temperature-controlled conditions. A mononuclear cell (MNC) fraction was prepared from the marrow, a portion of which was suspended in solution with 20% pre-screened fetal bovine serum and plated in culture flasks. This was maintained at 37 deg C in a 5% CO2 incubator, non-adherent cells were removed at 48 hr, and a portion of the cells were passaged (at 12–14 d, when 80% confluent) into additional flasks. MSC were harvested at 21 d, washed, and resuspended in sterile saline. MSC were identified according to ISCT criteria, including adherence, morphology, growth characteristics, and flow cytometry (⫹CD73, CD90, CD105; -CD14, CD34, CD45, HLA-DR), plus differentiation into adipocytes. Criteria for releasing specimens from the marrow processing lab to the marrow donor/ treatment center included Gram stain, and Mycoplasma and Endotoxin assays. RESULTS: A total of 8 subjects were enrolled, age 56 ⫹/- 22 (mean ⫹/- SD). The marrow volume aspirated INTRODUCTION: Non-invasive electromagnetic brain stimulation might be of value to reduce motor deficits after stroke, by either increasing ipsilesional excitability or decreasing contralesional excitability. The safety of these methods requires further study. The current study examined safety and behavioral effects of increasing ipsilesional excitability, delivered during a single session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the ipsilesional primary motor cortex. METHODS: This unblinded, active-treatment-only, single-dose, two-center study was approved by the U.S. FDA and local IRBs. Entry criteria included age 18 – 85 years; infarct ⬎ 11 weeks prior, hemispheric in location, and ⬎ 15 mm from the stimulation target; and no contraindication to TMS or MRI. Anatomical MRI was obtained and used to define the rTMS target, the center of the hand area knob within gray matter of posterior precentral gyrus. Each subject’s head was registered to his/her MRI using frameless stereotaxy. Single pulse rTMS applied to the stroke-affected hemisphere with a figure-of-8 coil defined the motor threshold (0 –100% of TMS device output) for the paretic first dorsal interosseus muscle, after which rTMS was applied at 90% of this threshold. If TMS elicited no motor response, stimulation was set at 65% of device output. rTMS application consisted of 40 trains, each having 40 pulses (20 Hz X 2 sec), each train separated by 28 sec Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 618 Stroke Vol 39, No 2 February 2008 of silence, for a total of 1600 pulses over 20 min. Subjects were assessed before, during the hour after, and 1 wk after rTMS. RESULTS: The 12 subjects enrolled were 4.7 ⫹/- 4.9 y post-stroke (mean ⫹/- SD), age 67 ⫹/- 12 y, baseline NIHSS score 4 ⫹/- 2, and arm motor Fugl-Meyer 34 ⫹/- 16 (of 66). rTMS was well tolerated and without adverse events. SBP increased from pre- to immediately post-rTMS by 7 mm Hg (p⫽.043). None of the 7 behavioral measures assessed across rTMS showed a decrement, and several showed improvement. The total # pegs placed on 9-hole pegboard increased 83% (p⫽0.04) from pre- to 1 hr post-rTMS, accounted for by 4/12 subjects, among whom baseline motor status was significantly greater than those not showing pegboard gains; a trend (p⫽.057) suggested retention of these gains at 7 days post-rTMS. Grip strength and range of motion each increased (p⬍.03 each), in 7 or more subjects, during the hour post-rTMS. Arm motor Fugl-Meyer score increased by 1.5 ⫹/1.7 points by 1 week post-rTMS (p⬍.02), a gain seen in 8/12 patients. CONCLUSIONS: A single session of high frequency rTMS to motor cortex was safe. Results suggest gains in several measures of arm motor function, though no control group was included. Gains lasted days beyond the session, and might be most likely in those with lesser deficits. Future studies can have larger sample size, include sham-treatment controls, employ multiple rTMS sessions, and evaluate interactions with concomitant secondary therapies. potential confounders. Results: Participants (63% female, 54% Caucasian, and 81% with IS) had mean age of 67 years (SD 14) and mean admit FIM score of 47 (SD 16). For subjects with left HP and SI, no difference was found in FIM gain between those with left side facing door [Mean⫽18 (SD15), n⫽27] compared to right side facing door [Mean⫽19, (SD 15), n⫽37], p⫽0.863. Therefore, no multivariate modeling was performed. Among subjects with right HP and SI, those with right side facing door had a significantly greater FIM gain [Mean⫽24, (SD 13), n⫽22] compared to those with left side facing door [Mean⫽16, (SD 11), n⫽26], p⫽0.02. For these subjects, differences in the proportion with IS vs. ICH and Caucasian race were present in relationship to side facing door. The multivariate linear regression model of FIM gain found a negative association with left side facing door and IS vs. ICH, p⬍0.05 for both predictors. Race was not statistically significant. For rehab efficiency, the linear regression model demonstrated a negative association with left side facing door and IS vs. ICH and a positive association with Caucasian race and admit FIM score. p⬍0.05 for all predictors Conclusion: For subjects with right HP and SI undergoing stroke rehabilitation, bed orientation that forces attention to the affected side is independently associated with greater FIM increase and greater rehab efficiency. P197 Sildenafil Treatment Of Subacute Ischemic Stroke: A Safety Study At 25 Mg Daily For 2 Weeks. Recovery II P195 Repetitive Transcranial Magnetic Stimulation in Acute Stroke Patients: A Preliminary Report. Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 A-Hyun Cho, Sang-Ho Pae, Seung-Jae Lee, Dong-Won Yang, Beum-Saeng Kim, Young-Min Shon; The Catholic Univ, St.Mary’s Hosp, Seoul, Republic of Korea Background: Repetitive transcranial magnetic stimulation (rTMS) has been reported as a method to modify cortical excitability in rehabilitation of chronic stroke patients. Although brain plasticity begins to work immediately after brain injury, there is only one report about rTMS in acute stroke period showing short-term outcome results. We hypothesized that rTMS might be safe even in acute stroke patients and improve neurological outcome. Methods: We consecutively included stroke patients 1) who were admitted within 14 days, 2) with aphasia or limb weakness, 3) without epileptiform discharge on electroencephalogram after stroke. About 2–14 days after stroke onset, rTMS was applied over the cortical motor area of index stroke hemisphere (120% of resting motor threshold of the non-stroke hemisphere, 3-second trains of 10-Hz stimulation with 27 seconds between each train, 10 sessions, 5 days). We evaluated an adverse effect, NIHSS before rTMS and at the end of the last rTMS session, and modified Rankin scale (mRS) at 3 months. Results: Between October 2005 and June 2007, total 47 patients underwent rTMS. Mean age was 63.4 ⫾ 13.8 years and 20 (42.5%) was mal. Most common stroke location was MCA territory infarction followed by corona radiata or basal ganglia lacunar infarct. Adverse effects were observed in 6 patients (fatigue in 2, headache, dizziness, somnolent, seizure in a patient respectively). However, all the symptoms were transient. In the patient with seizure after rTMS, intermittent rhythmic slowing was observed at electroencephalogram before rTMS. Early improvement (any improvement of NIHSS) was observed in 23 (51.1%) patients and favorable outcome (mRS 0 –2) in 27 (81.8%) patients among 33 patients in whom mRS could be checked, and excellent outcome (mRS 0 –1) in 14 (42.4%). Conclusion: Repetitive transcranial magnetic stimulation as a therapeutic trial after acute ischemic stroke seems to be safe. Randomized controlled study for proving long-term clinical outcome is required. P196 A Naturally Occurring Forced-Use Study of Stroke Patients Undergoing Inpatient Rehabilitation. Aninda B Acharya, Yang Liu, Saint Louis Univ, St Louis, MO; Genevieve N Olucha, SSM Rehab, St Louis, MO; R. Charles Callison, Saint Louis Univ, St Louis, MO; Megan A Markey, Paula M Juelich, Gerard J Erker; SSM Rehab, St Louis, MO Objective: To determine how the physical orientation of a patient in relation to the hospital room door affected stroke outcome in those with ipsilateral spatial inattention (SI) undergoing inpatient rehabilitation. Methods: Adults undergoing inpatient rehabilitation at SSM Rehab in St. Louis, Missouri (June 2005-April 2007) with hemispheric ischemic stroke (IS) or intracerebral hemorrhage (ICH) and evidence of SI, and residing in same room during entire hospital stay were eligible subjects for this study (n⫽112). Side affected by stroke and presence of SI were determined by clinical exam and neuropsychological evaluation, including a clock drawing task. Clocks drawn asymmetrically or predominantly on one side of the drawing area were considered evidence of SI. Subjects with SI were grouped by side of hemiparesis (HP) and side oriented to hospital room door, right or left. Disability level was measured with the Functional Independence Measure (FIM). Outcomes of interest were (1) change from admission to discharge in FIM score (FIM Gain) and (2) FIM gain divided by length of stay (rehab efficiency). Descriptive statistics for baseline sociodemographic and medical characteristics were performed. Independent t-tests compared subjects’ FIM Gain by side affected and orientation in relation to door. If the t-test was statistically significant, then multivariate linear regression models of both FIM gain and rehab efficiency were developed to determine the association between these outcomes and side facing door correcting for Brian Silver, Sharon McCarthy, Mei Lu, Panayiotis Mitsias, Andrew Russman, Angelos Katramados, Daniel C Morris, Christopher Lewandowski, Michael Chopp; Henry Ford Hosp, Detroit, MI Background: In several animal studies of young and aged rats with ischemic stroke, treatment with sildenafil (which augments cyclic guanine monophosphate [cGMP] in the central nervous system) has been correlated with neurogenesis, angiogensis, synaptogenesis, and improved functional outcomes compared with placebo. We studied whether a daily dose of 25 mg of sildenafil could be given safely to patients with subacute ischemic stroke. Methods: Patients with ischemic stroke were recruited between days three and seven after onset. Inclusion criteria included ages 18 – 80 and NIH stroke scale score (NIHSS) 2–21. Exclusion criteria included use of other CYP450 3A4 inhibitors, nitrates, and alpha blockers. Patients were treated for two weeks with 25 mg daily. The primary outcome measure was the occurrence of any of the following during the treatment period: stroke worsening, new stroke, myocardial infarction, or death from any cause. Secondary outcome measures were NIHSS, Barthel indices (BI), and modifed Rankin score (mRS) at 90 days. Results: Twelve patients were recruited (mean age 60, five females). Median NIHSS at entry was 9.5 (range 2–20). During the treatment period with sildenafil, there was one death which was attributed to pulmonary embolism. Another patient developed an asymptomatic deep vein thrombosis detected during random surveillance. There were no occurrences of stroke worsening, new stroke, or myocardial infarction during the study period. One patient died following suicide two months after study entry (and six weeks after treatment with sildenafil had been completed). Including the two patients who died, data are available for 90 day follow-up on ten patients. Among the eight survivors, median NIHSS was 2 (range 0 –11), median BI was 92.5 (range 35–100), median mRS was 1 (range 0 – 4). Two patients have been followed less than 90 days with data pending. Conclusion: Sildenafil 25 mg daily for two weeks appeared to be safe in this group of patients with mild to moderate severity stroke. Further studies of higher doses will be tested. P198 Response to Exercise Tolerance Testing in Subacute Stroke across Severity Levels. Dorian K Rose, Andrea L Behrman, Univ of Florida, Gainesville, FL; Yong Cen, Kathy J Sullivan, Univ of Southern California, Los Angeles, CA; A. Danny Martin, Richard S Schofield, Univ of Florida, Gainesville, FL; Julie K Tilson, Univ of Southern California, Los Angeles, CA; Steve E Nadeau, Univ of Florida, Gainesville, FL; Bruce H Dobkin, Univ of California, Los Angeles, Los Angeles, CA; Sam Wu, Univ of Florida, Gainesville, FL; Pamela W Duncan; Duke Univ, Durham, NC Background/Purpose: Atherosclerotic lesions throughout the vascular system are a common co-morbidity associated with cardiovascular-related diseases including stroke. Post-stroke hemiparesis with mobility limitations further contributes to cardiovascular deconditioning. To ensure adequate cardiovascular functional capacity and exercise tolerance during an exercisebased RCT, an Exercise Tolerance Test (ETT) was incorporated into the screening phase. The purpose of this study was to determine if there were differences in ETT performance between individuals with moderate versus severe walking impairment at 2 months-post-stroke. Methods: Participants included a cohort of 145 individuals with subacute stroke (58⫹/-10 dys post onset) prospectively enrolled in the Locomotor Experience Applied Post-Stroke (LEAPS) RCT, stratified as either severe (walking velocity ⬍ 0.4 m/sec; n⫽69; age: 62⫹/-17 yrs) or moderate (walking velocity ⬎0.4 m/s ⬍ 0.8 m/s; n⫽76; age: 66⫹/-12 yrs). Screening via chart review 5–30 days post-stroke excluded those with serious cardiac conditions. Minimum ability to walk 10 feet and advance the paretic limb was determined during this initial phase with the ETT as the final screen prior to enrollment in the exercise phase of the study. After baseline vitals and ECG recording, pedaling commenced at 0 Watts (W) with workload increasing 10 W/minute while maintaining cycling cadence between 40 - 60 revolutions per minute. The ETT, supervised by a cardiologist, was terminated according to a prescribed list of cardiac criteria, subjective fatigue or inability to maintain the required pedaling cadence. Results: Those with moderate stroke pedaled longer (6.4⫹/-2.3 min) than those with severe stroke (5.5 ⫹/- 1.9 min; p ⬍ .05), with an estimated maximum exercise capacity of 3.7 (95% Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations CI: 1.7–5.7) METS for the moderate and 3.4 (95% CI: 1.4 –5.4) METS for the severe group (p ⫽ NS). Reasons for test termination were similar across groups: peripheral fatigue (53% moderate; 52% severe) or attainment of 90% THR or a Borg Rate of Perceived Exertion of 18 (39% moderate; 41% severe). Mean percent THR achieved was identical for both severity groups, 75⫹/-13%. Mean percent THR achieved was 73⫹/-11% for those whom the ETT was terminated secondary to fatigue. In the overall cohort, 97% (141/145) proceeded to trial participation. Failures were due to severe hypertension, ischemia, and lower extremity claudication. Conclusions: ETT performance was similar regardless of stroke severity. Despite the presence of hemiparesis participants were able to exercise at increasing workloads. The maximum exercise capacity, estimated by MET level, of the entire cohort indicates deconditioning at just two months post-stroke. 619 patients with unfavorable outcome (n⫽26, median 23.0 ml, IQR 1.2 - 60.2 ml) (p⫽0.07). The smallest ischemic lesion volume at which the PPV for unfavorable outcome was 100% was 70 ml; none of the patients with DWI lesion volume ⱖ 70 ml achieved a good clinical outcome. The sensitivity and specificity for unfavorable outcome at this cutoff were 19% and 100% respectively. All patients in the validation cohort who had DWI lesion volume ⱖ 70 ml attained an unfavorable clinical outcome as well. Conclusion: Patients with infarcts ⱖ 70 ml are not likely to achieve good clinical outcome if untreated. If confirmed in larger datasets, this volume threshold on DWI can be used as a selection tool or prognostic marker in therapeutic trials or clinical stroke research. P199 Long-Term Behavioral Symptoms in Ischemic Stroke Survivors. Beth K Rush, Thomas G Brott, Mayo Clinic, Jacksonville, FL; Robert D Brown, Jr, Mayo Clinic, Rochester, MN; Scott L Silliman, Univ of Florida College of Medicine, Jacksonville, FL; Dale M Gamble, Sothear H Luke, Alexa N Richie, Mayo Clinic, Jacksonville, FL; Colleen S Albers, Mayo Clinic, Rochester, MN; Rebecca B McNeil, Jorge A Trejo, James F Meschia; Mayo Clinic, Jacksonville, FL Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Background: Behavioral sequelae of stroke are poorly characterized, yet can complicate rehabilitation, recovery, and quality of life. Prior studies have focused on depression or anxiety, without parallel inquiry into other symptoms. This study hypothesized a wider array and higher prevalence of behavioral symptoms in stroke survivors relative to age-comparable stroke-free controls. Methods: We conducted a case-control study of behavioral symptoms. Cases were recruited from St. Luke’s Hospital and Shands Hospital (Jacksonville, FL), and Saint Mary’s Hospital (Rochester, MN). Non-demented stroke-free community controls were concurrently enrolled. National Institutes of Health Stroke Scale (NIHSS) was administered to cases after hospitalization for acute stroke. Mini Mental State Exam (MMSE) and Beck Depression Inventory-2 (BDI-2) were administered to cases and controls in an outpatient appointment; participant informants completed the Neuropsychiatric Inventory Questionnaire at that time. MMSE and BDI-2 scores were compared using multivariable regression, with control for covariates of age, education, and premorbid cognitive status. Prevalence and number of Neuropsychiatric Inventory Questionnaire symptoms were compared using Fisher’s Exact and Cochran-Armitage tests, respectively. Results: Fifty-three cases and 30 controls were enrolled. Cases were 72% (38/53) men, median age was 71 years (IQR: 63 - 79 years), and median education was14 years (IQR: 12 - 16 years). NIHSS was administered at a median of 3 days from stroke onset (IQR: 2 - 6.5 days). Median NIHSS score was 2 (IQR: 1 - 4). Median time from stroke onset to behavioral evaluation was 31 months (IQR: 12 - 39 months). Controls were 33% (10/30) men, median age was 74 years (IQR: 63 - 79 years), and median education was16 years (IQR: 14 - 17 years). Cases and controls did not significantly differ on MMSE (Mean: 27.4 vs. 28.3, p ⫽ .64) or BDI-2 (Mean: 7.8 vs. 5.3, p ⫽ .07). A wider array of overall behavioral symptoms was reported for cases vs. controls on the Neuropsychiatric Inventory Questionnaire (Median: 2 vs. 0.5, p ⫽ .02). Cases had a higher prevalence of irritability/lability than controls (40% vs. 13%, p ⫽ .01) with similar results noted for apathy/indifference (21% vs. 3%, p ⫽ .05), and agitation/aggression (32% vs. 13%, p ⫽ .07). There were no significant differences on other Neuropsychiatric Inventory Questionnaire items including depression and anxiety. Conclusions: Mild ischemic stroke survivors have a wider array and a higher prevalence of long-term behavioral symptoms compared to stroke-free controls, even in the absence of depression or clinically significant cognitive impairment. P200 An Infarct Volume Threshold on Early DWI to Predict Unfavorable Clinical Outcome. Ethem Murat Arsava, Hakan Ay, AA Martinos Cntr for BioMed Imaging, Massachusetts General Hosp, Boston, MA; Aneesh B. Singhal, Massachusetts General Hosp, Boston, MA; Ona Wu, AA Martinos Cntr for BioMed Imaging, Massachusetts General Hosp, Boston, MA; Karen L. Furie, Massachusetts General Hosp, Boston, MA; A.Gregory Sorensen; AA Martinos Cntr for BioMed Imaging, Massachusetts General Hosp, Boston, MA Background: Although the mismatch between DWI and perfusion-weighted MRI indicates salvageable brain tissue and therefore is an attractive target for therapeutic intervention, the correlation between baseline mismatch volume and clinical outcome is only moderate (r⫽0.46 – 0.67). Because the volume of ischemic tissue on DWI is also important in determining the clinical outcome, we sought to identify a volume cut-off for DWI lesion that can correctly identify patients with unfavorable clinical outcome. Methods: We calculated the volume of acute lesion on DWI obtained within 12 hours of symptom onset in a prospective cohort of 72 consecutive patients who did not receive any thrombolytic or experimental treatment (derivation cohort). The clinical outcome was assessed using modified Rankin Score (mRS) at 3 months (interquartile range 2 - 4 months). The mRS was dichotomized with unfavorable outcome defined as mRS ⱖ 3. The positive predictive value (PPV) for unfavorable outcome for each decimal of ischemic lesion volume on DWI was calculated. The minimum volume at which a PPV of 100% was achieved was defined to be the cutoff for unfavorable outcome. The reproducibility of results was assessed in a separate cohort of 44 untreated patients using the same methodology (validation cohort). Results: Ischemic lesion volume on DWI ranged from 0.0 to 264.8 ml (median 6.4 ml, IQR 1.4 - 29.9 ml). There was a statistically significant correlation between DWI lesion volume and mRS (r⫽0.25, p⫽0.04). Patients with good outcome had smaller DWI lesion volume (n⫽46, median 4.8 ml, IQR 1.4 - 24.1 ml) than P201 Brain-Behavior Relationships of Gait Asymmetry in the Chronic Stage of Stroke Recovery. Lisa D Alexander, 1. Heart and Stroke Foundation Cntr for Stroke Recovery at Sunnybrook Health Sciences Cntr, 2. Sunnybrook Health Sciences Cntr Rsch Institute, 3. Univ of Toronto, Toronto, Canada; William E McIlroy, 1,2,3, Dept of Kinesiology, Univ of Waterloo, Waterloo, Canada; Fuqiang Q Gao, 1,2,3, & 4: L.C. Campbell Cognitive Neurology Rsch Unit, Toronto, Canada; Kara Patterson, 1,2,3, Toronto Rehabilitation Institute, 5: Graduate Dept of Rehabilitation Science, Univ of Toronto, Toronto, Canada; Sandra E Black; Univ of Toronto, Rotman Rsch Institute, Baycrest, Toronto, Canada Background: While much is known about altered motor patterning and spatiotemporal characteristics of hemiparetic gait, associations of site of lesion damage and control of walking are poorly understood. In particular, correlations between lesion location and post-stroke gait asymmetry have not been investigated. Temporal symmetry is an important parameter in the control of walking. Temporal gait asymmetry after stroke is a salient index of walking competency which significantly impacts daily ambulation. The current study investigated whether subtraction lesion analysis methods could distinguish brain regions associated with persisting temporal gait asymmetry in chronic stroke patients. Methods: Preliminary retrospective analysis of 19 chronic stroke patients with neuroimaging and gait data available revealed 8 patients with symmetric gait and 11 with asymmetric gait. Chedoke-McMaster and NIH stroke scales quantified clinical impairment. Spatiotemporal gait parameters were recorded using a GaitRite instrumented walking surface. From a 95% confidence interval created around mean values for 24 healthy adults, temporal symmetry values from 0.9 to 1.1 were considered normal. Lesions were traced from digital 3-D T1-weighted MRI and co-registered to the Montreal Neurological Institute brain template. Region of interest images were generated and lesion overlays were created for both symmetric and asymmetric groups. The lesion overlay of symmetric patients was subtracted from asymmetric patients to highlight voxels more frequently lesioned in asymmetric patients and relatively spared in symmetric patients. Results: Demographic data and clinical measures were comparable between groups. Average temporal gait symmetry was 1.01 (SD 0.05) for symmetric and 2.26 (SD 0.96) for asymmetric patients. After subtraction analysis, damage to specific portions of the external capsule (Talairach coordinates x,y,z: -31,4,0), extreme capsule (-34,8,–5), insula (-36,7,–9), periventricular corona radiata (-27,-17,26) and posterolateral putamen (-28,-12,9) was evident 80 –100% more frequently in asymmetric patients than symmetric patients. Conclusions: Our lesion analysis approach which dichotomized patients by temporal gait symmetry suggests that damage to multiple structures in a distributed functional network of cerebral regions is correlated with the control of walking. Additional recruitment currently underway should further advance our understanding of these hitherto unexplored cortical and subcortical networks. Such knowledge may guide therapy in the early phase of stroke by highlighting the need to prioritize gait re-training when there is damage to key regions. Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 620 Stroke Vol 39, No 2 February 2008 Prevention P202 Cerebral Glycolysis Metabolism during Physical Exercise and Neuroprotection in Stroke. Miao Guo, Yimin Wu, Shane Sprague, Univ Texas Health Science Cntr, San Antonio, TX; Xunming Ji, Xuanwu Hosp Capital Med Univ, Beijing, China; David F Jimenez, Yuchuan Ding; Univ Texas Health Science Cntr, San Antonio, TX Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 It has been reported that physical exercise increases the metabolism rate in muscles. The purpose of this study was to test whether exercise preconditioning increases cerebral glycolysis metabolism in association with hypoxic induced factor1␣ (HIF-1␣), leading to reduced brain injury after stroke. HIF-1␣ and downstream key molecules in glycolysis, including glucose transporter 1(GLUT1), glucose transporter 3(GLUT3), phosphofructokinase (PFK), and lactate dehydrogenase (LDH) were investigated. Adult male Sprague Dawley rats were subjected to a 30 minute exercise program on a treadmill each day for 1 to 3 weeks. Stroke was induced by a 2-hour middle cerebral artery (MCA) occlusion using an intraluminal filament in exercised rats for 3 weeks and non-exercised controls. Brain infarct volume was determined by Nissl staining. The gene and protein expressions of HIF-1␣, GLUT1, GLUT3, PFK, and LDH were determined in the brain region supplied by MCA using real time PCR and Western Blot. Pre-ischemic exercise significantly (p⬍0.05) reduces brain infarct volume and neurological deficits in stroke. HIF-1␣ mRNA and protein levels were significantly (p⬍0.05) increased during exercise prior to ischemia/reperfusion injury (I/R). As compared to non-exercised rats, I/R injury did not further increase HIF-1␣ expression. Physical exercise also significantly (p⬍0.05) raised the levels of mRNA and protein of GLUT1, GLUT3, PFK, and LDH. Interestingly, this increase after physical exercise was further significantly (p⬍0.05) enhanced during ischemia and reperfusion at 6, 12, and 24 hours. Our results indicated that the metabolic function in brain after stroke can be enhanced by the pre-ischemic exercise, leading to reduction in brain injury. This neuroprotection caused by physical exercise may be attributable to the increased level of HIF-1␣ which regulates glycolysis factors. P203 What Predict Severe Carotid Disease In Patients Presenting with Transient Ischemic Attack? Mai N Nguyen-Huynh, UCSF, San Francisco, CA; Stephen Sidney, Alan S Go, Allan Bernstein, Div of Rsch, Kaiser Permanente Med Care Program, Oakland, CA; S Claiborne Johnston; UCSF, San Francisco, CA What Predict Severe Carotid Disease In Patients Presenting with Transient Ischemic Attack? Background. Expedited performance of carotid ultrasound in patients with transient ischemic attack (TIA) may significantly improve stroke prevention after TIA. However, urgent ultrasound in all patients with TIA may not be feasible or cost-effective. Among a large community-based sample of patients presenting with TIA, we examined whether there were characteristics predictive of having severe carotid stenosis that may benefit from early intervention. Methods. We identified all patients diagnosed with TIA by emergency medicine physicians from 16 hospitals in Kaiser Permanente of Northern California during 2003. We reviewed medical records of all cases with severe (70 –99%) stenosis by ultrasound in either internal carotid artery within 3 months of the TIA, and of an equal number of randomly selected controls without severe carotid disease (0 – 69% stenosis). Patient demographics, comorbidities, presenting symptoms, exam findings, hospital and factors associated with an early increased risk of stroke after TIA (age, symptom duration, diabetes, hypertension, speech disturbance, weakness) were evaluated. To evaluate associations with severe carotid disease, we used logistic regression with robust standard errors (clustering at the hospital level) in order to account for management differences between hospitals. Results. Among 2912 patients with TIA, 1942 (66.7%) had carotid ultrasounds performed, and 166 (8.5%) of these showed 70 –99% stenosis. We randomly selected 166 controls with 0 – 69% stenosis and excluded six due to missing or incomplete records. Mean age was 73.2 years and 49% were female. In multivariable analysis, patients with severe carotid stenosis were more likely to be smokers, or have a history of atrial fibrillation, coronary disease, peripheral arterial disease, or known carotid disease; but less likely to present with symptoms of numbness, speech changes, or dizziness [Table]. However, a sizeable number of patients complaining of numbness anywhere, speech changes, or dizziness were also found to have severe carotid disease on ultrasound [Table]. Conclusions - Severe carotid stenosis is not uncommon in patients presenting with TIA and is detected in all patient types. Independent predictors of severe carotid disease included current smoking, known vascular disease, and prior atrial fibrillation. Although all patients with TIA should have carotid imaging as part of the work-up, our findings identified a subset of patients who may be targeted for expedited carotid ultrasound. TABLE. SIGNIFICANT PREDICTORS OF SEVERE CAROTID DISEASE IN PATIENTS PRESENTING WITH TIA. Univariate analysis Odds ratio (p-value) Multivariate analysis Odds ratio (p-value) Cohort characteristics # of patients with severe stenosis (%) Age ⱖ 70 years (n⫽220) Gender (n⫽326) 123 (55.9) 1.85 (0.01) 1.43 (0.24) 166 (50.9) 0.75* (0.30) 0.87 (0.70) Univariate analysis Odds ratio (p-value) Multivariate analysis Odds ratio (p-value) 145 (54.3) 5 (31.3) 5 (33.3) 9 (50.0) –** 0.38 (0.09) 0.42 (0.24) 0.84 (0.75) – 0.43 (0.14) 0.65 (0.55) 1.01 (0.99) 25 (73.5) 2.97 (<0.001) 2.37 (0.013) 56 (63.6) 2.03 (<0.001) 1.72 (0.04) 18 (81.8) 4.74 (0.005) 3.65 (0.03) 32 (82.1) 5.22 (0.002) – 29 (65.9) 2.05 (0.01) 2.73 (0.01) 71 (45.8) 0.67 (0.03) 0.51 (<0.001) 58 (45.0) 0.67 (0.03) 0.54 (0.001) 13 (36.1) 0.50 (0.04) 0.52 (0.05) Cohort characteristics # of patients with severe stenosis (%) Race White (n⫽267) African American (n⫽16) Asian (n⫽15) Hispanic (n⫽18) History of atrial fibrillation (n⫽34) History of CAD (n⫽88) History of peripheral vascular disease (n⫽22) History of carotid disease (n⫽39) Current smoking (n⫽44) Speech changes (n⫽155) Symptom numbness (n⫽129) Symptom dizzy (n⫽36) *female vs. male gender; **white as the reference group. P204 NR2 Peptide Indicates Early Neurological Adverse Events During Carotid Revascularization. Svetlana A Dambinova, Emory Univ, Atlanta, GA; Robert E Brightwell, Imperial College London, St. Mary’s Hosp, London, United Kingdom; German A Khunteev, Galina A Izykenova, Dept. Neurology, Pavlov’ State Med Univ, St. Petersburg, Russian Federation; Nicholas J Cheshire; Imperial College London, St. Mary’s Hosp, London, United Kingdom Objectives. Complication rates in terms of clinical stroke for carotid revasculization have fallen since their inception. As overt complication rates decline, it would be reasonable to use biomarkers of cerebral ischemia to assess the sub-clinical morbidity caused by carotid endarterectomy (CEA) and carotid artery stenting (CAS). This study attempts to evaluate the profile of NR2 peptide in patients underwent CEA and CAS. NR2 peptide, the fragment of NMDA receptors proposed as a biomarker of cerebral ischemia (Dambinova et al, 2003), will be correlated with haemodynamic and embolic events detected using trans-cranial Doppler (TCD). Methods. 50 patients with internal carotid artery stenosis requiring intervention were recruited. 23 patients underwent CAS, and 27 underwent CEA. Patients were stratified as suffered from previous TIA/stroke with infarct registered on MRI or CT (n⫽20) and those with events but no radiological findings (n⫽23). TCD was performed peri-operatively to record mean Middle Cerebral Artery (MCA) velocity and number of High Intensity Transient Signals (HITS) in the MCA of the operated side. Plasma was drawn at six time points in a 48 hour post-operative period, and then assayed for NR2 peptide using ELISA technique. Results. Treatment modality (CAS versus CEA) had direct effect on NR2 peptide and level of the biomarker was associated with changes in MCA velocity (p ⬍ 0.05) defined by TCD. CAS caused more HITS (p 1/4 0.028) that correlated with high levels of NR2 peptide. NR2 peptide levels declined after revasculization in the CAS group but not after CEA (p⬍0.01). NR2 peptide increased significantly at 1 and 6 hours in those patients with a post-operative neurological deficit assessed by NIHSS (ROC curve 0.99). CAS caused 2 times less new brain injuries (26% cases) than CEA (52% cases) defined by MRI. Conclusions. NR2 peptide indicates acute cerebral ischemia within 6 hours of procedure and associated with adverse neurological events after carotid revasculization. Trans-cranial Doppler findings suggest that the mechanisms of rise in NR2 peptide levels may be due to increased micro-embolization and cerebral hypoperfusion respectively. P205 Strokes Following Open Heart Surgery Aren’t Directly Related to the Stenotic Carotid Artery. Yuebing Li, Karen Boutron, Joanne Rodgers, Debra Walicki, Claranne Mathiesen, Qiang Li, Yevgeniy Isayev, John Castaldo; Lehigh Valley Hosp, Allentown, PA Background: Severe carotid stenosis increases the risk of stroke in the general population. Whether it also increases the risk of perioperative stroke during open heart surgery remains controversial. There is no consensus whether patients requiring open heart surgery should receive preoperative non-invasive carotid assessment, and whether carotid revasculization procedures are warranted preoperatively when significant carotid stenosis exists. Methods: We did a retrospective analysis of 4332 patients receiving non-emergent coronary artery bypass grafting and/or valve replacement in a single institution over the last five years. 76 cases with clinically significant ischemic stroke and 239 patients with ⬎⫽ 50% carotid stenosis or occlusion (5 symptomatic, 231 asymptomatic) were identified. All the stroke cases were Abstracts and presentations are embargoed for release at date and time of presentation or time of AHA/ASA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation. 2008 ISC Poster Presentations classified according to the standard TOAST criteria. The involved vascular territory was determined with an independent review of the imaging and definitive clinical information. Results: Of the 76 stroke cases, 57 (75%) were cardioembolic, 4 (5.3%) large vessel, 12 (15.8%) lacunar, 3 (3.9%) undetermined subtypes. A total of 18 patients were found with significant carotid stenosis. Only 1 patient suffered from stroke in the territory of the diseased carotid. Presurgical carotid revasculization was performed in 74 patients. 7 (13.2%) of 53 patients having combined carotid endarterectomy/open heart surgery developed postoperative stroke. None of the 16 patients receiving staged surgery (CEA then CABG) suffered from stroke. Of the 5 patients having received carotid stenting, 1 had a stroke. Postoperative strokes occurred on 12 (10.3%) of the 116 patients with ⬎⫽ 80% carotid stenosis or carotid occlusion, and 6 (4.9%) of the 123 patients with 50 –79% carotid stenosis. Of the 165 patients without any carotid revasculization procedures, 10 (6.1%) suffered from stroke; 16 patients had ⬎ ⫽ 80% stenosis (without occlusion) but none developed stroke postoperatively. Conclusions: Most postoperative strokes following cardiac surgery are not related to ipsilateral carotid stenosis. While high-grade carotid stenosis is an indicator for higher incidence of postoperative cerebrovascular complications, carotid revasculization procedure has little role in preventing such complications in this group of patients. P206 Continuous Cerebral Hemodynamics Monitoring during Cardiac Surgery Decreases Perioperative Stroke and Neurological Complications. Alexander Razumovsky, Sentinent Neurocare Services, Inc., Cockeysville, MD; Stephen M Oppenheimer, Sentinent Med Services, Inc., Cockeysville, MD; John C Laschinger; Midatlantic Cardiovascular Associates, PA, Towson, MD Downloaded from http://stroke.ahajournals.org/ by guest on January 15, 2017 Cardiac surgery (CS)-related stroke incidence increases with age and risk factor multiple. Generally no intraoperative monitoring of intracerebral hemodynamic variables (s